content,title,event,actual_side,price_change_percentage,market_cap,float_shares,avg_volume,beta,recent_volume,float_ratio,sector_performance,day_of_week,hour,days_since_event,combined_sentiment,volatility,prev_news_sentiment
all patients treated in the edithal trial maintained hemoglobin levels above the transfusion threshold and are transfusion free post renizgamglogene autogedtemcel reni cel infusion,editas medicine announces new safety and efficacy data from the edithal trial of reni cel in 7 patients with transfusion dependent beta thalassemia presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1340909090909091,1.3105556047468256,0.048818637502848025
san diego march 21 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment and prevention of rare diseases today announced that the company is scheduled to present at two upcoming investor conferences,capricor therapeutics to present at upcoming investor conferences,conference_call_webinar,UP,1.0219003304516356,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,3,8,464,0.09999999999999999,1.3427880947904531,0.11363636363636363
jupiter fla and nes ziona israel feb 23 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs and israel institute for biological research iibr announced it has advanced its collaboration with the israel institute for biological research iibr and its commercial arm life science research israel lsri to target emerging disease solutions this partnership aims to leverage dyadic s expertise in microbial platforms for flexible scale protein bioproduction and the iibr s antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio threats through this collaboration both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization to date the framework is non binding and subject to the execution of a binding agreement to be negotiated by the parties through collaborative out licensing initiatives,dyadic advances collaboration with israel institute for biological research iibr targeting bio threats and emerging disease solutions,partnerships,UP,0.0,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,2,491,0.15757575757575756,0.7846450948942033,0.0
needham mass april 25 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology asco annual meeting taking place may 31 to june 4 2024 in chicago il the first presentation will feature data from the ongoing phase 1 clinical trial of can 3110 in patients with recurrent high grade glioma the presentation will focus on patients recruited in cohort c treated with multiple injections of can 3110 up to six demonstrating that this approach is both feasible and well tolerated the second presentation will show topline overall survival data from the phase 2 clinical trial of can 2409 plus valacyclovir in combination with continued immune checkpoint inhibitor ici treatment in patients with non resectable stage iii iv non small cell lung cancer nsclc who have an inadequate response to front line anti pd l 1 therapy,candel therapeutics announces upcoming presentations at the 2024 asco annual meeting,clinical_study,DOWN,-2.479340341131657,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,429,0.02285714285714286,1.2870358800144117,0.11927989790957705
03 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 02 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 3626 25 4973estimated mtd return 0 01 0 02 estimated ytd return 2 96 3 77 estimated itd return 183 63 154 97 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 20n apremium discount to estimated nav 4 10 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 44 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl eur nav s,fund_data_announcement,UP,0.7352898896360429,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,5,268,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
media release,quadient obtient un prêt schuldschein de 25 millions d euros auprès de la berd pour financer des programmes de r d en république tchèque,financing_agreements,DOWN,-1.960782480441495,528319008.0,22771639.0,0.0,1.149,0.0,0.04310206268406682,0.19535099655549074,2,7,241,0.0,0.39343620296100096,0.0
celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental derived biomaterials at icbst23 the international conference on biomaterials science and tissue engineering celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human placental derived biomaterials at icbst23 the international conference on biomaterials science and tissue engineering,celularity human placental derived advanced biomaterials demonstrate superior biocompatibility and better support differentiated cell functions in studies,conference_call_webinar,UP,0.4081628681073311,45263988.0,11684589.0,65020.0,0.764,90700.0,0.2581431622860982,0.09346626282280733,1,9,711,0.13333333333333333,1.6050367793919866,0.08101851851851852
myco announces it has received the issuance of a notice of allowance by the united states patent and trademark office for myco 005 compound,mydecine innovations group receives notice of allowance from uspto for its myco 005 compound,patents,UP,4.761907465063339,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,0,2,558,0.0,5.6468521991492,0.13485449735449737
mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,clinical_study,DOWN,-5.735299106184534,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,0,8,404,0.0,34.079934680222834,0.06363636363636363
atev demonstrated superiority at six and 12 months co primary endpoints compared to autogenous fistula the current standard of care for hemodialysis access,humacyte announces presentation of positive results from v007 phase 3 av access clinical trial at the american society of nephrology s kidney week 2024,clinical_study,UP,0.5366678381449244,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,0,7,243,0.12545454545454546,1.1173068527438073,0.05154292929292929
03 oct 2024 07 00 cest ctp n v regulatory news ctp europe s largest listed developer owner and manager of industrial and logistics properties by gross lettable area gla has leased 33 000 sqm of warehouse and office space at ctpark prešov north to dejong a leading manufacturer and supplier of stainless steel hot water tanks this is the first occupant for ctpark prešov north which comprises 43 5 hectares of land in total and a gla of 200 000 sqm dejong operates as a stand alone business within rheem global water and is the top manufacturer of water heating products in north america it selected ctpark prešov north after a comprehensive site selection process and its new facility comprising 29 800 sqm of warehouse space and 3 200 sqm of office space will provide a geographically strategic base from which to meet the increasing demand for hot water tanks across europe construction has already started on site and is scheduled to finish in early 2026 it is,hot water tank manufacturer dejong selects ctpark presov north for flagship facility in slovakia taking 33 000 sqm long term lease,business_contracts,UP,0.1199068189313267,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,5,268,0.08356643356643355,0.8866002429130597,0.0
san diego june 25 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced that the u s food and drug administration fda has scheduled a pre bla biologics license application meeting with the company in the third quarter of 2024 for deramiocel cap 1002 for the treatment of duchenne muscular dystrophy dmd capricor s goal for this meeting will be to finalize its bla filing plans based on all currently available data as well as to work with the fda to outline the rolling bla submission timeline,capricor therapeutics announces for the treatment of duchenne muscular dystrophy,regulatory_filings,UP,1.4613814659467588,432852864.0,40176259.0,3124730.0,0.85,8768900.0,0.09281735744735652,0.09346626282280733,1,8,368,0.2333333333333333,1.3427880947904531,0.1685123966942149
missing,valneva déclaration d actions et de droits de vote 31 juillet 2024,voting_rights,DOWN,-1.828822228271539,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,2,326,-0.2,0.6494694268312979,0.2126984126984127
norwood mass feb 28 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today announced the appointment of dr dominic smethurst ma mrcp as the company s chief medical officer cmo in this role dr smethurst will lead the clinical development of the company s investigational oncology drugs crb 701 a next generation nectin 4 targeting antibody drug conjugate adc developed in partnership with cspc and crb 601 a tgfβ blocking monoclonal antibody targeting the integrin αvβ8 additionally dr smethurst will help guide strategic development of crb 913 the company s highly peripherally restricted cb1 inverse agonist for the treatment of obesity,corbus pharmaceuticals appoints dr dominic smethurst as chief medical officer,management_changes,DOWN,-1.764476754343736,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,8,486,0.052000000000000005,0.9919200800994142,-0.057575757575757586
data demonstrate a low major adverse event rate of 0 through 30 days post procedure data demonstrate a low major adverse event rate of 0 through 30 days post procedure,inspiremd presents positive 30 day follow up results from the c guardians u s investigational device exemption ide clinical trial at viva23,clinical_study,UP,9.242146234319629,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,2,14,604,0.07045454545454546,0.6085732039686736,0.0
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions talasmäki sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name ville talasmäkiposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80025 5 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 1 324 unit price 41 9316 eur aggregated transactions 1 volume 1 324 volume weighted average price 41 9316 eur____________________________________________ trans,sampo plc managers transactions talasmäki,management_changes,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
jupiter fla june 28 2024 globe newswire dyadic international inc dyadic nasdaq dyai announced today that they have entered into a development and commercialization partnership with proliant health and biologicals phb a leading supplier of purified proteins for the diagnostic nutrition and cell culture markets,dyadic international inc and proliant health and biologicals announce recombinant albumin development and commercialization partnership,partnerships,DOWN,-2.5316506313829312,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,8,365,0.0,0.7846450948942033,0.1434434910327768
copenhagen denmark aug 08 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines is proud to announce the presentation of one year clinical efficacy phase 2 data for its lead compound evx 01 at the european society for medical oncology esmo congress 2024 taking place in barcelona spain from september 13 17 2024 the evx 01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma skin cancer,evaxion to present one year clinical efficacy data from its phase 2 study on lead cancer vaccine candidate evx 01 at the esmo congress 2024 in september,clinical_study,DOWN,-1.9999980926513672,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,3,8,324,0.20000000000000004,1.4249795072460607,0.14227693602693603
moonlake immunotherapeutics announces pricing of 400 million upsized public offering of class a ordinary shares,moonlake immunotherapeutics announces pricing of 400 million upsized public offering of class a ordinary shares,shares_issue,UP,1.6026221310773858,2922039296.0,28324751.0,691265.0,1.23,267600.0,0.009693487366434102,0.09346626282280733,2,5,731,-0.125,0.5366763308656862,0.0
27 sep 2024 08 15 cest bekaert s a update on the liquidity agreement period from 19 september 2024 to 25 september 2024 liquidity agreement in relation to the renewed liquidity agreement with kepler cheuvreux announced on 25 june 2024 bekaert announces today that kepler cheuvreux on behalf of bekaert has bought 13 600 shares during the period from 19 september 2024 to 25 september 2024 on euronext brussels during the same period kepler cheuvreux on behalf of bekaert has sold 6 100 shares on euronext brussels the tables below provide an overview of the transactions under the liquidity agreement during the period from 19 september 2024 to 25 september 2024 purchase of sharesdatenumber of sharesaverage price highest price lowest price total amount 19 september 202460036 7536 8036 7022 05020 september 20244 30036 2936 7035 96156 04723 september 20241 50035 7835 9035 6453 67024 september 202460036 2536 3036 2021 75025 september 20246 60035 7136 0035 40235,bekaert update on the liquidity agreement,trading_information,UP,0.4955955580622765,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.0,0.8866002429130597,0.0
inside information 2024 09 20 07 46 cest as madara cosmetics has received the notification of sustainability manager anete vabule on transactions with securities issued by as madara cosmetics the shares of as madara cosmetics are admitted to trading on nasdaq baltic first north market the certified adviser for as madara cosmetics is zab eversheds sutherland bitāns sia as madara cosmetics was founded in 2006 and has become one of the leading cosmetics manufacturers in northern europe and a leader in latvia the company s brand mádara is a pioneer in the natural skincare and make up segment in latvia since november 2017 the company s shares have been listed on the nasdaq baltic alternative market first north for more information visit investors madaracosmetics com contact information address 131 zeltiņu street mārupe district mārupe lv 2167 latvia contact person gunta šulte member of the management board e mail ir madaracosmeti,on transactions under regulation no 596 2014,trading_information,UP,1.239666229762992,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,281,0.275,0.8866002429130597,0.275
media release,lancement d une augmentation de capital d un montant d environ 36 6 m avec maintien du droit préférentiel de souscription des actionnaires,shares_issue,DOWN,-6.88946716859099,67170584.0,14323264.0,15862.954545454546,1.806,9661.0,0.2132371515483623,0.1515999603296736,0,7,243,0.0,0.5487288764223092,0.0
radnor pa june 03 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other diseases driven by dysregulated aldosterone today announced that management will be participating in a fireside chat at the goldman sachs 45th annual global healthcare conference being held in miami fl on june 10 13 2024,mineralys therapeutics to participate in the goldman sachs 45th annual global healthcare conference,conference_call_webinar,UP,1.87940299541848,919949376.0,43490817.0,793180.0,-0.18,767600.0,0.04727522854474984,0.09346626282280733,0,8,390,-0.041666666666666664,0.8131647725786432,0.022115308933490754
immunocore announces transition of chief financial officer,immunocore announces transition of chief financial officer,management_changes,DOWN,-7.103823312288768,1603205376.0,37423034.0,614630.0,0.835,788600.0,0.023342632553647324,0.09346626282280733,3,7,303,0.0,0.44240182162750774,0.10378787878787878
cft1946 is well tolerated at all dose levels no dose limiting toxicities,c4 therapeutics presents monotherapy data demonstrating proof of mechanism and early evidence of proof of concept from ongoing cft1946 phase 1 trial in braf v600 mutant solid tumors at the european society for medical oncology esmo congress 2024,clinical_study,DOWN,-1.37825650377019,106510656.0,49730521.0,1021690.0,2.946,941900.0,0.4669065318685109,0.09346626282280733,4,10,287,0.025,0.8954742650579008,0.04130099698281516
immunocore announces clinical trial collaboration and supply agreement with bristol myers squibb to evaluate imc f106c prame hla a02 in combination with nivolumab in its registrational phase 3 first line advanced cutaneous melanoma trial,immunocore announces clinical trial collaboration and supply agreement with bristol myers squibb to evaluate imc f106c prame hla a02 in combination with nivolumab in its registrational phase 3 first line advanced cutaneous melanoma trial,clinical_study,UP,0.9111608899671612,1602703104.0,37423034.0,614630.0,0.835,788600.0,0.023349947913996177,0.09346626282280733,3,7,492,0.325,0.44240182162750774,0.11666666666666665
media release,information regarding dividend from solstad maritime holding as,dividend_reports_and_estimates,DOWN,-4.296642448914433,4289897472.0,29760087.0,70112.7,2.413,93652.0,0.006937249012183385,0.1515999603296736,1,15,241,0.0,0.40970189616126773,0.0
media release,valmetin osavuosikatsaus 1 tammikuuta 30 syyskuuta 2024 ennätyskorkea marginaali kolmannella vuosineljänneksellä mutta markkina aktiviteetti odotettua matalampi,earnings_releases_and_operating_results,DOWN,-0.0830583796804002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,240,0.0,0.8866002429130597,-0.016941094619666055
company aligned with fda that ruby is a single phase 1 2 3 trial,editas medicine announces fourth quarter and full year 2023 results and business updates,clinical_study,UP,9.242146234319629,182494112.0,83382193.0,2526680.0,2.096,3015800.0,0.45690346985003,0.09346626282280733,2,7,486,0.09285714285714286,1.3105556047468256,0.0327972027972028
media release,information regarding dividend from solstad maritime holding as,dividend_reports_and_estimates,DOWN,-4.296642448914433,4289897472.0,29760087.0,70112.7,2.413,93652.0,0.006937249012183385,0.1515999603296736,1,15,241,0.0,0.40970189616126773,0.0
media release,shell plc third quarter 2024 interim dividend,dividend_reports_and_estimates,UP,0.9792533652911048,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,3,8,240,0.0,0.21899596821966708,0.0
public joint stock company invl baltic farmland legal entity code 303299781 the registered address gyneju str 14 vilnius lithuania hereinafter the company or invl baltic farmland informs that on the initiative and decision of the management board the general extraordinary shareholders meeting hereinafter the meeting is to be held on 21 october 2024 the place of the meeting the office of company the address gyneju str 14 vilnius the meeting will start at 8 30 a m registration starts at 8 00 a m the meeting s accounting day 14 october 2024 the persons who are shareholders of the company at the end of accounting day of the meeting or authorized persons by them or the persons with whom shareholders concluded the agreements on the disposal of voting right shall have the right to attend and vote at the meeting the total number of the company s shares is 3 291 549 shares considering that the company has acquired its own shares the total number of votes a,convocation of the general extraordinary shareholders meeting of invl baltic farmland and draft resolutions on agenda issue,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.19437229437229436,0.8866002429130597,0.0
i henhold til vedtægternes pkt 4 5 indkaldes hermed til ordinær generalforsamling i orphazyme a s til afholdelse den 18 april 2024 kl 15 00 på selskabets adresse hos visionhouse lyskær 8a 2730 herlev med følgende dagsorden,indkaldelse til ordinær generalforsamling den 18 april 2024 kl 15 00,annual_general_meeting,DOWN,-0.3361909426663528,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,458,0.0,0.8866002429130597,0.0
results for the 1st half of 2024,eurobio scientific results for the 1st half of 2024,earnings_releases_and_operating_results,UP,0.2003977376017373,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,12,276,-0.16666666666666666,0.4336088389568585,0.005602240896358544
san diego oct 09 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced positive top line results from its global phase 3 gemini 1 trial evaluating the safety and efficacy of imsidolimab il 36r mab in patients with generalized pustular psoriasis gpp flares investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation erythema and scaling through week 4 after a single dose of 750mg iv imsidolimab top line data also demonstrate a favorable safety and tolerability profile,anaptys announces positive top line phase 3 clinical trial results of imsidolimab il 36r in generalized pustular psoriasis gpp,clinical_study,UP,6.077922474254261,687209856.0,17605381.0,784220.0,-0.266,445700.0,0.02561863868262099,0.09346626282280733,0,8,628,0.3092352092352092,0.871343469962729,0.22239669421487604
istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias,windtree announces positive phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients in early cardiogenic shock,clinical_study,DOWN,-1.5564187895738903,1360169.0,3660923.0,6680965.0,0.764,1224200.0,2.6915206860323972,0.09346626282280733,0,8,271,0.12945075757575758,2.339794177443606,0.03578643578643579
redwood city calif june 14 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells hscs at the european hematology association eha hybrid congress being held june 13 16 2024 in madrid spain,jasper therapeutics presents data from preclinical briquilimab study at the 2024 eha hybrid congress,clinical_study,UP,0.2465056103789856,80969120.0,9908441.0,280900.0,2.725,505700.0,0.12237308494892868,0.09346626282280733,4,8,379,0.19999999999999998,0.9821837329226573,0.14004741290455575
media release,guerbet nombre d actions et de droits de vote composant le capital de la société au 30 septembre 2024,voting_rights,DOWN,-1.6541330437911184,278437920.0,5878020.0,15366.363636363636,0.764,6888.0,0.02111070216298125,0.09346626282280733,2,15,240,0.0,0.41864543118833314,0.0
adelaide australia and cambridge mass july 18 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a biotechnology company developing novel potential first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced the initiation of patient screening for the phase 3 affirm 1 trial evaluating the safety and efficacy of bnc210 for the acute as needed treatment of social anxiety disorder sad,bionomics initiates affirm 1 a phase 3 clinical trial with bnc210 for social anxiety disorder,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,345,0.015627705627705626,0.8866002429130597,0.0550333583203713
27 sep 2024 08 30 cest casino guichard perrachon casino group sells over 200m of commercial real estate assets to tikehau capital paris 27 september 2024 following the signature in june 2024 of an agreement with tikehau capital covering a portfolio of 30 real estate assets casino group announced that on thursday 26 september 2024 it had finalized the sale of 26 of these for a net selling price of over 200 million euros excluding subsequent earn outs the sale of the remaining assets provided for in the agreements will be finalized in the coming weeks once the usual conditions precedent have been lifted the overall portfolio comprises hypermarket and supermarket premises leased to casino intermarché carrefour and auchan as well as ancillary lots within these real estate complexes some of which offer real estate development potential tikehau capital has entrusted casino group with the property management of these assets for a period of 5 years the net proc,casino group real estate asset sales,business_contracts,DOWN,-0.3016839287324527,112574064.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.1515999603296736,4,6,274,0.057692307692307696,0.8866002429130597,0.0
alvotech nasdaq alvo tekur þátt í 22 árlegri heilbrigðisráðstefnu fjárfestingabankans morgans stanleys í new york,alvotech tekur þátt í árlegri heilbrigðisráðstefnu fjárfestingabankans morgans stanley,conference_call_webinar,UP,0.5046212296880009,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,0,9,306,0.13636363636363635,0.44264539487962035,0.08049943883277216
alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide announced today the initiation of a confirmatory patient study for avt16 a biosimilar candidate to entyvio vedolizumab the objective of the study is to demonstrate comparative efficacy safety and immunogenicity of avt16 and entyvio in male and female participants 18 80 years old with moderate to severe active ulcerative colitis alvotech is one of two companies known to have initiated a global or multi country confirmatory patient study for a biosimilar candidate to entyvio,alvotech initiates confirmatory patient study for avt16 a proposed biosimilar to entyvio,clinical_study,UP,0.2685741518915451,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,2,5,276,-0.004166666666666666,0.44264539487962035,0.07366372053872054
san diego oct 29 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that it has entered into definitive agreements for the purchase and sale of 745 342 shares of the company s common stock at an offering price of 4 025 per share of common stock in a registered direct offering priced at the market under nasdaq rules in addition in a concurrent private placement the company will issue unregistered warrants to purchase up to 745 342 shares of common stock the warrants have an exercise price of 3 90 per share will be exercisable upon issuance and will expire five years following issuance the closing of the offering is expected to occur on or about october 29 2024 subject to the satisfaction of customary closing conditions,biora therapeutics announces 3 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,242,-0.1074074074074074,1.027516639474094,0.08148448773448774
innovative design enables five minute pegfilgrastim cbqv delivery time,coherus announces u s launch of udenyca onbody a novel and proprietary state of the art delivery system for pegfilgrastim cbqv,product_services_announcement,DOWN,-2.7027002147700405,85025264.0,110892497.0,1236840.0,0.883,1425300.0,1.3042299639316615,0.09346626282280733,2,8,493,0.5,1.0144535837204522,0.0
conference call to begin at 4 30 p m et conference call to begin at 4 30 p m et,vaxart to host full year 2023 business update and financial results conference call on march 14,conference_call_webinar,DOWN,-5.000004967053534,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,3,8,478,0.175,1.025768835125998,-0.04583333333333334
epa approved an amendment to the label of interline herbicideto include camelina,yield10 bioscience announces addition of camelina to interline herbicide label,product_services_announcement,UP,0.4366808135300151,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,401,0.0,0.8866002429130597,0.02698621553884711
edo platform observed to drive 25 fold higher level of oligonucleotide delivery to myotube nuclei compared to naked oligonucleotide,pepgen inc presents pgn edodm1 preclinical data supporting the company s enhanced delivery oligonucleotide platform and pgn edodm1 program at two medical conferences,clinical_study,UP,0.8561594621799556,45482052.0,12870456.0,168500.0,1.294,155200.0,0.28297878908365875,0.09346626282280733,2,8,661,0.125,1.4553932872573117,0.025
media release,the goldman sachs group inc disclosure in borr drilling limited,company_regulatory_filings,UP,1.4718186039315284,443918176.0,174743108.0,6645095.0,1.794,4344400.0,0.3936381014504799,0.1515999603296736,1,9,241,-0.07142857142857142,0.6240735891345442,0.052678571428571436
sampo plc stock exchange release 3 october 2024 at 8 30 am eest sampo plc s share buybacks 2 october 2024 on 2 october 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 851 910 sampo a shares representing 1 43 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 september 20,sampo plc s share buybacks 2 october 2024,changes_in_companys_own_shares,DOWN,-0.1667147099862665,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,268,0.1625,0.8866002429130597,-0.012601010101010102
phase 2 open label connect1 edo51 study open in canada,pepgen reports second quarter 2023 financial results and recent corporate developments,clinical_study,DOWN,-0.2000045776367187,45482052.0,12870456.0,168500.0,1.294,155200.0,0.28297878908365875,0.09346626282280733,1,8,690,0.0,1.4553932872573117,0.0
media release,program for kjøp av egenkapitalbevis for ansatte i sparebanken vest,capital_investment,UP,1.1410738067002315,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,2,14,240,0.0,0.20896972559163385,0.055
company presenting an in vivo study of pt cd16 a genetically modified allogeneic cell therapy derived from human placental circulating t p t cells at aacr annual meeting 2024 company presenting an in vivo study of pt cd16 a genetically modified allogeneic cell therapy derived from human placental circulating t p t cells at aacr annual meeting 2024,celularity to present data showing cancer tumor reduction by off the shelf cell therapy derived from human placental cells,clinical_study,UP,9.242146234319629,45263988.0,11684589.0,65020.0,0.764,90700.0,0.2581431622860982,0.09346626282280733,3,9,477,0.0,1.6050367793919866,0.09236746586746587
mainz germany july 30 2024 globe newswire biontech se nasdaq bntx biontech or the company today announced positive topline data from the ongoing phase 2 clinical trial eudract no 2020 002195 12 nct04526899 in patients with unresectable stage iii or iv melanoma whose disease had progressed following anti pd l 1 containing treatment the randomized trial evaluates the clinical activity and safety of the investigational mrna cancer immunotherapy bnt111 in combination with libtayo cemiplimab an anti pd 1 monoclonal antibody being developed by regeneron and assesses the two single agents alone,biontech announces positive topline phase 2 results for mrna immunotherapy candidate bnt111 in patients with advanced melanoma,clinical_study,UP,1.466339492110126,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,1,6,333,0.1471861471861472,0.5503225880253886,0.055827721661055006
special closed ended type real estate investment company invl baltic real estate legal entity code 152105644 the registered address gyneju str 14 vilnius lithuania hereinafter the company or invl baltic real estate informs that on the initiative and decision of the management company invl asset management uab hereinafter the management company the general extraordinary shareholders meeting hereinafter the meeting is to be held on 21 october 2024 the place of the meeting the office of company the address gyneju str 14 vilnius the meeting will start at 08 00 a m registration starts at 07 45 a m the meeting s accounting day 14 october 2024 the persons who are shareholders of the company at the end of accounting day of the meeting or authorized persons by them or the persons with whom shareholders concluded the agreements on the disposal of voting right shall have the right to attend and vote at the meeting the total number of the company s shares is 8 06,convocation of the general extraordinary shareholders meeting of invl baltic real estate and draft resolutions on agenda issue,annual_general_meeting,DOWN,-0.9090900224102624,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.18537414965986393,0.8866002429130597,0.0
media release,aker horizons asa invitation to presentation of third quarter results 2024,clinical_study,DOWN,-3.2496329736071154,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,247,0.0,0.8866002429130597,0.13961675579322638
media release,riber solide croissance de l activite a fin septembre 2024,financial_results,UP,1.8115924814873587,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,8,241,0.0,0.4818751066598002,0.049342105263157895
moonlake immunotherapeutics starts phase 3 vela program of the nanobody sonelokimab in patients with moderate to severe hidradenitis suppurativa,moonlake immunotherapeutics starts phase 3 vela program of the nanobody sonelokimab in patients with moderate to severe hidradenitis suppurativa,clinical_study,UP,0.3686447061722066,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,3,8,408,0.0,0.5366763308656862,0.058094098883572566
media release,immutep receives regulatory clearance for phase i study of first in class lag 3 agonist antibody designed to treat autoimmune diseases,clinical_study,UP,1.9704414983633087,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,346,0.25,0.7476881311953882,0.1293304098498904
company maintains solid cash position of 158 9 million company maintains solid cash position of 158 9 million,rapt therapeutics reports fourth quarter and full year 2023 financial results,financial_results,UP,0.6564492744928128,146013760.0,6191111.0,99294.6,-0.137,87900.0,0.042400873725873506,0.09346626282280733,3,8,478,0.06999999999999999,1.6028075568485736,0.09107975357975359
jupiter fla march 27 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic therapeutic and nutritional biopharmaceutical products for human and animal health and wellness today announced that its management will be attending the following industry events during the month of april 2024,dyadic to attend industry events in april,trade_show,UP,4.430375401359936,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,458,0.08333333333333333,0.7846450948942033,0.157106290174472
biologics license application bla for hav accepted by fda,humacyte first quarter 2024 financial results and business update,regulatory_filings,DOWN,-0.4424774559935741,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,4,7,414,0.125,1.1173068527438073,0.03636363636363636
all patients treated in the edithal trial maintained hemoglobin levels above the transfusion threshold and are transfusion free post renizgamglogene autogedtemcel reni cel infusion,editas medicine announces new safety and efficacy data from the edithal trial of reni cel in 7 patients with transfusion dependent beta thalassemia presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1340909090909091,1.3105556047468256,0.048818637502848025
new york april 18 2024 globe newswire tg therapeutics inc nasdaq tgtx announced that it has been awarded a national contract with the department of veterans affairs va for briumvi ublituximab xiiy to be the preferred agent listed on the va national formulary for anti cd20 antibody indications for patients with relapsing forms of multiple sclerosis rms,tg therapeutics awarded national contract by the department of veterans affairs for briumvi as the preferred anti cd20 for relapsing forms of multiple sclerosis,business_contracts,UP,1.2301018816781355,5891398656.0,135060602.0,1756590.0,1.939,1677400.0,0.022925048852779586,0.09346626282280733,3,7,436,0.04545454545454545,0.6256004090066075,0.045570500927643774
media release,fly play hf manager s transactions,regulatory_filings,UP,1.8181801105005104,1730814080.0,11842744.0,1296563.9411764706,0.45,1037764.0,0.006842297007429013,0.1515999603296736,0,12,242,0.8,0.7000376628051228,0.0
media release,archer limited private placement successfully completed,mergers_acquisitions,UP,3.0491852271965074,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,1,240,0.2261904761904762,0.8866002429130597,0.0
la jolla calif may 28 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova conducted two poster presentations at the 92nd european atherosclerosis society eas 2024 congress held online may 26 29 2024,medicinova announces two poster presentations at the 92nd eas congress 2024 the annual meeting of the european atherosclerosis society regarding the use of mn 001 tipelukast for cardiometabolic conditions,clinical_study,DOWN,-1.4925358528601556,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,396,0.0,0.8018560055721619,0.11601010101010101
toronto april 23 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today that the u s food drug administration fda has granted the company s type c meeting request for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the meeting date assigned by the fda is june 9 2024,revive therapeutics announces type c meeting request granted by fda for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,431,0.04,1.8889707456546947,0.10962100077251592
media release,euronext oslo børs diana shipping inc received application for listing of bonds,exchange_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,239,0.0,0.8866002429130597,0.1573829386987282
investor webcast on tuesday september 24 2024 at 8 30 a m et investor webcast on tuesday september 24 2024 at 8 30 a m et,capricor therapeutics to provide duchenne muscular dystrophy program update on september 24 2024,conference_call_webinar,UP,1.188117633928445,431938688.0,40176259.0,3124730.0,0.85,8768900.0,0.09301380060681205,0.09346626282280733,0,9,278,0.0,1.3427880947904531,0.1320885942760943
malvern pa april 29 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced the data from its phase ii iii alzheimer study of buntanetap in mild to moderate ad patients based on these data the company plans to conduct a pivotal phase iii trial in biomarker positive early ad patients,annovis bio announces statistically significant phase ii iii data in patients with early alzheimer s disease,clinical_study,DOWN,-7.103823312288768,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,0,10,424,0.2044507575757576,1.368989555493872,0.050015782828282826
media release,norsk hydro status share buyback program,changes_in_companys_own_shares,DOWN,-0.319386759699206,108946178048.0,1148146500.0,4473395.3,1.218,3924732.0,0.010538657900363834,0.1515999603296736,2,12,240,0.0,0.3181340754469693,0.0
new york april 23 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced that the u s food and drug administration fda has allowed its intranasal foralumab non active secondary progressive multiple sclerosis na spms expanded access ea program to expand from 10 patients to a total of 30 patients,tiziana life sciences announces fda allowance for additional twenty patients to be enrolled in the intranasal foralumab multiple sclerosis expanded access program,clinical_study,UP,9.242146234319629,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,7,431,-0.0494949494949495,1.1109140250580023,0.047704315886134066
needham mass may 14 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the first quarter ended march 31 2024 and provided a corporate update,candel therapeutics reports first quarter 2024 financial results and recent corporate highlights,financial_results,DOWN,-2.2548975150706254,242456992.0,41997569.0,917740.0,-0.866,856900.0,0.17321657195186188,0.09346626282280733,1,8,410,0.07142857142857142,1.2870358800144117,0.09356716322892793
company announcement inside information,inside information faron announces first hma failed mds patient dosed with bexmarilimab as part of phase 2 of bexmab trial,clinical_study,UP,0.5571025460913265,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,2,536,-0.125,0.7633342480324978,0.024704055864770147
tampa fla july 23 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its second quarter financial results after the close of the u s markets on tuesday july 30 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report second quarter 2024 financial results on tuesday july 30 2024,conference_call_webinar,DOWN,-0.3463616922080888,1112470400.0,45834212.0,557500.0,0.511,435200.0,0.041200387893466646,0.09346626282280733,1,8,340,0.022727272727272724,0.7130794063724827,0.1496315836940837
copenhagen denmark aug 12 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines will provide a business update and report its second quarter 2024 financial results on wednesday august 14 2024 before opening of the nasdaq cm,evaxion to announce business update and second quarter 2024 financial results on august 14,earnings_releases_and_operating_results,DOWN,-5.246665220347692,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,7,320,0.0,1.4249795072460607,0.15382154882154883
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
nexobrid interest surges 5 million in q1 2024 revenue with 24 million forecast for the year,mediwound reports first quarter 2024 financial results and provides company update,financial_results,DOWN,-3.4851085290965536,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,7,395,0.125,0.6433034533898109,0.1344343434343434
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
media release,stmicroelectronics reports 2024 third quarter financial results,financial_results,DOWN,-0.689650206789829,26516213760.0,642508707.0,7578905.0,1.228,8781800.0,0.024230786220664408,0.19535099655549074,3,7,240,0.0,0.5353904419526144,-0.15
after successful seismic a and b studies in early cardiogenic shock seismic c will treat more severe scai stage c cardiogenic shock to complete the assessment of the intended phase 3 patient population,windtree therapeutics initiates seismic c study of istaroxime in scai stage c cardiogenic shock for planned completion of phase 2b and transition to phase 3,clinical_study,DOWN,-3.658533128225512,1377011.0,3660923.0,6680965.0,0.764,1224200.0,2.6586011295479848,0.09346626282280733,2,8,241,0.36250000000000004,2.339794177443606,0.057652423534458166
san diego sept 25 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced two presentations at options xii for the control of influenza conference to be held september 29 through october 2 2024 in brisbane australia the presentations one oral and one poster will highlight safety and pharmacokinetic pk data from clinical studies of cd388 cidara s influenza drug fc conjugate dfc candidate,cidara therapeutics announces two presentations on innovative drug fc conjugate cd388 at the 2024 options xii for the control of influenza conference,clinical_study,UP,1.9498521406401248,634742016.0,4118697.0,696580.0,0.795,3470400.0,0.006488773227830565,0.09346626282280733,2,8,276,0.05555555555555556,1.357695941787151,0.06863107263107263
media release,vinci annonce l acquisition de fm conway limited au royaume uni,mergers_acquisitions,DOWN,-0.5811123236039649,68908859392.0,414372263.0,1028346.7727272727,0.967,1204247.0,0.006013338004084083,0.1515999603296736,2,8,241,-0.07142857142857142,0.19953581178454047,0.0
data reinforces mechanism of action and selection of 10 mg kg every three weeks repeat dosing regimen with pembrolizumab in ongoing mss crc dose expansion cohort,adagene announces poster presentation on optimal dose selection for masked anti ctla 4 safebody adg126 at upcoming society for immunotherapy of cancer sitc 38th annual meeting,clinical_study,UP,3.35570147625903,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,8,625,0.1,0.845882180665701,0.16527777777777777
calendrier des publications financières du 2eme semestre,eurobio scientific calendrier des publications financières du 2eme semestre,financial_calendar,UP,1.807224278111647,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,5,340,0.0,0.4336088389568585,0.0
all ruby patients with 5 months follow up have achieved a normal hemoglobin level and a fetal hemoglobin level of,editas medicine announces new edit 301 safety and efficacy data in 17 patients presented today at the american society of hematology ash annual meeting and in a company sponsored webinar,clinical_study,DOWN,-5.167463844107009,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,0,12,564,0.09545454545454546,1.3105556047468256,0.0
media release,rentefastsettelse,bond_fixing,DOWN,-0.1940257513701026,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,0,13,242,0.0,0.20896972559163385,0.0
norwood mass oct 29 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a fireside chat and one on one investor meetings at the guggenheim securities healthcare innovation conference to be held november 11 13 2024 in boston ma,corbus pharmaceuticals to present at the guggenheim securities healthcare innovation conference,conference_call_webinar,DOWN,-0.9791912234882628,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,1,8,242,0.0,0.9919200800994142,0.0701116427432217
kraig labs otcqb kblb achieves key milestone for true commercial scale production levels and great colony health,kraig biocraft laboratories nears completion of largest production batch of parental line spider silk silkworms,product_services_announcement,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,257,0.2875,0.8071333009212691,0.11782039141414141
mainz biomed reports increased demand for enhanced coloalert existing partners to transition to new version ganzimmun diagnostics to feature coloalert,mainz biomed reports increased demand for enhanced coloalert existing partners to transition to new version,product_services_announcement,UP,3.70370002440479,5531532.0,2706585.0,75055.0,0.305,78500.0,0.4893011556292181,0.09346626282280733,1,8,263,0.13636363636363635,34.079934680222834,-0.020575068870523416
missing,immix biopharma announces dr raymond comenzo internationally recognized al amyloidosis expert director of the myeloma and amyloid program at tufts medical center joins scientific advisory board,advisory,DOWN,-3.2786918350693264,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,3,9,282,-0.07500000000000001,0.9253604538231538,0.01770793876262626
rockville md june 26 2023 globe newswire opgen inc nasdaq opgn opgen a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease and opgen subsidiary ares genetics which strives to become a leader in bacterial genomics and ai powered prediction of antimicrobial resistance amr announced today that one of its key patents under opposition has been successfully maintained,opgen subsidiary ares genetics successfully maintains key patent under opposition in europe,patents,UP,0.0,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,0,7,733,0.375,1.807174583649316,0.11415584415584416
27 sep 2024 08 00 cest claranova se regulatory news claranova euronext paris fr0013426004 cla est heureuse d annoncer que plusieurs membres de son équipe dirigeante ont récemment renforcé leur engagement envers l entreprise en augmentant leur participation dans le capital de la société à travers des achats d actions sur le marché cette initiative illustre leur confiance dans la stratégie de croissance de claranova et leur implication pour en assurer son succès durable eric gareau directeur général de claranova et d avanquest a acquis 50 000 titres le 26 septembre 2024 portant sa participation totale à 153 689 actions xavier rojo directeur administratif et financier de claranova a acquis 25 993 titres le 20 septembre 2024 portant sa participation totale à 50 000 actions mathieu laforge vice président exécutif opérations d avanquest a acquis 19 600 actions le 2 août 2024 ces acquisitions témoignent de la confiance renouvelée des dirigeants,claranova la direction du groupe capitalise sur l avenir,major_shareholder_announcements,UP,0.4048611328405748,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,274,0.0,0.8866002429130597,0.0
media release,bcs third quarter financial results,earnings_releases_and_operating_results,DOWN,-7.103823312288768,64402014208.0,13292123540.0,12481905.0,1.06,13712800.0,0.2063929785964498,0.1515999603296736,3,7,240,0.0,0.3600217284985099,0.08425925925925926
media release,correction vilniaus baldai ab interim condensed consolidated financial statement for the twelve months of fy2024 ended august 31 2024,interim_information,UP,7.344628141386898,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,241,0.0,0.8866002429130597,0.0481737012987013
irvine calif nov 08 2023 globe newswire biomerica inc nasdaq bmra the company a global provider of advanced medical products today announced that several new gastrointestinal gi groups have signed up and begun using the company s revolutionary infoods ibs product this expansion demonstrates growing recognition and adoption of the infoods ibs test in the medical community broadening biomerica s influence in providing innovative solutions for irritable bowel syndrome ibs while positioning the company for product revenue growth over the coming quarters these new groups join gastro health a group with 390 gi physicians which was the company s first large physician group customer in addition several additional gastro health office locations have started using the infoods ibs therapy for their ibs patients,biomerica expands infoods ibs reach with addition of several new gi groups,product_services_announcement,UP,7.058823611909541,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,2,8,598,0.13641358641358642,1.5245042583012947,0.05666666666666667
boca raton florida sept 30 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of alzheimer s disease ad announced today that it closed enrollment for its phase 2 trial on friday 27 september this global blinded randomized phase 2 trial the ad02 trial is focused on patients with early ad and biomarkers of elevated neuroinflammation,inmune bio inc completes enrollment for phase 2 trial in early alzheimer s disease,clinical_study,UP,3.8314232594049966,162957200.0,15213010.0,781395.0,1.567,974600.0,0.09335586276641965,0.09346626282280733,0,8,271,0.025,0.8435084668920305,0.14011201560114603
needham mass nov 28 2023 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced a strategic restructuring to focus on continuation and expansion of development of can 3110 as well as the enlighten discovery platform while reducing the company s workforce and expenses associated with enabling commercial readiness of can 2409 the company expects to present initial activity and biomarker data for repeated injections of can 3110 in recurrent high grade glioma in the second half of 2024 and new data for the second drug candidate based on the enlighten discovery platform in q3 2024 the company plans to continue to collect clinical data for key readouts for can 2409 in non small cell lung cancer nsclc with topline overall survival data of the open label phase 2 clinical trial expected in q2 2024 pancreatic cancer with an update on overall survival based on an interim analysis of the randomized open label clinical trial in q2 2024 and prostate cancer with topline data for both fully enrolled randomized blinded placebo controlled phase 2 and phase 3 clinical trials in q4 2024,candel therapeutics announces restructuring to prioritize resources on key value drivers for expanded development of can 3110 the enlighten discovery platform and key clinical readouts for can 2409,clinical_study,UP,4.081628681073312,242497072.0,41997569.0,917740.0,-0.866,856900.0,0.17318794265689114,0.09346626282280733,1,9,578,-0.012959001782531194,1.2870358800144117,0.0
research includes the first ever application of ascas12a in vivo optimized lnp delivery and gene editing rna guide modifications,editas medicine preclinical data highlights advancement of in vivo gene editing medicine technologies at the american society of gene and cell therapy annual meeting,clinical_study,DOWN,-0.7194237817389376,182418768.0,83382193.0,2526680.0,2.096,3015800.0,0.45709218362882487,0.09346626282280733,4,6,414,0.125,1.3105556047468256,0.04720906544435956
media release,wärtsilän tammi syyskuun osavuosikatsaus 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,11530422272.0,388303386.0,1013444.6,1.147,878088.0,0.033676423711119396,0.1515999603296736,1,7,242,0.0,0.32861945847596113,0.0
new york july 24 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the u s food and drug administration fda has granted fast track designation for its intranasal formulation of foralumab a fully human anti cd3 monoclonal antibody for the treatment of non active secondary progressive multiple sclerosis na spms,tiziana life sciences granted fda fast track designation,clinical_study,UP,9.242146234319629,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,2,7,339,0.012878787878787885,1.1109140250580023,0.0377000481000481
cambridge mass jan 03 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that the company s president and ceo gilmore o neill m b m m sc will present at the 42nd annual j p morgan healthcare conference on tuesday january 9 2024 4 30 p m pt 7 30 p m et in san francisco ca,editas medicine to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-2.0040061967810527,181238416.0,83382193.0,2526680.0,2.096,3015800.0,0.46006908932596274,0.09346626282280733,2,7,542,0.0,1.3105556047468256,0.057272727272727274
25 9 2024 08 30 01 eest gofore oyj total number of voting rights and capital gofore plctotal number of voting rights and capital25 september 2024 at 8 30 a m eet gofore plc s new shares registered in the trade register as previously announced gofore plc has decided on a directed share issue on 17 september 2024 for the transfer of savings shares acquired with accrued savings based on the employee share savings plan crewshare s savings period 2024 2025 a total of 43 123 new shares have been entered into the trade register today on 25 september 2024 after the trade registration the total amount of shares is 15 703 262 the total share subscription price 850 834 10 euros will be credited in full to the company s reserve for invested unrestricted equity the new shares will be traded on the main list of nasdaq helsinki ltd on 26 september 2024 gofore is an international digital transformation consultancy with finnish roots we have over 1 400 impact driven people in 19 lo,gofore plc s new shares registered in the trade register,shares_issue,UP,1.6203721078171185,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,276,0.06888111888111888,0.8866002429130597,0.0
moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,clinical_study,DOWN,-7.103823312288768,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,2,10,625,0.11363636363636363,0.5366763308656862,-0.03166666666666666
san diego oct 29 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that it has entered into definitive agreements for the purchase and sale of 745 342 shares of the company s common stock at an offering price of 4 025 per share of common stock in a registered direct offering priced at the market under nasdaq rules in addition in a concurrent private placement the company will issue unregistered warrants to purchase up to 745 342 shares of common stock the warrants have an exercise price of 3 90 per share will be exercisable upon issuance and will expire five years following issuance the closing of the offering is expected to occur on or about october 29 2024 subject to the satisfaction of customary closing conditions,biora therapeutics announces 3 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,242,-0.1074074074074074,1.027516639474094,0.08148448773448774
boston sept 13 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced upcoming presentations in september and october,elicio therapeutics announces three upcoming presentations focused on its lymph node targeted mkras specific amphiphile vaccines,clinical_study,UP,2.457000010192833,127896016.0,10299137.0,63410.0,2.164,22500.0,0.08052742628042456,0.09346626282280733,4,8,288,0.0,0.8558055682194762,0.041934277843368756
immuneering announces first patient dosed in its phase 1 2a trial of imm 6 415 to treat advanced solid tumors with raf or ras mutations,immuneering announces first patient dosed in its phase 1 2a trial of imm 6 415 to treat advanced solid tumors with raf or ras mutations,clinical_study,UP,1.2552288733465695,112455312.0,27271404.0,2516685.0,0.002,1980700.0,0.24250881096661756,0.09346626282280733,2,8,458,0.21666666666666667,1.2966226301621697,0.08505509641873278
se venligst vedlagte,bestyrelsesmedlemmers direktørers eller nærtstående personers handel med orphazyme aktier,press_releases,UP,7.893823399166728,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,2,253,0.0,0.8866002429130597,0.0
zug switzerland aug 15 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the appointment of dr sharon klier an executive leader with extensive experience in clinical development across early and late stage programs regulatory submissions and approvals to the role of chief development officer in this key role dr klier will oversee and provide strategic leadership across the clinical development and operations of oculis robust ophthalmology pipeline,oculis appoints sharon klier m d m s m p h as chief development officer,management_changes,UP,0.0,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,8,317,-0.039999999999999994,0.4640841922034435,0.05012626262626263
longeveron announces 9 0 million registered direct offering,longeveron announces 9 0 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-5.384616231071858,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,3,8,345,0.1,1.063123411629147,0.12037037037037036
ne pas distribuer publier ou diffuser en tout ou en partie directement ou indirectement aux etats unis ou a toute personne des etats unis ou dans toute autre juridiction dans laquelle la distribution la publication ou la diffusion serait illégale,eurobio scientific conclusion d un accord entre eurobio scientific et un consortium mené par l équipe d entrepreneurs et dirigeants d eurobio scientific ik partners et nextstage am en vue du dépôt d une offre publique d achat volontaire a,mergers_acquisitions,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,15,331,0.0,0.4336088389568585,0.0036904761904761898
kraig labs otcqb kblb bam 1 spider silk hybrid strain continues to set records for silkworm size growth and robustness,kraig biocraft laboratories announces production update for bam 1 spider silk hybrids,press_releases,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,1,7,382,0.0,0.8071333009212691,0.1418939393939394
media release,valberedning utsedd inför itabs årsstämma 2025,annual_general_meeting,UP,4.240285495725315,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,11,242,0.0,0.8866002429130597,0.0
electrocore granted two new u s patents electrocore granted two new u s patents,electrocore expands intellectual property portfolio,patents,DOWN,-1.6339854003679126,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,1,8,452,0.19090909090909092,0.8324549917316175,0.0
oxurion receives transparency notification from atlas special opportunities llc,oxurion receives transparency notification from atlas special opportunities llc,major_shareholder_announcements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,12,344,0.35714285714285715,2.0692591020840054,0.14954212454212457
media release,bghl gbp nav s,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,247,0.0,0.8866002429130597,-0.006122448979591832
enea has signed a contract for traffic management for deployment with a tier one service provider in the middle east the contract value for the first year is usd 2 0 million with a potential total contract value of usd 5 5m over a period of 5 years the solution is part of the customer s mobile network modernization and enables efficient management of mobile data traffic optimization of video and enhanced quality of experience traffic management allows service providers to classify manage and accelerate network traffic which by reducing the data volume also supports service availability in the event of instability or outages in international ip links the agreement includes software licenses professional services and support software licenses corresponding to a value of usd 1 4 million are recognized in the third quarter of 2024 while remaining parts of the agreement are delivered during the coming year the contract value for the first year is usd 2 0 million with a poten,enea signs usd 2 million contract for traffic management,business_contracts,UP,0.9302361066951308,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.075,0.8866002429130597,0.0
leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational clinical and diagnostic applications of akoya s spatial biology solutions leading immunotherapy and immunobiology experts will offer strategic direction and expertise in translational clinical and diagnostic applications of akoya s spatial biology solutions,akoya biosciences announces that garry nolan ph d james allison ph d and padmanee sharma m d ph d join newly created scientific advisory board,advisory,DOWN,-1.3916534541067953,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,2,8,535,0.13636363636363635,0.8573192373918191,0.2209090909090909
meaningful improvement in overall survival os and tolerability observed in patients receiving trilaciclib in combination with a trop2 adc,meaningful improvement in overall survival os and tolerability observed in patients receiving trilaciclib in combination with a trop2 antibody drug conjugate adc,clinical_study,DOWN,-0.733501434941693,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,396,0.25,0.8866002429130597,0.025
florham park n j aug 29 2023 globe newswire celularity inc nasdaq celu celularity a biotechnology company developing allogeneic cell therapies and biomaterial products announced today a multi year research collaboration services agreement with regeneron pharmaceuticals inc regeneron to support the research of regeneron s allogeneic cell therapy candidates,celularity announces multi year research collaboration services agreement with regeneron,partnerships,UP,9.242146234319629,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,1,9,669,0.0,1.6050367793919866,0.06320461945461946
in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,clinical_study,DOWN,-1.0101000370632516,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,1,6,424,0.19318181818181818,1.2777111391401192,0.022727272727272724
media release,international petroleum corporation to release third quarter 2024 financial and operational results on november 5 2024,earnings_releases_and_operating_results,DOWN,-0.4132231404958678,17525362688.0,64661008.0,268294.15789473685,1.53,842590.0,0.0036895674658005686,0.1515999603296736,3,9,240,0.0,0.413754093849161,0.0
los angeles oct 10 2023 globe newswire renovaro biosciences inc nasdaq renb renovaro an advanced pre clinical biotechnology firm in cell gene and immunotherapy focused on solid tumors with short life expectancy is pleased to announce the appointment of leni boeren and ruud hendriks as independent directors,renovaro biosciences appoints two finance industry experts to board of directors,management_changes,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,8,627,0.11666666666666665,1.5631250973582267,0.15
media release,multiconsult asa status on share buy back,changes_in_companys_own_shares,DOWN,-0.2624671916010498,5436934656.0,19112772.0,18444.0,0.605,11946.0,0.003515358048106731,0.1515999603296736,0,7,243,0.0,0.2460638043724043,0.0
g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,conference_call_webinar,DOWN,-6.304347127506984,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,10,401,0.0,0.8866002429130597,0.03571428571428571
châtillon france may 31 2024,dbv technologies announces plan to implement ads ratio change,corporate_action,DOWN,-6.666669978035689,244630752.0,65520906.0,40445.0,0.319,55700.0,0.2678359342164799,0.09346626282280733,4,9,392,0.0,5.515503027122887,0.0
eften tähesaju tee oü finalized the transaction by which the company sold the property located at tähesaju 5 in the tähesaju retail park in lasnamäe tallinn to the as kinnisvara info earlier i e 15 08 2024 the fund announced about the sale contract under law of obligations of the property the preconditions for the closing of the transaction set forth in the sale contract under law of obligations of the property have been fulfilled including the possession of the property has been transferred to the as kinnisvara info eften tähesaju oü the subsidiary of eften real estate fund as sold the property for 4 675 thousand euros i e below the book value the fund will receive a total of 2 million euros from the transaction which will be used for new investments despite the unstable payment behavior of the tenant of the tähesaju property the fund earned ca 300 thousand euros in net cash flow from the investment since it was made in 2018 viljar arakasmember of the management boa,subsidiary of eften real estate fund as finalized the sale of a property in the tähesaju commercial area,business_contracts,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,284,0.07662337662337662,0.8866002429130597,0.0
kraig labs otcqb kblb achieved full capacity at its current production location and will open additional production facilities,kraig biocraft laboratories expands facilities to support spider silk production growth,capital_investment,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,8,362,0.11666666666666665,0.8071333009212691,0.1303503787878788
26 sep 2024 15 02 cest brie picardie crcam rapport financier semestriel 2024 la caisse régionale de crédit agricole mutuel brie picardie compte au 30 juin 2024 206 agences de proximité 1 agence gestion de la relation à distance 2 agences crédit agricole en ligne 3 agences courtiers 1 agence habitat à distance 3 agences banque privée 5 centres d affaires entreprises 3 agences collectivités publiques 3 centres d affaires professionnels de l immobilier 2 pôles institutionnels et associations 3 équipes de conseillers mobiles assurances agriculteurs et professionnels 1 plateforme front office assurances agriculteurs et professionnels 1 plateforme allocation d actifs et gestion conseillée 1 banque d affaires 1 agence evènements de la vie 85 caisses locales 18 administrateurs de la caisse régionale 859 administrateurs de caisses locales plus de 433 000 sociétaires plus de 1 1 million de clients pièce jointe rapport financier semestriel 2024 rapport,crédit agricole brie picardie rapport financier semestriel 2024,financial_results,DOWN,-0.474321679287626,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
biocardia will provide a q2 2024 corporate update and report its financial results by conference call on tuesday august 13 2024,biocardia to host q2 2024 corporate update and financial results conference call on august 13 2024,conference_call_webinar,UP,0.0,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,2,7,325,0.0,1.32107885633281,0.08538961038961039
zug switzerland june 27 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care announces in collaboration with euretina the ramin tadayoni award,oculis and euretina announces the ramin tadayoni award,contests_awards,DOWN,-0.8438850485279373,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,6,366,0.0,0.4640841922034435,0.06683501683501684
mainz biomed webinar on early detection of colorectal cancer exploring new laboratory diagnostic options,mainz biomed webinar on early detection of colorectal cancer exploring new laboratory diagnostic options,conference_call_webinar,DOWN,-5.769225478877488,5569681.0,2706585.0,75055.0,0.305,78500.0,0.48594973392551566,0.09346626282280733,0,8,467,0.11818181818181818,34.079934680222834,0.01
the following resolutions have been adopted at the extraordinary general meeting of shareholders of panevezio statybos trestas ab held on 25 september 2024 1 revocation of the resolution on election of the new member to the board of panevezio statybos trestas ab adopted at the general meeting of shareholders on 30 april 2024 to revoke the resolution on election of the new member to the board of panevezio statybos trestas ab adopted at the general meeting of shareholders on 30 april 2024 the ground for revocation of the resolution the data of the board member have not been registered with the registre of legal entities by the term established by the law 2 election of the member to the board of panevezio statybos trestas ab to elect gintautas mazeika born in 1967 as the member to the board of panevezio statybos trestas ab education finance and business administration emba participation in activities of other companies pro bro group uab svaros broliai uab an ind,resolutions of extraordinary general meeting of shareholders,management_changes,DOWN,-0.2079037244971741,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,9,275,0.16786616161616164,0.8866002429130597,0.0
palo alto calif sept 18 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced the continuing support from endeavor distribution llc endeavor on scilex s commercial products and the satisfaction of the fsf 33433 llc 10 million loan under the commitment side letter dated june 11 2024 the commitment side letter,scilex holding company announces the continuing support from endeavor distribution llc in the multi year agreement for scilex s commercial products and the satisfaction of fsf 33433 llc 10 million loan,financing_agreements,DOWN,-0.9615375798129148,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,9,283,0.275,1.0327724261931344,0.25113493566618567
media release,altrad announces waiver of minimum acceptance condition confirmation that there will be no increase in the offer price and final extension of the offer period for the recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,UP,1.9753067581741897,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,240,0.25,0.8866002429130597,0.18295959595959596
malvern pa oct 10 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines today announced that dr shankar musunuri chairman chief executive officer and co founder of ocugen will join a panel discussion during the 2024 maxim healthcare virtual summit presented by maxim group llc taking place from tuesday october 15 through thursday october 17 2024,ocugen to participate in 2024 maxim healthcare virtual summit,conference_call_webinar,UP,0.0,300821152.0,287364635.0,6243265.0,4.237,6951700.0,0.9552673842562773,0.09346626282280733,3,7,261,0.0,0.7661975315521313,0.05904713804713804
innovative design enables five minute pegfilgrastim cbqv delivery time,coherus announces u s launch of udenyca onbody a novel and proprietary state of the art delivery system for pegfilgrastim cbqv,product_services_announcement,DOWN,-2.7027002147700405,85025264.0,110892497.0,1236840.0,0.883,1425300.0,1.3042299639316615,0.09346626282280733,2,8,493,0.5,1.0144535837204522,0.0
rmat designation follows fda s review of available safety and efficacy data from the first three patients dosed with the low dose of tsha 102 across both reveal phase 1 2 trials adolescent adult and pediatric,taysha gene therapies announces regenerative medicine advanced therapy rmat designation granted by u s fda for tsha 102 in rett syndrome,clinical_study,UP,2.8925591337169574,625056704.0,136885482.0,5054745.0,1.016,2606600.0,0.21899690239943415,0.09346626282280733,3,8,422,0.23000000000000004,1.0149166236087122,0.08142857142857143
kb 7898 a p300 kat inhibitor is the company s first development candidate for autoimmune diseases and originates from its proprietary discovery engine that decodes complex transcription factor regulatory networks,kronos bio announces selection of autoimmune development candidate for sjögren s disease,product_services_announcement,UP,0.7049374916527984,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,0,8,264,-0.024999999999999994,0.6178272804340184,0.044049289188178076
positive phase 2b data announced for bnc210 on reduction of total symptom severity and multiple symptom clusters in post traumatic stress disorder ptsd with a discussion with the u s food drug administration fda anticipated in q2 24,bionomics provides a review of 2023 and of 2024 plans,clinical_study,DOWN,-4.761907645273734,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,523,0.07575757575757576,0.8866002429130597,0.03799212968368812
media release,b2 impact asa invitation to q3 2024 results on thursday 7 november,earnings_releases_and_operating_results,UP,0.0,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,8,242,0.0,0.2679946872688963,0.0
03 oct 2024 07 00 cest beerenberg as not for release publication or distribution in whole or in part directly or indirectly into or within canada australia new zealand south africa hong kong japan or any other jurisdiction in which the release publication or distribution would be unlawful 3 october 2024 reference is made to the announcement made on 4 september 2024 by beerenberg as beerenberg or the company and altrad investment authority s a s altrad or the offeror regarding the issuance of an offer document the offer document and the start of the offer period for the board recommended unregulated voluntary cash offer to acquire all outstanding shares in the company the shares not already owned by the offeror the offer the initial offer period for the offer expired at 16 30 norwegian time on 2 october 2024 the offeror hereby announces an extension of the offer period for the offer to 16 30 norwegian time on 16 october 2024,extension of offer period for altrad s recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,UP,0.7537669417370157,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,5,268,0.1457070707070707,0.8866002429130597,0.18113636363636365
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
conference call scheduled for tuesday november 14 2023 at 9 00 am et conference call scheduled for tuesday november 14 2023 at 9 00 am et,immucell to announce unaudited financial results for the quarter ended september 30 2023,earnings_releases_and_operating_results,UP,5.426360815665099,54496424.0,6007971.0,25445.0,0.306,14200.0,0.11024523370560975,0.09346626282280733,1,12,598,0.0,0.6298264199719535,0.0
topline data anticipated in late september 2024 topline data anticipated in late september 2024,windtree completes enrollment of phase 2b study of istaroxime in early cardiogenic shock,clinical_study,UP,9.242146234319629,1381404.0,3660923.0,6680965.0,0.764,1224200.0,2.6501465176009336,0.09346626282280733,2,8,297,-0.16666666666666666,2.339794177443606,0.03566181293454021
ad hoc mitteilung gemäss art 53 kr,santhera gibt die finanzergebnisse für das halbjahr 2024 bekannt und informiert über den aktuellen stand des unternehmens,financial_results,DOWN,-2.766398067949684,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,3,1,289,0.0,0.5209522992128177,0.07142857142857142
oxurion receives eur 450 000 in the framework of the atlas funding programeleventh tranche fully issued and paid up,oxurion receives eur 450 000 in the framework of the atlas funding program eleventh tranche fully issued and paid up,financing_agreements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,2,13,443,0.0,2.0692591020840054,0.0
safety transcript splicing correction and clinical outcome measures data at 5 mg kg pgn edodm1 dose level in patients from freedom dm1 clinical trial expected in 2024,pepgen announces first patient dosed in phase 1 freedom dm1 clinical trial of pgn edodm1 for myotonic dystrophy type 1 dm1,clinical_study,DOWN,-0.1508330122054487,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,0,8,558,0.075,1.4553932872573117,0.0553030303030303
media release,scana company renews frame agreement with an international rig company for subsea services,business_contracts,UP,0.653594160147165,706685568.0,252199232.0,373200.75,0.233,169690.0,0.35687616023311797,0.1515999603296736,1,15,241,0.0,0.4567925069648355,0.0
florham park n j july 27 2023 globe newswire celularity inc nasdaq celu celularity a biotechnology company developing placental derived allogeneic cell therapies and biomaterial products today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the purchase and sale of 8 571 428 shares of its class a common stock together with warrants to purchase up to 8 571 428 shares of its class a common stock at a combined purchase price of 0 35 per share and accompanying warrant together the securities pursuant to a registered direct offering resulting in total gross proceeds of approximately 3 million before deducting placement agent commissions and other estimated offering expenses the warrants will have an exercise price of 0 35 will be exercisable beginning six months after the date of issuance and will expire five years following the initial exercise date the closing of the offering and sale of the securities is expected to occur on or about july 31 2023 subject to the satisfaction of customary closing conditions,celularity inc announces 3 million registered direct offering,shares_issue,DOWN,-1.428570066179548,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,9,702,-0.09716117216117218,1.6050367793919866,0.09527777777777777
media release,stmicroelectronics annonce ses résultats financiers du troisième trimestre 2024,financial_results,DOWN,-0.689650206789829,26516213760.0,642508707.0,7578905.0,1.228,8781800.0,0.024230786220664408,0.19535099655549074,3,7,240,0.0,0.5353904422343919,-0.15
boston oct 24 2024 globe newswire x4 pharmaceuticals inc nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that it will report financial results for the third quarter ended september 30 2024 and present results from its concluded phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on wednesday november 13 2024,x4 pharmaceuticals to report third quarter 2024 financial and phase 2 chronic neutropenia study results during conference call and webcast on november 13 2024,clinical_study,DOWN,-0.5952422485284217,12503571.0,4364496.0,363495.0,0.663,396700.0,0.34905996055046995,0.09346626282280733,3,8,247,0.049999999999999996,1.4412990038402507,0.1265977961432507
media release,nanobiotix participera à plusieurs conférences investisseurs en novembre,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,8,240,0.0,0.5536010581445269,0.0
02 oct 2024 08 30 cest artmarket com ex artprice com information mensuelle relative au nombre total de droits de vote et d actions composant le capital social article l 233 8 ii du code du commerce et article 223 16 du règlement général de l amf dénomination sociale de l émetteur artmarket com domaine de la source 69270 st romain au mont d or date d arrêté des informations nombre total d actions composant le capital social nombre total de droits de vote théoriques nombre total de droits de vote réels 30 septembre 2024 6 651 515 8 759 529 8 759 529 toutes les actions de la société disposent des mêmes droits de vote à l exception des actions auto détenues qui perdent leur droit de vote et des actions détenues sous la forme nominative depuis plus de 2 ans qui bénéficient de droits de vote double a propos d artmarket com artmarket com est cotée sur eurolist by euronext paris la dernière analyse tpi comptabilise plus de 18 000 actionnaires individue,information mensuelle relative au nombre total de droits de vote et d actions composant le capital social,voting_rights,DOWN,-1.162795081790876,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.009090909090909092,0.8866002429130597,0.15625
media release,torm plc capital increase in connection with delivery of one 2015 built mr vessel,share_capital_increase,DOWN,-3.110170791459808,10941282304.0,57061410.0,376187.8888888889,-0.051,374739.0,0.005215239714556953,0.1515999603296736,0,14,242,0.0,0.4410338895373702,0.0
media release,xbrane biopharma presents nomination committee,annual_general_meeting,DOWN,-1.0548512993026444,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,239,0.0,0.8866002429130597,-0.009523809523809523
media release,programme for the acquisition of own shares of šiaulių bankas ab approved,changes_in_companys_own_shares,UP,0.7370985601597579,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,240,0.6,0.8866002429130597,0.06622013788680457
agreement will supply tb 161 for rad 602 a potential first in class radiopharmaceutical for treatment of brain cancers agreement will supply tb 161 for rad 602 a potential first in class radiopharmaceutical for treatment of brain cancers,radiopharm theranostics enters into supply agreement with terthera for terbium 161 isotope,clinical_study,UP,0.0,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,0,7,803,0.125,0.9771277191333917,0.20037878787878785
malvern pa april 29 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced the data from its phase ii iii alzheimer study of buntanetap in mild to moderate ad patients based on these data the company plans to conduct a pivotal phase iii trial in biomarker positive early ad patients,annovis bio announces statistically significant phase ii iii data in patients with early alzheimer s disease,clinical_study,DOWN,-7.103823312288768,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,0,10,424,0.2044507575757576,1.368989555493872,0.050015782828282826
new york and mainz germany august 16 2024 pfizer inc nyse pfe pfizer and biontech se nasdaq bntx biontech today announced top line results from their phase 3 clinical trial to evaluate the companies combined mrna vaccine candidate against influenza and covid 19 in healthy individuals 18 64 years of age the combination candidate consists of pfizer s mrna based influenza vaccine candidate with the companies licensed covid 19 vaccine the phase 3 trial measured two primary immunogenicity objectives immunogenicity against sars cov 2 as well as immunogenicity against influenza a and b of which one was met in a separate phase 2 trial pfizer evaluated trivalent tirv influenza mrna standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18 64 years of age the companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza b and will discuss next steps with health authorities,pfizer and biontech provide update on mrna based combination vaccine program against influenza and covid 19 in individuals 18 64 years of age,clinical_study,DOWN,-3.43839541547278,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,4,6,316,0.30727272727272725,0.5503225880253886,0.08867815055315056
company eliminates three executive officer roles and appoints new executive leadership team company eliminates three executive officer roles and appoints new executive leadership team,kronos bio implements new leadership structure to drive pipeline advancement,management_changes,UP,2.542380672253542,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,3,8,520,0.13636363636363635,0.6178272804340184,0.0
media release,resolutions of the general extraordinary shareholders meeting of invl baltic farmland,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19166666666666665,0.8866002429130597,0.19437229437229436
mainz biomed reports mid year 2024 financial results and provides corporate update,mainz biomed reports mid year 2024 financial results and provides corporate update,clinical_study,DOWN,-2.9702981009232525,5588755.0,2706585.0,75055.0,0.305,78500.0,0.48429122407405584,0.09346626282280733,0,8,250,0.0,34.079934680222834,-0.013751646903820816
transaction aligns to coherus strategic focus on oncology conference call monday january 22 2024 at 8 30 a m eastern time,coherus announces agreement to divest ophthalmology franchise to sandoz in 170 million upfront all cash deal,mergers_acquisitions,UP,9.242146234319629,85349872.0,110892497.0,1236840.0,0.883,1425300.0,1.299269634522709,0.09346626282280733,0,1,523,0.0,1.0144535837204522,0.0
copenhagen denmark july 03 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines today issued the following letter to shareholders,evaxion reinforces milestone timeline and provides shareholder update,press_releases,UP,0.0,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,2,8,360,0.0,1.4249795072460607,0.12097643097643096
in8bio announces pricing of 12 4 million private placement,in8bio announces pricing of 12 4 million private placement,financing_agreements,UP,0.0,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,1,8,270,0.0,1.2777111391401192,0.08425324675324675
nidlegy phase iii pivotal trial meets the study s primary objective for patients with locally advanced fully resectable melanoma,nidlegy phase iii pivotal trial meets the study s primary objective demonstrating statistically significant and clinically meaningful improvement in recurrence free survival for patients with locally advanced fully resectable melanoma,clinical_study,UP,1.897010621398652,926076608.0,35018869.0,31367.18181818182,0.152,19588.0,0.25000035609542787,0.09346626282280733,0,8,621,0.35227272727272724,0.3376005673725286,0.0
media release,bghl gbp nav s,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,246,0.0,0.8866002429130597,-0.005612244897959179
malvern pa sept 03 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dr shankar musunuri chairman chief executive officer and co founder of ocugen will participate in a fireside chat at the h c wainwright 26th annual global investment conference taking place from september 9 11 2024 in new york ny,ocugen to participate in a fireside chat at the h c wainwright 26th annual global investment conference,conference_call_webinar,UP,0.0,300791936.0,287364635.0,6243265.0,4.237,6951700.0,0.9553601696290156,0.09346626282280733,1,7,298,0.04545454545454545,0.7661975315521313,0.0644229797979798
châtillon france le 31 mai 2024,dbv technologies annonce son intention de modifier le ratio d ads,corporate_action,DOWN,-6.666669978035689,244630752.0,65520906.0,40445.0,0.319,55700.0,0.2678359342164799,0.09346626282280733,4,9,392,0.0,5.515503027122887,0.0
rockville md june 20 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported that its principal scientist dr matthias klein has presented results from the clinical trial for its unyvero urinary tract infection panel during asm microbe s in depth symposium session the year in clinical microbiology on june 17th in houston tx based on over 1 800 patient samples the presentation titled multi center clinical trial using a novel semi quantitative multiplex pcr based diagnostic panel for urinary tract specimens summarized the objectives of the clinical trial the unyvero uti panel coverage and result evaluation recommendations based on multiple reference testing methods applied during the study,opgen presents unyvero urinary tract infection panel trial results at asm microbe 2023 conference,clinical_study,UP,0.0,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,1,7,739,-0.05,1.807174583649316,0.09090909090909091
sydney australia march 28 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce that the company will participate in jefferies inaugural radiopharma innovation summit being held in new york city on april 3rd 2023 riccardo canevari chief executive officer and managing director of radiopharm theranostics and vittorio puppo chief operating officer will be available for 1x1 meetings,radiopharm theranostics invited to participate in jefferies radiopharma innovation summit,trade_show,DOWN,-2.85755628922936,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,1,7,823,0.2590909090909091,0.9771277191333917,0.14166666666666666
irvine calif july 01 2024 globe newswire biomerica inc nasdaq bmra a global provider of advanced medical products is proud to announce a major enhancement to its infoods ibs system aimed at simplifying and transforming the patient experience,biomerica launches at home sample collection for infoods ibs significantly expanding access for millions of ibs sufferers,product_services_announcement,DOWN,-2.272725117600642,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,0,7,362,0.2729166666666667,1.5245042583012947,0.14687826062826068
media release,successful completion of secondary placement of existing shares in schibsted asa,prospectus_announcement,DOWN,-2.9585798816568047,74326786048.0,149678416.0,815521.947368421,0.905,160075.0,0.0020137883522010243,0.1515999603296736,1,8,242,0.225,0.31528575193047,0.0
remedy entertainment plc stock exchange release september 27 2024 at 1 00 p m eest shareholders of remedy entertainment plc are summoned to the company s extraordinary general meeting which will be held on october 24 2024 starting at 09 00 a m eest at the company s office at luomanportti 3 02200 espoo finland the reception of attendees who have preregistered for the meeting will commence at 8 30 a m eest on the meeting venue the company s shareholders can use their right to vote by way of advance voting advance voting instructions can be found in section c of this notice a matters on the agenda of the extraordinary general meeting 1 opening of the meeting 2 calling the meeting to order 3 election of persons to scrutinise the minutes and to supervise the counting of votes 4 recording the legality of the meeting 5 recording the attendance at the meeting and adoption of the list of votes 6 approval of the material terms and conditions of convertible loan an,remedy entertainment plc notice to the extraordinary general meeting of remedy entertainment plc,extraordinary_general_meeting,UP,1.8028915589732963,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.1794642857142857,0.8866002429130597,0.05119047619047619
new york june 28 2024 globe newswire eyenovia inc eyenovia or the company nasdaq eyen a commercial stage ophthalmic company announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder providing for the purchase and sale of 7 575 757 shares of common stock and warrants to purchase up to 7 575 757 shares of common stock the offering the combined offering price for each share of common stock and accompanying warrant is 0 66,eyenovia announces pricing of 5m registered direct offering,shares_issue,DOWN,-3.1791844034276804,28243178.0,2433609.0,8930490.0,1.002,41800300.0,0.08616625933526319,0.09346626282280733,4,8,365,-0.0948051948051948,2.4441832149286684,0.0035227272727272724
watertown mass aug 29 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that c4t management will participate in fireside chats at two september investor conferences,c4 therapeutics to participate in upcoming september investor conferences,conference_call_webinar,UP,0.3139714487570719,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,3,7,303,0.0,0.8954742650579008,0.050615852401566686
south san francisco calif may 08 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced that management will present at the bofa securities 2024 health care conference on tuesday may 14 2024 at 5 00 p m p t in las vegas nv,akero therapeutics to present at the bofa securities 2024 health care conference,conference_call_webinar,DOWN,-2.0436001525185925,4377293312.0,65983030.0,1904080.0,-0.16,4370200.0,0.015073933889491206,0.09346626282280733,2,7,416,-0.012222222222222218,1.1395320392459187,-0.06122592592592593
istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments,windtree announces positive topline results from its phase 2b seismic extension study of istaroxime in early cardiogenic shock,clinical_study,DOWN,-6.441718980408064,1376645.0,3660923.0,6680965.0,0.764,1224200.0,2.659307955209949,0.09346626282280733,2,8,276,0.2396103896103896,2.339794177443606,0.018801106301106305
parsippany n j oct 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its third quarter financial results after the close of the u s markets on wednesday november 6 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report third quarter 2024 financial results on wednesday november 6 2024,conference_call_webinar,DOWN,-1.1641487740788885,1112970496.0,45834212.0,557500.0,0.511,435200.0,0.04118187513930288,0.09346626282280733,2,8,241,0.022727272727272724,0.7130794063724827,0.1400731339367703
publication annual report annual shareholders meeting,publication annual report annual shareholders meeting,annual_report,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,0,11,438,0.0,2.0692591020840054,0.17857142857142858
south san francisco calif may 29 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced that management will present at the jefferies global healthcare conference on wednesday june 5 2024 at 4 00 p m e t in new york ny,akero therapeutics to present at the jefferies global healthcare conference,conference_call_webinar,DOWN,-2.4102528889973955,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,2,7,395,0.007003367003367005,1.1395320392459187,-0.024357473544973543
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
arcutis will host a kol virtual event july 29 2024,arcutis to host zoryve roflumilast cream 0 fda approval call with kol,product_services_announcement,UP,1.4359009571564505,1723660928.0,85869346.0,2010100.0,1.778,2359700.0,0.0498180034165049,0.09346626282280733,0,8,341,0.0,0.6903751128737089,0.08476831810165143
san francisco may 15 2023 globe newswire vir biotechnology inc nasdaq vir today announced the appointment of jeff calcagno m d as executive vice president and chief business officer dr calcagno will be responsible for leading the company s business development efforts optimizing existing alliances and establishing new strategic industry and public private partnerships he reports to vir s chief executive officer marianne de backer m sc ph d mba and joins vir s executive management team,vir biotechnology appoints jeff calcagno m d as executive vice president and chief business officer,management_changes,UP,0.202508043657502,702249024.0,93935488.0,1328370.0,1.229,971400.0,0.13376378576497672,0.09346626282280733,0,8,775,0.08409090909090909,0.8653389999075153,0.16477272727272727
saint herblain france and schlieren zurich august 1 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company and limmatech biologics ag a clinical stage biotech company developing vaccines for the prevention of life threatening diseases today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development manufacturing and commercialization of shigella4v s4v a tetravalent bioconjugate vaccine candidate against shigellosis,valneva and limmatech enter into a strategic partnership to accelerate the development of the world s most clinically advanced tetravalent shigella vaccine candidate,licensing_agreements,DOWN,-1.4966004753969215,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,331,0.45,0.6494694268312979,0.06944444444444443
guggenheim s inaugural healthcare innovation conference nov 11 13,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,3,240,0.0,0.5536010581445269,0.0
media release,ab akola group s notification about the annual information for the financial year 2023 2024,financial_results,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.06441783324900209
27 sep 2024 17 45 cest aventador résiliation du contrat de liquidité contracté avec tsaf et nouveau code mnémonique paris le 27 09 2024 à 17 45 aventador euronext growth paris ticker alave isin fr001400iv58 société de portefeuille cotée sur le marché euronext growth a résilié en date du 23 septembre 2024 le contrat de liquidité confié le 25 novembre 2021 à la société tsaf tradition securities and futures les moyens suivants figuraient au compte de liquidité au 23 09 2024 après bourse 0 actions aventador 21 145 28 les moyens suivants figuraient au compte de liquidité au 30 06 2024 lors du bilan semestriel du contrat de liquidité 306 618 actions algreen 18 832 81 il est rappelé que lors de la mise en œuvre du contrat le 25 11 2021 les moyens suivants figuraient au compte de liquidité 25 000 00 aventador annonce le changement de son code mnémonique sur le marché euronext growth paris le nouveau code mnémonique d aventador est dorénavant ala,résiliation du contrat de liquidité contracté avec tsaf et nouveau code mnémonique,exchange_announcement,UP,6.666663044856685,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,273,0.0,0.8866002429130597,0.0
new york june 28 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough therapies in neurodegenerative disease secondary to active neuroinflammatory processes today announced that it had received non dilutive funding of 3 4 million and issued a corporate update video available here,tiziana receives 3 4 million in non dilutive funding,financing_agreements,UP,4.545457008456409,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,4,11,364,0.020606060606060607,1.1109140250580023,0.03841229757896425
media release,nytt antal aktier och röster i itab shop concept ab publ,changes_in_share_capital_and_votes,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.012500000000000004
lynx 2 follows spa agreement with fda,first patient enrolled in lynx 2 phase 3 study evaluating phentolamine ophthalmic solution 0 ps for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery,clinical_study,DOWN,-2.7173951423122418,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,10,442,0.041666666666666664,0.8866002429130597,-0.02689548546691404
enlight research updated its analysis of invl technology a company that invests in it businesses following the publication of operating results for the first half of 2024 the report also sketches possible scenarios for the sale of invl technology invl technology s shares have appreciated sharply on expectations that its calculated net asset value will be confirmed when the company divest exits holding companies we expect the first exit to take place before the end of the year and the proceeds to be promptly distributed to shareholders enlight research analyst mattias wallander says when describing one of the scenarios invl technology owns and manages the cybersecurity company nrd cyber security the govtech company nrd companies and the baltic it company novian the company that invests in it businesses announced that its equity and net asset value were both eur 43 95 million at the end of june 2024 or eur 3 6658 per share in mid march this year the company announced th,enlight research sketches possible scenarios for sale of invl technology,research_analysis_and_reports,UP,0.621117414559334,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,6,282,0.06736111111111111,0.8866002429130597,0.2857142857142857
kraig labs otcqb kblb completes second expansion wave and transitioning spider silk manufacturing operations to its new larger production center,kraig biocraft laboratories completes new production center expands capacity more than eightfold,capital_investment,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,292,0.08181818181818182,0.8071333009212691,0.12495490620490621
new haven conn july 30 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that it will release its second quarter 2024 financial results on tuesday august 6 2024 before the open of the u s financial markets the company s management team will also host a conference call and webcast at 8 00 am et that day to discuss these results and provide a general business update,bioxcel therapeutics to report second quarter 2024 financial results on august 6 2024,earnings_releases_and_operating_results,DOWN,-0.8547000709448132,12717704.0,5544250.0,450810.0,-0.13,78500.0,0.4359474005685303,0.09346626282280733,1,7,333,-0.04595959595959595,1.4586588351104455,0.033181096681096686
redwood city calif april 24 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced the first presentation of clinical data for chs 114 a highly selective cytolytic anti ccr8 antibody at the upcoming asco annual meeting which will be held from may 31 to june 4 2024 at mccormick place in chicago,coherus announces presentation at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-7.103823312288768,84909328.0,110892497.0,1236840.0,0.883,1425300.0,1.306010771867138,0.09346626282280733,2,10,429,0.1366666666666667,1.0144535837204522,0.23249999999999998
jupiter fla and bunnik the netherlands feb 28 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health today announced its dutch subsidiary dyadic nederland bv has entered into a strategic partnership agreement and collaboration with rabian bv rabian a dutch innovative sme founded by experienced entrepreneurs and vaccine scientists the aim is to develop highly efficacious scalable and affordable rabies prophylactics and vaccines utilizing dyadic s c1 protein production platform this collaboration seeks to address the global burden of rabies a disease that annually claims tens of thousands of lives,dyadic announces strategic partnership agreement to develop affordable rabies prophylactics and vaccines using its proprietary c1 cell microbial protein production platform,partnerships,DOWN,-0.7042247017941755,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,486,0.26681818181818184,0.7846450948942033,0.07878787878787878
jerusalem march 04 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides announced today that it received notice from the nasdaq stock market llc nasdaq on march 1 2024 informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550 a 2 the rule for continued listing on the nasdaq capital market and the matter is now closed,entera bio regains compliance with nasdaq minimum bid price requirement,exchange_announcement,UP,3.47221877287949,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,0,8,481,-0.1,0.6915109749530333,0.07184214594928881
mainz germany october 21 2024 globe newswire biontech se nasdaq bntx biontech or the company will announce its financial results for the third quarter 2024 on monday november 4 2024 additionally the company will host a conference call and webcast that day at 8 00 a m et 2 00 p m cet for investors financial analysts and the general public to discuss its financial results and provide a corporate update,biontech to report third quarter 2024 financial results and corporate update on november 4 2024,clinical_study,DOWN,-0.1699873111909098,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,250,0.005000000000000002,0.5503225880253886,0.004198532948532951
media release,delfingroup raises 4 9 million euros from citadele bank for business development,clinical_study,DOWN,-0.3745270276379158,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,249,0.0,0.8866002429130597,0.17936109212425003
tel aviv israel and miami jan 31 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention carotid stent system eps for the prevention of stroke today announced that it has received ce mark recertification under the european union s new medical device regulation mdr regulatory framework mdr replaced the previous mdd framework which had governed the approval and marketing of medical devices in the eu until may of 2021,inspiremd receives ce mark recertification under eu s new medical device regulation mdr regulatory framework,regulatory_filings,DOWN,-0.3389827220887212,65865896.0,16849440.0,286250.0,0.613,4867100.0,0.2558143291636084,0.09346626282280733,2,7,514,0.01515151515151515,0.6085732039686736,0.10213636363636362
statistically significant week 96 results from the phase 2b harmony study of efx in patients with pre cirrhotic mash reported during the first quarter of 2024 phase 3 synchrony histology and synchrony real world studies in patients with pre cirrhotic mash f2 f3 continue to enroll synchrony outcomes study in patients with compensated cirrhosis due to mash f4 on track to be initiated in second quarter of 2024,akero therapeutics reports first quarter 2024 financial results and provides business update,clinical_study,UP,2.6442363681879915,4379286528.0,65983030.0,1904080.0,-0.16,4370200.0,0.015067073044461,0.09346626282280733,4,7,414,0.1357142857142857,1.1395320392459187,-0.04722486772486772
conference call to begin at 4 30 p m et,vaxart to host second quarter 2024 business update and financial results conference call on august 8,conference_call_webinar,DOWN,-1.515159040990203,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,330,0.0,1.025768835125998,0.08874458874458874
infusion related reactions in patients receiving 30 minute briumvi infusions were all mild grade 1 and resolved completely,new briumvi ublituximab xiiy data from the enhance phase 3b study show rapid 30 minute infusions are well tolerated in patients with relapsing forms of multiple sclerosis,clinical_study,UP,4.66507208872852,5897748992.0,135060602.0,1756590.0,1.939,1677400.0,0.022900364559970746,0.09346626282280733,2,7,283,0.11393939393939394,0.6256004090066075,0.050606697224344285
inside information valmet to supply a complete pulp mill with full scope automation and flow control solutions to arauco in brazil valmet oyj s stock exchange release inside information on september 25 2024 at 01 45 a m eest the board of directors of arauco have today approved an investment of a complete pulp mill and selected valmet as the supplier for the project valmet s scope will be the delivery of complete pulp mill including also full scope automation and flow control solutions to arauco the new pulp mill will be the world s largest single phase pulp mill project with 3 5 million tonne per year pulp production capacity the new mill is estimated to start up in the second half of 2027 the pulp mill will be built in inocência in the state of mato grosso do sul brazil the contract is estimated to be finalized by the end of 2024 the value of the order for valmet is over eur 1 billion and it is expected to be included in valmet s orders received for the fourth quart,inside information valmet to supply a complete pulp mill with full scope automation and flow control solutions to arauco in brazil,business_contracts,UP,8.428963680972963,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,0,276,0.09890228818800244,0.8866002429130597,0.0
phase 2 open label connect1 edo51 study open in canada,pepgen reports second quarter 2023 financial results and recent corporate developments,clinical_study,DOWN,-0.2000045776367187,45482052.0,12870456.0,168500.0,1.294,155200.0,0.28297878908365875,0.09346626282280733,1,8,690,0.0,1.4553932872573117,0.0
durham n c may 06 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale will release its financial results for the first quarter ended march 31 2024 on friday may 10 2024 management will host a webcast and conference call at 8 00 a m et to provide a corporate and financial update,humacyte to present first quarter financial results and provide corporate update on may 10 2024,earnings_releases_and_operating_results,UP,2.040819857186725,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,0,8,418,0.045454545454545456,1.1173068527438073,0.03333333333333333
first two subjects dosed in phase 1 clinical trial of zkn 013 zkn 013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations,eloxx pharmaceuticals provides pipeline and financing updates,clinical_study,UP,0.0,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,3,11,351,0.10499999999999998,2.2721670857062097,0.07032498453927026
san diego and suzhou china oct 09 2024 globe newswire adagene inc adagene nasdaq adag a company transforming the discovery and development of novel antibody based therapies today announced poster presentations at the upcoming sitc 39th annual meeting taking place in houston nov 6 10 2024,adagene announces upcoming poster presentations on masked anti ctla 4 safebody adg126 muzastotug at society for immunotherapy of cancer sitc 39th annual meeting,clinical_study,DOWN,-3.9946135377027217,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,2,6,262,0.0,0.845882180665701,0.12332057823129253
farmington hills mich may 10 2024 globe newswire ocuphire pharma inc nasdaq ocup a clinical stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders today announced financial results for the first quarter ended march 31 2024 and provided a corporate update,ocuphire pharma announces financial results for first quarter 2024 and provides corporate update,financial_results,UP,2.55101792567082,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,414,0.03571428571428571,0.8866002429130597,-0.011601345083487943
media release,pareto bank asa vurderer utstedelse av senior preferred obligasjonslån,financing_agreements,DOWN,-0.9077132949647496,6372872704.0,46145176.0,38558.55,0.663,36744.0,0.007240875213314162,0.1515999603296736,0,11,242,0.0,0.2272865108365386,0.0
eyenovia is planning for a u s launch for clobetasol in late september 2024 eyenovia is planning for a u s launch for clobetasol in late september 2024,eyenovia announces taiwan export license approval to commence shipment of clobetasol propionate ophthalmic suspension 0 to the u s,licensing_agreements,UP,2.04082332264615,27588490.0,2433609.0,8930490.0,1.002,41800300.0,0.08821102568498675,0.09346626282280733,3,7,296,-0.3,2.4441832149286684,0.011924880674880678
company announcementfor rockwool a srelease no 55 2024to nasdaq copenhagen 2 october 2024 rockwool a s transactions in connection with share buy back programme as mentioned in announcement no 02 2024 rockwool a s has initiated a share buy back programme which will run from 8 february 2024 until 7 february 2025 during this period the company will buy own shares for up to a maximum of 160 meur the programme is implemented in accordance with eu commission regulation no 596 2014 of 16 april 2014 and eu commission delegated regulation no 2016 1052 of 8 march 2016 which together constitute the safe harbour regulation the following transactions have been executed during the period 25 september 1 october 2024 with the transactions stated above rockwool a s owns 375 483 b shares corresponding to 1 74 percent of the company s total share capital an overview showing the transaction data for the period 25 september 1 october 2024 is enclosed further information,rockwool a s transactions in connection with share buy back programme,changes_in_companys_own_shares,DOWN,-1.8770226537216828,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.12222222222222223,0.8866002429130597,0.0
london vereinigtes königreich 1 oktober 2024 globe newswire biontech se nasdaq bntx biontech oder das unternehmen gibt heute zusammen mit ihrem tochterunternehmen für künstliche intelligenz artificial intelligence ai instadeep ltd instadeep einen einblick in die anwendung von ai dies findet im rahmen des ai day statt der teil der innovation series des unternehmens ist,biontech stellt auf dem ersten ai day ihre fähigkeiten im bereich künstliche intelligenz und deren anwendung in der forschung und entwicklung vor,press_releases,UP,0.9598442799227952,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,1,6,270,-0.6,0.5503225880253886,0.07133170327614773
lawrenceville n j may 15 2024 globe newswire imunon inc nasdaq imnn a clinical stage drug development company focused on developing non viral dna mediated immunotherapy and next generation vaccines announces that an abstract describing a phase 2 study with imnn 001 plus bevacizumab avastin and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the american society of clinical oncology asco annual meeting to be held in chicago from may 31st to june 4th,abstract on phase 2 study with imunon s imnn 001 plus bevacizumab accepted for presentation at the american society of clinical oncology annual meeting,clinical_study,DOWN,-1.4814800424667631,17677966.0,12808492.0,12655315.0,2.143,945100.0,0.7245455727203005,0.09346626282280733,2,8,409,0.1,2.964855117372811,0.04996843434343434
new york sept 27 2024 globe newswire eyenovia inc nasdaq eyen eyenovia or the company an ophthalmic technology company with two fda approved products and a late stage asset in development for the treatment of pediatric progressive myopia today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8 695 653 shares of its common stock or common stock equivalents in lieu thereof and warrants to purchase up to an aggregate of 8 695 653 shares of common stock in a registered direct offering at a combined offering price of 0 46 per share and accompanying warrant the warrants have an exercise price of 0 50 per share will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date the closing of the offering is expected to take place on or about september 30 2024 subject to the satisfaction of customary closing conditions,eyenovia inc announces pricing of 4 million registered direct offering,financing_agreements,DOWN,-4.967603008863069,27747046.0,2433609.0,8930490.0,1.002,41800300.0,0.08770695806681547,0.09346626282280733,4,8,274,-0.11303030303030304,2.4441832149286684,-0.00017015392015391485
oslo norway 12 may 2023 pci biotech ose pcib today announces its interim q1 2023 results please find enclosed the report and presentation,pci biotech interim q1 2023 results,financial_results,UP,5.316972081561827,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,4,1,778,0.0,0.8869841129646596,0.02500000000000001
news release regulated informationdecember 18 2023 1 00 am et 07 00 am cet,mdxhealth announces completion of transition to single listing on nasdaq,exchange_announcement,DOWN,-1.5337408730844513,110873952.0,35018869.0,71620.0,-490677.56,106500.0,0.3158439684733164,0.09346626282280733,0,1,558,-0.07142857142857142,0.6181119561491973,0.1517857142857143
through selective inhibition of proinflammatory transcription p300 kat inhibition modulates the activity and function of multiple pro inflammatory signaling pathways that drive chronic inflammatory diseases,kronos bio to present data at acr convergence 2024 to support p300 kat inhibition as an approach to anti inflammatory therapy,clinical_study,UP,2.999997138977051,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,2,8,276,0.0,0.6178272804340184,0.049555450336700335
new york sept 19 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the national institutes of health nih national institute on aging have awarded a 4 million grant to dr howard weiner as principal investigator at brigham and women s hospital to be the key research site to study nasal anti cd3 for the treatment of alzheimer s disease ad this significant grant will fund a key research study over the next several years advancing preclinical and ultimately clinical studies of intranasal anti cd3 as a potential treatment for this devastating neurodegenerative condition,tiziana life sciences announces 4 million grant awarded by national institutes of health to study anti cd3 in alzheimer s disease,clinical_study,UP,0.93457850215429,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,3,7,282,-0.048863636363636366,1.1109140250580023,0.06117061552545424
company plans to complete rolling bla submission by end of 2024 application may be eligible for priority review by fda,capricor therapeutics announces initiation of rolling submission of biologics license application bla with u s fda for deramiocel for the treatment of duchenne muscular dystrophy,regulatory_filings,UP,1.2933264406969984,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,2,9,262,0.1,1.3427880947904531,0.11897276334776337
san diego aug 26 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that company leadership will participate in the h c wainwright 26th annual global investment conference september 9 11 2024,biora therapeutics to present at h c wainwright 26th annual global investment conference,conference_call_webinar,UP,1.769909761735451,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,306,0.0,1.027516639474094,0.08061147186147186
webinar to focus on a nephrologist s perspective on the use of furoscix for fluid overload in heart failure and potential use in chronic kidney disease webinar to focus on a nephrologist s perspective on the use of furoscix for fluid overload in heart failure and potential use in chronic kidney disease,scpharmaceuticals to host key opinion leader kol webinar on october 22 2024,conference_call_webinar,DOWN,-0.4728127857288839,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,1,8,256,-0.09047619047619047,0.7082528246818063,-0.02412281295093794
woburn mass march 26 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today reported that the plant biosafety office pbo of the canadian food inspection agency cfia recently reviewed information on the company s e3902 camelina sativa camelina and determined that e3902 is not a plant with novel trait pnt and is not subject to a pre market notification under part v of the seeds regulations yield10 s e3902 camelina combines genome edits in three proprietary genetic traits c3008a c3008b and c3009 that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental camelina line e3902 camelina remains subject to other applicable requirements of the seeds act and regulations in canada,yield10 bioscience announces that the plant biosafety office of the canadian food inspection agency has cleared genome edited e3902 camelina for planting in canada,regulatory_filings,DOWN,-2.7777860562003345,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,459,-0.05208333333333333,0.8866002429130597,0.05413919413919414
ad hoc announcement pursuant to art 53 lr,addex convenes annual general meeting 2024,annual_general_meeting,UP,7.174891679918677,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,388,0.05000000000000002,0.972373032385036,-0.009642857142857142
media release,immutep announces successful meeting with fda on phase iii design in non small cell lung cancer,clinical_study,DOWN,-1.546396377020874,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,0,8,341,0.25,0.7476881311953882,0.13938620902906618
media release,announcement of the net asset value of invl technology as of 30 september 2024,fund_data_announcement,UP,1.657463621407091,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,9,240,0.0,0.8866002429130597,0.1518308080808081
media release,sampo plc s share buybacks 28 october 2024,changes_in_companys_own_shares,UP,0.6596639524811563,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,0.031961805555555556
special closed ended type private equity investment company invl technology legal entity code 300893533 the registered address gyneju str 14 vilnius lithuania hereinafter the company or invl technology informs that on the initiative and decision of the management company invl asset management uab hereinafter the management company the general extraordinary shareholders meeting hereinafter the meeting is to be held on 21 october 2024 the place of the meeting the office of company the address gyneju str 14 vilnius the meeting will start at 09 00 a m registration starts at 08 45 a m the meeting s accounting day 14 october 2024 the persons who are shareholders of the company at the end of accounting day of the meeting or authorized persons by them or the persons with whom shareholders concluded the agreements on the disposal of voting right shall have the right to attend and vote at the meeting the total number of shares of the company is 12 175 321 unit,convocation of the general extraordinary shareholders meeting of invl technology and draft resolutions on agenda issue,voting_rights,DOWN,-0.5813947847045612,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.16320346320346318,0.8866002429130597,0.1765376984126984
clinical trial demonstrates the ability of nvns to accelerate sensorimotor learning in usaf simulator based pilot training clinical trial demonstrates the ability of nvns to accelerate sensorimotor learning in usaf simulator based pilot training,study suggests non invasive vagus nerve stimulation nvns is effective in accelerating united states air force pilot training,clinical_study,UP,0.49422952426343,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,1,8,291,0.6,0.8324549917316175,0.12672567511853225
tampa fla july 23 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its second quarter financial results after the close of the u s markets on tuesday july 30 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report second quarter 2024 financial results on tuesday july 30 2024,conference_call_webinar,DOWN,-0.3463616922080888,1112470400.0,45834212.0,557500.0,0.511,435200.0,0.041200387893466646,0.09346626282280733,1,8,340,0.022727272727272724,0.7130794063724827,0.1496315836940837
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,-0.2
media release,vistin pharma asa third quarter and ytd 2024 financial results,financial_results,UP,3.053432113605758,1108615040.0,23746972.0,16660.55,0.728,37366.0,0.021420394946112222,0.09346626282280733,3,7,240,0.0,0.2967357847083616,0.0
nordecon as together with its subsidiary eurocon ukraine tov as joint bidders and the estonian centre for international development estdev have signed a construction contract for the reconstruction of a building into an apartment complex for internally displaced persons in ovruch zhytomyr oblast ukraine the contract value is 1 8 million euros plus vat and the construction period is 275 days nordecon www nordecon com is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment geographically the group operates in estonia ukraine and sweden the parent of the group is nordecon as a company registered and located in tallinn estonia the consolidated revenue of the group in 2023 was 278 million euros currently nordecon group employs 430 people since 18 may 2006 the company s shares have been quoted in the main list of the nasdaq tallinn stock exchange andri hõbemäginordeco,construction contract apartment building in ovruch ukraine,business_contracts,UP,1.2048243447951394,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,282,-0.013888888888888886,0.8866002429130597,0.0
sydney australia march 28 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce that the company will participate in jefferies inaugural radiopharma innovation summit being held in new york city on april 3rd 2023 riccardo canevari chief executive officer and managing director of radiopharm theranostics and vittorio puppo chief operating officer will be available for 1x1 meetings,radiopharm theranostics invited to participate in jefferies radiopharma innovation summit,trade_show,DOWN,-2.85755628922936,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,1,7,823,0.2590909090909091,0.9771277191333917,0.14166666666666666
san diego aug 28 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that the company s management will provide a corporate update at the h c wainwright 26th annual global investment conference to be held september 9 11 2024,bioatla to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.117317394007622,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,2,8,304,-0.022222222222222223,1.087702859114621,0.015315355940355942
this announcement does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas šiaulių bankas has successfully placed eur 50 million issue of fixed rate reset perpetual additional tier 1 temporary write down notes the annual fixed rate coupon on the notes up to the reset date will be 8 75 the nearest reset date is set after 5 years settlement will take place on 17 october 2024 it is intended to list the notes on the global exchange market multilateral trading facility operated by euronext dublin the notes have been allocated to almost 20 institutional and professional investors mostly from uk we have made another significant step for both the bank and the lithuanian capital market being the first issuer in the country to issue at1 notes we are grateful to our international investors who consistently show confidence in the bank s prospects this is,šiaulių bankas has successfully placed eur 50 million note issue on the international market,financing_agreements,DOWN,-0.3694533820828873,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,256,0.22281746031746036,0.8866002429130597,0.043625841750841755
petach tikva israel feb 28 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that company management will participate in a fireside chat at the barclays 26th annual global healthcare conference taking place in miami beach fl march 12 14 2024,polypid to participate in barclays 26th annual global healthcare conference,conference_call_webinar,UP,9.223746543148277,37239588.0,4610773.0,1395250.0,1.25,337200.0,0.12381374895984348,0.09346626282280733,2,7,486,-0.09999999999999999,0.7168605096826995,-0.061201814058956916
woburn mass may 01 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today announced that it will effect a 1 for 24 reverse stock split of its common stock following stockholder approval of the reverse stock split at its special stockholder meeting held on april 26 2024 the 1 for 24 reverse stock split will be effective as of 5 00 p m eastern time after the close of trading on the nasdaq capital market on thursday may 2 2024 and the company s common stock will begin trading on a split adjusted basis on friday may 3 2024,yield10 bioscience announces 1 for 24 reverse stock split,reverse_stock_split,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,423,0.07142857142857142,0.8866002429130597,0.039976190476190485
ad hoc announcement pursuant to art 53 lr,addex enters into at the market ads offering agreement with h c wainwright co llc,financing_agreements,DOWN,-1.563938160843887,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,514,0.0,0.972373032385036,-0.23333333333333328
rockaway n j june 06 2024 globe newswire electrocore inc nasdaq ecor electrocore or the company a commercial stage bioelectronic medicine and wellness company today announced the closing of its previously announced registered direct offering of 225 000 registered pre funded warrants to purchase shares of common stock the registered pre funded warrants to an institutional accredited investor the concurrent private placement of unregistered common stock warrants to purchase up to 112 500 shares of common stock to the investor and the separate private placement of an aggregate of 1 208 310 shares of common stock or pre funded warrants to purchase common stock and common stock warrants to purchase up to an aggregate of 604 150 shares of common stock to certain institutional and accredited investors and directors and officers of the company,electrocore inc announces closing of 9 3 million registered direct offering and concurrent private placements priced at market under nasdaq rules,warrants_and_certificates,UP,1.2066353291880865,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,3,8,387,-0.12349206349206351,0.8324549917316175,0.146010101010101
new york march 05 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced that dr howard weiner will present positive data of intranasal anti cd3 monoclonal antibody in models of alzheimer s and parkinson s disease at ad pd march 5 9 2024 ad pd is the annual international conference on alzheimer s and parkinson s diseases and related neurological disorders in lisbon portugal,tiziana life sciences announces podium presentation at ad pd of nasal anti cd3 in alzheimer s disease,clinical_study,DOWN,-2.127657550770317,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,7,480,0.07272727272727272,1.1109140250580023,0.05000000000000001
125 million of non dilutive capital extends projected cash runway into late 2025 excluding expected commercial sales from xolremdi mavorixafor,x4 pharmaceuticals announces 125 million capital infusion from 105 million sale of priority review voucher and 20 million drawdown from existing loan facility,financing_agreements,UP,0.9615375798129148,12503571.0,4364496.0,363495.0,0.663,396700.0,0.34905996055046995,0.09346626282280733,3,6,415,-0.13333333333333333,1.4412990038402507,0.14583333333333331
la jolla calif march 12 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova s collaborator perenlei enkhbaatar md phd faha professor department of anesthesiology director translational intensive care unit charles robert allen professor in anesthesiology university of texas medical branch presented new data and results of a nonclinical study evaluating mn 166 ibudilast in a chlorine gas induced acute lung injury ciali model at the society of toxicology sot 63rd annual meeting and toxexpo in salt lake city utah,medicinova announces new data and results of mn 166 ibudilast in chlorine gas induced acute lung injury presented at the 63rd annual meeting of the society of toxicology,clinical_study,UP,2.1739109777848307,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,473,0.21038961038961038,0.8018560055721619,0.06439393939393939
summary highlights including post period events,faron reports half year financial results january 1 june 30 2023,financial_results,DOWN,-0.5347588469389063,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,0,669,-0.08333333333333333,0.7633342480324978,0.0
metsä board oyj pörssitiedote muutokset hallitus johto tilintarkastus 4 10 2024 klo 9 00 di laura remes on nimitetty metsä board oyj n liiketoiminnan kehitysjohtajaksi ja johtoryhmän jäseneksi remes siirtyy metsä boardiin upm ltä jossa hän on työskennellyt erilaisissa liiketoiminnan kehitys ja johtotehtävissä hän aloittaa tehtävässään myöhemmin täsmennettävänä ajankohtana ja tulee raportoimaan toimitusjohtaja mika joukiolle metsä boardin kehityksestä vastaavan markku leskelän vastuualue sisältää jatkossa tuotekehityksen ja vastuullisuuden kun remes aloittaa uudessa tehtävässään metsä boardin johtoryhmään kuuluvat toimitusjohtaja mika joukio talousjohtaja henri sederholm tuotekehitys ja vastuullisuusjohtaja markku leskelä myynti ja toimitusketjujohtaja jussi noponen tuotanto ja teknologiajohtaja harri pihlajaniemi liiketoiminnan kehitysjohtaja laura remes myöhemmin täsmennettävästä ajankohdasta alkaen sekä henkilöstöjohtaja camilla wikström metsä board oyj lisätieto,laura remes on nimitetty metsä boardin liiketoiminnan kehitysjohtajaksi ja johtoryhmän jäseneksi,management_changes,UP,0.0798664124754002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,0.0,0.8866002429130597,0.0
media release,the goldman sachs group inc disclosure in borr drilling limited,clinical_study,UP,2.4485798602961446,445090784.0,174743108.0,6645095.0,1.794,4344400.0,0.39260104743035973,0.1515999603296736,4,8,246,-0.07142857142857142,0.6240735767174858,0.09404761904761905
oslo norway 12 february 2024 pci biotech ose pcib invites to a webcast presentation of the company s second half 2023 interim report on wednesday 14 february 2024 08 30am 09 30am cet local time,pci biotech invitation to second half interim 2023 results presentation,interim_information,DOWN,-4.176905875277916,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,0,3,502,-0.06666666666666667,0.8869841129646596,0.009773662551440335
novaturas group the largest tour operator in the baltic states announces its summer holiday programme for 2025 the company operating in this market for the longest period presenting its 26th summer season will continue to offer the widest range of leisure and sightseeing trips in the region with the launch of the 2025 summer travel programme we invite customers to choose from a wide range of flights and hotels as well as to use extra benefits we offer both the most popular holiday destinations and those that have been rediscovered and established in recent years we monitor our customers preferences and strive to ensure that we offer the destinations with the greatest potential in addition as the leader in the baltic tourism market we are always looking for new experiences and benefits to motivate our customers to plan their holidays in advance and to give us a competitive advantage as a company says kristijonas kaikaris ceo of novaturas group lithuanian travellers,novaturas presents next summer destinations and the widest range of travels in the region,product_services_announcement,UP,0.310558707279667,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,283,0.23737373737373735,0.8866002429130597,0.0
san diego oct 09 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced it will host a virtual r d event for the investment community on rosnilimab a pd 1 agonist antibody at 4 15pm et 1 15pm pt on wednesday oct 25,anaptys to provide overview of rosnilimab a pd 1 agonist at virtual r d event on wednesday oct 25,conference_call_webinar,UP,6.077922474254261,687209856.0,17605381.0,784220.0,-0.266,445700.0,0.02561863868262099,0.09346626282280733,0,8,628,0.5,0.871343469962729,0.26581595172504263
new york und mainz deutschland 27 juni 2024 pfizer inc nyse pfe pfizer und biontech se nasdaq bntx biontech gaben heute bekannt dass der ausschuss für humanarzneimittel committee for medicinal products for human use chmp der europäischen arzneimittel agentur european medicines agency ema eine positive beurteilung für die marktzulassung marketing authorization des an omikron jn 1 angepassten monovalenten covid 19 impfstoffs comirnaty jn 1 der unternehmen für die aktive immunisierung zur vorbeugung von covid 19 verursacht durch sars cov 2 bei personen ab 6 monaten ausgesprochen hat die anpassung basiert auf der empfehlung der technischen beratungsgruppe für die zusammensetzung von covid 19 impfstoffen technical advisory group on covid 19 vaccine composition der weltgesundheitsorganisation world health organization who und der notfall taskforce emergency task force etf der ema die vorschlagen covid 19 impfstoffe zu aktualisieren um die sars cov 2 variante jn 1 für die impfkampagne 2024 2025 abzudecken die notfall taskforce erklärte es gibt hinweise darauf dass eine anpassung an jn 1 ausreichend ist um die wirksamkeit der impfstoffe gegen das sich fortlaufend weiterentwickelnde sars cov 2 aufrechtzuerhalten 1 2,pfizer und biontech erhalten positive chmp empfehlung für an omikron jn 1 angepassten covid 19 impfstoff in der europäischen union,regulatory_filings,DOWN,-2.6051151795463814,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,3,10,365,0.0984848484848485,0.5503225880253886,0.08888888888888889
media release,résultats semestriels 2024 et point sur les activités opérationnelles,financial_results,UP,1.0344874539926634,12196446.0,85702564.0,176590.63636363635,1.101,385968.0,7.0268473291317814,0.1515999603296736,3,8,240,0.0,0.8249974782717295,0.0
herbicide tolerance is critical to planting the camelina crop on large acreage for the biofuel and omega 3 oil markets herbicide tolerance is critical to planting the camelina crop on large acreage for the biofuel and omega 3 oil markets,yield10 bioscience reports that proprietary varieties of winter camelina show tolerance to commonly used herbicides in first field tests,product_services_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,485,0.0630952380952381,0.8866002429130597,0.051928571428571435
media release,steady growth for europris and öob integration proceeding according to plan,earnings_releases_and_operating_results,DOWN,-4.728297171868995,13779245056.0,131827655.0,273180.35,0.452,163716.0,0.009567117390266406,0.1515999603296736,3,7,240,0.16666666666666666,0.23704210464472134,0.0
new york sept 11 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions today announced the promotion of meg alexander to president and chief operating officer coo alexander will work in collaboration with ovid s leadership team to advance ovid s development pipeline of potential disease halting neurotherapeutics and define and execute its go forward strategy,meg alexander takes on expanded role as president and coo at ovid therapeutics strengthening leadership for future growth,management_changes,DOWN,-0.9009000301245093,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,2,8,290,0.10909090909090909,0.7642184815786688,0.16151641648394893
durham n c oct 08 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale announced that its late breaking abstract on the v007 phase 3 clinical trial of the acellular tissue engineered vessel atev in arteriovenous access for patients with end stage renal disease was accepted for an oral presentation at the american society of nephrology s asn kidney week 2024 the late breaking abstract titled prospective randomized trial of humacyte s acellular tissue engineered vessel versus autologous arteriovenous fistula for hemodialysis access will be presented at the asn meeting in san diego on october 26 2024,humacyte late breaking abstract accepted for oral presentation on v007 phase 3 av access clinical trial at the american society of nephrology s kidney week 2024,clinical_study,UP,0.0,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,1,8,263,-0.11249999999999999,1.1173068527438073,0.058378051346801345
media release,the goldman sachs group inc disclosure in norwegian air shuttle asa,company_regulatory_filings,DOWN,-0.3354173423953867,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,3,7,240,0.0,0.4683640137646959,0.03125
miami may 16 2024 globe newswire fortress biotech inc nasdaq fbio fortress an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long term value for shareholders through product revenue equity holdings and dividend and royalty revenue today announced that lindsay a rosenwald m d chairman president and chief executive officer will participate in a fireside chat at the alliance global partners a g p virtual healthcare company showcase on tuesday may 21 2024 at 4 20 p m et,fortress biotech to participate in the alliance global partners a g p virtual healthcare company showcase,conference_call_webinar,UP,0.5747120924395414,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,3,8,408,0.1125,0.6928276660424207,0.09430014430014429
new york june 06 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced the qualitative results for all 10 non active secondary progressive multiple sclerosis na spms patients enrolled in the intermediate size patient population expanded access ea program receiving foralumab for at least six months,tiziana life sciences announces six month qualitative improvement in neuroimaging in of multiple sclerosis patients receiving intranasal foralumab,clinical_study,UP,1.9801961500356329,198875296.0,63394363.0,242895.0,0.107,139700.0,0.31876439293898023,0.09346626282280733,3,9,387,-0.09949494949494948,1.1109140250580023,0.041912684265625444
live event and webcast today at 10 am et,valneva hosts investor day in new york city,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.13636363636363635,0.6494694268312979,0.028525641025641018
šiaulių bankas ab plans an offering of fixed rate reset perpetual additional tier 1 temporary write down notes subject to market conditions this notice does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas on 14 october 2024 the management board of šiaulių bankas ab approved an offering of fixed rate reset perpetual additional tier 1 temporary write down which would follow subject to market conditions šiaulių bankas ab has mandated goldman sachs bank europe se as lead manager to arrange a series of virtual fixed income investor meetings commencing on 14 october relevant stabilisation regulations including fca icma will apply this communication is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful no action has been,šiaulių bankas ab plans a bond offering subject to market conditions,financing_agreements,DOWN,-0.6142500205394381,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,14,256,-0.01464646464646464,0.8866002429130597,0.10189814814814815
notice to the shareholders of ab akola group vilnius 9 october 2024 hereby we announce the annual general meeting of shareholders hereinafter the meeting of ab akola group registered address subačiaus st 5 vilnius lithuania code 148030011 hereinafter the company is convened the date time and venue of the meeting 31 october 2024 at 10 00 a m radisson collection astorija hotel conference hall fuga didžioji st 35 2 vilnius lithuania the accounting day of the meeting is 24 october 2024 only the persons who are the shareholders of the company at the end of the accounting day of the meeting shall have the right to attend and vote at the meeting the rights accounting day is 15 november 2024 only the persons who are the shareholders of the company at the end of the rights accounting day shall have proprietary rights on the day the meeting is convened the total number of the company s shares is 167 170 481 and the number of shares granting voting rights is 166,notice on convening the annual general meeting of shareholders of ab akola group,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,0,261,0.0642857142857143,0.8866002429130597,0.20330578512396694
live event and webcast today at 10 am et,valneva hosts investor day in new york city,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.13636363636363635,0.6494694268312979,0.028525641025641018
media release,xbrane biopharma presents nomination committee,annual_general_meeting,DOWN,-1.0548512993026444,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,239,0.0,0.8866002429130597,-0.009523809523809523
berwyn pa dec 01 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced the appointment of andrew walsh as vp finance,annovis bio appoints andrew walsh as vice president finance,management_changes,UP,2.4734987492151,44136244.0,15624645.0,595065.0,1.618,805900.0,0.35400939418406335,0.09346626282280733,4,7,575,0.0,1.368989555493872,0.1096590909090909
anticipated 2024 milestones include present reni cel clinical data updates mid year and year end initiate the ruby clinical trial adolescent cohort establish in vivo preclinical proof of concept for an undisclosed indication and continue to sublicense foundational ip,editas medicine highlights 2024 anticipated milestones and strategic priorities at the j p morgan healthcare conference,clinical_study,DOWN,-0.660070611765802,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,0,8,537,0.0,1.3105556047468256,0.03181818181818182
toronto june 12 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the type c meeting written responses received by the company from the u s food drug administration fda for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the study,revive therapeutics provides update on fda type c meeting for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-6.666661699612825,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,9,381,0.04,1.8889707456546947,0.09926750064376327
san diego jan 02 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee rebecca nolan olson who is joining oncternal as safety manager,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,543,0.13636363636363635,0.8866002429130597,-0.3333333333333333
presented cohort one low dose data from both trials of tsha 102 at 2024 irsf rett syndrome scientific meeting that demonstrated durable improvements across consistent clinical domains and an encouraging safety profile in adult up to 52 weeks and pediatric up to 22 weeks patients,taysha gene therapies reports second quarter 2024 financial results and provides corporate update,clinical_study,UP,2.392353721925213,627672000.0,136885482.0,5054745.0,1.016,2606600.0,0.21808441670171683,0.09346626282280733,0,8,320,0.05833333333333333,1.0149166236087122,0.008774081668818517
malvern pa march 20 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today announced successful completion of data cleaning for its phase ii iii study of buntanetap in patients with mild to moderate alzheimer s disease ad topline efficacy data is expected in april,annovis bio provides data announcement update for the phase ii iii study of buntanetap in alzheimer s disease,clinical_study,UP,9.242146234319629,44190808.0,15624645.0,595065.0,1.618,805900.0,0.3535722858925775,0.09346626282280733,2,7,465,0.24583333333333332,1.368989555493872,0.03335137085137085
toronto march 12 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders announced today a corporate update on the research clinical and regulatory initiatives with bucillamine and its long covid diagnostic product,revive therapeutics provides corporate update,press_releases,UP,0.0,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,473,0.05,1.8889707456546947,0.11909816782544055
santa ana calif oct 17 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today presented a poster with interim phase i trial data on the use of its investigational nk cell therapy snk01 to treat patients with alzheimer s disease ad at the xxvi world congress of neurology wcn annual meeting in montreal qc canada and online,nkgen biotech presents interim phase i trial data at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,DOWN,-1.9999980926513672,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,1,8,620,0.3,2.657355742098314,0.3
boca raton florida april 22 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease today announced today that it has entered into definitive agreements for the sale and purchase of 571 592 shares of its common stock with above market warrant exercise price that include an acceleration clause upon positive top line data in the company s phase 2 alzhzimer s disease program as further described below the warrants give the investor the right to purchase 571 592 additional shares of its common stock in a registered direct offering the offering was priced at the market based on the friday april 19th nasdaq consolidated closing bid price of 8 32 per share the exercise price of the warrants is 9 152 which represents a premium to the price at which the common shares were offered the warrants terminate on the earlier of 1 the two 2 year anniversary of the initial exercise date of the warrant or 2 thirty 30 trading days following the reporting of top line data emacc in the phase 2 alzheimer s program of xpro1595 the termination date the gross proceeds of this offering are approximately 4 8 million before deducting placement agent fees and expenses the closing of the offering is expected to occur on or about april 24 2024 subject to the satisfaction of customary closing conditions members of management and the company s board of directors and certain key employees participated in the offering and will pay a combined offering price for the common stock and warrants of 8 445 per share and warrant and in the case of officers and directors that participated in the offering if the warrant termination date is on a blackout date then the officers and directors will have an additional 60 days from the termination of the blackout date to exercise the warrant,inmune bio inc raises approximately 4 8 million in gross proceeds through registered direct offering with officers employees and directors purchasing approximately of the offering,warrants_and_certificates,UP,0.3584197536603377,162957200.0,15213010.0,781395.0,1.567,974600.0,0.09335586276641965,0.09346626282280733,0,8,432,-0.030808080808080802,0.8435084668920305,0.16
media release,guerbet nombre d actions et de droits de vote composant le capital de la société au 30 septembre 2024,voting_rights,DOWN,-1.6541330437911184,278437920.0,5878020.0,15366.363636363636,0.764,6888.0,0.02111070216298125,0.09346626282280733,2,15,240,0.0,0.41864543118833314,0.0
pcrx 201 is the first gene therapy product candidate to receive rmat designation for osteoarthritis designation supported by encouraging preliminary data from 72 patient phase 1 study,pacira biosciences announces pcrx 201 granted regenerative medicine advance therapy rmat designation for the treatment of osteoarthritis of the knee,clinical_study,UP,0.0327232626197546,1112470400.0,45834212.0,557500.0,0.511,435200.0,0.041200387893466646,0.09346626282280733,2,7,472,0.25,0.7130794063724827,0.1820283189033189
san diego may 08 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced that the company is scheduled to present at various upcoming scientific and medical conferences,capricor therapeutics to present at upcoming scientific and medical conferences,conference_call_webinar,DOWN,-1.8315000720495704,434224096.0,40176259.0,3124730.0,0.85,8768900.0,0.09252425042759488,0.09346626282280733,2,9,416,0.049999999999999996,1.3427880947904531,0.12272727272727273
alvotech nasdaq alvo tilkynnti í dag að evrópska lyfjastofnunin ema hafi samþykkt að taka til afgreiðslu umsókn um markaðsleyfi fyrir avt03 fyrirhugaða líftæknilyfjahliðstæðu við prolia og xgeva sem innihalda virka efnið denosumab,evrópska lyfjastofnunin samþykkir að taka til afgreiðslu umsókn um markaðsleyfi fyrir avt03 fyrirhugaða hliðstæðu við prolia og xgeva,regulatory_filings,UP,0.0,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,5,261,0.0,0.44264539487962035,0.058653198653198645
media release,onward arc ex system named one of time s best inventions of 2024,contests_awards,UP,1.502149655653979,222153600.0,26272993.0,71.81818181818181,0.879,0.0,0.11826498872851937,0.09346626282280733,3,6,240,1.0,0.6060210048053989,0.0
19 million revenue in 2023 24 million projected revenue in 2024nexobrid commercially launched in u s japan indiapotential blockbuster escharex to begin phase iii in the second half of 2024 42 million cash runway through profitability,mediwound reports fourth quarter and full year 2023 financial results and provides company update,financial_results,DOWN,-0.7682451116406452,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,3,7,464,0.030555555555555555,0.6433034533898109,0.14787878787878786
la jolla calif may 28 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova conducted two poster presentations at the 92nd european atherosclerosis society eas 2024 congress held online may 26 29 2024,medicinova announces two poster presentations at the 92nd eas congress 2024 the annual meeting of the european atherosclerosis society regarding the use of mn 001 tipelukast for cardiometabolic conditions,clinical_study,DOWN,-1.4925358528601556,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,396,0.0,0.8018560055721619,0.11601010101010101
watertown mass sept 19 2023 globe newswire eloxx pharmaceuticals inc nasdaq elox a leader in ribosomal rna targeted genetic therapies for rare diseases today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380 590 of its shares of common stock or common stock equivalents in lieu thereof at a purchase price of 5 255 per share or common stock equivalent in lieu thereof in a registered direct offering priced at the market under nasdaq rules in a concurrent private placement eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380 590 of its shares of common stock the warrants will have an exercise price 5 13 per share will become exercisable immediately upon issuance and have a term of five and one half years from the date of issuance the offering is expected to close on or about september 20 2023 subject to the satisfaction of customary closing conditions,eloxx pharmaceuticals announces 2 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-0.1831543738455693,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,648,-0.10303030303030303,2.2721670857062097,0.15067828662565508
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
after successful seismic a and b studies in early cardiogenic shock seismic c will treat more severe scai stage c cardiogenic shock to complete the assessment of the intended phase 3 patient population,windtree therapeutics initiates seismic c study of istaroxime in scai stage c cardiogenic shock for planned completion of phase 2b and transition to phase 3,clinical_study,DOWN,-3.658533128225512,1377011.0,3660923.0,6680965.0,0.764,1224200.0,2.6586011295479848,0.09346626282280733,2,8,241,0.36250000000000004,2.339794177443606,0.057652423534458166
management and scientific medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of can 2409 in nsclc management and scientific medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of can 2409 in nsclc,candel therapeutics to host non small cell lung cancer nsclc r d breakfast panel during 2024 asco annual meeting,clinical_study,UP,1.5652200450067937,244501184.0,41997569.0,917740.0,-0.866,856900.0,0.17176836656954594,0.09346626282280733,0,8,404,-0.05,1.2870358800144117,0.0909626230171213
call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial,biocardia completes enrollment of cardiamp cell therapy for the treatment of chronic myocardial ischemia trial open label roll in cohort,clinical_study,DOWN,-2.6315723429754274,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,3,9,429,0.3333333333333333,1.32107885633281,-0.09702380952380951
four unique icd 10 pcs codes effective october 1 2024 for replacement of arteries in the upper and lower extremities using humacyte s hav,centers for medicare medicaid services cms issues icd 10 pcs codes for humacyte s human acellular vessel hav,clinical_study,DOWN,-4.964544283696593,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,0,8,376,0.24375,1.1173068527438073,0.05688131313131314
se venligst vedhæftede,ledende medarbejderes transaktioner,press_releases,DOWN,-0.8807045636509208,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,14,268,0.0,0.8866002429130597,0.0
third rmat designation by fda for atev,humacyte acellular tissue engineered vessel atev receives fda s regenerative medicine advanced therapy rmat designation for patients with advanced peripheral artery disease pad,clinical_study,UP,9.242146234319629,335320768.0,121934248.0,3834265.0,2.0,1449900.0,0.3636346437092736,0.09346626282280733,0,8,362,0.26666666666666666,1.1173068527438073,0.08124368686868687
media release,wolters kluwer 2024 nine month trading update,financial_results,UP,1.1250019073486328,32456935424.0,234261050.0,547487.9545454546,0.259,726796.0,0.007217596083540829,0.1515999603296736,2,8,241,0.0,0.21375743879343068,0.0
tampa fla oct 07 2024 globe newswire pacira biosciences inc nasdaq pcrx the industry leader in the delivery of innovative non opioid pain therapies today announced the granting of inducement awards on october 2 2024 to 55 new employees under pacira s amended and restated 2014 inducement plan as a material inducement to each employee s entry into employment with the company in accordance with nasdaq listing rule 5635 c 4 the awards were approved by the compensation committee of the board of directors,pacira biosciences reports inducement grants under nasdaq listing rule 5635 c 4,corporate_action,UP,0.1815906686780804,1112238976.0,45834212.0,557500.0,0.511,435200.0,0.041208960474336045,0.09346626282280733,0,8,264,0.3181818181818182,0.7130794063724827,0.1297009363892481
second rare disease program with rz358 in phase 3 development,rezolute announces fda clearance of ind application for phase 3 registrational study of rz358 for treatment of hypoglycemia due to tumor hyperinsulinism,clinical_study,DOWN,-7.103823312288768,377643968.0,77797779.0,825115.0,1.04,796000.0,0.20600826596547148,0.09346626282280733,0,7,327,0.05833333333333333,0.6820409900648857,-0.008932900432900431
malvern pa jan 24 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases has announced a postponement in the phase iii study data release for buntanetap in parkinson s disease this adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results,annovis bio refines timeline for parkinson s phase iii study data announcement,clinical_study,DOWN,-7.103823312288768,44136244.0,15624645.0,595065.0,1.618,805900.0,0.35400939418406335,0.09346626282280733,2,8,521,-0.125,1.368989555493872,0.07146464646464647
approximately 40 centers currently open,polypid announces enrollment of the 100th patient in the ongoing shield ii phase 3 trial,clinical_study,DOWN,-3.32369966094949,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,0,7,502,-0.2,0.7168605096826995,0.0005291005291005272
longeveron management to present at the roth healthcare opportunities conference speaking on emerging frontiers in neuroscience panel and hosting 1x1s,longeveron to participate in the 3rd annual roth healthcare opportunities conference,conference_call_webinar,DOWN,-1.0638287753851583,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,9,269,0.0,1.063123411629147,0.10808080808080807
riga 2024 09 17 16 14 cest jsc saf tehnika informs about the purchase of its shares by koka zirgs ltd information is attached about saf tehnika saf tehnika jsc is an iso certified wireless data transmission equipment manufacturer the company s products are produced in latvia europe and sold in over 130 countries worldwide saf tehnika has been listed on nasdaq riga since 2004 saf tehnika wholly owns subsidiaries saf north america llc which operates from denver co usa and serves the north american market and saf tehnika asia pte ltd in singapore additional information zane jozepa cfo member of the board zane jozepa saftehnika com www saftehnika com attachments kokazirgs_safakcijas_100924_2 pdf kokazirgs_safakcijas_110924 pdf,on transactions under regulation no 596 2014,changes_in_companys_own_shares,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,14,283,0.0,0.8866002429130597,0.0
mdxhealth to present third quarter 2024 financial resultsand corporate update on november 6,mdxhealth to present third quarter 2024 financial results and corporate update on november 6,earnings_releases_and_operating_results,UP,0.0,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,8,257,0.0,0.6181119561491973,0.05842490842490843
ad hoc announcement pursuant to art 53 lr,santhera secures up to chf 69 million in royalty and debt financing to fund operations to cash flow break even,financing_agreements,UP,1.5544101361056366,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,375,0.0,0.5209522992128177,0.05000000000000001
data show that vaxart s hpv vaccine constructs stimulate specific t cell immune responses reduce tumor size and increase survival in an animal model of human papillomavirus hpv related tumorigenesis,vaxart announces publication in vaccines of preclinical data supporting the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination for hpv related cervical dysplasia,clinical_study,UP,0.0,121368992.0,226926647.0,9325470.0,1.148,2676900.0,1.8697250694806793,0.09346626282280733,2,8,304,0.041666666666666664,1.025768835125998,0.06264323911382734
seattle nov 28 2023 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it will host a virtual kol event to discuss new data from the vista 101 clinical trial of kva12123 in patients with advanced solid tumors details are as follows,kineta to host kol event to review new data from vista 101 clinical trial of kva12123 in patients with advanced solid tumors on december 5 2023,clinical_study,DOWN,-0.3225803474481751,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,578,0.1787878787878788,0.8866002429130597,0.18181818181818182
imm 1 104 is synergistic with chemotherapy in pancreatic cancer models,imm 1 104 is synergistic with chemotherapy in pancreatic cancer models,clinical_study,UP,3.301895067929056,112574064.0,27271404.0,2516685.0,0.002,1980700.0,0.24225299354920685,0.09346626282280733,1,12,444,0.0,1.2966226301621697,0.09602272727272727
oslo 24 may 2023 pci biotech holding asa pci biotech or the company issue this notification on behalf of its chairman hans peter bøhn,disclosure of voting rights for chairman of the board,annual_general_meeting,UP,4.105266823332772,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,2,4,766,0.0,0.8869841129646596,0.016666666666666673
san diego june 25 2024 globe newswire in a release issued under the headline capricor therapeutics announces for the treatment of duchenne muscular dystrophy on tuesday june 25th by capricor therapeutics please note that the words pre bla meeting with fda for deramiocel were omitted from the headline the corrected release follows,correction capricor therapeutics,regulatory_filings,DOWN,-4.526754341253899,432852864.0,40176259.0,3124730.0,0.85,8768900.0,0.09281735744735652,0.09346626282280733,1,10,367,0.0,1.3427880947904531,0.1739141414141414
r d discussion in new york city to review il 12 s potential to treat ovarian cancer,imunon to host r d day on september 18th,clinical_study,DOWN,-1.72413633637985,17679998.0,12808492.0,12655315.0,2.143,945100.0,0.7244622991473189,0.09346626282280733,2,8,304,0.06818181818181818,2.964855117372811,0.05311528749028749
missing,valneva déclaration d actions et de droits de vote 31 juillet 2024,voting_rights,DOWN,-1.828822228271539,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,2,326,-0.2,0.6494694268312979,0.2126984126984127
neha motwani a senior healthcare investment banker has been elected to the longeveron board of directors,neha motwani elected to longeveron board of directors,management_changes,UP,4.830924940876222,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,1,9,354,0.0,1.063123411629147,0.075
san diego may 06 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that the u s food and drug administration fda has cleared its investigational new drug ind application to evaluate ba3361 cab nectin 4 antibody drug conjugate adc for the treatment of multiple tumor types,bioatla announces fda clearance of investigational new drug application for ba3361 a cab nectin 4 antibody drug conjugate for the treatment of multiple tumors,clinical_study,UP,0.0,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,0,8,418,0.01991341991341991,1.087702859114621,0.012037037037037034
transcode therapeutics completes initial dosing of first co hort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,transcode therapeutics completes initial dosing of first cohort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,clinical_study,DOWN,-0.7393730208448788,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,261,0.125,2.0874185587937095,-0.011931818181818184
west lafayette ind sept 16 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services has amended certain terms of its credit agreement in addition inotiv has closed the sale of 22 6 million aggregate principal amount of senior secured second lien pik notes due february 2027 the second lien notes and warrants to purchase common shares to certain investors in a private offering,inotiv inc amends its credit agreement and secures additional liquidity,financing_agreements,DOWN,-1.923075159625829,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,0,8,285,-0.010714285714285716,1.3015467599292592,0.03879818594104308
bt 600 was well tolerated and met all trial objectives demonstrating the navicap platform s ability to deliver therapeutics directly to the colon,biora therapeutics announces positive clinical trial results for bt 600,clinical_study,UP,0.0,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,362,0.16363636363636364,1.027516639474094,0.10707972582972582
pharmacokinetic and tissue data confirm navicap platform delivers topically through the entire colon with lower systemic concentrations as desired,biora therapeutics announces supplemental data from phase 1 clinical trial of bt 600 as presented at kol event,clinical_study,UP,3.038309297990525,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,3,8,345,0.0,1.027516639474094,0.10076433982683983
media release,ab akola group s notification about the annual information for the financial year 2023 2024,financial_results,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.06441783324900209
adelaide australia and cambridge mass july 03 2023 globe newswire bionomics limited nasdaq bnox asx bno bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced key leadership updates to drive its ongoing transformation to a u s focused company streamline its allocation of capital and support its next stage of strategic growth,bionomics announces key leadership updates to drive u s focused transformation and next stage of strategic growth,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,726,0.0005238095238095264,0.8866002429130597,0.0005820105820105849
norwood mass march 06 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a panel discussion at bmo capital markets inaugural bmo obesity summit to be held on march 20 2024 in new york city ny,corbus pharmaceuticals to participate in the bmo capital markets inaugural obesity summit,conference_call_webinar,UP,9.242146234319629,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,2,8,479,0.13636363636363635,0.9919200800994142,0.015474747474747474
media release,nomination committee appointed for itab s annual general meeting 2025,annual_general_meeting,UP,4.240285495725315,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,11,242,0.05000000000000002,0.8866002429130597,0.0
los angeles april 15 2024 globe newswire immix biopharma inc nasdaq immx immixbio company we or us or immx a clinical stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and other autoimmune diseases today announced that updated nxc 201 clinical data has been selected for presentation at the upcoming 27th annual meeting of the american society of gene cell therapy asgct to be held in baltimore may 7 11 2024,immix biopharma announces late breaking nxc 201 clinical data abstract accepted for oral presentation at the 27th annual meeting of the american society of gene and cell therapy asgct,clinical_study,DOWN,-4.659493827949631,61330060.0,18058632.0,290605.0,0.301,58200.0,0.2944499320561565,0.09346626282280733,0,9,438,-0.10625,0.9253604538231538,0.05958964646464646
fda grants pre bla meeting request and rolling bla submission after review of hope 2 and hope 2 ole 3 year results san diego june 11 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the successful completion of a type b meeting with the u s food and drug administration fda on next steps for the biologics license application bla submission with its lead asset cap 1002 for the treatment of duchenne muscular dystrophy dmd additionally deramiocel has been selected as the proposed international nonproprietary name inn for cap 1002 by the world health organization,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy with an aim to expedite bla pathway,clinical_study,DOWN,-0.554523730449676,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,382,0.2554545454545455,1.3427880947904531,0.09606060606060605
tuhura has an exclusive right to negotiate to acquire kineta s kva12123 immuno oncology drug program,kineta announces exclusivity and right of first offer agreement for its vista blocking antibody with tuhura biosciences,mergers_acquisitions,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,355,0.2738095238095238,0.8866002429130597,0.0838722551957846
media release,bghl eur nav s,clinical_study,UP,0.7299298019120962,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,247,0.0,0.8866002429130597,-0.006122448979591832
announced positive outcomes from the c guardians ide clinical trial of the cguard prime carotid stent system demonstrating a one year primary endpoint event rate of 1 the lowest for any carotid stent or embolic protection device pivotal trial,inspiremd reports second quarter 2024 financial results and provides business update,clinical_study,DOWN,-2.7027000903735274,67091308.0,16849440.0,286250.0,0.613,4867100.0,0.25114192139464625,0.09346626282280733,1,8,326,0.2254545454545455,0.6085732039686736,0.08794871794871795
newly issued patents extend exclusivity of ublituximab through 2042 newly issued patents extend exclusivity of ublituximab through 2042,tg therapeutics announces issuance of additional patents for briumvi ublituximab xiiy,patents,UP,3.4431141464668182,5894573568.0,135060602.0,1756590.0,1.939,1677400.0,0.022912701053254544,0.09346626282280733,1,7,487,0.13636363636363635,0.6256004090066075,0.03333333333333333
moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,financial_results,DOWN,-1.5947867861013068,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,1,8,417,0.125,0.5366763308656862,0.04025252525252525
marlborough mass oct 28 2024 globe newswire akoya biosciences inc nasdaq akya akoya the spatial biology company today announced that it will release financial results for the third quarter of 2024 after the market closes on thursday november 14 2024 company management will host a conference call to discuss financial results at 5 00 p m et,akoya bioscience to report third quarter 2024 financial results on november 14 2024,financial_results,UP,1.0714275678809635,61193896.0,12648900.0,228670.0,1.352,488000.0,0.20670198870815482,0.09346626282280733,0,8,243,0.0,0.8573192373918191,0.21144628099173557
media release,presentation of 3 rd quarter 2024 results,financial_results,UP,6.52037601435522,4289897472.0,29760087.0,70112.7,2.413,93652.0,0.006937249012183385,0.1515999603296736,1,7,242,0.0,0.40970189616126773,0.0
rockville md may 08 2023 globe newswire opgen inc nasdaq opgn opgen or the company announced today that the company will provide a business update and report its first quarter 2023 financial results after the close of the u s financial markets on monday may 15th 2023 opgen s management team will host a live conference call and audio webcast at 4 30 p m eastern time to discuss the company s financial results and provide an update on business activities,opgen to provide business update and financial results for the first quarter 2023 on may 15th at 4 30 p m eastern time,earnings_releases_and_operating_results,UP,3.4031444165644493,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,0,7,782,0.09090909090909091,1.807174583649316,0.0
conference call and webcast to be held at 8 30 a m edt,inspiremd to report second quarter 2024 financial results and provide corporate business update on tuesday august 6th,earnings_releases_and_operating_results,UP,2.409643485941096,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,1,7,333,0.0,0.6085732039686736,0.09942028985507247
media release,riber solid business growth at end september 2024,earnings_releases_and_operating_results,UP,1.8115924814873587,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,8,241,0.0,0.4818751066598002,0.049342105263157895
sunnyvale calif sept 18 2024 globe newswire biocardia inc nasdaq bcda a global leader in cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases announced today that the company has regained full compliance with the nasdaq capital market s listing requirements as required by the hearing panel s the panel decision on may 13 2024,biocardia regains full compliance with nasdaq listing requirements,exchange_announcement,UP,3.5842345669686178,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,2,8,283,0.2333333333333333,1.32107885633281,0.04343377976190477
notice of delisting will not immediately result in the suspension or delisting of the company s securities notice of delisting will not immediately result in the suspension or delisting of the company s securities,centogene announces receipt of nasdaq notice of delisting and intention to request a hearing,exchange_announcement,UP,0.5454599218358603,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,486,0.0,3.598197549072007,0.18154761904761904
san carlos calif may 01 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer will report its first quarter 2024 financial results on thursday may 9 2024 management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4 30 p m et,iovance biotherapeutics to host first quarter 2024 financial results conference call and webcast on thursday may 9 2024,conference_call_webinar,DOWN,-0.2546666693652358,601114624.0,280347936.0,11775260.0,0.863,9708200.0,0.4663801624629914,0.09346626282280733,2,6,423,0.10606060606060606,0.901765204231867,0.004242424242424242
media release,totens sparebank last day of trading today,mergers_acquisitions,UP,0.5442480256261943,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,7,240,0.0,0.8866002429130597,0.0
redwood city calif may 13 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced the expansion of its mast cell development portfolio with a phase 1b 2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024,jasper therapeutics announces briquilimab development program in asthma,clinical_study,DOWN,-0.1875246522352597,81119344.0,9908441.0,280900.0,2.725,505700.0,0.12214646361045524,0.09346626282280733,0,8,411,0.125,0.9821837329226573,0.15674042007375338
media release,glaston makes a change to the executive leadership team,management_changes,DOWN,-1.639344147877593,56298360.0,15339800.0,14584.2,0.607,41169.0,0.2724733011760911,0.1515999603296736,3,15,239,0.0,0.2342753450337208,0.0
media release,decisive new step in the completion of the financial restructuring atos accelerated safeguard plan approved by the specialized commercial court of nanterre,clinical_study,UP,0.3654785367553472,24416421888.0,158122098.0,963560.0,0.703,746300.0,0.006476055284648921,0.1515999603296736,3,8,247,0.04545454545454545,0.17227971872538478,0.0
media release,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.22733091145371848
immunocore to report second quarter 2024 financial results and host call on august 8 2024,immunocore to report second quarter 2024 financial results and host call on august 8 2024,earnings_releases_and_operating_results,UP,0.0251846885165219,1603205376.0,37423034.0,614630.0,0.835,788600.0,0.023342632553647324,0.09346626282280733,3,7,331,0.0,0.44240182162750774,0.12685185185185185
moonlake immunotherapeutics reports full year 2023 financial results recent business highlights and announces an r d day on march 10,moonlake immunotherapeutics reports full year 2023 financial results recent business highlights and announces an r d day on march 10,financial_results,UP,1.3025837808154643,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,3,8,485,0.11666666666666665,0.5366763308656862,0.05309343434343434
seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience,pacira biosciences appoints shawn cross as chief financial officer,clinical_study,DOWN,-1.0863381163181691,1110849792.0,45834212.0,557500.0,0.511,435200.0,0.04126049474022857,0.09346626282280733,0,8,250,0.15,0.7130794063724827,0.1382682491980013
helocyte a majority owned subsidiary of fortress biotech is developing triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications as well as hiv,fortress biotech announces first patient dosed in multi center phase 2 study of triplex for control of cmv in patients undergoing liver transplantation,clinical_study,UP,1.1764694332664312,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,1,8,410,0.049999999999999996,0.6928276660424207,0.10316017316017315
recently initiated serenity at home pivotal phase 3 trial for agitation associated with bipolar disorders or schizophrenia,bioxcel therapeutics announces clinical prioritization and update on bxcl501 late stage programs for agitation,clinical_study,DOWN,-0.941921779059158,11996430.0,5544250.0,450810.0,-0.13,78500.0,0.4621583254351503,0.09346626282280733,3,7,282,0.06666666666666667,1.4586588351104455,0.05906375787954736
san diego oct 14 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that adi mohanty ceo of biora therapeutics will present on the company s 00 size biojet device at the 14th annual partnership opportunities in drug delivery podd meeting taking place in boston october 28 29 2024,biora therapeutics to reveal 00 size biojet device at the 14th annual partnership opportunities in drug delivery meeting,product_services_announcement,DOWN,-3.260866466677246,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,257,0.0,1.027516639474094,0.07500338203463203
rockville md april 25 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that based on the strength of the science and its relevance virage the phase 2b randomized open label placebo controlled multicenter clinical trial of systemically administered vcn 01 in combination with standard of care soc chemotherapy gemcitabine nab paclitaxel as a first line therapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma pdac has been accepted for presentation as a trial in progress poster at the 2024 american society of clinical oncology asco annual meeting being held in chicago il from may 31 june 4,theriva biologics to discuss the trial design for virage a phase 2b clinical study of systemically administered vcn 01 in combination with chemotherapy in pancreatic ductal adenocarcinoma at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-2.702702702702702,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,3,8,429,0.06070707070707071,1.5225134880447404,0.0
san diego sept 05 2024 globe newswire cidara therapeutics inc nasdaq cdtx the company a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced that jeffrey stein ph d president and chief executive officer will present at the h c wainwright 26th annual global investment conference,cidara to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,UP,1.0163564211867586,621253440.0,4118697.0,696580.0,0.795,3470400.0,0.0066296566502714255,0.09346626282280733,3,8,296,-0.05555555555555555,1.357695941787151,-0.03590007215007215
rokiskio suris ab received a notification on the disposal of block of voting rights by the group of shareholders of rokiskio suris ab attached dalius trumpa ceo tel 370 458 55200 attachment attachments notification of disposal of a holding 01 10 2024 pdf,notification on the disposal of voting rights,voting_rights,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,13,269,0.0,0.8866002429130597,0.12777777777777777
zkn 013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa rdeb and jeb and familial adenomatous polyposis fap,eloxx pharmaceuticals announces fda clearance to begin single ascending dose study of zkn 013,clinical_study,DOWN,-1.2931056335432467,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,788,-0.03571428571428571,2.2721670857062097,0.0
enrollment in the two pivotal trials of lorundrostat for the treatment of uhtn or rhtn is on track with topline data expected for advance htn trial in q4 2024 and launch htn trial in 2h 2025,mineralys therapeutics reports fourth quarter and full year 2023 financial results and provides corporate update,clinical_study,DOWN,-0.2987301032667582,916690560.0,43490817.0,793180.0,-0.18,767600.0,0.04744329100541845,0.09346626282280733,3,7,464,0.125,0.8131647725786432,-0.0671590909090909
san diego may 01 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee anne c hansen who is joining oncternal as senior director clinical data management,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,DOWN,-2.406747928283236,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,423,0.13636363636363635,0.8866002429130597,-0.04194725028058362
lifting of fda hold allows freedom dm1 study to launch in the u s with target dose levels of 5 mg kg 10 mg kg and 20 mg kg,pepgen inc announces fda has lifted the clinical hold on its investigational new drug application for freedom dm1 phase 1 study of pgn edodm1 for myotonic dystrophy type 1 dm1,clinical_study,DOWN,-0.57034616925724,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,3,7,625,0.13636363636363635,1.4553932872573117,0.045
media release,nytt antal aktier och röster i itab shop concept ab publ,changes_in_share_capital_and_votes,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.012500000000000004
zug switzerland and boston may 29 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today announced that members of its senior management team are scheduled to participate in the following investor conferences in june,crispr therapeutics to participate in upcoming investor conferences,conference_call_webinar,DOWN,-2.151714627812774,4069457152.0,85970729.0,2651100.0,1.742,2455300.0,0.021125846959157268,0.09346626282280733,2,8,395,-0.16666666666666666,0.5620956775766307,0.04026875901875901
cambridge mass oct 01 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced that interim data from the ongoing phase 1 study of nexiguran ziclumeran nex z also known as ntla 2001 will be presented in a late breaking oral presentation at the 2024 american heart association aha scientific sessions taking place november 16 18 in chicago illinois nex z is an investigational in vivo crispr based gene editing therapy designed to be a single dose treatment for transthyretin attr amyloidosis intellia leads development and commercialization of nex z as part of a multi target discovery development and commercialization collaboration with regeneron the presentation will include safety reduction in serum ttr and biomarkers of disease progression and functional capacity data in patients with attr amyloidosis with cardiomyopathy attr cm,intellia therapeutics to present new clinical data from the phase 1 study of nexiguran ziclumeran nex z for the treatment of transthyretin attr amyloidosis at the 2024 aha scientific sessions,clinical_study,UP,0.0486629160735013,975751872.0,98412511.0,6353695.0,2.134,5288300.0,0.10085813189195705,0.09346626282280733,1,7,270,-0.04701298701298701,0.7800307612939593,0.045902208171945
boston march 13 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda granted both orphan drug and rare pediatric disease designations for pgn edo51 an investigational therapeutic for duchenne muscular dystrophy dmd patients whose mutations are amenable to an exon 51 skipping approach pepgen is evaluating pgn edo51 for the treatment of dmd in the ongoing connect1 phase 2 trial and expects to begin enrolling patients in the connect2 phase 2 trial later this year,pepgen receives u s fda orphan drug and rare pediatric disease designations for pgn edo51 for the treatment of duchenne muscular dystrophy,clinical_study,UP,1.943840874123164,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,2,7,472,0.16,1.4553932872573117,0.05014351851851852
company plans to initiate trial following recent meeting with fda,bioxcel therapeutics announces tranquility in care pivotal phase 3 trial plan with bxcl501 for agitation associated with alzheimer s dementia,clinical_study,UP,2.33463746134859,12172660.0,5544250.0,450810.0,-0.13,78500.0,0.45546741632478027,0.09346626282280733,2,7,444,0.16666666666666666,1.4586588351104455,0.05727118119975263
positive phase 2b data announced for bnc210 on reduction of total symptom severity and multiple symptom clusters in post traumatic stress disorder ptsd with a discussion with the u s food drug administration fda anticipated in q2 24,bionomics provides a review of 2023 and of 2024 plans,clinical_study,DOWN,-4.761907645273734,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,523,0.07575757575757576,0.8866002429130597,0.03799212968368812
media release,recording of lhv group s 22 october investor webinar,clinical_study,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
furoscix auto injector being developed as a complement to the furoscix on body infusor,scpharmaceuticals announces first participant enrolled in pivotal pharmacokinetic study of furoscix auto injector furosemide 80mg ml injection,clinical_study,UP,0.6507534078599104,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,2,8,430,0.2833333333333333,0.7082528246818063,0.0
pratteln switzerland june 18 2024 santhera pharmaceuticals six sann announces that its shareholders approved all motions by the board of directors at the annual general meeting agm held today in pratteln switzerland with a large majority participating shareholders represented a total of 4 535 785 shares or 35 of the company s share capital,santhera s shareholders approve all board proposals at today s annual general meeting,annual_general_meeting,DOWN,-0.3061197182379018,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,9,375,0.07857142857142857,0.5209522992128177,0.04000000000000001
company expects enrollment in phase 1 proof of concept study of dna based vaccine technology to begin in q2the application follows guidance provided to imunon in pre ind meeting with the fda,imunon files ind application to begin human testing of imnn 101,clinical_study,DOWN,-2.150535566956493,17677966.0,12808492.0,12655315.0,2.143,945100.0,0.7245455727203005,0.09346626282280733,2,8,472,0.0,2.964855117372811,0.0
on the 30 september 2024 flerie ab s net asset value nav was sek 4 262 million and nav per share was sek 54 59 indirect shares in provell pharmaceuticals for more information ted fjällman ceoemail ir flerie com flerie in briefflerie is an active long term life science investor with a broad and diversified portfolio of innovative companies based on pioneering science we invest in product development and commercial growth opportunities globally alongside other leading investors focusing predominantly on private companies that are otherwise difficult to access flerie s active ownership model broad network and resources support and accelerate the development of the portfolio projects creating value for shareholders flerie ab s ordinary share is listed on nasdaq stockholm with the ticker flerie for further information please visit www flerie com attachments net asset value 30 september 2024 pdf,net asset value 30 september 2024,financial_results,DOWN,-0.166289803526105,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,-0.003921568627450981,0.8866002429130597,0.0
the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk,cidara therapeutics announces first subjects dosed in phase 2b navigate trial evaluating cd388 for the prevention of seasonal influenza,clinical_study,DOWN,-0.7985816231790068,629035328.0,4118697.0,696580.0,0.795,3470400.0,0.006547640198675773,0.09346626282280733,0,8,278,0.25,1.357695941787151,-0.02205339105339105
confirmed partial responses prs doubled to four since asco gi in mss crc patients without liver and peritoneal metastases for overall response rate orr of 4 17 with adg126 10 mg kg every three weeks q3w in combination with pembrolizumab,adagene presents results at esmo congress that show best in class therapeutic potential for anti ctla 4 safebody adg126 muzastotug in combination with keytruda pembrolizumab in advanced metastatic microsatellite stable mss colorectal cancer crc,clinical_study,UP,0.2865326772473052,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,0,3,285,0.28333333333333327,0.845882180665701,0.1126530612244898
cambridge mass july 30 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the authorization of its clinical trial application cta by the united kingdom s medicine and healthcare products regulatory agency mhra to initiate a phase 1 2 study evaluating ntla 3001 for the treatment of alpha 1 antitrypsin deficiency aatd associated lung disease aatd is a rare genetic disease that most commonly manifests in lung dysfunction due to insufficient levels of alpha 1 antitrypsin aat protein ntla 3001 is a systemically administered in vivo crispr cas9 based targeted gene insertion candidate it is designed to precisely insert a healthy copy of the serpina1 gene which encodes the aat protein with the potential to restore permanent expression of functional aat protein to therapeutic levels after a single dose this approach seeks to improve patient outcomes including eliminating the need for weekly intravenous infusions of aat augmentation therapy or lung transplant in severe cases,intellia therapeutics receives authorization to initiate phase 1 2 clinical trial of ntla 3001 for the treatment of alpha 1 antitrypsin deficiency,clinical_study,UP,0.222715162408892,975751872.0,98412511.0,6353695.0,2.134,5288300.0,0.10085813189195705,0.09346626282280733,1,7,333,0.15044642857142856,0.7800307612939593,0.04506541606541605
san diego march 07 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced preclinical poster presentations at the upcoming 2024 american association for cancer research aacr annual meeting to be held at the san diego convention center in san diego california from april 5 10 2024,bioatla announces poster presentations at the 2024 american association for cancer research aacr annual meeting,press_releases,DOWN,-1.056337052691263,23560018.0,45152550.0,596440.0,0.911,569400.0,1.9164904712721358,0.09346626282280733,3,8,478,-0.03888888888888889,1.087702859114621,0.0
new haven conn aug 07 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that vimal mehta ph d ceo of bioxcel therapeutics will participate in a fireside chat at the canaccord genuity 44th annual growth conference in boston on tuesday august 13 2024 at 1 p m et dr mehta will be joined by vincent j o neill m d executive vice president chief of product development and medical officer,bioxcel therapeutics to participate in canaccord genuity 44th annual growth conference,conference_call_webinar,UP,5.208334691512119,12051540.0,5544250.0,450810.0,-0.13,78500.0,0.4600449403146818,0.09346626282280733,2,7,325,-0.15454545454545454,1.4586588351104455,0.04275040319157967
south san francisco calif oct 15 2024 globe newswire vaxart inc nasdaq vxrt today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at idweek taking place october 16 19 2024 at the los angeles convention center in los angeles,vaxart to present norovirus data at idweek 2024 underscoring commitment to address significant unmet need,clinical_study,UP,1.265821543245696,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,1,8,256,0.05500000000000001,1.025768835125998,0.05393597630439736
media release,reminder of last day of offer period for altrad s recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,UP,0.9852254702272264,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,241,0.25,0.8866002429130597,0.16619949494949496
top line data from vega 3 phase 3 trial expected in first half of 2025,ocuphire pharma initiates vega 3 phase 3 trial evaluating phentolamine ophthalmic solution 0 for presbyopia,clinical_study,DOWN,-0.8264454667762735,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,296,0.12083333333333335,0.8866002429130597,-0.023879216022073164
san diego aug 06 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that company leadership will participate in the canaccord genuity 44th annual growth conference august 13 15 2024,biora therapeutics to participate in canaccord genuity 44th annual growth conference,conference_call_webinar,UP,1.1200027465820312,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,326,0.0,1.027516639474094,0.08956830206830207
gaithersburg md oct 19 2023 globe newswire neximmune inc a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen specific t cells in oncology autoimmune and infectious diseases today announced that three abstracts have been accepted for poster presentation at the upcoming society for immunotherapy of cancer sitc 38th annual meeting in san diego ca being held november 1 5 2023,neximmune announces presentations at the society for immunotherapy of cancer s 38th annual meeting,conference_call_webinar,DOWN,-6.592180616329356,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,8,618,0.0,2.2666992986423327,0.017114448051948054
needham mass april 25 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology asco annual meeting taking place may 31 to june 4 2024 in chicago il the first presentation will feature data from the ongoing phase 1 clinical trial of can 3110 in patients with recurrent high grade glioma the presentation will focus on patients recruited in cohort c treated with multiple injections of can 3110 up to six demonstrating that this approach is both feasible and well tolerated the second presentation will show topline overall survival data from the phase 2 clinical trial of can 2409 plus valacyclovir in combination with continued immune checkpoint inhibitor ici treatment in patients with non resectable stage iii iv non small cell lung cancer nsclc who have an inadequate response to front line anti pd l 1 therapy,candel therapeutics announces upcoming presentations at the 2024 asco annual meeting,clinical_study,DOWN,-2.479340341131657,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,429,0.02285714285714286,1.2870358800144117,0.11927989790957705
jerusalem april 08 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides announced today that data from the phase 2 trial of its lead clinical compound eb613 oral pth 1 34 tablets for the treatment of post menopausal women with low bmd or osteoporosis compared to placebo were published in the journal of bone and mineral research jbmr,entera bio announces publication of oral pth 1 34 peptide tablets eb613 phase 2 trial data in the journal of bone and mineral research,clinical_study,UP,0.7556667801907433,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,0,8,446,0.0,0.6915109749530333,0.04968344155844156
selskabet annoncerede i selskabsmeddelelse 13 2024 at man havde indledt en proces med at gennemføre et identitetsskifte med nasdaq for fortsat at kunne bevare sin status som børsnoteret selskab,business update opdatering på identitetsændring,exchange_announcement,DOWN,-0.5681818181818182,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,283,0.0,0.8866002429130597,0.0
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,-0.2
warrington pa jan 31 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing late stage interventions for critical cardiovascular disorders today announced that it has engaged ladenburg thalmann co inc ladenburg to evaluate strategic alternatives for the company with the goal of maximizing stockholder value,windtree therapeutics announces engagement of strategic advisor to support assessment of strategic alternatives,licensing_agreements,UP,0.0,1351382.0,3660923.0,6680965.0,0.764,1224200.0,2.7090215793905794,0.09346626282280733,2,8,514,-0.15,2.339794177443606,0.03197150072150072
cambridge mass may 02 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies will present its first quarter 2024 financial results and operational highlights in a conference call on may 9 2024 at 8 a m et,intellia therapeutics to hold conference call to discuss first quarter 2024 earnings and company updates,conference_call_webinar,UP,1.3333299424913194,976642688.0,98412511.0,6353695.0,2.134,5288300.0,0.10076613710335791,0.09346626282280733,3,7,422,0.125,0.7800307612939593,-0.04892857142857143
tel aviv israel and miami march 26 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for the prevention of stroke today announced that an abstract of the one year outcomes from its c guardians ide clinical trial of the cguard prime carotid stent system for the treatment of carotid artery stenosis has been accepted for presentation at the leipzig interventional course linc 2024 which is being held may 28 31 in leipzig germany,inspiremd announces abstract of one year follow up results from the c guardians u s investigational device exemption ide clinical trial accepted for presentation at linc 2024,clinical_study,UP,2.16450015388836,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,1,7,459,0.0,0.6085732039686736,0.08025401069518716
media release,totalenergies se third quarter 2024 results,earnings_releases_and_operating_results,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.2171799740446715,0.0
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
adelaide australia and cambridge mass oct 07 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that spyridon spyros papapetropoulos m d ph d president and chief executive officer of bionomics issued the following letter to bionomics shareholders regarding recent achievements executional efficiencies and the positive outlook for the company s future,bionomics issues shareholder letter highlighting recent achievements and strategic vision,management_statements,UP,1.398593747264647,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,264,0.021137347500983866,0.8866002429130597,0.051730409121101766
media release,crcam brie picardie déclaration hebdomadaire rachats réalisés dans les conditions de l article 5 du règlement mar,changes_in_companys_own_shares,UP,0.389970428128025,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,10,242,0.0,0.8866002429130597,0.0
palo alto calif july 17 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that that it has entered into a memorandum of understanding mou for collaboration agreement with acea a china based company focused on the development of innovative treatments for high unmet needs under the terms of the mou acea may receive exclusive rights to develop and commercialize of ztlido in mainland china taiwan hong kong macau including the current formulation and a right of first negotiation for a future next generation formulation of a 3x version of ztlido sp 103 the mou provides scilex with the opportunity to expand collaboration with acea across other products in scilex s non opioid pain management portfolio in the greater china region,scilex holding company announces collaboration to leverage acea therapeutics r d expertise and local market connections to support the expansion of ztlido program in ex us and potentially provide additional access to patients in certain key markets in far east region,partnerships,DOWN,-3.061227592911475,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,9,346,0.1865625,1.0327724261931344,0.27254419191919194
four device performance studies demonstrate the navicap platform s ability to deliver therapeutics directly to the colon under variable gi conditions,biora therapeutics presents clinical data on device function of the navicap platform at digestive disease week 2024,clinical_study,UP,0.0,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,404,0.1,1.027516639474094,0.10849567099567099
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
mr huff was the former ceo of labcorp diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare mr huff was the former ceo of labcorp diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare,diagnostics industry leader gary huff appointed to biomerica strategic advisory board,advisory,UP,2.941173720662243,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,2,8,493,0.125,1.5245042583012947,0.061578421578421576
florham park n j nov 24 2023 globe newswire celularity inc nasdaq celu the company a biotechnology company developing allogeneic cell therapies and biomaterial products announced today that on november 21 2023 the company received notification from the listing qualifications department of the nasdaq stock market llc nasdaq stating that the company is not in compliance with nasdaq s continued listing requirements of the company s failure to timely file a form 10 q for the third quarter of 2023,celularity inc announces receipt of nasdaq notice regarding late form 10 q filing,company_regulatory_filings,UP,7.00000524520874,45742972.0,11684589.0,65020.0,0.764,90700.0,0.25544009252394007,0.09346626282280733,4,13,581,-0.20555555555555557,1.6050367793919866,0.05417538810395953
san diego june 27 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced it will host a virtual r d day around the company s clinical programs and pipeline updates on thursday july 25 2024 at 10 00 am et to register click here,bioatla to host virtual r d day on clinical program and pipeline updates on july 25 2024,conference_call_webinar,UP,0.7092191985804456,23671014.0,45152550.0,596440.0,0.911,569400.0,1.9075038357038696,0.09346626282280733,3,8,366,-0.044444444444444446,1.087702859114621,0.019425204425204422
cambridge mass jan 03 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that the company s president and ceo gilmore o neill m b m m sc will present at the 42nd annual j p morgan healthcare conference on tuesday january 9 2024 4 30 p m pt 7 30 p m et in san francisco ca,editas medicine to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-2.0040061967810527,181238416.0,83382193.0,2526680.0,2.096,3015800.0,0.46006908932596274,0.09346626282280733,2,7,542,0.0,1.3105556047468256,0.057272727272727274
mainz biomed organizes hallo doc event to highlight innovations in colorectal cancer treatment,mainz biomed organizes hallo doc event to highlight innovations in colorectal cancer treatment,press_releases,UP,2.999997138977051,5531532.0,2706585.0,75055.0,0.305,78500.0,0.4893011556292181,0.09346626282280733,1,8,466,0.0,34.079934680222834,0.04090909090909091
new york march 05 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced that dr howard weiner will present positive data of intranasal anti cd3 monoclonal antibody in models of alzheimer s and parkinson s disease at ad pd march 5 9 2024 ad pd is the annual international conference on alzheimer s and parkinson s diseases and related neurological disorders in lisbon portugal,tiziana life sciences announces podium presentation at ad pd of nasal anti cd3 in alzheimer s disease,clinical_study,DOWN,-2.127657550770317,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,7,480,0.07272727272727272,1.1109140250580023,0.05000000000000001
lexington mass sept 23 2024 globe newswire t2 biosystems inc nasdaq ttoo the company a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes today highlighted a recently published article in the lancet a world leading medical journal the article titled changing the culture of blood culture was authored by sally davies richard a marfuggi rick a bright steve brozak and michael osterholm on september 20 2024,t2 biosystems highlights new article published in the lancet changing the culture of blood culture,clinical_study,UP,0.9132411143357496,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,0,9,278,0.2090909090909091,1.9596557041969667,0.09852897102897103
kraig labs otcqb kblb bam 1 spider silk spring production trials exceed expectations and implementing next phase of its recombinant spider silk plan,kraig biocraft laboratories spring spider silk production trials exceed expectations,press_releases,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,3,8,415,0.0,0.8071333009212691,0.236489898989899
assessment by specialist ai team from personalaize highlights the strength potential and visionary talent behind the innovative software as a service saas platform assessment by specialist ai team from personalaize highlights the strength potential and visionary talent behind the innovative software as a service saas platform,independent expert assessment validates renovarocube s potential as a groundbreaking ai platform starting with early cancer detection,press_releases,UP,3.448278117136017,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,284,0.029999999999999992,1.5631250973582267,0.06765989386957127
novaturas group the leader in the baltic tourism market generated revenues of eur 22 6 mln in september compared to eur 24 1 mln during the same period last year the number of customers served was 27 thsnd compared to 29 thsnd in september last year in total between january and september 2024 the company recorded revenues of eur 152 mln and 192 thsnd customers compared to revenues of eur 164 mln and 210 thsnd customers in the corresponding period in 2023 we noticed a drop in demand in the summer season due to the very wide travel offer on the market however we started october with a load factor of almost for travel this month and we see the increasing load factor in autumn as a sign of strong customer trust in our services this results in a lower balance of last minute trips which implies a positive outlook for the company we are optimizing the winter travel program taking into account travelers behavior and choices however when evaluating winter sales,preliminary september results of novaturas high load factor strong winter early booking positions,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,257,0.09157828282828283,0.8866002429130597,0.19435531788472962
rockaway n j april 30 2024 globe newswire electrocore inc the company nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced the results of its most recent truvaga plus consumer study conducted earlier this year based on a 30 day in home use test by an independent third party research firm truvaga plus helped its users improve sleep focus stress energy and mood,truvaga plus demonstrates health benefits in latest consumer study paving the way for market expansion,clinical_study,UP,3.508777066574668,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,1,8,424,0.1,0.8324549917316175,0.1731818181818182
kraig labs otcqb kblb achieves key milestone for true commercial scale production levels and great colony health,kraig biocraft laboratories nears completion of largest production batch of parental line spider silk silkworms,product_services_announcement,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,257,0.2875,0.8071333009212691,0.11782039141414141
jerusalem march 26 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides announced today that the american society for bone and mineral research asbmr announced on march 25 2024 that the u s food and drug administration fda has communicated to the sabre study to advance bmd as a regulatory endpoint project team that a ruling to qualify the treatment related change in bone mineral density bmd as a surrogate endpoint for fractures in future trials of new anti osteoporosis drugs would be provided within 10 months,entera bio announces key regulatory milestone for oral pth 1 34 peptide eb613 phase 3 program fda ruling on qualifying bmd as a surrogate endpoint for osteoporosis drugs is expected within 10 months,clinical_study,UP,9.242146234319629,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,1,8,459,0.006060606060606058,0.6915109749530333,0.054530423280423276
media release,marel q3 2024 investor meeting presentation,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.0,0.8866002429130597,0.0
new york aug 14 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced that it has received a notification from the nasdaq stock market llc nasdaq listing qualifications department informing the company that it has regained compliance with the nasdaq listing minimum bid price requirement for continued listing on the nasdaq capital market exchange,tiziana life sciences regains compliance with nasdaq listing minimum bid price rule,exchange_announcement,UP,0.0,195136160.0,63394363.0,242895.0,0.107,139700.0,0.32487245316296065,0.09346626282280733,2,7,318,0.06818181818181818,1.1109140250580023,0.03674538424538425
mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,clinical_study,DOWN,-5.735299106184534,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,0,8,404,0.0,34.079934680222834,0.06363636363636363
guggenheim s inaugural healthcare innovation conference nov 11 13,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,3,240,0.0,0.5536010581445269,0.0
moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,clinical_study,DOWN,-7.103823312288768,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,2,10,625,0.11363636363636363,0.5366763308656862,-0.03166666666666666
needham mass march 28 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the fourth quarter and year ended december 31 2023 and provided a corporate update,candel therapeutics reports fourth quarter and full year 2023 financial results and recent corporate highlights,financial_results,DOWN,-0.6493500461665078,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,457,0.04375,1.2870358800144117,0.11384358288770052
pratteln switzerland october 1 2024 santhera pharmaceuticals six sann announces the positive outcome of the lionheart study confirming vamorolone s distinctive action also as a mineralocorticoid receptor antagonist setting it apart from other corticosteroids,santhera announces positive topline results from lionheart study with agamree vamorolone demonstrating unique mineralocorticoid receptor antagonism,clinical_study,UP,1.5819139391402794,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,270,0.16090909090909092,0.5209522992128177,0.05122655122655123
boston feb 20 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda has granted fast track designation to pgn edodm1 an investigational candidate for the treatment of myotonic dystrophy type 1 dm1 receiving fast track designation from the fda for pgn edodm1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the dm1 community said james mcarthur ph d president and ceo of pepgen patients with dm1 currently have no available treatment options that target the root cause of the disease which leads to progressive neuromuscular symptoms and reduction in life expectancy following robust preclinical data we are now evaluating pgn edodm1 in the ongoing freedom dm1 phase 1 trial and expect to report preliminary data later this year we believe that pgn edodm1 has the potential to be disease modifying and improve outcomes for patients living with dm1,pepgen receives u s fda fast track designation for pgn edodm1 for the treatment of myotonic dystrophy type 1,clinical_study,DOWN,-1.079917699762323,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,1,8,494,0.07045454545454546,1.4553932872573117,0.04170935545935545
rockville md oct 16 2024 globe newswire theriva biologics nyse american tovx theriva or the company a clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the european commission has adopted the european medicines agency ema recommendation to grant orphan medicinal product designation to lead clinical candidate vcn 01 theriva s systemic selective stroma degrading oncolytic adenovirus for the treatment of retinoblastoma the united states food and drug administration fda has previously granted orphan drug designation and rare pediatric disease designation to vcn 01 for the treatment of retinoblastoma,theriva biologics announces orphan medicinal product designation granted by the european commission to vcn 01 for the treatment of retinoblastoma,clinical_study,UP,0.7194237817389376,3592451.0,8173972.0,1624850.0,0.833,91200.0,2.2753189953043202,0.09346626282280733,2,8,255,0.03666666666666667,1.5225134880447404,0.061530568846358324
media release,danske bank a s revises 2024 net profit upwards now expects a net profit in the range of dkk 22 5 23 5 billion,earnings_releases_and_operating_results,DOWN,-0.994642651307372,212863959040.0,655783007.0,1036566.3333333334,0.707,1113237.0,0.003080761111263413,0.1515999603296736,3,7,240,0.0,0.2786156283369768,0.0
sydney australia oct 09 2023 globe newswire radiopharm theranostics asx rad a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce it has been granted human research ethics committee hrec approval to commence its first in human phase i study in australia for the company s therapy for patients with pdl1 positive non small cell lung cancer nsclc,rad receives approval for phase 1 therapeutic study of pdl1 nanobody in non small cell lung cancer,clinical_study,UP,0.0,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,0,7,628,0.06818181818181819,0.9771277191333917,0.21784511784511784
zug switzerland oct 02 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the appointment of daniel s char to the role of chief legal officer leading oculis legal compliance and corporate governance functions mr char brings over 35 years of success in global legal leadership experience at both large and smaller biotech companies,oculis announces appointment of daniel s char as chief legal officer,management_changes,UP,0.9098399941186142,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,2,4,269,0.13142857142857142,0.4640841922034435,0.02292929292929293
innofactor plc managers transactions on october 11 2024 at 16 45 finnish time innofactor oyj managers transactions ____________________________________________ person subject to the notification requirementname anna lindénposition member of the board deputy memberissuer innofactor oyjlei 7437008oskqfedzyd835notification type initial notificationreference number 81082 5 4 ____________________________________________ transaction date 2024 10 11venue nasdaq helsinki ltd xhel instrument type shareisin fi0009007637nature of transaction disposal transaction details 1 volume 140165 unit price 1 68 eur aggregated transactions 1 volume 140165 volume weighted average price 1 68 eur espoo october 11 2024 innofactor plc eija theis general counsel additional information eija theis general counselinnofactor plctel 358 44 343 4278eija theis innofactor com distribution nasdaq helsinkimain mediawww innofactor com innofactorinnofactor is the leading driver of the modern,innofactor plc managers transactions anna lindén,managers_transactions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,259,-0.002777777777777763,0.8866002429130597,0.0
boston dec 22 2023 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer announced today that it has entered into a subscription agreement to sell 1 213 000 shares of its common stock at a purchase price of 5 81 per share in a private placement to gkcc llc gkcc llc is an entity controlled by a member of elicio s board of directors gross proceeds of the private placement are expected to be approximately 7 0 million before deducting expenses the private placement is expected to close on december 22 2023 subject to the satisfaction of customary closing conditions,elicio therapeutics announces 7 0 million private placement financing,shares_issue,DOWN,-0.8620722256998448,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,4,9,554,-0.10666666666666666,0.8558055682194762,0.02666666666666667
carmel ind sept 30 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that both the rationale and design of the phase 2 avail trial of mbx 2109 the company s potential long acting parathyroid hormone pth peptide prodrug in adults with hypoparathyroidism hp were featured in a poster presentation at the american society for bone and mineral research asbmr 2024 annual meeting held in toronto on canada september 27 30 2024,mbx biosciences presents mbx 2109 phase 2 avail hypoparathyroidism trial rationale and design at the asbmr 2024 annual meeting,clinical_study,DOWN,-2.5052207196509784,382040896.0,13610404.0,237885.0,0.8755,391100.0,0.03562551586100353,0.09346626282280733,0,8,271,-0.0125,0.928688678995062,0.0
san carlos calif april 30 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer today announced that senior leadership plans to present at the following conferences,iovance biotherapeutics to present at upcoming conferences,press_releases,DOWN,-1.080632729231244,599411520.0,280347936.0,11775260.0,0.863,9708200.0,0.46770528534386524,0.09346626282280733,1,6,424,0.0,0.901765204231867,0.010606060606060605
pharmacosmos group to acquire g1 therapeutics,pharmacosmos group to acquire g1 therapeutics,mergers_acquisitions,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,325,0.0,0.8866002429130597,0.04833333333333333
2023 annual results,eurobio scientific 2023 annual results,earnings_releases_and_operating_results,UP,0.4975119657066306,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,11,443,0.0,0.4336088389568585,0.0
media release,positive initial clinical data reported from immutep s efti combined with radiotherapy and checkpoint inhibitor from phase ii trial in soft tissue sarcoma,clinical_study,UP,5.000004584972843,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,3,8,422,0.10909090909090909,0.7476881311953882,0.11931818181818182
sydney australia sept 18 2024 globe newswire immutep limited asx imm nasdaq immp immutep or the company a clinical stage biotechnology company developing novel lag 3 immunotherapies for cancer and autoimmune disease today announces new data from eftisarc neo a phase ii investigator initiated trial of eftilagimod alpha efti in combination with radiotherapy plus keytruda pembrolizumab for patients with soft tissue sarcoma sts will be presented at the connective tissue oncology society ctos 2024 annual meeting taking place 13 16 november 2024 in san diego california,new data to be presented from eftisarc neo phase ii evaluating novel triple combination including immutep s efti in soft tissue sarcoma,clinical_study,UP,0.4484300617814165,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,283,0.08025974025974025,0.7476881311953882,0.10660254532434983
cambridge mass aug 28 2024 globe newswire editas medicine inc nasdaq edit a clinical stage gene editing company today announced that management will participate in the following upcoming investor conferences to discuss the company and its programs including reni cel,editas medicine to participate in upcoming investor conferences,conference_call_webinar,DOWN,-1.0471194385354707,181573264.0,83382193.0,2526680.0,2.096,3015800.0,0.4592206537632104,0.09346626282280733,2,9,304,0.0,1.3105556047468256,0.07408449575116241
needham mass april 25 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology asco annual meeting taking place may 31 to june 4 2024 in chicago il the first presentation will feature data from the ongoing phase 1 clinical trial of can 3110 in patients with recurrent high grade glioma the presentation will focus on patients recruited in cohort c treated with multiple injections of can 3110 up to six demonstrating that this approach is both feasible and well tolerated the second presentation will show topline overall survival data from the phase 2 clinical trial of can 2409 plus valacyclovir in combination with continued immune checkpoint inhibitor ici treatment in patients with non resectable stage iii iv non small cell lung cancer nsclc who have an inadequate response to front line anti pd l 1 therapy,candel therapeutics announces upcoming presentations at the 2024 asco annual meeting,clinical_study,DOWN,-2.479340341131657,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,429,0.02285714285714286,1.2870358800144117,0.11927989790957705
malvern pa feb 14 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase ii iii study of its lead candidate buntanetap in patients with mild to moderate alzheimer s disease ad,annovis bio announces last patient last visit in the phase ii iii study of buntanetap in alzheimer s disease,clinical_study,UP,2.985076468072456,44036864.0,15624645.0,595065.0,1.618,805900.0,0.3548083033342247,0.09346626282280733,2,7,500,0.05555555555555555,1.368989555493872,0.03428030303030303
san diego sept 19 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced the appointment of rick bright ph d philip krause m d mario barro ph d and frederick g hayden m d facp to its scientific advisory board sab,cidara therapeutics strengthens its scientific advisory board with infectious disease experts,advisory,UP,2.4956967703022856,632867904.0,4118697.0,696580.0,0.795,3470400.0,0.006507988434818777,0.09346626282280733,3,8,282,0.12222222222222225,1.357695941787151,-0.03808401475068141
the combined company aims to accelerate precision personalized medicine for longevity powered by mutually reinforcing ai and biotechnology platforms for early diagnosis better targeted treatments and drug discovery,renovaro biosciences and ai health company gedi cube sign definitive agreement to combine,mergers_acquisitions,DOWN,-4.668305877316483,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,4,9,638,0.3,1.5631250973582267,0.0
san carlos calif april 30 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer today announced that senior leadership plans to present at the following conferences,iovance biotherapeutics to present at upcoming conferences,press_releases,DOWN,-1.080632729231244,599411520.0,280347936.0,11775260.0,0.863,9708200.0,0.46770528534386524,0.09346626282280733,1,6,424,0.0,0.901765204231867,0.010606060606060605
jupiter fla and bunnik the netherlands feb 28 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health today announced its dutch subsidiary dyadic nederland bv has entered into a strategic partnership agreement and collaboration with rabian bv rabian a dutch innovative sme founded by experienced entrepreneurs and vaccine scientists the aim is to develop highly efficacious scalable and affordable rabies prophylactics and vaccines utilizing dyadic s c1 protein production platform this collaboration seeks to address the global burden of rabies a disease that annually claims tens of thousands of lives,dyadic announces strategic partnership agreement to develop affordable rabies prophylactics and vaccines using its proprietary c1 cell microbial protein production platform,partnerships,DOWN,-0.7042247017941755,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,486,0.26681818181818184,0.7846450948942033,0.07878787878787878
missing,mdxhealth reports preliminary q2 and half year 2024 revenues and raises 2024 revenue guidance,earnings_releases_and_operating_results,DOWN,-1.2820501064172196,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,8,355,-0.18333333333333335,0.6181119561491973,0.10389610389610392
g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,conference_call_webinar,DOWN,-6.304347127506984,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,10,401,0.0,0.8866002429130597,0.03571428571428571
27 sep 2024 17 45 cest aventador termination of the liquidity contract entered into with tsaf and new ticker symbol paris 27 09 2024 at 5 45 pm aventador euronext growth paris ticker alave isin fr001400iv58 holding company listed on euronext growth paris market terminated the liquidity contract entrusted on november 25 2021 to the company tsaf tradition securities and futures on september 23 2024 the following assets were in the liquidity account on september 23 2024 after the close of trading 0 aventador shares 21 145 28 the following assets were in the liquidity account on june 30 2024 during the semi annual review of the liquidity contract 306 618 algreen shares 18 832 81 it is recalled that when the contract was implemented on november 25 2021 the following assets were in the liquidity account 25 000 00 aventador announces the change of its ticker symbol on the euronext growth paris market the new ticker symbol for aventador is now alav,termination of the liquidity contract entered into with tsaf and new ticker symbol,exchange_announcement,UP,6.666663044856685,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,273,0.06818181818181818,0.8866002429130597,0.0
new york may 30 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced that howard l weiner m d chairman of tiziana s scientific advisory board and co director of the ann romney center for neurologic diseases at brigham and women s hospital a founding member of mass general brigham healthcare system is being honored with the prestigious giants of ms award for his outstanding contributions in the area of multiple sclerosis ms research the award ceremony will take place on may 30 2024 at the consortium of multiple sclerosis centers annual meeting being held in nashville tennessee,tiziana life sciences scientific board chairman to receive prestigious award for multiple sclerosis research,contests_awards,DOWN,-1.0638287753851583,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,3,7,394,0.08376623376623378,1.1109140250580023,0.034706589706589706
oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis ms patients with pira as measured by changes in pet scans oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis ms patients with pira as measured by changes in pet scans,tiziana life sciences announces new quantitative pet imaging data on foralumab at the annual meeting of the american academy of neurology,clinical_study,UP,9.242146234319629,195136160.0,63394363.0,242895.0,0.107,139700.0,0.32487245316296065,0.09346626282280733,3,7,436,0.03409090909090909,1.1109140250580023,0.06363636363636364
media release,satisfied customers and high return on equity in the third quarter,earnings_releases_and_operating_results,UP,1.1410738067002315,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,2,12,240,0.22,0.20896972559163385,0.0
reykjavik iceland aug 26 2024 globe newswire alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide announces its participation in the morgan stanley 22nd annual global healthcare conference in new york members of the management team will hold an in person fireside chat on september 5 2024 starting at 5 35 pm edt 21 35 gmt,alvotech to participate in the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,UP,0.5046212296880009,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,0,9,306,0.02727272727272727,0.44264539487962035,0.08715277777777777
27 sep 2024 10 08 cest oslo børs har mottatt søknad om børsnotering av isin no0013335653 markedsmisbruksforordningen mar gjelder fra søknadstidspunktet herunder låntagers informasjonsplikt om innsideinformasjon more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site oslo børs oslo børs newspoint,euronext oslo børs færder kommune mottatt søknad om notering av obligasjonslån,exchange_announcement,UP,0.4901956201103737,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.5,0.8866002429130597,0.08930555555555555
turku finland and boston jan 25 2024 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company pursuing a clever approach to reprogramming myeloid cells to activate anti tumor immunity in hematological and solid tumor microenvironments today provided details from its further analysis of data from the completed phase 1 part of the ongoing bexmab trial,detailed analysis of bexmab data provides insights into patient profiles of responding hma failed mds population,clinical_study,UP,1.4881009611887892,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,3,2,520,0.05277777777777778,0.7633342480324978,0.01472378547378547
finanskalender 27 september 2024 vedhæftet fil vedlagte filer finanskalender 2024 2025 pdf,finanskalender 27 september 2024,financial_calendar,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.0,0.8866002429130597,0.0
norwood mass may 30 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will provide a corporate update and participate in one on one investor meetings at the 45th annual goldman sachs global healthcare conference to be held june 10 13 2024 in miami beach fl,corbus pharmaceuticals to present at the 45th annual goldman sachs global healthcare conference,conference_call_webinar,DOWN,-1.6781598672099496,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,3,8,394,0.0,0.9919200800994142,0.04372222222222222
immuneering to present at the morgan stanley 22nd annual global healthcare conference,immuneering to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.8849549119871483,110116240.0,27271404.0,2516685.0,0.002,1980700.0,0.24766014531553202,0.09346626282280733,3,8,303,0.0,1.2966226301621697,0.08863636363636364
cambridge mass june 25 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today presented new data demonstrating for the first time the potential for redosing with an investigational in vivo crispr cas9 genome editing therapy these data from the ongoing phase 1 study of ntla 2001 a single dose treatment in development for transthyretin attr amyloidosis were presented at the peripheral nerve society annual meeting taking place june 22 25 in montreal canada,intellia announces positive clinical proof of concept data for redosing a crispr based therapy with its proprietary lnp based delivery platform,clinical_study,DOWN,-2.8340110984520823,975233920.0,98412511.0,6353695.0,2.134,5288300.0,0.10091169819031726,0.09346626282280733,1,15,367,0.10844155844155845,0.7800307612939593,0.02357142857142857
farmington hills mich may 06 2024 globe newswire ocuphire pharma inc nasdaq ocup ocuphire a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders today announced that clinical data from its zeta 1 trial evaluating apx3330 in diabetic retinopathy dr on a validated binocular person level scale was presented yesterday at the association for research in vision and ophthalmology arvo annual meeting taking place may 5 9 2024 in seattle washington the presentation titled oral apx3330 a ref 1 inhibitor slows progression of diabetic retinopathy on a binocular drss person level scale was delivered by daniel su m d a practicing retina specialist at retina vitreous associates medical group la retina in los angeles california,ocuphire pharma announces presentation on apx3330 at the arvo 2024 annual meeting,clinical_study,UP,1.0050241623450802,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,418,0.0,0.8866002429130597,-0.01325868009541479
media release,enefit green interim report for q3 2024,earnings_releases_and_operating_results,DOWN,-1.3468000494176686,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,9,240,-0.2,0.8866002429130597,-0.07522727272727274
zug switzerland aug 15 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the appointment of dr sharon klier an executive leader with extensive experience in clinical development across early and late stage programs regulatory submissions and approvals to the role of chief development officer in this key role dr klier will oversee and provide strategic leadership across the clinical development and operations of oculis robust ophthalmology pipeline,oculis appoints sharon klier m d m s m p h as chief development officer,management_changes,UP,0.0,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,8,317,-0.039999999999999994,0.4640841922034435,0.05012626262626263
pratteln switzerland september 10 2024 santhera pharmaceuticals six sann announces the signing of an exclusive distribution agreement with genesis pharma for agamree vamorolone for the treatment of duchenne muscular dystrophy dmd in 20 markets in central and eastern europe,santhera enters into an exclusive distribution agreement with genesis pharma for agamree vamorolone in central and eastern europe,geographic_expansion,UP,1.3043466092057148,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,291,0.0,0.5209522992128177,0.07738095238095238
biologics license application bla for hav accepted by fda on february 8 2024,humacyte fourth quarter and year end 2023 financial results and business update,financial_results,UP,0.833339183418994,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,4,7,463,0.0,1.1173068527438073,0.05
yield10 achieves a significant milestone in the development of camelina as a commercial crop for producing biofuels and omega 3 oils,usda aphis determines that yield10 bioscience s glufosinate tolerant camelina may be planted and bred in the united states,product_services_announcement,DOWN,-6.451613109971017,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,591,0.1875,0.8866002429130597,0.018571428571428572
media release,subsidiary of eften real estate fund as acquired the elp logistics oü logistics center,mergers_acquisitions,UP,0.5235621961910748,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,253,0.05,0.8866002429130597,0.11580437309603979
toronto june 10 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the meeting written responses received by the company from the u s food drug administration fda of the revive lc poc lateral flow test kit the product for feedback on the classification development and regulatory submission strategy for a point of care in vitro diagnostic device that aids in the detection of post covid 19 conditions the fda has determined that the product should follow the de novo regulatory pathway and the company would be required to conduct a clinical study for the de novo submission for possible approval,revive therapeutics provides update from fda meeting for long covid diagnostic product,clinical_study,UP,0.0,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,0,7,383,0.0625,1.8889707456546947,0.10143029479927877
confirmed objective response rate orr of in pd l1 positive tps patients with no prior checkpoint inhibitor therapy cpi,rapt therapeutics announces positive data including objective response rates and progression free survival from its phase 2 trial of flx475 in combination with a checkpoint inhibitor in patients with advanced nsclc,clinical_study,UP,6.970326051315709,142045104.0,6191111.0,99294.6,-0.137,87900.0,0.04358552900211189,0.09346626282280733,4,12,602,0.20681818181818182,1.6028075568485736,0.16145833333333334
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl gbp nav s,fund_data_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
media release,two national airlines choose a seamless multi orbit ifc future with ses open orbits,product_services_announcement,DOWN,-4.347824604401455,33236662.0,5203991.0,38994.47368421053,-1.546,15503.0,0.15657381598669565,0.19535099655549074,2,8,241,0.03333333333333333,2.144966214298392,0.0888888888888889
conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time,mediwound to report second quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-2.8636885808582586,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,4,8,330,0.0,0.6433034533898109,0.14575491759702286
sampo plc stock exchange release 25 september 2024 at 8 30 am eest sampo plc s share buybacks 24 september 2024 on 24 september 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 312 345 sampo a shares representing 1 33 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 sep,sampo plc s share buybacks 24 september 2024,changes_in_companys_own_shares,UP,0.0965273090080709,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,276,0.1625,0.8866002429130597,0.0
rockaway n j sept 26 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company announced today that management will participate in the following investor events,electrocore to participate in upcoming investor conferences,conference_call_webinar,DOWN,-1.4705938038939923,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,3,8,275,0.0,0.8324549917316175,0.14213496572871573
10 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 09 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 3795 25 5158estimated mtd return 0 07 0 09 estimated ytd return 3 02 3 85 estimated itd return 183 79 155 16 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 20n apremium discount to estimated nav 4 16 n a sterling sharesamsterdam aex london lse market closen agbx 2 380 00premium discount to estimated navn a 6 72 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,261,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
geneva switzerland july 12 2024 addex therapeutics six adxn and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that mikhail kalinichev head of translational science will present at the thirteenth london international cough symposium taking place july 18 19 2024 at imperial college in london u k,addex to present at the thirteenth london international cough symposium 13th lics,clinical_study,DOWN,-1.0119052619891058,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,351,-0.041666666666666664,0.972373032385036,-0.00401960784313725
media release,aker bp key information related to cash dividend,dividend_reports_and_estimates,UP,2.086106029551391,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.05397727272727274
adelaide australia and cambridge mass oct 01 2024 globe newswire bionomics limited nasdaq bnox bionomics or the company a clinical stage biotechnology company developing novel potential first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need today announced its intention to re domicile from australia to the united states via a proposed scheme of arrangement between bionomics and its shareholders the scheme that will be governed by australian law implementation of the scheme is subject to approval of bionomics shareholders as well as regulatory and court approvals,bionomics limited announces intention to re domicile to the united states,corporate_action,UP,7.061500586949597,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,270,-0.02328571428571428,0.8866002429130597,0.054991979704006815
sydney australia june 05 2024 globe newswire immutep limited acn 009 237 889 asx imm nasdaq immp immutep or the company is pleased to announce the successful completion of its institutional placement placement and the institutional component institutional entitlement offer of its 1 for 16 pro rata accelerated non renounceable entitlement offer entitlement offer and together with the placement the offer of new fully paid ordinary shares in immutep new shares,immutep successfully completes institutional placement and institutional component of entitlement offer,shares_issue,DOWN,-7.103823312288768,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,2,6,388,0.2787569573283859,0.7476881311953882,0.09772727272727272
media release,chiffre d affaires de capgemini au 3ème trimestre 2024,earnings_releases_and_operating_results,DOWN,-1.7892695828851255,24334401536.0,169611141.0,417051.0,0.951,403238.0,0.006970014888144237,0.19535099655549074,2,7,241,0.0,0.29691516676147794,0.0
27 sep 2024 08 30 cest casino guichard perrachon casino group sells over 200m of commercial real estate assets to tikehau capital paris 27 september 2024 following the signature in june 2024 of an agreement with tikehau capital covering a portfolio of 30 real estate assets casino group announced that on thursday 26 september 2024 it had finalized the sale of 26 of these for a net selling price of over 200 million euros excluding subsequent earn outs the sale of the remaining assets provided for in the agreements will be finalized in the coming weeks once the usual conditions precedent have been lifted the overall portfolio comprises hypermarket and supermarket premises leased to casino intermarché carrefour and auchan as well as ancillary lots within these real estate complexes some of which offer real estate development potential tikehau capital has entrusted casino group with the property management of these assets for a period of 5 years the net proc,casino group real estate asset sales,business_contracts,DOWN,-0.3016839287324527,112574064.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.1515999603296736,4,6,274,0.057692307692307696,0.8866002429130597,0.0
transcode therapeutics announces appointment of daniel vlock m d as chief medical officer,transcode therapeutics announces appointment of daniel vlock m d as chief medical officer,management_changes,UP,0.0,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,8,457,0.0,2.0874185587937095,0.0
company reaffirms commitment to maintaining appropriate standards of animal welfare company reaffirms commitment to maintaining appropriate standards of animal welfare,inotiv reaches agreement to resolve previously announced investigation into shuttered cumberland facility,law_legal_issues,UP,9.242146234319629,62522460.0,31206932.0,922240.0,4.102,583600.0,0.49913154408831645,0.09346626282280733,0,13,389,0.2777777777777778,1.3015467599292592,0.01574344023323615
los angeles ca march 20 2024 globe newswire immix biopharma inc nasdaq immx immixbio company we or us or immx a clinical stage biopharmaceutical company trailblazing cell therapies in al amyloidosis and other autoimmune diseases today announced memorial sloan kettering cancer center as lead clinical site for its nxc 201 relapsed refractory al amyloidosis multi site clinical trial,immix biopharma announces major comprehensive cancer center as lead site for nxc 201 al amyloidosis clinical trial,clinical_study,UP,2.2388037792902336,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,2,9,464,-0.065625,0.9253604538231538,0.0721111111111111
los angeles feb 05 2024 globe newswire immix biopharma inc nasdaq immx the company a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced that it intends to offer and sell shares of its common stock in an underwritten public offering all of the shares of common stock in the underwritten public offering are to be sold by the company the company also expects to grant the underwriters a 30 day option to purchase additional shares of common stock offered in the public offering the offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering,immix biopharma announces proposed public offering of common stock,shares_issue,DOWN,-7.103823312288768,61330060.0,18058632.0,290605.0,0.301,58200.0,0.2944499320561565,0.09346626282280733,0,15,508,-0.13666666666666666,0.9253604538231538,-0.037500000000000006
hear from the 30 000 relapsed or refractory al amyloidosis patients in the united states today in their own words hear from the 30 000 relapsed or refractory al amyloidosis patients in the united states today in their own words,immix biopharma announces be proactive in al al amyloidosis awareness initiative,press_releases,DOWN,-7.103823312288768,61628348.0,18058632.0,290605.0,0.301,58200.0,0.29302476191638305,0.09346626282280733,1,9,479,0.6,0.9253604538231538,-0.059861111111111115
adelaide australia and cambridge mass july 25 2023 globe newswire bionomics limited asx bno nasdaq bnox bionomics or the company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it has submitted a formal request to the australian securities exchange asx to be removed from the official list of the asx in keeping with the company s ongoing transformation to a u s focused organization the main consequence of an asx delisting for shareholders is that from the time the proposed asx delisting is scheduled to take effect on august 28 2023 bionomics shares will no longer be quoted or traded on the asx and will only be tradable in the form of american depositary shares on the nasdaq global market nasdaq under the symbol bnox,bionomics announces intention to delist from the australian securities exchange asx,exchange_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,704,0.014325396825396826,0.8866002429130597,0.0005529100529100557
media release,argan complète son parc logistique normand de bolbec,geographic_expansion,UP,0.2894422316255524,1612706688.0,12060258.0,31954.954545454544,0.782,14598.0,0.0074782712130725655,0.1515999603296736,1,7,242,0.0,0.2170511352010478,0.0
all ruby patients with 5 months follow up have achieved a normal hemoglobin level and a fetal hemoglobin level of,editas medicine announces new edit 301 safety and efficacy data in 17 patients presented today at the american society of hematology ash annual meeting and in a company sponsored webinar,clinical_study,DOWN,-5.167463844107009,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,0,12,564,0.09545454545454546,1.3105556047468256,0.0
media release,amundi third quarter and nine month 2024 results,earnings_releases_and_operating_results,DOWN,-2.828854436110023,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,241,0.0,0.8866002429130597,0.0
favorable clinical safety and tolerability profile observed with no evidence of crs associated cytokines,kineta unveils positive new data from vista 101 clinical trial of kva12123 at the society for immunotherapy of cancer s sitc 38th annual meeting,clinical_study,DOWN,-1.9138738514697824,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,600,0.18181818181818182,0.8866002429130597,0.0
abstracts to include preclinical data on several drug fc conjugate dfc candidates including multispecific cd73 pd 1 dfc ccr5 targeting dfc and cbo421 cd73 targeting dfc abstracts to include preclinical data on several drug fc conjugate dfc candidates including multispecific cd73 pd 1 dfc ccr5 targeting dfc and cbo421 cd73 targeting dfc,cidara therapeutics to present preclincal data on multiple novel drug fc conjugate candidates at american association for cancer research aacr annual meeting 2024,annual_general_meeting,DOWN,-2.7142865317208424,638568128.0,4118697.0,696580.0,0.795,3470400.0,0.006449894411266326,0.09346626282280733,2,8,479,0.0,1.357695941787151,-0.05555555555555555
needham mass june 18 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that paul peter tak md phd fmedsci candel s president and chief executive officer will participate in a fireside chat at the h c wainwright 2nd annual immune cell engager virtual conference on tuesday june 25 2024 at 3 00 p m et,candel therapeutics to participate in the h c wainwright 2nd annual immune cell engager virtual conference,conference_call_webinar,DOWN,-0.8310241623697936,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,1,8,375,0.0,1.2870358800144117,0.08716815514084421
lexington mass may 22 2024 globe newswire t2 biosystems inc nasdaq ttoo the company a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes today announced that it received written notice from the nasdaq stock market llc nasdaq on may 21 2024 informing the company that it has regained compliance with the market value of listed securities mvls requirement as set forth in nasdaq listing rule 5550 b 2 the rule for continued listing on the nasdaq capital market,t2 biosystems regains compliance with nasdaq continued listing requirements,exchange_announcement,DOWN,-1.6513702550545175,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,2,9,402,0.0,1.9596557041969667,0.03311965811965811
media release,polight asa continues to build positive momentum in several segments,business_contracts,DOWN,-7.103823312288768,725118720.0,112518348.0,613349.45,1.511,331673.0,0.15517231164573989,0.19535099655549074,3,7,240,0.11363636363636363,0.8385781649627817,0.0
mss crc case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion with a confirmed partial response at adg126 10 mg kg every three weeks plus pembrolizumab,adagene presents data demonstrating the best in class therapeutic index for masked anti ctla 4 safebody adg126 at sitc 2023,clinical_study,UP,1.5037579158775027,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,12,602,0.4333333333333333,0.845882180665701,0.13645833333333332
yield10 bioscience files rsr with usda aphis for elite camelina designed to produce epa dha omega 3 oils,yield10 bioscience files request for regulatory status review with usda aphis for camelina designed to produce the epa and dha components of omega 3 oil,regulatory_filings,DOWN,-4.166670805877945,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,537,0.0,0.8866002429130597,0.10385714285714287
aaic poster presentation highlights xpro s significant effects on a wide range of synaptic proteins and pathways,inmune bio inc announces new phase 1 study data demonstrating dose dependent effect of xpro on proteins that regulation synapses in alzheimer s patients,clinical_study,UP,0.9324000514850754,160151632.0,15213010.0,781395.0,1.567,974600.0,0.09499128925517288,0.09346626282280733,0,9,334,0.13712121212121212,0.8435084668920305,0.13842468584656084
dallas july 23 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has added three new u s clinical trial sites for its 2024 burn pivotal study university medical center umc burn center at texas tech university health sciences center led by principal investigator alan pang m d tampa general hospital burn center led by principal investigator jared troy m d and university of south alabama usa health emergency department led by andrew bright d o,spectral ai adds three new clinical trial sites to expedite emergency department patient enrollment,clinical_study,UP,0.0,55099652.0,17924135.0,466020.0,0.698,473400.0,0.3253039601774617,0.09346626282280733,1,8,340,0.10162337662337663,0.9904696515070965,0.11222016079158938
company to demonstrate mydcombi and avenova and share data for clobetasol propionate ophthalmic suspension 0 at the american society of cataract and refractive surgery ascrs annual meeting april 5 8 in boston,eyenovia to feature its suite of commercial products and the optejet dispenser at upcoming national eyecare meetings,trade_show,DOWN,-1.970953741106604,27891188.0,2433609.0,8930490.0,1.002,41800300.0,0.08725368743705,0.09346626282280733,2,7,451,0.0,2.4441832149286684,0.0
saint herblain france and schlieren zurich august 1 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company and limmatech biologics ag a clinical stage biotech company developing vaccines for the prevention of life threatening diseases today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development manufacturing and commercialization of shigella4v s4v a tetravalent bioconjugate vaccine candidate against shigellosis,valneva and limmatech enter into a strategic partnership to accelerate the development of the world s most clinically advanced tetravalent shigella vaccine candidate,licensing_agreements,DOWN,-1.4966004753969215,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,331,0.45,0.6494694268312979,0.06944444444444443
pratteln schweiz 24 september 2024 santhera pharmaceuticals six sann gibt bekannt dass das schweizerische heilmittelinstitut swissmedic das zulassungsgesuch marketing authorization application maa für agamree vamorolon für die behandlung von duchenne muskeldystrophie dmd zur prüfung akzeptiert hat,santhera gibt annahme des zulassungsantrags für agamree vamorolon bei duchenne muskeldystrophie durch swissmedic bekannt,regulatory_filings,UP,0.0,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,277,0.0,0.5209522992128177,0.054531490015360985
amsterdam sept 11 2024 globe newswire nasdaq renb the board of renovaro inc renb intends to seek strategic investors to acquire up to of renovarocube cube currently a wholly owned subsidiary,renovarocube announces strategic offering of up to ownership,capital_investment,UP,2.7859229207045826,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,2,9,290,0.0,1.5631250973582267,0.08286921411921412
media release,coinshares appoints lisa avellini as group general counsel,management_changes,DOWN,-4.752851848902593,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.05000000000000002,0.8866002429130597,0.0
new york may 30 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced that howard l weiner m d chairman of tiziana s scientific advisory board and co director of the ann romney center for neurologic diseases at brigham and women s hospital a founding member of mass general brigham healthcare system is being honored with the prestigious giants of ms award for his outstanding contributions in the area of multiple sclerosis ms research the award ceremony will take place on may 30 2024 at the consortium of multiple sclerosis centers annual meeting being held in nashville tennessee,tiziana life sciences scientific board chairman to receive prestigious award for multiple sclerosis research,contests_awards,DOWN,-1.0638287753851583,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,3,7,394,0.08376623376623378,1.1109140250580023,0.034706589706589706
as indexo bank hereinafter referred to as indexo bank has attracted more than 10 000 customers in its first month of operation since august 28 in comparison for the pension management company ipas indexo which currently has over 137 000 clients it took more than a year to attract its first 10 000 customers at indexo bank all customer applications are submitted through the new bank s mobile app and it is currently evident that the proportion of apple users slightly exceeds that of android platform users among indexo bank s clients the first month has been very successful for indexo bank in terms of customer acquisition the highest customer activity of course was seen during the first few days of operations but the inflow of new customers continues even now it is too early to draw conclusions about specific user habits or customer profiles we see that some customers are transferring their salary payments to indexo bank others are actively using payment cards and,indexo bank attracts more than 10 000 customers in its first month of operation,press_releases,UP,0.4065056094269542,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,270,0.21376262626262627,0.8866002429130597,0.1040909090909091
new haven conn may 28 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that ceo vimal mehta ph d will present at the jefferies global healthcare conference in new york city the presentation is set for wednesday june 5 at 3 p m et and will highlight bioxcel therapeutics late stage clinical programs with bxcl501 for the acute treatment of agitation associated with alzheimer s dementia bipolar disorders and schizophrenia dr mehta will be joined by vincent j o neill m d executive vice president chief of product development and medical officer,bioxcel therapeutics to present at jefferies global healthcare conference,conference_call_webinar,UP,0.0,11997035.0,5544250.0,450810.0,-0.13,78500.0,0.4621350191943259,0.09346626282280733,1,7,396,-0.0027272727272727227,1.4586588351104455,0.03778950216450217
south san francisco calif may 03 2023 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced the appointment of michael listgarten as general counsel,rapt therapeutics announces the appointment of michael listgarten as general counsel,management_changes,UP,1.7643680781263908,143367984.0,6191111.0,99294.6,-0.137,87900.0,0.04318335814779958,0.09346626282280733,2,8,787,0.05625000000000001,1.6028075568485736,0.0
media release,coinshares appoints lisa avellini as group general counsel,management_changes,DOWN,-4.752851848902593,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.05000000000000002,0.8866002429130597,0.0
cambridge mass and rostock germany and berlin feb 28 2024 globe newswire centogene n v nasdaq cntg the company the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced that the company has decided to explore a range of strategic alternatives focused on sustainable long term value creation for the benefit of its stakeholders,centogene explores strategic alternatives,joint_venture,UP,0.5454599218358603,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,486,0.08333333333333333,3.598197549072007,0.18154761904761904
toronto april 02 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to provide an update on the company s clinical study the study nct05322954 evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator initiated ind at the university of wisconsin madison school of medicine and public health and school of pharmacy,revive therapeutics provides update on psilocybin clinical study for methamphetamine use disorder,clinical_study,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,452,0.16,1.8889707456546947,0.10341513985453381
media release,arctic bioscience q3 2024 operational update,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.1313131313131313
continuing to open connect1 edo51 trial sites in canada,pepgen reports third quarter 2023 financial results and recent corporate developments,financial_results,DOWN,-3.9999961853027344,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,2,8,598,0.0,1.4553932872573117,0.0711038961038961
fourth quarter and full year 2023 briumvi u s net revenue of approximately 40 million and 89 million respectively,tg therapeutics provides business update and reports fourth quarter and year end 2023 financial results,financial_results,UP,9.242146234319629,5892985856.0,135060602.0,1756590.0,1.939,1677400.0,0.022918874285518056,0.09346626282280733,2,7,486,-0.00714285714285715,0.6256004090066075,0.05909090909090909
g1 therapeutics to release first quarter 2024 financial results and provide business update on may 1 2024,g1 therapeutics to release first quarter 2024 financial results and provide business update on may 1 2024,conference_call_webinar,UP,1.7156905139790426,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,437,0.125,0.8866002429130597,0.0
copenhagen denmark sept 16 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines announces positive one year data from the ongoing phase 2 trial with its lead asset evx 01 an ai designed personalized cancer vaccine,evaxion reports convincing one year data from phase 2 trial on ai designed personalized cancer vaccine evx 01,clinical_study,UP,0.9999990463256836,15601928.0,155104950.0,157745.0,0.102,38700.0,9.94139634537475,0.09346626282280733,0,7,285,0.36363636363636365,1.4249795072460607,0.11745679012345679
in a release issued under the same headline on monday march 11th by dyadic international inc nasdaq dyai please note that the city in the dateline should be jupiter fla not juniper fla the corrected release follows,correction dyadic announces closing of private placement of 6 0 million convertible notes to accelerate near term revenue growth and commercialization,financing_agreements,UP,3.5461044474619707,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,0,9,473,0.025,0.7846450948942033,0.1799100378787879
leveraging akoya s market leading phenoimager ht platform and clinical development expertise with neracare s immunoprint test and best in class clinical data the partnership will focus on increasing access to life saving therapies for early stage melanoma patients leveraging akoya s market leading phenoimager ht platform and clinical development expertise with neracare s immunoprint test and best in class clinical data the partnership will focus on increasing access to life saving therapies for early stage melanoma patients,akoya biosciences and neracare enter into an exclusive agreement to enable personalized therapy selection for early stage melanoma patients,partnerships,DOWN,-0.2433145634300717,60944124.0,12648900.0,228670.0,1.352,488000.0,0.207549131397803,0.09346626282280733,3,8,415,0.4600000000000001,0.8573192373918191,0.15176767676767675
malvern pa may 29 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that the company will present at the 2024 bio international convention taking place in san diego ca from june 3 6 2024,ocugen to present at bio international convention 2024,trade_show,DOWN,-3.5087754766280086,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,7,395,0.0,0.7661975315521313,0.10606060606060606
selskabet annoncerede i selskabsmeddelelse 13 2024 at man havde indledt en proces med at gennemføre et identitetsskifte med nasdaq for fortsat at kunne bevare sin status som børsnoteret selskab,business update opdatering på identitetsændring,exchange_announcement,DOWN,-0.5681818181818182,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,283,0.0,0.8866002429130597,0.0
media release,disclosure of large shareholding,major_shareholder_announcements,UP,2.203024783091614,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,14,239,0.21428571428571427,0.8866002429130597,0.11857142857142858
media release,quadient obtient un prêt schuldschein de 25 millions d euros auprès de la berd pour financer des programmes de r d en république tchèque,financing_agreements,DOWN,-1.960782480441495,528319008.0,22771639.0,0.0,1.149,0.0,0.04310206268406682,0.19535099655549074,2,7,241,0.0,0.39343620296100096,0.0
la jolla calif may 20 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that it has received a notice of allowance from the u s patent and trademark office for a pending patent application which covers mn 166 ibudilast for the prevention of metastasis of eye cancer,medicinova receives notice of allowance for new patent covering mn 166 ibudilast for the prevention of metastasis of eye cancer,patents,UP,0.0,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,0,6,404,0.04545454545454545,0.8018560055721619,0.13012121212121214
media release,change in the number of shares and votes in egetis therapeutics,shares_issue,UP,1.5963441544008423,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,240,0.0,0.8866002429130597,0.043333333333333335
new york may 28 2024 globe newswire tg therapeutics inc nasdaq tgtx today announced the schedule of upcoming presentations highlighting study designs for post marketing studies being undertaken for briumvi ublituximab xiiy in patients with relapsing forms of multiple sclerosis rms at the 2024 consortium of multiple sclerosis centers cmsc annual meeting being held may 29 june 1 2024 in nashville tennessee abstracts are now available online and can be accessed on the cmsc meeting website at www mscare org 2024 or by clicking on the following link https meridian allenpress com ijmsc article 26 s1 1 500896 abstracts from the 38th annual meeting of the details for the upcoming briumvi presentations are outlined below,tg therapeutics announces schedule of upcoming presentations for briumvi ublituximab in multiple sclerosis at the 2024 consortium of multiple sclerosis centers annual meeting,clinical_study,UP,0.598446361153002,5889810432.0,135060602.0,1756590.0,1.939,1677400.0,0.022931230734728,0.09346626282280733,1,7,396,0.07662337662337662,0.6256004090066075,0.05121753246753247
biopharmaceutical industry veteran nurit tweezer zaks m d m b a appointed to board following retirement of anat tsour segal biopharmaceutical industry veteran nurit tweezer zaks m d m b a appointed to board following retirement of anat tsour segal,polypid announces the addition of dr nurit tweezer zaks to its board of directors,management_changes,UP,0.8905813439588344,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,1,7,599,0.0,0.7168605096826995,-0.04285714285714286
media release,totalenergies se third quarter 2024 results,earnings_releases_and_operating_results,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.2171800030740666,0.0
candel therapeutics sets path to success recent achievements pave the way for a promising 2024 propelled by key value drivers and catalysts,candel therapeutics sets path to success recent achievements pave the way for a promising 2024 propelled by key value drivers and catalysts,clinical_study,UP,2.9230852465660844,244501184.0,41997569.0,917740.0,-0.866,856900.0,0.17176836656954594,0.09346626282280733,0,8,509,0.125,1.2870358800144117,0.06018716577540107
global license of industry leading elite herbicide tolerant camelina accelerates biofuel feedstock production global license of industry leading elite herbicide tolerant camelina accelerates biofuel feedstock production,yield10 bioscience grants global license to vision bioenergy oilseeds for herbicide tolerant camelina cultivated for the production of biofuel feedstock,licensing_agreements,UP,4.166662527455388,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,500,0.0,0.8866002429130597,0.05769841269841271
biocardia announced today the completion of its last protocol specified follow up visit in cardiamp hf multi center trial,biocardia completes phase iii randomized double blind controlled trial of autologous cell therapy for ischemic heart failure,clinical_study,UP,3.305781867105094,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,0,9,243,-0.18333333333333332,1.32107885633281,0.05460434173669467
media release,immutep quarterly activities report q4 fy24,clinical_study,DOWN,-1.3953585338433494,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,332,0.0,0.7476881311953882,0.14789496218067646
west lafayette ind may 14 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that it will issue its financial results for the fiscal 2024 second quarter ended march 31 2024 on wednesday may 15 2024 after the close of the stock market the company will host a conference call that same day at 4 30 p m eastern time to discuss the results,inotiv inc to report fiscal 2024 second quarter financial results and host conference call on wednesday may 15 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,62350696.0,31206932.0,922240.0,4.102,583600.0,0.5005065540888268,0.09346626282280733,1,7,410,0.0,1.3015467599292592,0.03673469387755102
waltham mass sept 04 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will present a corporate overview at the h c wainwright 26th annual global investment conference on tuesday september 10 2024 at 10 00 a m et the company will also attend in person and virtual one on one meetings during the conference,checkpoint therapeutics to present at h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-0.4524882484455325,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,2,8,297,0.0,0.8866002429130597,0.08978517316017315
publication of detailed analysis on inkmune biology compared to cytokine stimulated cells demonstrates important anti tumor memory like nk cell characteristics,inmune bio inc publishes novel biology on natural killer cancer immunotherapy inkmune in the journal for immunotherapy of cancer,clinical_study,UP,0.4683836303477929,164126192.0,15213010.0,781395.0,1.567,974600.0,0.09269093381512196,0.09346626282280733,1,8,340,0.3,0.8435084668920305,0.15956624779541442
pdufa goal date of december 28 2024 set by fda pdufa goal date of december 28 2024 set by fda,checkpoint therapeutics announces fda acceptance of bla resubmission of cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma,regulatory_filings,UP,3.822938938456823,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,7,338,0.4,0.8866002429130597,0.07753908128908128
conference call and webcast today at 8 30 a m et,ocugen provides business update with second quarter 2024 financial results,financial_results,UP,7.627121811795395,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,3,6,324,0.0,0.7661975315521313,0.08052059052059052
conference call to begin at 4 30 p m et,vaxart to host second quarter 2024 business update and financial results conference call on august 8,conference_call_webinar,DOWN,-1.515159040990203,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,330,0.0,1.025768835125998,0.08874458874458874
media release,tonner drones signs first contract for its consultancy business,business_contracts,UP,2.272723424286861,10594011.0,70055589.0,12466009.545454545,1.018,14797393.0,6.612754036219143,0.1515999603296736,0,8,243,0.25,1.793725488267577,0.0
amsterdam oct 17 2024 globe newswire nasdaq renb renovarocube a leader in ai driven cancer diagnostics by integrating multi omics with liquid biopsies is excited to announce the presentation of its latest research at the molecular analysis for precision oncology congress on october 16 2024,renovarocube presents novel insights on non invasive cancer diagnostics using oxford nanopore sequencing,clinical_study,UP,0.1070650009700113,60241652.0,90925076.0,7542515.0,0.529,816400.0,1.5093390201185053,0.09346626282280733,3,9,254,0.4375,1.5631250973582267,0.058884980759980755
kimmtrak tebentafusp tebn net revenues of 75 3 million in 2q 2024 driven by us growth,immunocore reports second quarter financial results and provides a business update,earnings_releases_and_operating_results,UP,5.230352914273522,1603958912.0,37423034.0,614630.0,0.835,788600.0,0.02333166624158512,0.09346626282280733,3,7,324,0.0,0.44240182162750774,0.11416666666666667
agreement will supply tb 161 for rad 402 a potential next generation radiopharmaceutical for treatment of advanced prostate cancer agreement will supply tb 161 for rad 402 a potential next generation radiopharmaceutical for treatment of advanced prostate cancer,radiopharm theranostics expands supply agreement with terthera for terbium 161 isotope use in prostate cancer,clinical_study,UP,5.682690183793894,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,3,8,674,0.13333333333333333,0.9771277191333917,0.2284090909090909
confirmed objective response rate orr of 15 in all patients regardless of pd l1 or hpv status,rapt therapeutics announces promising results from phase 2 trial of tivumecirnon in combination with anti pd 1 immunotherapy in cpi experienced head and neck cancer patients,clinical_study,UP,1.442306369719372,145104272.0,6191111.0,99294.6,-0.137,87900.0,0.04266663492857054,0.09346626282280733,1,12,444,0.35,1.6028075568485736,0.08957405689548548
zug switzerland sept 19 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care in collaboration with euretina today announced the winner of the inaugural ramin tadayoni award,oculis and euretina announce the winner of the inaugural ramin tadayoni award,contests_awards,UP,0.2521066185480524,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,13,281,0.0,0.4640841922034435,0.024693084693084694
turku finland and boston sept 22 2023 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company focused on tackling cancers via novel immunotherapies announces that the extraordinary general meeting the egm of the company took place today september 22 2023 in turku finland the egm approved all proposals of the board of directors board as set out in the notice of the egm published on september 1 2023,faron pharmaceuticals ltd results of the extraordinary general meeting,management_changes,UP,0.915028679105613,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,4,6,645,0.2033333333333333,0.7633342480324978,-0.02753246753246753
malvern pa oct 09 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines today announced that the u s food and drug administration fda has lifted the clinical hold on the investigational new drug application for the phase 1 clinical trial evaluating ocu200 a recombinant fusion protein consisting of tumstatin and transferrin for treating diabetic macular edema dme,ocugen inc announces removal of clinical hold on investigational new drug application for ocu200 phase 1 clinical trial,clinical_study,UP,0.2087655784795626,303391008.0,287364635.0,6243265.0,4.237,6951700.0,0.9471758470837738,0.09346626282280733,2,6,262,0.13636363636363635,0.7661975315521313,0.05568555116381203
media release,number of shares and votes in nanologica ab publ,shares_issue,UP,0.881056435883782,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,239,0.0,0.8866002429130597,0.025151515151515154
cambridge mass june 14 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the appointment of brian goff to its board of directors,intellia therapeutics names brian goff to its board of directors,management_changes,DOWN,-0.3081661268389825,973680192.0,98412511.0,6353695.0,2.134,5288300.0,0.10107272573539218,0.09346626282280733,4,7,379,0.0,0.7800307612939593,-0.008571428571428574
in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,clinical_study,DOWN,-1.0101000370632516,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,1,6,424,0.19318181818181818,1.2777111391401192,0.022727272727272724
media release,rapport financier semestriel 2024,financial_results,UP,1.6574619748698909,54895992.0,186301764.0,303098.4090909091,-1.119,117419.0,3.393722514386843,0.09346626282280733,2,7,241,0.0,0.4428343691040069,0.0
nkgen s neurodegenerative program continues to advance with dosing in the phase 1 2a clinical trial anticipated to commence by year end 2023,nkgen biotech announces fda clearance of investigational new drug application for snk01 nk cell therapy to treat alzheimer s disease,clinical_study,UP,9.242146234319629,16295543.0,10616620.0,134195.0,1.199,86400.0,0.651504524887572,0.09346626282280733,1,8,613,0.13636363636363635,2.657355742098314,0.2857142857142857
san diego and suzhou china april 28 2023 globe newswire adagene inc adagene nasdaq adag a platform driven clinical stage biotechnology company transforming the discovery and development of novel antibody based therapies today announced updates to its board of directors the board including the following,adagene announces updates to its board of directors,management_changes,UP,0.0,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,7,792,0.0,0.845882180665701,0.31666666666666665
planegg martinsried october 24 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer today reported financial results and provided a business update for the third quarter ended september 30 2024 the quarterly statement q3 2024 can be found on the website https medigene com investors media reports presentations during the third quarter of 2024 our focus remained on executing our strategic plan and creating additional value for both patients and our shareholders beyond t cell receptor engineered t cell tcr t therapies by expanding our ability to apply our sensitive specific and potentially safer 3s tcrs into new modalities said selwyn ho ceo at medigene we are excited to have announced a three year strategic partnership with wuxi biologics to co research tcr guided t cell engagers tcr tces for solid tumors extending our pipeline our mdg3010 program will be a joint development with wuxi biologics aiming to create bispecific therapeutics that target cancer cells with precision while minimizing off target effects the target for this bispecific will be revealed later as for our lead program mdg1015 we received fda clearance for our investigational new drug application and are on track for the clinical trial application submission filing with the european medicines agency ema in q4 2024 in line with our guidance since 2023 and subject to additional financing we anticipate initiating and generating an early data read out for the epitome 1015 i trial by the end of 2025,medigene ag reports financial results and business update for q3 2024,clinical_study,DOWN,-3.751342462021844,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,1,247,0.04256628787878788,1.3169799228985475,0.061390128968253965
media release,hexagon agility receives new wave of rng fuel system orders for class 8 series trucks with cummins x15n natural gas engine,business_contracts,DOWN,-2.463769187598724,305879840.0,146671949.0,363495.0,1.191,331336.5,0.4795083879996799,0.1515999603296736,2,7,241,0.11818181818181818,0.8866002429130597,0.0
media release,innofactor plc managers transactions,corporate_action,UP,0.2976187730795046,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,243,0.0,0.8866002429130597,0.001851851851851864
media release,recording of lhv group s 22 october investor webinar,financial_results,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
transcode therapeutics announces publication of study with lead therapeutic candi date revealing mechanisms behind candidate s preclinical efficacy against,transcode therapeutics announces publication of study with lead therapeutic candidate revealing mechanisms behind candidate s preclinical efficacy against metastatic cancer,clinical_study,DOWN,-1.5625030922818393,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,1,7,291,-0.4,2.0874185587937095,0.027622377622377625
rockville md aug 03 2023 globe newswire opgen inc nasdaq opgn opgen or the company announced today that the company will provide a business update and report its second quarter 2023 financial results after the close of the u s financial markets on thursday august 10th 2023 opgen s management team will host a live conference call and audio webcast at 4 30 p m eastern time to discuss the company s financial results and provide an update on business activities,opgen to provide business update and financial results for the second quarter 2023 on august 10th at 4 30 p m eastern time,conference_call_webinar,UP,3.389827220887213,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,695,0.01948051948051948,1.807174583649316,0.16796846011131725
florham park n j jan 04 2024 globe newswire celularity inc nasdaq celu the company a biotechnology company developing allogeneic cell therapies and advanced biomaterial products today confirmed that it has entered into an exclusive u s strategic commercialization agreement with biocellgraft inc biocellgraft under which celularity will manufacture advanced biomaterial products for biocellgraft which biocellgraft will distribute in the united states for use in multiple dental oral healthcare applications a copy of biocellgraft s announcement of the agreement can be accessed here https www prweb com releases biocellgraft finalizes commercialization agreement with celularity for the manufacture and distribution of products for therapeutic use in oral healthcare 302025082 html,celularity confirms commercialization agreement with biocellgraft for the manufacture and distribution of advanced biomaterial products for use in oral healthcare,partnerships,DOWN,-7.103823312288768,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,13,540,0.32,1.6050367793919866,0.025778388278388274
jerusalem oct 16 2023 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins presented 2 posters at the annual society of bone and mineral research asbmr 2023 annual meeting held on october 13 16 2023 in vancouver bc canada both posters will be available on the company s website www enterabio com,entera bio reports rapid pharmacodynamic pd response and consistent pharmacokinetic pk data for its first in class oral pth 1 34 mini tablets at the asbmr 2023 annual meeting,clinical_study,UP,2.60273880886081,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,0,8,621,0.3,0.6915109749530333,0.0
los angeles oct 16 2024 globe newswire renovaro inc nasdaq renb a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence today announced a strategic restructuring and leadership transition of senior management and the board of directors to realign resources focused on the company s ai platform renovarocube for multi cancer early detection and patient monitoring the board with the support of a supermajority of shareholders appointed david weinstein as director and new ceo and four new directors maurice van tilburg chairman douglas calder james a mcnulty cpa and mark a collins phd,renovaro announces strategic restructuring and leadership transition,management_changes,DOWN,-4.802256961851933,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,2,9,255,-0.05681818181818182,1.5631250973582267,0.06940345008526827
media release,keskon osavuosikatsaus 1 1 30 9 2024 rakentamisen ja talotekniikan kaupassa käänne parempaan,earnings_releases_and_operating_results,UP,4.41912221461097,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.05625
media release,cenergy holdings reports on the progress of its share buyback program,changes_in_companys_own_shares,UP,2.441860800372244,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
san diego march 15 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced it will participate in a virtual fireside chat on the treatment landscape new treatment options for prostate cancer,oncternal participating in virtual fireside chat with key opinion leader on treatment landscape new treatment options for prostate cancer,clinical_study,DOWN,-4.347827942766616,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,9,470,0.0909090909090909,0.8866002429130597,-0.08477633477633477
seattle feb 22 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it will present new preclinical data on kva12123 the company s anti vista antibody in acute myeloid leukemia aml at the american association for cancer research aacr blood cancer discovery symposium to be held on march 4 6 in boston massachusetts thierry guillaudeux ph d chief scientific officer of kineta will be presenting the poster,kineta to present new preclinical data on its anti vista antibody kva12123 in acute myeloid leukemia at the aacr blood cancer discovery symposium,clinical_study,UP,1.153854265721184,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,492,0.21038961038961038,0.8866002429130597,0.08365414347557207
media release,quadient obtient un prêt schuldschein de 25 millions d euros auprès de la berd pour financer des programmes de r d en république tchèque,financing_agreements,DOWN,-1.960782480441495,528319008.0,22771639.0,0.0,1.149,0.0,0.04310206268406682,0.19535099655549074,2,7,241,0.0,0.39343620296100096,0.0
sydney australia june 05 2024 globe newswire immutep limited acn 009 237 889 asx imm nasdaq immp immutep or the company is pleased to announce the successful completion of its institutional placement placement and the institutional component institutional entitlement offer of its 1 for 16 pro rata accelerated non renounceable entitlement offer entitlement offer and together with the placement the offer of new fully paid ordinary shares in immutep new shares,immutep successfully completes institutional placement and institutional component of entitlement offer,shares_issue,DOWN,-7.103823312288768,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,2,6,388,0.2787569573283859,0.7476881311953882,0.09772727272727272
conference call to begin at 4 30 p m et conference call to begin at 4 30 p m et,vaxart to host full year 2023 business update and financial results conference call on march 14,conference_call_webinar,DOWN,-5.000004967053534,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,3,8,478,0.175,1.025768835125998,-0.04583333333333334
reykjavik iceland sept 25 2024 globe newswire alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide announced today the initiation of a confirmatory patient study for avt16 a biosimilar candidate to entyvio vedolizumab the objective of the study is to demonstrate comparative efficacy safety and immunogenicity of avt16 and entyvio in male and female participants 18 80 years old with moderate to severe active ulcerative colitis alvotech is one of two companies known to have initiated a global or multi country confirmatory patient study for a biosimilar candidate to entyvio,alvotech initiates confirmatory patient study for avt16 a proposed biosimilar to entyvio,clinical_study,UP,0.2685741518915451,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,2,5,276,-0.004166666666666666,0.44264539487962035,0.08073921028466483
san diego oct 24 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis announced today that seven abstracts will be featured tomorrow friday october 25 at the 2024 acaai annual scientific meeting taking place in boston massachusetts the posters highlight a wide range of studies focused on intranasal epinephrine administration including cardiovascular safety human factor study of carrying two devices at all times and real world administration data in pediatric patients,ars pharmaceuticals showcases intranasal epinephrine data at 2024 american college of allergy asthma immunology acaai annual scientific meeting,clinical_study,UP,0.8722822657448963,1691729280.0,51755600.0,1240295.0,0.872,1940800.0,0.030593311005410986,0.09346626282280733,3,8,247,0.12000000000000002,0.6899910717831225,0.24093489843489843
media release,argan completed its bolbec logistics parc normandy,geographic_expansion,UP,0.2894422316255524,1612706688.0,12060258.0,31954.954545454544,0.782,14598.0,0.0074782712130725655,0.1515999603296736,1,7,242,0.0,0.2170511352010478,0.0
company to host webcast on 12th july at 9am aest 7pm et 11 july,immutep announces details for oral presentation at esmo virtual plenary session and webcast to discuss clinical results,clinical_study,UP,3.723407054767728,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,360,0.0,0.7476881311953882,0.1422634508348794
zug switzerland oct 21 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announces the acceleration of patient enrollment for both phase 3 diamond trials of ocs 01 eye drops in dme and expansion of the diamond program committees with globally renowned retina experts,oculis accelerates enrollment in both diamond phase 3 trials of ocs 01 in diabetic macular edema and expands its diamond program committees,clinical_study,UP,9.242146234319629,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,0,13,249,0.0,0.4640841922034435,0.03540003206669873
moonlake completes patient randomization ahead of schedule for its phase 2 trial in active psoriatic arthritis psa and provides calendar of next readouts,moonlake completes patient randomization ahead of schedule for its phase 2 trial in active psoriatic arthritis psa and provides calendar of next readouts,clinical_study,UP,0.0185293373754896,2929339136.0,28324751.0,691265.0,1.23,267600.0,0.009669331437901494,0.09346626282280733,1,8,704,-0.06666666666666667,0.5366763308656862,-0.125
new york feb 06 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders today announced that management will participate in a virtual presentation at the oppenheimer 34th annual healthcare life sciences conference on tuesday february 13 2024 at 12 40 p m et,ovid therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,DOWN,-0.8310241623697936,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,508,0.21212121212121213,0.7642184815786688,0.0639558853844568
kraig labs otcqb kblb signs production agreement for its recombinant spider silk technology building on its new spider silk production hybrids success,kraig biocraft laboratories announces new spider silk production contract,business_contracts,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,355,0.19090909090909092,0.8071333009212691,0.1250874125874126
adelaide australia and cambridge mass oct 23 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it will be participating and presenting at the thinkequity conference being held october 30 2024 at the mandarin oriental hotel in new york ny,bionomics to present at the thinkequity conference,clinical_study,UP,0.9836036420195928,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,248,0.017700216450216452,0.8866002429130597,0.04858930493508416
boca raton florida sept 03 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company focused on developing treatments that harness a patient s innate immune system to fight disease today announced that management will participate in the following investor conferences in september and october 2024,inmune bio inc to present at the baird 2024 global healthcare conference,conference_call_webinar,DOWN,-0.3021145207289472,160967584.0,15213010.0,781395.0,1.567,974600.0,0.09450977409215511,0.09346626282280733,1,9,298,0.0,0.8435084668920305,0.13834801092154034
jupiter fla march 28 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a biotechnology company focused on the efficient large scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non pharmaceutical applications including food nutrition and wellness today announced that michael tarnok is stepping down as chairman of dyadic s board of directors the board and that current member of the board patrick lucy has been appointed to succeed him in each case effective immediately mr tarnok will continue to serve as a director through the end of his current term which will end at the company s annual meeting in june 2025 at which time he expects to retire in addition dr barry buckland announced that he is retiring and therefore will not stand for re election at the company s annual meeting in june 2024 the board has decided not to fill the vacancy due to dr buckland s retirement which will result in a reduction of the size of the board from seven to six members finally joseph hazelton has been appointed chief operating officer effective immediately and will oversee the day to day operations of the company,dyadic announces change in board and management leadership roles,management_changes,UP,0.6134963492337805,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,3,8,457,0.11337301587301588,0.7846450948942033,0.15095854377104378
oslo norway 12 february 2024 pci biotech ose pcib invites to a webcast presentation of the company s second half 2023 interim report on wednesday 14 february 2024 08 30am 09 30am cet local time,pci biotech invitation to second half interim 2023 results presentation,interim_information,DOWN,-4.176905875277916,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,0,3,502,-0.06666666666666667,0.8869841129646596,0.009773662551440335
media release,torm plc capital increase in connection with delivery of one 2015 built mr vessel,share_capital_increase,DOWN,-3.110170791459808,10941282304.0,57061410.0,376187.8888888889,-0.051,374739.0,0.005215239714556953,0.1515999603296736,0,14,242,0.0,0.4410338832756232,0.0
alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in col4a and patients have significant unmet medical needs with no disease modifying treatments currently available,eloxx pharmaceuticals key opinion leader event highlights significant unmet need in treatment of alport syndrome patients with nonsense mutations and additional positive results from phase 2 clinical study evaluating elx 02,clinical_study,DOWN,-0.9852207491816546,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,9,731,0.2396103896103896,2.2721670857062097,0.19635714285714287
kraig labs otcqb kblb signs key agreements with lam dong agro forestry research experiment center for spider silkworm rearing and breeding,kraig biocraft laboratories reports signing landmark agreements in south east asia,geographic_expansion,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,425,-0.05,0.8071333009212691,0.3797348484848485
zug switzerland may 30 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the results from its 2024 annual general meeting held on may 29 2024 at ochsen zug kolinplatz 11 ch 6300 zug switzerland at 3 30 p m cest including election of new members to its board of directors as well as the recent appointment of two new members to its scientific advisory board sab and the establishment of a loan facility of up to chf 50 million,oculis publishes results of 2024 annual general meeting and announces appointments to its board of directors and scientific advisory board,annual_general_meeting,DOWN,-1.0058665757705016,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,4,394,0.062121212121212126,0.4640841922034435,0.0
saint herblain france and new york ny september 3 2024 valneva se nasdaq valn euronext paris vla and pfizer inc nyse pfe announced today positive immunogenicity and safety data from their vla15 221 phase 2 study following a second booster vaccination of their lyme disease vaccine candidate vla15 given one year after receiving the first booster dose the immune response and safety profile of vla15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose showing compatibility with the anticipated benefit of a booster vaccination prior to each lyme season there are currently no approved human vaccines for lyme disease and vla15 is the lyme disease vaccine candidate which has advanced the furthest along the clinical development timeline with two phase 3 trials in progress the centers for disease control and prevention cdc has estimated that approximately 476 000 people in the u s are diagnosed and treated for lyme disease each year and 129 000 cases are reported annually in europe 1 2,valneva and pfizer report further positive phase 2 booster results for lyme disease vaccine candidate,clinical_study,UP,0.0,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,1,298,0.07272727272727272,0.6494694268312979,0.056410256410256404
media release,jūratė lingienė elected as the new chairperson of the board at ab kn energies,clinical_study,UP,0.425532778337998,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,245,0.13636363636363635,0.8866002429130597,0.13222222222222224
g1 therapeutics provides second quarter 2024 financial results and operational highlights,g1 therapeutics provides second quarter 2024 financial results and operational highlights,mergers_acquisitions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,324,0.0,0.8866002429130597,0.04578947368421053
shield i study is one of the largest phase 3 trials in the prevention of ssis in colorectal resection conducted in over a decade,polypid announces publication in international journal of surgery highlighting results of phase 3 shield i trial of d plex₁₀₀ in prevention of surgical site infections in abdominal colorectal surgery,clinical_study,UP,0.0,37502512.0,4610773.0,1395250.0,1.25,337200.0,0.12294571094330961,0.09346626282280733,0,7,250,0.0,0.7168605096826995,-0.030597678465325528
tiziana life sciences to dose first patient with moderate alzheimer s disease with foralumab,tiziana life sciences to dose first patient with moderate alzheimer s disease with foralumab,clinical_study,DOWN,-4.123713430708066,199810080.0,63394363.0,242895.0,0.107,139700.0,0.31727309753341776,0.09346626282280733,2,7,367,0.125,1.1109140250580023,0.030540688267961
ab utenos trikotažas hereinafter the company dinary of the extraordinary general meeting of shareholders agenda and decisions of the meeting it was of the decided grant thornton baltic uab to be the auditor of ab utenos trikotažas for the audit of the set of financial statements for the years 2024 2025 determine that the remuneration for the audit is as follows in the first year eur 32 900 plus vat in the second year eur 34 300 plus vat additional information is available from aurimas likus finance director tel no 370 618 07809 nomeda kaučikienė managing director of ab utenos trikotažas,on 03 october 2024 decisions of the general extraordinary of shareholders,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,267,0.17708333333333331,0.8866002429130597,0.07500000000000001
patients can request a prescription from their existing healthcare provider or meet with a physician virtually to request a prescription for neffy ahead of product availability expected by late september,ars pharmaceuticals launches pre ordering services for neffy to help patients access the first and only needle free treatment for type i allergic reactions including anaphylaxis,product_services_announcement,UP,0.0,1694184576.0,51755600.0,1240295.0,0.872,1940800.0,0.030548973667435867,0.09346626282280733,2,8,297,0.05000000000000001,0.6899910717831225,0.253832152695789
cambridge mass and rostock germany and berlin dec 13 2023 globe newswire centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced the company reached its initial recruitment and genetic testing milestone in the observational efront study being conducted to advance the genetic understanding of frontotemporal dementia ftd,centogene s frontotemporal dementia ftd genetic study efront reaches initial patient enrollment milestone,clinical_study,DOWN,-4.724405014224391,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,563,0.075,3.598197549072007,0.0
adelaide australia and cambridge mass june 15 2023 globe newswire bionomics limited nasdaq bnox asx bno bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it will present at the following upcoming investor conferences in june,bionomics to present at upcoming june investor conferences,conference_call_webinar,UP,2.040814340536656,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,744,0.0005820105820105849,0.8866002429130597,0.0
media release,immutep signs exclusive license agreement with cardiff university for next generation anti lag 3 molecules for cancer,licensing_agreements,UP,1.5037579158775027,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,1,8,368,0.0,0.7476881311953882,0.1580705009276438
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
media release,share buyback transaction details october 24 october 28 2024,changes_in_companys_own_shares,DOWN,-0.9594571479278884,32456935424.0,234261050.0,547487.9545454546,0.259,726796.0,0.007217596083540829,0.1515999603296736,1,10,241,0.0,0.21375743879343068,0.0
saint herblain france october 21 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company announces today that members of its senior leadership team will present datasets on the world s first and only approved chikungunya vaccine ixchiq at several leading scientific conferences during the fourth quarter of 2024,valneva to present on chikungunya at several leading scientific conferences,clinical_study,DOWN,-0.3577497249859914,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,0,11,249,0.03571428571428571,0.6494694268312979,0.06024955436720141
san diego jan 31 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will present at guggenheim s 6th annual biotechnology conference,anaptys to present at guggenheim s 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.6268266469592575,687797504.0,17605381.0,784220.0,-0.266,445700.0,0.025596750348195505,0.09346626282280733,2,9,514,0.16666666666666666,0.871343469962729,0.23443865057501423
norwood mass oct 16 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company an oncology and obesity company with a diversified portfolio announced today that it has completed enrollment of the dose escalation part of its bridging phase 1 clinical trial of crb 701 sys6002 the dose escalation part of this open label study nct06265727 is being conducted in the us and the uk the three part phase 1 trial is evaluating the safety pharmacokinetics and efficacy of crb 701 in patients with advanced solid tumors associated with high nectin 4 expression the part a dose escalation of the phase 1 study is evaluating four predetermined doses 1 8 mg kg 2 7 mg kg 3 6 mg kg and 4 5 mg kg and will be followed by part b dose optimization and part c dose expansion that will determine recommended optimized doses and seek preliminary efficacy signals,corbus announces enrollment completion of dose escalation stage of phase 1 clinical trial of its next generation nectin 4 targeting adc crb 701,clinical_study,UP,0.0,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,8,255,0.11200000000000002,0.9919200800994142,0.06778451178451178
new york june 11 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced it has received acceptance of its submission for intranasal foralumab to receive fast track designation approval for the treatment of non active secondary progressive multiple sclerosis na spms to the u s food and drug administration fda,fda accepts tiziana life sciences fast track designation submission for treatment of multiple sclerosis,clinical_study,DOWN,-6.000000238418579,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,8,382,0.014718614718614726,1.1109140250580023,0.03405670461226017
durham n c oct 04 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately 30 0 million worth of its common stock and warrants in a registered direct offering,humacyte announces pricing of 30 0 million registered direct offering,financing_agreements,UP,1.893937512479722,337414848.0,121934248.0,3834265.0,2.0,1449900.0,0.36137783717212113,0.09346626282280733,4,8,267,-0.025000000000000005,1.1173068527438073,0.06200318401405358
after successful seismic a and b studies in early cardiogenic shock seismic c will treat more severe scai stage c cardiogenic shock to complete the assessment of the intended phase 3 patient population,windtree therapeutics initiates seismic c study of istaroxime in scai stage c cardiogenic shock for planned completion of phase 2b and transition to phase 3,clinical_study,DOWN,-3.658533128225512,1377011.0,3660923.0,6680965.0,0.764,1224200.0,2.6586011295479848,0.09346626282280733,2,8,241,0.36250000000000004,2.339794177443606,0.057652423534458166
moonlake immunotherapeutics to present mira trial data of nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the aad annual meeting 2024,moonlake immunotherapeutics to present mira trial data of nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the aad annual meeting 2024,clinical_study,UP,0.5106090840141404,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,0,8,481,-0.15,0.5366763308656862,0.057983682983682984
the combined companies aim to disrupt cancer diagnosis and treatment through early disease and recurrence detection prediction of response to treatment and personalized therapy,cutting edge ai company gedicube and cyclomics sign binding loi to join forces and position themselves at the forefront of the global liquid biopsy marketplace,mergers_acquisitions,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,500,-0.16666666666666666,1.5631250973582267,0.18178726035868895
geneva switzerland may 31 2024 addex therapeutics six and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that it will issue its q1 2024 financial results on june 6 2024 tim dyer ceo and mikhail kalinichev head of translational science will provide a business update and a review of the addex product pipeline during a teleconference and webcast for investors analysts and media at 16 00 cest 15 00 bst 10 00 edt 07 00 pdt the same day,addex therapeutics to release q1 2024 financial results and host conference call on june 6 2024,conference_call_webinar,DOWN,-2.893518403540428,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,393,-0.0625,0.972373032385036,-0.0008333333333333318
performance des ventes du premier semestre en ligne avec les perspectives financières 2024,valneva publie ses résultats financiers du premier semestre 2024 et fait un point sur ses activités,financial_results,UP,9.242146234319629,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,1,319,0.0,0.6494694268312979,0.06262626262626263
juniper fla march 11 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction utilizing its advanced microbial platforms to develop and manufacture prophylactic therapeutic and nutritional biopharmaceutical products for human and animal health and wellness announced today that it entered into a securities purchase agreement on march 8 2024 pursuant to which the company has sold and issued an aggregate principal amount of 6 0 million of its 8 senior secured convertible promissory notes due march 8 2027 the convertible notes in a private placement in reliance on the exemption from registration provided by section 4 a 2 of the securities act of 1933 as amended the securities act the purchasers of the convertible notes include immediate family members and family trusts related to mark emalfarb our president and chief executive officer and a member of our board of directors including the francisco trust an existing holder of more than of the company s outstanding common stock collectively the purchasers,dyadic announces closing of private placement of 6 0 million convertible notes to accelerate near term revenue growth and commercialization,financing_agreements,UP,2.1739109777848307,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,0,8,474,0.1125,0.7846450948942033,0.18954004329004331
needham mass oct 04 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced the company will present a poster at the society for immunotherapy of cancer s sitc 39th annual meeting taking place november 6 10 2024 in houston texas and virtually,candel therapeutics to present preclinical data on therapeutic potential of can 3110 in melanoma at sitc 2024 annual meeting,clinical_study,UP,0.0,243749632.0,41997569.0,917740.0,-0.866,856900.0,0.17229797910012845,0.09346626282280733,4,9,267,0.0,1.2870358800144117,0.07040504838298955
san diego april 26 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced two poster presentations highlighting data on cd388 at the 34th european society of clinical microbiology and infectious diseases escmid conference being held april 27 30 2024 in barcelona spain,cidara therapeutics announces presentations highlighting phase 1 and phase 2a clinical data on cd388 at escmid 2024,clinical_study,DOWN,-2.6923106266902046,621253440.0,4118697.0,696580.0,0.795,3470400.0,0.0066296566502714255,0.09346626282280733,4,8,428,-0.1111111111111111,1.357695941787151,0.020093795093795094
lexington mass oct 07 2024 globe newswire t2 biosystems inc nasdaq ttoo the company a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes today announced that it has entered into a multi year exclusive u s agreement with cardinal health nyse cah under the agreement cardinal health will have exclusive rights to sell t2 biosystems fda cleared direct from blood diagnostics for the rapid detection of sepsis causing pathogens including the t2dx instrument the t2bacteria panel and the t2candida panel,t2 biosystems announces exclusive u s agreement with cardinal health to sell its fda cleared direct from blood diagnostics for rapid detection of sepsis causing pathogens,business_contracts,UP,0.5494500096186173,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,0,9,264,0.1,1.9596557041969667,0.09953171828171826
novel immunotherapy approach targets soluble tumor necrosis factor to overcome resistance and enhance therapeutic outcome in high risk breast cancer,inmune bio inc presents data on inb03 s role as an immune check point modulator in the treatment of high risk breast cancer at aacr 2024,clinical_study,UP,0.1934187987835764,163892400.0,15213010.0,781395.0,1.567,974600.0,0.09282315714456559,0.09346626282280733,0,8,446,0.16,0.8435084668920305,0.0
copenhagen denmark april 17 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines announces that the first patient in its evx 01 phase 2 trial in metastatic melanoma received the last vaccine dose in combination with keytruda nct05309421,evaxion announces phase 2 clinical trial update first patient completed dosing with personalized cancer vaccine evx 01,clinical_study,UP,1.4851471125267248,15601928.0,155104950.0,157745.0,0.102,38700.0,9.94139634537475,0.09346626282280733,2,8,437,0.16666666666666666,1.4249795072460607,0.0
los angeles oct 16 2024 globe newswire renovaro inc nasdaq renb a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence today announced a strategic restructuring and leadership transition of senior management and the board of directors to realign resources focused on the company s ai platform renovarocube for multi cancer early detection and patient monitoring the board with the support of a supermajority of shareholders appointed david weinstein as director and new ceo and four new directors maurice van tilburg chairman douglas calder james a mcnulty cpa and mark a collins phd,renovaro announces strategic restructuring and leadership transition,management_changes,DOWN,-4.802256961851933,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,2,9,255,-0.05681818181818182,1.5631250973582267,0.06940345008526827
new york feb 28 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders today announced that management will participate in a panel titled orphan epilepsies at the td cowen 44th annual health care conference on wednesday march 6 2024 at 10 30 a m et in boston massachusetts,ovid therapeutics to present at the td cowen 44th annual health care conference,conference_call_webinar,DOWN,-1.101933857039758,21731064.0,50354780.0,1012130.0,0.065,720700.0,2.317179683424613,0.09346626282280733,2,8,486,0.21212121212121213,0.7642184815786688,0.13803854875283447
missing,valneva déclaration d actions et de droits de vote 31 août 2024,voting_rights,UP,0.4184063131376948,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,12,296,-0.2,0.6494694268312979,0.06282828282828283
multispecific cd73 pd 1 dfc demonstrates improved tumor reduction compared to pd 1 monotherapy in nonclinical study,cidara therapeutics presents promising new data on novel drug fc conjugate candidates at the american association for cancer research aacr annual meeting 2024,clinical_study,UP,1.7543927160695634,635260800.0,4118697.0,696580.0,0.795,3470400.0,0.006483474188868572,0.09346626282280733,4,15,448,0.11212121212121212,1.357695941787151,-0.027777777777777776
palo alto calif july 23 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that it has added to its board of directors a highly accomplished leader in interventional and multidisciplinary spine musculoskeletal and orthopedic care annu navani m d,scilex holding company strengthens board of directors with appointment of highly accomplished leader in interventional and multidisciplinary spine musculoskeletal and orthopedic care annu navani m d,management_changes,DOWN,-1.1494241848790827,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,9,340,0.37499999999999994,1.0327724261931344,0.23569489538239538
lawrenceville n j oct 07 2024 globe newswire imunon inc nasdaq imnn the company a clinical stage company in late stage development with its dna mediated immunotherapy today announced that the compensation committee of the company s board of directors approved the grant of i inducement stock options to purchase a total of 60 000 shares of the company s common stock to one individual hired by imunon during the fourth quarter of 2024 and ii inducement stock options to purchase a total of 50 000 shares of common stock to susan eylward hired by imunon as general counsel and secretary effective october 7 2024 collectively the inducement option grants the inducement option grants were approved in accordance with nasdaq listing rule 5635 c 4 and were made on october 7 2024 as a material inducement to each employee s entry into employment with the company,imunon reports inducement grant under nasdaq listing rule 5635 c 4,management_changes,DOWN,-0.9259250061011975,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,264,-0.027777777777777766,2.964855117372811,0.05367330714552936
media release,shell plc 2025 interim dividend timetable,dividend_reports_and_estimates,UP,0.9792533652911048,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,3,8,240,0.0,0.21899598590029368,0.0
ctx310 led to durable reductions of angiopoietin like 3 protein angptl3 and triglyceride levels in non human primates nhps after a single dose,crispr therapeutics announces preclinical data at the american heart association aha scientific sessions 2023,clinical_study,UP,4.33418123499679,4072911872.0,85970729.0,2651100.0,1.742,2455300.0,0.021107927620782067,0.09346626282280733,0,5,600,-0.023809523809523808,0.5620956775766307,0.0
16 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 15 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 4129 25 5457estimated mtd return 0 19 0 21 estimated ytd return 3 14 3 97 estimated itd return 184 13 155 46 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 3 56 n a sterling sharesamsterdam aex london lse market closen agbx 2 380 00premium discount to estimated navn a 6 83 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl eur nav s,fund_data_announcement,UP,2.1897824446097944,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,255,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
media release,akastor asa third quarter results 2024,earnings_releases_and_operating_results,UP,1.6081820792888155,3347887616.0,49279280.0,50456.2,0.215,44471.0,0.014719514407977068,0.1515999603296736,2,7,241,0.0,0.29384574384909407,0.0
media release,nordic unmanned launches contemplated private placement,financing_agreements,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,241,0.0,0.8866002429130597,0.0
media release,director pdmr shareholding,regulatory_filings,UP,0.2162359787506383,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,2,12,240,0.0,0.21899598590029368,0.0
new york oct 10 2023 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure related disorders today announced that management will participate in a presentation at the jefferies inaugural biotech cns neuro summit on thursday october 12 2023 at 3 30 p m et in new york,ovid therapeutics to present at the jefferies biotech cns neuro summit,conference_call_webinar,DOWN,-2.7173951423122418,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,627,0.06818181818181818,0.7642184815786688,0.0
media release,euronext oslo børs b2 impact asa received application for listing of bonds,exchange_announcement,DOWN,-0.4115222299809098,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,9,241,0.0,0.2679946975487692,0.0
ad hoc announcement pursuant to art 53 lr,santhera announces half year 2024 financial results and provides corporate update,financial_results,DOWN,-2.766398067949684,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,3,1,289,-0.05555555555555555,0.5209522992128177,0.07142857142857142
new haven conn april 25 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that it will release its first quarter 2024 financial results on thursday may 9 2024 before the open of the u s financial markets bioxcel therapeutics management team will also host a conference call and webcast at 8 00 am et that day to discuss the company s financial results and provide a general business update,bioxcel therapeutics to report first quarter 2024 financial results on may 9 2024,financial_results,UP,0.3690033329333297,12766154.0,5544250.0,450810.0,-0.13,78500.0,0.4342928966703676,0.09346626282280733,3,7,429,0.00863636363636364,1.4586588351104455,0.02972943722943723
in 2024 q3 3 1 million tons of cargo and 2 7 million passengers passed through the harbors of tallinna sadam compared to the same period of previous year the cargo volume increased by 7 and the number of passengers increased by 4 the number of vessel calls increased by 5 reaching 1922 calls the number of passengers travelling between the estonian mainland and the main islands increased by 1 and the number of vehicles increased by 3 the number of charter days of the icebreaker botnica decreased by utility rate of the vessel was valdo kalm the chairman of the management board of tallinna sadam commented on the results the third quarter has been positive in terms of operational volumes cargo volumes have continued to grow and this time across all types of cargo in total the volume increased by 209 thousand tons the volumes of general cargo liquid bulk and containers grew the most the number of passengers was 113 thousand more t,as tallinna sadam operational volumes for 2024 q3 and 9 months,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,262,0.08772727272727272,0.8866002429130597,-0.06999999999999999
sampo plc stock exchange release 27 september 2024 at 8 30 am eest sampo plc s share buybacks 26 september 2024 on 26 september 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 493 490 sampo a shares representing 1 36 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 sep,sampo plc s share buybacks 26 september 2024,changes_in_companys_own_shares,DOWN,-0.0237659177697431,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,274,0.1625,0.8866002429130597,0.1625
pratteln schweiz 1 oktober 2024 santhera pharmaceuticals six sann gibt das positive ergebnis der lionheart studie bekannt das die einzigartige wirkung von vamorolon auch als mineralokorticoid rezeptor antagonist bestätigt und es somit von anderen kortikosteroiden unterscheidet,santhera s lionheart studie mit agamree vamorolon zeigt positive topline ergebnisse und einzigartigen mineralokorticoid rezeptor antagonismus,clinical_study,UP,1.5819139391402794,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,270,0.22727272727272727,0.5209522992128177,0.05122655122655123
kraig labs otcqb kblb begins first bam 1 parental strains production at its new production center with capacity to support 25 tons of spider silk,kraig biocraft laboratories launches spider silk production at recently completed higher capacity facility,geographic_expansion,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,278,0.10727272727272727,0.8071333009212691,0.12299414600550965
boca raton florida april 25 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease today announced today that it has entered into definitive agreements for the sale and purchase of 986 000 shares of its common stock and warrants to purchase up to an aggregate of 986 000 shares of its common stock at an offering price of 9 84 per share of common stock and accompanying warrant the warrants include an acceleration clause upon positive top line data in the company s phase 2 alzheimer s disease program as further described below the offering was priced at the market under nasdaq rules based on the average of the previous 5 days closing prices or 9 84 per share which includes 0 125 per warrant the warrants terminate on the earlier of 1 the two 2 year anniversary of the initial exercise date of the warrant or 2 thirty 30 trading days following the reporting of positive top line data emacc in the phase 2 alzheimer s program of xpro1595 the termination date the gross proceeds of this offering are approximately 9 7 million before deducting placement agent fees and expenses the closing of the offering is expected to occur on or about april 29 2024 subject to the satisfaction of customary closing conditions,inmune bio inc announces 9 7 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-4.237286385257309,162957200.0,15213010.0,781395.0,1.567,974600.0,0.09335586276641965,0.09346626282280733,3,9,429,-0.018265993265993267,0.8435084668920305,0.1307354797979798
rockville md may 14 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that company s management will provide a corporate update and participate in a fireside chat at the a g p 2024 virtual healthcare conference,theriva biologics to participate in the a g p virtual healthcare conference,conference_call_webinar,DOWN,-2.702702702702702,3592451.0,8173972.0,1624850.0,0.833,91200.0,2.2753189953043202,0.09346626282280733,1,8,410,0.04,1.5225134880447404,0.04465768799102132
02 oct 2024 10 00 cest nel asa october 2 2024 oslo norway nel asa s nel ose nel epc partner saipem unveils ivhyt 100 a scalable and modular 100 mw green hydrogen solution leveraging nel s technology advancing the decarbonization of hard to abate industries and renewable hydrogen production the innovative renewable hydrogen generation solution has been designed and industrialized to be scalable modular and to facilitate the installation and commissioning of large scale systems ivhyt 100 is powered by nel s alkaline electrolysers which have been tested in the market for decades demonstrating world class robustness durability and energy efficiency making it the ideal choice for businesses seeking to optimize their operations and total cost of ownership the project is part of a collaboration between the two companies where nel as the technology provider will offer its alkaline and pem proton exchange membrane electrolyser technology as well as an,nel asa saipem presents solution for large scale green hydrogen production utilizing nel s technology,partnerships,UP,0.460829037404248,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,269,0.14211309523809523,0.8866002429130597,0.0
media release,carl johan hugner new ceo of nyfosa,management_changes,DOWN,-0.0868042333074207,112574064.0,35018869.0,105765.0,0.8755,89500.0,0.25000035609542787,0.1515999603296736,0,7,243,0.13636363636363635,0.04641707976494245,0.0
wa el hashad chief executive officer of longeveron will participate in a fireside chat at the ubs virtual organ restoration and cell therapy day oct 15th,longeveron to present at the ubs virtual organ restoration and cell therapy day,conference_call_webinar,UP,0.5405400180747055,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,9,264,0.0,1.063123411629147,0.09976689976689976
arcutis today announced new results from the integument ole long term open label study of investigational once daily roflumilast cream 0,arcutis announces new long term data of roflumilast cream 0 for the treatment of mild to moderate atopic dermatitis ad in adults and children down to age six presented at revolutionizing alopecia areata vitiligo and eczema conference,clinical_study,UP,5.898877570852176,1726044928.0,85869346.0,2010100.0,1.778,2359700.0,0.049749195172745814,0.09346626282280733,0,14,382,0.03894500561167227,0.6903751128737089,0.0
ad hoc mitteilung gemäss art 53 kr,santhera veröffentlicht einladung zur ordentlichen generalversammlung,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.0,0.5209522992128177,0.0
estimated balance of 75 million upon 175 million paydown of principal projected in q2 2024 revenue covenant reduced to 125 million term loan annual interest expense projected to be reduced by,coherus amends term loan agreement with pharmakon advisors lp,financing_agreements,DOWN,-3.398055106173815,85338280.0,110892497.0,1236840.0,0.883,1425300.0,1.2994461219513682,0.09346626282280733,0,8,509,0.0,1.0144535837204522,0.0
se vedhæftede,ledende medarbejderes transaktioner,company_regulatory_filings,UP,0.5714285714285714,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,12,282,0.0,0.8866002429130597,0.0
zug switzerland oct 02 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the appointment of daniel s char to the role of chief legal officer leading oculis legal compliance and corporate governance functions mr char brings over 35 years of success in global legal leadership experience at both large and smaller biotech companies,oculis announces appointment of daniel s char as chief legal officer,management_changes,UP,0.9098399941186142,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,2,4,269,0.13142857142857142,0.4640841922034435,0.02292929292929293
florham park n j jan 18 2024 globe newswire celularity inc nasdaq celu has posted a letter to shareholders from robert j hariri m d ph d chairman ceo and founder which is included below and can also be accessed here,celularity releases ceo letter to shareholders,press_releases,UP,4.332134469456686,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,13,526,0.0,1.6050367793919866,0.09933379120879121
spatial biology 2 0 solutions enable discovery and translational workflows at an unprecedented speed and scale,akoya biosciences to showcase new spatial biology 2 0 solutions and spatial phenotyping data at sitc 2023,trade_show,DOWN,-0.2941173583166078,60944124.0,12648900.0,228670.0,1.352,488000.0,0.207549131397803,0.09346626282280733,1,9,606,0.36818181818181817,0.8573192373918191,0.0
guggenheim s inaugural healthcare innovation conference nov 11 13,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,3,240,0.0,0.5536010581445269,0.0
media release,immutep quarterly activities report q4 fy24,clinical_study,DOWN,-1.3953585338433494,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,332,0.0,0.7476881311953882,0.14789496218067646
pratteln schweiz 10 juni 2024 santhera pharmaceuticals six sann gibt bekannt dass das partnerunternehmen sperogenix therapeutics in china ein frühzugangsprogramm early access program eap gegen bezahlung für agamree vamorolon für patienten mit duchenne muskeldystrophie dmd gestartet hat,santhera gibt den beginn eines early access programms für agamree in china durch seinen partner sperogenix bekannt,product_services_announcement,UP,1.458326917555852,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,0,1,383,0.1,0.5209522992128177,0.03333333333333335
turku finland and boston nov 02 2023 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company focused on tackling cancers via novel immunotherapies today announces that it will present phase 1 2 data from its ongoing bexmab study of bexmarilimab in combination with standard of care soc in relapsed refractory r r acute myeloid leukemia aml and myelodysplastic syndromes mds patients having failed hypomethylating agents hmas at the 65th american society of hematology ash annual meeting,faron to present phase 1 2 data from bexmab study of bexmarilimab in combination with standard of care in myeloid malignancies at the 65th american society of hematology annual meeting,clinical_study,UP,0.0,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,3,9,604,0.03888888888888889,0.7633342480324978,0.08236345598845599
all three patients response rate treated with elx 02 showed an improvement in podocyte foot process effacement post treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of elx 02,eloxx pharmaceuticals reports drug response in all patients treated with elx 02 in phase 2 clinical study for alport syndrome,clinical_study,UP,5.0526267603824015,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,8,684,0.0,2.2721670857062097,0.17882683982683983
cambridge mass sept 12 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced that data from the phase 2 study of ntla 2002 will be presented at the 2024 american college of allergy asthma immunology acaai annual scientific meeting taking place october 24 28 in boston massachusetts ntla 2002 is an investigational in vivo crispr based gene editing therapy in development as a single dose treatment for hereditary angioedema hae a rare genetic condition that leads to potentially life threatening swelling attacks,intellia therapeutics to present data from the phase 2 study of ntla 2002 for the treatment of hereditary angioedema hae at the 2024 acaai annual scientific meeting,clinical_study,DOWN,-0.1976235604300166,973680192.0,98412511.0,6353695.0,2.134,5288300.0,0.10107272573539218,0.09346626282280733,3,7,289,0.045714285714285714,0.7800307612939593,0.045912648308481636
south san francisco calif jan 31 2024 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced that brian wong m d ph d president and chief executive officer will participate in a fireside chat at the guggenheim healthcare talks 6th annual biotechnology conference on wednesday february 7 2024 at 2 00 p m et,rapt therapeutics to participate in the guggenheim healthcare talks 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.316831381014078,142045104.0,6191111.0,99294.6,-0.137,87900.0,0.04358552900211189,0.09346626282280733,2,8,514,0.0625,1.6028075568485736,0.13628584956709955
cambridge mass june 14 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the appointment of brian goff to its board of directors,intellia therapeutics names brian goff to its board of directors,management_changes,DOWN,-0.3081661268389825,973680192.0,98412511.0,6353695.0,2.134,5288300.0,0.10107272573539218,0.09346626282280733,4,7,379,0.0,0.7800307612939593,-0.008571428571428574
moonlake immunotherapeutics announces positive regulatory feedback from both fda and ema on path for the phase 3 program for the nanobody sonelokimab in psoriatic arthritis,moonlake immunotherapeutics announces positive regulatory feedback from both fda and ema on path for the phase 3 program for the nanobody sonelokimab in psoriatic arthritis,clinical_study,DOWN,-0.7199406053349006,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,0,8,383,0.22727272727272727,0.5366763308656862,0.05518939393939394
radnor pa feb 08 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other diseases driven by abnormally elevated aldosterone today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing the pipe for gross proceeds of approximately 120 million before deducting estimated fees and expenses,mineralys therapeutics announces 120 million private placement financing,financing_agreements,UP,9.242146234319629,911150656.0,43490817.0,793180.0,-0.18,767600.0,0.04773175183885287,0.09346626282280733,3,8,506,-0.10500000000000001,0.8131647725786432,-0.05454545454545454
oxurion signs a letter of intent and enters into exclusive negotiations to potentially acquire a pioneering french cro in stem cell production,oxurion signs a letter of intent and enters into exclusive negotiations to potentially acquire a pioneering french cro in stem cell production,mergers_acquisitions,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,0,12,354,0.0,2.0692591020840054,0.16200396825396826
petach tikva israel april 24 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the u s financial markets on wednesday may 8 2024 the company will host a conference call and webcast at 8 30 am eastern time to discuss the results and provide an update on business operations,polypid to report first quarter 2024 financial results and operational highlights on may 8 2024,earnings_releases_and_operating_results,UP,2.3411374793250963,37494360.0,4610773.0,1395250.0,1.25,337200.0,0.12297244172190164,0.09346626282280733,2,7,430,0.028571428571428574,0.7168605096826995,-0.0660515873015873
media release,norsk hydro reminder invitation to hydro s capital markets day london,conference_call_webinar,DOWN,-0.319386759699206,108946178048.0,1148146500.0,4473395.3,1.218,3924732.0,0.010538657900363834,0.1515999603296736,2,10,240,0.0,0.3181340754469693,0.0
new york aug 08 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions today announced the appointment of amanda banks m d as chief development officer dr banks will oversee ovid s clinical development medical and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the company s leadership team,ovid therapeutics appoints dr amanda banks experienced biotech leader physician as chief development officer,management_changes,UP,0.5714280264718192,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,3,8,324,0.24727272727272726,0.7642184815786688,0.16252140090485956
new u s patent covers the design and composition of the bvp,humacyte announces allowance of u s patent covering biovascular pancreas bvp,patents,UP,4.119846140548016,337414848.0,121934248.0,3834265.0,2.0,1449900.0,0.36137783717212113,0.09346626282280733,3,8,282,0.13636363636363635,1.1173068527438073,0.05862316345270891
missing,important advances in oxurion s r d program on geographic atrophy secondary to amd,clinical_study,UP,9.242146234319629,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,0,12,417,-0.033333333333333326,2.0692591020840054,0.17857142857142858
mainz biomed announces distribution partnership with praxisdienst for coloalert,mainz biomed announces distribution partnership with praxisdienst for coloalert,partnerships,UP,5.10203585134164,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,3,8,492,0.0,34.079934680222834,0.0
hkfoods oyj pörssitiedote sisäpiiritieto 26 9 2024 klo 14 hkfoods oyj päivittää vuoden 2024 taloudellista ohjeistustaan jatkuvien liiketoimintojen myönteisen tuloskehityksen vuoksi päivitetty ohjeistus vuodelle 2024 vuonna 2024 hkfoods arvioi konsernin jatkuvien toimintojen vertailukelpoisen liiketuloksen kasvavan selvästi vuodesta 2023 hkfoods arvioi nyt konsernin vuoden 2024 vertailukelpoisen liiketuloksen olevan 22 25 miljoonaa euroa konsernin jatkuvien liiketoimintojen vertailukelpoinen liiketulos vuodelta 2023 oli 11 6 miljoonaa euroa hkfoods julkistaa tammi syyskuun 2024 osavuosikatsauksen keskiviikkona 6 11 2024 noin klo 8 30 aikaisempi 9 2 2024 julkaistu ohjeistus vuodelle 2024 vuonna 2024 hkfoods arvioi konsernin jatkuvien toimintojen vertailukelpoisen liiketuloksen paranevan vuodesta 2023 hkfoods oyj hallitus lisätiedot juha ruohola toimitusjohtaja hkfoods oyj p 0400 647 160 mika tilli talousjohtaja hkfoods oyj p 050 538 5793 hkfoods media service desk p,sisäpiiritieto positiivinen tulosvaroitus hkfoodsin jatkuvien toimintojen vertailukelpoinen liiketulos kasvaa selvästi vuodesta 2023,financial_results,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
nexobrid interest surges 5 million in q1 2024 revenue with 24 million forecast for the year,mediwound reports first quarter 2024 financial results and provides company update,financial_results,DOWN,-3.4851085290965536,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,7,395,0.125,0.6433034533898109,0.1344343434343434
project funding exceeds 7 0 million project funding exceeds 7 0 million,spectral ai awarded additional funding from medical technology enterprise consortium to support ongoing development of deepview snapshot m,contests_awards,UP,0.0,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,3,8,296,0.0,0.9904696515070965,0.06342564298446653
san diego oct 16 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced two upcoming presentations at idweek 2024 to be held october 16 19 2024 in los angeles ca the presentations will highlight clinical data on the safety pharmacokinetics and prophylactic activity of cidara s clinical stage influenza dfc asset cd388,cidara therapeutics announces two presentations on drug fc conjugate cd388 at idweek 2024,clinical_study,UP,2.6057064044715603,642134784.0,4118697.0,696580.0,0.795,3470400.0,0.006414069292966382,0.09346626282280733,2,8,255,-0.16666666666666666,1.357695941787151,0.06781385281385281
redwood city calif may 14 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced results for the fiscal quarter ended march 31 2024 and reported recent corporate developments,jasper therapeutics reports first quarter 2024 financial results and recent corporate developments,clinical_study,DOWN,-0.7225415071122696,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,8,410,0.10625,0.9821837329226573,0.15356637806637807
media release,crcam alpes provence avis financier au 30 septembre 2024,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,15,241,0.0,0.8866002429130597,0.0
media release,wärtsilän tammi syyskuun osavuosikatsaus 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,11530422272.0,388303386.0,1013444.6,1.147,878088.0,0.033676423711119396,0.1515999603296736,1,7,242,0.0,0.32861949612372426,0.0
warrington pa jan 25 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing late stage interventions for critical cardiovascular disorders today announced that the company entered an exchange and termination agreement with affiliates of deerfield management company collectively deerfield pursuant to which deerfield has agreed to terminate its rights under the company s 2017 exchange and termination agreement to receive up to 15 000 000 in development and commercial milestone payments associated with aerosurf an acute pulmonary drug device combination intended to treat premature infants with respiratory distress syndrome windtree out licensed global rights to aerosurf in 2022,windtree eliminates 15 million contingent liability to deerfield management company,exchange_announcement,UP,6.521738880047693,1351382.0,3660923.0,6680965.0,0.764,1224200.0,2.7090215793905794,0.09346626282280733,3,8,520,0.033333333333333326,2.339794177443606,0.03151755651755652
reykjavik iceland parsippany n j oct 22 2024 globe newswire alvotech nasdaq alvo and teva pharmaceuticals a u s affiliate of teva pharmaceutical industries ltd nyse and tase teva today announced that the u s food and drug administration fda has approved selarsdi ustekinumab aekn in a new presentation 130 mg 26 ml 5 mg ml solution in a single dose vial for intravenous infusion this approval paves the way for selarsdi to further align its label with the indications of the reference product stelara ustekinumab in the u s at launch which is expected in the first quarter of 2025,alvotech and teva announce u s fda approval of additional presentation of selarsdi ustekinumab aekn expanding its label to include further indications approved for reference product stelara ustekinumab,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.03582251082251082,0.44264539487962035,0.05175282234105764
watertown mass sept 03 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced the continued evolution of its board of directors with the appointment of stephen steve fawell ph d as a director with this appointment malcolm salter has decided to retire from the board of directors after nearly a decade of service,c4 therapeutics appoints veteran biotechnology leader stephen fawell ph d to board of directors,management_changes,DOWN,-0.1582314653514814,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,1,7,298,0.05,0.8954742650579008,0.04428887085137085
media release,the recording of šiaulių bankas investor conference webinar of introducing the financial results for q3 2024,conference_call_webinar,UP,0.365856220366224,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,10,239,0.0,0.8866002429130597,0.10728012728012729
hkfoods plc stock exchange release inside information 26 september 2024 at 2 p m finnish time hkfoods plc updates its financial guidance for 2024 due to the positive performance of its continuing operations updated guidance for 2024 hkfoods expects that the group s comparable ebit 2024 from continuing operations will grow clearly compared to 2023 hkfoods now estimates that the group s comparable ebit in 2024 will be eur 22 25 million the group s comparable ebit for the group s continuing operations 2023 was eur 11 6 million hkfoods will publish the interim report for january september 2024 on wednesday 6 november 2024 at about 8 30 eet previous guidance for 2024 published on 9 february 2024 in 2024 hkfoods estimates that the group s comparable ebit from continuing operations will improve compared to 2023 hkfoods plc board of directors for further information juha ruohola ceo tel 358 400 647 160 mika tilli cfo tel 358 50 538 5793 hkfoods media service desk tel 358,inside information positive profit warning hkfoods plc s comparable ebit from continuing operations will grow clearly compared to 2023,financial_results,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.04535984848484849,0.8866002429130597,0.0
malvern pa sept 05 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that arun upadhyay phd ocugen s chief scientific officer head of research development will be among the featured speakers at the 5th annual gene therapy for ophthalmic disorders conference which is being held september 10 12 2024 in boston mass,ocugen cso to participate in 5th annual gene therapy for ophthalmic disorders summit,conference_call_webinar,DOWN,-0.862068168189925,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,3,7,296,0.0,0.7661975315521313,0.06330718954248366
sydney australia march 03 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce that through its wholly owned subsidiary radiopharm theranostics usa inc it has entered into a binding agreement to acquire pharma15 corporation pharma15 a private us based venture which is developing next generation therapeutic radiopharmaceuticals for prostate cancer pharma15 was founded by leading radiopharmaceutical scientist professor david ulmert and ceo suzanne dance,radiopharm theranostics partners with next generation preclinical platform for therapeutic radiopharmaceuticals,mergers_acquisitions,UP,0.0,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,4,8,848,0.125,0.9771277191333917,0.15
nkgen s snk01 program continues to show positive progress with the fda ind clearance in october 2023 and now the cta clearance by health canada for a phase 1 2a clinical trial in moderate alzheimer s disease patients,nkgen biotech announces clearance of clinical trial application by health canada for snk01 nk cell therapy to treat alzheimer s disease,clinical_study,UP,9.242146234319629,16295543.0,10616620.0,134195.0,1.199,86400.0,0.651504524887572,0.09346626282280733,2,8,549,0.11363636363636363,2.657355742098314,0.23737373737373735
media release,financial results for q1 q3 2024,financial_results,DOWN,-0.3053388522781488,24061241344.0,114481009.0,12961.055555555555,0.103,2569.0,0.0047579011973356644,0.1515999603296736,3,8,240,0.0,0.4833531340410722,0.0
new york sept 26 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions presented the results of a head to head animal study evaluating whether ov329 could be found to accumulate in mouse retinas and brains as has been previously shown to occur with vigabatrin vgb the only fda approved gaba aminotransferase gaba at inhibitor,ovid therapeutics presents pre clinical study results demonstrating ov329 does not accumulate in animal eyes in contrast with vigabatrin,clinical_study,DOWN,-0.8928562875609045,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,3,8,275,0.06742424242424241,0.7642184815786688,0.15923704659729504
strive is the first phase 2 sub protocol trial initiated under vir s new prevail platform trial investigating the company s novel therapies in two chronic hepatitis b virus patient populations,vir biotechnology announces first patient dosed in new phase 2 chronic hepatitis b virus trial evaluating combinations of vir 2218 vir 3434 peg ifnα and an nrti,clinical_study,DOWN,-0.7364987775877799,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,3,8,779,0.19318181818181818,0.8653389999075153,0.13636363636363635
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions magnusson sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name torbjörn magnussonposition chief executive officerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80026 5 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 7 042 unit price 41 9316 eur aggregated transactions 1 volume 7 042 volume weighted average price 41 9316 eur____________________________________________,sampo plc managers transactions magnusson,company_regulatory_filings,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.07333333333333333,0.8866002429130597,0.1625
alvotech nasdaq alvo and teva pharmaceuticals a u s affiliate of teva pharmaceutical industries ltd nyse and tase teva today announced that the u s food and drug administration fda has approved selarsdi ustekinumab aekn in a new presentation 130 mg 26 ml 5 mg ml solution in a single dose vial for intravenous infusion this approval paves the way for selarsdi to further align its label with the indications of the reference product stelara ustekinumab in the u s at launch which is expected in the first quarter of 2025,alvotech and teva announce u s fda approval of additional presentation of selarsdi ustekinumab aekn expanding its label to include further indications approved for reference product stelara ustekinumab,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.03582251082251082,0.44264539487962035,0.05175282234105764
engineered camelina is intended to enable the land based production of omega 3 oils used in aquafeed petfood and human nutrition engineered camelina is intended to enable the land based production of omega 3 oils used in aquafeed petfood and human nutrition,rothamsted research grants yield10 bioscience an exclusive global commercial license to advanced technology for producing omega 3 products in camelina,licensing_agreements,UP,4.9295813075798725,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,376,0.08,0.8866002429130597,0.025636904761904757
accelerating healthcare with award winning ai big steps forward in 2023 and the early days of 2024 accelerating healthcare with award winning ai big steps forward in 2023 and the early days of 2024,message from renovaro bioscience inc s ceo the hon mark dybul md,partnerships,UP,0.0,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,1,8,529,0.20000000000000004,1.5631250973582267,0.13148148148148145
media release,as tallinna vesi will hold an investor conference webinar to introduce the results for the 3rd quarter of 2024,clinical_study,UP,0.4926127351136131,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,245,0.0,0.8866002429130597,0.11818181818181818
media release,disclosure of significant shareholding in atlantic sapphire asa,clinical_study,UP,5.632185207394196,595463232.0,13903269.0,52395.0,0.75,40800.0,0.0233486607616438,0.1515999603296736,3,9,247,0.375,0.3468292883317439,0.012352693602693605
pre specified blinded interim analysis for sample size re estimation indicates that the ongoing phase 2 3 study in alzheimer s disease ad is sufficiently powered to continue as planned without any additional patients pre specified blinded interim analysis for sample size re estimation indicates that the ongoing phase 2 3 study in alzheimer s disease ad is sufficiently powered to continue as planned without any additional patients,annovis bio announces positive interim independent analysis for statistical power in its alzheimer s study,clinical_study,UP,3.8961064696895664,44036864.0,15624645.0,595065.0,1.618,805900.0,0.3548083033342247,0.09346626282280733,3,8,625,0.11363636363636363,1.368989555493872,0.028125
cambridge mass feb 22 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today reported operational highlights and financial results for the fourth quarter and year ended december 31 2023,intellia therapeutics announces fourth quarter and full year 2023 financial results and highlights recent company progress,financial_results,DOWN,-1.41368739817983,973680192.0,98412511.0,6353695.0,2.134,5288300.0,0.10107272573539218,0.09346626282280733,3,7,492,0.05833333333333333,0.7800307612939593,-0.09940476190476191
electrocore granted two new u s patents electrocore granted two new u s patents,electrocore expands intellectual property portfolio,patents,DOWN,-1.6339854003679126,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,1,8,452,0.19090909090909092,0.8324549917316175,0.0
miami oct 07 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for the prevention of stroke today announced that the u s food and drug administration fda has approved the company s investigational device exemption ide application to initiate the cguardians ii pivotal study of its cguard prime 80cm carotid stent system during transcarotid revascularization tcar procedures,inspiremd announces approval of investigational device exemption ide application for cguardians ii pivotal study of the cguard prime 80cm carotid stent system,clinical_study,DOWN,-1.515159040990203,66784956.0,16849440.0,286250.0,0.613,4867100.0,0.2522939447620509,0.09346626282280733,0,7,264,0.5,0.6085732039686736,0.10563218390804598
zug switzerland aug 27 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced results for the quarter ended june 30 2024 and provided an overview of the company s progress,oculis reports q2 financial results and provides recent company update,clinical_study,UP,1.1814294104779912,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,1,4,305,0.0,0.4640841922034435,0.0321010101010101
conference call to begin at 4 30 p m et,vaxart to host first quarter 2024 business update and financial results conference call on may 13,earnings_releases_and_operating_results,UP,0.0,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,1,8,417,0.125,1.025768835125998,0.08544864226682408
media release,rentefastsettelse,bond_fixing,DOWN,-0.1940257513701026,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,0,13,242,0.0,0.20896972559163385,0.0
lawrenceville n j may 06 2024 globe newswire imunon inc nasdaq imnn a clinical stage drug development company focused on developing dna mediated immunotherapy and next generation vaccines announces that the company will host a conference call at 11 00 a m et on monday may 13 2024 to discuss financial results for the first quarter ended march 31 2024 and provide an update on its clinical development programs with imnn 001 a dna based interleukin 12 il 12 immunotherapy in phase 2 clinical development for the treatment of first line locally advanced stage ovarian cancer and on its placcine modality a proprietary mono or multi cistronic dna plasmid and a synthetic dna delivery technology for the expression of pathogen antigens for the development of next generation vaccines,imunon to hold first quarter 2024 financial results and business update conference call on monday may 13 2024,conference_call_webinar,DOWN,-1.5037668789816911,17822234.0,12808492.0,12655315.0,2.143,945100.0,0.7186804976300951,0.09346626282280733,0,11,417,0.14375,2.964855117372811,0.01401515151515151
media release,多品牌联盟合力推出全球首款 纤维到纤维 生物再生型服装 carbios on patagonia puma pvh corp 与 salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
company expects enrollment in phase 1 proof of concept study of dna based vaccine technology to begin in q2the application follows guidance provided to imunon in pre ind meeting with the fda,imunon files ind application to begin human testing of imnn 101,clinical_study,DOWN,-2.150535566956493,17677966.0,12808492.0,12655315.0,2.143,945100.0,0.7245455727203005,0.09346626282280733,2,8,472,0.0,2.964855117372811,0.0
new york sept 26 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions presented the results of a head to head animal study evaluating whether ov329 could be found to accumulate in mouse retinas and brains as has been previously shown to occur with vigabatrin vgb the only fda approved gaba aminotransferase gaba at inhibitor,ovid therapeutics presents pre clinical study results demonstrating ov329 does not accumulate in animal eyes in contrast with vigabatrin,clinical_study,DOWN,-0.8928562875609045,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,3,8,275,0.06742424242424241,0.7642184815786688,0.15923704659729504
los angeles oct 10 2023 globe newswire renovaro biosciences inc nasdaq renb renovaro an advanced pre clinical biotechnology firm in cell gene and immunotherapy focused on solid tumors with short life expectancy is pleased to announce the appointment of leni boeren and ruud hendriks as independent directors,renovaro biosciences appoints two finance industry experts to board of directors,management_changes,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,8,627,0.11666666666666665,1.5631250973582267,0.15
media release,recording of lhv group s 22 october investor webinar,clinical_study,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
on track to announce topline data in q1 2025,mineralys therapeutics completes target enrollment in pivotal advance htn trial of lorundrostat for the treatment of hypertension,clinical_study,UP,0.1709440862369388,916690560.0,43490817.0,793180.0,-0.18,767600.0,0.04744329100541845,0.09346626282280733,2,8,276,0.5,0.8131647725786432,0.08510678210678212
new 38 7 million term loan with a may 2029 maturity 37 5 million royalty monetization financing based on future sales of loqtorzi and udenyca,coherus announces full repayment of pharmakon advisors 75 million term loan,financing_agreements,UP,0.8968601235628331,84758616.0,110892497.0,1236840.0,0.883,1425300.0,1.3083330312991426,0.09346626282280733,3,7,415,0.1621212121212121,1.0144535837204522,0.18608333333333332
norwood mass feb 28 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today announced the appointment of dr dominic smethurst ma mrcp as the company s chief medical officer cmo in this role dr smethurst will lead the clinical development of the company s investigational oncology drugs crb 701 a next generation nectin 4 targeting antibody drug conjugate adc developed in partnership with cspc and crb 601 a tgfβ blocking monoclonal antibody targeting the integrin αvβ8 additionally dr smethurst will help guide strategic development of crb 913 the company s highly peripherally restricted cb1 inverse agonist for the treatment of obesity,corbus pharmaceuticals appoints dr dominic smethurst as chief medical officer,management_changes,DOWN,-1.764476754343736,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,8,486,0.052000000000000005,0.9919200800994142,-0.057575757575757586
initiated phase 3 synchrony outcomes trial of lead candidate efruxifermin efx in patients with compensated cirrhosis f4 due to mash,akero therapeutics reports second quarter 2024 financial results and provides business update,clinical_study,UP,1.5242645652423397,4379684864.0,65983030.0,1904080.0,-0.16,4370200.0,0.015065702681570835,0.09346626282280733,4,7,323,-0.041666666666666664,1.1395320392459187,-0.01808530543530543
finansielle resultater og business update,delårsrapport 2024 fortsat eksekvering på strategi,financial_results,UP,4.102247433174875,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,2,312,0.0,0.8866002429130597,0.0
fda grants pre bla meeting request and rolling bla submission after review of hope 2 and hope 2 ole 3 year results san diego june 11 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the successful completion of a type b meeting with the u s food and drug administration fda on next steps for the biologics license application bla submission with its lead asset cap 1002 for the treatment of duchenne muscular dystrophy dmd additionally deramiocel has been selected as the proposed international nonproprietary name inn for cap 1002 by the world health organization,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy with an aim to expedite bla pathway,clinical_study,DOWN,-0.554523730449676,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,382,0.2554545454545455,1.3427880947904531,0.09606060606060605
redwood city calif oct 24 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma is presenting data from preclinical studies evaluating briquilimab at the american college of allergy asthma immunology acaai annual scientific meeting taking place october 24 28 2024 in boston massachusetts,jasper therapeutics to present preclinical briquilimab data at the american college of allergy asthma immunology acaai annual scientific meeting,clinical_study,UP,0.5513719237909561,81870440.0,9908441.0,280900.0,2.725,505700.0,0.12102586721165784,0.09346626282280733,3,8,247,0.12,0.9821837329226573,0.15267587140257946
selskabet har afholdt ekstraordinær generalforsamling den 21 oktober 2024 kl 10 00 på selskabets adresse lyskær 8a 2730 herlev med følgende dagsorden,referat fra ekstraordinær generalforsamling,clinical_study,DOWN,-4.696800970514925,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,4,250,0.0,0.8866002429130597,0.0
radnor pa oct 22 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other prevalent cardiovascular diseases driven by dysregulated aldosterone today announced full details for its upcoming virtual kol event being held on wednesday october 30 2024 at 10 00 am et to register for the event please click here,mineralys to host virtual kol event on the unmet medical need in uncontrolled and resistant hypertension and lorundrostat as a potential treatment on october 30 2024,clinical_study,DOWN,-0.1446095748350239,915387072.0,43490817.0,793180.0,-0.18,767600.0,0.04751084904987603,0.09346626282280733,1,8,249,0.056249999999999994,0.8131647725786432,0.11103760822510823
phase 1 2 study of kb 0742 is on track to clear 80mg four days on three days off schedule in the third quarter of 2024 topline data from expansion cohort at this schedule expected in the first half of 2025,kronos bio reports recent business progress and fourth quarter and full year 2023 financial results,clinical_study,UP,0.8264454667762735,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,3,7,464,0.04814814814814815,0.6178272804340184,0.03409090909090909
media release,tme pharma awarded 2 4 million german federal grant to support nox a12 phase 2 trial in brain cancer,clinical_study,UP,8.108104298461395,7567473.0,35018869.0,709344.8636363636,1.573,202300.0,0.25000035609542787,0.09346626282280733,3,8,240,0.0,0.8573564202514549,0.0
media release,better collective share buyback program,changes_in_companys_own_shares,UP,3.196356470412,7888917504.0,36824135.0,59876.52631578947,1.026,55837.0,0.004667831167118768,0.19535099655549074,0,7,243,0.5,0.5727887509119637,0.0
saint herblain france le 21 octobre 2024 valneva se nasdaq valn euronext paris vla société spécialisée dans les vaccins annonce aujourd hui que des membres de son équipe de direction présenteront des données sur le premier et le seul vaccin autorisé au monde contre le chikungunya ixchiq durant différentes conférences scientifiques de premier plan organisées au cours du quatrième trimestre 2024,valneva effectuera des présentations sur le chikungunya lors de différentes conférences scientifiques de premier plan,clinical_study,DOWN,-0.3577497249859914,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,0,11,249,0.0,0.6494694268312979,0.06024955436720141
media release,bekaert update over de liquiditeitsovereenkomst,clinical_study,UP,0.1158104066794088,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,246,0.0,0.8866002429130597,0.0
redwood city calif march 15 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu announced additional positive phase 1b 2a data on briquilimab as a conditioning agent in the treatment of fanconi anemia fa,new positive data presented on briquilimab conditioning in patients with fanconi anemia,clinical_study,DOWN,-0.4106791782468576,81044232.0,9908441.0,280900.0,2.725,505700.0,0.12225966926307599,0.09346626282280733,4,8,470,0.2381818181818182,0.9821837329226573,0.09158730158730159
media release,franchissement d une nouvelle étape décisive dans la réalisation de la restructuration financière arrêté du plan de sauvegarde accélérée d atos par le tribunal de commerce spécialisé de nanterre,clinical_study,UP,0.3654785367553472,24416421888.0,158122098.0,963560.0,0.703,746300.0,0.006476055284648921,0.1515999603296736,3,8,247,0.0,0.17227978832070448,0.0
02 oct 2024 09 44 cest eqs newswire 02 10 2024 09 44 cet cest paris france media outreach newswire 2 octobre 2024 le 24 septembre 2024 la troisième étape de l événement d échange culturel panda wandering l exposition de photographies le monde des pandas des grands pandas a été inaugurée en grande pompe à la galerie d art du grand palais à paris en france de nombreux invités distingués ont assisté à la cérémonie d ouverture créant une atmosphère festive et animée des personnalités politiques commerciales et artistiques de chine et de france étaient présentes la première dame de france brigitte macron a envoyé un message de félicitations souhaitant un grand succès à l exposition de photographies sur les pandas des figures éminentes telles que m pubu dunzhu vice gouverneur du gouvernement provincial du sichuan m lu shaye ambassadeur de chine en france m emmanuel mandon député de l assemblée nationale française et membre du groupe d amitié,l exposition de photographies des grands pandas le monde des pandas s ouvre en grande pompe à paris france,press_releases,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,269,0.5,0.8866002429130597,0.22620370370370368
new york april 22 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced additional positive clinical results from its intermediate sized expanded access program eap for non active secondary progressive multiple sclerosis na spms patients the data demonstrate multiple improvements in foralumab treated patients with showing an improvement in fatigue after six months of follow up fatigue is a debilitating symptom for many ms patients and is measured by the modified fatigue impact scale mfis,tiziana life sciences announces additional clinical improvements among multiple sclerosis patients in its expanded access program,clinical_study,UP,4.477607558580467,195136160.0,63394363.0,242895.0,0.107,139700.0,0.32487245316296065,0.09346626282280733,0,7,432,0.05378787878787879,1.1109140250580023,0.047095959595959594
topline data from the phase 1 portion of phase 1 2a trial of imm 1 104 expected in march 2024,immuneering reports fourth quarter and full year 2023 financial results and provides business updates,clinical_study,DOWN,-1.9354820846890508,113175024.0,27271404.0,2516685.0,0.002,1980700.0,0.2409666288208607,0.09346626282280733,4,8,484,0.06249999999999999,1.2966226301621697,0.12152777777777779
sunnyvale calif july 25 2024 globe newswire biocardia inc nasdaq bcda a global leader in cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases announced today that the confirmatory phase 3 trial of its autologous cardiamp cell therapy product candidate for patients with ischemic heart failure of reduced ejection fraction hfref has commenced enrollment in the united states,patient enrollment commenced in pivotal phase 3 trial of cardiamp cell therapy for the treatment of ischemic heart failure,clinical_study,UP,0.3521123508970877,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,3,7,338,-0.033333333333333326,1.32107885633281,0.10806878306878305
single infusion of anx005 demonstrated significant improvements across multiple functional and prognostic measures that expedited recovery in gbs patients,annexon to present pivotal phase 3 data on early and durable benefits with first in class c1q blocking antibody anx005 in guillain barré syndrome at 2024 pns annual meeting,clinical_study,DOWN,-0.7462679264300778,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,1,8,375,0.16479591836734692,0.7558344054121836,0.1861627435064935
media release,norwegian air shuttle asa nas mandatory notification of trade employee share savings plan,changes_in_companys_own_shares,UP,0.987658088589892,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,2,8,241,0.0,0.4683640137646959,0.0625
remedy entertainment oyj sisäpiiritieto 27 9 2024 klo 9 00 sisäpiiritieto remedy tekee tencentin kanssa 15 miljoonan euron vaihtovelkakirjalainasopimuksen remedy entertainment oyj remedy tai yhtiö on tänään allekirjoittanut vaihtovelkakirjalainasopimuksen tencent holdings limitedin tencent konserniyhtiön kanssa 15 miljoonan euron määräisen vakuudettoman vaihtovelkakirjalainan ottamisesta laina lainalle maksetaan vuotuista pääomitettavaa korkoa ja sen kiinteä vaihtosuhde on 27 20 euroa osakkeelta vastaten 63 n preemiota remedyn osakkeen päätöskurssiin nasdaq helsingin pörssissä 26 9 2024 laina edellyttää remedyn ylimääräisen yhtiökokouksen hyväksymistä joka on tarkoitus järjestää 24 10 2024 mennessä remedy julkaisee kutsun ylimääräiseen yhtiökokoukseen erikseen laina maksetaan remedylle vaihtovelkakirjalainasopimuksen mukaisesti ylimääräisen yhtiökokouksen hyväksynnän jälkeen ja tiettyjen tavanomaisten lainan noston edellytysten täytyttyä mu,sisäpiiritieto remedy tekee tencentin kanssa 15 miljoonan euron vaihtovelkakirjalainasopimuksen,financing_agreements,UP,0.2409578750574071,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.0,0.8866002429130597,0.0
pratteln switzerland july 31 2024 santhera pharmaceuticals six sann announces the board of directors has appointed dr oliver p kronenberg as chief legal officer and corporate secretary of santhera pharmaceuticals ag effective august 1 2024,santhera appoints dr oliver p kronenberg as chief legal officer and company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.25,0.5209522992128177,0.03714285714285715
cambridge mass may 14 2024 globe newswire editas medicine inc nasdaq edit a clinical stage gene editing company today announced that two abstracts including one oral presentation and one poster presentation detailing clinical data from the ruby and edithal trials of renizgamglogene autogedtemcel reni cel have been accepted for presentation at the european hematology association eha hybrid congress being held june 13 16 2024 in madrid spain and via livestream,editas medicine to present clinical data from the ruby and edithal trials of reni cel at the european hematology association 2024 congress in june,clinical_study,DOWN,-3.0716774927414563,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,1,10,409,0.0,1.3105556047468256,0.051530784030784024
media release,hexagon purus asa mandatory notification of trade,shares_issue,DOWN,-7.008085924255639,934099520.0,189095204.0,501623.0,1.081,537849.0,0.20243582182763567,0.1515999603296736,3,13,239,0.0,1.126065167473528,0.0
spatial biology 2 0 solutions enable discovery and translational workflows at an unprecedented speed and scale,akoya biosciences to showcase new spatial biology 2 0 solutions and spatial phenotyping data at sitc 2023,trade_show,DOWN,-0.2941173583166078,60944124.0,12648900.0,228670.0,1.352,488000.0,0.207549131397803,0.09346626282280733,1,9,606,0.36818181818181817,0.8573192373918191,0.0
san diego feb 26 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy epinephrine nasal spray an investigational new drug the trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch hives urticaria and erythema scores as early as 5 minutes after dosing urticaria is a skin disorder that causes itchy hives and or angioedema of chronic urticaria cases1 are non responsive to first line antihistamine therapy,ars pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in phase 2 urticaria clinical study,clinical_study,UP,2.6347221952553848,1692711424.0,51755600.0,1240295.0,0.872,1940800.0,0.03057556017297843,0.09346626282280733,0,9,488,0.3488636363636363,0.6899910717831225,0.3202020202020202
eurobio scientific rapport financier annuel 2023,eurobio scientific rapport financier annuel 2023,annual_report,DOWN,-1.108032216493058,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,4,11,427,0.0,0.4336088389568585,0.0
redwood city calif july 31 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a late stage biopharmaceutical company committed to developing novel transformative therapies for serious rare diseases today announced that nevan charles elam chief executive officer and founder of rezolute will participate in a fireside chat during the btig virtual biotechnology conference on monday august 5 2024 at 12 00 p m et,rezolute to participate in the btig virtual biotechnology conference,conference_call_webinar,DOWN,-0.222227308485243,379380256.0,77797779.0,825115.0,1.04,796000.0,0.20506543967327598,0.09346626282280733,2,8,332,-0.1111111111111111,0.6820409900648857,0.016611652236652237
media release,šiaulių bankas invitation to q3 2024 financial results webinar,conference_call_webinar,DOWN,-0.1222550986926836,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,13,242,0.0,0.8866002429130597,0.07946416546416549
media release,bluenord invitation to third quarter 2024 results,financial_results,UP,1.153846153846154,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,14,241,0.0,0.8866002429130597,0.18623737373737373
media release,polight asa continues to build positive momentum in several segments,business_contracts,DOWN,-7.103823312288768,725118720.0,112518348.0,613349.45,1.511,331673.0,0.15517231164573989,0.19535099655549074,3,7,240,0.11363636363636363,0.8385781649627817,0.0
media release,launch of a capital increase of approximately 36 6 million with preferential subscription rights,share_capital_increase,DOWN,-6.88946716859099,67170584.0,14323264.0,15862.954545454546,1.806,9661.0,0.2132371515483623,0.1515999603296736,0,7,243,-0.4,0.5487288764223092,0.0
media release,ab akola group receives permission to acquire latvian grain exporter,mergers_acquisitions,UP,0.3999996185302734,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,240,0.0,0.8866002429130597,0.08773120818575364
farmington hills mich march 08 2024 globe newswire ocuphire pharma inc nasdaq ocup a clinical stage biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of retinal and refractive eye disorders today announced financial results for the fourth quarter and full year ended december 31 2023 and provided a corporate update,ocuphire pharma announces financial results for fourth quarter and full year 2023 and provides corporate update,financial_results,DOWN,-1.2605129565465132,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,477,0.049999999999999996,0.8866002429130597,-0.04611935683364255
27 sep 2024 08 30 cest artmarket com ex artprice com la société artmarket annonce que son rapport financier semestriel au 30 juin 2024 de 121 pages est mis à la disposition du public et a été déposé auprès de l autorité des marchés financiers amf ce rapport financier semestriel 2024 est disponible sur le site internet d artprice com www artprice com d actusnews www actusnews fr le résultat net du groupe artprice by artmarket ressort à 340 k au 30 06 24 contre 330 k au 30 06 23 le chiffre d affaires consolidé ressort en augmentation à 4 168 k au 30 06 24 contre 4 063k au 30 06 23 les capitaux propres ressortent à 31 881 k au 30 06 24 contre 31 046 k au 30 06 23 en dépit du choc inflationniste le plus fort depuis 1970 ainsi que de l explosion des taux d intérêts et de la guerre russie ukraine le chiffre d affaires d artmarket com atteint au premier semestre 2024 son record de ca s1 depuis sa création en 1997 avec 4 168 k les différents rappels suiva,artmarket com rapport financier s1 2024 les capitaux propres supérieurs à 31m eur record ca s1 l ia intuitive artmarket r unique au monde constituera le relais de croissance 2024 2029 d artprice by artmarket,financial_results,UP,1.1494296972653992,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,274,0.125,0.8866002429130597,0.1875
media release,sisäpiiritieto valmet vahvistaa allekirjoittaneensa araucon kanssa sopimukset aiemmin tiedotettuun projektiin liittyen,business_contracts,UP,0.3690043248877174,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,8,242,0.0,0.8866002429130597,0.04945114409400122
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
mainz biomed provides half year 2024 corporate update industry leading clinical data position the company for fda premarket approval study,mainz biomed provides half year 2024 corporate update,clinical_study,UP,7.246378564303781,5512458.0,2706585.0,75055.0,0.305,78500.0,0.4909942170987969,0.09346626282280733,1,8,361,-0.08333333333333333,34.079934680222834,0.04518716577540107
media release,wärtsilän tammi syyskuun osavuosikatsaus 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,11530422272.0,388303386.0,1013444.6,1.147,878088.0,0.033676423711119396,0.1515999603296736,1,7,242,0.0,0.32861949612372426,0.0
newport beach calif aug 28 2023 globe newswire biomerica inc nasdaq bmra a global biomedical company leading the way in innovative gastroenterology solutions today announced the appointment of jack kenny former ceo and board member of meridian bioscience inc to its board of directors meridian biosciences formerly traded on nasdaq under vivo is a leading global provider of diagnostic testing solutions meridian biosciences was acquired on january 31 2023 by sd biosensor inc and sjl partners llc in an all cash transaction valued at approximately 1 53 billion,diagnostics industry leader jack kenny joins biomerica s board of directors,management_changes,UP,0.0,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,0,8,670,0.016666666666666663,1.5245042583012947,0.0
unblinded interim analysis to be conducted during the current quarter,polypid announces last patient in for planned unblinded interim analysis in the ongoing shield ii phase 3 trial evaluating d plex₁₀₀ for the prevention of abdominal colorectal surgical site infections,clinical_study,UP,2.0348817464659645,37298696.0,4610773.0,1395250.0,1.25,337200.0,0.12361753880082027,0.09346626282280733,1,7,270,0.0,0.7168605096826995,-0.03251003336940836
waltham mass may 10 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced financial results for the first quarter ended march 31 2024 and recent corporate updates,checkpoint therapeutics reports first quarter 2024 financial results and recent corporate updates,financial_results,UP,0.6410326948300152,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,4,8,414,0.0625,0.8866002429130597,0.07628787878787878
mainz biomed webinar on early detection of colorectal cancer exploring new laboratory diagnostic options,mainz biomed webinar on early detection of colorectal cancer exploring new laboratory diagnostic options,conference_call_webinar,DOWN,-5.769225478877488,5569681.0,2706585.0,75055.0,0.305,78500.0,0.48594973392551566,0.09346626282280733,0,8,467,0.11818181818181818,34.079934680222834,0.01
nexobrid interest surges 5 million in q1 2024 revenue with 24 million forecast for the year,mediwound reports first quarter 2024 financial results and provides company update,financial_results,DOWN,-3.4851085290965536,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,7,395,0.125,0.6433034533898109,0.1344343434343434
biomerica reports first quarter 2024 financial results revenues excluding covid test sales increased 16 for first fiscal quarter of 2024,repeat biomerica reports first quarter 2024 financial results,financial_results,UP,2.7777750183035925,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,4,13,623,0.15,1.5245042583012947,0.025555555555555557
missing,mdxhealth appoints sanford j siegel m d to board of directors,management_changes,DOWN,-1.2820501064172196,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,8,355,-0.2,0.6181119561491973,0.10389610389610392
all patients treated in the edithal trial maintained hemoglobin levels above the transfusion threshold and are transfusion free post renizgamglogene autogedtemcel reni cel infusion,editas medicine announces new safety and efficacy data from the edithal trial of reni cel in 7 patients with transfusion dependent beta thalassemia presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1340909090909091,1.3105556047468256,0.048818637502848025
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
in8bio demonstrates robust and reproducible gamma delta t cell therapy manufacturing in oral presentation at asgct 2024,in8bio demonstrates robust and reproducible gamma delta t cell therapy manufacturing in oral presentation at asgct 2024,clinical_study,UP,1.9801961500356329,7446425.0,2577285.0,392516.85,0.183,187400.0,0.34611038182752124,0.09346626282280733,0,8,411,0.0,1.2777111391401192,0.125
media release,invitation to enefit green investor webinars presenting q3 2024 interim results,conference_call_webinar,DOWN,-0.2657773099176188,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,243,-0.2,0.8866002429130597,-0.012840909090909097
the company s management will host a webcast and conference call on wednesday may 15 2024 after the close of financial markets,biora therapeutics to report first quarter 2024 financial results and provide corporate update,conference_call_webinar,UP,1.1983977764023646,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,417,0.0625,1.027516639474094,0.11999458874458874
repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greater than injection,ars pharma announces favorable topline results from repeat dosing study of neffy epinephrine nasal spray under nasal allergen challenge conditions readies data for response to fda s complete response letter,clinical_study,DOWN,-3.765690070481453,1694184576.0,51755600.0,1240295.0,0.872,1940800.0,0.030548973667435867,0.09346626282280733,1,9,494,0.275,0.6899910717831225,0.18560606060606064
media release,avnotering av kindred group plc,exchange_announcement,DOWN,-0.390625,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,14,242,0.0,0.8866002429130597,0.0
newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501 newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501,bioxcel therapeutics announces european patent office s grant of patent for method of treating agitation in dementia using sublingual dexmedetomidine,patents,DOWN,-1.7421586867605077,12766154.0,5544250.0,450810.0,-0.13,78500.0,0.4342928966703676,0.09346626282280733,4,7,470,0.17454545454545456,1.4586588351104455,-0.030684523809523807
sydney australia march 03 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce the appointment of dr ken herrmann to the company s scientific advisory board sab,dr ken herrmann appointed to rad scientific advisory board,advisory,UP,0.0,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,4,7,848,0.5,0.9771277191333917,-0.2
tel aviv israel and miami april 03 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for the prevention of stroke today announced that marvin slosman chief executive officer will deliver a company update presentation at the 23rd annual needham virtual healthcare conference which is being held april 8 11 2024,inspiremd to present at the 23rd annual needham virtual healthcare conference,conference_call_webinar,UP,4.186042333822812,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,2,8,451,0.0,0.6085732039686736,0.07579545454545454
on track to present additional clinical data from the ruby trial and the edithal trial by year end,editas medicine announces second quarter 2024 results and business updates,financial_results,UP,4.273510543552606,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,2,7,325,0.0,1.3105556047468256,0.07693389943389943
company maintains solid cash position of 141 6 million company maintains solid cash position of 141 6 million,rapt therapeutics reports first quarter 2024 financial results,clinical_study,DOWN,-7.103823312288768,143037264.0,6191111.0,99294.6,-0.137,87900.0,0.04328320345948452,0.09346626282280733,3,8,415,0.0625,1.6028075568485736,0.10693578643578647
ad hoc announcement pursuant to art 53 lr,addex provides update on adx71149 phase 2 epilepsy study,clinical_study,DOWN,-7.103823312288768,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,0,1,425,0.0,0.972373032385036,0.002592592592592597
vi skal herved oplyse at der er foretaget ændringer i prospektet for investeringsforeningen danske invest prospektet kan fra i dag ses på www danskeinvest dk med venlig hilsen danske investmanagement a s tina hjorth hettinghead of fund products,offentliggørelse af prospekt for investeringsforeningen danske invest,prospectus_announcement,UP,0.0654852180693568,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,9,274,0.0,0.8866002429130597,0.0
new data show istisociclib kb 0742 triggered cell death in preclinical ovarian cancer models of platinum and parp inhibitor parpi resistance,kronos bio highlights data at aacr ovarian cancer research symposium that supports clinical evaluation of istisociclib in advanced ovarian cancer,clinical_study,UP,0.9708728874782327,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,0,8,278,0.2681818181818182,0.6178272804340184,0.018323112073112074
not for distribution publication or release in whole or in part directly or indirectly in the united states or to any us person or to any other jurisdiction in which the distribution publication or release would be unlawful,eurobio scientific conclusion of an agreement between eurobio scientific and a consortium led by eurobio scientific s team of entrepreneurs and managers ik partners and nextstage am with a view to file a voluntary tender offer at a price,mergers_acquisitions,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,15,331,0.05833333333333335,0.4336088389568585,0.0036904761904761898
spectral ai s deepview system designed to provide equity in burn care access while optimizing healthcare resources spectral ai s deepview system designed to provide equity in burn care access while optimizing healthcare resources,american burn association study highlights inequities in access to specialized burn care,clinical_study,UP,1.4814800424667631,55225816.0,17924135.0,466020.0,0.698,473400.0,0.3245607996086468,0.09346626282280733,1,8,291,0.0,0.9904696515070965,0.05990199615199617
media release,nanologica s rights issue registered conversion of btu to shares and warrants,shares_issue,DOWN,-3.404252210749046,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,10,240,0.0,0.8866002429130597,0.04191919191919192
eurobio scientific completes acquisition of endopredict genomic test from myriad genetics,eurobio scientific completes acquisition of endopredict genomic test from myriad genetics,mergers_acquisitions,DOWN,-0.2036628864129181,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,4,1,330,0.0,0.4336088389568585,0.007326007326007327
zug switzerland and boston may 29 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today announced that members of its senior management team are scheduled to participate in the following investor conferences in june,crispr therapeutics to participate in upcoming investor conferences,conference_call_webinar,DOWN,-2.151714627812774,4069457152.0,85970729.0,2651100.0,1.742,2455300.0,0.021125846959157268,0.09346626282280733,2,8,395,-0.16666666666666666,0.5620956775766307,0.04026875901875901
san diego nov 01 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer of anaptys and or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in november,anaptys announces participation in november investor conferences,conference_call_webinar,DOWN,-1.0423058360543165,687503680.0,17605381.0,784220.0,-0.266,445700.0,0.02560768983811112,0.09346626282280733,2,9,605,0.125,0.871343469962729,0.3438773011500284
longeveron announces positive type c meeting with fda clarifying regulatory pathway to bla submission for lomecel b for hypoplastic left heart syndrome,longeveron announces positive type c meeting with u s fda regarding pathway to bla for lomecel b in hypoplastic left heart syndrome hlhs,clinical_study,UP,0.4901956201103737,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,1,9,298,0.11363636363636363,1.063123411629147,0.11833333333333333
transcode therapeutics reports publication of united states patent application covering transcode s rig i agonist immunotherapeutic,transcode therapeutics reports publication of united states patent application covering transcode s rig i agonist immunotherapeutic,patents,UP,1.9145731157602923,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,1,8,494,0.0,2.0874185587937095,0.0
cambridge mass and rostock germany and berlin dec 19 2023 globe newswire centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced the voting results of the company s extraordinary general meeting all voting items on the agenda which included the adoption of dutch statutory annual accounts for the financial year ended december 31 2022 were passed by the requisite majority,centogene announces voting results of extraordinary general meeting,voting_rights,DOWN,-1.72413633637985,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,1,6,557,0.15238095238095237,3.598197549072007,0.075
media release,jūratė lingienė elected as the new chairperson of the board at ab kn energies,management_changes,UP,0.425532778337998,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,245,0.13636363636363635,0.8866002429130597,0.13222222222222224
media release,new number of shares and votes in itab shop concept ab publ,shares_issue,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.13636363636363635,0.8866002429130597,0.012500000000000004
media release,lhv group financial calendar for 2025,financial_calendar,UP,0.1430647955548679,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,254,0.0,0.8866002429130597,0.0838364315423139
boston jan 11 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that the first patient has been dosed at northwell health cancer institute and the feinstein institutes for medical research new york as part of the randomized phase 2 amplify 7p study of eli 002 7p as an adjuvant monotherapy in kras mutated pancreatic ductal adenocarcinoma pdac,elicio therapeutics announces first patient dosed in randomized phase 2 pancreatic cancer study,clinical_study,DOWN,-1.6245515019423795,127896016.0,10299137.0,63410.0,2.164,22500.0,0.08052742628042456,0.09346626282280733,3,8,534,0.1590909090909091,0.8558055682194762,0.02327380952380953
moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,financial_results,DOWN,-1.5947867861013068,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,1,8,417,0.125,0.5366763308656862,0.04025252525252525
media release,arctic bioscience 3 kvartal 2024 operasjonell oppdatering,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.1313131313131313
conference call and webcast scheduled for wednesday may 29th at 8 30 am eastern time conference call and webcast scheduled for wednesday may 29th at 8 30 am eastern time,mediwound to report first quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-1.0477316762418971,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,8,402,0.125,0.6433034533898109,0.1367929292929293
south san francisco calif oct 24 2024 globe newswire vaxart inc nasdaq vxrt today announced that it will present research featuring its covid 19 and norovirus oral pill vaccine candidates at the world vaccine congress europe 2024 taking place in barcelona spain on october 28 31 2024,vaxart to showcase its covid 19 and norovirus oral pill vaccine candidates at world vaccine congress europe 2024,clinical_study,UP,0.0,120729968.0,226926647.0,9325470.0,1.148,2676900.0,1.8796215286000904,0.09346626282280733,3,8,247,0.0,1.025768835125998,0.05398917748917749
san mateo calif and cambridge mass sept 03 2024 globe newswire kronos bio inc nasdaq kron a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription today announced the following upcoming conferences,kronos bio announces participation in medical and investor conferences in september,conference_call_webinar,UP,0.0,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,1,8,298,-0.09375,0.6178272804340184,0.03700196408529742
recently initiated serenity at home pivotal phase 3 trial for agitation associated with bipolar disorders or schizophrenia,bioxcel therapeutics announces clinical prioritization and update on bxcl501 late stage programs for agitation,clinical_study,DOWN,-0.941921779059158,11996430.0,5544250.0,450810.0,-0.13,78500.0,0.4621583254351503,0.09346626282280733,3,7,282,0.06666666666666667,1.4586588351104455,0.05906375787954736
petach tikva israel jan 31 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will report its fourth quarter and full year 2023 financial results and operational highlights before the open of the u s financial markets on wednesday february 14 2024 the company will host a conference call and webcast at 8 30 am eastern time to discuss the results and provide an update on business operations,polypid to report fourth quarter and full year 2023 financial results and operational highlights on february 14 2024,earnings_releases_and_operating_results,UP,3.034898401126696,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,2,7,514,0.04444444444444444,0.7168605096826995,-0.02142857142857143
tampa fla march 06 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will participate in an analyst led fireside chat at the barclays 26th annual global healthcare conference at 1 35 pm et on wednesday march 13 2024 in miami live audio of the event can be accessed by visiting the events page of the company s website at investor pacira com a replay of the webcast will also be available for two weeks following the event,pacira biosciences to participate in fireside chat at the barclays 26th annual global healthcare conference,conference_call_webinar,UP,0.2038025300745919,1111081344.0,45834212.0,557500.0,0.511,435200.0,0.04125189595479339,0.09346626282280733,2,8,479,0.10727272727272727,0.7130794063724827,0.19270768913626055
media release,norden iværksætter aktietilbagekøb,changes_in_companys_own_shares,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.3751516281224713,0.0
la jolla calif oct 26 2023 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that its collaborator genzyme corporation a subsidiary of sanofi has treated the first patient in a clinical trial of sar444836 for the treatment of phenylketonuria pku sar444836 is a phenylalanine hydroxylase pah replacement gene therapy product based on adeno associated virus aav vector technology which is covered under medicinova s assignment agreement with genzyme corporation,medicinova s collaborator initiates clinical development of a gene therapy product for the treatment of phenylketonuria,clinical_study,UP,0.5154634107374384,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,4,1,610,0.08333333333333333,0.8018560055721619,0.0
patient dosing initiated in phase 3 archer ii trial of c1q inhibitor anx007 topline data expected in second half 2026,annexon provides update on archer ii global registrational program in geographic atrophy,clinical_study,DOWN,-7.103823312288768,263862160.0,82380157.0,1425435.0,1.259,925100.0,0.31220906021537914,0.09346626282280733,0,8,327,-0.06666666666666667,0.7558344054121836,0.17700553273257352
awarded additional 6 7 million to advance nexobrid as a non surgical field care solution r d project budget increased to 14 4 million awarded additional 6 7 million to advance nexobrid as a non surgical field care solution r d project budget increased to 14 4 million,mediwound secures additional u s department of defense funding to advance nexobrid development for the u s army,financing_agreements,UP,1.8464487957984947,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,3,7,548,0.0,0.6433034533898109,0.12
cambridge mass jan 03 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that the company s president and ceo gilmore o neill m b m m sc will present at the 42nd annual j p morgan healthcare conference on tuesday january 9 2024 4 30 p m pt 7 30 p m et in san francisco ca,editas medicine to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-2.0040061967810527,181238416.0,83382193.0,2526680.0,2.096,3015800.0,0.46006908932596274,0.09346626282280733,2,7,542,0.0,1.3105556047468256,0.057272727272727274
media release,amundi résultats du troisième trimestre et des neuf mois 2024,earnings_releases_and_operating_results,DOWN,-2.828854436110023,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,241,0.0,0.8866002429130597,0.0
media release,atos publie son chiffre d affaires du troisième trimestre 2024,clinical_study,UP,0.3654785367553472,24416421888.0,158122098.0,963560.0,0.703,746300.0,0.006476055284648921,0.1515999603296736,3,7,247,0.0,0.17227978832070448,0.0
media release,morrow bank asa q3 2024 highlights strong growth increased profitability and updated ambitions,earnings_releases_and_operating_results,UP,1.2084580829157887,2635189504.0,92971885.0,436382.6,1.159,149714.0,0.03528091048437934,0.1515999603296736,3,7,240,0.43333333333333335,0.3747834297716561,0.0
irvine calif oct 30 2024 globe newswire biomerica inc nasdaq bmra a leading global provider of advanced medical diagnostics is excited to announce a major enhancement to its infoods ibs platform us consumers can now seamlessly order the infoods ibs test directly from infoodsibs com and consequently collect a sample in the comfort of their home as part of this ordering process a licensed physician remotely authorizes the test ensuring professional medical oversight without the need for visiting a doctor s office,biomerica announces direct to consumer availability of infoods ibs test targeting relief for bloating and gastrointestinal pain,product_services_announcement,UP,0.0,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,2,8,241,0.10340909090909092,1.5245042583012947,0.15793297388885624
media release,chiffre d affaires de capgemini au 3ème trimestre 2024,earnings_releases_and_operating_results,DOWN,-1.7892695828851255,24334401536.0,169611141.0,417051.0,0.951,403238.0,0.006970014888144237,0.19535099655549074,2,7,241,0.0,0.29691516676147794,0.0
miami oct 15 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for the prevention of stroke today announced the establishment of its global headquarters in miami florida the new facility will ideally position the company to support the anticipated u s launch and commercialization of the cguard prime carotid stent system in the first half of 2025 if approved,inspiremd announces establishment of global headquarters in miami florida to support anticipated u s launch and commercialization of the cguard prime carotid stent system,geographic_expansion,UP,1.532574784649095,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,1,7,256,0.1866161616161616,0.6085732039686736,0.11877777777777779
irvine calif april 29 2024 globe newswire biomerica inc nasdaq bmra is proud to announce a multi year exclusive distribution agreement with one of the uae s most substantial healthcare conglomerates this strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region,biomerica and leading uae healthcare company forge a path to enhanced colorectal and breast screening with exclusive multi year distribution agreement,partnerships,UP,8.955224013376348,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,0,8,425,0.65,1.5245042583012947,0.10113992068537524
new york june 17 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions reports that takeda pharmaceutical company limited takeda has announced topline data from its phase 3 skyline and skyway studies evaluating soticlestat for the treatment of dravet syndrome ds and lennox gastaut syndrome lgs,ovid therapeutics reports on takeda s announcement of phase 3 topline study results for soticlestat,clinical_study,DOWN,-7.103823312288768,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,0,6,376,0.21623376623376622,0.7642184815786688,0.16356988249845392
immunocore reports fourth quarter and full year 2023 financial results and provides a business update,immunocore reports fourth quarter and full year 2023 financial results and provides a business update,financial_results,DOWN,-2.7537188020561354,1601949440.0,37423034.0,614630.0,0.835,788600.0,0.023360933288880826,0.09346626282280733,2,7,486,0.11666666666666665,0.44240182162750774,0.18611111111111112
ad hoc mitteilung gemäss art 53 kr,santhera gibt die finanzergebnisse für das halbjahr 2024 bekannt und informiert über den aktuellen stand des unternehmens,financial_results,DOWN,-2.766398067949684,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,3,1,289,0.0,0.5209522992128177,0.07142857142857142
copenhagen denmark sept 26 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines today announced that it has entered into an option and license agreement with msd tradename of merck co inc rahway nj usa for two preclinical vaccine candidates the agreement expands the companies current collaboration and carries significant value for evaxion,evaxion significantly expands vaccine development collaboration with msd,licensing_agreements,UP,6.007069995652863,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,3,7,275,0.25,1.4249795072460607,0.11767577738165974
malvern pa june 20 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that the first patient has been dosed in its phase 3 limelight clinical trial for ocu400 a modifier gene therapy product candidate being developed for retinitis pigmentosa rp,ocugen inc announces first patient dosed in phase 3 limelight clinical trial for ocu400 first gene therapy in phase 3 with a broad retinitis pigmentosa indication,clinical_study,DOWN,-1.449273985189887,300791936.0,287364635.0,6243265.0,4.237,6951700.0,0.9553601696290156,0.09346626282280733,3,6,373,0.1825,0.7661975315521313,0.05111111111111111
redwood city calif jan 24 2024 globe newswire rezolute inc nasdaq rzlt a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced the addition of daron evans ms mba to its leadership team as chief financial officer as well as the grant of share options as a material inducement for his appointment the inducement grant,rezolute expands leadership team with appointment of daron evans ms mba as chief financial officer,management_changes,UP,2.941173720662243,376775840.0,77797779.0,825115.0,1.04,796000.0,0.20648292894788584,0.09346626282280733,2,8,521,-0.008333333333333331,0.6820409900648857,0.022361111111111113
interim data from additional mss crc patients dosed at 10 mg kg every three weeks q3w in combination with pembrolizumab anticipated in 2024 at a medical conference,adagene announces progress and expansion of clinical collaboration program for masked anti ctla 4 safebody adg126 muzastotug in combination with keytruda pembrolizumab to demonstrate further efficacy in patients with metastatic microsatellite stable mss colorectal cancer crc,clinical_study,DOWN,-1.428570066179548,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,6,505,0.0,0.845882180665701,0.16557050092764378
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions janbu holthe sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name ingrid janbu holtheposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80017 4 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 2 639 unit price 41 9316 eur aggregated transactions 1 volume 2 639 volume weighted average price 41 9316 eur____________________________________________,sampo plc managers transactions janbu holthe,corporate_action,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
media release,the goldman sachs group inc disclosure in norwegian air shuttle asa,company_regulatory_filings,DOWN,-0.3354173423953867,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,3,7,240,0.0,0.4683640137646959,0.03125
reykjavik iceland oct 10 2024 globe newswire alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today that the european medicines agency ema has accepted a marketing authorization application for avt03 a proposed biosimilar candidate to prolia and xgeva denosumab,european medicines agency confirms acceptance of marketing application for avt03 a proposed biosimilar to prolia and xgeva,regulatory_filings,UP,0.0,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,5,261,0.0,0.44264539487962035,0.06284271284271284
first u s commercial sales of xolremdi mavorixafor following april 2024 fda approval,x4 pharmaceuticals reports second quarter 2024 financial results and provides corporate updates,financial_results,UP,9.242146234319629,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,3,6,324,0.041666666666666664,1.4412990038402507,0.11676767676767676
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions wennerklint sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name ricard wennerklintposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80023 5 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 2 615 unit price 41 9316 eur aggregated transactions 1 volume 2 615 volume weighted average price 41 9316 eur____________________________________________,sampo plc managers transactions wennerklint,corporate_action,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
reported topline data from the investigator sponsored phase 1 trial of intravitreal vcn 01 in pediatric patients with refractory retinoblastoma trial results were determined to be positive by the study monitoring committee,theriva biologics reports first quarter 2024 operational highlights and financial results,clinical_study,UP,0.0,3592451.0,8173972.0,1624850.0,0.833,91200.0,2.2753189953043202,0.09346626282280733,1,7,417,0.1590909090909091,1.5225134880447404,0.06070707070707071
mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,clinical_study,DOWN,-5.735299106184534,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,0,8,404,0.0,34.079934680222834,0.06363636363636363
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
the following decisions were adopted at the extraordinary general meeting of shareholders of litgrid ab company code 302564383 registered address at karlo gustavo emilio manerheimo st 8 lt 05131 vilnius which was held on 13th september 2024 1 regarding the adoption of financial investment decision for the project construction of the harmony link interconnector 1 to approve the 22 august 2024 litgrid ab decision of the board in accordance with clause 5 3 of the 12 july 2024 harmony link cooperation agreement hereinafter hlca concluded between the polish electricity transmission system operator pse s a hereinafter pse s a and litgrid ab on the basis of the 10 july 2024 decision of the litgrid ab board to adopt a financial investment decision fid for the implementation of the technical solution for the overland link of the project construction of the harmony link interconnector in the territory of the republic of lithuania hereinafter the project as well a,decisions adopted at the extraordinary general meeting of shareholders of litgrid ab,capital_investment,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,287,0.08518518518518518,0.8866002429130597,0.0
dsmc has reviewed the safety and pharmacokinetic data from cohort 2 and recommended that the study proceed to enroll patients into cohort 3 dsmc has reviewed the safety and pharmacokinetic data from cohort 2 and recommended that the study proceed to enroll patients into cohort 3,theriva biologics announces positive outcome of data and safety monitoring committee dsmc review in phase 1b 2a clinical trial of syn 004 ribaxamase in allogeneic hematopoietic cell transplant recipients,clinical_study,UP,9.242146234319629,3592451.0,8173972.0,1624850.0,0.833,91200.0,2.2753189953043202,0.09346626282280733,3,8,268,0.22727272727272727,1.5225134880447404,0.052322671156004495
terveystalo plc stock exchange release 27 september 2024 at 12 45 eest the shareholders nomination board of terveystalo plc comprises the representatives of the four largest shareholders of the company as of 2 september 2024 and in addition the chairman of the board of directors if a shareholder refrains from exercising their right to appoint a proxy the right of appointment shall pass to the next largest shareholder in the list of shareholders the duties of the nomination board include for example the search preparation and presentation of member candidates for the board of directors and matters concerning the remuneration of the board of directors the nomination board shall elect a chairman from amongst its members following the above the members of terveystalo s nomination board are risto murto varma mutual pension insurance company tomas von rettig rettig group ab timo ritakallio pohjola insurance ltd and op life assurance company ltd kari kauniskangas chairman o,composition of terveystalo plc s shareholders nomination board,major_shareholder_announcements,DOWN,-0.4081628681073311,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,273,0.22857142857142856,0.8866002429130597,0.0
media release,recording of lhv group s 22 october investor webinar,clinical_study,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
rockville md july 31 2024 globe newswire theriva biologics inc nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the u s food and drug administration fda granted rare pediatric drug designation rpdd for vcn 01 for the treatment of retinoblastoma vcn 01 theriva s lead product candidate is a systemic selective stroma degrading oncolytic adenovirus previously the fda granted orphan drug designation to vcn 01 for treatment of retinoblastoma,theriva biologics receives rare pediatric drug designation by the u s fda for vcn 01 for the treatment of retinoblastoma,product_services_announcement,DOWN,-7.103823312288768,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,8,332,0.0988888888888889,1.5225134880447404,0.049659320477502294
farmington hills mich may 03 2024 globe newswire ocuphire pharma inc nasdaq ocup a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders today announced that george magrath m d m b a m s chief executive officer of ocuphire will present a company overview at the aegis virtual conference being held may 7 9 2024 company management will also be participating in one on one meetings throughout the conference,ocuphire pharma to present at the aegis virtual conference,conference_call_webinar,UP,4.864866606417649,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,421,0.0,0.8866002429130597,-0.015468460111317256
palo alto calif aug 29 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced fda approval of a supplemental new drug application for label updates to gloperba,scilex holding company announces fda final approval to precision dosing for gloperba label,product_services_announcement,DOWN,-1.8018000602490185,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,303,0.3090909090909091,1.0327724261931344,0.25310286646224145
los angeles and amsterdam april 30 2024 globe newswire renovarocube wholly owned subsidiary of renovaro inc nasdaq renb a company at the forefront of ai driven healthcare innovation proudly unveils flamingo a potentially groundbreaking multi cancer detection model contributing to its mission to transform early cancer diagnostics leveraging ultra low pass whole genome sequencing ulp wgs of cell free dna cfdna flamingo represents a promising leap forward in the fight against cancer,transforming cancer detection renovarocube introduces flamingo a novel ai model based on fragmentomics,product_services_announcement,UP,2.597407925529181,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,1,11,423,0.24285714285714285,1.5631250973582267,0.08746706192358367
the company s neurodegenerative clinical program remains on track with continued advancement of the alzheimer s phase 2 trial and anticipation of parkinson s phase 1 2a trial initiation,nkgen biotech secures additional financing of 5 million to continue advancing its clinical programs,clinical_study,UP,0.0,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,3,8,443,0.0,2.657355742098314,0.22272727272727275
stada and alvotech launch uzpruvo the first approved ustekinumab biosimilar to stelara across europe,stada and alvotech launch uzpruvo the first approved ustekinumab biosimilar to stelara across europe,product_services_announcement,UP,0.8375241623460453,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,0,6,341,0.25,0.44264539487962035,0.11574074074074074
eurobio scientific finalise l acquisition du test génomique endopredict auprès de myriad genetics,eurobio scientific finalise l acquisition du test génomique endopredict auprès de myriad genetics,mergers_acquisitions,DOWN,-0.2036628864129181,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,4,1,330,0.0,0.4336088389568585,0.007326007326007327
media release,marel 3f 2024 fjárfestakynning,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.0,0.8866002429130597,0.0
media release,shareholding disclosure nordnet ab publ,major_shareholder_announcements,UP,0.9063417451213552,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.0
new york july 01 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions and graviton bioscience corporation a privately held clinical stage biotechnology company focused on developing rho associated coiled coil containing protein kinase 2 rock2 inhibitors and other innovative therapeutic compounds today announced the results from their phase 1 healthy volunteer study evaluating the safety tolerability and pharmacokinetic pk profile of multiple ascending doses of ov888 gv101 capsule ovid and graviton plan to progress to a phase 2 clinical study in cerebral cavernous malformations ccm later this year,ovid therapeutics and graviton bioscience announce topline data from a phase 1 clinical trial studying ov888 gv101 capsule a potential first in class therapy for cerebral cavernous malformations,clinical_study,DOWN,-5.07151821092433,21844840.0,50354780.0,1012130.0,0.065,720700.0,2.305110955264493,0.09346626282280733,0,8,362,0.15613636363636363,0.7642184815786688,0.1723471964543393
data served as foundation for current vaccine candidate for planned phase 2 research,vaxart announces publication in vaccines of non human primate preclinical data demonstrating its next generation vaccine candidates elicit mucosal and systemic immunogenicity and reduce viral shedding after sars cov 2 challenge,clinical_study,UP,0.8333325054910776,120410456.0,226926647.0,9325470.0,1.148,2676900.0,1.8846091488931824,0.09346626282280733,0,8,509,0.0,1.025768835125998,-0.09166666666666667
san francisco june 29 2023 globe newswire vir biotechnology inc nasdaq vir today announced the appointment of sasha damouni ellis as executive vice president and chief corporate affairs officer effective july 10 2023 ms damouni ellis will be responsible for the company s strategic approach to corporate communications government affairs investor relations and patient advocacy as well as for establishing vir s corporate social responsibility and environmental social and governance efforts she will report to vir s chief executive officer marianne de backer m sc ph d mba and will join the company s executive management team,vir biotechnology appoints sasha damouni ellis as executive vice president and chief corporate affairs officer,management_changes,DOWN,-0.3617292937098507,707764736.0,93935488.0,1328370.0,1.229,971400.0,0.13272134541611297,0.09346626282280733,3,9,730,0.10833333333333334,0.8653389999075153,0.08615702479338842
vancouver british columbia sept 20 2023 globe newswire mydecine innovations group inc mydecine or the company neo myco otc mycof fse 0nfa a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and ptsd is pleased to announce that further to the company s news release dated september 15 2023 and september 19 2023 the company has closed its previously announced offering by way of prospectus supplement the offering pursuant to the offering the company issued 18 750 000 common shares of the company each a share at a price of 0 20 per share for aggregate gross proceeds of 3 750 000 a previous news release incorrectly stated that the company issued 18 7500 000 shares for aggregate gross proceeds of 3 7500 000,mydecine innovations announces amended press release relating to the closing of prospectus supplement financing,shares_issue,DOWN,-5.882356034843122,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,2,12,646,0.030952380952380946,5.6468521991492,0.0
orphazyme a s har afholdt ordinær generalforsamling den 18 april 2024 kl 15 00 på selskabets adresse hos visionhouse lyskær 8a 2730 herlev med følgende dagsorden,referat fra ordinær generalforsamling den 18 april 2024 kl 15 00,annual_general_meeting,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,435,0.0,0.8866002429130597,0.0
media release,volue asa extraordinary general meeting held,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,13,240,0.19166666666666665,0.8866002429130597,0.0
zug switzerland oct 15 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced that an update on the diamond phase 3 program with ocs 01 an optireach formulation of high concentration dexamethasone eye drop for diabetic macular edema dme will be presented by david eichenbaum m d at innovate retina in addition riad sherif m d oculis chief executive officer will be presenting at eyecelerator 2024 ahead of the american academy of ophthalmology annual meeting where oculis will be exhibiting booth 5452,oculis diamond phase 3 program in diabetic macular edema to be presented at innovate retina and eyecelerator 2024,clinical_study,DOWN,-2.619209767161926,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,1,4,256,0.05333333333333334,0.4640841922034435,0.03649170274170274
aims to leverage diversified data to accelerate and de risk drug discovery and clinical development aims to leverage diversified data to accelerate and de risk drug discovery and clinical development,centogene and the laboratory of human genetics of infectious diseases at institut imagine announce rare disease research collaboration,partnerships,DOWN,-2.5000074505803007,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,3,6,520,0.15,3.598197549072007,0.18605442176870746
media release,codelab capital as strategic update,capital_investment,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,14,239,0.0,0.8866002429130597,0.0
yavne israel oct 08 2024 globe newswire mediwound ltd nasdaq mdwd a global leader in next generation enzymatic therapeutics for tissue repair today announced that chief executive officer ofer gonen will take part in a fireside chat during the 2024 maxim healthcare virtual summit the fireside chat hosted by michael okunewitch senior biotechnology analyst at maxim will take place on wednesday october 16 2024 at 9 30 a m et,mediwound to participate in the 2024 maxim healthcare virtual summit,conference_call_webinar,UP,1.1649328036727749,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,8,263,0.0,0.6433034533898109,0.11631687242798353
toronto dec 20 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to announce the results of its annual general and special meeting of shareholders held tuesday december 19 2023 the meeting in toronto ontario all matters presented to the shareholders of the company the shareholders for approval as set out in the company s notice of meeting and information circular dated november 10 2023 respectively were approved by an overwhelming majority of votes cast at the meeting of the 357 646 841 shares issued and outstanding on the record date for the meeting 143 297 862 shares being of the shares were voted,revive therapeutics announces results of annual general and special meeting of shareholders,annual_general_meeting,UP,9.242146234319629,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,12,555,0.26142857142857145,1.8889707456546947,0.09999999999999999
live event and webcast today at 10 am et,valneva hosts investor day in new york city,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.13636363636363635,0.6494694268312979,0.028525641025641018
durham n c aug 12 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale will release its financial results for the second quarter ended june 30 2024 on tuesday august 13 2024 management will host a webcast and conference call at 8 30 a m et to discuss recent corporate updates from its acellular tissue engineered vessel atev programs,humacyte to present second quarter financial results and provide corporate update on august 13 2024,financial_results,DOWN,-7.103823312288768,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,0,8,320,0.0,1.1173068527438073,0.09839257964257965
šiaulių bankas ab plans an offering of fixed rate reset perpetual additional tier 1 temporary write down notes subject to market conditions this notice does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas on 14 october 2024 the management board of šiaulių bankas ab approved an offering of fixed rate reset perpetual additional tier 1 temporary write down which would follow subject to market conditions šiaulių bankas ab has mandated goldman sachs bank europe se as lead manager to arrange a series of virtual fixed income investor meetings commencing on 14 october relevant stabilisation regulations including fca icma will apply this communication is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful no action has been,šiaulių bankas ab plans a bond offering subject to market conditions,financing_agreements,DOWN,-0.6142500205394381,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,14,256,-0.01464646464646464,0.8866002429130597,0.10189814814814815
media release,loomis delårsrapport januari september 2024,financial_results,UP,0.7495296080540479,26788276224.0,68321667.0,152052.05263157896,0.624,194074.0,0.00255043163019163,0.1515999603296736,1,7,242,0.0,0.29653145860700736,0.0
palo alto calif sept 03 2024 globe newswire semnur pharmaceuticals inc semnur a wholly owned subsidiary of scilex holding company nasdaq sclx scilex an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain and denali capital acquisition corp a cayman islands exempted company and special purpose acquisition company nasdaq deca the spac today announced the signing of an agreement and plan of merger for a proposed business combination by and among semnur the spac and denali merger sub inc a delaware corporation and wholly owned subsidiary of the spac which provides for a pre transaction equity value of semnur at 2 5 billion prior to the closing of the transaction the spac will be redomesticated as a delaware corporation upon closing of the transaction the combined company the combined company will be renamed semnur pharmaceuticals inc and its common stock and warrants are expected to be listed on nasdaq under the ticker symbols smnr and smnrw respectively the boards of directors of each of the spac semnur and scilex have unanimously approved the proposed transaction the closing of the transaction which is expected to occur by the first quarter of 2025 is subject to the approval of the spac s shareholders any applicable regulatory approval and the satisfaction or waiver of certain other closing conditions,semnur pharmaceuticals inc a wholly owned subsidiary of scilex holding company and denali capital acquisition corp nasdaq deca announce signing of a merger agreement for a proposed business combination providing for a pre transaction equity value of semnur of 2 5 billion,mergers_acquisitions,UP,4.347832396711109,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,9,298,0.0941468253968254,1.0327724261931344,0.2547375219027005
cyprium received 4 5 million payment upon closing and remains eligible to receive royalties and up to 129 million in aggregate development and sales milestones,cyprium therapeutics a fortress biotech subsidiary company completes asset transfer of cutx 101 copper histidinate product candidate for treatment of menkes disease to sentynl therapeutics a wholly owned subsidiary of zydus lifesciences ltd,licensing_agreements,UP,0.7490629346450939,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,2,8,570,0.0,0.6928276660424207,0.04123376623376623
zug sviss aug 27 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis eða félagið alþjóðlegt líftæknifyrirtæki sem hefur það að markmiði að þróa augnlyf sem bæta sjón í alvarlegum augnsjúkdómum birti í dag uppgjör fyrir ársfjórðunginn sem lauk 30 júní og kynnti nýlega áfanga í rekstri félagsins,oculis birtir uppgjör fyrir annan ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins,clinical_study,UP,1.1814294104779912,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,1,4,305,0.0,0.4640841922034435,0.0321010101010101
media release,the goldman sachs group inc disclosure in norwegian air shuttle asa,company_regulatory_filings,DOWN,-0.3354173423953867,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,3,7,240,0.0,0.4683640137646959,0.03125
findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator,pacira announces publication of pivotal study of exparel as a sciatic nerve block in the popliteal fossa for patients after bunionectomy,clinical_study,UP,0.7526555735494656,1112470400.0,45834212.0,557500.0,0.511,435200.0,0.041200387893466646,0.09346626282280733,3,8,499,0.24722222222222223,0.7130794063724827,0.3645021645021645
the combined companies aim to disrupt cancer diagnosis and treatment through early disease and recurrence detection prediction of response to treatment and personalized therapy,cutting edge ai company gedicube and cyclomics sign binding loi to join forces and position themselves at the forefront of the global liquid biopsy marketplace,mergers_acquisitions,DOWN,-2.7397233430072485,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,3,9,499,-0.16666666666666666,1.5631250973582267,0.13009931245225362
two year extension for research and development of alpha beta t cell medicines for the treatment of cancer and autoimmune diseases two year extension for research and development of alpha beta t cell medicines for the treatment of cancer and autoimmune diseases,editas medicine and bristol myers squibb extend alpha beta t cell collaboration,partnerships,UP,0.0,182402032.0,83382193.0,2526680.0,2.096,3015800.0,0.4571341233742396,0.09346626282280733,2,8,423,0.0,1.3105556047468256,0.03708719851576995
enrollment in the two pivotal trials of lorundrostat for the treatment of uhtn or rhtn is on track with topline data expected for advance htn trial in q4 2024 and launch htn trial in 2h 2025,mineralys therapeutics reports fourth quarter and full year 2023 financial results and provides corporate update,clinical_study,DOWN,-0.2987301032667582,916690560.0,43490817.0,793180.0,-0.18,767600.0,0.04744329100541845,0.09346626282280733,3,7,464,0.125,0.8131647725786432,-0.0671590909090909
malvern pa oct 17 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines today announced that it will host a conference call and live webcast to discuss the company s third quarter 2024 financial results and provide a business update at 8 30 a m et on friday november 8 2024,ocugen to host conference call on friday november 8 at 8 30 a m et to discuss business updates and third quarter 2024 financial results,conference_call_webinar,DOWN,-0.8519718980924357,303712224.0,287364635.0,6243265.0,4.237,6951700.0,0.9461740828712907,0.09346626282280733,3,7,254,0.02727272727272727,0.7661975315521313,0.05668525252525252
media release,financial calendar,financial_calendar,UP,4.038006526213018,64402014208.0,13292123540.0,12481905.0,1.06,13712800.0,0.2063929785964498,0.1515999603296736,3,12,239,0.0,0.3600217276357509,0.028086419753086418
radnor pa oct 22 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other prevalent cardiovascular diseases driven by dysregulated aldosterone today announced full details for its upcoming virtual kol event being held on wednesday october 30 2024 at 10 00 am et to register for the event please click here,mineralys to host virtual kol event on the unmet medical need in uncontrolled and resistant hypertension and lorundrostat as a potential treatment on october 30 2024,clinical_study,DOWN,-0.1446095748350239,915387072.0,43490817.0,793180.0,-0.18,767600.0,0.04751084904987603,0.09346626282280733,1,8,249,0.056249999999999994,0.8131647725786432,0.11103760822510823
innofactor plc managers transactions on october 11 2024 at 16 45 finnish time innofactor oyj managers transactions ____________________________________________ person subject to the notification requirementname heikki nikkuposition member of the board deputy memberissuer innofactor oyjlei 7437008oskqfedzyd835notification type initial notificationreference number 81084 5 4 ____________________________________________ transaction date 2024 10 11venue nasdaq helsinki ltd xhel instrument type shareisin fi0009007637nature of transaction disposal transaction details 1 volume 52895 unit price 1 68 eur aggregated transactions 1 volume 52895 volume weighted average price 1 68 eur espoo october 11 2024 innofactor plc eija theis general counsel additional information eija theis general counselinnofactor plctel 358 44 343 4278eija theis innofactor com distribution nasdaq helsinkimain mediawww innofactor com innofactorinnofactor is the leading driver of the modern d,innofactor plc managers transactions heikki nikku,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,15,259,-0.002777777777777763,0.8866002429130597,0.0
pratteln switzerland september 24 2024 santhera pharmaceuticals six sann announces that swissmedic the swiss agency for therapeutic products has accepted for review the marketing authorization application maa for agamree vamorolone for the treatment of duchenne muscular dystrophy dmd,santhera announces acceptance by swissmedic of marketing authorization application for agamree vamorolone in duchenne muscular dystrophy,regulatory_filings,UP,0.0,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,277,0.0,0.5209522992128177,0.054531490015360985
waltham mass sept 21 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a panel presentation at the cantor global healthcare conference on thursday september 28 2023 at 10 20 a m et in new york city the company will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the cantor global healthcare conference,conference_call_webinar,DOWN,-1.1904750923180183,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,646,0.04545454545454545,0.8866002429130597,0.0
petach tikva israel july 31 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will report its second quarter 2024 financial results and operational highlights before the open of the u s financial markets on wednesday august 14 2024 the company will host a conference call and webcast at 8 30 am eastern time to discuss the results and provide an update on business operations,polypid to report second quarter 2024 financial results and operational highlights on august 14 2024,earnings_releases_and_operating_results,DOWN,-0.2849000139722797,37502512.0,4610773.0,1395250.0,1.25,337200.0,0.12294571094330961,0.09346626282280733,2,7,332,-0.04285714285714286,0.7168605096826995,-0.023378813646670778
carmel ind sept 30 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that both the rationale and design of the phase 2 avail trial of mbx 2109 the company s potential long acting parathyroid hormone pth peptide prodrug in adults with hypoparathyroidism hp were featured in a poster presentation at the american society for bone and mineral research asbmr 2024 annual meeting held in toronto on canada september 27 30 2024,mbx biosciences presents mbx 2109 phase 2 avail hypoparathyroidism trial rationale and design at the asbmr 2024 annual meeting,clinical_study,DOWN,-2.5052207196509784,382040896.0,13610404.0,237885.0,0.8755,391100.0,0.03562551586100353,0.09346626282280733,0,8,271,-0.0125,0.928688678995062,0.0
expanded collaborations to support rapid testing in advanced animal models in q4 2024 expanded collaborations to support rapid testing in advanced animal models in q4 2024,biora therapeutics shares progress on smaller biojet clinical device with largest payload of any ingestible injectable at the 14th annual podd meeting,product_services_announcement,UP,9.242146234319629,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,243,0.26666666666666666,1.027516639474094,0.07059141838553604
company to demonstrate mydcombi and avenova and share data for clobetasol propionate ophthalmic suspension 0 at the american society of cataract and refractive surgery ascrs annual meeting april 5 8 in boston,eyenovia to feature its suite of commercial products and the optejet dispenser at upcoming national eyecare meetings,trade_show,DOWN,-1.970953741106604,27891188.0,2433609.0,8930490.0,1.002,41800300.0,0.08725368743705,0.09346626282280733,2,7,451,0.0,2.4441832149286684,0.0
redwood city calif jan 23 2024 globe newswire rezolute inc nasdaq rzlt a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that the u k medicines and healthcare products regulatory agency mhra has awarded the innovative medicine designation the innovation passport to rz358 for the treatment of hypoglycemia due to congenital hyperinsulinism hi the innovation passport designation was granted based on the substantial unmet medical need in this condition and the potential for rz358 to benefit patients as evidenced by the phase 2 rize study in congenital hi which safely demonstrated significant improvements in hypoglycemia events,rezolute receives innovation passport designation from the u k innovative licensing and access pathway steering group for rz358 in the treatment of hypoglycemia due to congenital hyperinsulinism,clinical_study,UP,2.040814340536656,377643968.0,77797779.0,825115.0,1.04,796000.0,0.20600826596547148,0.09346626282280733,1,8,522,0.15916666666666668,0.6820409900648857,-0.004999999999999999
saint herblain france et schlieren zurich le 1 août 2024 valneva se nasdaq valn euronext paris vla société spécialisée dans les vaccins et limmatech biologics ag société de biotechnologie développant des vaccins pour la prévention des maladies potentiellement mortelles ont annoncé aujourd hui la conclusion d un partenariat stratégique via la signature d un accord de licence exclusif pour le développement la production et la commercialisation de shigella4v s4v un candidat vaccin bioconjugué tétravalent contre la shigellose,valneva et limmatech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde,licensing_agreements,DOWN,-1.4966004753969215,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,331,0.0,0.6494694268312979,0.06944444444444443
the company has completed its admission to the access segment of the aqse growth market and trading will commence at 8 00 a m gm oct 10 2023 myig,mydecine innovations group announces admission to trading on the aqse growth market in london uk and first day of dealings,exchange_announcement,UP,0.0,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,1,2,627,0.25,5.6468521991492,0.030952380952380946
keskisuomalainen oyj johtohenkilöiden liiketoimet pörssitiedote 27 9 2024 klo 13 00 keskisuomalainen oyj johdon liiketoimet____________________________________________ilmoitusvelvollinennimi vesa kangaskorpiasema toimitusjohtajaliikkeeseenlaskija keskisuomalainen oyjlei 743700j7nht5olsj3b78ilmoituksen luonne ensimmäinen ilmoitusviitenumero 79320 5 4____________________________________________liiketoimen päivämäärä 2024 09 23kauppapaikka nasdaq helsinki ltd xhel instrumenttityyppi osakeisin fi0009007546liiketoimen luonne hankinta x liiketoimi on tehty omaisuudenhoidon nojallaliiketoimien yksityiskohtaiset tiedot 1 volyymi 53 yksikköhinta 7 96 eurliiketoimien yhdistetyt tiedot 1 volyymi 53 keskihinta 7 96 eur lisätietoja vesa pekka kangaskorpi toimitusjohtaja keskisuomalainen oyj p 050 688 33 keskisuomalainen oyj vesa pekka kangaskorpi toimitusjohtaja www keskisuomalainen com,keskisuomalainen oyj n johtohenkilöiden liiketoimet kangaskorpi,major_shareholder_announcements,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,12,273,0.0,0.8866002429130597,0.0
established medium dose as safe and tolerable dose in current ocu410st clinical trial dsmb determination to proceed with high dose cohort dosing,ocugen announces data and safety monitoring board approves enrollment in high dose cohort 3 in gardian study for stargardt disease,clinical_study,UP,1.1673140921804177,300791936.0,287364635.0,6243265.0,4.237,6951700.0,0.9553601696290156,0.09346626282280733,4,7,372,0.20500000000000002,0.7661975315521313,0.08865079365079365
pratteln switzerland july 31 2024 santhera pharmaceuticals six sann announces the board of directors has appointed dr oliver p kronenberg as chief legal officer and corporate secretary of santhera pharmaceuticals ag effective august 1 2024,santhera appoints dr oliver p kronenberg as chief legal officer and company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.25,0.5209522992128177,0.03714285714285715
transcode therapeutics completes initial dosing of first co hort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,transcode therapeutics completes initial dosing of first cohort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,clinical_study,DOWN,-0.7393730208448788,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,261,0.125,2.0874185587937095,-0.011931818181818184
after successful seismic a and b studies in early cardiogenic shock seismic c will treat more severe scai stage c cardiogenic shock to complete the assessment of the intended phase 3 patient population,windtree therapeutics initiates seismic c study of istaroxime in scai stage c cardiogenic shock for planned completion of phase 2b and transition to phase 3,clinical_study,DOWN,-3.658533128225512,1377011.0,3660923.0,6680965.0,0.764,1224200.0,2.6586011295479848,0.09346626282280733,2,8,241,0.36250000000000004,2.339794177443606,0.057652423534458166
redwood city calif july 31 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a late stage biopharmaceutical company committed to developing novel transformative therapies for serious rare diseases today announced that nevan charles elam chief executive officer and founder of rezolute will participate in a fireside chat during the btig virtual biotechnology conference on monday august 5 2024 at 12 00 p m et,rezolute to participate in the btig virtual biotechnology conference,conference_call_webinar,DOWN,-0.222227308485243,379380256.0,77797779.0,825115.0,1.04,796000.0,0.20506543967327598,0.09346626282280733,2,8,332,-0.1111111111111111,0.6820409900648857,0.016611652236652237
media release,capgemini q3 2024 revenues,earnings_releases_and_operating_results,DOWN,-1.7892695828851255,24334401536.0,169611141.0,417051.0,0.951,403238.0,0.006970014888144237,0.19535099655549074,2,7,241,0.0,0.29691516676147794,0.0
yield10 bioscience files rsr with usda aphis for elite camelina designed to produce epa dha omega 3 oils,yield10 bioscience files request for regulatory status review with usda aphis for camelina designed to produce the epa and dha components of omega 3 oil,regulatory_filings,DOWN,-4.166670805877945,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,537,0.0,0.8866002429130597,0.10385714285714287
new york jan 08 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced positive findings have been seen in a total of six out of eight intermediate size patient population expanded access ea patients these patients have shown improvements in fatigue scores measured by the modified fatigue impact scale mfis pet scan findings showing a reduction in microglial activation was also seen in the six patients with mfis score improvement at the three month evaluation period pet scan findings for two additional ea patients 10 total are planned to be available in late january,tiziana life sciences announces updated clinical and pet scan findings for intranasal foralumab in two new multiple sclerosis patients,clinical_study,DOWN,-3.278695092153664,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,0,7,537,0.07500000000000001,1.1109140250580023,0.0
brisbane calif oct 16 2024 globe newswire annexon inc nasdaq annx a biopharmaceutical company focused on upstream c1q to advance therapies for neuroinflammatory diseases of the body brain and eye today announced that it has granted inducement to seven new non executive employees under the terms of the 2022 employment inducement award plan the equity awards were approved on october 10 2024 in accordance with nasdaq listing rule 5635 c 4,annexon reports inducement grants to new employees under nasdaq listing rule 5635 c 4,corporate_action,UP,0.6711435169794355,262216464.0,82380157.0,1425435.0,1.259,925100.0,0.31416851460555123,0.09346626282280733,2,8,255,0.13636363636363635,0.7558344054121836,0.13311729865939048
pratteln schweiz 31 juli 2024 santhera pharmaceuticals six sann gibt bekannt dass der verwaltungsrat dr oliver p kronenberg per 1 august 2024 zum chief legal officer und corporate secretary der santhera pharmaceuticals ag ernannt hat,santhera ernennt dr oliver p kronenberg zum chief legal officer und company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.13333333333333333,0.5209522992128177,0.03714285714285715
media release,seb issues additional tier 1 capital,financing_agreements,UP,0.1967233126280737,324812570624.0,1517564746.0,3596234.789473684,0.496,4637069.0,0.004672124428819348,0.1515999603296736,1,8,242,0.0,0.2367499341217176,0.0
new york oct 30 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced positive results demonstrating the anti inflammatory potential of our anti cd3 antibody foralumab in combination with semaglutide a glp 1 agonist marketed by novo nordisk nyse nvo under the brand names ozempic and wegovy the data show that the combination of nasal anti cd3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet induced obesity dio providing a potential novel approach to combat obesity related inflammation and liver inflammation and dysfunction,tiziana life sciences announces positive results from ozempic and nasal anti cd3 combination study,clinical_study,UP,9.242146234319629,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,2,8,241,0.08441558441558442,1.1109140250580023,0.05773204515392016
durham n c march 18 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale will release its financial results for the fourth quarter and year ended december 31 2023 on friday march 22 2024 management will host a webcast and conference call at 8 00 a m et to provide a corporate and financial update,humacyte to present 2023 fourth quarter and year end financial results and provide corporate update on march 22 2024,financial_results,UP,5.864199279666832,337600992.0,121934248.0,3834265.0,2.0,1449900.0,0.36117858326672214,0.09346626282280733,0,8,467,0.0,1.1173068527438073,0.1
media release,lhv pank completed the acquisition of part of tbb pank s credit portfolio,clinical_study,DOWN,-0.142446610710075,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,250,0.0,0.8866002429130597,0.04395265257618199
chief executive officer amro albanna to present at 9 00am eastern time on thursday october 12 2023 chief executive officer amro albanna to present at 9 00am eastern time on thursday october 12 2023,aditxt inc to present at 8th annual dawson james conference,conference_call_webinar,DOWN,-2.376912546027333,3413280.0,2120031.0,105450.0,1.329,58200.0,0.6211125369146393,0.09346626282280733,4,8,631,0.0,1.9040013355592613,0.0
copenhagen denmark aug 08 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines is proud to announce the presentation of one year clinical efficacy phase 2 data for its lead compound evx 01 at the european society for medical oncology esmo congress 2024 taking place in barcelona spain from september 13 17 2024 the evx 01 vaccine is a personalized therapy currently being assessed in patient with advanced melanoma skin cancer,evaxion to present one year clinical efficacy data from its phase 2 study on lead cancer vaccine candidate evx 01 at the esmo congress 2024 in september,clinical_study,DOWN,-1.9999980926513672,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,3,8,324,0.20000000000000004,1.4249795072460607,0.14227693602693603
data from animal model study demonstrate xpro converts microglia from a demyelinating cell to a remyelinating cell,inmune bio inc announces publication in cell reports demonstrating xpro promotes remyelination,clinical_study,UP,4.399995803833008,158748848.0,15213010.0,781395.0,1.567,974600.0,0.09583067966578251,0.09346626282280733,3,15,246,0.0,0.8435084668920305,0.12490678303178303
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
missing,medigene ag implements announced 2 1 share capital reduction and consolidation of the shares effective august 29 2024,changes_in_share_capital_and_votes,DOWN,-0.8968601235628331,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,0,5,306,0.19999999999999998,1.3169799228985475,0.03844832251082251
toronto dec 18 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to announce that it has signed a collaboration agreement with attwill medical solutions lp ams for the clinical and commercial development of the company s next generation lyophilized formulation of bucillamine,revive therapeutics collaborates with attwill medical solutions for the clinical and commercial development of a novel lyophilized formulation of bucillamine,partnerships,UP,0.0,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,0,7,558,0.1,1.8889707456546947,0.09999999999999999
adelaide australia and cambridge mass july 31 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced the favorable outcomes of an eop2 meeting with the fda supporting the advancement of its lead asset bnc210 for the treatment of ptsd into phase 3 based on the positive results of the recently completed phase 2b attune study,bionomics announces successful end of phase 2 meeting with the fda on the development of bnc210 in post traumatic stress disorder,clinical_study,UP,1.9184691354424803,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,332,0.12325108225108228,0.8866002429130597,0.05315689866833962
retail turnover including vat of apranga group amounted to eur 28 5 million in september 2024 and increased by 6 compared to september 2023 the retail turnover including vat of apranga group totalled eur 89 8 million in q3 2024 and increased by 7 year on year in q3 2024 the retail turnover of the group in lithuania increased by 6 in latvia increased by 15 and in estonia decreased by 0 year on year in january through september 2024 the retail turnover of apranga group including vat totalled eur 251 4 million and increased by 8 year on year in january through september 2024 the retail turnover of apranga group in lithuania amounted to eur 148 6 million and increased by 7 year on year in the same period the retail turnover of the group in latvia reached eur 64 9 million and increased by 16 whereas in estonia amounted to eur 37 8 million and increased by 3 year on year in 9 months of 2024 apranga group opened 5 new stores renovated 11 stores an,turnover of apranga group in september 2024,earnings_releases_and_operating_results,UP,0.532854926490006,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,13,269,-0.08787878787878789,0.8866002429130597,0.0
san diego oct 22 2024 globe newswire oncternal therapeutics inc nasdaq onct the company today announced updated data from its phase 1 2 study of onct 534 for the treatment of patients with relapsed or refractory metastatic castration resistant prostate cancer mcrpc,oncternal therapeutics announces updated safety and efficacy data for phase 1 2 study of onct 534 for the treatment of r r metastatic castration resistant prostate cancer,clinical_study,DOWN,-5.741621554409346,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,249,0.0,0.8866002429130597,0.020242905242905243
media release,fiskars corporation s directed share issue without consideration based on the restricted share plan,shares_issue,DOWN,-2.9754206792492868,1157121792.0,36127016.0,13413.65,0.866,11916.0,0.03122144639377771,0.1515999603296736,1,9,242,0.0,0.21141836657863777,0.0
all patients treated in the ruby trial are free of vaso occlusive events post renizgamglogene autogedtemcel reni cel infusion,editas medicine reports new safety and efficacy data from the ruby trial of reni cel in 18 patients with sickle cell disease presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1787878787878788,1.3105556047468256,0.06364859777903256
toronto april 18 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today that the u s food drug administration fda has accepted the company s meeting request for the revive lc poc lateral flow test kit the product for feedback on the classification development and regulatory submission strategy for a point of care in vitro diagnostic device that aids in the detection of post covid 19 conditions the meeting date assigned by the fda is june 7 2024,revive therapeutics announces fda acceptance of meeting request for long covid diagnostic product,regulatory_filings,UP,0.0,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,3,7,436,0.08333333333333333,1.8889707456546947,0.11149869130388612
oslo norway 28 august 2024 pci biotech ose pcib today announces its interim first half 2024 results please find enclosed the interim report and presentation highlights review,pci biotech first half 2024 interim results,earnings_releases_and_operating_results,UP,1.070154948684371,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,2,1,304,0.04166666666666668,0.8869841129646596,-0.014293981481481477
media release,eviden manages coordination of cyderco project for the european cybersecurity competence center eccc,press_releases,DOWN,-0.4285659181827463,24371947520.0,158122098.0,963560.0,0.703,746300.0,0.006487872906760633,0.1515999603296736,0,10,242,-0.05,0.17227974100099383,0.04545454545454545
media release,the world s first fiber to fiber biorecycled clothing unveiled by multi brand consortium carbios on patagonia puma pvh corp and salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.25,0.8866002429130597,0.0
media release,morrow bank asa submitted application for a swedish banking license,geographic_expansion,UP,1.2084580829157887,2635189504.0,92971885.0,436382.6,1.159,149714.0,0.03528091048437934,0.1515999603296736,3,7,240,0.0,0.3747834297716561,0.43333333333333335
company granted extension to regain compliance with nasdaq listing requirements company granted extension to regain compliance with nasdaq listing requirements,biora therapeutics announces positive nasdaq listing decision,exchange_announcement,DOWN,-0.8746347173728525,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,2,8,304,0.22727272727272727,1.027516639474094,0.07328315623770168
terveystalo oyj pörssitiedote 27 9 2024 klo 12 45 terveystalo oyj n osakkeenomistajien nimitystoimikunta koostuu yhtiön neljän suurimman osakkeenomistajan edustajista 2 9 2024 omistustilanteen mukaan sekä yhtiön hallituksen puheenjohtajasta osakkeenomistajan jättäessä käyttämättä oikeuttaan edustajan nimeämiseen siirtyy nimitysoikeus osakasluettelon mukaan seuraavaksi suurimmalle osakkeenomistajalle nimitystoimikunnan tehtäviin kuuluvat muun muassa hallituksen jäsenehdokkaiden etsintä jäsenten ehdollepanon valmistelu ja esittely sekä hallituksen palkitsemisasiat nimitystoimikunta valitsee keskuudestaan puheenjohtajan edellä esitetyn mukaisesti terveystalon nimitystoimikunnan jäsenet ovat nimitystoimikunta valitsi järjestäytymiskokouksessaan 27 9 2024 puheenjohtajakseen risto murron osakkeenomistajien nimitystoimikunta toimittaa yhtiökokousta koskevat ehdotuksensa terveystalon hallitukselle viimeistään 1 helmikuuta 2025 lisätietoja nimitystoimikunnan tehtävistä ja kokoonpanost,terveystalo oyj n osakkeenomistajien nimitystoimikunnan kokoonpano,nomination_committee,DOWN,-0.4081628681073311,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,273,0.0,0.8866002429130597,0.0
media release,ramsay sante communiqué de mise à disposition du deu 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
rockville md april 25 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that based on the strength of the science and its relevance virage the phase 2b randomized open label placebo controlled multicenter clinical trial of systemically administered vcn 01 in combination with standard of care soc chemotherapy gemcitabine nab paclitaxel as a first line therapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma pdac has been accepted for presentation as a trial in progress poster at the 2024 american society of clinical oncology asco annual meeting being held in chicago il from may 31 june 4,theriva biologics to discuss the trial design for virage a phase 2b clinical study of systemically administered vcn 01 in combination with chemotherapy in pancreatic ductal adenocarcinoma at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-2.702702702702702,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,3,8,429,0.06070707070707071,1.5225134880447404,0.0
phase 3 startup activities are underway with trial initiation expected in q1 2024 phase 3 startup activities are underway with trial initiation expected in q1 2024,ocuphire pharma receives fda agreement under special protocol assessment for lynx 2 phase 3 trial of phentolamine ophthalmic solution for the treatment of decreased visual acuity under dim mesopic light conditions,clinical_study,UP,0.6493500461665078,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,541,0.03673469387755103,0.8866002429130597,0.0
needham mass april 09 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced the presentation of a poster during the american association for cancer research aacr annual meeting taking place april 5 through 10 in san diego which focused on a first in class multimodal immunotherapy candidate for induction of tertiary lymphoid structures tls being developed as a novel therapeutic strategy for solid tumors from candel s enlighten discovery platform,candel therapeutics presents preclinical data at aacr on immunotherapy candidate for induction of tertiary lymphoid structures in solid tumors,clinical_study,DOWN,-2.79937532105862,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,1,8,445,0.06999999999999999,1.2870358800144117,0.09025985962566843
over 8 000 patients 12 years of age and older with severe scd or tdt may be eligible for treatment,european commission approves first crispr cas9 gene edited therapy casgevy exagamglogene autotemcel for the treatment of sickle cell disease scd and transfusion dependent beta thalassemia tdt,product_services_announcement,DOWN,-5.29827697855226,4064042496.0,85970729.0,2651100.0,1.742,2455300.0,0.02115399361217703,0.09346626282280733,1,2,501,0.13888888888888887,0.5620956775766307,-0.09523809523809523
hear from the 30 000 relapsed or refractory al amyloidosis patients in the united states today in their own words hear from the 30 000 relapsed or refractory al amyloidosis patients in the united states today in their own words,immix biopharma announces be proactive in al al amyloidosis awareness initiative,press_releases,DOWN,-7.103823312288768,61628348.0,18058632.0,290605.0,0.301,58200.0,0.29302476191638305,0.09346626282280733,1,9,479,0.6,0.9253604538231538,-0.059861111111111115
norwood mass oct 29 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a fireside chat and one on one investor meetings at the guggenheim securities healthcare innovation conference to be held november 11 13 2024 in boston ma,corbus pharmaceuticals to present at the guggenheim securities healthcare innovation conference,conference_call_webinar,DOWN,-0.9791912234882628,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,1,8,242,0.0,0.9919200800994142,0.0701116427432217
jupiter fla june 28 2024 globe newswire dyadic international inc dyadic nasdaq dyai announced today that they have entered into a development and commercialization partnership with proliant health and biologicals phb a leading supplier of purified proteins for the diagnostic nutrition and cell culture markets,dyadic international inc and proliant health and biologicals announce recombinant albumin development and commercialization partnership,partnerships,DOWN,-2.5316506313829312,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,8,365,0.0,0.7846450948942033,0.1434434910327768
media release,the goldman sachs group inc disclosure in norwegian air shuttle asa,company_regulatory_filings,DOWN,-0.3354173423953867,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,3,7,240,0.0,0.4683640137646959,0.03125
conference call to begin at 4 30 p m et,vaxart to host second quarter 2024 business update and financial results conference call on august 8,conference_call_webinar,DOWN,-1.515159040990203,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,330,0.0,1.025768835125998,0.08874458874458874
continuing the substantial growth trajectory that began during 2023 for the first quarter 2024 and the full year 2024 celularity expects triple digit percentage increases in combined net sales of its advanced biomaterial product and biobanking businesses compared to the first quarter 2023 and the full year 2023,celularity announces net sales expectations for first quarter 2024 and full year 2024 reiterates advanced biomaterial product commercial and development pipeline,earnings_releases_and_operating_results,UP,7.894735686336514,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,9,513,0.23636363636363636,1.6050367793919866,0.0820820251177394
media release,issues commercial paper,regulatory_filings,DOWN,-1.6474464372833295,23518791680.0,106596428.0,286256.4,1.529,128154.0,0.004532393902304423,0.1515999603296736,1,15,241,0.0,0.2696091308854634,0.0
cambridge mass and rostock germany and berlin march 19 2024 globe newswire centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced the extension of an ongoing partnership with takeda tse 4502 nyse tak to diagnose patients with lysosomal storage disorders lsds,centogene extends strategic partnership with takeda to continue providing access to genetic testing for patients with lysosomal storage disorders,partnerships,UP,1.4285700905079517,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,1,6,466,0.15,3.598197549072007,0.15357142857142855
san diego jan 31 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will present at guggenheim s 6th annual biotechnology conference,anaptys to present at guggenheim s 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.6268266469592575,687797504.0,17605381.0,784220.0,-0.266,445700.0,0.025596750348195505,0.09346626282280733,2,9,514,0.16666666666666666,0.871343469962729,0.23443865057501423
research published in the lancet s eclinicalmedicineescharex outperforms non surgical standard of care in debridement and promotion of healthy granulation tissue,mediwound announces publication of the escharex phase ii chronex study results for venous leg ulcers,clinical_study,UP,0.151518625260117,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,8,334,0.25,0.6433034533898109,0.13996352413019078
next confirms nexobrid s proven safety and efficacy in eschar removal significantly reducing surgical procedures for burn patients next confirms nexobrid s proven safety and efficacy in eschar removal significantly reducing surgical procedures for burn patients,mediwound announces positive results from the u s nexobrid expanded access protocol next,clinical_study,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,327,0.16287878787878787,0.6433034533898109,0.12587924701561065
media release,archer limited notice of record date special general meeting,shares_issue,UP,3.0491852271965074,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,240,0.11190476190476191,0.8866002429130597,0.2261904761904762
secured additional r d collaborations with solventum and mölnlycke for optimal trial consistency and patient outcomes,mediwound announces phase ii head to head study evaluating escharex vs collagenase in patients with venous leg ulcers,clinical_study,UP,0.0,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,3,7,261,0.0,0.6433034533898109,0.11216269841269841
as delfingroup dgr1r isin lv0000101806 will close the list of shareholders for dividend payment on 30 september 2024 at the end of the working day of the nasdaq csd latvian settlement system proceeding from the above the ex date is 27 september 2024 from that date the new owner of the shares is not entitled to dividends as delfingroup will pay dividend 0 0202 eur per share on 1 october 2024 as delfingroup confirms that the dividends are paid from profits earned in the second quarter of 2024 subscribe to delfingroup news and updates here about delfingroup as delfingroup is a licenced fintech company established in 2009 and operates under the brand names banknote and vizia the company has been profitable every year since 2010 delfingroup continuously develops and offers consumer and pawn loans loans developed for senior citizens buy now pay later loans bnpl loans and the sale of pre owned goods online and at more than 90 branches across latvia and lithuania,dividend payment ex date of as delfingroup,dividend_reports_and_estimates,UP,0.3883560992219452,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,13,276,0.11948051948051949,0.8866002429130597,0.19932128300549354
cantargia cantargia ab nasdaq stockholm canta today presented data from preclinical experiments showing the high potential of the il1rap targeting antibody can10 in treatment of dermatological diseases the results show overexpression of il1rap in a number cell types in hidradenitis suppurativa hs and psoriasis skin lesions the treatment effect of can10 in models of skin inflammation was potent and superior to il 1β blockade the results are presented at the eadv congress sep 25 28 in amsterdam we are intrigued by the opportunities of can10 in treatment of a number of skin diseases the broad mechanism of action of can10 seem well suited for this huge disease segment and preparations are ongoing for the first phase 2 study in hs planned to start 2025 said göran forsberg ceo of cantargia the can10 antibody targeting il1rap has a broad and potent mechanism of action by potently blocking the activity of il 1 il 33 and il 36 phase 1 clinical trial is ongoing ahead of the firs,cantargia presents new results at eadv 2024 highlighting the potential of can10 treatment in dermatology,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,276,0.24795454545454548,0.8866002429130597,0.0
west lafayette ind sept 16 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services has amended certain terms of its credit agreement in addition inotiv has closed the sale of 22 6 million aggregate principal amount of senior secured second lien pik notes due february 2027 the second lien notes and warrants to purchase common shares to certain investors in a private offering,inotiv inc amends its credit agreement and secures additional liquidity,financing_agreements,DOWN,-1.923075159625829,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,0,8,285,-0.010714285714285716,1.3015467599292592,0.03879818594104308
media release,aurg52 pro nøkkelinformasjon ved innfrielse av deler av obligasjonslån,bond_fixing,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
copenhagen denmark june 03 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines reported data from its ongoing phase 2 study at the american society of clinical oncology asco annual meeting 2024 the data demonstrated vaccine induced immune response in metastatic melanoma patients treated with the company s ai immunology designed personalized cancer vaccine evx 01 in combination with an anti pd1 inhibitor the evx 01 vaccine targets neoantigens antigenic sequences derived from cancer mutations that are displayed on the surface of the cancer cells allowing the immune system to recognize attack and eliminate the malignant cells,evaxion presents positive and validating immune data from ongoing phase 2 trial with ai designed evx 01 vaccine at the asco annual meeting 2024,clinical_study,UP,0.8174378955344656,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,8,390,0.11363636363636363,1.4249795072460607,0.14583333333333331
mainz germany september 17 2024 globe newswire biontech se nasdaq bntx biontech alongside its artificial intelligence ai company instadeep ltd instadeep will host an ai day an edition of biontech s innovation series at 09 00 a m edt 3 00 p m cest on tuesday october 1st 2024 in london united kingdom the event will provide an overview of biontech s and instadeep s ai strategy and capabilities and the application of ai in biontech s pipeline and internal processes,biontech to host ai day as an edition of its innovation series on october 1 2024,conference_call_webinar,UP,3.18295963903887,24727029760.0,97284490.0,1237590.0,1.285,391100.0,0.003934337886282384,0.09346626282280733,1,6,284,-0.3,0.5503225880253886,0.14911662411662407
newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501 newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501,bioxcel therapeutics announces european patent office s grant of patent for method of treating agitation in dementia using sublingual dexmedetomidine,patents,DOWN,-1.7421586867605077,12766154.0,5544250.0,450810.0,-0.13,78500.0,0.4342928966703676,0.09346626282280733,4,7,470,0.17454545454545456,1.4586588351104455,-0.030684523809523807
los angeles and amsterdam april 18 2024 globe newswire renovaro inc nasdaq renb a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence announces the distinguished professor geert kazemier md phd as the new chairman of its scientific advisory board this pivotal move signifies a major leap forward in renovaro s quest to redefine cancer diagnosis and treatment through cutting edge ai and immunotherapy technologies,renovaro inc proudly announces the appointment of professor dr geert kazemier as the chairman of its scientific advisory board a move that heralds a new era of innovation and progress in its mission to reshape cancer screening diagnosis and patient care,management_changes,UP,1.3513500451867635,60241652.0,90925076.0,7542515.0,0.529,816400.0,1.5093390201185053,0.09346626282280733,3,8,436,0.06217532467532467,1.5631250973582267,0.08558441558441558
16 oct 2024 07 00 cest nel asa october 16 2024 oslo norway nel asa nel ose nel reported revenues of nok 366 million in the third quarter of 2024 up from nok 303 million in the same quarter last year ebitda in the quarter was nok 90 million q3 2023 62 the alkaline segment contributed positively to group ebitda but this was more than offset by the negative contribution from the pem segment due to unusually low revenues in the quarter order intake was nok 161 million q3 2023 338 million at the end of the quarter the order backlog was nok 1 872 million down year over year the cash balance was nok 1 941 million at quarter end quarterly highlights revenue from continuing operations in the third quarter 2024 was nok 366 million up from the third quarter 2023 q3 2023 303 revenue was positively impacted by delivery of alkaline electrolyser equipment whereas revenue from sale of pem electrolyser equipment was low ebitda in th,nel asa third quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-0.4576654794112185,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,255,0.02493265993265993,0.8866002429130597,0.14211309523809523
european orphan drug designation odd qualifies nxc 201 for,immix biopharma awarded european union orphan drug designation for nxc 201 in multiple myeloma,clinical_study,UP,0.0,61887608.0,18058632.0,290605.0,0.301,58200.0,0.2917972205356523,0.09346626282280733,0,9,424,-0.041666666666666664,0.9253604538231538,0.04576967592592592
media release,immutep appoints leading research institute to conduct first in human phase i study of imp761,clinical_study,DOWN,-0.4424774559935741,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,3,8,436,0.125,0.7476881311953882,0.0
moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,clinical_study,DOWN,-7.103823312288768,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,2,10,625,0.11363636363636363,0.5366763308656862,-0.03166666666666666
petach tikva israel may 01 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that company management will present at the citizens jmp life sciences conference taking place in new york ny from may 13 14 2024,polypid to participate in citizens jmp life sciences conference,conference_call_webinar,UP,5.82565725739285,37502512.0,4610773.0,1395250.0,1.25,337200.0,0.12294571094330961,0.09346626282280733,2,7,423,-0.05454545454545454,0.7168605096826995,-0.06665079365079365
west lafayette ind july 25 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that it will issue its financial results for the fiscal 2024 third quarter ended june 30 2024 on thursday august 8 2024 after the close of the stock market the company will host a conference call that same day at 4 30 p m eastern time to discuss the results,inotiv inc to report fiscal 2024 third quarter financial results and host conference call on thursday august 8 2024,earnings_releases_and_operating_results,UP,0.9950239314132612,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,3,8,338,0.0,1.3015467599292592,0.04310909549004787
media release,invl technology interim unaudited information for 9 months of 2024,financial_results,UP,1.657463621407091,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,9,240,0.0,0.8866002429130597,0.17713594276094277
media release,bcs third quarter financial results,earnings_releases_and_operating_results,DOWN,-7.103823312288768,64402014208.0,13292123540.0,12481905.0,1.06,13712800.0,0.2063929785964498,0.1515999603296736,3,7,240,0.0,0.3600217284985099,0.08425925925925926
at all doses studied vax 31 demonstrated robust opsonophagocytic activity immune responses for all 31 serotypes at middle and high doses vax 31 met or exceeded regulatory immunogenicity criteria for all 31 serotypes,vaxcyte reports positive topline data from phase 1 2 study of vax 31 its 31 valent pneumococcal conjugate vaccine candidate in adults aged 50 and older,clinical_study,UP,9.242146234319629,4300993536.0,115925698.0,1672660.0,1.204,957300.0,0.026953236974127832,0.09346626282280733,1,7,298,0.09078787878787879,0.8014129308283596,0.16388888888888886
toronto nov 21 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders provides an update on the development of a next generation lyophilized formulation of bucillamine,revive therapeutics provides update of novel bucillamine formulation development,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,585,0.09999999999999999,1.8889707456546947,0.0
remedy entertainment oyj pörssitiedote 27 9 2024 klo 13 00 remedy entertainment oyj n osakkeenomistajat kutsutaan yhtiön ylimääräiseen yhtiökokoukseen joka pidetään 24 10 2024 klo 09 00 alkaen yhtiön toimitiloissa osoitteessa luomanportti 3 02200 espoo kokoukseen ilmoittautuneiden vastaanottaminen kokouspaikalla aloitetaan klo 8 30 yhtiön osakkeenomistajat voivat käyttää äänioikeuttaan myös äänestämällä ennakkoon ennakkoäänestysohjeet löytyvät tämän yhtiökokouskutsun osasta c a ylimääräisessä yhtiökokouksessa käsiteltävät asiat 1 kokouksen avaaminen 2 kokouksen järjestäytyminen 3 pöytäkirjantarkastajien ja ääntenlaskun valvojien valitseminen 4 kokouksen laillisuuden toteaminen 5 läsnä olevien toteaminen ja ääniluettelon vahvistaminen 6 vaihtovelkakirjalainan pääehtojen hyväksyminen ja hallituksen valtuuttaminen päättämään osakkeisiin oikeuttavien erityisten oikeuksien antamisesta hallitus ehdottaa ylimääräiselle yhtiökokoukselle että se hyväksyy tencent holdings lt,remedy entertainment oyj kutsu remedy entertainment oyj n ylimääräiseen yhtiökokoukseen,corporate_action,UP,1.8028915589732963,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.05119047619047619
carmel ind oct 28 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that its management team will participate in the following upcoming investor conferences,mbx biosciences to participate in upcoming november investor conferences,conference_call_webinar,UP,0.0,381706656.0,13610404.0,237885.0,0.8755,391100.0,0.03565671121019173,0.09346626282280733,0,8,243,0.0,0.928688678995062,-0.0125
miami sept 20 2024 globe newswire fortress biotech inc nasdaq fbio fortress or company an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long term value for shareholders through product revenue equity holdings and dividend and royalty revenue today announced that on september 19 2024 it entered into securities purchase agreements with healthcare focused institutional investors for the issuance and sale of 3 939 394 shares of its common stock or pre funded warrants in lieu thereof in a registered direct offering at a purchase price of 1 65 per share in a concurrent private placement the company also agreed to issue to the same investors warrants to purchase up to 3 939 394 shares of common stock the private placement warrants have an exercise price of 1 84 per share will be exercisable commencing six months from the date of issuance and will expire five and one half years following the date of issuance,fortress biotech announces pricing of 8 million registered direct offering and concurrent private placements,financing_agreements,DOWN,-7.103823312288768,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,4,8,281,-0.009722222222222222,0.6928276660424207,0.08249358666025332
the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk,cidara therapeutics announces first subjects dosed in phase 2b navigate trial evaluating cd388 for the prevention of seasonal influenza,clinical_study,DOWN,-0.7985816231790068,629035328.0,4118697.0,696580.0,0.795,3470400.0,0.006547640198675773,0.09346626282280733,0,8,278,0.25,1.357695941787151,-0.02205339105339105
vancouver british columbia oct 12 2023 globe newswire mydecine innovations group inc mydecine or the company neo myco aqse myig otc mycof fse 0nfa a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and ptsd announces that it has completed its admission to the access segment of the aqse growth market aqse and that trading commenced at 8 00 a m gmt on tuesday 10 october 2023 admission under the ticker myig,mydecine innovations group announces admission to trading on the aqse growth market in london uk,exchange_announcement,DOWN,-2.9411736347271384,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,3,2,625,0.1111111111111111,5.6468521991492,0.10396825396825397
attune trial met its primary endpoint showing bnc210 treatment led to a statistically significant reduction in total ptsd symptom severity at 12 weeks,bionomics announces positive topline results from the phase 2b attune clinical trial of bnc210 in patients with post traumatic stress disorder ptsd,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,639,0.25056818181818186,0.8866002429130597,0.012836309220147604
collaboration to accelerate research to determine role of gba gene collaboration to accelerate research to determine role of gba gene,centogene and the michael j fox foundation announce research project to validate genetic risk factors of parkinson s disease using multiomics,research_analysis_and_reports,UP,0.0,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,1,6,522,0.0,3.598197549072007,0.10079365079365078
san diego sept 12 2024 globe newswire oncternal therapeutics inc nasdaq onct the company today announced its decision to discontinue its clinical trials evaluating onct 534 its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer and onct 808 its ror1 targeting autologous car t program for the treatment of patients with aggressive b cell lymphoma and to explore strategic alternatives,oncternal therapeutics announces termination of its clinical studies and exploration of strategic alternatives,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,289,0.1,0.8866002429130597,0.014545969903112755
i fortsættelse af børsmeddelelse af 24 maj 2024 skal det for de nedenfor nævnte afdelinger andelsklasser oplyses at fusionen vil blive gennemført på basis af de anførte indre værdier og heraf beregnede ombytningsforhold det forventes at vp securities a s vil registrere ombytningen således at de nye andele vil være i medlemmernes depoter den 1 oktober 2024 da ombytningerne vil svare til et helt antal andele i den fortsættende afdeling vil de fleste investorer i den ophørende afdeling få udbetalt restværdien i forhold til værdien af det hele antal andele dette vil ske i form af et kontant udligningsbeløb udbetalingen sker til den bankkonto der er tilknyttet investorens depot med venlig hilsen danske investmanagement a s robert bruun mikkelstrupadm direktør,meddelelse vedrørende fusion af afdelinger under investeringsforeningen danske invest,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,273,0.0,0.8866002429130597,0.0
series h warrants exercisable following release of positive outcomes results related to one year follow up from the company s c guardians pivotal trial,inspiremd announces full exercise of series h warrant tranche for gross proceeds of 17 9 million,warrants_and_certificates,DOWN,-1.1999988555908203,67091308.0,16849440.0,286250.0,0.613,4867100.0,0.25114192139464625,0.09346626282280733,0,7,362,0.17954545454545454,0.6085732039686736,0.0917893217893218
redwood city calif may 30 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced that senior management will present at the 2024 jefferies global healthcare conference on thursday june 6 2024 at 8 30 a m eastern daylight time 5 30 a m pacific daylight time the presentation will be accessible via webcast through a link on the investor events and presentations section of the coherus website https investors coherus com events presentations this webcast will be available for replay until july 7 2024,coherus management to present at the 2024 jefferies global healthcare conference,conference_call_webinar,UP,1.6304331981279736,84886144.0,110892497.0,1236840.0,0.883,1425300.0,1.3063674679344606,0.09346626282280733,3,9,394,0.12916666666666668,1.0144535837204522,0.18472537878787879
media release,oslo børs trading suspension,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,241,0.0,0.8866002429130597,0.0
media release,argan complète son parc logistique normand de bolbec,geographic_expansion,UP,0.2894422316255524,1612706688.0,12060258.0,31954.954545454544,0.782,14598.0,0.0074782712130725655,0.1515999603296736,1,7,242,0.0,0.2170511352010478,0.0
fireside chat scheduled for tuesday june 11 2024 at 1 20 pm et fireside chat scheduled for tuesday june 11 2024 at 1 20 pm et,tg therapeutics to participate in the goldman sachs 45th annual global healthcare conference,conference_call_webinar,DOWN,-0.5692609120757544,5889810432.0,135060602.0,1756590.0,1.939,1677400.0,0.022931230734728,0.09346626282280733,4,7,386,0.0,0.6256004090066075,0.04704045954045953
upgraded tac stim enhances energy focus and readiness upgraded tac stim enhances energy focus and readiness,electrocore announces the commercial launch of tac stim,product_services_announcement,UP,0.6430938913094892,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,1,8,368,0.0,0.8324549917316175,0.11708243145743145
the gen 2 optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041 the gen 2 optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041,eyenovia announces commencement of manufacturing of its advanced second generation optejet device,product_services_announcement,UP,3.4816259178048523,28136226.0,2433609.0,8930490.0,1.002,41800300.0,0.0864937962895237,0.09346626282280733,1,7,270,0.2,2.4441832149286684,-0.013447818521347932
on 25th september 2024 šiaulių bankas ab repaid a eur 478 81 million loan taken out under the ecb s tltro iii programme the funds were borrowed for a period of three years starting on 29th september 2021 the final interest rate set on the loan was 1 the objective of the tltro iii programme was to increase and support bank lending to businesses and individuals during times of economic instability after this repayment šiaulių bankas has no outstanding loans under the tltro iii programme additional information tomas varenbergas head of investment management division tomas varenbergas sb lt,šiaulių bankas repays tltro iii loan,financing_agreements,UP,0.1398666806605595,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,275,-0.009999999999999998,0.8866002429130597,0.0
capricor to receive 15 million equity investment at a premium as well as 20 million upfront payment upon signing definitive agreement with up to 715 million in potential milestones and a double digit percentage of product revenue,capricor therapeutics signs binding term sheet with nippon shinyaku for european expansion and commercialization of deramiocel for the treatment of duchenne muscular dystrophy,financing_agreements,UP,9.242146234319629,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,284,0.0,1.3427880947904531,0.13985851158645277
yavne israel sept 03 2024 globe newswire mediwound ltd nasdaq mdwd the global leader in next generation enzymatic therapeutics for tissue repair today announced that ofer gonen chief executive officer will participate in a fireside chat hosted by swayampakula ramakanth managing director senior equity research on tuesday september 10 2024 at 3 30 p m et at the h c wainwright 26th annual global investment conference,mediwound to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.6313172757874788,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,8,298,0.0,0.6433034533898109,0.12562222222222222
media release,totalenergies annonce le troisième acompte sur dividende de 0 79 action au titre de l exercice 2024 en hausse de près de par rapport à 2023,dividend_reports_and_estimates,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.1,0.21718002104766534,0.0
new york june 11 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced it has received acceptance of its submission for intranasal foralumab to receive fast track designation approval for the treatment of non active secondary progressive multiple sclerosis na spms to the u s food and drug administration fda,fda accepts tiziana life sciences fast track designation submission for treatment of multiple sclerosis,clinical_study,DOWN,-6.000000238418579,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,8,382,0.014718614718614726,1.1109140250580023,0.03405670461226017
media release,rentefastsettelse,bond_fixing,DOWN,-2.0100483246901604,919176704.0,111689277.0,363495.0,0.405,331336.5,0.12151012587020482,0.1515999603296736,3,14,239,0.0,0.8866002429130597,0.0
media release,totalenergies se résultats du troisième trimestre 2024,earnings_releases_and_operating_results,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.21718002104766534,0.0
needham mass feb 13 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the u s food and drug administration fda granted fast track designation for can 3110 a first in class replication competent herpes simplex virus 1 hsv 1 oncolytic viral immunotherapy candidate for the treatment of patients with recurrent high grade glioma hgg to improve overall survival,can 3110 receives fda fast track designation for treatment of recurrent high grade glioma,clinical_study,UP,7.194246393597346,244250656.0,41997569.0,917740.0,-0.866,856900.0,0.17194454945496646,0.09346626282280733,1,7,501,0.21,1.2870358800144117,0.08179144385026738
all ruby patients with 5 months follow up have achieved a normal hemoglobin level and a fetal hemoglobin level of,editas medicine announces new edit 301 safety and efficacy data in 17 patients presented today at the american society of hematology ash annual meeting and in a company sponsored webinar,clinical_study,DOWN,-5.167463844107009,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,0,12,564,0.09545454545454546,1.3105556047468256,0.0
former global controller of merck co inc enhances financial operational and strategic transformational expertise former global controller of merck co inc enhances financial operational and strategic transformational expertise,coherus biosciences appoints rita karachun cpa cgma to its board of directors,management_changes,UP,1.1235944521335182,84874552.0,110892497.0,1236840.0,0.883,1425300.0,1.3065458890433967,0.09346626282280733,2,9,388,0.0,1.0144535837204522,0.1804516317016317
media release,arctic bioscience 3 kvartal 2024 operasjonell oppdatering,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.1313131313131313
sydney australia aug 07 2024 globe newswire immutep limited asx imm nasdaq immp immutep or the company a clinical stage biotechnology company developing novel lag 3 immunotherapies for cancer and autoimmune disease today announces its management will present at the following investor conferences,immutep to participate in upcoming investor conferences,conference_call_webinar,UP,1.092895106966884,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,325,-0.023809523809523808,0.7476881311953882,0.12817563388991962
geneva switzerland may 31 2024 addex therapeutics six and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that it will issue its q1 2024 financial results on june 6 2024 tim dyer ceo and mikhail kalinichev head of translational science will provide a business update and a review of the addex product pipeline during a teleconference and webcast for investors analysts and media at 16 00 cest 15 00 bst 10 00 edt 07 00 pdt the same day,addex therapeutics to release q1 2024 financial results and host conference call on june 6 2024,conference_call_webinar,DOWN,-2.893518403540428,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,393,-0.0625,0.972373032385036,-0.0008333333333333318
media release,muutos hkfoods oyj n johtoryhmässä,management_changes,UP,0.2409679392354332,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,239,0.0,0.8866002429130597,0.022679924242424244
new york may 14 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions today reported business updates and financial results for the first quarter ended march 31 2024,ovid therapeutics reports business updates and first quarter 2024 financial results,financial_results,DOWN,-0.6622510282393388,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,410,0.20519480519480518,0.7642184815786688,0.15894489108774823
26 sep 2024 14 18 cest jml finance luxembourg sarl key word s bond julius meinl living 2019 2024 bonds redeemed 26 sep 2024 14 18 cet cest julius meinl living 2019 2024 bonds redeemed julius meinl living plc through its group companies acquires prime real estate assets in major european political and economic capital cities for development into top rated hotel properties that comprise mainly apartments and that the group then operates itself julius meinl living julius meinl living is fully owned by the julius meinl family who over the last 162 years have demonstrated their expertise and excellence in consumer goods retail and real estate julius meinl living is pleased to confirm that today it paid in full the principal and final coupon in relation to all outstanding jml finance luxembourg s à r l 2019 2024 bonds isin xs2042981576 accordingly these bonds have now been redeemed dissemination of a financial wire news transmitted by,julius meinl living 2019 2024 bonds redeemed,bond_fixing,DOWN,-0.244504364517161,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,274,0.1786111111111111,0.8866002429130597,0.0
news release regulated informationnovember 27 2023 1 00 am et 7 00 am cet,mdxhealth announces completion of mandatory ads exchange and commencement of transition period to single listing on nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,-0.07142857142857142,0.6181119561491973,0.0
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
carmel ind sept 30 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that both the rationale and design of the phase 2 avail trial of mbx 2109 the company s potential long acting parathyroid hormone pth peptide prodrug in adults with hypoparathyroidism hp were featured in a poster presentation at the american society for bone and mineral research asbmr 2024 annual meeting held in toronto on canada september 27 30 2024,mbx biosciences presents mbx 2109 phase 2 avail hypoparathyroidism trial rationale and design at the asbmr 2024 annual meeting,clinical_study,DOWN,-2.5052207196509784,382040896.0,13610404.0,237885.0,0.8755,391100.0,0.03562551586100353,0.09346626282280733,0,8,271,-0.0125,0.928688678995062,0.0
new york june 24 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a late stage biopharmaceutical company committed to developing novel transformative therapies for serious rare diseases today announced the closing of its underwritten public offering of 11 250 000 shares of its common stock at a price to the public of 4 00 per share and to certain investors in lieu of common stock pre funded warrants to purchase 3 750 000 shares of its common stock at a price to the public of 3 999 per pre funded warrant in each case before underwriting discounts and commissions all of the shares and warrants in the public offering were sold by the company,rezolute announces closing of public offering with approximately 60m in gross proceeds,shares_issue,UP,1.5189919107293248,377643968.0,77797779.0,825115.0,1.04,796000.0,0.20600826596547148,0.09346626282280733,0,8,369,-0.08551226551226551,0.6820409900648857,0.04448520923520923
alvotech nasdaq alvo and teva pharmaceuticals a u s affiliate of teva pharmaceutical industries ltd nyse and tase teva today announced that the u s food and drug administration fda has approved selarsdi ustekinumab aekn in a new presentation 130 mg 26 ml 5 mg ml solution in a single dose vial for intravenous infusion this approval paves the way for selarsdi to further align its label with the indications of the reference product stelara ustekinumab in the u s at launch which is expected in the first quarter of 2025,alvotech and teva announce u s fda approval of additional presentation of selarsdi ustekinumab aekn expanding its label to include further indications approved for reference product stelara ustekinumab,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.03582251082251082,0.44264539487962035,0.05175282234105764
qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024 qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024,qiagen erhält fda zulassung für qiastat dx mini panel für eine präzisere ambulante behandlung von atemwegserkrankungen,product_services_announcement,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.22727272727272727,0.2568422597431085,0.08276515151515151
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
lawrenceville n j july 31 2024 globe newswire imunon inc nasdaq imnn a clinical stage company in late stage development with its dna mediated immunotherapy today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at the market under nasdaq rules in a concurrent private placement and also pursuant to the securities purchase agreements the company has agreed to issue to the investors unregistered warrants to purchase shares of common stock upon the closing of the offering which is anticipated to occur on or about august 1 2024 the company expects to receive gross proceeds of 10 million before deducting placement agent fees and other offering expenses payable by the company the closing of the offering is subject to customary closing conditions,imunon announces 10 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,2,8,332,-0.11018518518518518,2.964855117372811,0.07441534914361002
longeveron launches contract development and manufacturing business for stem cell therapies 15 000 sf state of the art gmp facility with 8 cleanrooms,longeveron announces contract development and manufacturing business and first contract,business_contracts,UP,3.636360089641049,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,9,390,0.25,1.063123411629147,0.0
cambridge mass oct 07 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the initiation of haelo a global pivotal phase 3 study of ntla 2002 for the treatment of hereditary angioedema hae ntla 2002 is a wholly owned investigational in vivo crispr based gene editing therapy in development as a single dose treatment for this potentially life threatening disease patient screening is active following intellia s successful end of phase 2 meeting and submission of an investigational new drug application amendment to the u s food and drug administration fda,intellia therapeutics announces initiation of haelo phase 3 study of ntla 2002 an investigational in vivo crispr gene editing treatment for hereditary angioedema hae,clinical_study,DOWN,-0.1667631296675838,975751872.0,98412511.0,6353695.0,2.134,5288300.0,0.10085813189195705,0.09346626282280733,0,7,264,0.14770021645021647,0.7800307612939593,0.041256448412698404
media release,international petroleum corporation to release third quarter 2024 financial and operational results on november 5 2024,earnings_releases_and_operating_results,DOWN,-0.4132231404958678,17525362688.0,64661008.0,268294.15789473685,1.53,842590.0,0.0036895674658005686,0.1515999603296736,3,9,240,0.0,0.413754093849161,0.0
zug switzerland and boston feb 15 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today announced that members of its senior management team will present at the citi 2024 virtual oncology leadership summit on wednesday february 21 2024 at 1 00 p m et,crispr therapeutics to present at the citi 2024 virtual oncology leadership summit,conference_call_webinar,UP,0.8982781835129983,4073775360.0,85970729.0,2651100.0,1.742,2455300.0,0.02110345352965167,0.09346626282280733,3,8,499,-0.1111111111111111,0.5620956775766307,0.018163780663780656
media release,disclosure of large shareholding announcement by archer limited,major_shareholder_announcements,UP,0.971273522294907,5633885696.0,76674972.0,232163.65,0.8755,107863.0,0.013609607318522354,0.1515999603296736,3,8,240,0.07142857142857142,0.38970552185929963,0.0
02 oct 2024 09 44 cest eqs newswire 02 10 2024 09 44 cet cest paris france media outreach newswire 2 october 2024 on september 24 2024 the third stop of the cultural exchange event featuring panda wandering panda s world photography exhibition of giant pandas was grandly inaugurated at the paris grand palais art gallery in france the opening ceremony was attended by numerous distinguished guests creating a lively and celebratory atmosphere dignitaries from both china and france including representatives from political business and art sectors were present france s first lady brigitte macron sent a message of congratulations wishing the panda photography exhibition great success prominent figures such as pubu dunzhu vice governor of the sichuan provincial government lu shaye chinese ambassador to france emmanuel mandon french national assembly deputy and member of the france china friendship group and french girl ninon vernay jointly u,panda s world photography exhibition of giant pandas grandly opens in paris france,government_news,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,269,0.188755980861244,0.8866002429130597,0.22620370370370368
10 oct 2024 08 30 cest cegedim boulogne billancourt france le 10 octobre 2024 le management de la qualité du circuit des dmi et leur traçabilité sont au cœur des enjeux réglementaires d un établissement de santé cegedim business services acteur majeur de la transformation digitale et phast expert en interopérabilité sémantique annoncent un partenariat pour répondre à ces nouvelles exigences sedistock va désormais s appuyer sur le catalogue d interopérabilité ciodm pour renforcer la traçabilité des dispositifs médicaux à l hôpital un partenariat pour renforcer l interopérabilité des applications sur le circuit informatisé des dmi fluidifier les échanges d informations sur le circuit des dmi est un enjeu primordial au regard des exigences croissantes en matière de traçabilité c est précisément l objectif de ce partenariat sedistock de cegedim business services la solution de gestion des dispositifs médicaux actuellement déployée dans divers services hospitali,cegedim business services et phast annoncent un partenariat stratégique pour renforcer la traçabilité des dispositifs médicaux implantables dmi dans les hôpitaux,partnerships,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,261,0.0,0.8866002429130597,0.0
san diego and suzhou china aug 29 2024 globe newswire adagene inc adagene nasdaq adag a platform driven clinical stage biotechnology company transforming the discovery and development of novel antibody based therapies today announced the company s participation in several upcoming investor conferences in new york city management will host investor meetings and adagene s chairman chief executive officer and president of r d peter luo ph d will present at the following events,adagene to participate in investor conferences in september,conference_call_webinar,UP,0.2097916846765789,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,7,303,0.03409090909090909,0.845882180665701,0.11826464351974557
media release,arctic bioscience q3 2024 operational update,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.1313131313131313
media release,immutep announces first in human phase i study of imp761 progresses to dose escalation portion of trial,clinical_study,UP,0.9803912402207476,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,3,8,254,0.125,0.7476881311953882,0.08773783755926613
media release,gensight biologics announces publication of meta analyses showing better outcomes for nd4 lhon patients treated with lumevoq,clinical_study,UP,4.950490277705512,26181592.0,88078594.0,341553.13636363635,1.962,36807.0,3.364142027726962,0.09346626282280733,0,7,243,0.5,0.808158900198927,0.0
durham n c may 30 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale today announced that laura niklason m d ph d founder president and chief executive officer will present at the jefferies global healthcare conference in new york ny on thursday june 6 2024 management will also be available for one on one meetings,humacyte to present at the jefferies global healthcare conference,conference_call_webinar,UP,0.0,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,3,8,394,0.0595959595959596,1.1173068527438073,0.0564935064935065
new york aug 23 2024 globe newswire eyenovia inc eyenovia or the company nasdaq eyen a commercial stage ophthalmic company announced today the closing of its public offering of 12 850 000 shares of common stock at a price per share of 0 40 the offering,eyenovia announces closing of public offering,shares_issue,UP,2.645510766102637,28164478.0,2433609.0,8930490.0,1.002,41800300.0,0.08640703371104552,0.09346626282280733,4,11,308,-0.03272727272727273,2.4441832149286684,-0.0011135707726616776
malvern pa aug 28 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dosing is complete in the third cohort of its phase 1 2 gardian clinical trial for ocu410st aav hrora a modifier gene therapy candidate being developed for stargardt disease stargardt disease affects approximately 100 000 people in the united states u s and europe,ocugen announces completion of dosing in subjects with stargardt disease in high dose cohort of phase 1 2 gardian clinical trial of ocu410st a modifier gene therapy,clinical_study,DOWN,-0.7518789579387514,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,6,304,-0.008000000000000007,0.7661975315521313,0.07476911976911978
this announcement and the information contained herein is restricted and is not for release publication or distribution in whole or in part directly or indirectly in into or from the united states australia canada japan the republic of south africa singapore hong kong or any other jurisdiction in which such release publication or distribution would be unlawful,inside information announcement of the results of placing the issue price and registration of placing shares with the trade register,shares_issue,UP,1.6442471236705312,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,4,2,610,0.04375000000000001,0.7633342480324978,0.08665383998717333
news release regulated informationdecember 18 2023 1 00 am et 07 00 am cet,mdxhealth announces completion of transition to single listing on nasdaq,exchange_announcement,DOWN,-1.5337408730844513,110873952.0,35018869.0,71620.0,-490677.56,106500.0,0.3158439684733164,0.09346626282280733,0,1,558,-0.07142857142857142,0.6181119561491973,0.1517857142857143
dna vaccine proof of concept study expected to demonstrate an mrna better platform,first participants vaccinated in imunon s imnn 101 phase 1 clinical trial,clinical_study,UP,4.511273747632508,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,2,8,388,0.21666666666666667,2.964855117372811,0.05497159090909091
san diego july 15 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its phase 1 2 study of onct 534 for the treatment of patients with metastatic castration resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors arpi patients in the sixth cohort are receiving onct 534 the company s dual action androgen receptor inhibitor daari at a dose of 1200 mg taken orally once each day the decision to proceed to this higher dose level was made by the study s safety review committee src after reviewing data from the fifth dose level of 600 mg onct 534 daily an initial update on onct 534 safety and efficacy based on prostate specific antigen psa levels from this study is expected in the third quarter of 2024 and will include data from this 1200 mg dose cohort,oncternal announces enrollment completed and dosing initiated for sixth dose cohort of phase 1 2 study of onct 534 for the treatment of r r metastatic castration resistant prostate cancer,clinical_study,UP,1.171877013014985,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,348,0.03571428571428571,0.8866002429130597,0.012917637917637913
new york feb 06 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders today announced that management will participate in a virtual presentation at the oppenheimer 34th annual healthcare life sciences conference on tuesday february 13 2024 at 12 40 p m et,ovid therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,DOWN,-0.8310241623697936,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,508,0.21212121212121213,0.7642184815786688,0.0639558853844568
mainz biomed to showcase at the gynecology conference in stuttgart germany strengthening connections within the medical community,mainz biomed to showcase at the gynecology conference in stuttgart germany strengthening connections within the medical community,trade_show,UP,0.5235597192677354,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,1,8,487,0.0,34.079934680222834,0.0
miami march 12 2024 globe newswire fortress biotech inc nasdaq fbio fortress an innovative biopharmaceutical company focused on efficiently acquiring developing and commercializing or monetizing promising therapeutic products and product candidates today announced that lindsay a rosenwald m d chairman president and chief executive officer will participate in a fireside chat at the 36th annual roth conference on monday march 18 2024 at 2 00 p m pt in dana point california the company will also attend one on one meetings during the conference,fortress biotech to participate in 36th annual roth conference,conference_call_webinar,DOWN,-0.4999995231628418,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,1,8,473,0.35,0.6928276660424207,0.041450216450216446
oxurion receives transparency notification from atlas special opportunities llc,oxurion receives transparency notification from atlas special opportunities llc,major_shareholder_announcements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,13,428,0.35714285714285715,2.0692591020840054,0.11904761904761905
led by long standing investor ecor1 capital with participation from additional existing and new investors including sanofi led by long standing investor ecor1 capital with participation from additional existing and new investors including sanofi,anaptys announces pricing of 100 million underwritten registered direct offering,shares_issue,UP,9.242146234319629,687209856.0,17605381.0,784220.0,-0.266,445700.0,0.02561863868262099,0.09346626282280733,2,5,318,0.05454545454545454,0.871343469962729,0.20749710306528488
media release,polight asa continues to build positive momentum in several segments,business_contracts,DOWN,-7.103823312288768,725118720.0,112518348.0,613349.45,1.511,331673.0,0.15517231164573989,0.19535099655549074,3,7,240,0.11363636363636363,0.8385781649627817,0.0
south san francisco calif jan 16 2024 globe newswire vaxart inc nasdaq vxrt today announced that it has entered into a common stock purchase agreement with ra capital management for the sale of 15 384 615 shares of its common stock in a registered direct offering at an offering price of 0 65 per share,vaxart announces 10 0 million registered direct offering with ra capital management,shares_issue,UP,7.142860944173759,120729968.0,226926647.0,9325470.0,1.148,2676900.0,1.8796215286000904,0.09346626282280733,1,9,529,-0.1,1.025768835125998,0.0
potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over activation tumor hyperinsulinism potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over activation tumor hyperinsulinism,rezolute reports validation of the potential use of rz358 for treatment of non islet cell tumor hypoglycemia nicth,clinical_study,UP,3.93258727961852,379241376.0,77797779.0,825115.0,1.04,796000.0,0.20514053561497467,0.09346626282280733,2,7,479,0.14285714285714285,0.6820409900648857,0.01797619047619048
sampo plc stock exchange release 4 october 2024 at 8 30 am eest sampo plc s share buybacks 3 october 2024 on 3 october 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 947 141 sampo a shares representing 1 44 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 september 20,sampo plc s share buybacks 3 october 2024,changes_in_companys_own_shares,DOWN,-0.0241714257426052,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,267,0.1625,0.8866002429130597,0.001990740740740736
planegg martinsried may 28 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today announced the submission of three patents to the european patent office this underscores medigene s commitment to advancing t cell based immunotherapies for the treatment of solid tumors,medigene ag expands its end to end platform by submitting three development optimization technology patents to the european patent office,patents,DOWN,-3.278695092153664,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,3,396,0.0,1.3169799228985475,0.04242424242424242
malvern pa may 20 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that arun upadhyay phd chief scientific officer head of research development ocugen will speak at the international society for cell gene therapy isct annual meeting being held may 29 june 1 2024 in vancouver canada,ocugen announces cso to present on modifier gene therapy at international society for cell gene therapy 2024,conference_call_webinar,UP,1.0471194385354707,302631712.0,287364635.0,6243265.0,4.237,6951700.0,0.9495522894837934,0.09346626282280733,0,7,404,0.0,0.7661975315521313,0.0
för att ytterligare stärka holmens position och konkurrenskraft kommer anders jernhall vice vd och cfo fokusera på strategiska frågor i en renodlad roll som vice vd stefan loréhn kommer tillträda som ny cfo under våren 2025 genom att renodla rollerna på det här sättet stärker vi förmågan att utveckla koncernen säger henrik sjölund vd och koncernchef i holmen med sin analytiska förmåga och strategiska blick är anders central för holmens utveckling stefan loréhn är en nygammal holmenkollega som med sin erfarenhet och profil kommer axla rollen som cfo på ett utmärkt sätt fortsätter henrik sjölund stefan loréhn är idag cfo på lkab och har dessförinnan ett långt förflutet på holmen vår affärsidé att äga och förädla skog ligger helt rätt i tiden men det är en utmaning att navigera rätt i omställningen till en fossilfri värld att kunna lägga mer tid på holmens långsiktiga utveckling känns därför mycket angeläget säger anders jernhall stefan loréhn och jag har arbetat n,holmen stärker koncernledningen,management_changes,UP,0.776254314265839,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,274,0.0,0.8866002429130597,0.0
theriva biologics y la universidad autónoma de barcelona recibirán un total de 2 28 millones de euros en apoyo del proyecto thericel una plataforma de células en suspensión para la producción de terapias basadas en virus theriva biologics y la universidad autónoma de barcelona recibirán un total de 2 28 millones de euros en apoyo del proyecto thericel una plataforma de células en suspensión para la producción de terapias basadas en virus,theriva biologics obtiene financiación para la fabricación del plan nacional de transferencia de conocimiento del gobierno español,financing_agreements,DOWN,-1.9704414983633087,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,0,8,285,0.0,1.5225134880447404,0.055400475341651816
during year 5 of treatment with briumvi the annualized relapse rate was 0 020 equivalent to one relapse occurring every 50 years of patient treatment,new data for briumvi ublituximab xiiy demonstrate that of patients with relapsing multiple sclerosis were free from disability progression after 5 years of treatment,clinical_study,UP,4.66507208872852,5897748992.0,135060602.0,1756590.0,1.939,1677400.0,0.022900364559970746,0.09346626282280733,2,7,283,0.1787878787878788,0.6256004090066075,0.04259537337662338
gaithersburg md feb 16 2023 globe newswire neximmune inc nasdaq nexi a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen specific t cells today announced that new positive preclinical data will be presented in an abstract titled prior antigen exposure enhances the t cell response to bispecific t cell engager therapy at the 2023 tandem meetings transplantation cellular therapy meetings of astct and cibmtr taking place on february 15 19 2023 in orlando florida,neximmune announces data showing aim act t cells enhance the response to bispecific t cell engager therapy at the 2023 tandem meetings transplantation cellular therapy meetings of astct and cibmtr,clinical_study,UP,9.242146234319629,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,863,0.09090909090909091,2.2666992986423327,0.0
qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024 qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024,qiagen erhält fda zulassung für qiastat dx mini panel für eine präzisere ambulante behandlung von atemwegserkrankungen,product_services_announcement,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.22727272727272727,0.2568422597431085,0.08276515151515151
mainz biomed reports positive topline results from pooled study evaluating novel mrna biomarkers and proprietary ai algorithm,mainz biomed reports positive topline results from pooled study evaluating novel mrna biomarkers and proprietary ai algorithm for integration into pivotal fda pma clinical trial for next generation colorectal cancer diagnostic,clinical_study,UP,9.242146234319629,5493384.0,2706585.0,75055.0,0.305,78500.0,0.49269903578559227,0.09346626282280733,3,9,429,0.23863636363636365,34.079934680222834,0.05126262626262626
san diego feb 05 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis today announced that new clinical data including efficacy outcomes supporting neffy epinephrine nasal spray will be presented during the 2024 american academy of allergy asthma and immunology aaaai the meeting will be held february 23 26 2024 in washington dc,ars pharmaceuticals to present positive clinical efficacy data for neffy epinephrine nasal spray at 2024 aaaai annual meeting,clinical_study,UP,0.1574839217641623,1692711424.0,51755600.0,1240295.0,0.872,1940800.0,0.03057556017297843,0.09346626282280733,0,9,509,0.18560606060606064,0.6899910717831225,0.0
27 sep 2024 12 00 cest swedbank ab the annual general meeting of swedbank ab will be held in stockholm thursday 27 march 2025 the members of the nomination committee are lennart haglund appointed by sparbankernas ägareförening and chair of the nomination committee ylva wessén appointed by folksam anders oscarsson appointed by amf annette björkman appointed by the owner group sparbanksstiftelserna magnus tell appointed by alecta tjänstepension göran persson chair of the board of directors of swedbank ab publ the nomination committee is assigned to prepare and present proposals to the 2025 agm regarding the election of chair of the agm members and chair of the board of directors and external auditor the nomination committee will also make proposals regarding the number of board members remuneration to the board members as well as external auditor s fee furthermore proposals for principles on how the nomination committee for agm 2026 shall be appoin,nomination committee for the agm 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,10,273,0.012500000000000004,0.8866002429130597,0.0
data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate,intellia therapeutics to present the first ever clinical data from patients redosed with an investigational in vivo crispr gene editing therapy at the peripheral nerve society annual meeting 2024,clinical_study,DOWN,-0.5964199634410936,978341376.0,98412511.0,6353695.0,2.134,5288300.0,0.10059117749099472,0.09346626282280733,0,7,376,0.125,0.7800307612939593,-0.006857142857142862
second quarter 2024 u s briumvi net revenue of 72 6 million,tg therapeutics reports second quarter 2024 financial results and raises briumvi ublituximab xiiy full year revenue guidance,earnings_releases_and_operating_results,UP,9.242146234319629,5883460608.0,135060602.0,1756590.0,1.939,1677400.0,0.022955979651899456,0.09346626282280733,1,7,326,0.06999999999999999,0.6256004090066075,0.04076839826839826
needham mass march 28 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the fourth quarter and year ended december 31 2023 and provided a corporate update,candel therapeutics reports fourth quarter and full year 2023 financial results and recent corporate highlights,financial_results,DOWN,-0.6493500461665078,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,457,0.04375,1.2870358800144117,0.11384358288770052
needham mass sept 03 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that paul peter tak md phd fmedsci candel s president and chief executive officer will present at the 26th annual global investment conference being held in person and virtually on september 9 11 2024,candel therapeutics to present at h c wainwright 26th annual global investment conference,conference_call_webinar,UP,2.2222236350730613,243499136.0,41997569.0,917740.0,-0.866,856900.0,0.1724752280024517,0.09346626282280733,1,8,298,0.0,1.2870358800144117,0.07322125031830913
media release,valmet s interim review january 1 september 30 2024 record high third quarter margin but slower market activity than expected,earnings_releases_and_operating_results,DOWN,-0.0830583796804002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,240,0.02,0.8866002429130597,-0.016941094619666055
los angeles oct 10 2023 globe newswire renovaro biosciences inc nasdaq renb renovaro an advanced pre clinical biotechnology firm in cell gene and immunotherapy focused on solid tumors with short life expectancy is pleased to announce the appointment of leni boeren and ruud hendriks as independent directors,renovaro biosciences appoints two finance industry experts to board of directors,management_changes,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,8,627,0.11666666666666665,1.5631250973582267,0.15
media release,hexagon purus asa mandatory notification of trade,shares_issue,DOWN,-7.008085924255639,934099520.0,189095204.0,501623.0,1.081,537849.0,0.20243582182763567,0.1515999603296736,3,13,239,0.0,1.126065167473528,0.0
turku finland and boston jan 03 2024 globe newswire faron pharmaceuticals oy faron or company aim farn first north faron a clinical stage biopharmaceutical company pursuing a clever approach to reprogramming myeloid cells to activate immunity in hematological and solid tumor microenvironments today announces that dr markku jalkanen chief executive officer will present at the 42nd annual j p morgan healthcare conference on thursday january 11 2024 at 12pm pt in san francisco,faron pharmaceuticals to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-0.6925168331116789,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,2,2,542,0.08333333333333333,0.7633342480324978,0.020194111444111436
new york und mainz deutschland 20 september 2024 pfizer inc nyse pfe pfizer und biontech se nasdaq bntx biontech gaben heute bekannt dass der ausschuss für humanarzneimittel committee for medicinal products for human use chmp der europäischen arzneimittel agentur european medicines agency ema eine positive beurteilung für die marktzulassung marketing authorization des an omikron kp 2 angepassten monovalenten covid 19 impfstoffs comirnaty kp 2 der unternehmen für die aktive immunisierung zur vorbeugung von covid 19 verursacht durch sars cov 2 bei personen ab 6 monaten ausgesprochen hat die europäische kommission ek wird die empfehlung des chmp prüfen eine endgültige entscheidung wird in kürze erwartet im anschluss an die entscheidung der ek werden pfizer und biontech den an omikron kp 2 angepassten covid 19 impfstoff den mitgliedstaaten der europäischen union eu ausliefern die genau diese formulierung bestellt haben,pfizer und biontech erhalten positive chmp empfehlung für an omikron kp 2 angepassten covid 19 impfstoff in der europäischen union,regulatory_filings,DOWN,-0.9599162834847244,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,4,8,281,0.1181818181818182,0.5503225880253886,0.06923440756774091
media release,financial calendar,financial_calendar,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,14,239,0.0,0.8866002429130597,0.0
south san francisco calif jan 02 2024 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced that brian wong m d ph d president and chief executive officer will present a company overview at the 42nd annual j p morgan healthcare conference on wednesday january 10 2024 at 9 00 a m pacific time,rapt therapeutics to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-2.012072403720535,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,1,8,543,0.03125,1.6028075568485736,0.1512909709338281
waltham mass aug 12 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced financial results for the second quarter ended june 30 2024 and recent corporate updates,checkpoint therapeutics reports second quarter 2024 financial results and recent corporate updates,financial_results,UP,0.0,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,8,320,0.0,0.8866002429130597,0.09451070858965595
longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society mtg,longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society chss 51st annual meeting,clinical_study,DOWN,-0.5434777327093245,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,9,262,0.17500000000000002,1.063123411629147,0.09264069264069263
26 sep 2024 14 18 cest jml finance luxembourg sarl key word s bond julius meinl living 2019 2024 bonds redeemed 26 sep 2024 14 18 cet cest julius meinl living 2019 2024 bonds redeemed julius meinl living plc through its group companies acquires prime real estate assets in major european political and economic capital cities for development into top rated hotel properties that comprise mainly apartments and that the group then operates itself julius meinl living julius meinl living is fully owned by the julius meinl family who over the last 162 years have demonstrated their expertise and excellence in consumer goods retail and real estate julius meinl living is pleased to confirm that today it paid in full the principal and final coupon in relation to all outstanding jml finance luxembourg s à r l 2019 2024 bonds isin xs2042981576 accordingly these bonds have now been redeemed dissemination of a financial wire news transmitted by,julius meinl living 2019 2024 bonds redeemed,bond_fixing,DOWN,-0.244504364517161,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,274,0.1786111111111111,0.8866002429130597,0.0
conference call to be held wednesday february 28 2024 at 8 30 am et conference call to be held wednesday february 28 2024 at 8 30 am et,tg therapeutics to host conference call on fourth quarter and year end 2023 financial results and business update,conference_call_webinar,DOWN,-0.5952375461590091,5885048320.0,135060602.0,1756590.0,1.939,1677400.0,0.02294978641738663,0.09346626282280733,4,7,491,0.0,0.6256004090066075,0.0
media release,norden iværksætter aktietilbagekøb,changes_in_companys_own_shares,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.37515160223877836,0.0
media release,delårsrapport 9 månader 1 januari 30 september 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,0.02500000000000001
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report second quarter 2024 financial results and provide a corporate update on thursday august 1 2024,conference_call_webinar,DOWN,-0.2421362858288849,162489600.0,15213010.0,781395.0,1.567,974600.0,0.09362451504588601,0.09346626282280733,3,8,338,0.0,0.8435084668920305,0.17036884411884412
fda grants pre bla meeting request and rolling bla submission after review of hope 2 and hope 2 ole 3 year results san diego june 11 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the successful completion of a type b meeting with the u s food and drug administration fda on next steps for the biologics license application bla submission with its lead asset cap 1002 for the treatment of duchenne muscular dystrophy dmd additionally deramiocel has been selected as the proposed international nonproprietary name inn for cap 1002 by the world health organization,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy with an aim to expedite bla pathway,clinical_study,DOWN,-0.554523730449676,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,382,0.2554545454545455,1.3427880947904531,0.09606060606060605
san diego march 19 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that it plans to host a conference call and webcast on tuesday march 26 2024 at 4 30 p m et to discuss its financial results for the fourth quarter and full year ended december 31 2023 and provide business highlights,bioatla to announce fourth quarter and full year 2023 financial results and provide business highlights on march 26 2024,conference_call_webinar,UP,0.0,23285456.0,45152550.0,596440.0,0.911,569400.0,1.9390880728296667,0.09346626282280733,1,8,466,0.06296296296296296,1.087702859114621,-0.03888888888888889
kesko corporation stock exchange release on 2 10 2024 at 11 30 not for release publication or distribution in whole or in part directly or indirectly in or into the united states australia canada hong kong japan singapore or such other countries or otherwise in such circumstances in which the offering of the notes or the release publication or distribution would be unlawful kesko corporation kesko announced its decision to issue green notes of eur 300 million on 25 september 2024 the notes the notes mature on 2 february 2030 and they carry annual interest of 3 500 percent the issue price of the notes is 99 317 percent the finnish financial supervisory authority has today approved the listing prospectus of the notes the prospectus is available in english on kesko s website at https www kesko fi investor kesko has today submitted an application for the notes to be admitted to trading on the list of sustainable bonds of nasdaq helsinki ltd trading in the notes,listing prospectus for kesko s eur 300 million green notes available,prospectus_announcement,DOWN,-0.4971282975870993,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,10,268,0.05625,0.8866002429130597,0.0
communiqué du 22 octobre 2024,eurobio scientific communiqué du 22 octobre 2024 relatif à la mise à disposition de la note d information dans le cadre de l offre publique d achat visant les actions de la société eurobio scientific initiée par eb development,clinical_study,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,10,248,0.0,0.4336088389568585,-0.003246753246753246
boston jan 09 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced the publication of data from the phase 1 amplify 201 study of eli 002 2p in nature medicine the paper lymph node targeted mkras specific amphiphile vaccine in pancreatic and colorectal cancer the phase 1 amplify 201 trial details expanded and updated results originally presented at the 2023 american society of clinical oncology asco annual meeting and the 2023 aacr special conference on pancreatic cancer,nature medicine publishes updated preliminary phase 1 data from elicio therapeutic s amplify 201 phase 1 solid tumor study of eli 002,clinical_study,UP,3.8363133927396,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,1,6,536,0.14642857142857144,0.8558055682194762,-0.017777777777777774
media release,nanologica s rights issue registered conversion of btu to shares and warrants,shares_issue,DOWN,-3.404252210749046,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,10,240,0.0,0.8866002429130597,0.04191919191919192
west lafayette ind may 14 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that it will issue its financial results for the fiscal 2024 second quarter ended march 31 2024 on wednesday may 15 2024 after the close of the stock market the company will host a conference call that same day at 4 30 p m eastern time to discuss the results,inotiv inc to report fiscal 2024 second quarter financial results and host conference call on wednesday may 15 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,62350696.0,31206932.0,922240.0,4.102,583600.0,0.5005065540888268,0.09346626282280733,1,7,410,0.0,1.3015467599292592,0.03673469387755102
malvern pa oct 02 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dr shankar musunuri chairman chief executive officer and co founder of ocugen will present at the 2024 cell gene meeting on the mesa being held october 7 9 2024 at the arizona biltmore in phoenix az,ocugen to present at the 2024 cell gene meeting on the mesa,conference_call_webinar,DOWN,-1.05263058828844,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,6,269,0.0,0.7661975315521313,0.06098893698893699
pratteln schweiz 18 juni 2024 santhera pharmaceuticals six sann gibt bekannt dass die aktionäre an der heutigen generalversammlung gv in pratteln schweiz allen anträgen des verwaltungsrats mit grosser mehrheit zugestimmt haben die teilnehmenden aktionäre vertraten 4 535 785 aktien oder 35 des aktienkapitals des unternehmens,santhera s aktionäre stimmen an heutiger generalversammlung allen anträgen des verwaltungsrats zu,annual_general_meeting,DOWN,-0.3061197182379018,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,9,375,0.0,0.5209522992128177,0.04000000000000001
media release,多品牌联盟合力推出全球首款 纤维到纤维 生物再生型服装 carbios on patagonia puma pvh corp 与 salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
rockaway n j april 08 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced the launch of its direct to consumer mobile app enabled product for general wellness truvaga plus which will be available on www truvaga com beginning april 8 2024,electrocore announces the launch of truvaga plus for general wellness,product_services_announcement,UP,0.6644511956770989,39700316.0,5517155.0,83945.0,0.804,91500.0,0.13897005253056424,0.09346626282280733,0,8,446,0.12000000000000002,0.8324549917316175,0.19090909090909092
new york and mainz germany august 16 2024 pfizer inc nyse pfe pfizer and biontech se nasdaq bntx biontech today announced top line results from their phase 3 clinical trial to evaluate the companies combined mrna vaccine candidate against influenza and covid 19 in healthy individuals 18 64 years of age the combination candidate consists of pfizer s mrna based influenza vaccine candidate with the companies licensed covid 19 vaccine the phase 3 trial measured two primary immunogenicity objectives immunogenicity against sars cov 2 as well as immunogenicity against influenza a and b of which one was met in a separate phase 2 trial pfizer evaluated trivalent tirv influenza mrna standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18 64 years of age the companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza b and will discuss next steps with health authorities,pfizer and biontech provide update on mrna based combination vaccine program against influenza and covid 19 in individuals 18 64 years of age,clinical_study,DOWN,-3.43839541547278,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,4,6,316,0.30727272727272725,0.5503225880253886,0.08867815055315056
media release,bluenord positive preliminary results on hemj well,exchange_announcement,UP,1.96078431372549,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.22727272727272727,0.8866002429130597,0.10416666666666667
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
additional 6 7m in funding resulting in approximately 67m in gross proceeds additional 6 7m in funding resulting in approximately 67m in gross proceeds,rezolute announces exercise of underwriters option to purchase additional shares and concurrent private placement,shares_issue,UP,0.0,379241376.0,77797779.0,825115.0,1.04,796000.0,0.20514053561497467,0.09346626282280733,3,8,366,-0.16,0.6820409900648857,0.03266725698543881
patient treated in trial achieved a remission after eight weeks of treatment demonstrating a significant reduction in proteinuria,eloxx pharmaceuticals intends to advance elx 02 into pivotal trial for the treatment of alport syndrome with nonsense mutations following achievement of remission in patient in phase 2 study,clinical_study,DOWN,-3.492435220091153,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,8,766,0.2916666666666667,2.2721670857062097,-0.03571428571428571
g1 therapeutics to release second quarter 2024 financial results and provide business update on august 8 2024,g1 therapeutics to release second quarter 2024 financial results and provide business update on august 8 2024,conference_call_webinar,UP,6.182796164101456,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,11,337,0.0,0.8866002429130597,0.051176470588235295
jerusalem aug 20 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and small therapeutic proteins today announced that management will be participating in the following investor and scientific conferences,entera bio to participate in upcoming investor and scientific conferences,conference_call_webinar,UP,1.8518500803374949,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,1,8,312,-0.125,0.6915109749530333,0.046040043290043305
media release,recording of lhv group s 22 october investor webinar,financial_results,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
partial response and stable disease reported in combination cohort and durable stable disease observed in monotherapy cohortsno dose limiting toxicities observed at any dose levelcleared fifth of six monotherapy cohorts and second of four combination cohortskineta is actively exploring strategic alternatives to maximize value for all stakeholders,kva12123 clears additional cohorts in monotherapy and in combination therapy arms in the phase 1 2 vista 101 clinical trial initial clinical response data reported,clinical_study,UP,6.826088071996192,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,473,-0.058333333333333334,0.8866002429130597,0.0927601044788545
media release,lhv pank completed the acquisition of part of tbb pank s credit portfolio,clinical_study,DOWN,-0.142446610710075,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,250,0.0,0.8866002429130597,0.04395265257618199
analysis further supports obesity associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment resistant hypertension,mineralys therapeutics presents new post hoc analysis from target htn phase 2 trial of lorundrostat in late breaking poster session at asn kidney week 2023 meeting,clinical_study,DOWN,-0.1280377992053975,916364736.0,43490817.0,793180.0,-0.18,767600.0,0.0474601600120937,0.09346626282280733,3,10,603,-0.05454545454545454,0.8131647725786432,0.0
media release,the world s first fiber to fiber biorecycled clothing unveiled by multi brand consortium carbios on patagonia puma pvh corp and salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.25,0.8866002429130597,0.0
arcutis today announced the fda has accepted its snda for zoryve roflumilast foam 0 for scalp and body psoriasis,fda accepts arcutis supplemental new drug application for zoryve roflumilast foam for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over,regulatory_filings,DOWN,-0.2076890708825607,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,1,8,277,0.13636363636363635,0.6903751128737089,0.04597881240038103
lawrenceville n j oct 07 2024 globe newswire imunon inc nasdaq imnn the company a clinical stage company in late stage development with its dna mediated immunotherapy today announced that the compensation committee of the company s board of directors approved the grant of i inducement stock options to purchase a total of 60 000 shares of the company s common stock to one individual hired by imunon during the fourth quarter of 2024 and ii inducement stock options to purchase a total of 50 000 shares of common stock to susan eylward hired by imunon as general counsel and secretary effective october 7 2024 collectively the inducement option grants the inducement option grants were approved in accordance with nasdaq listing rule 5635 c 4 and were made on october 7 2024 as a material inducement to each employee s entry into employment with the company,imunon reports inducement grant under nasdaq listing rule 5635 c 4,management_changes,DOWN,-0.9259250061011975,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,264,-0.027777777777777766,2.964855117372811,0.05367330714552936
spatial biology 2 0 solutions enable discovery and translational workflows at an unprecedented speed and scale,akoya biosciences to showcase new spatial biology 2 0 solutions and spatial phenotyping data at sitc 2023,trade_show,DOWN,-0.2941173583166078,60944124.0,12648900.0,228670.0,1.352,488000.0,0.207549131397803,0.09346626282280733,1,9,606,0.36818181818181817,0.8573192373918191,0.0
waltham mass sept 04 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will present a corporate overview at the h c wainwright 26th annual global investment conference on tuesday september 10 2024 at 10 00 a m et the company will also attend in person and virtual one on one meetings during the conference,checkpoint therapeutics to present at h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-0.4524882484455325,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,2,8,297,0.0,0.8866002429130597,0.08978517316017315
tucson ariz and cambridge mass and rostock germany and berlin june 20 2024 globe newswire critical path institute c path a leader in forming collaborations that accelerate drug development and centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases are pleased to announce the signing of a memorandum of understanding mou to advance drug development for lysosomal diseases lds and improve the quality of life for those impacted by these conditions,c path and centogene mou to enhance collaboration in lysosomal disease research and drug development,partnerships,UP,1.184598171731983,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,3,8,373,0.2,3.598197549072007,0.14734172077922075
se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del vcn 01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos,theriva biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024,clinical_study,DOWN,-4.761904761904762,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,6,416,0.0,1.5225134880447404,0.08038383838383838
san mateo calif and cambridge mass dec 04 2023 globe newswire kronos bio inc nasdaq kron a company dedicated to transforming the lives of those affected by cancer today announced that jorge dimartino m d ph d chief medical officer and executive vice president of clinical development and charles lin ph d senior vice president of trn mapping will participate in a fireside chat at the h c wainwright 4th annual precision oncology virtual conference on wednesday december 6 2023 at 11 00 a m et,kronos bio announces participation in h c wainwright 4th annual precision oncology virtual conference,conference_call_webinar,DOWN,-1.666674945089223,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,0,8,572,0.0,0.6178272804340184,0.0
27 sep 2024 08 15 cest bekaert s a update over de liquiditeitsovereenkomst periode van 19 september 2024 tot 25 september 2024 liquiditeitsovereenkomst in het kader van het hernieuwde liquiditeitscontract met kepler cheuvreux aangekondigd op 25 juni 2024 maakt bekaert vandaag bekend dat kepler cheuvreux namens bekaert 13 600 aandelen heeft aangekocht in de periode van 19 september 2024 tot 25 september 2024 op euronext brussels tijdens dezelfde periode heeft kepler cheuvreux namens bekaert 6 100 aandelen verkocht op euronext brussels de onderstaande tabellen geven een overzicht van de transacties in het kader van het liquiditeitscontract tijdens de periode van 19 september 2024 tot 25 september 2024 aankoop van aandelen datumaantal aandelengemiddelde prijs hoogste prijs laagste prijs totaal bedrag 19 september 202460036 7536 8036 7022 05020 september 20244 30036 2936 7035 96156 04723 september 20241 50035 7835 9035 6453 67024 september 202460036 2536 30,bekaert update over de liquiditeitsovereenkomst,changes_in_companys_own_shares,UP,0.4955955580622765,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.0,0.8866002429130597,0.0
phase 2a efficacy and safety trial enrollment initiation expected in h1 2025,bioxcel therapeutics announces u s department of defense grant to university of north carolina to fund study of bxcl501 sublingual dexmedetomidine for treating acute stress disorder,clinical_study,UP,0.5692526222367394,12057596.0,5544250.0,450810.0,-0.13,78500.0,0.4598138799807192,0.09346626282280733,1,7,256,0.25,1.4586588351104455,0.0601005181687
santa ana calif oct 17 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today presented a poster with interim phase i trial data on the use of its investigational nk cell therapy snk01 to treat patients with alzheimer s disease ad at the xxvi world congress of neurology wcn annual meeting in montreal qc canada and online,nkgen biotech presents interim phase i trial data at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,DOWN,-1.9999980926513672,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,1,8,620,0.3,2.657355742098314,0.3
lifting of fda hold allows freedom dm1 study to launch in the u s with target dose levels of 5 mg kg 10 mg kg and 20 mg kg,pepgen inc announces fda has lifted the clinical hold on its investigational new drug application for freedom dm1 phase 1 study of pgn edodm1 for myotonic dystrophy type 1 dm1,clinical_study,DOWN,-0.57034616925724,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,3,7,625,0.13636363636363635,1.4553932872573117,0.045
toronto nov 21 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders provides an update on the development of a next generation lyophilized formulation of bucillamine,revive therapeutics provides update of novel bucillamine formulation development,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,585,0.09999999999999999,1.8889707456546947,0.0
phenocycler fusion system selected as the centre s platform technology for advanced spatial biology studies phenocycler fusion system selected as the centre s platform technology for advanced spatial biology studies,akoya biosciences technology enables queensland spatial biology centre to revolutionize the diagnosis and treatment of cancer and other diseases,product_services_announcement,UP,1.4084542176344366,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,3,8,527,0.225,0.8573192373918191,0.2068181818181818
redwood city calif feb 23 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 in mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu is presenting results from three preclinical studies evaluating briquilimab at the 2024 american academy of allergy asthma immunology aaaai annual meeting being held february 23 26 in washington d c one study will be featured in an oral presentation and two studies in poster presentations,jasper therapeutics presents data from preclinical briquilimab studies at the american academy of allergy asthma and immunology aaaai annual meeting,clinical_study,DOWN,-0.8247414977229304,81870440.0,9908441.0,280900.0,2.725,505700.0,0.12102586721165784,0.09346626282280733,4,8,491,0.15,0.9821837329226573,0.036111111111111115
cft1946 preclinical data accepted for a poster presentation at the aacr annual meeting 2024,c4 therapeutics reports fourth quarter and full year 2023 financial results and recent business highlights,clinical_study,UP,0.0,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,3,7,492,0.0875,0.8954742650579008,0.0
san diego may 07 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that it plans to host a conference call and webcast on tuesday may 14 2024 at 4 30 p m et to discuss its financial results for the first quarter ended march 31 2024 and provide business highlights,bioatla to announce first quarter 2024 financial results and provide business highlights on may 14 2024,conference_call_webinar,UP,0.0,23671014.0,45152550.0,596440.0,0.911,569400.0,1.9075038357038696,0.09346626282280733,1,8,417,0.05238095238095238,1.087702859114621,0.014662497995831325
seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience,pacira biosciences appoints shawn cross as chief financial officer,clinical_study,DOWN,-1.0863381163181691,1110849792.0,45834212.0,557500.0,0.511,435200.0,0.04126049474022857,0.09346626282280733,0,8,250,0.15,0.7130794063724827,0.1382682491980013
new york june 17 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions reports that takeda pharmaceutical company limited takeda has announced topline data from its phase 3 skyline and skyway studies evaluating soticlestat for the treatment of dravet syndrome ds and lennox gastaut syndrome lgs,ovid therapeutics reports on takeda s announcement of phase 3 topline study results for soticlestat,clinical_study,DOWN,-7.103823312288768,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,0,6,376,0.21623376623376622,0.7642184815786688,0.16356988249845392
transcode therapeutics and akribion genomics report progress developing crispr derived technology for cancer treatment,transcode therapeutics and akribion genomics report progress developing crispr derived technology for cancer treatment,partnerships,UP,2.86122759645592,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,0,9,474,0.0,2.0874185587937095,0.0
boston sept 01 2023 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that it will be presenting at upcoming medical meetings and an investor conference ashling holland director of preclinical development at pepgen will be giving a talk titled pgn edodm1 nonclinical data demonstrated mechanistic and meaningful activity for the potential treatment of myotonic dystrophy type 1 dm1 at the 2023 myotonic dystrophy foundation annual conference on september 9 2023 in washington d c,pepgen announces presentations at the 2023 myotonic dystrophy foundation annual conference ottawa neuromuscular disease meeting and h c wainwright 25th annual global investment conference,clinical_study,UP,2.2222200356674184,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,4,8,666,0.1,1.4553932872573117,0.0
vertex pharmaceuticals to obtain a non exclusive license for cas9 for casgevy exagamglogene autotemcel,editas medicine and vertex pharmaceuticals enter into non exclusive license agreement for cas9,licensing_agreements,UP,5.487804405277464,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,2,9,563,0.0,1.3105556047468256,0.0715909090909091
media release,nordic unmanned launches contemplated private placement,financing_agreements,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,241,0.0,0.8866002429130597,0.0
media release,ramsay sante availability of the universal registration document 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
media release,wärtsilä s interim report january september 2024,interim_information,DOWN,-7.103823312288768,11530422272.0,388303386.0,1013444.6,1.147,878088.0,0.033676423711119396,0.1515999603296736,1,7,242,0.0,0.32861949612372426,0.0
jerusalem aug 01 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins today announced that new comparative pharmacological data for its investigational agent eb613 vs forteo was selected for presentation at the american society for bone and mineral research asbmr 2024 annual meeting which will be held on september 27 30 2024 in toronto on canada,entera s eb613 the first once daily pth 1 34 tablet treatment dedicated to post menopausal women with high risk osteoporosis abstract selected for presentation at the asbmr 2024 annual meeting key sabre update also expected,clinical_study,UP,9.242146234319629,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,3,8,331,0.06376623376623378,0.6915109749530333,0.04477388682745826
copenhagen denmark sept 09 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines announces new pre clinical data demonstrating the ability of its novel evx b2 mrna gonorrhea vaccine candidate in eliminating gonorrhea bacteria by triggering a targeted immune response,evaxion obtains pre clinical proof of concept for mrna gonorrhea vaccine candidate evx b2,clinical_study,UP,0.5797095840604812,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,7,292,0.13636363636363635,1.4249795072460607,0.11832426832426832
seattle nov 28 2023 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it will host a virtual kol event to discuss new data from the vista 101 clinical trial of kva12123 in patients with advanced solid tumors details are as follows,kineta to host kol event to review new data from vista 101 clinical trial of kva12123 in patients with advanced solid tumors on december 5 2023,clinical_study,DOWN,-0.3225803474481751,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,578,0.1787878787878788,0.8866002429130597,0.18181818181818182
toronto jan 16 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders today announced an update on the company s project evaluating bucillamine as a potential treatment for nerve agent exposure with defence r d canada suffield research centre drdc an agency of the canadian department of national defence the company and the drdc have finalized the research protocol and expect the project to be completed by the end of q2 2024,revive therapeutics provides update evaluating bucillamine for nerve agent exposure with defence research and development canada,clinical_study,DOWN,-4.000000596046439,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,529,0.09999999999999999,1.8889707456546947,0.13660419126328216
advance htn trial of lorundrostat for the treatment of uhtn or rhtn is anticipated to deliver topline data in q4 2024,mineralys therapeutics reports first quarter 2024 financial results and provides corporate update,clinical_study,UP,0.2047828493289582,917016448.0,43490817.0,793180.0,-0.18,767600.0,0.04742643067619219,0.09346626282280733,3,7,415,0.08333333333333333,0.8131647725786432,0.015993506493506497
kraig labs otcqb kblb completed third commercial spider silk production cycle primarily focused on producing bam 1 recombinant spider silk hybrids,kraig biocraft laboratories successfully completes third commercial spider silk production cycle,press_releases,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,313,0.19166666666666665,0.8071333009212691,0.11800239234449761
record fourth quarter 2023 cguard eps revenue of 1 76 million increased 71 over fourth quarter 2022,inspiremd reports fourth quarter and full year 2023 financial results and provides business update,earnings_releases_and_operating_results,DOWN,-2.6616033694073624,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,2,7,479,0.06999999999999999,0.6085732039686736,0.08245129870129868
selskabet har afholdt ekstraordinær generalforsamling den 21 oktober 2024 kl 10 00 på selskabets adresse lyskær 8a 2730 herlev med følgende dagsorden,referat fra ekstraordinær generalforsamling,clinical_study,DOWN,-4.696800970514925,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,4,250,0.0,0.8866002429130597,0.0
media release,marel q3 2024 investor meeting presentation,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.0,0.8866002429130597,0.0
adelaide australia and cambridge mass july 25 2023 globe newswire bionomics limited asx bno nasdaq bnox bionomics or the company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it has submitted a formal request to the australian securities exchange asx to be removed from the official list of the asx in keeping with the company s ongoing transformation to a u s focused organization the main consequence of an asx delisting for shareholders is that from the time the proposed asx delisting is scheduled to take effect on august 28 2023 bionomics shares will no longer be quoted or traded on the asx and will only be tradable in the form of american depositary shares on the nasdaq global market nasdaq under the symbol bnox,bionomics announces intention to delist from the australian securities exchange asx,exchange_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,704,0.014325396825396826,0.8866002429130597,0.0005529100529100557
redwood city calif may 30 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that nevan charles elam chief executive officer and founder of rezolute will participate in a fireside chat during the jefferies global healthcare conference on thursday june 6 2024 at 1 00 p m et in new york city,rezolute to participate in the jefferies global healthcare conference,conference_call_webinar,UP,0.7263857660994884,376775840.0,77797779.0,825115.0,1.04,796000.0,0.20648292894788584,0.09346626282280733,3,8,394,0.020606060606060607,0.6820409900648857,0.0471384479717813
cambridge mass and rostock germany and berlin sept 25 2024 globe newswire centogene n v the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced data from the company s rostock international parkinson s disease ropad further supporting the association of a rab32 gene mutation with parkinson s disease pd the study published in the lancet neurology builds on research from emil k gustavsson and colleagues who previously identified the rab32 c 213c g p ser71arg dbsnp rs200251693 variant as a novel monogenic cause of pd,centogene data on novel genetic risk factor for parkinson s disease in the lancet neurology,clinical_study,DOWN,-7.103823312288768,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,8,276,0.0638888888888889,3.598197549072007,0.15139235764235762
company announcementfor rockwool a srelease no 55 2024to nasdaq copenhagen 2 october 2024 rockwool a s transactions in connection with share buy back programme as mentioned in announcement no 02 2024 rockwool a s has initiated a share buy back programme which will run from 8 february 2024 until 7 february 2025 during this period the company will buy own shares for up to a maximum of 160 meur the programme is implemented in accordance with eu commission regulation no 596 2014 of 16 april 2014 and eu commission delegated regulation no 2016 1052 of 8 march 2016 which together constitute the safe harbour regulation the following transactions have been executed during the period 25 september 1 october 2024 with the transactions stated above rockwool a s owns 375 483 b shares corresponding to 1 74 percent of the company s total share capital an overview showing the transaction data for the period 25 september 1 october 2024 is enclosed further information,rockwool a s transactions in connection with share buy back programme,changes_in_companys_own_shares,DOWN,-1.8770226537216828,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.12222222222222223,0.8866002429130597,0.0
the management board of eften real estate fund as registry code 12864036 seat tallinn a lauteri 5 calls the extraordinary general meeting of shareholders on 16 october 2024 at 15 00 venue of the general meeting radisson collection hotel second floor conference centre hall tallinn address tallinn rävala 3 the registration of participants of the general meeting starts at 14 00 on 16 october 2024 at the venue of the meeting the registration ends at 15 00 if possible we request that all shareholders arrive in time considering the time required to register the participants of the meeting the list of shareholders who shall be entitled to participate in the extraordinary general meeting shall be fixed seven days prior to the date of the general meeting i e on 09 october 2024 as at the end of the working day of the registrar of the settlement system of the fund s securities the shareholders may also participate by appointing a representative or vote prior to the meeting on,eften real estate fund as notice calling the extraordinary general meeting of shareholders,annual_general_meeting,DOWN,-0.5390753543607132,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,277,0.11250000000000002,0.8866002429130597,0.09370941558441559
cambridge mass aug 08 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today reported operational highlights and financial results for the second quarter ended june 30 2024,intellia therapeutics announces second quarter 2024 financial results and highlights recent company progress,clinical_study,UP,3.613329315161578,975233920.0,98412511.0,6353695.0,2.134,5288300.0,0.10091169819031726,0.09346626282280733,3,7,324,0.0,0.7800307612939593,0.04861339232662761
berwyn pa dec 05 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase iii study of its lead candidate buntanetap in patients with early parkinson s disease pd topline data results are expected in january 2024,annovis bio announces last patient last visit in the phase iii study of buntanetap in parkinson s disease,clinical_study,UP,1.522838707828475,44198596.0,15624645.0,595065.0,1.618,805900.0,0.3535099847968021,0.09346626282280733,1,7,571,0.0,1.368989555493872,0.08772727272727272
san diego dec 26 2023 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today updated the status of its dose escalation dose expansion phase 1 2 study onct 808 101 evaluating the company s ror1 targeting autologous car t cell therapy onct 808 for the treatment of patients with relapsed or refractory aggressive b cell lymphoma including patients who have failed previous cd19 car t treatment,oncternal therapeutics updates the status of its phase 1 2 study of onct 808 a ror1 targeting autologous car t in patients with relapsed or refractory aggressive b cell lymphoma,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,550,-0.3333333333333333,0.8866002429130597,0.0
media release,bekaert update on the liquidity agreement,clinical_study,UP,0.1158104066794088,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,246,0.0,0.8866002429130597,0.0
certara shared the results from its collaboration with ichnos glenmark innovation igi on the first in human dose prediction and selection for isb 2001,certara ichnos glenmark innovation collaboration optimizes dosing strategy for potential first in class cancer drug,clinical_study,DOWN,-0.8310263455393667,1746449024.0,121837605.0,1806725.0,1.448,1507200.0,0.06976304680279062,0.09346626282280733,2,8,283,0.125,0.5462989777603723,0.07363636363636364
boca raton florida april 23 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease is delighted to announce the successful completion of the extended stability validation for xprotm continuous storage in solution at 2 8c the 24 and 30 month stability test samples passed all chemistry and potency assays allowing the company to make a conservative claim of 24 month stability the 24 month stability claim is consistent with other pegylated cytokines such as alpha interferon and allows the company to design a global supply chain using proven and established systems with this data the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid formulation drugs at 2 8c which is routine across the pharmaceutical industry the 24 month stability data confirms that xprotm can mirror these established supply chain strategies,inmune bio inc announces 24 month stability validation of xpro for phase iii readiness and commercial supply chain modeling development of novel immunogenicity assay,press_releases,DOWN,-2.4000010770909923,158748848.0,15213010.0,781395.0,1.567,974600.0,0.09583067966578251,0.09346626282280733,1,8,431,0.196875,0.8435084668920305,0.0645959595959596
02 oct 2024 08 00 cest beerenberg as not for release publication or distribution in whole or in part directly or indirectly into or within canada australia new zealand south africa hong kong japan or any other jurisdiction in which the release publication or distribution would be unlawful 2 october 2024 reference is made to the announcement made on 4 september 2024 by beerenberg as beerenberg or the company and altrad investment authority s a s altrad or the offeror regarding the issuance of an offer document the offer document and the start of the offer period for the board recommended unregulated voluntary cash offer to acquire all outstanding shares in the company the shares not already owned by the offeror the offer shareholders who want to accept the offer must complete and return the acceptance form which is included in the offer document and available on www danskebank no beerenberg the webpage of danske bank norwegian bra,reminder of last day of offer period for altrad s recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,DOWN,-2.7568978615324222,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,269,0.18113636363636365,0.8866002429130597,0.0
partners able to claim up to tax relief partners able to claim up to tax relief,centogene receives french research tax credit accreditation,government_news,DOWN,-2.3999977111816406,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,521,0.3333333333333333,3.598197549072007,0.07559523809523809
jupiter fla may 08 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic therapeutic and nutritional biopharmaceutical products for human and animal health and wellness today announced that its management will be attending the following industry and investor events during the month of may 2024,dyadic to attend industry and investor events in may,conference_call_webinar,UP,2.12766605030108,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,416,0.08333333333333333,0.7846450948942033,0.14806734931734933
saint herblain france et schlieren zurich le 1 août 2024 valneva se nasdaq valn euronext paris vla société spécialisée dans les vaccins et limmatech biologics ag société de biotechnologie développant des vaccins pour la prévention des maladies potentiellement mortelles ont annoncé aujourd hui la conclusion d un partenariat stratégique via la signature d un accord de licence exclusif pour le développement la production et la commercialisation de shigella4v s4v un candidat vaccin bioconjugué tétravalent contre la shigellose,valneva et limmatech signent un partenariat stratégique pour accélérer le développement du candidat vaccin tétravalent contre la shigellose le plus avancé au monde,licensing_agreements,DOWN,-1.4966004753969215,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,331,0.0,0.6494694268312979,0.06944444444444443
istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias,windtree announces positive phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients in early cardiogenic shock,clinical_study,DOWN,-1.5564187895738903,1360169.0,3660923.0,6680965.0,0.764,1224200.0,2.6915206860323972,0.09346626282280733,0,8,271,0.12945075757575758,2.339794177443606,0.03578643578643579
copenhagen denmark july 16 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines today showcases improved performance of its key building block evaxmhc within its ai immunology platform at the 32nd intelligent systems for molecular biology ismb conference taking place in montreal canada from july 12 16 2024,evaxion showcases improved performance of key building block in ai immunology at computational biology conference,press_releases,DOWN,-1.8736111966031144,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,1,7,347,0.26666666666666666,1.4249795072460607,0.10081369248035914
innovative design enables five minute pegfilgrastim cbqv delivery time,coherus announces u s launch of udenyca onbody a novel and proprietary state of the art delivery system for pegfilgrastim cbqv,product_services_announcement,DOWN,-2.7027002147700405,85025264.0,110892497.0,1236840.0,0.883,1425300.0,1.3042299639316615,0.09346626282280733,2,8,493,0.5,1.0144535837204522,0.0
turku finland and boston sept 22 2023 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company focused on tackling cancers via novel immunotherapies is pleased to announce the appointment of ms christine roth and dr marie louise fjällskog as non executive directors of the company with immediate effect following the passing of all resolutions put to shareholders of the company at the extraordinary general meeting held earlier today,faron pharmaceuticals announces board changes,management_changes,DOWN,-1.16579894037145,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,4,11,644,0.18888888888888888,0.7633342480324978,0.01094516594516594
02 oct 2024 08 00 cest beerenberg as not for release publication or distribution in whole or in part directly or indirectly into or within canada australia new zealand south africa hong kong japan or any other jurisdiction in which the release publication or distribution would be unlawful 2 october 2024 reference is made to the announcement made on 4 september 2024 by beerenberg as beerenberg or the company and altrad investment authority s a s altrad or the offeror regarding the issuance of an offer document the offer document and the start of the offer period for the board recommended unregulated voluntary cash offer to acquire all outstanding shares in the company the shares not already owned by the offeror the offer shareholders who want to accept the offer must complete and return the acceptance form which is included in the offer document and available on www danskebank no beerenberg the webpage of danske bank norwegian bra,reminder of last day of offer period for altrad s recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,DOWN,-2.7568978615324222,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,269,0.18113636363636365,0.8866002429130597,0.0
interim data from additional mss crc patients dosed at 10 mg kg every three weeks q3w in combination with pembrolizumab anticipated in 2024 at a medical conference,adagene announces progress and expansion of clinical collaboration program for masked anti ctla 4 safebody adg126 muzastotug in combination with keytruda pembrolizumab to demonstrate further efficacy in patients with metastatic microsatellite stable mss colorectal cancer crc,clinical_study,DOWN,-1.428570066179548,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,6,505,0.0,0.845882180665701,0.16557050092764378
santa ana calif oct 11 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today announced an upcoming poster presentation on an interim report of a phase i study of snk01 in patients with alzheimer s disease at the xxvi world congress of neurology wcn annual meeting to be held in montreal qc canada and online between october 15 19 2023,nkgen announces poster presentation at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,UP,1.5822769290571204,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,2,8,626,0.3,2.657355742098314,0.0
malvern pa july 29 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that it will host a conference call and live webcast to discuss the company s second quarter 2024 financial results and provide a business update at 8 30 a m et on thursday august 8 2024,ocugen to host conference call on thursday august 8 at 8 30 a m et to discuss business updates and second quarter 2024 financial results,conference_call_webinar,DOWN,-1.219511042741837,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,7,334,0.02727272727272727,0.7661975315521313,0.10319444444444445
designation for bxcl701 in combination with a checkpoint inhibitor cpi for treatment of patients with metastatic scnc with progression on chemotherapy and no evidence of microsatellite instability,bioxcel therapeutics receives fda fast track designation for bxcl701 for treatment of small cell neuroendocrine prostate cancer scnc,clinical_study,UP,9.242146234319629,12767970.0,5544250.0,450810.0,-0.13,78500.0,0.4342311267961939,0.09346626282280733,0,7,502,-0.024999999999999994,1.4586588351104455,0.0
conference call to begin at 4 30 p m et conference call to begin at 4 30 p m et,vaxart to host full year 2023 business update and financial results conference call on march 14,conference_call_webinar,DOWN,-5.000004967053534,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,3,8,478,0.175,1.025768835125998,-0.04583333333333334
transcode therapeutics announces publication of study with lead therapeutic candi date revealing mechanisms behind candidate s preclinical efficacy against,transcode therapeutics announces publication of study with lead therapeutic candidate revealing mechanisms behind candidate s preclinical efficacy against metastatic cancer,clinical_study,DOWN,-1.5625030922818393,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,1,7,291,-0.4,2.0874185587937095,0.027622377622377625
immunocore to present at upcoming investor conferences,immunocore to present at upcoming investor conferences,conference_call_webinar,UP,0.0,1604712320.0,37423034.0,614630.0,0.835,788600.0,0.023320712088756194,0.09346626282280733,4,7,484,0.0,0.44240182162750774,0.16875
in8bio to present at the h c wainwright 26th annual global investment conference,in8bio to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-0.9523800873701952,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,3,6,303,0.0,1.2777111391401192,0.09829545454545453
san diego aug 28 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that the company s management will provide a corporate update at the h c wainwright 26th annual global investment conference to be held september 9 11 2024,bioatla to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.117317394007622,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,2,8,304,-0.022222222222222223,1.087702859114621,0.015315355940355942
zug switzerland june 10 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced positive topline results from its phase 2b relief trial with licaminlimab a novel anti tnfα biologic eye drop with an established dual anti inflammatory and anti apoptotic mechanism of action in patients with dry eye disease ded,oculis announces positive topline results of phase 2b relief trial with licaminlimab designed to transform the treatment paradigm of dry eye disease with a precision medicine strategy,clinical_study,UP,1.2658195249076385,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,0,5,383,0.07020202020202021,0.4640841922034435,0.08686868686868687
in august lhv s lending continued at a faster than planned pace which had a positive impact on the company s profit number the consolidated loan portfolio of as lhv group increased by eur 87 million over the month deposits increased by eur 254 million on a consolidated basis the volume of the funds managed by lhv grew by eur 4 million in august payments related to financial intermediaries amounted to 6 1 million per month in august the consolidated net profit of as lhv group was eur 12 2 million among the subsidiaries as lhv pank earned eur 11 8 million lhv bank ltd eur 13 thousand as lhv varahaldus eur 240 thousand and as lhv kindlustus eur 129 thousand in net profit over the month the number of the lhv pank clients increased by 3 600 strong results were driven by client activity and good home loan lending performance of the increase of eur 50 million in the loan portfolio retail loans accounted for eur 36 million and corporate loans for eur 14 million in august th,lhv group results for august 2024,financial_results,UP,0.1510608618536461,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,284,0.17007575757575757,0.8866002429130597,0.009978991596638665
rockville md oct 12 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the company for cash the existing warrants wherein the investor agreed to exercise the existing warrants to purchase up to a maximum of 10 892 728 common shares at an exercise price of 0 7785 per share as part of the agreement the existing holder has agreed to pay an additional 0 25 consideration per share resulting in gross proceeds of up to approximately 11 2 million assuming full exercise of the existing warrants and before deducting offering fees and expenses,opgen enters into warrant inducement transaction for up to 11 2 million in gross proceeds,warrants_and_certificates,DOWN,-7.103823312288768,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,12,624,-0.10833333333333334,1.807174583649316,0.14746915584415585
company expects enrollment in phase 1 proof of concept study of dna based vaccine technology to begin in the second quarter,imunon s ind application cleared to begin human testing of imnn 101,clinical_study,UP,0.8771921569070334,17822234.0,12808492.0,12655315.0,2.143,945100.0,0.7186804976300951,0.09346626282280733,3,8,436,0.0,2.964855117372811,0.015289256198347102
som meddelt i selskabsmeddelelse 7 2024 og 10 2024 har selskabet haft en uoverensstemmelse med zevra som var køber af den tidligere aktivitet orphazyme har dags dato modtaget eur 450 000 fra zevra og der er ikke længere udeståender parterne imellem,forlig af udestående samt ændring af guidance,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,11,364,0.0,0.8866002429130597,0.0
media release,enefit green interim report for q3 2024,earnings_releases_and_operating_results,DOWN,-1.3468000494176686,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,9,240,-0.2,0.8866002429130597,-0.07522727272727274
adelaide australia and cambridge mass july 31 2023 globe newswire bionomics limited nasdaq bnox asx bno bionomics or the company a clinical stage biopharmaceutical company developing novel allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system cns disorders with high unmet medical need today released its appendix 4c quarterly cashflow report highlights during the quarter ended 30 june 2023 quarter and up to the date of this announcement include,quarterly activities and cashflow report,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,698,-0.048952380952380956,0.8866002429130597,0.008816402116402118
media release,equinor asa tilbakekjøp av egne aksjer,changes_in_companys_own_shares,UP,0.4419934464203499,686391361536.0,833726970.0,3882914.5,0.022,6264036.0,0.0012146524806697652,0.1515999603296736,1,8,242,0.0,0.29388453068177606,0.0
media release,euronext oslo børs b2 impact asa received application for listing of bonds,exchange_announcement,DOWN,-0.4115222299809098,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,9,241,0.0,0.2679946975487692,0.0
innofactor plc managers transactions on october 16 2024 at 9 30 finnish time innofactor oyj managers transactions ____________________________________________ person subject to the notification requirementname onni bidco oyposition closely associated person x legal person 1 person discharging managerial responsibilities in issuername sami ensioposition chief executive officer 2 person discharging managerial responsibilities in issuername antti kummuposition member of the board issuer innofactor oyjlei 7437008oskqfedzyd835notification type initial notificationreference number 81429 5 4 ____________________________________________ transaction date 2024 10 11venue nasdaq helsinki ltd xhel instrument type shareisin fi0009007637nature of transaction acquisition transaction details 1 volume 5 unit price 1 68 eur 2 volume 100 unit price 1 68 eur 3 volume 86 unit price 1 68 eur 4 volume 1262 unit price 1 68 eur 5 volume 5000 unit price 1 68 eur,innofactor plc managers transactions,managers_transactions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,255,0.011111111111111118,0.8866002429130597,-0.002777777777777763
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
needham mass may 30 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the u s food and drug administration fda has granted orphan drug designation to can 3110 a next generation oncolytic viral immunotherapy for the treatment of recurrent high grade glioma rhgg glioblastoma gbm is the most common and aggressive form of high grade glioma,fda grants orphan drug designation for can 3110 for the treatment of recurrent high grade glioma,clinical_study,UP,1.3651864172907773,244501184.0,41997569.0,917740.0,-0.866,856900.0,0.17176836656954594,0.09346626282280733,3,8,394,0.11333333333333334,1.2870358800144117,0.0787560311205822
waltham mass sept 21 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a panel presentation at the cantor global healthcare conference on thursday september 28 2023 at 10 20 a m et in new york city the company will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the cantor global healthcare conference,conference_call_webinar,DOWN,-1.1904750923180183,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,646,0.04545454545454545,0.8866002429130597,0.0
conference call to be held wednesday february 28 2024 at 8 30 am et conference call to be held wednesday february 28 2024 at 8 30 am et,tg therapeutics to host conference call on fourth quarter and year end 2023 financial results and business update,conference_call_webinar,DOWN,-0.5952375461590091,5885048320.0,135060602.0,1756590.0,1.939,1677400.0,0.02294978641738663,0.09346626282280733,4,7,491,0.0,0.6256004090066075,0.0
certara a global leader in model informed drug development today announced the celebration of the 25th anniversary of the simcyp consortium,certara s simcyp consortium celebrates 25th anniversary,press_releases,UP,0.0920831417861723,1745637888.0,121837605.0,1806725.0,1.448,1507200.0,0.06979546321579382,0.09346626282280733,1,8,277,0.0,0.5462989777603723,0.09931818181818183
new haven conn oct 29 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience today announced that vimal mehta ph d ceo and vincent j o neill m d executive vice president chief of product development and medical officer will present at the thinkequity conference in new york city the presentation is set for wednesday october 30 at 2 p m et,bioxcel therapeutics to present at thinkequity conference,conference_call_webinar,DOWN,-1.499248954662312,12057596.0,5544250.0,450810.0,-0.13,78500.0,0.4598138799807192,0.09346626282280733,1,7,242,-0.05454545454545454,1.4586588351104455,0.06835701737875652
recent 11 3 million grant from the california institute for regenerative medicine cirm intended to fund the phase 1 clinical trial at city of hope the investigational new drug application for which has now been accepted by the food and drug administration,fortress biotech subsidiary helocyte announces option agreement with city of hope for exclusive worldwide rights to use a novel bispecific cmv hiv car t cell therapy optionally in combination with triplex for the treatment of adults living with hiv 1,clinical_study,UP,0.3448272460139292,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,0,9,621,0.06818181818181818,0.6928276660424207,0.0
dallas aug 19 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that dr jeffrey carter will present data from an ongoing prospective multicenter study analyzing the use of spectral ai s deepview system which utilizes non invasive multispectral imaging technology and proprietary ai to detect non healing areas of a wound following thermal burn injury,spectral ai announces podium presentation at bba isbi joint conference assessing burn wound severity using multispectral imaging and artificial intelligence,clinical_study,DOWN,-1.9354820846890508,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,0,8,313,-0.04285714285714284,0.9904696515070965,0.08747204184704187
media release,aker bp reports third quarter 2024,earnings_releases_and_operating_results,UP,2.086106029551391,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,241,0.0,0.8866002429130597,0.10795454545454548
farmington hills mich aug 08 2024 globe newswire ocuphire pharma inc nasdaq ocup a clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of patients with retinal and refractive eye disorders today announced that george magrath m d m b a m s chief executive officer will present at the canaccord genuity 44th annual growth conference to take place in boston ma august 14 2024 and at the h c wainwright 4th annual ophthalmology virtual conference to take place virtually on august 15 2024,ocuphire pharma to present at two investor conferences in august,conference_call_webinar,UP,0.6097555213709185,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,324,-0.08333333333333333,0.8866002429130597,-0.0279178613594198
anticipated 2024 milestones include present reni cel clinical data updates mid year and year end initiate the ruby clinical trial adolescent cohort establish in vivo preclinical proof of concept for an undisclosed indication and continue to sublicense foundational ip,editas medicine highlights 2024 anticipated milestones and strategic priorities at the j p morgan healthcare conference,clinical_study,DOWN,-0.660070611765802,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,0,8,537,0.0,1.3105556047468256,0.03181818181818182
dallas sept 26 2024 globe newswire taysha gene therapies inc nasdaq tsha taysha or the company a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that it will present previously disclosed clinical data on its tsha 102 program in evaluation for rett syndrome during an oral presentation at the upcoming 9th world rett syndrome congress taking place in queensland australia from october 2 5 2024,taysha gene therapies announces oral presentation on tsha 102 in rett syndrome at upcoming 9th world rett syndrome congress,clinical_study,UP,0.9950239314132612,627384320.0,136885482.0,5054745.0,1.016,2606600.0,0.21818441684994613,0.09346626282280733,3,8,275,-0.05555555555555555,1.0149166236087122,0.00876281613123719
27 sep 2024 11 44 cest bergen carbon solutions as bergen 27 september 2024 bergen carbon solutions as bcs ose bcs reference is made to the stock exchange announcement dated 29 march 2023 regarding a mou with the korean chemical company tkg huchems and the stock exchange announcement dated 19 september 2023 regarding the extension of the mou as of today bergen carbon solutions has extended this mou with tkg huchems for the second time with one more year the mou will remain in effect until 25 september 2025 under the same terms as the original mou from march 2023 the intent of the mou is to develop carbon nano tubes cnt utilizing technology from bergen carbon solutions targeting battery cell manufacturers in the asian region odd strømsnes ceo of bergen carbon solutions comments this second extension of our partnership demonstrates the long term commitment and confidence that we have developed with our partner in south korea our relationship mov,bcs extension of tkg huchems mou,partnerships,UP,8.80000114440918,64409448448.0,13292123540.0,12481905.0,1.06,13712800.0,0.2063691563937424,0.1515999603296736,4,9,273,0.08425925925925926,0.3600217284985099,0.0
longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society mtg,longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society chss 51st annual meeting,clinical_study,DOWN,-0.5434777327093245,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,9,262,0.17500000000000002,1.063123411629147,0.09264069264069263
eight abstracts highlighting new data from vir s chronic hepatitis b and chronic hepatitis delta programs have been accepted for presentation at aasld,vir biotechnology announces multiple abstracts highlighting new chronic hepatitis b and hepatitis delta data accepted for presentation at aasld s the liver meeting 2023,clinical_study,DOWN,-0.9009000301245093,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,2,8,626,0.0909090909090909,0.8653389999075153,0.06285511363636363
woburn mass may 15 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today announced that company has received a final delisting notice from nasdaq the delisting is a result of failure to regain compliance with the minimum stockholders equity requirement for continued listing on the nasdaq capital market set forth in nasdaq listing rule 5550 b 1 requiring companies listed on the nasdaq capital market to maintain stockholder s equity of at least 2 500 000 suspension of trading in the company s common stock on the nasdaq exchange will be effective at the open of trading on may 16 2024,yield10 bioscience announces delisting from nasdaq,delisting_notice,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,409,-0.05277777777777779,0.8866002429130597,0.041941964285714284
san diego feb 01 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee damien bresson who is joining oncternal as senior director preclinical and translation science,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,DOWN,-2.661209996927158,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,513,0.13636363636363635,0.8866002429130597,-0.1216329966329966
san mateo calif and cambridge mass may 21 2024 globe newswire kronos bio inc nasdaq kron a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription today announced that it has appointed deborah knobelman ph d as chief operating officer and chief financial officer effective june 3 2024 dr knobelman will oversee the finance accounting business development investor relations and corporate strategy functions,kronos bio appoints deborah knobelman ph d as chief operating officer and chief financial officer,management_changes,UP,0.0,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,1,8,403,0.0375,0.6178272804340184,0.0369023569023569
attributes revenue growth to adding strategic capacity key integration initiatives optimization of infrastructure and right sizing its global footprint attributes revenue growth to adding strategic capacity key integration initiatives optimization of infrastructure and right sizing its global footprint,inotiv ranked number 127 fastest growing company in north america on the 2023 deloitte technology fast 500,contests_awards,UP,6.25000084665689,62498416.0,31206932.0,922240.0,4.102,583600.0,0.4993235668564784,0.09346626282280733,2,7,598,0.11020408163265305,1.3015467599292592,0.0
rockville md july 31 2024 globe newswire theriva biologics inc nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the u s food and drug administration fda granted rare pediatric drug designation rpdd for vcn 01 for the treatment of retinoblastoma vcn 01 theriva s lead product candidate is a systemic selective stroma degrading oncolytic adenovirus previously the fda granted orphan drug designation to vcn 01 for treatment of retinoblastoma,theriva biologics receives rare pediatric drug designation by the u s fda for vcn 01 for the treatment of retinoblastoma,product_services_announcement,DOWN,-7.103823312288768,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,8,332,0.0988888888888889,1.5225134880447404,0.049659320477502294
media release,cenergy holdings fait état de l avancement de son programme de rachat d actions propres,changes_in_companys_own_shares,UP,2.441860800372244,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
the board of directors of senzime ab publ senzime or the company has today resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of sek 6 20 per share hereinafter the share issue the subscription price corresponds to the volume weighted average price vwap of the share during the latest 5 trading days the persons entitled to subscribe for the share issue include a few existing shareholders with a long term engagement for the company such as the crafoord family segulah medical acceleration fjärde ap fonden carnegie fonder swedbank robur fonder fredrik rapp and professor sorin j brull as well as a number of new swedish and international institutional investors for example ab strati binding subscription forms or subscription undertakings have been entered into for the entire share issue through the share issue senzime will raise a total of approximately 86 msek before transaction costs about the share issuethe share i,senzime carries out a directed share issue of 86 million sek,shares_issue,DOWN,-0.143681448664164,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,-0.014876033057851245,0.8866002429130597,0.0
endomines finland plc inside information 2 10 2024 at 14 00 eest inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly pampalo s gold production increased by 21 4 percent in july september compared to the corresponding period in 2023 in january september 2024 gold production has increased by 9 9 percent compared to the corresponding period in 2023 published production volumes are based on preliminary data the final figures may change slightly after final specifications have been received for all deliveries to customers however the change in the figures reported here is not expected to be significant the company s full year 2024 production is expected to increase in line with guidance by 15 compared to the previous year in terms of production volumes the quarter was clearly the best since the start of 2022 the growth of our production continued according to the plan towards the annual pr,inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly,earnings_releases_and_operating_results,DOWN,-0.240969365109148,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.21845238095238093,0.8866002429130597,0.0
media release,as tallinna vesi will hold an investor conference webinar to introduce the results for the 3rd quarter of 2024,conference_call_webinar,UP,0.4926127351136131,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,245,0.0,0.8866002429130597,0.11818181818181818
presentation details efficacy and tolerability results from the successful phase 3 program that led to fda approval of clobetasol propionate suspension 0 for pain and inflammation following ocular surgery presentation details efficacy and tolerability results from the successful phase 3 program that led to fda approval of clobetasol propionate suspension 0 for pain and inflammation following ocular surgery,eyenovia announces presentation of phase 3 clobetasol study results at the american academy of ophthalmology aao 2024 expo,clinical_study,UP,2.2222267845531776,27709572.0,2433609.0,8930490.0,1.002,41800300.0,0.08782557161113856,0.09346626282280733,2,7,255,0.3,2.4441832149286684,-0.0015896063812730404
biocardia to host 2023 financial results and corporate update conference call on march 27 2024,biocardia to host 2023 financial results and corporate update conference call on march 27 2024,conference_call_webinar,UP,5.263161417079773,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,2,7,465,0.0,1.32107885633281,-0.19404761904761902
pratteln schweiz 31 juli 2024 santhera pharmaceuticals six sann gibt bekannt dass der verwaltungsrat dr oliver p kronenberg per 1 august 2024 zum chief legal officer und corporate secretary der santhera pharmaceuticals ag ernannt hat,santhera ernennt dr oliver p kronenberg zum chief legal officer und company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.13333333333333333,0.5209522992128177,0.03714285714285715
media release,valmet s interim review january 1 september 30 2024 record high third quarter margin but slower market activity than expected,earnings_releases_and_operating_results,DOWN,-0.0830583796804002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,240,0.02,0.8866002429130597,-0.016941094619666055
certara shared the results from its collaboration with ichnos glenmark innovation igi on the first in human dose prediction and selection for isb 2001,certara ichnos glenmark innovation collaboration optimizes dosing strategy for potential first in class cancer drug,clinical_study,DOWN,-0.8310263455393667,1746449024.0,121837605.0,1806725.0,1.448,1507200.0,0.06976304680279062,0.09346626282280733,2,8,283,0.125,0.5462989777603723,0.07363636363636364
gabab pam selection of drug candidates under indivior collaboration expected by end of q2 2024,addex therapeutics reports q1 2024 financial results and provides corporate update,financial_results,UP,4.449394687301958,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,3,1,387,-0.03333333333333333,0.972373032385036,-0.005666666666666663
information on the total number of voting rights denominator following conversion notice from atlas,information on the total number of voting rights denominator following conversion notice from atlas,share_capital_increase,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,4,12,343,0.0,2.0692591020840054,0.16437074829931975
malvern pa jan 24 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases has announced a postponement in the phase iii study data release for buntanetap in parkinson s disease this adjustment is due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results,annovis bio refines timeline for parkinson s phase iii study data announcement,clinical_study,DOWN,-7.103823312288768,44136244.0,15624645.0,595065.0,1.618,805900.0,0.35400939418406335,0.09346626282280733,2,8,521,-0.125,1.368989555493872,0.07146464646464647
rätt att delta och anmälan aktieägare som önskar delta i årsstämman skall dels vara införd i den av euroclear sweden ab förda aktieboken senast den 28 oktober 2024 dels till duroc anmäla sin avsikt att delta senast den 30 oktober 2024 varvid antalet eventuella biträden skall uppges anmälan om deltagande skall ske per brev till duroc ab box 5277 10246 stockholm eller via e post till info durocgroup com vid anmälan uppges namn person eller organisationsnummer adress telefonnummer samt eventuella biträden sker deltagande med stöd av fullmakt bör denna insändas före årsstämman fullmaktsformulär finns på www duroc com aktieägare som låtit förvaltarregistrera sina aktier måste för att äga rätt att delta på årsstämman och utöva sin rösträtt begära att tillfälligt registreras i den av euroclear sweden ab förda aktieboken sådan omregistrering måste vara verkställd senast på avstämningsdagen den 28 oktober 2024 förslag till dagordning 1 stämmans öppnande och val av,kallelse till årsstämma i duroc ab publ 2024,annual_general_meeting,UP,1.5075434681407116,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,9,274,0.0,0.8866002429130597,0.0
san diego may 01 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee anne c hansen who is joining oncternal as senior director clinical data management,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,DOWN,-2.406747928283236,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,423,0.13636363636363635,0.8866002429130597,-0.04194725028058362
new york may 13 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by rare epilepsies and brain conditions today announced that management will participate in a fireside chat at the h c wainwright 2nd annual bioconnect investor conference on monday may 20 2024 at 3 00 p m et,ovid therapeutics to present at the h c wainwright 2nd annual bioconnect investor conference,conference_call_webinar,UP,0.0,22051056.0,50354780.0,1012130.0,0.065,720700.0,2.283554130015361,0.09346626282280733,0,7,411,0.15606060606060604,0.7642184815786688,0.159305426716141
media release,glaston makes a change to the executive leadership team,management_changes,DOWN,-1.639344147877593,56298360.0,15339800.0,14584.2,0.607,41169.0,0.2724733011760911,0.1515999603296736,3,15,239,0.0,0.2342753450337208,0.0
san diego aug 07 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis today announced its participation in the 2024 wedbush pacgrow healthcare conference being held august 13 14 2024 in new york city company management will participate in one on one meetings with investors on wednesday august 14 2024,ars pharmaceuticals to participate in the 2024 wedbush pacgrow healthcare conference,conference_call_webinar,DOWN,-1.0224890646804758,1693693568.0,51755600.0,1240295.0,0.872,1940800.0,0.030557829927355548,0.09346626282280733,2,9,325,0.3181818181818182,0.6899910717831225,0.25080492424242423
transcode therapeutics announces safety review committee approval of second cohort opening in phase 1 ttx mc138 clinical trial following favorable review o,transcode therapeutics announces safety review committee approval of second cohort opening in phase 1 ttx mc138 clinical trial following favorable review of cohort 1 safety data,clinical_study,UP,3.278685320900652,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,2,7,248,0.0,2.0874185587937095,0.020670995670995666
south san francisco calif oct 21 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced an upcoming oral presentation and two late breaking poster presentations at the 75th annual american association for the study of liver diseases aasld the liver meeting 2024 taking place from november 15 19 2024 in san diego the presentations will highlight findings from the 96 week phase 2b harmony study evaluating the efficacy and safety of lead product candidate efruxifermin efx in patients with pre cirrhotic metabolic dysfunction associated steatohepatitis mash fibrosis stage 2 or 3 f2 f3 along with insights from an analysis using ai and digital based pathology,akero therapeutics to present data reinforcing the efficacy of efruxifermin at the 75th annual aasld the liver meeting 2024,clinical_study,DOWN,-0.8965699116267896,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,0,7,250,-0.04666666666666666,1.1395320392459187,-0.015071087862754526
boston feb 20 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda has granted fast track designation to pgn edodm1 an investigational candidate for the treatment of myotonic dystrophy type 1 dm1 receiving fast track designation from the fda for pgn edodm1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the dm1 community said james mcarthur ph d president and ceo of pepgen patients with dm1 currently have no available treatment options that target the root cause of the disease which leads to progressive neuromuscular symptoms and reduction in life expectancy following robust preclinical data we are now evaluating pgn edodm1 in the ongoing freedom dm1 phase 1 trial and expect to report preliminary data later this year we believe that pgn edodm1 has the potential to be disease modifying and improve outcomes for patients living with dm1,pepgen receives u s fda fast track designation for pgn edodm1 for the treatment of myotonic dystrophy type 1,clinical_study,DOWN,-1.079917699762323,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,1,8,494,0.07045454545454546,1.4553932872573117,0.04170935545935545
electrocore granted two new u s patents electrocore granted two new u s patents,electrocore expands intellectual property portfolio,patents,DOWN,-1.6339854003679126,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,1,8,452,0.19090909090909092,0.8324549917316175,0.0
mainz biomed partners with trusted health advisors to support u s go to market strategy for next generation early colorectal cancer diagnostic,mainz biomed partners with trusted health advisors to support u s go to market strategy for next generation early colorectal cancer diagnostic,partnerships,UP,3.3707900535517603,5569681.0,2706585.0,75055.0,0.305,78500.0,0.48594973392551566,0.09346626282280733,1,8,480,0.05,34.079934680222834,0.0
study to enroll 15 acute stroke patients across three u s sites study to enroll 15 acute stroke patients across three u s sites,inspiremd announces strategic agreement with jacobs institute to execute early feasibility study of cguard eps for the treatment of acute stroke patients with tandem lesions,clinical_study,UP,2.56411040166298,67688696.0,16849440.0,286250.0,0.613,4867100.0,0.2489254631231188,0.09346626282280733,0,7,579,0.475,0.6085732039686736,0.031060606060606063
palo alto calif july 17 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that that it has entered into a memorandum of understanding mou for collaboration agreement with acea a china based company focused on the development of innovative treatments for high unmet needs under the terms of the mou acea may receive exclusive rights to develop and commercialize of ztlido in mainland china taiwan hong kong macau including the current formulation and a right of first negotiation for a future next generation formulation of a 3x version of ztlido sp 103 the mou provides scilex with the opportunity to expand collaboration with acea across other products in scilex s non opioid pain management portfolio in the greater china region,scilex holding company announces collaboration to leverage acea therapeutics r d expertise and local market connections to support the expansion of ztlido program in ex us and potentially provide additional access to patients in certain key markets in far east region,partnerships,DOWN,-3.061227592911475,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,9,346,0.1865625,1.0327724261931344,0.27254419191919194
the following resolutions have been adopted at the extraordinary general meeting of shareholders of panevezio statybos trestas ab held on 25 september 2024 1 revocation of the resolution on election of the new member to the board of panevezio statybos trestas ab adopted at the general meeting of shareholders on 30 april 2024 to revoke the resolution on election of the new member to the board of panevezio statybos trestas ab adopted at the general meeting of shareholders on 30 april 2024 the ground for revocation of the resolution the data of the board member have not been registered with the registre of legal entities by the term established by the law 2 election of the member to the board of panevezio statybos trestas ab to elect gintautas mazeika born in 1967 as the member to the board of panevezio statybos trestas ab education finance and business administration emba participation in activities of other companies pro bro group uab svaros broliai uab an ind,resolutions of extraordinary general meeting of shareholders,management_changes,DOWN,-0.2079037244971741,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,9,275,0.16786616161616164,0.8866002429130597,0.0
27 sep 2024 08 50 cest ses interim dividend of eur 0 25 per a share approved as part of eur 450 million of cash returns in 2024 highlighting ses s continued commitment to shareholder returns the ses board of directors has approved the payment of an interim dividend of eur 0 25 per a share eur 0 1 per b share to be paid to shareholders on 17 october 2024 in line with the announcement made in february 2024 and ses s commitment to shareholder returns the implementation of a semi annual dividend distribution brings greater alignment between the cash generation of the business and cash returns to shareholders the interim dividend to be paid next month will be followed subject to shareholder approval by the payment of a final dividend of at least eur 0 25 per a share eur 0 1 per b share in april 2025 including the ongoing share buyback programme ses is returning eur 450 million to shareholders in 2024 and more than eur 1 billion since the beginning of 2021 e,ses confirms interim dividend of eur 0 25,dividend_reports_and_estimates,DOWN,-5.282339263977126,33236662.0,5203991.0,38994.47368421053,-1.546,15503.0,0.15657381598669565,0.19535099655549074,4,6,274,0.0888888888888889,2.144966214298392,0.0
san carlos calif march 04 2024 globe newswire iovance biotherapeutics inc nasdaq iova a commercial biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer today announced that the u s food and drug administration fda lifted a partial clinical hold placed on the registrational iov lun 202 trial investigating ln 145 til cell therapy in non small cell lung cancer nsclc in collaboration with the fda and an independent data monitoring committee iovance developed additional safety measures and monitoring upon reviewing this proposal the fda has cleared iovance to resume patient enrollment in iov lun 202,iovance biotherapeutics announces fda has lifted clinical hold on the iov lun 202 registrational trial in non small cell lung cancer,clinical_study,UP,7.802259645685303,596072192.0,280347936.0,11775260.0,0.863,9708200.0,0.4703254735963257,0.09346626282280733,0,6,481,-0.08333333333333333,0.901765204231867,0.10454545454545454
lawrenceville n j april 11 2024 globe newswire imunon inc nasdaq imnn imunon or the company a clinical stage drug development company focused on developing dna mediated immuno oncology therapies and next generation vaccines today announced that on april 10 2024 it received written notice from the staff of the nasdaq stock market llc nasdaq informing the company that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550 a 2 the minimum bid price requirement for continued listing on the nasdaq capital market accordingly imunon complies with all applicable listing standards and its common stock will maintain its listing on the nasdaq capital market under the symbol imnn,imunon reports compliance with nasdaq listing requirements,exchange_announcement,UP,2.758617968111434,17679998.0,12808492.0,12655315.0,2.143,945100.0,0.7244622991473189,0.09346626282280733,3,8,443,-0.15,2.964855117372811,0.031818181818181815
to approve the remuneration policy of the management board and the supervisory council riga october 1 2024 the management board joint stock company amber latvijas balzams,resolutions of joint stock company amber latvijas balzams extraordinary general meeting of shareholders of october 1 2024,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,13,269,0.19166666666666665,0.8866002429130597,0.21749999999999997
recently initiated serenity at home pivotal phase 3 trial for agitation associated with bipolar disorders or schizophrenia,bioxcel therapeutics announces clinical prioritization and update on bxcl501 late stage programs for agitation,clinical_study,DOWN,-0.941921779059158,11996430.0,5544250.0,450810.0,-0.13,78500.0,0.4621583254351503,0.09346626282280733,3,7,282,0.06666666666666667,1.4586588351104455,0.05906375787954736
mainz biomed presented industry leading results of its pooled study at asco 2024,mainz biomed presented industry leading results of its pooled study at asco 2024,clinical_study,UP,2.416567045518537,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,0,8,390,0.0,34.079934680222834,0.04801136363636363
norwood mass may 01 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a panel discussion as part of the btig obesity health forum to be held virtually on may 8 2024,corbus pharmaceuticals to participate in the btig obesity health forum,conference_call_webinar,DOWN,-0.7289429025107999,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,2,8,423,0.0,0.9919200800994142,0.04792121212121213
redwood city calif april 23 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that a poster titled an analysis of overnight hypoglycemia in patients with congenital hyperinsulinism results from the rz358 606 rize study will be presented at the pediatric endocrine society pes annual meeting to be held may 2 5 2024 at the sheraton grand chicago riverwalk,phase 2 rize study sub analyses to be presented at the 2024 pediatric endocrine society annual meeting,clinical_study,UP,3.107348437846431,376775840.0,77797779.0,825115.0,1.04,796000.0,0.20648292894788584,0.09346626282280733,1,8,431,0.15555555555555556,0.6820409900648857,0.033586309523809525
we hereby inform that by the decision of the board of ab kn energies hereinafter the company darius šilenskis has been elected as the company s chief executive officer this will mark his second term of office as the company s chief executive officer commencing on november 12 2024 the press release is available here https www kn lt en news news darius silenskis re elected as ceo of kn energies for another term 8676 head of communication milda ancevčė m ancevice kn lt,the chief executive officer of ab kn energies has been elected,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,259,0.2,0.8866002429130597,0.06444444444444446
san diego oct 22 2024 globe newswire oncternal therapeutics inc nasdaq onct the company today announced updated data from its phase 1 2 study of onct 534 for the treatment of patients with relapsed or refractory metastatic castration resistant prostate cancer mcrpc,oncternal therapeutics announces updated safety and efficacy data for phase 1 2 study of onct 534 for the treatment of r r metastatic castration resistant prostate cancer,clinical_study,DOWN,-5.741621554409346,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,249,0.0,0.8866002429130597,0.020242905242905243
amsterdam sept 13 2024 globe newswire nasdaq renb renovarocube cube the company a leading ai driven innovator using multi omics technology for cancer profiling is pleased to announce two scientific presentations at a leading cancer conference the european society for medical oncology esmo congress on september 15 2024,renovarocube to present cutting edge cancer diagnostics research at european society for medical oncology congress,conference_call_webinar,DOWN,-2.0933996157467987,60224444.0,90925076.0,7542515.0,0.529,816400.0,1.50977028530143,0.09346626282280733,4,9,288,-0.014285714285714282,1.5631250973582267,0.07979998396665063
effective immediately clinical sites in the vista 101 phase 1 phase 2 clinical trial can resume screening of patients for enrollment in the clinical study,kineta reopens enrollment for the vista 101 clinical trial evaluating kva12123 in patients with advanced solid tumor cancer,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,9,313,0.3333333333333333,0.8866002429130597,0.09442432567432568
san francisco june 29 2023 globe newswire vir biotechnology inc nasdaq vir today announced the appointment of sasha damouni ellis as executive vice president and chief corporate affairs officer effective july 10 2023 ms damouni ellis will be responsible for the company s strategic approach to corporate communications government affairs investor relations and patient advocacy as well as for establishing vir s corporate social responsibility and environmental social and governance efforts she will report to vir s chief executive officer marianne de backer m sc ph d mba and will join the company s executive management team,vir biotechnology appoints sasha damouni ellis as executive vice president and chief corporate affairs officer,management_changes,DOWN,-0.3617292937098507,707764736.0,93935488.0,1328370.0,1.229,971400.0,0.13272134541611297,0.09346626282280733,3,9,730,0.10833333333333334,0.8653389999075153,0.08615702479338842
sydney australia oct 29 2024 globe newswire immutep limited asx imm nasdaq immp immutep or the company a clinical stage biotechnology company developing novel lag 3 immunotherapies for cancer and autoimmune disease provides an update on its activities for the quarter ended 30 september 2024 q1 fy25,immutep quarterly activities report q1 fy25,clinical_study,UP,0.0,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,1,8,242,-0.07142857142857142,0.7476881311953882,0.08369856334142048
anx007 demonstrated significant broad based protection from vision loss in foveal and non foveal patients and in low light settings,annexon presents new neuroprotection data showing anx007 protects vision and vision associated structures in geographic atrophy at arvo 2024 annual meeting,clinical_study,DOWN,-3.469389244597508,262216464.0,82380157.0,1425435.0,1.259,925100.0,0.31416851460555123,0.09346626282280733,1,12,416,0.19477272727272726,0.7558344054121836,0.0
26 sep 2024 15 02 cest brie picardie crcam rapport financier semestriel 2024 la caisse régionale de crédit agricole mutuel brie picardie compte au 30 juin 2024 206 agences de proximité 1 agence gestion de la relation à distance 2 agences crédit agricole en ligne 3 agences courtiers 1 agence habitat à distance 3 agences banque privée 5 centres d affaires entreprises 3 agences collectivités publiques 3 centres d affaires professionnels de l immobilier 2 pôles institutionnels et associations 3 équipes de conseillers mobiles assurances agriculteurs et professionnels 1 plateforme front office assurances agriculteurs et professionnels 1 plateforme allocation d actifs et gestion conseillée 1 banque d affaires 1 agence evènements de la vie 85 caisses locales 18 administrateurs de la caisse régionale 859 administrateurs de caisses locales plus de 433 000 sociétaires plus de 1 1 million de clients pièce jointe rapport financier semestriel 2024 rapport,crédit agricole brie picardie rapport financier semestriel 2024,financial_results,DOWN,-0.474321679287626,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
media release,circio holding asa registration of share capital increase following conversion of convertible bonds,share_capital_increase,DOWN,-7.103823312288768,112574064.0,35018869.0,1395416.9473684211,0.8755,515815.0,0.25000035609542787,0.1515999603296736,3,10,239,0.0,3.1777118544203193,0.0
south san francisco calif aug 30 2024 globe newswire vaxart inc nasdaq vxrt the company or vaxart today announced that on august 26 2024 the compensation committee of the board of directors granted inducement equity awards covering an aggregate of 32 250 shares of its common stock to two new non executive employees to induce them to accept employment with vaxart,vaxart inc reports inducement grants under nasdaq listing rule 5635 c 4,corporate_action,UP,0.0,120729968.0,226926647.0,9325470.0,1.148,2676900.0,1.8796215286000904,0.09346626282280733,4,8,302,-0.08181818181818182,1.025768835125998,0.06147787397787398
tampa fla april 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its first quarter financial results after the close of the u s markets on tuesday may 7 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report first quarter 2024 financial results on tuesday may 7 2024,earnings_releases_and_operating_results,DOWN,-0.7293613522977731,1111081344.0,45834212.0,557500.0,0.511,435200.0,0.04125189595479339,0.09346626282280733,1,8,424,0.10606060606060606,0.7130794063724827,0.188501443001443
mainz germany september 05 2024 biontech se nasdaq bntx biontech or the company will present clinical trial data for selected assets from its multi platform oncology pipeline at the european society for molecular oncology esmo congress 2024 in barcelona spain from september 13 17 2024 the oral and poster presentations will feature programs across biontech s clinical pipeline including mrna based cancer vaccines next generation immunomodulators and targeted therapy approaches,biontech to present clinical data updates across mrna and immunomodulatory oncology portfolio at esmo congress 2024,clinical_study,DOWN,-0.2022021028573034,24755877888.0,97284490.0,1237590.0,1.285,391100.0,0.003929753185895178,0.09346626282280733,3,7,296,0.0,0.5503225880253886,0.1615430094596761
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
yield10 bioscience files rsr with usda aphis for elite camelina designed to produce epa dha omega 3 oils,yield10 bioscience files request for regulatory status review with usda aphis for camelina designed to produce the epa and dha components of omega 3 oil,regulatory_filings,DOWN,-4.166670805877945,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,537,0.0,0.8866002429130597,0.10385714285714287
fiscal year 2023 strategic transformation of the group,eurobio scientific fiscal year 2023 strategic transformation of the group,earnings_releases_and_operating_results,UP,0.8974319629808093,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,11,514,0.0,0.4336088389568585,0.0
media release,insider information positive profit warning pihlajalinna upgrades its profitability guidance for 2024 and provides preliminary information on revenue and profitability for the third quarter of 2024,earnings_releases_and_operating_results,UP,5.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.11363636363636363,0.8866002429130597,0.0
berwyn pa dec 11 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced its founder president and ceo was selected to participate in the 139th yale ceo summit in new york on december 11 12 2023,annovis bio to participate in the 139th yale ceo summit,press_releases,DOWN,-7.103823312288768,43843952.0,15624645.0,595065.0,1.618,805900.0,0.35636944862999576,0.09346626282280733,0,13,564,0.06818181818181818,1.368989555493872,0.0731060606060606
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
media release,seb emitterar primärkapitaltillskott,financing_agreements,UP,0.1967233126280737,324812570624.0,1517564746.0,3596234.789473684,0.496,4637069.0,0.004672124428819348,0.1515999603296736,1,8,242,0.0,0.2367499341217176,0.0
communiqué de presse information réglementée18 decembre 2023 01 00 et 07 00 cet,mdxhealth annonce la réalisation de sa transition vers une cotation unique sur le nasdaq,exchange_announcement,DOWN,-1.5337408730844513,110873952.0,35018869.0,71620.0,-490677.56,106500.0,0.3158439684733164,0.09346626282280733,0,1,558,0.375,0.6181119561491973,0.1517857142857143
san diego dec 26 2023 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today updated the status of its dose escalation dose expansion phase 1 2 study onct 808 101 evaluating the company s ror1 targeting autologous car t cell therapy onct 808 for the treatment of patients with relapsed or refractory aggressive b cell lymphoma including patients who have failed previous cd19 car t treatment,oncternal therapeutics updates the status of its phase 1 2 study of onct 808 a ror1 targeting autologous car t in patients with relapsed or refractory aggressive b cell lymphoma,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,550,-0.3333333333333333,0.8866002429130597,0.0
fda assigns prescription drug user fee act pdufa target action date of march 6 2025 fda assigns prescription drug user fee act pdufa target action date of march 6 2025,scpharmaceuticals announces filing acceptance of supplemental new drug application snda seeking to expand furoscix indication to include chronic kidney disease,regulatory_filings,DOWN,-0.8264454667762735,207472560.0,31628202.0,294455.0,0.361,185600.0,0.15244522938358693,0.09346626282280733,3,8,338,0.11212121212121212,0.7082528246818063,0.2833333333333333
phase 3 synchrony studies actively screening and on track to begin enrolling by the end of 2023 south san francisco calif nov 13 2023 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today reported third quarter financial results for the period ending september 30 2023 and provided business updates,akero therapeutics reports third quarter 2023 financial results and provides business update,clinical_study,UP,0.4261393461776828,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,0,7,593,-0.022962962962962966,1.1395320392459187,0.0
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report first quarter 2024 financial results and provide a corporate update on thursday may 9,conference_call_webinar,DOWN,-0.4464302820210845,160853024.0,15213010.0,781395.0,1.567,974600.0,0.09457708423311954,0.09346626282280733,1,8,417,0.08333333333333333,0.8435084668920305,0.14913737717309147
02 oct 2024 08 58 cest aker horizons asa new ppa product gives businesses a better alternative for their electricity supply mainstream renewable power mainstream the pureplay global wind and solar company majority owned by aker horizons asa has reached financial close on its 50 mw ilikwa solar pv plant the power from the plant will supply multiple private commercial and industrial customers under flexible shorter term power purchase agreements ppas in a new to market product called renewable energy supply agreements resas this new product opens up the energy market in south africa by giving a wider range of businesses access to affordable reliable and renewable power through shorter term energy contracts of between five and 10 years commenting on the announcement mainstream s general manager for africa hein reyneke said we are excited to bring this new product to market offering customers the opportunity to secure flexible clean and lower cos,mainstream renewable power reaches financial close on 50 mw solar pv plant to provide new flexible ppas to private customers in south africa,product_services_announcement,DOWN,-0.6766964400073892,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.13961675579322638,0.8866002429130597,0.0
berwyn pa nov 27 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company addressing neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd and developing novel and transformative therapies announced that ad phase ii iii study of its lead compound buntanetap has exceeded full enrollment,annovis bio announces full enrollment of its phase ii iii alzheimer s disease trial exceeding original projections,clinical_study,UP,4.615387549767128,44107012.0,15624645.0,595065.0,1.618,805900.0,0.354244014534469,0.09346626282280733,0,7,579,0.26875,1.368989555493872,0.05662878787878787
25 sep 2024 08 00 cest riber 2024 first half earnings solid half year revenues growth gross margin up by and operating income at breakevennet profit of 0 2m despite the lower seasonal revenues strong increase in order book at june 30 2024 reaching 36 0m outlook confirmed revenues exceeding 40m with growth in earnings expected for the full year bezons september 25 2024 8 00am riber a global market leader for semiconductor industry equipment is releasing its earnings for the first half of 2024 m h1 2024h1 2023changerevenuessystems revenuesservices and accessories revenues13 79 44 312 28 53 6 13 10 19 gross margin of revenues4 834 8 3 932 3 21 2 5 ptsoperating income of revenues 0 0 0 2 1 1 9 3 97 9 1 ptsnet income of revenues0 21 2 1 2 10 2 113 11 4 pts key developments in the first half of 2024 despite an uncertain macroeconomic environment riber achieved solid business growth this performance reflects it,riber 2024 first half earnings,earnings_releases_and_operating_results,DOWN,-0.7782093947869452,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,6,276,0.06578947368421052,0.4818751066598002,0.0
media release,scana selskap forlenger rammekontrakt med et internasjonalt riggselskap for subsea tjenester,business_contracts,UP,0.653594160147165,706685568.0,252199232.0,373200.75,0.233,169690.0,0.35687616023311797,0.1515999603296736,1,15,241,0.0,0.4567925069648355,0.0
media release,court approved ab utenos trikotazas submitted restructuring plan court decision came into force,clinical_study,UP,1.626013453082938,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.12604166666666666
positive phase 2b data announced for bnc210 on reduction of total symptom severity and multiple symptom clusters in post traumatic stress disorder ptsd with a discussion with the u s food drug administration fda anticipated in q2 24,bionomics provides a review of 2023 and of 2024 plans,clinical_study,DOWN,-4.761907645273734,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,523,0.07575757575757576,0.8866002429130597,0.03799212968368812
16 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 15 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 4129 25 5457estimated mtd return 0 19 0 21 estimated ytd return 3 14 3 97 estimated itd return 184 13 155 46 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 3 56 n a sterling sharesamsterdam aex london lse market closen agbx 2 380 00premium discount to estimated navn a 6 83 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,255,-0.006122448979591831,0.8866002429130597,-0.006122448979591832
certara has appointed rona anhalt as chief human resources officer and daniel corcoran as general counsel,certara appoints new chief human resources officer general counsel,management_changes,UP,0.1222405236487904,1746449024.0,121837605.0,1806725.0,1.448,1507200.0,0.06976304680279062,0.09346626282280733,1,8,403,0.04727272727272728,0.5462989777603723,0.0
cambridge mass and menlo park calif feb 15 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies and recode therapeutics a clinical stage genetic medicines company using tissue specific delivery to power the next wave of mrna and gene correction therapeutics today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis cf cf is a genetic disease caused by mutations in the cftr gene leading to the accumulation of thick mucus in the lungs digestive systems and other organs cf can result in life threatening infections respiratory failure and other serious complications,intellia therapeutics and recode therapeutics announce strategic collaboration to develop novel gene editing therapies for cystic fibrosis,partnerships,DOWN,-1.16690210641292,976673728.0,98412511.0,6353695.0,2.134,5288300.0,0.10076293462047543,0.09346626282280733,3,7,499,-0.17142857142857143,0.7800307612939593,0.11666666666666665
company to provide a clinical update on the edit 301 ruby trial for scd and edithal trial for tdt in december at the american society of hematology ash annual meeting and in a company sponsored webinar,editas medicine announces third quarter 2023 results and business updates,clinical_study,UP,3.129442156839537,181238416.0,83382193.0,2526680.0,2.096,3015800.0,0.46006908932596274,0.09346626282280733,4,7,603,0.0,1.3105556047468256,0.0
announced today that all 3 patients response rate treated with elx 02 showed an improvement in podocyte foot process effacement post treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of elx 02,eloxx pharmaceuticals reports second quarter 2023 financial and operating results and provides business update,clinical_study,UP,5.0526267603824015,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,8,684,0.0,2.2721670857062097,0.16765016233766233
missing,valneva déclaration d actions et de droits de vote 31 juillet 2024,voting_rights,DOWN,-1.828822228271539,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,2,326,-0.2,0.6494694268312979,0.2126984126984127
communiqué de presse information réglementée27 novembre 2023 1 00 edt 7 00 cet,mdxhealth annonce la réalisation de l échange obligatoire d ads et le début de la période de transition vers une cotation unique sur le nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,0.375,0.6181119561491973,0.0
media release,totalenergies announces the third interim dividend of 0 79 share for fiscal year 2024 an increase close to compared to 2023,dividend_reports_and_estimates,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.21717997337861888,0.0
media release,quadient obtient un prêt schuldschein de 25 millions d euros auprès de la berd pour financer des programmes de r d en république tchèque,financing_agreements,DOWN,-1.960782480441495,528319008.0,22771639.0,0.0,1.149,0.0,0.04310206268406682,0.19535099655549074,2,7,241,0.0,0.39343620296100096,0.0
san diego april 03 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis announced today that it has submitted its response to the u s food and drug administration fda for its new drug application nda for neffy epinephrine nasal spray for the treatment of type i allergic reactions including anaphylaxis,ars pharmaceuticals submits response to fda complete response letter for neffy epinephrine nasal spray,regulatory_filings,UP,0.3232832705686129,1700077312.0,51755600.0,1240295.0,0.872,1940800.0,0.03044308610830988,0.09346626282280733,2,9,451,0.24545454545454545,0.6899910717831225,0.2952272727272728
boston feb 20 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda has granted fast track designation to pgn edodm1 an investigational candidate for the treatment of myotonic dystrophy type 1 dm1 receiving fast track designation from the fda for pgn edodm1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the dm1 community said james mcarthur ph d president and ceo of pepgen patients with dm1 currently have no available treatment options that target the root cause of the disease which leads to progressive neuromuscular symptoms and reduction in life expectancy following robust preclinical data we are now evaluating pgn edodm1 in the ongoing freedom dm1 phase 1 trial and expect to report preliminary data later this year we believe that pgn edodm1 has the potential to be disease modifying and improve outcomes for patients living with dm1,pepgen receives u s fda fast track designation for pgn edodm1 for the treatment of myotonic dystrophy type 1,clinical_study,DOWN,-1.079917699762323,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,1,8,494,0.07045454545454546,1.4553932872573117,0.04170935545935545
enrollment in beacon and spotlight studies progressing faster than expected enrollment in the 240mg single dose cohort of the beacon study ongoing,jasper therapeutics reports second quarter 2024 financial results and recent corporate developments,clinical_study,UP,2.146682726155015,81269560.0,9908441.0,280900.0,2.725,505700.0,0.12192069207708274,0.09346626282280733,1,7,319,-0.02857142857142857,0.9821837329226573,0.14404425204425206
the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk,cidara therapeutics announces first subjects dosed in phase 2b navigate trial evaluating cd388 for the prevention of seasonal influenza,clinical_study,DOWN,-0.7985816231790068,629035328.0,4118697.0,696580.0,0.795,3470400.0,0.006547640198675773,0.09346626282280733,0,8,278,0.25,1.357695941787151,-0.02205339105339105
the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock,windtree announces publication of positive istaroxime phase 2b study trial design,clinical_study,DOWN,-7.103823312288768,1379940.0,3660923.0,6680965.0,0.764,1224200.0,2.65295809962752,0.09346626282280733,2,8,262,0.13168044077134985,2.339794177443606,0.04827501202501203
new haven conn may 21 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that rob risinger m d chief medical officer of neuroscience will deliver oral and poster presentations at the 2024 american society of clinical psychopharmacology ascp annual meeting the meeting will take place may 28 to 31 2024 in miami beach fl,bioxcel therapeutics announces oral and poster presentations at the 2024 american society of clinical psychopharmacology ascp annual meeting,clinical_study,UP,0.0,12051540.0,5544250.0,450810.0,-0.13,78500.0,0.4600449403146818,0.09346626282280733,1,7,403,-0.09272727272727273,1.4586588351104455,0.049654663518299884
company announcementfor rockwool a srelease no 55 2024to nasdaq copenhagen 2 october 2024 rockwool a s transactions in connection with share buy back programme as mentioned in announcement no 02 2024 rockwool a s has initiated a share buy back programme which will run from 8 february 2024 until 7 february 2025 during this period the company will buy own shares for up to a maximum of 160 meur the programme is implemented in accordance with eu commission regulation no 596 2014 of 16 april 2014 and eu commission delegated regulation no 2016 1052 of 8 march 2016 which together constitute the safe harbour regulation the following transactions have been executed during the period 25 september 1 october 2024 with the transactions stated above rockwool a s owns 375 483 b shares corresponding to 1 74 percent of the company s total share capital an overview showing the transaction data for the period 25 september 1 october 2024 is enclosed further information,rockwool a s transactions in connection with share buy back programme,changes_in_companys_own_shares,DOWN,-1.8770226537216828,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.12222222222222223,0.8866002429130597,0.0
metsä board corporation stock exchange release changes board management auditors 4 october 2024 at 9 00 a m eest laura remes m sc technology has been appointed svp business development and a member of the corporate management team at metsä board remes joins metsä board from upm where she has worked in various business development and management positions she will start in her position at a time to be specified later and will report to ceo mika joukio markku leskelä responsible for metsä board s development will be responsible for product development and sustainability when remes starts in her new position metsä board s corporate management team consists of ceo mika joukio cfo henri sederholm svp product development and sustainability markku leskelä svp sales and supply chain jussi noponen svp production and technology harri pihlajaniemi svp business development laura remes from a time to be specified later and svp human resources camilla wikström metsä boar,laura remes has been appointed svp business development and a member of the corporate management team at metsä board,management_changes,UP,0.0798664124754002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,0.053636363636363635,0.8866002429130597,0.0
the management board of rokiškio sūris ab in accordance with the decision of the general extraordinary meeting of shareholders of rokiškio sūris ab held on 27 june 2024 has decided to buy back up to 3 228 117 three million two hundred and twenty eight thousand one hundred and seventeen units of the company s shares rokiškio sūris ab ordinary registered shares with a nominal value of eur 0 29 this buy back of treasury shares is carried out in order to complete the implementation of the decision of the strategic investor fonterra to withdraw from the capital of rokiškio sūris ab the company will buy back its own shares at a price of eur 2 20 per share company s announcement on fonterra s withdrawal from the capital of rokiškio sūris ab strategic investor fonterra decided to withdraw from the share capital of ab rokiškio sūris the company shall ensure that all shareholders have an equal opportunity to transfer their shares in the company put orders are accumulated over the lifeti,on the acquisition of own shares of rokiškio sūris ab,changes_in_companys_own_shares,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,282,0.14333333333333334,0.8866002429130597,0.0
boston feb 05 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that robert connelly chief executive officer will present at the upcoming oppenheimer 34th annual healthcare life sciences conference on february 13 2024 at 12 40 pm et,elicio therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,UP,2.272725056025656,128455904.0,10299137.0,63410.0,2.164,22500.0,0.08017643937953993,0.09346626282280733,0,8,509,0.0,0.8558055682194762,0.05125300625300625
media release,digitalist group structures its financing,financing_agreements,UP,0.0,21395900.0,87201943.0,317019.45,0.324,554653.0,4.075637996064667,0.19535099655549074,0,9,243,0.0,1.2621794536906874,0.0
lexington mass sept 20 2024 globe newswire t2 biosystems inc nasdaq ttoo the company a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes today announced that it has successfully defended against an opposition filed against a key patent for its direct from whole blood detection method in the european union,t2 biosystems achieves successful defense of patent for direct from whole blood pathogen detection method in the european union,patents,UP,0.4545450112051311,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,4,9,281,0.23333333333333334,1.9596557041969667,0.08355070855070856
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions svensson sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 2 ____________________________________________ person subject to the notification requirement name klas svenssonposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80001 5 8____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 483 unit price 41 9316 eur aggregated transactions 1 volume 483 volume weighted average price 41 9316 eur____________________________________________ transactio,sampo plc managers transactions svensson,regulatory_filings,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
16 oct 2024 00 50 cest atlantic sapphire asa not for release publication or distribution directly or indirectly in canada japan australia or the united states or any other jurisdiction in which such release publication or distribution would be unlawful this announcement does not constitute an offer of any of the securities described herein reference is made to previous stock exchange announcements from atlantic sapphire asa atlantic sapphire or the company and together with its consolidated subsidiaries the group regarding the company s partially underwritten rights issue the rights issue in which the company shall issue in total 6 417 000 001 new shares the offer shares to raise gross proceeds of up to the nok equivalent of usd 64 million of which a consortium of new investors and existing shareholders jointly the underwriters agreed to underwrite subscription of offer shares for gross proceeds of the nok equivalent of usd 60 millio,atlantic sapphire asa resolution to increase the share capital for settlement of underwriting commission,shares_issue,DOWN,-7.103823312288768,595463232.0,13903269.0,52395.0,0.75,40800.0,0.0233486607616438,0.1515999603296736,2,0,255,-0.0018939393939393923,0.34682929013051456,0.026599326599326602
geneva switzerland january 9 2024 addex therapeutics six and nasdaq adxn a clinical stage pharmaceutical company pioneering allosteric modulation based drug discovery and development today announced that dr robert lütjens head of discovery biology will present at the swiss equities baader conference being held in bad ragaz switzerland january 10 12 2024,addex to present at the swiss equities baader conference,conference_call_webinar,UP,6.2420414510598325,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,1,1,536,-0.23333333333333328,0.972373032385036,0.0
communiqué de presse du 30 septembre 2024 relatif au depôt d une offre publique d achat,eb development communiqué de presse du 30 septembre 2024 relatif au depôt d une offre publique d achat visant les actions de la société eurobio scientific,tenders_offers,UP,1.6032048348648946,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,0,11,270,0.0,0.4336088389568585,-0.0037593984962406004
investor webcast moved to friday september 13 2024 investor webcast moved to friday september 13 2024,c4 therapeutics announces european society for medical oncology esmo changed the previously accepted cft1946 preliminary phase 1 abstract to a proffered paper presentation,clinical_study,UP,2.807023326372626,107220728.0,49730521.0,1021690.0,2.946,941900.0,0.46381443147821194,0.09346626282280733,2,7,318,-0.05555555555555555,0.8954742650579008,0.06831108706108706
rockville md may 16 2024 globe newswire opgen inc nasdaq opgn opgen or the company today announced that the company s board of directors has approved a 1 for 10 reverse stock split of its shares of common stock the reverse stock split the reverse stock split will become effective at 12 01 a m est on may 20 2024 and the company s common stock will open for trading on the nasdaq capital market on a post split basis under the company s existing trading symbol opgn the new cusip number for the company s common stock following the reverse stock split will be 68373l505,opgen announced 1 for 10 reverse stock split,corporate_action,DOWN,-4.328019658291313,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,408,-0.023376623376623377,1.807174583649316,0.0884378121878122
call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial,biocardia completes enrollment of cardiamp cell therapy for the treatment of chronic myocardial ischemia trial open label roll in cohort,clinical_study,DOWN,-2.6315723429754274,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,3,9,429,0.3333333333333333,1.32107885633281,-0.09702380952380951
the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases,neximmune announces research collaboration with national institute of neurological disorders and stroke ninds of the national institutes of health nih,partnerships,DOWN,-0.7692307692307693,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,996,0.0,2.2666992986423327,0.0
eurobio scientific finalise l acquisition du test génomique endopredict auprès de myriad genetics,eurobio scientific finalise l acquisition du test génomique endopredict auprès de myriad genetics,mergers_acquisitions,DOWN,-0.2036628864129181,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,4,1,330,0.0,0.4336088389568585,0.007326007326007327
renowned sericulture expert dr nirmal kumar rejoins kraig labs otcqb kblb team in asia to complete second bam 1 spider silk hybrids production cycle,kraig biocraft laboratories prepares for second bam 1 hybrid spider silk production harvest,product_services_announcement,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,327,0.03333333333333333,0.8071333009212691,0.11423796791443849
adelaide australia and cambridge mass oct 16 2023 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced the successful and favorable outcomes of an end of phase 2 meeting eop2 meeting with the u s food and drug administration fda supporting the advancement of its lead asset bnc210 for the acute treatment of social anxiety disorder sad into phase 3 registrational studies based on the recently completed phase 2 prevail dataset,bionomics announces successful end of phase 2 meeting with the fda and solidifies plans to initiate the registrational program for bnc210 in social anxiety disorder,clinical_study,UP,5.154634107374385,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,621,0.13727891156462585,0.8866002429130597,0.03660949647995103
02 oct 2024 13 04 cest bluenord asa please see attachment on www newsweb no more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site 628893_bluenord asa notification td 01 10 2024 pdf bluenord asa oslo børs newspoint bluenord asa nore asa 19 27 8 usd step c sub conv no0010379266 no0010851520 bnor oslo børs,notification of major holdings,exchange_announcement,UP,1.7653167185877467,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,268,0.10416666666666667,0.8866002429130597,0.0
adelaide australia and cambridge mass july 25 2023 globe newswire bionomics limited asx bno nasdaq bnox bionomics or the company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it has submitted a formal request to the australian securities exchange asx to be removed from the official list of the asx in keeping with the company s ongoing transformation to a u s focused organization the main consequence of an asx delisting for shareholders is that from the time the proposed asx delisting is scheduled to take effect on august 28 2023 bionomics shares will no longer be quoted or traded on the asx and will only be tradable in the form of american depositary shares on the nasdaq global market nasdaq under the symbol bnox,bionomics announces intention to delist from the australian securities exchange asx,exchange_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,704,0.014325396825396826,0.8866002429130597,0.0005529100529100557
media release,festi hf presentation of q3 2024 results,earnings_releases_and_operating_results,UP,3.333333333333333,86528614400.0,35018869.0,705422.1176470588,0.168,536328.0,0.25000035609542787,0.1515999603296736,3,9,240,0.0,0.21924478895264377,0.0
media release,danske bank a s revises 2024 net profit upwards now expects a net profit in the range of dkk 22 5 23 5 billion,earnings_releases_and_operating_results,DOWN,-0.994642651307372,212863959040.0,655783007.0,1036566.3333333334,0.707,1113237.0,0.003080761111263413,0.1515999603296736,3,7,240,0.0,0.27861563161930136,0.0
dallas aug 05 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that it will report its financial results for the second quarter ended june 30 2024 and host a corporate update conference call and webcast on monday august 12 2024 at 8 30 am eastern time,taysha gene therapies to release second quarter 2024 financial results and host conference call and webcast on august 12,financial_results,DOWN,-5.714280524221172,626364352.0,136885482.0,5054745.0,1.016,2606600.0,0.21853970706174544,0.09346626282280733,0,8,327,0.0,1.0149166236087122,0.013161122503227776
highly regarded renal pathologist and transmission electron microscopy tem expert independently confirms previously reported qualitative assessment by mayo clinic of tem biopsy scans,eloxx pharmaceuticals reports independent confirmation of positive biopsy results in all patients treated with elx 02 in phase 2 clinical study for alport syndrome,clinical_study,UP,1.870742424087607,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,7,649,0.044121212121212124,2.2721670857062097,0.15659812409812413
new york and mainz germany june 27 2024 pfizer inc nyse pfe pfizer and biontech se nasdaq bntx biontech today announced that the committee for medicinal products for human use chmp of the european medicines agency ema has recommended marketing authorization for the companies omicron jn 1 adapted monovalent covid 19 vaccine comirnaty jn 1 for active immunization to prevent covid 19 caused by sars cov 2 in individuals 6 months of age and older the adaptation is based on the recommendation from the world health organization who technical advisory group on covid 19 vaccine composition and the european medicines agency s emergency task force etf to update covid 19 vaccines to target the sars cov 2 variant jn 1 for the 2024 2025 vaccination campaign etf stated that evidence indicates that targeting jn 1 will help maintain the effectiveness of the vaccines as sars cov 2 continues to evolve 1 2,pfizer and biontech receive positive chmp opinion for omicron jn 1 adapted covid 19 vaccine in the european union,regulatory_filings,DOWN,-2.6051151795463814,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,3,10,365,0.04410774410774411,0.5503225880253886,0.08888888888888889
sampo plc stock exchange release 10 october 2024 at 8 30 am eest sampo plc s share buybacks 9 october 2024 on 9 october 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 8 316 283 sampo a shares representing 1 51 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 september 2,sampo plc s share buybacks 9 october 2024,changes_in_companys_own_shares,UP,0.0737345662490312,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,261,0.1625,0.8866002429130597,0.024920634920634926
vista blocking kva12123 monoclonal antibody mab engineered to provide strong single agent anti tumor activity while minimizing cytokine related adverse events,kineta publishes preclinical data demonstrating the potential of anti vista antibody kva12123 as an immunomodulatory therapy for cancer,clinical_study,UP,5.154634107374385,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,563,0.09047619047619049,0.8866002429130597,0.17954545454545456
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report third quarter 2024 financial results and provide corporate update on october 31 2024,clinical_study,UP,4.399995803833008,158748848.0,15213010.0,781395.0,1.567,974600.0,0.09583067966578251,0.09346626282280733,3,9,247,0.0,0.8435084668920305,0.12990305435305435
26 sep 2024 15 02 cest brie picardie crcam rapport financier semestriel 2024 la caisse régionale de crédit agricole mutuel brie picardie compte au 30 juin 2024 206 agences de proximité 1 agence gestion de la relation à distance 2 agences crédit agricole en ligne 3 agences courtiers 1 agence habitat à distance 3 agences banque privée 5 centres d affaires entreprises 3 agences collectivités publiques 3 centres d affaires professionnels de l immobilier 2 pôles institutionnels et associations 3 équipes de conseillers mobiles assurances agriculteurs et professionnels 1 plateforme front office assurances agriculteurs et professionnels 1 plateforme allocation d actifs et gestion conseillée 1 banque d affaires 1 agence evènements de la vie 85 caisses locales 18 administrateurs de la caisse régionale 859 administrateurs de caisses locales plus de 433 000 sociétaires plus de 1 1 million de clients pièce jointe rapport financier semestriel 2024 rapport,crédit agricole brie picardie rapport financier semestriel 2024,financial_results,DOWN,-0.474321679287626,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
media release,lhv pank completed the acquisition of part of tbb pank s credit portfolio,mergers_acquisitions,DOWN,-0.142446610710075,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,250,0.0,0.8866002429130597,0.04395265257618199
16 oct 2024 08 09 cest borr drilling limited please see attachment on www newsweb no more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site 629695_borr drilling cob 14 oct 2024 form pdf borr drilling limited oslo børs newspoint borr drilling bmg1466r1732 borr oslo børs,notification of major holdings,company_regulatory_filings,DOWN,-0.0904145348107686,442721632.0,174743108.0,6645095.0,1.794,4344400.0,0.39470198736527967,0.1515999603296736,2,8,255,0.03392857142857143,0.6240735940428164,0.12410714285714286
missing,valneva se déclaration d actions et de droits de vote 30 septembre 2024,voting_rights,UP,3.730018363735442,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,4,1,267,-0.2,0.6494694268312979,0.04756944444444444
adelaide australia and cambridge mass may 31 2024 globe newswire bionomics limited nasdaq bnox bionomics or the company a clinical stage biotechnology company developing novel potential first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced it has entered into a securities purchase agreement with an institutional accredited investor to purchase american depository shares ads or pre funded warrants in lieu thereof and accompanying warrants in a three tranche private placement,bionomics limited announces private placement of up to 70 0 million,financing_agreements,UP,1.214577390087494,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,393,-0.006017316017316015,0.8866002429130597,0.05824655170656539
of evaluable participants at month 6 achieved target absolute neutrophil count anc increase with once daily oral mavorixafor stable dose g csf as of the interim analysis data cut off date,x4 pharmaceuticals announces positive interim clinical data from ongoing six month phase 2 trial of mavorixafor in chronic neutropenia cn and initiation of pivotal phase 3 cn trial,clinical_study,DOWN,-7.103823312288768,12156248.0,4364496.0,363495.0,0.663,396700.0,0.35903314904401423,0.09346626282280733,3,6,366,0.2318181818181818,1.4412990038402507,0.08954545454545454
14 of 15 participants enrolled achieved a clinical response,jasper therapeutics reports positive data from spotlight study of briquilimab in chronic inducible urticaria,clinical_study,UP,1.0659549964845572,81419784.0,9908441.0,280900.0,2.725,505700.0,0.12169574166396707,0.09346626282280733,0,7,257,0.22727272727272727,0.9821837329226573,0.15958380800486063
media release,ramsay sante availability of the universal registration document 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
warrington pa oct 17 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions and diseases today announced the issuance of an istaroxime patent for japan the patent is entitled istaroxime containing intravenous formulation for the treatment of heart failure ahf the claims are directed to intravenous administration of istaroxime using increased infusion times alone or in combination with other agents useful to treat ahf thereby improving treatment of heart failure and diastolic relaxation when compared to conventional protocols the application has been accorded patent no 7560134 with a registration date of september 24 2024 and will expire in 2039,windtree announces expansion of patents with issuance of istaroxime patent for japan,patents,UP,4.347830593924006,1352846.0,3660923.0,6680965.0,0.764,1224200.0,2.7060899762426764,0.09346626282280733,3,8,254,-0.033465608465608455,2.339794177443606,0.06217591681606833
media release,aventador annonce la réorganisation de sa direction,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,246,0.0,0.8866002429130597,0.03409090909090909
waltham mass jan 29 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the issuance and sale of an aggregate of 7 756 233 shares of its common stock or common stock equivalents in lieu thereof at a purchase price of 1 805 per share of common stock or per common stock equivalent in lieu thereof in a registered direct offering priced at the market in addition in a concurrent private placement checkpoint will issue and sell unregistered warrants to purchase up to 7 756 233 shares of common stock the warrants will have an exercise price of 1 68 per share will be exercisable immediately upon issuance and will expire five years following the issuance date,checkpoint therapeutics announces 14 million registered direct offering priced at the market,financing_agreements,UP,0.5952446419502754,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,8,516,-0.13714285714285715,0.8866002429130597,0.07760341510341509
media release,carl johan hugner new ceo of nyfosa,management_changes,DOWN,-0.0868042333074207,112574064.0,35018869.0,105765.0,0.8755,89500.0,0.25000035609542787,0.1515999603296736,0,7,243,0.13636363636363635,0.04641709038617369,0.0
cambridge mass and rostock germany and berlin sept 25 2024 globe newswire centogene n v the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced data from the company s rostock international parkinson s disease ropad further supporting the association of a rab32 gene mutation with parkinson s disease pd the study published in the lancet neurology builds on research from emil k gustavsson and colleagues who previously identified the rab32 c 213c g p ser71arg dbsnp rs200251693 variant as a novel monogenic cause of pd,centogene data on novel genetic risk factor for parkinson s disease in the lancet neurology,clinical_study,DOWN,-7.103823312288768,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,8,276,0.0638888888888889,3.598197549072007,0.15139235764235762
mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,mainz biomed awarded poster of distinction at digestive disease week positioning the company for its planned fda trial,clinical_study,DOWN,-5.735299106184534,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,0,8,404,0.0,34.079934680222834,0.06363636363636363
media release,torm plc capital increase in connection with delivery of one 2015 built mr vessel,share_capital_increase,DOWN,-3.110170791459808,10941282304.0,57061410.0,376187.8888888889,-0.051,374739.0,0.005215239714556953,0.1515999603296736,0,14,242,0.0,0.4410338951026056,0.0
tampa fla feb 22 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its fourth quarter and year ended december 31 2023 financial results before the open of the u s markets on thursday february 29 2024 following the release the company will host a live conference call and webcast at 8 30 a m et,pacira to report 2023 financial results on thursday february 29 2024,earnings_releases_and_operating_results,UP,0.1683475952059146,1112007296.0,45834212.0,557500.0,0.511,435200.0,0.04121754611221544,0.09346626282280733,3,8,492,0.022727272727272724,0.7130794063724827,0.32540885040885037
jupiter fla june 28 2024 globe newswire dyadic international inc dyadic nasdaq dyai announced today that they have entered into a development and commercialization partnership with proliant health and biologicals phb a leading supplier of purified proteins for the diagnostic nutrition and cell culture markets,dyadic international inc and proliant health and biologicals announce recombinant albumin development and commercialization partnership,partnerships,DOWN,-2.5316506313829312,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,8,365,0.0,0.7846450948942033,0.1434434910327768
04 oct 2024 07 00 cest atlantic sapphire asa not for release publication or distribution directly or indirectly in canada japan australia or the united states or any other jurisdiction in which such release publication or distribution would be unlawful this announcement does not constitute an offer of any of the securities described herein reference is made to the stock exchange announcements published by atlantic sapphire asa atlantic sapphire or the company on 17 september 2024 regarding the general meeting s approval of the share capital increase pertaining to a partially underwritten rights issue of between 5 267 773 852 to 6 844 800 000 new shares in the company at a subscription price of nok 0 10 per share the offer shares to raise gross proceeds of up to the nok equivalent of usd 64 million the rights issue in addition 641 700 006 new shares will be issued to settle the underwriting commission payable to the underwriters for the rights,atlantic sapphire asa last day of subscription period in the rights issue,shares_issue,UP,9.242146234319629,595463232.0,13903269.0,52395.0,0.75,40800.0,0.0233486607616438,0.1515999603296736,4,5,267,0.02196969696969697,0.34682929013051456,0.031228956228956235
if approved nexobrid will serve as an effective non surgical treatment for both pediatric and adult burn patients in the u s,mediwound announces that fda has accepted for review the supplement to the nexobrid bla to include pediatric patients with severe thermal burns,regulatory_filings,UP,1.5228452607710337,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,7,536,0.35,0.6433034533898109,0.08
ad hoc announcement pursuant to art 53 lr,santhera publishes agenda for its annual general meeting,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.05000000000000002,0.5209522992128177,0.0
norwood mass feb 28 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today announced the appointment of dr dominic smethurst ma mrcp as the company s chief medical officer cmo in this role dr smethurst will lead the clinical development of the company s investigational oncology drugs crb 701 a next generation nectin 4 targeting antibody drug conjugate adc developed in partnership with cspc and crb 601 a tgfβ blocking monoclonal antibody targeting the integrin αvβ8 additionally dr smethurst will help guide strategic development of crb 913 the company s highly peripherally restricted cb1 inverse agonist for the treatment of obesity,corbus pharmaceuticals appoints dr dominic smethurst as chief medical officer,management_changes,DOWN,-1.764476754343736,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,8,486,0.052000000000000005,0.9919200800994142,-0.057575757575757586
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,-0.2
alvotech nasdaq alvo and teva pharmaceuticals a u s affiliate of teva pharmaceutical industries ltd nyse and tase teva today announced that the u s food and drug administration fda has approved selarsdi ustekinumab aekn in a new presentation 130 mg 26 ml 5 mg ml solution in a single dose vial for intravenous infusion this approval paves the way for selarsdi to further align its label with the indications of the reference product stelara ustekinumab in the u s at launch which is expected in the first quarter of 2025,alvotech and teva announce u s fda approval of additional presentation of selarsdi ustekinumab aekn expanding its label to include further indications approved for reference product stelara ustekinumab,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.03582251082251082,0.44264539487962035,0.05175282234105764
los angeles and amsterdam april 24 2024 globe newswire renovaro inc nasdaq renb a trailblazer in ai driven early cancer diagnostics and therapeutics and cyclomics a leader in ultra sensitive 4th generation multi omics molecular biology proudly announce a significant milestone in their collaboration renovarocube has entered into an amendment to its binding letter of intent to acquire ownership of cyclomics further cementing their shared commitment to advancing state of the art technologies in cancer diagnostics and treatment their combined relationships with oxford nanopore and nvidia will further position renovarocube to be a leader in early cancer diagnostics and monitoring of treatment efficacy oxford nanopore is a leader in sequencing technologies and nvidia will provide vital super computing power and front edge software solutions such as parabricks bionemo monai and nemo,renovarocube to acquire ownership of cyclomics reinforcing cutting edge cancer diagnostics partnership,mergers_acquisitions,DOWN,-6.4356433890658415,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,2,9,430,0.11893939393939394,1.5631250973582267,0.08446969696969697
biocardia announces that the uspto has granted patent no 11 986 611 titled radial and transendocardial delivery catheter with a 2036 expiration date,biocardia announces united states patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach,Patents,UP,7.780324061596451,11236022.0,3886990.0,44615.0,0.838,135000.0,0.3459400488891887,0.09346626282280733,4,7,386,-0.1,1.32107885633281,0.1532312925170068
media release,carbios und das textilkonsortium der markenhersteller on patagonia puma pvh corp und salomon stellen das weltweit erste zu 100 biologisch von faser zu faser recycelte kleidungsstück vor,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
ad hoc announcement pursuant to art 53 lr,santhera publishes agenda for its annual general meeting,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.05000000000000002,0.5209522992128177,0.0
san diego jan 31 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will present at guggenheim s 6th annual biotechnology conference,anaptys to present at guggenheim s 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.6268266469592575,687797504.0,17605381.0,784220.0,-0.266,445700.0,0.025596750348195505,0.09346626282280733,2,9,514,0.16666666666666666,0.871343469962729,0.23443865057501423
upfront cash payment of 170 million strengthens capital structure,coherus completes divestiture of ophthalmology franchise,divestiture,UP,5.394185534957356,85326688.0,110892497.0,1236840.0,0.883,1425300.0,1.2996226573331897,0.09346626282280733,0,1,481,0.0,1.0144535837204522,0.3
achieved increase in total revenue compared to prior year period achieved increase in total revenue compared to prior year period,t2 biosystems announces preliminary third quarter 2024 financial results,earnings_releases_and_operating_results,UP,0.5494500096186173,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,0,9,264,0.0,1.9596557041969667,0.10858005630732905
reykjavik iceland oct 25 2024 globe newswire alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today its participation in the jefferies london healthcare conference november 19 20 2024 members of the management team will host one on one meetings on both days alvotech will be presenting at the conference on tuesday november 19 2024 at 9 00 9 25 am gmt,alvotech meeting investors and presenting at the jefferies 2024 london healthcare conference on november 19 20 2024,clinical_study,UP,0.3831432184220352,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,4,8,246,0.0,0.44264539487962035,0.04412127224627225
qiastat dx respiratory panel mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions with the new test and the 21 target qiastat dx respiratory panel plus clinicians can fine tune their diagnostic approach for individual patients promoting better diagnostic stewardship fda decision marks third positive u s regulatory outcome for qiastat dx to date in 2024 qiastat dx respiratory panel mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions with the new test and the 21 target qiastat dx respiratory panel plus clinicians can fine tune their diagnostic approach for individual patients promoting better diagnostic stewardship fda decision marks third positive u s regulatory outcome for qiastat dx to date in 2024,qiagen receives fda clearance for qiastat dx mini panel to improve precision in outpatient respiratory treatment,regulatory_filings,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.2725378787878788,0.2568422597431085,0.08276515151515151
planegg martinsried august 8 2024 medigene ag medigene fse mdg1 prime standard and wuxi biologics stock code 2269 hk enter into a three year multi target strategic partnership to design and co research t cell receptor tcr guided t cell engagers tcr tces for the treatment of difficult to treat tumors the collaboration combines the respective expertise of each company with medigene s 3s sensitive specific and safe tcr generation and characterization capabilities and wuxi biologics unique anti cd3 mab its industry leading tce platform and proprietary bispecific antibody platform wuxibody,medigene and wuxi biologics enter into a research collaboration for off the shelf tcr guided t cell engagers,partnerships,DOWN,-2.7649852114563966,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,4,324,0.06785714285714285,1.3169799228985475,0.03707792207792208
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
media release,rentefastsettelse,bond_fixing,DOWN,-0.1940257513701026,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,0,13,242,0.0,0.20896972559163385,0.0
zug switzerland august 10 2023 moonlake immunotherapeutics nasdaq mltx moonlake or the company a clinical stage biotechnology company focused on creating next level therapies for inflammatory diseases today announced its financial results for the second quarter of 2023,moonlake immunotherapeutics reports second quarter 2023 financial results and provides a business update,financial_results,UP,0.0,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,3,7,688,0.0,0.5366763308656862,-0.09583333333333333
south san francisco calif june 07 2023 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced that brian wong m d ph d president and chief executive officer will participate in a fireside chat at the goldman sachs global healthcare conference on monday june 12 2023 at 1 20 p m pt,rapt therapeutics to participate in the goldman sachs global healthcare conference,conference_call_webinar,UP,0.191300410422023,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,2,8,752,0.03125,1.6028075568485736,0.20486111111111113
g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negativ,g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negative breast cancer mtnbc,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,369,0.04,0.8866002429130597,0.057692307692307696
west lafayette ind sept 16 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services has amended certain terms of its credit agreement in addition inotiv has closed the sale of 22 6 million aggregate principal amount of senior secured second lien pik notes due february 2027 the second lien notes and warrants to purchase common shares to certain investors in a private offering,inotiv inc amends its credit agreement and secures additional liquidity,financing_agreements,DOWN,-1.923075159625829,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,0,8,285,-0.010714285714285716,1.3015467599292592,0.03879818594104308
florham park n j may 10 2023 globe newswire celularity inc nasdaq celu celularity a biotechnology company developing placental derived allogeneic cell therapies and biomaterial products today announced that it has been advised by farouk maamoun tamer co tamer group the exclusive distributor for celularity s branded halal certified biomaterial products in the kingdom of saudi arabia that it expects to submit purchase orders through the end of 2023 in the range of 60 million to 80 million,celularity announces advisory guidance from tamer group regarding anticipated 2023 purchase orders for celularity branded halal certified biomaterial products,product_services_announcement,UP,5.200940643017723,45742972.0,11684589.0,65020.0,0.764,90700.0,0.25544009252394007,0.09346626282280733,2,9,780,0.0,1.6050367793919866,0.0
waltham mass sept 21 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a panel presentation at the cantor global healthcare conference on thursday september 28 2023 at 10 20 a m et in new york city the company will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the cantor global healthcare conference,conference_call_webinar,DOWN,-1.1904750923180183,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,646,0.04545454545454545,0.8866002429130597,0.0
toronto sept 18 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures announced today its strategic focus on dedicating its resources to advancing the clinical development of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties the company has decided not to pursue the development of the long covid diagnostic product,revive therapeutics announces strategic focus on bucillamine for infectious diseases and medical countermeasures,clinical_study,UP,0.0,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,7,283,-0.016666666666666666,1.8889707456546947,0.08725282659077127
qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024 qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024,qiagen erhält fda zulassung für qiastat dx mini panel für eine präzisere ambulante behandlung von atemwegserkrankungen,product_services_announcement,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.22727272727272727,0.2568422597431085,0.08276515151515151
media release,xplora technologies as invitation to presentation of q3 2024 results,earnings_releases_and_operating_results,DOWN,-1.544400094292248,1855892352.0,20356814.0,45065.4,0.201,14970.0,0.010968747178715675,0.1515999603296736,3,15,239,0.0,0.5164688145896636,0.0
westlake village calif july 09 2024 globe newswire arcutis biotherapeutics inc nasdaq arqt a commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno dermatology today announced that the company has been in communication with the u s food and drug administration fda regarding its supplemental new drug application snda for roflumilast cream 0 for the treatment of mild to moderate atopic dermatitis ad for adults and children down to the age of 6 the fda has indicated that they are working to finalize the action letter and have not indicated they would extend the prescription drug user fee act pdufa goal date of july 7 2024,arcutis provides update on snda for roflumilast cream 0 for atopic dermatitis,regulatory_filings,DOWN,-2.2051820630964807,1721872896.0,85869346.0,2010100.0,1.778,2359700.0,0.04986973556496472,0.09346626282280733,1,8,354,0.1305916305916306,0.6903751128737089,0.03894500561167227
san diego and suzhou china may 04 2023 globe newswire adagene inc adagene nasdaq adag a platform driven clinical stage biotechnology company transforming the discovery and development of novel antibody based therapies today announced achievement of a milestone in its ongoing collaboration with exelixis for development of novel masked antibody drug conjugate adc candidates leveraging adagene s proprietary safebody precision masking technology,adagene achieves 3 million milestone in collaboration with exelixis for successful nomination of second safebody novel masked antibody drug conjugate,licensing_agreements,UP,0.0,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,9,786,0.375,0.845882180665701,0.15833333333333333
media release,stmicroelectronics annonce ses résultats financiers du troisième trimestre 2024,financial_results,DOWN,-0.689650206789829,26516213760.0,642508707.0,7578905.0,1.228,8781800.0,0.024230786220664408,0.19535099655549074,3,7,240,0.0,0.5353904081431587,-0.15
lawrenceville n j july 31 2024 globe newswire imunon inc nasdaq imnn a clinical stage company in late stage development with its dna mediated immunotherapy today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at the market under nasdaq rules in a concurrent private placement and also pursuant to the securities purchase agreements the company has agreed to issue to the investors unregistered warrants to purchase shares of common stock upon the closing of the offering which is anticipated to occur on or about august 1 2024 the company expects to receive gross proceeds of 10 million before deducting placement agent fees and other offering expenses payable by the company the closing of the offering is subject to customary closing conditions,imunon announces 10 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,2,8,332,-0.11018518518518518,2.964855117372811,0.07441534914361002
media release,totalenergies announces the third interim dividend of 0 79 share for fiscal year 2024 an increase close to compared to 2023,dividend_reports_and_estimates,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.21718000818528868,0.0
los angeles ca jan 24 2024 globe newswire immix biopharma inc immix biopharma company we or us nasdaq immx a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced a statement on january 2024 fda labeling change notifications for approved car t products,immix biopharma statement on january 2024 fda labeling change notification for approved car t products,clinical_study,DOWN,-1.9148867958104072,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,2,8,521,0.0,0.9253604538231538,-0.15000000000000002
inside information 2024 09 17 08 59 cest as madara cosmetics has received the notification of sustainability manager anete vabule on transactions with securities issued by as madara cosmetics the shares of as madara cosmetics are admitted to trading on nasdaq baltic first north market the certified adviser for as madara cosmetics is zab eversheds sutherland bitāns sia as madara cosmetics was founded in 2006 and has become one of the leading cosmetics manufacturers in northern europe and a leader in latvia the company s brand mádara is a pioneer in the natural skincare and make up segment in latvia since november 2017 the company s shares have been listed on the nasdaq baltic alternative market first north for more information visit investors madaracosmetics com contact information address 131 zeltiņu street mārupe district mārupe lv 2167 latvia contact person gunta šulte member of the management board e mail ir madaracosmeti,on transactions under regulation no 596 2014,trading_information,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,284,0.275,0.8866002429130597,0.0
norwood mass aug 06 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today provided a corporate update and reported financial results for the quarter ended june 30 2024,corbus pharmaceuticals reports second quarter 2024 financial results and provides a corporate update,financial_results,UP,0.6178451029074052,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,1,8,326,0.0,0.9919200800994142,0.037476190476190475
longeveron presents clinical data for stem cell therapy in alzheimer s disease findings offer potential mechanistic and clinical insights,longeveron presents lomecel b data for alzheimer s disease indication in late breaking poster presentation at the clinical trials on alzheimer s disease conference ctad24,clinical_study,UP,5.288468151403139,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,1,10,241,-0.15,1.063123411629147,0.08455387205387206
planegg martinsried june 27 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today provides a detailed overview of its lead candidate mdg1015 a first in class 3rd generation t cell receptor engineered t cell tcr t therapy at the 7th cell and gene therapy in depth focus summit from june 27 28 2024 in beijing china mdg1015 advances towards the clinic and targets the cancer testisantigens cta ny eso 1 lage 1a new york esophageal squamous cell carcinoma 1 l antigen family member 1a and is armored and enhanced by the company s pd1 41bb costimulatory switch protein csp,medigene presents efficient 6 day tcr t therapy production process with high stemness,clinical_study,DOWN,-1.2820501064172196,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,6,366,0.1351948051948052,1.3169799228985475,0.01840909090909091
florham park n j may 23 2023 globe newswire celularity inc nasdaq celu celularity a biotechnology company developing placental derived allogeneic cell therapies and biomaterial products today announced that it has received a 45 million purchase order for celularity private label halal certified biomaterial products from jamjoom medical store jamjoom dr walid swelim will serve as marketing manager for promotion and distribution of the products this marks the first purchase order received by celularity under its recently announced expansion into the middle east market as part of celularity s global market strategy,celularity announces 45 million purchase order first middle east private label agreement for celularity s halal certified biomaterial products,geographic_expansion,UP,3.7037037037037033,45263988.0,11684589.0,65020.0,0.764,90700.0,0.2581431622860982,0.09346626282280733,1,8,767,0.05555555555555555,1.6050367793919866,0.0
mainz deutschland 22 juli 2024 globe newswire biontech se nasdaq bntx biontech oder das unternehmen wird am montag den 5 august 2024 die ergebnisse für das zweite quartal 2024 veröffentlichen darüber hinaus wird das unternehmen am selben tag um 14 00 uhr mesz 8 00 uhr eastern daylight time eine telefonkonferenz samt webcast für investoren finanzanalysten sowie die allgemeine öffentlichkeit durchführen um die finanzergebnisse sowie ein unternehmensupdate zu präsentieren,biontech veröffentlicht am 5 august 2024 ergebnisse für das zweite quartal 2024 und informiert über operativen fortschritt,earnings_releases_and_operating_results,UP,1.4743764916086926,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,341,0.0,0.5503225880253886,0.0824915824915825
new york july 30 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions today announced that management will participate in two upcoming investor conferences in august,ovid therapeutics to present at upcoming august investor conferences,conference_call_webinar,DOWN,-0.9523800873701952,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,333,0.21266233766233766,0.7642184815786688,0.15311997526283241
adelaide australia and cambridge mass sept 14 2023 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced an update on the company s α7 nicotinic acetylcholine receptor nachr positive allosteric modulator pam collaboration with msd known as merck co inc rahway nj usa in the us and canada data for mk 4334 a novel clinical candidate developed by msd and derived from bionomics original α7 nachr pam candidate bnc375 was recently presented at the society for chemical industry sci and royal society of chemistry rsc 22nd medicinal chemistry symposium held in cambridge uk september 10 13 2023,bionomics announces update on the α7 nicotinic acetylcholine receptor nachr positive allosteric modulator pam collaboration with msd,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,653,0.08498032270759544,0.8866002429130597,-0.007776266061980347
extends maturity of long term debt as fortress late stage pipeline continues to advance and may generate up to three regulatory approvals on ndas and blas in the next 12 months and potentially a fourth bla filing as early as 2025 extends maturity of long term debt as fortress late stage pipeline continues to advance and may generate up to three regulatory approvals on ndas and blas in the next 12 months and potentially a fourth bla filing as early as 2025,fortress biotech reduces total debt and enters into new 35 million term loan with oaktree with maturity in 2027,financing_agreements,UP,2.845525697451868,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,3,8,338,-0.030303030303030304,0.6928276660424207,0.09690012368583796
media release,atos reports third quarter 2024 revenue,clinical_study,UP,0.3654785367553472,24416421888.0,158122098.0,963560.0,0.703,746300.0,0.006476055284648921,0.1515999603296736,3,7,247,0.0,0.17227975622079925,0.0
mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment,mediwound announces 25 million strategic private placement financing,financing_agreements,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,348,0.2,0.6433034533898109,0.13225718725718727
results of dose escalation portion from phase 1b 2 trials of adg126 in combination with anti pd 1 therapies including confirmed clinical responses pave way for dose expansion in specific tumors,adagene presents clinical data for anti ctla 4 safebody adg126 reinforcing best in class safety profile at repeat doses and showing early efficacy profile in advanced metastatic solid tumors,clinical_study,UP,4.827581444195009,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,1,9,802,0.31666666666666665,0.845882180665701,0.0
redwood city calif oct 23 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that it is commencing an open label extension study in chronic urticarias that will roll over patients from the beacon and spotlight studies upon completion of their initial follow up period additionally jasper also announced it has obtained regulatory clearance in the us and in the eu to further expand the beacon study in csu by adding a 360mg single dose cohort n 4 and that enrollment in this cohort has commenced jasper continues to plan to report initial data from all doses of the beacon study up through 240mg in csu during the week of january 6th 2025 data from the newly added 360mg single dose cohort is expected to be reported in the first half of 2025,jasper therapeutics announces further expansion of clinical program in chronic spontaneous urticaria,clinical_study,DOWN,-0.747010055279865,81119344.0,9908441.0,280900.0,2.725,505700.0,0.12214646361045524,0.09346626282280733,2,8,248,0.08405998763141619,0.9821837329226573,0.16296825396825396
the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk,cidara therapeutics announces first subjects dosed in phase 2b navigate trial evaluating cd388 for the prevention of seasonal influenza,clinical_study,DOWN,-0.7985816231790068,629035328.0,4118697.0,696580.0,0.795,3470400.0,0.006547640198675773,0.09346626282280733,0,8,278,0.25,1.357695941787151,-0.02205339105339105
ad hoc announcement pursuant to art 53 lr,santhera publishes agenda for its annual general meeting,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.05000000000000002,0.5209522992128177,0.0
naimish patel m d appointed to chief medical officer,crispr therapeutics strengthens executive leadership team with key appointments,management_changes,UP,0.0,4077230080.0,85970729.0,2651100.0,1.742,2455300.0,0.021085572144116035,0.09346626282280733,3,8,401,0.0,0.5620956775766307,0.04602143887858173
new york march 05 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced that dr howard weiner will present positive data of intranasal anti cd3 monoclonal antibody in models of alzheimer s and parkinson s disease at ad pd march 5 9 2024 ad pd is the annual international conference on alzheimer s and parkinson s diseases and related neurological disorders in lisbon portugal,tiziana life sciences announces podium presentation at ad pd of nasal anti cd3 in alzheimer s disease,clinical_study,DOWN,-2.127657550770317,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,7,480,0.07272727272727272,1.1109140250580023,0.05000000000000001
on the 30 september 2024 flerie ab s net asset value nav was sek 4 262 million and nav per share was sek 54 59 indirect shares in provell pharmaceuticals for more information ted fjällman ceoemail ir flerie com flerie in briefflerie is an active long term life science investor with a broad and diversified portfolio of innovative companies based on pioneering science we invest in product development and commercial growth opportunities globally alongside other leading investors focusing predominantly on private companies that are otherwise difficult to access flerie s active ownership model broad network and resources support and accelerate the development of the portfolio projects creating value for shareholders flerie ab s ordinary share is listed on nasdaq stockholm with the ticker flerie for further information please visit www flerie com attachments net asset value 30 september 2024 pdf,net asset value 30 september 2024,financial_results,DOWN,-0.166289803526105,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,-0.003921568627450981,0.8866002429130597,0.0
former chairman ceo and founder of chemocentryx inc former chairman ceo and founder of chemocentryx inc,immuneering appoints thomas j schall ph d to its board of directors,management_changes,UP,0.5897194229073216,112275376.0,27271404.0,2516685.0,0.002,1980700.0,0.2428974631089189,0.09346626282280733,1,8,473,0.0,1.2966226301621697,0.10119047619047618
the harju county court has decided to fully cancel the eur 300 000 fine decision that the financial intelligence unit made in the beginning of may and to end the proceedings against as lhv pank due to the absence of signs of misdemeanor the financial intelligence unit has 15 days to appeal the harju county court s order lhv group is the largest domestic financial group and capital provider in estonia the lhv group s key subsidiaries are lhv pank lhv varahaldus lhv kindlustus and lhv bank limited the group employs over 1 100 people as at the end of july lhv s banking services are being used by 437 000 clients the pension funds managed by lhv have 118 000 active clients and lhv kindlustus protects a total of 167 000 clients lhv bank limited a subsidiary of the group holds a banking licence in the united kingdom and provides banking services to international financial technology companies as well as loans to small and medium sized enterprises priit rumcommunications man,estonian financial intelligence unit s fine to lhv pank cancelled by court order,law_legal_issues,UP,0.151282176137583,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,13,284,0.009978991596638665,0.8866002429130597,0.0
04 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 03 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3746 25 5064 estimated mtd return 0 05 0 05 estimated ytd return 3 00 3 81 estimated itd return 183 75 155 06 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 40 n a premium discount to estimated nav 3 43 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 47 transactions in own securities purchased into treasury ordinary shares euro shares sterling sh,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,267,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
herbicide tolerance is critical to planting the camelina crop on large acreage for the biofuel and omega 3 oil markets herbicide tolerance is critical to planting the camelina crop on large acreage for the biofuel and omega 3 oil markets,yield10 bioscience reports that proprietary varieties of winter camelina show tolerance to commonly used herbicides in first field tests,product_services_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,485,0.0630952380952381,0.8866002429130597,0.051928571428571435
ad hoc announcement pursuant to art 53 lr,santhera publishes agenda for its annual general meeting,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.05000000000000002,0.5209522992128177,0.0
the combined company aims to accelerate precision personalized medicine for longevity powered by mutually reinforcing ai and biotechnology platforms for early diagnosis better targeted treatments and drug discovery,renovaro biosciences and ai health company gedi cube sign definitive agreement to combine,mergers_acquisitions,DOWN,-4.668305877316483,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,4,9,638,0.3,1.5631250973582267,0.0
study approximately half enrolled to the planned unblinded interim analysis,polypid announces enrollment of 200th patient in ongoing shield ii phase 3 trial evaluating d plex₁₀₀ for the prevention of abdominal colorectal surgical site infections,clinical_study,UP,0.0,37400604.0,4610773.0,1395250.0,1.25,337200.0,0.12328070958426234,0.09346626282280733,1,7,424,-0.16666666666666666,0.7168605096826995,-0.055537918871252215
barcelona spain and watertown mass march 13 2024 globe newswire almirall s a bme alm and eloxx pharmaceuticals inc otc elox announced today that the companies have entered into an exclusive license agreement for the asset zkn 013 under the agreement almirall obtains global rights to develop and commercialize zkn 013 including for the use in orphan dermatological diseases zkn 013 is a potentially promising oral nonsense mutation readthrough drug which enables the host cells to produce functional proteins which counteract the root cause of these rare dermatological and potentially other diseases,almirall and eloxx pharmaceuticals enter into exclusive agreement to license zkn 013 for rare dermatological diseases,licensing_agreements,UP,7.446807768615783,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,11,471,0.135,2.2721670857062097,0.07695254745254745
estimated 23 million annual agitation episodes in the at home setting 1 3,bioxcel therapeutics announces initiation of serenity at home pivotal phase 3 safety trial of bxcl501 for acute treatment of agitation associated with bipolar disorders or schizophrenia,clinical_study,UP,1.6666650109821552,12051540.0,5544250.0,450810.0,-0.13,78500.0,0.4600449403146818,0.09346626282280733,3,7,296,0.55,1.4586588351104455,0.031789522206188886
nkgen advances its neurodegenerative disease program with fda ind clearance for its phase 1 2a snk01 clinical trial in patients with parkinson s disease,nkgen biotech announces fda clearance of investigational new drug ind application for snk01 nk cell therapy in parkinson s disease,clinical_study,UP,9.242146234319629,16295543.0,10616620.0,134195.0,1.199,86400.0,0.651504524887572,0.09346626282280733,0,8,425,0.13636363636363635,2.657355742098314,0.20416666666666664
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
news release regulated informationnovember 27 2023 1 00 am et 7 00 am cet,mdxhealth announces completion of mandatory ads exchange and commencement of transition period to single listing on nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,-0.07142857142857142,0.6181119561491973,0.0
interim data from additional mss crc patients dosed at 10 mg kg every three weeks q3w in combination with pembrolizumab anticipated in 2024 at a medical conference,adagene announces progress and expansion of clinical collaboration program for masked anti ctla 4 safebody adg126 muzastotug in combination with keytruda pembrolizumab to demonstrate further efficacy in patients with metastatic microsatellite stable mss colorectal cancer crc,clinical_study,DOWN,-1.428570066179548,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,6,505,0.0,0.845882180665701,0.16557050092764378
moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,financial_results,DOWN,-1.5947867861013068,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,1,8,417,0.125,0.5366763308656862,0.04025252525252525
san diego and suzhou china july 12 2024 globe newswire adagene inc adagene nasdaq adag a company transforming the discovery and development of novel antibody based therapies today announced a poster presentation at the upcoming esmo congress taking place in barcelona spain 13 17 september 2024,adagene announces poster presentation on masked anti ctla 4 safebody adg126 muzastotug in combination with pembrolizumab in mss crc at upcoming european society for medical oncology esmo congress in september,clinical_study,UP,4.797043328133286,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,4,7,351,0.0,0.845882180665701,0.12736192379049524
qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024 qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024,qiagen erhält fda zulassung für qiastat dx mini panel für eine präzisere ambulante behandlung von atemwegserkrankungen,product_services_announcement,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.22727272727272727,0.2568422597431085,0.08276515151515151
patient treated in trial achieved a remission after eight weeks of treatment demonstrating a significant reduction in proteinuria,eloxx pharmaceuticals intends to advance elx 02 into pivotal trial for the treatment of alport syndrome with nonsense mutations following achievement of remission in patient in phase 2 study,clinical_study,DOWN,-3.492435220091153,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,8,766,0.2916666666666667,2.2721670857062097,-0.03571428571428571
rockaway n j june 11 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company announced today that its stock is on the preliminary additions list for inclusion in the russell microcap index after its 2024 annual reconstitution the newly reconstituted indexes will take effect after the market close on june 28 2024 with the newly effective reconstituted family of indices beginning trading after the open of trading on july 1 2024 according to a preliminary list of additions posted by ftse russell on may 24 2024,electrocore to join russell microcap index,exchange_announcement,UP,0.93312510701954,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,1,8,382,0.18409090909090908,0.8324549917316175,0.1075097917955061
media release,first half 2024 financial results and latest operational update,financial_results,UP,1.0344874539926634,12196446.0,85702564.0,176590.63636363635,1.101,385968.0,7.0268473291317814,0.1515999603296736,3,8,240,0.14583333333333334,0.8249974782717295,0.0
media release,launch of a capital increase of approximately 36 6 million with preferential subscription rights,share_capital_increase,DOWN,-6.88946716859099,67170584.0,14323264.0,15862.954545454546,1.806,9661.0,0.2132371515483623,0.1515999603296736,0,7,243,-0.4,0.5487288764223092,0.0
pharmacosmos group and g1 therapeutics announce expiration of hart scott rodino waiting period,pharmacosmos group and g1 therapeutics announce expiration of hart scott rodino waiting period,mergers_acquisitions,DOWN,-0.1402556622906882,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,296,0.0,0.8866002429130597,0.043500000000000004
02 oct 2024 08 58 cest aker horizons asa new ppa product gives businesses a better alternative for their electricity supply mainstream renewable power mainstream the pureplay global wind and solar company majority owned by aker horizons asa has reached financial close on its 50 mw ilikwa solar pv plant the power from the plant will supply multiple private commercial and industrial customers under flexible shorter term power purchase agreements ppas in a new to market product called renewable energy supply agreements resas this new product opens up the energy market in south africa by giving a wider range of businesses access to affordable reliable and renewable power through shorter term energy contracts of between five and 10 years commenting on the announcement mainstream s general manager for africa hein reyneke said we are excited to bring this new product to market offering customers the opportunity to secure flexible clean and lower cos,mainstream renewable power reaches financial close on 50 mw solar pv plant to provide new flexible ppas to private customers in south africa,product_services_announcement,DOWN,-0.6766964400073892,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.13961675579322638,0.8866002429130597,0.0
rockville md aug 03 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported today that its german subsidiary curetis gmbh has signed an extended and continued research and development r d collaboration agreement with find following the successful completion of the feasibility phase of the collaboration and having met all milestones on time and within budgets the parties now plan to collaborate on first phases of product development of an antimicrobial resistance amr cartridge from blood culture that is tailored to the needs of low and middle income countries lmics in terms of panel design and coverage of specific genetic variants of bacterial strains and their amr markers in such countries as well as ensuring attractive cost profile and pricing models that allow for access to such rapid testing in lmics,opgen s subsidiary curetis and find extend r d collaboration agreement,partnerships,UP,3.389827220887213,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,8,695,0.18,1.807174583649316,0.14940746753246753
reflects continued focus on adding intellectual property to support the strategic direction of the company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke reflects continued focus on adding intellectual property to support the strategic direction of the company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke,inspiremd announces issuance of key u s patent covering its switchguard neuroprotection system,patents,UP,1.834860579271824,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,2,7,556,0.15999999999999998,0.6085732039686736,0.09448051948051948
media release,arverne group lancement d une offre au public d actions existantes,corporate_action,UP,0.2500057220458984,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,241,0.0,0.8866002429130597,0.0
stockholm tele2 ab tele2 nasdaq stockholm tel2 a and tel2 b will publish its third quarter 2024 results on tuesday 22 october 2024 the presentation will be hosted by kjell johnsen president and ceo and charlotte hansson evp group cfo in addition hendrik de groot chief commercial officer will provide an update on the swedish consumer business tele2 will publish its financial results for the third quarter 2024 at 07 00 cest 06 00 bst 01 00 edt on tuesday 22 october 2024 teleconference and webcast tele2 will host a teleconference and webcast with presentation at 10 00 cest 09 00 bst 04 00 edt on tuesday 22 october 2024 the presentation will be held in english and will last no longer than 1 hour and 20 minutes registration for the webcast and a separate registration for the teleconference will be available at www tele2 com for the teleconference please note that dial in numbers and unique pin code or a call me facility will be provided when you regi,invitation to presentation of the third quarter 2024 results,earnings_releases_and_operating_results,UP,0.1755195989408967,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,267,0.08611111111111111,0.8866002429130597,0.0
new haven conn feb 13 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that it has terminated its proposed public offering of 60 0 million of shares of its common stock or in lieu of common stock to certain investors pre funded warrants to purchase shares of its common stock previously announced on february 8 2024 as a result of such termination no securities of the company are being sold pursuant to the offering,bioxcel therapeutics announces termination of proposed public offering,corporate_action,UP,9.242146234319629,12595372.0,5544250.0,450810.0,-0.13,78500.0,0.4401815206410736,0.09346626282280733,1,9,501,-0.1316017316017316,1.4586588351104455,-0.024999999999999994
single infusion of anx005 30 mg kg met primary endpoint delivering a highly statistically significant and clinically meaningful 2 4 fold improvement in gbs ds vs placebo at week 8 p 0 0058,annexon announces positive topline results from pivotal phase 3 trial for first in class c1q blocking antibody anx005 in guillain barré syndrome,clinical_study,UP,9.242146234319629,263313616.0,82380157.0,1425435.0,1.259,925100.0,0.31285946488995847,0.09346626282280733,1,7,389,0.2926055194805195,0.7558344054121836,0.15068181818181817
burlington mass aug 12 2024 globe newswire scpharmaceuticals inc nasdaq scph a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies advance patient care and reduce healthcare costs today announced the pricing of an underwritten public offering of 12 000 000 shares of its common stock at a public offering price of 4 00 per share and to select investors in lieu of common stock pre funded warrants to purchase up to 500 000 shares of common stock at a purchase price of 3 999 per underlying share for gross proceeds of approximately 50 0 million before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre funded warrants the pre funded warrants have an exercise price of 0 001 per share all of the shares and the pre funded warrants are being offered by scpharmaceuticals in addition the company has granted the underwriters a 30 day option to purchase up to an additional 1 875 000 shares of common stock from the company at the public offering price less the underwriting discounts and commissions the offering is expected to close on august 13 2024 subject to the satisfaction of customary closing conditions,scpharmaceuticals announces pricing of 50 0 million public offering,shares_issue,UP,6.746981362331772,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,9,319,-0.14388888888888887,0.7082528246818063,-0.007013373531230668
dr marie louise fjällskog outgoing cmo is proposed to continue key role in bexmarilimab s development as a board member,faron appoints dr birge berns md as interim chief medical officer,management_changes,UP,1.1538419685891477,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,3,2,646,0.0,0.7633342480324978,-0.03441558441558441
los angeles feb 13 2024 globe newswire renovaro inc nasdaq renb announced today that it completed its acquisition of gedi cube intl ltd gedicube renovaro which means renew combines the power of the ai health tech platform of gedicube with the advanced cell and gene therapy biotech platform of renovaro biosciences to accelerate precision personalized medicine and a new era in healthcare innovation the two subsidiaries will be under the parent organization which was renamed renovaro inc,ai pioneer gedi cube and biotech innovator renovaro biosciences combine forces to accelerate personalized medicine,mergers_acquisitions,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,501,0.2681818181818182,1.5631250973582267,0.15822510822510824
communiqué de presse information réglementée27 novembre 2023 1 00 edt 7 00 cet,mdxhealth annonce la réalisation de l échange obligatoire d ads et le début de la période de transition vers une cotation unique sur le nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,0.375,0.6181119561491973,0.0
company announcement inside information,insider information faron initiates phase 2 part of bexmab study of bexmarilimab in hma failed mds,clinical_study,UP,0.1709440862369388,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,0,2,600,-0.5,0.7633342480324978,0.07841122261576806
media release,stmicroelectronics announces status of common share repurchase program,changes_in_companys_own_shares,UP,2.001434533426933,26525786112.0,642508707.0,7578905.0,1.228,8781800.0,0.02422204206454547,0.19535099655549074,0,14,242,-0.3,0.5353904081431587,0.0
conference call to begin at 4 30 p m et,vaxart to host second quarter 2024 business update and financial results conference call on august 8,conference_call_webinar,DOWN,-1.515159040990203,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,330,0.0,1.025768835125998,0.08874458874458874
transcode therapeutics reports 2023 results provides business update,transcode therapeutics reports 2023 results provides business update,financial_results,DOWN,-1.026388515146004,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,2,9,451,0.0,2.0874185587937095,0.0
ad hoc announcement pursuant to art 53 lr,addex enters into at the market ads offering agreement with h c wainwright co llc,financing_agreements,DOWN,-1.563938160843887,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,514,0.0,0.972373032385036,-0.23333333333333328
san diego feb 22 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis today announced that it will host a virtual investor day highlighting neffy epinephrine nasal spray on thursday march 7 2024 at 1 00 p m et to participate in the event please register here,ars pharmaceuticals to host virtual neffy investor day on march 7 2024,conference_call_webinar,UP,0.5361925153952565,1694184576.0,51755600.0,1240295.0,0.872,1940800.0,0.030548973667435867,0.09346626282280733,3,9,492,0.5,0.6899910717831225,0.23030303030303034
media release,oslo børs status companies placed in recovery box and penalty bench,exchange_announcement,DOWN,-0.1739108080223499,580726080.0,80428108.0,4091945.0,0.575,4211400.0,0.13849577411780783,0.09346626282280733,0,8,243,0.0,0.963882818724342,0.0
oslo 25 may 2023 the annual general meeting in pci biotech holding asa took place today 25 may 2023,minutes from annual general meeting 2023,annual_general_meeting,DOWN,-2.1052611765768803,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,3,5,765,0.05000000000000002,0.8869841129646596,0.012500000000000004
proof of concept study for imunon s first vaccine utilizing its proprietary placcine platform is now open for enrollment,imunon announces site activation for imnn 101 phase 1 vaccine study,clinical_study,UP,2.898547970379774,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,9,411,0.125,2.964855117372811,0.04555481283422459
media release,torm plc capital increase in connection with delivery of one 2015 built mr vessel,share_capital_increase,DOWN,-3.110170791459808,10941282304.0,57061410.0,376187.8888888889,-0.051,374739.0,0.005215239714556953,0.1515999603296736,0,14,242,0.0,0.44103395543252777,0.0
company announcementfor rockwool a srelease no 55 2024to nasdaq copenhagen 2 october 2024 rockwool a s transactions in connection with share buy back programme as mentioned in announcement no 02 2024 rockwool a s has initiated a share buy back programme which will run from 8 february 2024 until 7 february 2025 during this period the company will buy own shares for up to a maximum of 160 meur the programme is implemented in accordance with eu commission regulation no 596 2014 of 16 april 2014 and eu commission delegated regulation no 2016 1052 of 8 march 2016 which together constitute the safe harbour regulation the following transactions have been executed during the period 25 september 1 october 2024 with the transactions stated above rockwool a s owns 375 483 b shares corresponding to 1 74 percent of the company s total share capital an overview showing the transaction data for the period 25 september 1 october 2024 is enclosed further information,rockwool a s transactions in connection with share buy back programme,changes_in_companys_own_shares,DOWN,-1.8770226537216828,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.12222222222222223,0.8866002429130597,0.0
oslo norway 9 may 2023 pci biotech ose pcib invites to a webcast presentation of the company s q1 2023 interim report on friday 12 may 2023 08 30am 09 30am cest local time,pci biotech invitation to q1 2023 results presentation,interim_information,UP,9.242146234319629,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,1,9,780,0.0,0.8869841129646596,0.05000000000000002
los angeles feb 05 2024 globe newswire immix biopharma inc nasdaq immx the company a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced that it intends to offer and sell shares of its common stock in an underwritten public offering all of the shares of common stock in the underwritten public offering are to be sold by the company the company also expects to grant the underwriters a 30 day option to purchase additional shares of common stock offered in the public offering the offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering,immix biopharma announces proposed public offering of common stock,shares_issue,DOWN,-7.103823312288768,61330060.0,18058632.0,290605.0,0.301,58200.0,0.2944499320561565,0.09346626282280733,0,15,508,-0.13666666666666666,0.9253604538231538,-0.037500000000000006
radnor pa may 02 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other diseases driven by dysregulated aldosterone today announced it will report its financial results from the first quarter ended march 31 2024 before the financial markets open on thursday may 9 2024,mineralys therapeutics to announce first quarter 2024 financial results and host conference call on thursday may 9 2024,earnings_releases_and_operating_results,UP,2.2656246682163377,919949376.0,43490817.0,793180.0,-0.18,767600.0,0.04727522854474984,0.09346626282280733,3,8,422,0.05357142857142857,0.8131647725786432,0.028920454545454548
media release,finalization of acquisition of a controlling stake in agrogeneration,mergers_acquisitions,UP,1.0344874539926634,12196446.0,85702564.0,176590.63636363635,1.101,385968.0,7.0268473291317814,0.1515999603296736,3,8,240,0.0,0.8249974782717295,0.0
jupiter fla march 26 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial protein production platforms today announced the online publication of the manuscript filamentous fungus produced human monoclonal antibody provides protection against sars cov 2 in hamster and nonhuman primate models in nature communications springer nature an international journal publishing peer reviewed research in all fields of science and technology,dyadic announces publication of c1 monoclonal antibody in nonhuman primate study in nature communications,clinical_study,UP,0.6097555213709185,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,1,8,459,0.1,0.7846450948942033,0.1628169191919192
02 oct 2024 08 58 cest aker horizons asa new ppa product gives businesses a better alternative for their electricity supply mainstream renewable power mainstream the pureplay global wind and solar company majority owned by aker horizons asa has reached financial close on its 50 mw ilikwa solar pv plant the power from the plant will supply multiple private commercial and industrial customers under flexible shorter term power purchase agreements ppas in a new to market product called renewable energy supply agreements resas this new product opens up the energy market in south africa by giving a wider range of businesses access to affordable reliable and renewable power through shorter term energy contracts of between five and 10 years commenting on the announcement mainstream s general manager for africa hein reyneke said we are excited to bring this new product to market offering customers the opportunity to secure flexible clean and lower cos,mainstream renewable power reaches financial close on 50 mw solar pv plant to provide new flexible ppas to private customers in south africa,product_services_announcement,DOWN,-0.6766964400073892,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.13961675579322638,0.8866002429130597,0.0
on the annual meeting of shareholders of jsc amber latvijas balzams which took place on october 1 2024 the shareholders decided to amend the articles of association of the company to reduce the number of the management board members and supervisory board members till the number stipulated by law during the shareholders meeting a new supervisory board was elected for the next five years valizhan abidov velga celmiņa and boriss nešatajevs according to the resolution of the newly elected supervisory board valizhan abidov who served at the supervisory board for significant period was appointed as the chairman while boriss ņešatajevs was appointed as the deputy considering the amendments in the articles of association guntars betlers decided to leave his position in the management board while continuing his role as the leader of the logistic division within the company joint stock company amber latvijas balzams is the leading producer of alcoholic beverages in th,amber latvijas balzams announces changes in the management and supervisory board,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,261,0.07954545454545454,0.8866002429130597,0.2045833333333333
media release,sisäpiiritieto positiivinen tulosvaroitus pihlajalinna nostaa kannattavuusohjeistusta vuodelle 2024 ja antaa ennakkotiedot vuoden 2024 kolmannen vuosineljänneksen liikevaihdosta ja kannattavuudesta,earnings_releases_and_operating_results,UP,5.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.0
lawrenceville n j july 31 2024 globe newswire imunon inc nasdaq imnn a clinical stage company in late stage development with its dna mediated immunotherapy today announced that it has entered into definitive securities purchase agreements for a registered direct offering of its common stock priced at the market under nasdaq rules in a concurrent private placement and also pursuant to the securities purchase agreements the company has agreed to issue to the investors unregistered warrants to purchase shares of common stock upon the closing of the offering which is anticipated to occur on or about august 1 2024 the company expects to receive gross proceeds of 10 million before deducting placement agent fees and other offering expenses payable by the company the closing of the offering is subject to customary closing conditions,imunon announces 10 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,2,8,332,-0.11018518518518518,2.964855117372811,0.07441534914361002
planegg martinsried october 29 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will attend bio europe from november 4 6 2024 in stockholm as well as at the investival showcase biotech heathcare medtech conference on november 18 2024 in london in addition the company will present at the deutsches eigenkapitalforum from november 25 27 2024 in frankfurt,medigene to present at upcoming investor conferences,trade_show,DOWN,-1.6930006855879798,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,6,242,0.0,1.3169799228985475,0.05994214119214119
of evaluable participants at month 6 achieved target absolute neutrophil count anc increase with once daily oral mavorixafor stable dose g csf as of the interim analysis data cut off date,x4 pharmaceuticals announces positive interim clinical data from ongoing six month phase 2 trial of mavorixafor in chronic neutropenia cn and initiation of pivotal phase 3 cn trial,clinical_study,DOWN,-7.103823312288768,12156248.0,4364496.0,363495.0,0.663,396700.0,0.35903314904401423,0.09346626282280733,3,6,366,0.2318181818181818,1.4412990038402507,0.08954545454545454
pma based on overwhelmingly positive results from the pivotal c guardians clinical study that were first presented at linc 2024 in may,inspiremd announces submission of premarket approval application to fda seeking u s regulatory approval of the cguard prime carotid stent system,clinical_study,UP,0.3676467043408923,67688696.0,16849440.0,286250.0,0.613,4867100.0,0.2489254631231188,0.09346626282280733,0,7,285,0.32575757575757575,0.6085732039686736,0.09777056277056276
new york and san diego oct 18 2023 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure related disorders and ligand pharmaceuticals incorporated nasdaq lgnd today announced that ligand has acquired a 13 percent portion of the royalties and milestones owed to ovid related to the potential approval and commercialization of soticlestat in return ovid will receive a 30 million payment less certain reimbursable expenses,ovid therapeutics and ligand pharmaceuticals enter into a 30 million agreement for a interest in soticlestat royalties and milestones extending ovid s cash runway into 2026,partnerships,DOWN,-2.01883744274344,21731064.0,50354780.0,1012130.0,0.065,720700.0,2.317179683424613,0.09346626282280733,2,8,619,0.06914038342609771,0.7642184815786688,0.06818181818181818
san diego aug 01 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that it plans to host a conference call and webcast on thursday august 8 2024 at 4 30 p m et to discuss its financial results for the second quarter ended june 30 2024 and provide business highlights,bioatla to announce second quarter 2024 financial results and provide business highlights on august 8 2024,conference_call_webinar,UP,2.209949299826521,23390608.0,45152550.0,596440.0,0.911,569400.0,1.930370942046483,0.09346626282280733,3,8,331,-0.019047619047619046,1.087702859114621,0.02022435236720951
media release,banco comercial português s a informa sobre resultados do bank millennium polónia nos primeiros nove meses de 2024,financial_results,UP,0.0710947833929026,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,242,0.0,0.8866002429130597,0.0
tel aviv israel and miami jan 31 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention carotid stent system eps for the prevention of stroke today announced that it has received ce mark recertification under the european union s new medical device regulation mdr regulatory framework mdr replaced the previous mdd framework which had governed the approval and marketing of medical devices in the eu until may of 2021,inspiremd receives ce mark recertification under eu s new medical device regulation mdr regulatory framework,regulatory_filings,DOWN,-0.3389827220887212,65865896.0,16849440.0,286250.0,0.613,4867100.0,0.2558143291636084,0.09346626282280733,2,7,514,0.01515151515151515,0.6085732039686736,0.10213636363636362
media release,totalenergies se third quarter 2024 results,earnings_releases_and_operating_results,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.0,0.21718000818528868,0.0
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
missing,medigene ag implements announced 2 1 share capital reduction and consolidation of the shares effective august 29 2024,changes_in_share_capital_and_votes,DOWN,-0.8968601235628331,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,0,5,306,0.19999999999999998,1.3169799228985475,0.03844832251082251
media release,shell plc 3rd quarter 2024 unaudited results,earnings_releases_and_operating_results,UP,0.9792533652911048,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,3,8,240,0.0,0.21899596206973576,0.0
results from ovation 2 study of imnn 001 to be highlighted in late breaking acceptance,imunon to present phase 2 data of imnn 001 in treatment of newly diagnosed ovarian cancer at sitc 39th annual meeting,clinical_study,UP,1.041671905356266,17824266.0,12808492.0,12655315.0,2.143,945100.0,0.7185985666955375,0.09346626282280733,2,9,241,-0.05454545454545454,2.964855117372811,0.045528198653198654
media release,euronext oslo børs bw energy limited received application for listing of bonds,exchange_announcement,DOWN,-0.4347842672596807,8877470720.0,51507273.0,112603.25,1.177,77531.0,0.005802021163974056,0.1515999603296736,3,14,239,-0.07142857142857142,0.38625946949671847,0.0
kraig labs otcqb kblb leverages new production center s expanded capacity to launch its largest bam 1 cycle for finished silk reeling and future product,kraig biocraft laboratories leverages new production center for largest ever batch of spider silk parental lines,product_services_announcement,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,271,0.014545454545454539,0.8071333009212691,0.12231060606060608
media release,sydbank share buyback programme transactions in week 43,changes_in_companys_own_shares,DOWN,-0.9036144578313252,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,10,242,0.0,0.8866002429130597,0.3
first half sales performance in line with full year 2024 guidance,valneva reports half year 2024 financial results and provides corporate updates,financial_results,UP,9.242146234319629,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,1,319,0.044444444444444446,0.6494694268312979,0.06262626262626263
conference call scheduled for wednesday may 15 2024 at 9 00 am et conference call scheduled for wednesday may 15 2024 at 9 00 am et,immucell to announce unaudited financial results for the quarter ended march 31 2024,conference_call_webinar,UP,3.754941884763912,54496424.0,6007971.0,25445.0,0.306,14200.0,0.11024523370560975,0.09346626282280733,2,13,415,0.0,0.6298264199719535,0.0
media release,le premier vêtement biorecyclé 100 fibre à fibre du monde dévoilé par carbios on patagonia puma pvh corp et salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
endomines finland plc inside information 2 10 2024 at 14 00 eest inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly pampalo s gold production increased by 21 4 percent in july september compared to the corresponding period in 2023 in january september 2024 gold production has increased by 9 9 percent compared to the corresponding period in 2023 published production volumes are based on preliminary data the final figures may change slightly after final specifications have been received for all deliveries to customers however the change in the figures reported here is not expected to be significant the company s full year 2024 production is expected to increase in line with guidance by 15 compared to the previous year in terms of production volumes the quarter was clearly the best since the start of 2022 the growth of our production continued according to the plan towards the annual pr,inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly,earnings_releases_and_operating_results,DOWN,-0.240969365109148,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.21845238095238093,0.8866002429130597,0.0
se venligst vedlagte vedhæftede filer vedlagte filer indberetning af ledende medarbejder mhi 25_09_2024 pdf indberetning af ledende medarbejder mhi 26_09_2024 pdf selskabsmeddelelse 24_2024 ledende medarbejderes transaktioner_mhi pdf,ledende medarbejderes transaktioner,company_regulatory_filings,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,273,0.0,0.8866002429130597,0.0
new york june 28 2024 globe newswire eyenovia inc eyenovia or the company nasdaq eyen a commercial stage ophthalmic company announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder providing for the purchase and sale of 7 575 757 shares of common stock and warrants to purchase up to 7 575 757 shares of common stock the offering the combined offering price for each share of common stock and accompanying warrant is 0 66,eyenovia announces pricing of 5m registered direct offering,shares_issue,DOWN,-3.1791844034276804,28243178.0,2433609.0,8930490.0,1.002,41800300.0,0.08616625933526319,0.09346626282280733,4,8,365,-0.0948051948051948,2.4441832149286684,0.0035227272727272724
media release,guerbet nombre d actions et de droits de vote composant le capital de la société au 30 septembre 2024,voting_rights,DOWN,-1.6541330437911184,278437920.0,5878020.0,15366.363636363636,0.764,6888.0,0.02111070216298125,0.09346626282280733,2,15,240,0.0,0.41864543118833314,0.0
new york jan 08 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced positive findings have been seen in a total of six out of eight intermediate size patient population expanded access ea patients these patients have shown improvements in fatigue scores measured by the modified fatigue impact scale mfis pet scan findings showing a reduction in microglial activation was also seen in the six patients with mfis score improvement at the three month evaluation period pet scan findings for two additional ea patients 10 total are planned to be available in late january,tiziana life sciences announces updated clinical and pet scan findings for intranasal foralumab in two new multiple sclerosis patients,clinical_study,DOWN,-3.278695092153664,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,0,7,537,0.07500000000000001,1.1109140250580023,0.0
media release,odfjell se presentation of third quarter 2024 results,earnings_releases_and_operating_results,DOWN,-0.3021102076463132,8592970752.0,15844521.0,49070.1,0.011,52497.0,0.0018438932771081774,0.1515999603296736,1,13,241,0.0,0.4144217492691169,0.0
new york july 10 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions announced that eneuro a peer reviewed open access journal from the society for neuroscience published several preclinical studies validating ov329 s mechanism of action and anti convulsant properties,eneuro publishes findings on the anti convulsant properties of ov329 and its potential effectiveness in treatment resistant seizures,clinical_study,DOWN,-1.56626647054105,22100832.0,50354780.0,1012130.0,0.065,720700.0,2.2784110571040945,0.09346626282280733,2,8,353,0.06948051948051948,0.7642184815786688,0.1700313631946285
waltham mass march 22 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced financial results for the full year ended december 31 2023 and recent corporate highlights,checkpoint therapeutics reports full year 2023 financial results and recent corporate highlights,financial_results,DOWN,-0.5263152941442201,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,4,8,463,0.0875,0.8866002429130597,0.07526859504132231
ad hoc announcement pursuant to art 53 lr,addex s partner discontinues adx71149 development in epilepsy,clinical_study,UP,0.925923527568133,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,0,1,341,0.0,0.972373032385036,-0.011190476190476186
boston jan 25 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced the publication of promising preclinical data in cancer immunology research a journal of the american association for cancer research aacr these preclinical data demonstrate that elicio s proprietary amp lymph node targeting immunotherapy platform carrying cognate peptide and adjuvant cargos boosted t cell receptor modified t cell therapies tcr t cells enhancing anti tumor function and eradicating solid tumors,elicio therapeutics announces publication of preclinical data demonstrating tcr t cell therapy in combination with lymph node targeted amphiphile immunotherapy enhanced anti tumor function and eradicated solid tumors,clinical_study,UP,1.5151500920837588,127896016.0,10299137.0,63410.0,2.164,22500.0,0.08052742628042456,0.09346626282280733,3,9,520,0.05,0.8558055682194762,0.05140963203463204
media release,polight asa continues to build positive momentum in several segments,business_contracts,DOWN,-7.103823312288768,725118720.0,112518348.0,613349.45,1.511,331673.0,0.15517231164573989,0.19535099655549074,3,7,240,0.11363636363636363,0.8385781649627817,0.0
dallas june 26 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced the pricing of an underwritten public offering of 14 361 113 shares of its common stock at a price to the public of 2 25 per share and in lieu of common stock to certain investors pre funded warrants to purchase 18 972 221 shares of its common stock at an offering price of 2 249 per pre funded warrant in each case before underwriting discounts and commissions all of the securities are being offered by taysha in addition taysha has granted the underwriters a 30 day option to purchase up to an additional of the shares of its common stock offered in the public offering at the public offering price less the underwriting discount the gross proceeds from the offering to taysha are expected to be approximately 75 million before deducting underwriting discounts and commissions and other offering expenses excluding any exercise of the underwriter s option to purchase additional shares the offering is expected to close on or about june 27 2024 subject to customary closing conditions,taysha gene therapies announces pricing of public offering of common stock and pre funded warrants,shares_issue,DOWN,-7.103823312288768,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,2,9,367,-0.12337092731829574,1.0149166236087122,0.10380952380952384
jerusalem nov 14 2023 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and small therapeutic proteins today reported corporate updates and financial results for the third quarter ended september 30th 2023,entera bio reports q3 2023 financial results highlights transformational steps and unveils vision as premier oral peptide company with five potential programs in development,financial_results,UP,0.0,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,1,7,592,-0.041666666666666664,0.6915109749530333,0.20974025974025973
selskabet har afholdt ekstraordinær generalforsamling den 21 oktober 2024 kl 10 00 på selskabets adresse lyskær 8a 2730 herlev med følgende dagsorden,referat fra ekstraordinær generalforsamling,clinical_study,DOWN,-4.696800970514925,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,4,250,0.0,0.8866002429130597,0.0
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in col4a and patients have significant unmet medical needs with no disease modifying treatments currently available,eloxx pharmaceuticals key opinion leader event highlights significant unmet need in treatment of alport syndrome patients with nonsense mutations and additional positive results from phase 2 clinical study evaluating elx 02,clinical_study,DOWN,-0.9852207491816546,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,9,731,0.2396103896103896,2.2721670857062097,0.19635714285714287
media release,recording of lhv group s 22 october investor webinar,financial_results,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience,pacira biosciences appoints shawn cross as chief financial officer,clinical_study,DOWN,-1.0863381163181691,1110849792.0,45834212.0,557500.0,0.511,435200.0,0.04126049474022857,0.09346626282280733,0,8,250,0.15,0.7130794063724827,0.1382682491980013
conference call scheduled for wednesday february 28 2024 at 9 00 am et conference call scheduled for wednesday february 28 2024 at 9 00 am et,immucell to announce unaudited financial results for the quarter and year ended december 31 2023,conference_call_webinar,DOWN,-2.4621232817268512,57165168.0,6007971.0,25445.0,0.306,14200.0,0.10509845785811388,0.09346626282280733,4,9,498,0.0,0.6298264199719535,0.0
27 sep 2024 10 08 cest oslo børs has received an application for isin no0013335653 to be admitted to stock exchange listing the market abuse regulation mar applies from the time the application has been made including the issuer s disclosure obligation on inside information more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site oslo børs oslo børs newspoint,euronext oslo børs færder kommune received application for listing of bonds,exchange_announcement,UP,0.4901956201103737,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.5,0.8866002429130597,0.08930555555555555
pratteln schweiz 10 september 2024 santhera pharmaceuticals six sann gibt die unterzeichnung einer exklusiven vertriebsvereinbarung mit genesis pharma für agamree vamorolon zur behandlung von duchenne muskeldystrophie dmd in 20 märkten in zentral und osteuropa bekannt,santhera schliesst mit genesis pharma eine exklusive vertriebsvereinbarung für agamree vamorolon in zentral und osteuropa ab,geographic_expansion,UP,1.3043466092057148,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,291,0.0,0.5209522992128177,0.07738095238095238
jerusalem june 03 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and small therapeutic proteins today announced phase 1 clinical data for its hypoparathyroidism focused investigational program eb612 as presented on june 1st at the endocrine society endo 2024 annual meeting,entera bio reports phase 1 clinical data of first in class oral pth 1 34 peptide candidate eb612 for patients with hypoparathyroidism at endo 2024,clinical_study,UP,0.0,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,0,8,390,0.0,0.6915109749530333,0.048218031968031975
media release,lancement d une augmentation de capital d un montant d environ 36 6 m avec maintien du droit préférentiel de souscription des actionnaires,shares_issue,DOWN,-6.88946716859099,67170584.0,14323264.0,15862.954545454546,1.806,9661.0,0.2132371515483623,0.1515999603296736,0,7,243,0.0,0.5487288764223092,0.0
safety transcript splicing correction and clinical outcome measures data at 5 mg kg pgn edodm1 dose level in patients from freedom dm1 clinical trial expected in 2024,pepgen announces first patient dosed in phase 1 freedom dm1 clinical trial of pgn edodm1 for myotonic dystrophy type 1 dm1,clinical_study,DOWN,-0.1508330122054487,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,0,8,558,0.075,1.4553932872573117,0.0553030303030303
approximately 40 centers currently open,polypid announces enrollment of the 100th patient in the ongoing shield ii phase 3 trial,clinical_study,DOWN,-3.32369966094949,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,0,7,502,-0.2,0.7168605096826995,0.0005291005291005272
media release,ab akola group s notification about the annual information for the financial year 2023 2024,financial_results,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.06441783324900209
company maintains strong cash position of 184 8 million company maintains strong cash position of 184 8 million,rapt therapeutics reports third quarter 2023 financial results,financial_results,UP,2.3539624917488884,145435008.0,6191111.0,99294.6,-0.137,87900.0,0.042569606074487926,0.09346626282280733,0,8,593,0.21666666666666667,1.6028075568485736,0.17053030303030303
media release,okea asa third quarter 2024 financial results,earnings_releases_and_operating_results,UP,2.592914422193692,1743609856.0,49214020.0,237131.55,0.316,511142.0,0.028225362359961332,0.1515999603296736,3,6,240,0.0,0.3605190803173505,0.0
virage the phase 2b clinical trial of vcn 01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma pdac is expected to complete enrollment in the third quarter of 2024,theriva biologics reports second quarter 2024 operational highlights and financial results,clinical_study,UP,0.0,3603094.0,8173972.0,1624850.0,0.833,91200.0,2.268598043792363,0.09346626282280733,1,8,319,0.0,1.5225134880447404,0.06278720538720539
media release,euronext oslo børs b2 impact asa received application for listing of bonds,exchange_announcement,DOWN,-0.4115222299809098,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,9,241,0.0,0.2679946872688963,0.0
new york feb 06 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders today announced that management will participate in a virtual presentation at the oppenheimer 34th annual healthcare life sciences conference on tuesday february 13 2024 at 12 40 p m et,ovid therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,DOWN,-0.8310241623697936,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,508,0.21212121212121213,0.7642184815786688,0.0639558853844568
media release,multiconsult asa status on share buy back,changes_in_companys_own_shares,DOWN,-0.2624671916010498,5436934656.0,19112772.0,18444.0,0.605,11946.0,0.003515358048106731,0.1515999603296736,0,7,243,0.0,0.2460638043724043,0.0
évènement en présentiel et retransmis en direct à 10h00 et 16h00 cet,valneva organise une journée investisseurs à new york le 10 octobre 2024,conference_call_webinar,DOWN,-1.1383547598285657,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,268,0.11818181818181818,0.6494694268312979,0.03253787878787878
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl gbp nav s,fund_data_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
assumes leadership role as company anticipates multiple near term clinical milestones,imunon appoints director dr stacy r lindborg as president and ceo,management_changes,UP,0.0,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,2,8,416,0.05,2.964855117372811,0.039962121212121206
immunocore converts phase 2 3 tebe am clinical trial into registrational phase 3 trial evaluating kimmtrak for previously treated advanced cutaneous melanoma,immunocore converts phase 2 3 tebe am clinical trial into registrational phase 3 trial evaluating kimmtrak for previously treated advanced cutaneous melanoma,clinical_study,UP,0.1295926010361311,1601949440.0,37423034.0,614630.0,0.835,788600.0,0.023360933288880826,0.09346626282280733,2,7,395,0.11666666666666668,0.44240182162750774,0.1142857142857143
approximately 40 centers currently open,polypid announces enrollment of the 100th patient in the ongoing shield ii phase 3 trial,clinical_study,DOWN,-3.32369966094949,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,0,7,502,-0.2,0.7168605096826995,0.0005291005291005272
los angeles oct 10 2023 globe newswire renovaro biosciences inc nasdaq renb renovaro an advanced pre clinical biotechnology firm in cell gene and immunotherapy focused on solid tumors with short life expectancy is pleased to announce the appointment of leni boeren and ruud hendriks as independent directors,renovaro biosciences appoints two finance industry experts to board of directors,management_changes,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,8,627,0.11666666666666665,1.5631250973582267,0.15
redwood city calif may 23 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced that senior management will present at the upcoming td cowen 5th annual oncology innovation virtual summit insights for asco eha on wednesday may 29 2024 at 12 00 p m eastern daylight time 9 00 a m pacific daylight time the presentation will be accessible via webcast through a link on the investor events and presentations section of the coherus website https investors coherus com events presentations this webcast will be available for replay until june 26 2024,coherus management to present at the td cowen 5th annual oncology innovation virtual summit insights for asco eha,conference_call_webinar,UP,0.0,85083232.0,110892497.0,1236840.0,0.883,1425300.0,1.303341379885522,0.09346626282280733,3,9,401,0.19375,1.0144535837204522,0.18390495867768594
eurobio scientific signs an agreement to acquire gene expression test for breast cancer endopredict,eurobio scientific signs an agreement to acquire gene expression test for breast cancer endopredict,mergers_acquisitions,UP,0.6954063073684339,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,12,416,0.0,0.4336088389568585,0.0
planegg martinsried august 8 2024 medigene ag medigene fse mdg1 prime standard and wuxi biologics stock code 2269 hk enter into a three year multi target strategic partnership to design and co research t cell receptor tcr guided t cell engagers tcr tces for the treatment of difficult to treat tumors the collaboration combines the respective expertise of each company with medigene s 3s sensitive specific and safe tcr generation and characterization capabilities and wuxi biologics unique anti cd3 mab its industry leading tce platform and proprietary bispecific antibody platform wuxibody,medigene and wuxi biologics enter into a research collaboration for off the shelf tcr guided t cell engagers,partnerships,DOWN,-2.7649852114563966,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,4,324,0.06785714285714285,1.3169799228985475,0.03707792207792208
first of multiple planned global submissions for lifileucel in 2024 and 2025,iovance biotherapeutics submits marketing authorization application to european medicines agency for lifileucel in advanced melanoma,regulatory_filings,UP,0.4993752897633959,596072192.0,280347936.0,11775260.0,0.863,9708200.0,0.4703254735963257,0.09346626282280733,4,7,365,0.13,0.901765204231867,0.03333333333333333
record revenues of 675 million in 2023,pacira biosciences reports fourth quarter and full year 2023 financial results,earnings_releases_and_operating_results,DOWN,-1.5379441217631988,1110386688.0,45834212.0,557500.0,0.511,435200.0,0.04127770306986966,0.09346626282280733,3,8,485,0.11666666666666665,0.7130794063724827,0.24973845598845595
数据将展示adg126的作用机制及与帕博利珠单抗联用连续给药的剂量优化 10 mg kg每3周一次的方案目前正在微卫星稳定型晚期结直肠癌中进行队列扩展研究,天演药业将在第38届sitc年会上以海报形式公布其精准掩蔽型抗ctla 4安全抗体safebody adg126剂量优化试验结果,clinical_study,UP,3.35570147625903,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,8,625,0.0,0.845882180665701,0.16527777777777777
media release,fornøyde kunder og høy egenkapitalavkastning i tredje kvartal,financial_results,UP,1.1410738067002315,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,2,12,240,0.0,0.20896972559163385,0.0
south san francisco calif march 27 2024 globe newswire vaxart inc nasdaq vxrt today announced that dr sean tucker founder and chief scientific officer will present at the world vaccine congress washington 2024 in washington d c on wednesday april 3 2024 the company has appeared repeatedly at the annual event in washington d c,vaxart to present at world vaccine congress washington 2024 on april 3,trade_show,UP,0.0,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,2,8,458,0.0,1.025768835125998,0.07918470418470418
celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of 11 4 million to 12 1 million for the fourth quarter 2023 and 22 06 million to 22 76 million for the full year 2023 reflecting triple digit increases compared to the fourth quarter 2022 and full year 2022 respectively these numbers do not include revenue from other sources including research contracts such as the company s previously announced multi year research collaboration services agreement with regeneron,celularity announces net sales and total revenue expectations for fourth quarter 2023 and full year 2023,earnings_releases_and_operating_results,UP,0.3571425226269879,45263988.0,11684589.0,65020.0,0.764,90700.0,0.2581431622860982,0.09346626282280733,2,12,541,0.05833333333333332,1.6050367793919866,0.021709020146520142
palo alto calif oct 16 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that it anticipates the filing of the registration statement with the sec before the end of october 2024 relating to the previously announced proposed business combination with denali capital acquisition corp nasdaq deca for a pre transaction equity value of 2 5 billion which transaction is expected to occur by the end of fourth quarter of 2024 or the first quarter of 2025,semnur pharmaceuticals inc a wholly owned subsidiary of scilex holding company provides timing to file in october 2024 a registration statement on form s 4 with the sec relating to the previously announced proposed business combination between semnur and denali with a pre transaction equity value of 2 5 billion,mergers_acquisitions,UP,5.198019089862187,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,4,255,0.07962962962962963,1.0327724261931344,0.24269265299094844
02 oct 2024 11 27 cest atlantic sapphire asa miami fl 2 october 2024 reference is made to previous stock exchange announcements from atlantic sapphire asa atlantic sapphire or the company and together with its consolidated subsidiaries the group regarding among other things a partially underwritten rights issue of up to 6 844 800 000 new shares the offer shares with preferential subscription rights for existing shareholders to raise gross proceeds of up to the nok equivalent of usd 64 million the rights issue of which an underwriting consortium has agreed to underwrite subscription of new shares for gross proceeds of the nok equivalent to usd 60 million in addition the company will issue up to 7 700 400 000 warrants to subscribers in the rights issue the underwriters and lenders in the convertible loan resolved to be issued by the company the warrants the following close associates to primary insiders have subscribed for offer shares a,atlantic sapphire asa mandatory notification of trades,shares_issue,UP,3.3591761313427644,597371392.0,13903269.0,52395.0,0.75,40800.0,0.023274079050641917,0.1515999603296736,2,9,269,0.031228956228956235,0.3468292883317439,0.0
arcutis today announced the enrollment of the last subject in the phase 1b study evaluating arq 255 for the treatment of alopecia areata,arcutis completes enrollment of phase 1b alopecia areata study evaluating arq 255,clinical_study,UP,0.0,1721276800.0,85869346.0,2010100.0,1.778,2359700.0,0.049887005971381244,0.09346626282280733,3,8,296,-0.08333333333333333,0.6903751128737089,0.045620624231735345
boca raton florida april 29 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease continues to advance its natural killer nk cell therapy inkmune in a phase i ii trial for men with metastatic castration resistant prostate cancer mcrpc the company is pleased to announce the successful completion of the first cohort in the trial following review by the safety review committee src approval has been granted to proceed with the second dose level cohort 2 the first patient of the second cohort has been identified and will undergo screening to prepare for treatment,inmune bio inc completes first cohort and initiates second cohort of phase 1 2 study of inkmune natural killer cell therapy in patients with metastatic castration resistant prostate cancer,clinical_study,UP,0.8857429743809627,162491952.0,15213010.0,781395.0,1.567,974600.0,0.09362315987194246,0.09346626282280733,0,8,425,0.2,0.8435084668920305,0.10093518518518518
elx 02 treatment improved podocyte foot process effacement in all three patients by an average of based on a blinded kidney biopsy analysis by nipoka gmbh,eloxx pharmaceuticals reports additional confirmation that all nonsense mutation alport syndrome patients treated with elx 02 in phase 2 study had improvement in kidney morphology and clinical benefit of reduction or stabilization of proteinuria,clinical_study,DOWN,-0.4629625030505988,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,8,628,-0.15,2.2721670857062097,0.10655505364201018
arcutis today announced the commercial launch of zoryve roflumilast cream 0 for the treatment of mild to moderate atopic dermatitis,arcutis launches zoryve roflumilast cream 0 for the treatment of atopic dermatitis,product_services_announcement,DOWN,-0.09929767140568,1727832960.0,85869346.0,2010100.0,1.778,2359700.0,0.04969771267704026,0.09346626282280733,0,7,334,0.1111111111111111,0.6903751128737089,0.0764750681417348
media release,bghl eur nav s,fund_data_announcement,DOWN,-0.7194203635955471,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,243,0.0,0.8866002429130597,-0.004761904761904758
media release,equinor asa share buy back,changes_in_companys_own_shares,UP,0.4419934464203499,686391361536.0,833726970.0,3882914.5,0.022,6264036.0,0.0012146524806697652,0.1515999603296736,1,8,242,0.0,0.29388449042292014,0.0
cambridge mass oct 07 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the initiation of haelo a global pivotal phase 3 study of ntla 2002 for the treatment of hereditary angioedema hae ntla 2002 is a wholly owned investigational in vivo crispr based gene editing therapy in development as a single dose treatment for this potentially life threatening disease patient screening is active following intellia s successful end of phase 2 meeting and submission of an investigational new drug application amendment to the u s food and drug administration fda,intellia therapeutics announces initiation of haelo phase 3 study of ntla 2002 an investigational in vivo crispr gene editing treatment for hereditary angioedema hae,clinical_study,DOWN,-0.1667631296675838,975751872.0,98412511.0,6353695.0,2.134,5288300.0,0.10085813189195705,0.09346626282280733,0,7,264,0.14770021645021647,0.7800307612939593,0.041256448412698404
ad hoc announcement pursuant to art 53 lr,addex enters into at the market ads offering agreement with h c wainwright co llc,financing_agreements,DOWN,-1.563938160843887,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,514,0.0,0.972373032385036,-0.23333333333333328
radnor pa may 06 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other diseases driven by dysregulated aldosterone today announced that management will be participating in a fireside chat at the bank of america securities health care conference being held in las vegas on may 14 16 2024,mineralys therapeutics to participate in the bank of america securities health care conference,conference_call_webinar,UP,1.621621940076997,919949376.0,43490817.0,793180.0,-0.18,767600.0,0.04727522854474984,0.09346626282280733,0,8,418,-0.125,0.8131647725786432,0.03165945165945166
cambridge mass jan 31 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that management will participate in the following upcoming investor conferences to discuss the company and its programs including reni cel,editas medicine to participate in upcoming investor conferences,conference_call_webinar,UP,0.2773922443924678,181648608.0,83382193.0,2526680.0,2.096,3015800.0,0.45903017875039265,0.09346626282280733,2,9,514,0.0,1.3105556047468256,0.02603305785123967
toronto april 02 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to provide an update on the company s clinical study the study nct05322954 evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator initiated ind at the university of wisconsin madison school of medicine and public health and school of pharmacy,revive therapeutics provides update on psilocybin clinical study for methamphetamine use disorder,clinical_study,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,452,0.16,1.8889707456546947,0.10341513985453381
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
milestone achievement advances commercialization timeline for deepview system for burn indication milestone achievement advances commercialization timeline for deepview system for burn indication,spectral ai completes burn center enrollment for u s burn pivotal study,clinical_study,UP,3.4246541787590608,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,1,8,305,0.2,0.9904696515070965,0.054889745670995686
watertown mass aug 03 2023 globe newswire eloxx pharmaceuticals inc nasdaq elox a leader in ribosomal rna targeted genetic therapies for rare diseases today announced that it received notice from the nasdaq listing qualifications panel the hearings panel of the nasdaq stock market llc nasdaq that it has determined to extend the exception granted on june 2 2023 to eloxx pharmaceuticals inc the company to regain compliance with listing rule 5550 b 2 which requires a listed company to have at least 35 million in market value of listed securities in order to qualify for continued listing on the nasdaq capital market until october 9 2023 following a request for an extension and update submitted by the company on july 27 2023,eloxx pharmaceuticals granted extension by nasdaq to regain compliance with the market value of listed securities continued listing requirement,regulatory_filings,UP,1.833563255373262,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,3,9,695,0.0,2.2721670857062097,0.191600185528757
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
santa ana calif oct 17 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today presented a poster with interim phase i trial data on the use of its investigational nk cell therapy snk01 to treat patients with alzheimer s disease ad at the xxvi world congress of neurology wcn annual meeting in montreal qc canada and online,nkgen biotech presents interim phase i trial data at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,DOWN,-1.9999980926513672,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,1,8,620,0.3,2.657355742098314,0.3
south san francisco calif oct 21 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced an upcoming oral presentation and two late breaking poster presentations at the 75th annual american association for the study of liver diseases aasld the liver meeting 2024 taking place from november 15 19 2024 in san diego the presentations will highlight findings from the 96 week phase 2b harmony study evaluating the efficacy and safety of lead product candidate efruxifermin efx in patients with pre cirrhotic metabolic dysfunction associated steatohepatitis mash fibrosis stage 2 or 3 f2 f3 along with insights from an analysis using ai and digital based pathology,akero therapeutics to present data reinforcing the efficacy of efruxifermin at the 75th annual aasld the liver meeting 2024,clinical_study,DOWN,-0.8965699116267896,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,0,7,250,-0.04666666666666666,1.1395320392459187,-0.015071087862754526
media release,norsk hydro reminder invitation to hydro s capital markets day london,conference_call_webinar,DOWN,-0.319386759699206,108946178048.0,1148146500.0,4473395.3,1.218,3924732.0,0.010538657900363834,0.1515999603296736,2,10,240,0.0,0.3181340754469693,0.0
16 oct 2024 00 50 cest atlantic sapphire asa not for release publication or distribution directly or indirectly in canada japan australia or the united states or any other jurisdiction in which such release publication or distribution would be unlawful this announcement does not constitute an offer of any of the securities described herein reference is made to previous stock exchange announcements from atlantic sapphire asa atlantic sapphire or the company and together with its consolidated subsidiaries the group regarding the company s partially underwritten rights issue the rights issue in which the company shall issue in total 6 417 000 001 new shares the offer shares to raise gross proceeds of up to the nok equivalent of usd 64 million of which a consortium of new investors and existing shareholders jointly the underwriters agreed to underwrite subscription of offer shares for gross proceeds of the nok equivalent of usd 60 millio,atlantic sapphire asa resolution to increase the share capital for settlement of underwriting commission,shares_issue,DOWN,-7.103823312288768,595463232.0,13903269.0,52395.0,0.75,40800.0,0.0233486607616438,0.1515999603296736,2,0,255,-0.0018939393939393923,0.3468292883317439,0.026599326599326602
media release,gentian diagnostics third quarter 2024 report,earnings_releases_and_operating_results,UP,3.61990598756426,999371584.0,6336272.0,36042.6,0.352,81.0,0.0063402563185146555,0.09346626282280733,3,8,240,0.0,0.5012591355890468,0.0
inside information 2024 09 24 16 00 cest as madara cosmetics has received the notification of sustainability manager anete vabule on transactions with securities issued by as madara cosmetics the shares of as madara cosmetics are admitted to trading on nasdaq baltic first north market the certified adviser for as madara cosmetics is zab eversheds sutherland bitāns sia as madara cosmetics was founded in 2006 and has become one of the leading cosmetics manufacturers in northern europe and a leader in latvia the company s brand mádara is a pioneer in the natural skincare and make up segment in latvia since november 2017 the company s shares have been listed on the nasdaq baltic alternative market first north for more information visit investors madaracosmetics com contact information address 131 zeltiņu street mārupe district mārupe lv 2167 latvia contact person gunta šulte member of the management board e mail ir madaracosmeti,on transactions under regulation no 596 2014,trading_information,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,14,276,0.275,0.8866002429130597,0.275
irvine calif oct 16 2024 globe newswire biomerica inc nasdaq bmra the company a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended august 31 2024,biomerica reports first quarter fiscal 2025 financial results,earnings_releases_and_operating_results,UP,0.0,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,2,9,255,0.1285714285714286,1.5245042583012947,0.15976807047119548
se venligst vedlagte,bestyrelsesmedlemmers direktørers eller nærtstående personers handel med orphazyme aktier,company_regulatory_filings,UP,2.0080321285140563,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,12,263,0.0,0.8866002429130597,0.0
tampa fla may 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will participate in an analyst led fireside chat at the 2024 jefferies global healthcare conference at 11 00 am et on thursday june 6 2024 in new york live audio of the event can be accessed by visiting the events page of the company s website at investor pacira com a replay of the webcast will also be available for two weeks following the event,pacira biosciences to participate in fireside chat at the 2024 jefferies global healthcare conference,conference_call_webinar,UP,0.751877346662958,1110386688.0,45834212.0,557500.0,0.511,435200.0,0.04127770306986966,0.09346626282280733,3,8,394,0.11212121212121212,0.7130794063724827,0.15213227513227512
media release,fiskars corporation s directed share issue without consideration based on the restricted share plan,shares_issue,DOWN,-2.9754206792492868,1157121792.0,36127016.0,13413.65,0.866,11916.0,0.03122144639377771,0.1515999603296736,1,9,242,0.0,0.21141844058764958,0.0
oslo norway 13 october 2023 pci biotech ose pcib today announced a research collaboration agreement with the aim to address critical pain points in the manufacturing of gene therapies,pci biotech initiates field testing of its proprietary technology for gene therapy manufacturing,partnerships,UP,3.676467043408923,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,4,4,624,0.0,0.8869841129646596,0.010995370370370378
san diego nov 01 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer of anaptys and or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in november,anaptys announces participation in november investor conferences,conference_call_webinar,DOWN,-1.0423058360543165,687503680.0,17605381.0,784220.0,-0.266,445700.0,0.02560768983811112,0.09346626282280733,2,9,605,0.125,0.871343469962729,0.3438773011500284
in8bio to present at international society for cell gene therapy isct 2024,in8bio to present at international society for cell gene therapy isct 2024,trade_show,UP,0.0,7446425.0,2577285.0,392516.85,0.183,187400.0,0.34611038182752124,0.09346626282280733,4,8,400,0.0,1.2777111391401192,0.08928571428571429
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report second quarter 2024 financial results and provide a corporate update on thursday august 1 2024,conference_call_webinar,DOWN,-0.2421362858288849,162489600.0,15213010.0,781395.0,1.567,974600.0,0.09362451504588601,0.09346626282280733,3,8,338,0.0,0.8435084668920305,0.17036884411884412
reykjavik iceland and london aug 15 2024 globe newswire alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma a uk headquartered global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines in europe today announced that the european medicines agency ema has accepted a marketing authorization application for avt06 alvotech s proposed biosimilar to eylea aflibercept the process to obtain marketing authorization could be completed in the third quarter of 2025,european medicines agency confirms acceptance of marketing application for avt06 a proposed biosimilar to eylea aflibercept,regulatory_filings,UP,1.2669627803791654,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,4,317,0.049999999999999996,0.44264539487962035,0.11944444444444444
toronto april 23 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today that the u s food drug administration fda has granted the company s type c meeting request for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the meeting date assigned by the fda is june 9 2024,revive therapeutics announces type c meeting request granted by fda for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,431,0.04,1.8889707456546947,0.10962100077251592
zug switzerland and boston jan 08 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today highlighted its strategic priorities and 2024 outlook as the company enters its next phase of growth,crispr therapeutics highlights strategic priorities and 2024 outlook,press_releases,DOWN,-0.1977895755833211,4069457152.0,85970729.0,2651100.0,1.742,2455300.0,0.021125846959157268,0.09346626282280733,0,7,537,-0.16666666666666666,0.5620956775766307,-0.023809523809523808
nasdaq determines that transcode therapeutics has regained compliance with continued listing requirements,nasdaq determines that transcode therapeutics has regained compliance with continued listing requirements,exchange_announcement,UP,9.242146234319629,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,0,7,383,0.0,2.0874185587937095,0.03590909090909091
aktsiaselts infortar registry code 10139414 and viroinvestment oü registry code 16894198 signed a share purchase agreement on september 13 2024 to acquire a shareholding at tallinna raamatutrükikoja osaühing trt registry code 10224203 according to the agreement obtaining approval from the competition authority and completion of additional operations are preconditions for closing of the transaction tallinna raamatutrükikoda is one of the most recognized players in its field in many manufacturing and export industries consolidation is a common trend and key to unlocking additional efficiencies this helps secure positions in both domestic and international markets noted priit tamme deputy managing director of infortar trt main area of activity is printing of books approximately 5 million printed materials are produced annually the company employs 104 people and it s production and warehouse space is approximately 8 000 sqm aktsiaselts vaba maa acquired in 2,aktsiaselts infortar signed a share purchase agreement to acquire a shareholding at tallinna raamatutrükikoja osaühing,mergers_acquisitions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,6,285,0.046666666666666676,0.8866002429130597,0.0
san diego may 30 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced the company will be presenting a poster at the american society for microbiology asm microbe 2024 conference to be held june 13 17 2024 at the georgia world congress center in atlanta georgia,cidara therapeutics to present preclinical data on cd388 at asm microbe 2024 conference,conference_call_webinar,UP,2.2842678911565506,642005120.0,4118697.0,696580.0,0.795,3470400.0,0.006415364724817148,0.09346626282280733,3,8,394,-0.08666666666666667,1.357695941787151,-0.02364117364117364
conference call begins today at 8 30 a m eastern time,imunon announces 11 1 month increase in overall survival in patients with newly diagnosed advanced ovarian cancer treated with imnn 001,clinical_study,UP,9.242146234319629,17868968.0,12808492.0,12655315.0,2.143,945100.0,0.7168008807223786,0.09346626282280733,1,8,333,0.1787878787878788,2.964855117372811,0.0696711432506887
eften real estate fund as s subsidiary eften tähesaju tee oü sold its property located at tähesaju road 5 tallinn in september the property was sold for 4 675 thousand euros which is 452 thousand euros below its book value the sale generated 1 9 million euros in cash proceeds after loan repayments the fund invested the proceeds from the sale into advance payments for logistics centers located at härgmäe str 8 piimamehe str 7 and paemurru road 3 in tallinn eften real estate fund as generated consolidated rental income of 2 551 thousand euros in september which is 26 thousand euros less compared to august the decrease in rental income is primarily due to the sale of the tähesaju property the fund s consolidated ebitda for september was 2 191 thousand euros an increase of 26 thousand euros from the previous month for the first nine months of this year the consolidated rental income of eften real estate fund was 23 045 thousand euros reflecting a 1 increase compared,the net asset value of eften real estate fund as shares as of 30 09 2024,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,261,0.06574074074074075,0.8866002429130597,0.12581709956709958
south san francisco calif april 30 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic disease today announced the appointment of scott gangloff as chief technology officer,akero therapeutics appoints scott gangloff as chief technology officer,management_changes,UP,1.8858252602359336,4381279232.0,65983030.0,1904080.0,-0.16,4370200.0,0.015060220201915676,0.09346626282280733,1,8,424,-0.3333333333333333,1.1395320392459187,0.0068009259259259255
alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and advanz pharma a uk headquartered global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines in europe today announced that the european medicines agency ema has accepted a marketing authorization application for avt06 alvotech s proposed biosimilar to eylea aflibercept the process to obtain marketing authorization could be completed in the third quarter of 2025,european medicines agency confirms acceptance of marketing application for avt06 a proposed biosimilar to eylea aflibercept,regulatory_filings,UP,1.2669627803791654,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,4,317,0.049999999999999996,0.44264539487962035,0.11944444444444444
media release,norden initiates share buy back programme,changes_in_companys_own_shares,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.3751516266942758,0.0
media release,réalisation de l acquisition d un bloc majoritaire d actions agrogeneration,mergers_acquisitions,UP,1.0344874539926634,12196446.0,85702564.0,176590.63636363635,1.101,385968.0,7.0268473291317814,0.1515999603296736,3,8,240,0.0,0.8249974782717295,0.0
biologics license application currently under review by u s fda pdufa goal date of december 28 2024 biologics license application currently under review by u s fda pdufa goal date of december 28 2024,checkpoint therapeutics announces cosibelimab longer term results in advanced cutaneous squamous cell carcinoma presented at esmo congress 2024,clinical_study,UP,0.4347822030685715,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,7,285,0.13333333333333333,0.8866002429130597,0.0816228846910665
sampo plc stock exchange release 27 september 2024 at 8 30 am eest sampo plc s share buybacks 26 september 2024 on 26 september 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 493 490 sampo a shares representing 1 36 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 sep,sampo plc s share buybacks 26 september 2024,changes_in_companys_own_shares,DOWN,-0.0237659177697431,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,274,0.1625,0.8866002429130597,0.1625
continuing to open connect1 edo51 trial sites in canada,pepgen reports third quarter 2023 financial results and recent corporate developments,financial_results,DOWN,-3.9999961853027344,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,2,8,598,0.0,1.4553932872573117,0.0711038961038961
dallas july 29 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it will report financial results for the second quarter ended june 30 2024 on monday august 12 2024 after the close of the stock market the company will host a corresponding conference call at 5 00 pm eastern time that day to discuss the results,spectral ai schedules 2024 second quarter financial results and conference call,conference_call_webinar,DOWN,-0.558658697003811,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,0,9,334,0.03750000000000001,0.9904696515070965,0.10412938912938914
rokiskio suris ab has completed the buy back of its own shares through the official offering market of the nasdaq vilnius stock exchange during the buy back period 23 september 2024 27 september 2024 the company acquired 861 274 treasury shares representing 2 of the company s authorised capital the total amount of the share purchase transaction is eur 1 894 802 80 settlement of repurchased shares will be on 1 october 2024 ceodalius trumpatel 370 458 55200,rokiskio suris ab acquires own shares,changes_in_companys_own_shares,UP,1.1976108173510196,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,273,0.24,0.8866002429130597,0.14333333333333334
petach tikva israel nov 01 2023 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the u s financial markets on wednesday november 8 2023 the company will host a conference call and webcast at 8 30 am eastern time to discuss the results and provide an update on business operations,polypid to report third quarter 2023 financial results and operational highlights on november 8 2023,conference_call_webinar,UP,0.0,37461748.0,4610773.0,1395250.0,1.25,337200.0,0.12307949431510777,0.09346626282280733,2,7,605,-0.04285714285714286,0.7168605096826995,0.0
preliminary monotherapy data from the ongoing cft1946 phase 1 trial in braf v600x solid tumors to be presented at esmo congress 2024 initiated monotherapy expansion cohort in melanoma and combination cohort with cetuximab in colorectal cancer,c4 therapeutics reports second quarter 2024 financial results and recent business highlights,clinical_study,UP,2.8358218302889533,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,3,7,331,0.0,0.8954742650579008,0.08197330447330446
oslo norway 23 august 2024 pci biotech ose pcib invites to a webcast presentation of the company s first half 2024 interim report on wednesday 28 august 2024 08 30am 09 00am cest local time,pci biotech invitation to first half interim 2024 results presentation,interim_information,UP,0.0,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,4,3,309,0.03333333333333334,0.8869841129646596,-0.01746913580246913
longeveron announces fda has granted fast track designation to cellular therapy lomecel b tm for the treatment of mild alzheimer s disease,longeveron announces u s fda grants fast track designation for lomecel b for the treatment of mild alzheimer s disease,clinical_study,UP,9.242146234319629,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,8,346,0.26666666666666666,1.063123411629147,0.10208333333333333
jupiter fla sept 23 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a biotechnology company focused on the efficient large scale manufacture of proteins for use in non pharmaceutical applications including food nutrition and wellness as well as animal and human health therapeutics and vaccines today provided an update on business progress and announced its attendance at the bioprocess international conference in boston september 23 26 2024,dyadic provides alternative proteins business update and announces attendance at bioprocess international conference,press_releases,DOWN,-2.439022026387315,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,0,9,277,0.04285714285714286,0.7846450948942033,0.11812993379169849
jerusalem march 20 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting glp 2 agonist developed by opko health inc nasdaq opk or opko with entera s proprietary n tab technology,entera bio announces robust pharmacokinetic data for first in class oral glp 2 peptide tablet treatment for patients with short bowel syndrome,clinical_study,UP,0.7092191985804456,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,2,8,465,0.08787878787878789,0.6915109749530333,0.05036187770562771
san diego april 18 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced that the first patient has been dosed in the fourth cohort of its phase 1 2 study of onct 534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors arpi patients in the fourth dosing cohort will receive onct 534 the company s dual action androgen receptor inhibitor daari at a dose of 300 mg taken orally each day the decision to proceed to this higher dose level was made by the study s safety review committee src after reviewing data from the patients treated to date including the third dose level of 160 mg onct 534 daily,oncternal announces first patient dosed in fourth cohort of phase 1 2 study of onct 534 for the treatment of r r metastatic castration resistant prostate cancer,clinical_study,DOWN,-0.7821195119105401,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,436,0.125,0.8866002429130597,-0.06281565656565657
eight abstracts highlighting new data from vir s chronic hepatitis b and chronic hepatitis delta programs have been accepted for presentation at aasld,vir biotechnology announces multiple abstracts highlighting new chronic hepatitis b and hepatitis delta data accepted for presentation at aasld s the liver meeting 2023,clinical_study,DOWN,-0.9009000301245093,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,2,8,626,0.0909090909090909,0.8653389999075153,0.06285511363636363
yield10 bioscience files rsr with usda aphis for elite camelina designed to produce epa dha omega 3 oils,yield10 bioscience files request for regulatory status review with usda aphis for camelina designed to produce the epa and dha components of omega 3 oil,regulatory_filings,DOWN,-4.166670805877945,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,537,0.0,0.8866002429130597,0.10385714285714287
jerusalem may 13 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and small therapeutic proteins today announced that it has been selected to present data for its investigational program eb612 at the endocrine society endo 2024 annual meeting which will be held on june 1 4 2024 in boston massachusetts,entera bio to present phase 1 data from first in class pth 1 34 peptide tablets eb612 for the treatment of hypoparathyroidism at endo 2024,clinical_study,UP,2.032518355322763,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,0,7,411,0.0,0.6915109749530333,0.045166765053128693
geneva switzerland may 8 2024 addex therapeutics six and nasdaq adxn a clinical stage pharmaceutical company pioneering allosteric modulation based drug development announced today that ceo tim dyer will present at the bio quity europe 2024 conference taking place may 12 14 2024 at the kursaal congress center in san sebastián spain,addex to present at bio quity europe 2024,conference_call_webinar,UP,2.131154717248582,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,416,-0.03333333333333333,0.972373032385036,0.002121212121212125
the u s addressable market for dry eye disease is valued at over 3 billion by independent sources the u s addressable market for dry eye disease is valued at over 3 billion by independent sources,eyenovia sgn nanopharma announce collaboration agreement to develop novel treatment for chronic dry eye disease,partnerships,UP,0.7299263086460758,27847944.0,2433609.0,8930490.0,1.002,41800300.0,0.08738918032871655,0.09346626282280733,1,8,333,-0.039999999999999994,2.4441832149286684,-0.01932156385281385
jupiter fla march 01 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health and alternative proteins for food nutrition and wellness today announced that its management will be attending the following industry events during the month of march 2024,dyadic to attend industry events in march,trade_show,DOWN,-2.222220063700145,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,8,484,0.184375,0.7846450948942033,0.1916060606060606
iso certification underscores the company s commitment to quality and excellence,biora therapeutics achieves iso 13485 certification,company_regulatory_filings,UP,0.154086737049499,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,292,0.0,1.027516639474094,0.0861156204906205
pratteln switzerland june 18 2024 santhera pharmaceuticals six sann announces that its shareholders approved all motions by the board of directors at the annual general meeting agm held today in pratteln switzerland with a large majority participating shareholders represented a total of 4 535 785 shares or 35 of the company s share capital,santhera s shareholders approve all board proposals at today s annual general meeting,annual_general_meeting,DOWN,-0.3061197182379018,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,9,375,0.07857142857142857,0.5209522992128177,0.04000000000000001
se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del vcn 01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos,theriva biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024,clinical_study,DOWN,-4.761904761904762,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,6,416,0.0,1.5225134880447404,0.08038383838383838
analysis further supports obesity associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment resistant hypertension,mineralys therapeutics presents new post hoc analysis from target htn phase 2 trial of lorundrostat in late breaking poster session at asn kidney week 2023 meeting,clinical_study,DOWN,-0.1280377992053975,916364736.0,43490817.0,793180.0,-0.18,767600.0,0.0474601600120937,0.09346626282280733,3,10,603,-0.05454545454545454,0.8131647725786432,0.0
nearing completion of enrollment the seismic extension phase 2b study in early cardiogenic shock patients is set to deliver new data nearing completion of enrollment the seismic extension phase 2b study in early cardiogenic shock patients is set to deliver new data,windtree therapeutics provides update on istaroxime clinical development and upcoming clinical trial data,clinical_study,DOWN,-0.8152165990639868,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,3,8,338,0.11818181818181818,2.339794177443606,0.017324033990700663
media release,new number of shares and votes in itab shop concept ab publ,shares_issue,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.13636363636363635,0.8866002429130597,0.012500000000000004
malvern pa oct 28 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines today announced that it will host an in person clinical showcase on tuesday november 12 2024 the event will take place from 10 a m noon et at the nasdaq marketsite in times square new york city,ocugen clinical showcase highlighting progress in retinal gene therapy clinical trials in new york city on tuesday november 12 2024,clinical_study,UP,2.4864866606417646,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,6,243,0.13636363636363635,0.7661975315521313,0.054731013842124955
g1 therapeutics added to the russell 2000 and 3000 indexes,g1 therapeutics added to the russell 2000 and 3000 indexes,corporate_action,UP,6.1403555553045885,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,362,0.0,0.8866002429130597,0.054375
copenhagen denmark sept 09 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines announces new exciting clinical phase 2 data for its lead compound evx 01 the data show that 11 out of 16 patients had objective clinical responses equaling a overall response rate orr 15 out of the 16 patients had reduction of their tumors target lesions,evaxion reports overall response rate in its phase 2 trial on lead cancer vaccine candidate evx 01,clinical_study,UP,0.5797095840604812,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,8,292,0.08727272727272727,1.4249795072460607,0.11961279461279462
summary highlights including post period events,faron reports half year financial results january 1 june 30 2023,financial_results,DOWN,-0.5347588469389063,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,0,669,-0.08333333333333333,0.7633342480324978,0.0
san diego oct 17 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the pricing of its underwritten offering of 4 412 000 shares of common stock at a public offering price of 17 00 per share capricor also granted the underwriters a 30 day option to purchase up to an additional 661 800 shares of its common stock at the public offering price less the underwriting discounts and commissions the offering is expected to close on october 18 2024 subject to the satisfaction of customary closing conditions,capricor therapeutics announces pricing of approximately 75 million public offering of common stock,shares_issue,DOWN,-5.850808140165851,433538464.0,40176259.0,3124730.0,0.85,8768900.0,0.09267057559165039,0.09346626282280733,3,6,254,-0.13030303030303034,1.3427880947904531,0.11682888669301712
los angeles feb 21 2024 globe newswire immix biopharma inc nasdaq immx a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced its 12 month progress update including shareholder letter,immix biopharma 12 month review progress update,clinical_study,UP,1.355930888354885,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,2,9,493,0.0,0.9253604538231538,-0.06841269841269841
ovaro kiinteistösijoitus oyjsisäpiiritietopörssitiedote 27 09 2024 kello 9 30 negatiivinen tulosvaroitus ovaro kiinteistösijoitus oyj n päivittää vuoden 2024 ohjeistustaan vanha oheistus ovaro kiinteistösijoitus ohjeistaa että vuoden 2024 tilikauden tulos paranee vuodesta 2023 uusi ohjeistus ovaro kiinteistösijoitus arvioi että vuoden 2024 tilikauden tulos heikkenee merkittävästi vertailuvuoteen 2023 nähden vuoden 2024 tulokseen vaikuttaa merkittävästi eräiden kehityshankkeiden myyntien ajoittuminen ohjeistuksen muutoksen syynä ovat merkittävän esisopimuksellisen kaupan siirtyminen myöhempään ajankohtaan sekä asuntomyyntien ennakoitua heikompi tulos ensin mainittu siirtyvä esisopimuksellinen kauppa on 4 1 2024 tiedotettu tampereen hervannan tonttikauppa jonka tulosvaikutus verojen jälkeen on arviolta noin 1 0 m ovaron tulos vuonna 2023 oli noin 2 6 miljoonaa euroa minkä johdosta kaupan siirtymisen vaikutus vuoden 2024 tulokseen on merkittävä ovaro kiinteistösijoitus oyj l,negatiivinen tulosvaroitus ovaro kiinteistösijoitus oyj n päivittää vuoden 2024 ohjeistustaan,financial_results,DOWN,-2.70935706024955,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.0,0.8866002429130597,0.0
rockville md april 25 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that based on the strength of the science and its relevance virage the phase 2b randomized open label placebo controlled multicenter clinical trial of systemically administered vcn 01 in combination with standard of care soc chemotherapy gemcitabine nab paclitaxel as a first line therapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma pdac has been accepted for presentation as a trial in progress poster at the 2024 american society of clinical oncology asco annual meeting being held in chicago il from may 31 june 4,theriva biologics to discuss the trial design for virage a phase 2b clinical study of systemically administered vcn 01 in combination with chemotherapy in pancreatic ductal adenocarcinoma at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-2.702702702702702,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,3,8,429,0.06070707070707071,1.5225134880447404,0.0
new york june 04 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced it has been honored with an invitation to apply for a prestigious grant from the als association head by james berry md mph and suma babu mbbs ms the director and co director of the neurological clinical research institute ncri at mass general hospital a founding member of mass general brigham the grant is offered as part of the hoffman als clinical trial awards program which is specifically designated to support a groundbreaking clinical trial,tiziana life sciences submits grant application to als association to fund clinical trial of intranasal foralumab,clinical_study,UP,0.0,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,9,389,0.0590909090909091,1.1109140250580023,0.040839045214045216
media release,ramsay sante availability of the universal registration document 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
ad hoc announcement pursuant to art 53 lr,addex shareholders approve all resolutions at annual general meeting,annual_general_meeting,DOWN,-4.683700929136315,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,0,1,362,0.05000000000000002,0.972373032385036,-0.007395833333333331
palo alto calif oct 28 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that it has set a record date of november 7 2024 the record date for the dividend of scilex preferred stock the dividend to its stockholders and certain other securityholders of scilex subject to the board s right to change the record date and conditioned upon the effectiveness of the filing of the certificate of designation with the secretary of state of the state of delaware the payment date the payment date will be determined by subsequent resolutions of the board which will be within 60 days following the record date,scilex holding company sets november 7 2024 as the record date for a dividend of preferred stock exchangeable for up to of scilex s ownership interest in semnur pharmaceuticals inc its wholly owned subsidiary,corporate_action,UP,8.362372425465292,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,0,6,243,0.16354166666666664,1.0327724261931344,0.23146798465808882
boston july 30 2024 globe newswire x4 pharmaceuticals inc nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that it will report financial results for the second quarter ended june 30 2024 and provide corporate updates on thursday august 8 2024,x4 pharmaceuticals to report second quarter 2024 financial results and host a conference call and webcast on august 8 2024,conference_call_webinar,UP,0.4624286777030121,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,1,8,333,0.049999999999999996,1.4412990038402507,0.12511363636363637
tel aviv israel and miami fla nov 02 2023 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for treatment of carotid artery disease and prevention of stroke today announced that the marvin slosman chief executive officer will participate in three upcoming investor conferences in november,inspiremd to participate in upcoming november investor conferences,conference_call_webinar,DOWN,-7.103823312288768,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,3,8,604,0.0,0.6085732039686736,0.07045454545454546
kraig labs otcqb kblb confirmed the exceptional strength and toughness of its commercially produced recombinant spider silk,kraig biocraft laboratories confirms strength and toughness of its commercially produced recombinant spider silk,product_services_announcement,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,1,7,319,0.26666666666666666,0.8071333009212691,0.10974326599326598
company maintains solid cash position of 141 6 million company maintains solid cash position of 141 6 million,rapt therapeutics reports first quarter 2024 financial results,clinical_study,DOWN,-7.103823312288768,143037264.0,6191111.0,99294.6,-0.137,87900.0,0.04328320345948452,0.09346626282280733,3,8,415,0.0625,1.6028075568485736,0.10693578643578647
media release,wästbygg gruppen ab publ publishes bond prospectus and applies for admission to trading of its bonds on nasdaq stockholm,prospectus_announcement,DOWN,-1.2195052453833148,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,10,239,0.0,0.8866002429130597,0.0
media release,innofactor plc managers transactions,managers_transactions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,240,0.0,0.8866002429130597,0.001388888888888898
simple 2 minute at home test detects an early warning sign of colorectal cancer the third most common cancer worldwide simple 2 minute at home test detects an early warning sign of colorectal cancer the third most common cancer worldwide,dubai government grants insurance reimbursement for biomerica s ez detect colorectal disease screening test,product_services_announcement,UP,4.854376011108917,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,1,8,641,0.06000000000000001,1.5245042583012947,0.008333333333333331
media release,akobo minerals reports nearly 3 kg of gold produced in october,earnings_releases_and_operating_results,UP,2.409643485941096,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,243,0.1,0.8866002429130597,0.0
brisbane calif sept 16 2024 globe newswire annexon inc nasdaq annx a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body brain and eye today announced that it has granted inducement to six new non executive employees under the terms of the 2022 employment inducement award plan the equity awards were approved on september 13 2024 in accordance with nasdaq listing rule 5635 c 4,annexon reports inducement grants to new employees under nasdaq listing rule 5635 c 4,corporate_action,UP,0.6944471119363338,263313616.0,82380157.0,1425435.0,1.259,925100.0,0.31285946488995847,0.09346626282280733,0,8,285,0.13636363636363635,0.7558344054121836,0.13462558192468904
not for release publication or distribution into or in the united states canada australia japan south africa or any other state or jurisdiction in which such release publication or distribution would be unlawful not for distribution to any u s person please see the important notice at the end of this press release,qiagen n v launches non us offering of net share settled convertible bonds,shares_issue,DOWN,-2.2095785205917715,10135903232.0,214509546.0,1439980.0,0.673,1302400.0,0.02116333799663489,0.09346626282280733,1,2,298,0.06875,0.2568422597431085,0.0
of patients demonstrated improvement or maintained stable cognitive function as per alzheimer s disease composite score adcoms following 11 weeks,nkgen biotech presented phase i clinical trial data at the 16th annual clinical trials on alzheimer s disease ctad conference,clinical_study,UP,4.571431023733957,16295543.0,10616620.0,134195.0,1.199,86400.0,0.651504524887572,0.09346626282280733,3,8,611,0.0,2.657355742098314,0.2670454545454546
needham mass may 14 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the first quarter ended march 31 2024 and provided a corporate update,candel therapeutics reports first quarter 2024 financial results and recent corporate highlights,financial_results,DOWN,-2.2548975150706254,242456992.0,41997569.0,917740.0,-0.866,856900.0,0.17321657195186188,0.09346626282280733,1,8,410,0.07142857142857142,1.2870358800144117,0.09356716322892793
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
san diego jan 04 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced that its board of directors board has approved a 1 for 20 reverse stock split of the company s common stock the reverse stock split will become effective at 12 01 a m eastern time on january 8 2024 the company s common stock is expected to begin trading on a split adjusted basis on the nasdaq capital market under the same symbol onct when the market opens on january 8 2024 with the new cusip number 68236p206,oncternal therapeutics announces reverse stock split,corporate_action,DOWN,-3.9999961853027344,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,541,0.006060606060606058,0.8866002429130597,-0.21590909090909088
media release,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,-0.004810495626822154
1 approval of the company s unaudited consolidated interim report january june 2024 to approve the company s unaudited consolidated interim report january june 2024 which were prepared by the management board and reviewed by the supervisory board of as delfingroup 2 payment of extraordinary dividends of the company 1 to pay extraordinary dividends in the total amount of eur 916 625 60 or eur 0 0202 per share from the profit of the second quarter of 2024 of as delfingroup 2 to set that the dividend ex date namely the date from which no dividends will be paid for the shares in respect to which a decision was made to pay extraordinary dividends shall be 27 september 2024 to set that the dividend record date shall be 30 september 2024 to set that the dividend payment date shall be 1 october 2024 the management board of as delfingroup subscribe to delfingroup news and updates here about delfingroup as delfingroup is a licenced fintech company established in,resolutions of the extraordinary meeting of shareholders of as delfingroup dated 16 september 2024,interim_information,UP,0.3960463117471667,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,13,284,0.2222222222222222,0.8866002429130597,0.0
copenhagen denmark aug 12 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines will provide a business update and report its second quarter 2024 financial results on wednesday august 14 2024 before opening of the nasdaq cm,evaxion to announce business update and second quarter 2024 financial results on august 14,earnings_releases_and_operating_results,DOWN,-5.246665220347692,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,7,320,0.0,1.4249795072460607,0.15382154882154883
boca raton fla sept 26 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology and inflammation company continues to advance its natural killer nk cell therapy inkmune in a phase i ii trial the care pc trial for men with metastatic castration resistant prostate cancer mcrpc the company is pleased to announce initial results from the first patient cohort in the trial,inkmune demonstrates excellent safety and increased nk cell activity in first dosing cohort,clinical_study,UP,1.440322899201239,164009296.0,15213010.0,781395.0,1.567,974600.0,0.09275699835941006,0.09346626282280733,3,8,275,0.35000000000000003,0.8435084668920305,0.13057165267392537
new york may 13 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced it has submitted an fda request to obtain orphan drug designation for intranasal foralumab for the treatment of non active secondary progressive multiple sclerosis na spms this request would make foralumab the first therapy for na spms to receive orphan drug designation our request is supported by clinical and non clinical evidence of foralumab s effectiveness in na spms the prevalence estimates in part are supported from the brigham women s hospital boston massachusetts longitudinal study the climb data of which allowed the estimate of na spms in the population,tiziana life sciences files for orphan drug designation for intranasal foralumab,product_services_announcement,UP,0.0,199810080.0,63394363.0,242895.0,0.107,139700.0,0.31727309753341776,0.09346626282280733,0,7,411,-0.009393939393939399,1.1109140250580023,0.0380989380989381
after a reduction in surgical site infection ssi rates during covid rates are now increasing signaling a return to pre covid levels,polypid hosts kol call to discuss significant unmet medical need in surgical site infections prevention and provides update on its ongoing shield ii phase 3 trial,clinical_study,UP,0.3584197536603377,37400604.0,4610773.0,1395250.0,1.25,337200.0,0.12328070958426234,0.09346626282280733,1,7,375,0.1875,0.7168605096826995,-0.03960026085026084
palo alto calif aug 09 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced a master distributor agreement with devart middle east food supplements devart middle east as master distributor and ch trading group llc ch trading group as territories distributor to expand the distribution of ztlido into the countries of morocco tunisia libya jordan iraq and south africa designated territories,scilex holding company enters into master distributor agreement among ch trading group and devart middle east for the distribution of ztlido in morocco tunisia libya jordan iraq and south africa,geographic_expansion,UP,0.0,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,4,9,323,0.22000000000000003,1.0327724261931344,0.2547753878066378
la jolla calif june 03 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova s collaborator gilbert youssef m d at harvard medical school attending physician center for neuro oncology at dana farber cancer institute and brigham and women s hospital presented new data and results of a phase 1b 2a clinical trial of mn 166 ibudilast in glioblastoma gbm at the american society of clinical oncology asco annual meeting 2024 held may 31 june 4th in chicago il,medicinova announces data from phase 1b 2a clinical trial of mn 166 ibudilast in glioblastoma patients at the american society of clinical oncology asco annual meeting 2024,clinical_study,UP,4.411760452090707,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,0,6,390,0.005194805194805192,0.8018560055721619,0.0696060606060606
redwood city calif oct 23 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that it is commencing an open label extension study in chronic urticarias that will roll over patients from the beacon and spotlight studies upon completion of their initial follow up period additionally jasper also announced it has obtained regulatory clearance in the us and in the eu to further expand the beacon study in csu by adding a 360mg single dose cohort n 4 and that enrollment in this cohort has commenced jasper continues to plan to report initial data from all doses of the beacon study up through 240mg in csu during the week of january 6th 2025 data from the newly added 360mg single dose cohort is expected to be reported in the first half of 2025,jasper therapeutics announces further expansion of clinical program in chronic spontaneous urticaria,clinical_study,DOWN,-0.747010055279865,81119344.0,9908441.0,280900.0,2.725,505700.0,0.12214646361045524,0.09346626282280733,2,8,248,0.08405998763141619,0.9821837329226573,0.16296825396825396
media release,bghl eur nav s,fund_data_announcement,DOWN,-0.7194203635955471,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,243,0.0,0.8866002429130597,-0.004761904761904758
cambridge mass and rostock germany and berlin sept 25 2024 globe newswire centogene n v the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced data from the company s rostock international parkinson s disease ropad further supporting the association of a rab32 gene mutation with parkinson s disease pd the study published in the lancet neurology builds on research from emil k gustavsson and colleagues who previously identified the rab32 c 213c g p ser71arg dbsnp rs200251693 variant as a novel monogenic cause of pd,centogene data on novel genetic risk factor for parkinson s disease in the lancet neurology,clinical_study,DOWN,-7.103823312288768,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,8,276,0.0638888888888889,3.598197549072007,0.15139235764235762
media release,aventador announces management reorganization,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,246,0.0,0.8866002429130597,0.03409090909090909
g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negativ,g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negative breast cancer mtnbc,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,369,0.04,0.8866002429130597,0.057692307692307696
san diego oct 29 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that it has entered into definitive agreements for the purchase and sale of 745 342 shares of the company s common stock at an offering price of 4 025 per share of common stock in a registered direct offering priced at the market under nasdaq rules in addition in a concurrent private placement the company will issue unregistered warrants to purchase up to 745 342 shares of common stock the warrants have an exercise price of 3 90 per share will be exercisable upon issuance and will expire five years following issuance the closing of the offering is expected to occur on or about october 29 2024 subject to the satisfaction of customary closing conditions,biora therapeutics announces 3 million registered direct offering priced at the market under nasdaq rules,financing_agreements,DOWN,-7.103823312288768,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,242,-0.1074074074074074,1.027516639474094,0.08148448773448774
media release,ramsay sante availability of the universal registration document 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
irvine calif march 28 2024 globe newswire biomerica inc nasdaq bmra a global biomedical company at the forefront of innovative gastroenterology solutions proudly announces that data from collaborators at the university of michigan utilizing its groundbreaking infoods ibs technologies will be presented in the ibs clinical session at the 2024 digestive disease week ddw annual meeting in washington dc ddw is renowned as the world s premier scientific and clinical meeting for digestive disease health care professionals,biomerica infoods ibs data to be presented at the upcoming digestive disease week ddw 2024 conference,clinical_study,UP,2.2471956014182424,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,3,8,457,0.43333333333333335,1.5245042583012947,0.06792057942057941
mainz deutschland 30 juli 2024 globe newswire biontech se nasdaq bntx biontech oder das unternehmen gab heute erste positive daten aus der laufenden klinischen phase 2 studie eudract nr 2020 002195 12 nct04526899 bei patientinnen und patienten mit inoperablem melanom im stadium iii oder iv bekannt deren erkrankung nach einer anti pd l 1 behandlung weiter fortschritt die randomisierte studie untersucht die klinische aktivität und sicherheit des mrna basierten krebsimmuntherapiekandidaten bnt111 in kombination mit libtayo cemiplimab einem monoklonalen anti pd 1 antikörper der von regeneron entwickelt wird sowie der beiden einzelnen komponenten als monotherapie,biontech gibt erste positive ergebnisse aus laufender phase 2 studie mit mrna basiertem immuntherapiekandidaten bnt111 bei fortgeschrittenem hautkrebs bekannt,clinical_study,UP,1.466339492110126,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,1,6,333,0.22727272727272727,0.5503225880253886,0.055827721661055006
ad hoc announcement pursuant to art 53 lr,addex and indivior select clinical candidates from gabab positive allosteric modulator research collaboration,licensing_agreements,UP,9.242146234319629,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,1,1,305,0.22727272727272727,0.972373032385036,-0.01068181818181818
the management board of eften real estate fund as registry code 12864036 seat tallinn a lauteri 5 calls the extraordinary general meeting of shareholders on 16 october 2024 at 15 00 venue of the general meeting radisson collection hotel second floor conference centre hall tallinn address tallinn rävala 3 the registration of participants of the general meeting starts at 14 00 on 16 october 2024 at the venue of the meeting the registration ends at 15 00 if possible we request that all shareholders arrive in time considering the time required to register the participants of the meeting the list of shareholders who shall be entitled to participate in the extraordinary general meeting shall be fixed seven days prior to the date of the general meeting i e on 09 october 2024 as at the end of the working day of the registrar of the settlement system of the fund s securities the shareholders may also participate by appointing a representative or vote prior to the meeting on,eften real estate fund as notice calling the extraordinary general meeting of shareholders,annual_general_meeting,DOWN,-0.5390753543607132,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,277,0.11250000000000002,0.8866002429130597,0.09370941558441559
02 oct 2024 09 30 cest aker bp asa aker bp asa the company is pleased to announce that it has successfully completed its senior notes offering the offering of i 750 million aggregate principal amount of 5 senior notes due 2034 the 2034 notes and ii 750 million aggregate principal amount of its 5 senior notes due 2054 the 2054 notes the 2034 notes and 2054 notes are collectively referred to as the notes the company intends to use the net proceeds of the offering for general corporate purposes and to purchase for cash any and all of its outstanding i 3 senior notes due 2025 the 2025 notes ii 2 senior notes due 2026 the january 2026 notes and iii 2 senior notes due 2026 the july 2026 notes and together with the 2025 notes and the january 2026 notes the notes the tender offers and each a tender offer the tender offers expired as of 5 00 p m new york city time on september 30 2024 the e,aker bp asa announces completion of senior notes offering,financing_agreements,UP,1.291433474209461,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,269,0.10795454545454548,0.8866002429130597,0.0
boca raton fla sept 17 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology and inflammation company today announced that results of additional analysis of blinded data from its ad02 phase ii alzheimer s disease ad trial demonstrated exceptional performance of the novel cognitive measure emacc as well as highly significant correlation between emacc and the clinical dementia rating sum of boxes cdr sb the accepted endpoint for ad trials,inmune bio announces results of additional blinded interim analysis of phase 2 alzheimer s disease trial demonstrating correlation between emacc and cdr sb endpoints,clinical_study,UP,2.1355574044616725,163658592.0,15213010.0,781395.0,1.567,974600.0,0.09295576733300993,0.09346626282280733,1,8,284,0.5208333333333333,0.8435084668920305,0.1119877631187155
media release,vallourec to showcase its cutting edge energy transition solutions at adipec 2024,trade_show,DOWN,-0.2763382438610058,3525931264.0,162901440.0,740660.0,2.188,750859.0,0.04620096870952502,0.1515999603296736,2,7,241,-0.6,0.31596392785341165,0.0
endomines finland plc inside information 2 10 2024 at 14 00 eest inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly pampalo s gold production increased by 21 4 percent in july september compared to the corresponding period in 2023 in january september 2024 gold production has increased by 9 9 percent compared to the corresponding period in 2023 published production volumes are based on preliminary data the final figures may change slightly after final specifications have been received for all deliveries to customers however the change in the figures reported here is not expected to be significant the company s full year 2024 production is expected to increase in line with guidance by 15 compared to the previous year in terms of production volumes the quarter was clearly the best since the start of 2022 the growth of our production continued according to the plan towards the annual pr,inside information endomines finland plc operational update jan sep 2024 a strong quarter increased production volumes significantly,earnings_releases_and_operating_results,DOWN,-0.240969365109148,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.21845238095238093,0.8866002429130597,0.0
media release,resolutions of the annual general meeting of shareholders of ab akola group,annual_general_meeting,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.05000000000000002,0.8866002429130597,0.07018496654860291
norwood mass may 09 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a fireside chat and one on one investor meetings at the 2024 rbc capital markets global healthcare conference to be held may 14 15 2024 in new york ny,corbus pharmaceuticals to participate in the 2024 rbc capital markets global healthcare conference,conference_call_webinar,UP,2.6657256060050303,102789112.0,7524021.0,127840.0,3.117,146300.0,0.07319861854629117,0.09346626282280733,3,8,415,0.04545454545454545,0.9919200800994142,0.04356473829201101
eurneffy offers adults and children 30 kg in europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the eu,eurneffy adrenaline nasal spray approved in the eu as the first and only needle free emergency treatment of allergic reactions anaphylaxis,product_services_announcement,UP,1.1574044605614096,1694184576.0,51755600.0,1240295.0,0.872,1940800.0,0.030548973667435867,0.09346626282280733,0,9,306,0.23376623376623376,0.6899910717831225,0.25583874458874456
saint herblain france et schlieren zurich le 16 octobre 2024 valneva se nasdaq valn euronext paris vla société spécialisée dans les vaccins et limmatech biologics ag société de biotechnologie développant des vaccins pour la prévention des maladies potentiellement mortelles ont annoncé que l agence de santé américaine food and drug administration fda a accordé le statut fast track à shigella4v s4v candidat vaccin bioconjugué tétravalent contre la shigellose le plus avancé au monde pour lequel valneva a obtenu une licence exclusive mondiale de limmatech,valneva and limmatech reçoivent le statut fast track de la fda pour leur candidat vaccin tétravalent contre la shigellose s4v,clinical_study,UP,2.003645502739252,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,11,254,0.2,0.6494694268312979,0.04760890151515151
cambridge mass and rostock germany and berlin may 14 2024 globe newswire centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced the discovery of a new small molecule together with evotec se frankfurt stock exchange evt mdax tecdax isin de0005664809 nasdaq evo the new molecule has the potential to treat patients with type 2 and type 3 gaucher disease otherwise known as neuronopathic gaucher disease the discovery has been the result of the collaborative work under the existing drug discovery partnership which has been in place since 2020,centogene and evotec discover promising new molecule to treat gaucher disease,partnerships,UP,0.0250104017485818,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,1,8,410,0.08238636363636363,3.598197549072007,0.15324675324675321
woburn mass nov 08 2023 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today announced that the company will report its third quarter 2023 financial results and provide a corporate update on tuesday november 14 2023,yield10 bioscience to announce third quarter 2023 financial results and host a conference call on tuesday november 14 2023,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,598,0.0,0.8866002429130597,0.037142857142857144
needham mass aug 13 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the second quarter ended june 30 2024 and provided a corporate update,candel therapeutics reports second quarter 2024 financial results and recent corporate highlights,financial_results,UP,0.0,244360896.0,41997569.0,917740.0,-0.866,856900.0,0.17186697907671775,0.09346626282280733,1,8,319,0.0,1.2870358800144117,0.07627213574823868
media release,netcompany final transactions in connection with share buyback programme,changes_in_companys_own_shares,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,241,0.0,0.8866002429130597,0.225
dallas july 02 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has achieved pediatric patient enrollment at burn centers for its 2024 pivotal study designed to validate the ai driven algorithm used by its deepview system for its burn indication,spectral ai achieves pediatric enrollment in burn centers for pivotal u s burn study,clinical_study,UP,1.5384600336500307,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,1,8,361,0.21666666666666667,0.9904696515070965,0.10434343434343435
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
oslo norway 4 may 2023 the annual general meeting of pci biotech holding asa will be held at the company s office at oslo cancer cluster innovation park on 25 may 2023 at 10 00am cest,pci biotech notice of annual general meeting 2023,annual_general_meeting,UP,0.0,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,3,4,786,0.05000000000000002,0.8869841129646596,0.0
norwood mass aug 20 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced the appointment of winston kung to its board of directors the appointment was effective as of august 16 2024 mr kung will also chair the audit committee,corbus pharmaceuticals strengthens board of directors with appointment of winston kung,management_changes,UP,1.2027504360192365,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,1,8,312,0.6,0.9919200800994142,0.034977777777777774
media release,nanobiotix participera à plusieurs conférences investisseurs en novembre,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,8,240,0.0,0.5536010581445269,0.0
selskabet har i forlængelse af sm 15 2024 hvor man ifm svar fra nasdaq havde opnået en betinget godkendelse for fortsat børsdrift med ønske om en opdateret risikobeskrivelse iht selskabet nye formål forretningsområde opdateret sin risikobeskrivelse og fået accept fra nasdaq som samtidig har godkendt selskabet til fortsat at være børsnoteret uden forbehold selskabet vil i forlængelse af denne meddelelse indkalde til en ekstraordinær generalforsamling hvor alle de fornødne forslag vil blive stillet samt vedhæfte de opdaterede risikoklassifikation af selskabet,business update nasdaq godkender identitetsændring,exchange_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,9,280,0.0,0.8866002429130597,0.0
marlborough mass nov 02 2023 globe newswire akoya biosciences inc nasdaq akya akoya the spatial biology company today announced that company management will be participating in three upcoming investor conferences,akoya to participate at three upcoming investor conferences,conference_call_webinar,UP,2.639293604222512,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,3,8,604,0.0,0.8573192373918191,0.36818181818181817
planegg martinsried october 17 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer presented a universal detection system for 3s specific sensitive and safe recombinant tcrs rtcrs unitope tracr at the american society of gene cell therapy asgct to be held october 16 17 2024 in philadelphia pa in the us,medigene presents unitope and tracr a universal detection system for 3s recombinant tcrs at asgct 2024,press_releases,UP,0.4975119657066306,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,5,254,0.08571428571428572,1.3169799228985475,0.06033255693581781
pratteln schweiz 31 juli 2024 santhera pharmaceuticals six sann gibt bekannt dass der verwaltungsrat dr oliver p kronenberg per 1 august 2024 zum chief legal officer und corporate secretary der santhera pharmaceuticals ag ernannt hat,santhera ernennt dr oliver p kronenberg zum chief legal officer und company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.13333333333333333,0.5209522992128177,0.03714285714285715
malvern pa oct 22 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies biologics and vaccines today announced that the data and safety monitoring board dsmb for the ocu410st gardian clinical trial recently convened and approved enrollment for the second phase of the phase 1 2 clinical trial ocu410st aav5 hrora is a novel modifier gene therapy candidate being developed for stargardt disease,data and safety monitoring board approves initiation of phase 2 of ocu410st gardian clinical trial for stargardt disease,clinical_study,DOWN,-0.2132232202152007,303712224.0,287364635.0,6243265.0,4.237,6951700.0,0.9461740828712907,0.09346626282280733,1,7,249,0.03333333333333333,0.7661975315521313,0.05555400155400155
copenhagen denmark july 16 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines today showcases improved performance of its key building block evaxmhc within its ai immunology platform at the 32nd intelligent systems for molecular biology ismb conference taking place in montreal canada from july 12 16 2024,evaxion showcases improved performance of key building block in ai immunology at computational biology conference,press_releases,DOWN,-1.8736111966031144,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,1,7,347,0.26666666666666666,1.4249795072460607,0.10081369248035914
media release,new number of shares and votes in itab shop concept ab publ,shares_issue,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.13636363636363635,0.8866002429130597,0.012500000000000004
boca raton florida sept 03 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company focused on developing treatments that harness a patient s innate immune system to fight disease today announced that management will participate in the following investor conferences in september and october 2024,inmune bio inc to present at the baird 2024 global healthcare conference,conference_call_webinar,DOWN,-0.3021145207289472,160967584.0,15213010.0,781395.0,1.567,974600.0,0.09450977409215511,0.09346626282280733,1,9,298,0.0,0.8435084668920305,0.13834801092154034
cambridge mass aug 28 2024 globe newswire editas medicine inc nasdaq edit a clinical stage gene editing company today announced that management will participate in the following upcoming investor conferences to discuss the company and its programs including reni cel,editas medicine to participate in upcoming investor conferences,conference_call_webinar,DOWN,-1.0471194385354707,181573264.0,83382193.0,2526680.0,2.096,3015800.0,0.4592206537632104,0.09346626282280733,2,9,304,0.0,1.3105556047468256,0.07408449575116241
longeveron lomecel b data in alzheimer s disease selected for late breaking poster presentation at clinical trials on alzheimer s disease conf ctad24,longeveron lomecel b data in alzheimer s disease selected for late breaking poster presentation at the clinical trials on alzheimer s disease conference ctad24,clinical_study,UP,1.6759827507484213,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,9,257,-0.3,1.063123411629147,0.107174688057041
needham mass april 04 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of can 2409 plus valacyclovir prodrug together with standard of care soc chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma pdac survival data were updated with eight months of further follow up since the first analysis presented at the 2023 society for immunotherapy sitc annual meeting based on the data presented at sitc the u s food and drug administration fda granted fast track designation to the company for can 2409 in combination with valacyclovir for the treatment of patients with pdac in december 2023,candel therapeutics announces positive interim data from randomized phase 2 clinical trial of can 2409 in non metastatic pancreatic cancer,clinical_study,UP,9.242146234319629,243749632.0,41997569.0,917740.0,-0.866,856900.0,0.17229797910012845,0.09346626282280733,3,8,450,0.13545454545454544,1.2870358800144117,0.08380347593582886
dallas july 29 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it will report financial results for the second quarter ended june 30 2024 on monday august 12 2024 after the close of the stock market the company will host a corresponding conference call at 5 00 pm eastern time that day to discuss the results,spectral ai schedules 2024 second quarter financial results and conference call,conference_call_webinar,DOWN,-0.558658697003811,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,0,9,334,0.03750000000000001,0.9904696515070965,0.10412938912938914
media release,delfingroup raises 4 9 million euros from citadele bank for business development,financing_agreements,DOWN,-0.3745270276379158,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,249,0.0,0.8866002429130597,0.17936109212425003
peer reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma delta t cell based adoptive cellular therapy peer reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma delta t cell based adoptive cellular therapy,in8bio announces publication on novel gamma delta t cell therapy for glioblastoma in frontiers in immunology,clinical_study,UP,0.8333325054910776,7439537.0,2577285.0,392516.85,0.183,187400.0,0.3464308329940425,0.09346626282280733,2,8,500,0.04545454545454545,1.2777111391401192,0.0
geneva switzerland july 12 2024 addex therapeutics six adxn and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that mikhail kalinichev head of translational science will present at the thirteenth london international cough symposium taking place july 18 19 2024 at imperial college in london u k,addex to present at the thirteenth london international cough symposium 13th lics,clinical_study,DOWN,-1.0119052619891058,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,351,-0.041666666666666664,0.972373032385036,-0.00401960784313725
copenhagen denmark sept 19 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines launches an enhanced version of its clinically validated ai immunology platform with an update of its eden ai prediction model among other improvements the model can now predict toxin antigens allowing for the development of improved bacterial vaccines,evaxion launches improved ai immunology platform for vaccine antigen prediction,product_services_announcement,UP,0.96154522143432,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,3,8,282,-0.125,1.4249795072460607,0.13284301346801347
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,0.0
redwood city calif feb 07 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu as well as lower to intermediate risk myelodysplastic syndromes lr mds and novel stem cell transplant conditioning regimens today announced that management will present at the oppenheimer 34th annual healthcare conference at 4 40pm est on february 13 2024 the conference is being held in a virtual format,jasper therapeutics to present at the oppenheimer 34th annual healthcare conference,conference_call_webinar,UP,9.242146234319629,80969120.0,9908441.0,280900.0,2.725,505700.0,0.12237308494892868,0.09346626282280733,2,8,507,0.15,0.9821837329226573,-0.07777777777777777
ne pas distribuer publier ou diffuser en tout ou en partie directement ou indirectement aux etats unis ou a toute personne des etats unis ou dans toute autre juridiction dans laquelle la distribution la publication ou la diffusion serait illégale,eurobio scientific premier semestre 2024 un solide debut d exercice dans un contexte incertain projet d offre publique,financial_results,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,15,331,0.0,0.4336088389568585,0.0
all pharmacokinetic endpoints were achieved all navicap devices performed as intended no safety signals observed,biora therapeutics achieves positive interim results for clinical trial of bt 600 advancing navicap platform development,clinical_study,UP,0.6711435169794355,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,3,8,450,0.22727272727272727,1.027516639474094,0.0
watertown mass july 08 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced that c4t management will participate in a fireside chat at the ubs targeted protein degradation tpd day taking place virtually on july 15 2024,c4 therapeutics to participate in the virtual ubs targeted protein degradation day,conference_call_webinar,UP,1.9911538267184308,107220728.0,49730521.0,1021690.0,2.946,941900.0,0.46381443147821194,0.09346626282280733,0,7,355,0.0,0.8954742650579008,0.10246663059163058
media release,immutep to present new phase iib data in pd l1 negative cps 1 head and neck cancer at esmo immuno oncology 2024,clinical_study,UP,1.57894588243266,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,0,8,243,-0.05454545454545454,0.7476881311953882,0.08922832405689547
dallas aug 05 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that it will report its financial results for the second quarter ended june 30 2024 and host a corporate update conference call and webcast on monday august 12 2024 at 8 30 am eastern time,taysha gene therapies to release second quarter 2024 financial results and host conference call and webcast on august 12,financial_results,DOWN,-5.714280524221172,626364352.0,136885482.0,5054745.0,1.016,2606600.0,0.21853970706174544,0.09346626282280733,0,8,327,0.0,1.0149166236087122,0.013161122503227776
bla to be supported by existing and natural history cardiac data as discussed with the fda,capricor therapeutics announces intent to file biologics license application for full approval of deramiocel for the treatment of duchenne muscular dystrophy cardiomyopathy,regulatory_filings,UP,9.242146234319629,435595328.0,40176259.0,3124730.0,0.85,8768900.0,0.09223298877989802,0.09346626282280733,1,8,277,0.13333333333333333,1.3427880947904531,0.12513656299840514
media release,muutos glastonin johtoryhmään,management_changes,DOWN,-1.639344147877593,56298360.0,15339800.0,14584.2,0.607,41169.0,0.2724733011760911,0.1515999603296736,3,15,239,0.0,0.2342753450337208,0.0
milestone results in 8 million payment to c4 therapeutics,c4 therapeutics announces delivery of second development candidate to biogen,licensing_agreements,UP,0.0,106155624.0,49730521.0,1021690.0,2.946,941900.0,0.4684680766418932,0.09346626282280733,1,7,291,0.0,0.8954742650579008,0.04543109668109668
advances plan to launch t2lyme panel for detection of early lyme disease advances plan to launch t2lyme panel for detection of early lyme disease,t2 biosystems announces letter of intent to enter strategic partnership for lyme disease,partnerships,UP,5.509636445175157,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,1,9,417,0.1,1.9596557041969667,0.125
media release,valmet s interim review january 1 september 30 2024 record high third quarter margin but slower market activity than expected,earnings_releases_and_operating_results,DOWN,-0.0830583796804002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,240,0.02,0.8866002429130597,-0.016941094619666055
missing,pfizer and biontech receive positive chmp opinion for omicron kp 2 adapted covid 19 vaccine in the european union,regulatory_filings,DOWN,-0.9599162834847244,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,4,8,281,0.009090909090909085,0.5503225880253886,0.06923440756774091
jupiter fla march 21 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health and alternative proteins for food nutrition and wellness today announced that joseph hazelton chief business officer and doug pace executive vice president of business development will be attending the future food tech innovation investment from farm to fork event march 21 22 2024 at the san francisco marriott marquis in california,dyadic to attend future food tech event march 21 22 2024 in san francisco california,trade_show,UP,0.5988018395350123,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,3,8,464,0.1638888888888889,0.7846450948942033,0.16269781144781145
media release,oslo børs status companies placed in recovery box and penalty bench,exchange_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,243,0.0,0.8866002429130597,0.2557472753854333
boston april 30 2024 globe newswire x4 pharmaceuticals inc nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that it will be reporting financial results for the first quarter ended march 31 2024 and providing corporate updates on tuesday may 7 2024,x4 pharmaceuticals to report first quarter 2024 financial results and host a conference call and webcast on may 7 2024,financial_results,UP,9.242146234319629,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,1,8,424,0.13333333333333333,1.4412990038402507,0.15
imm 1 104 has been well tolerated demonstrating the potential for a differentiated safety profile,immuneering announces positive topline results from phase 1 portion of its phase 1 2a clinical trial of imm 1 104 in ras mutant solid tumors,clinical_study,DOWN,-7.103823312288768,112995104.0,27271404.0,2516685.0,0.002,1980700.0,0.2413503154968555,0.09346626282280733,3,7,471,0.07575757575757576,1.2966226301621697,0.08854166666666667
alvotech nasdaq alvo og samstarfsaðili þess alþjóðlega lyfjafyrirtækið advanz pharma tilkynntu í dag að lyfjastofnun evrópu ema hafi samþykkt að taka til umsagnar umsókn um markaðsleyfi fyrir avt06 sem er fyrirhuguð líftæknilyfjahliðstæða alvotech við eylea aflibercept markaðsleyfi í evrópu gæti verið veitt á þriðja ársfjórðungi 2025,lyfjastofnun evrópu tekur til umsagnar umsókn um markaðsleyfi fyrir avt06 fyrirhugaða líftæknilyfjahliðstæðu við eylea,regulatory_filings,UP,1.2669627803791654,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,4,317,0.0,0.44264539487962035,0.11944444444444444
in order to further strengthen holmen s position and competitiveness anders jernhall deputy ceo and cfo will focus on strategic issues in the dedicated role as deputy ceo stefan loréhn will take over as new cfo in the spring of 2025 by streamlining the roles in this way we strengthen the ability to develop the group says henrik sjölund president and ceo of holmen with his analytical ability and strategic vision anders is central to holmen s development stefan loréhn is a familiar holmen colleague who with his experience and profile will take on the role of cfo in an excellent way henrik sjölund continues stefan loréhn is currently cfo at lkab and has a long history at holmen before that our business concept to own and add value to the forest is in line with the times but the transition to a fossil free world is challenging to navigate being able to spend more time on holmen s long term development therefore feels very important says anders jernhall stefan loré,holmen strengthens group management,management_changes,UP,0.776254314265839,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,274,0.31652597402597404,0.8866002429130597,0.0
investigator meeting for elpis ii the on going phase 2b clinical trial evaluating lomecel b as a potential adjunct treatment for hlhs,longeveron announces completion of successful investigator meeting for on going phase 2b clinical trial evaluating lomecel b as a potential treatment for hlhs a rare pediatric cardiac disease,clinical_study,UP,7.547174267346414,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,1,9,382,0.2,1.063123411629147,0.08333333333333333
media release,totalenergies annonce le troisième acompte sur dividende de 0 79 action au titre de l exercice 2024 en hausse de près de par rapport à 2023,dividend_reports_and_estimates,DOWN,-1.7585406260747782,119299293184.0,1876930066.0,5861360.545454546,0.705,8458818.0,0.015732952106473394,0.1515999603296736,3,8,240,0.1,0.21717999936763543,0.0
ad hoc announcement pursuant to art 53 lr,addex provides update on adx71149 phase 2 epilepsy study,clinical_study,DOWN,-7.103823312288768,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,0,1,425,0.0,0.972373032385036,0.002592592592592597
new york sept 26 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions presented the results of a head to head animal study evaluating whether ov329 could be found to accumulate in mouse retinas and brains as has been previously shown to occur with vigabatrin vgb the only fda approved gaba aminotransferase gaba at inhibitor,ovid therapeutics presents pre clinical study results demonstrating ov329 does not accumulate in animal eyes in contrast with vigabatrin,clinical_study,DOWN,-0.8928562875609045,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,3,8,275,0.06742424242424241,0.7642184815786688,0.15923704659729504
media release,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.22733091145371848
anx007 demonstrated significant broad based protection from vision loss in foveal and non foveal patients and in low light settings,annexon presents new neuroprotection data showing anx007 protects vision and vision associated structures in geographic atrophy at arvo 2024 annual meeting,clinical_study,DOWN,-3.469389244597508,262216464.0,82380157.0,1425435.0,1.259,925100.0,0.31416851460555123,0.09346626282280733,1,12,416,0.19477272727272726,0.7558344054121836,0.0
selskabet annoncerede i selskabsmeddelelse 13 2024 at man havde indledt en proces med at gennemføre et identitetsskifte med nasdaq for fortsat at kunne bevare sin status som børsnoteret selskab,business update opdatering på identitetsændring,exchange_announcement,DOWN,-0.5681818181818182,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,283,0.0,0.8866002429130597,0.0
cguard was the only investigational carotid stent approved by fda for inclusion in the trials,inspiremd congratulates crest 2 investigators on completion of trial enrollment,clinical_study,DOWN,-5.050508212877766,66380568.0,16849440.0,286250.0,0.613,4867100.0,0.25383091027482624,0.09346626282280733,0,7,327,0.0,0.6085732039686736,0.09527777777777775
palo alto calif july 24 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced the release of its inaugural sustainability report which highlights sustainability efforts by the company related to its environmental footprint contributing positively to society and improving access to medicine within the communities it serves,scilex holding company announces publication of its inaugural sustainability report,environmental_social_governance,UP,0.5882347166332156,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,10,338,0.33181818181818185,1.0327724261931344,0.253108033459596
eften härgmäe oü a subsidiary of eften real estate fund as signed on 19 09 2024 a contract under the law of obligations with conus assets oü for the acquisition of properties located at härgmäe st 8 and piimamehe st 7 in tallinn on which a newly constructed business and logistics building is located the total sale price of the properties is 8 800 000 euros plus vat of that 500 000 euros has been paid at the conclusion of the contract under the law of obligation and the remaining part is paid at the conclusion of the real rights contract the acquisition of the properties is financed from the fund s equity capital which was received from the sale of the tähesaju property and from the loan agreement which will be signed with swedbank as the transaction is scheduled to close by the end of october the properties will be used by the logistics company elp logistics oü under a long term lease 10 5 years agreement eften härgmäe oü is a subsidiary of eften real estate fun,establishment of a subsidiary and conclusion of purchase contract for the properties of the elp logistics oü logistics center,mergers_acquisitions,UP,0.2695479593836518,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,281,0.11079545454545456,0.8866002429130597,0.07662337662337662
media release,b2 impact asa invitation to q3 2024 results on thursday 7 november,earnings_releases_and_operating_results,UP,0.0,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,8,242,0.0,0.2679946975487692,0.0
copenhagen denmark may 28 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines provides business update and announces first quarter 2024 financial results,evaxion announces business update and first quarter 2024 financial results,financial_results,UP,0.0,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,1,8,396,0.125,1.4249795072460607,0.16666666666666666
malvern pa may 06 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced that maria maccecchini founder president and ceo of annovis issued a letter to stockholders providing a review of phase ii iii data from its alzheimer s study and sharing next steps,annovis bio ceo maria maccecchini issues letter to stockholders,clinical_study,UP,2.3166093894394555,44036864.0,15624645.0,595065.0,1.618,805900.0,0.3548083033342247,0.09346626282280733,0,7,418,0.0,1.368989555493872,0.08090277777777777
media release,hexagon agility receives new wave of rng fuel system orders for class 8 series trucks with cummins x15n natural gas engine,business_contracts,DOWN,-2.463769187598724,305879840.0,146671949.0,363495.0,1.191,331336.5,0.4795083879996799,0.1515999603296736,2,7,241,0.11818181818181818,0.8866002429130597,0.0
westlake village calif sept 19 2024 globe newswire arcutis biotherapeutics inc nasdaq arqt a commercial stage biopharmaceutical company focused on developing meaningful innovations in immuno dermatology today announced that the journal of american medical association dermatology jama dermatology published the positive results from two pivotal phase 3 studies integument 1 and integument 2 evaluating the efficacy and safety of zoryve roflumilast cream 0 as a once daily steroid free treatment for mild to moderate ad zoryve cream 0 was approved in july 2024 by the u s food and drug administration fda for the topical treatment of mild to moderate ad in adult and pediatric patients 6 years of age and older and is available in pharmacies nationwide,arcutis announces publication of zoryve roflumilast cream 0 pivotal results from phase 3 integument 1 and 2 trials in mild to moderate atopic dermatitis in journal of american medical association dermatology,clinical_study,UP,2.7884612739438746,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,282,0.18066378066378067,0.6903751128737089,0.037561001883918546
kraig biocraft labs otcqb kblb kicks off new bam 1 hybrid spring production trials on track to meet expectations and timeline,kraig biocraft laboratories announces successful launch of spring production trials in southeast asia for spider silk,press_releases,UP,9.242146234319629,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,439,0.4431818181818182,0.8071333009212691,0.0
media release,resolutions of the general extraordinary shareholders meeting of invl baltic real estate,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19444444444444442,0.8866002429130597,0.18537414965986393
data published online in the journal cytotherapy demonstrate that crispr mediated tissue factor gene knockout tfko in allogeneic stromal cells ascs leads to significantly lower tissue factor tf expression activity and thrombotic effects providing a feasible strategy potentially to improve the safety of asc based cell therapy,celularity tissue factor gene knockout of allogeneic stromal cells significantly lowers thrombotic effects study highlights critical importance of gene editing capability,clinical_study,UP,2.631582744894313,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,9,758,0.1875,1.6050367793919866,0.027777777777777776
missing,inside information faron presents phase 1 data from bexmab in myeloid malignancies trial at the 65th american society of hematology ash annual meeting,clinical_study,UP,4.193137592181954,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,0,2,565,-0.1,0.7633342480324978,0.0302102873977874
bilan semestriel du contrat de liquidite,eurobio scientific bilan semestriel du contrat de liquidité,trading_information,DOWN,-2.0979034037302804,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,11,359,0.0,0.4336088389568585,0.0
boston feb 20 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda has granted fast track designation to pgn edodm1 an investigational candidate for the treatment of myotonic dystrophy type 1 dm1 receiving fast track designation from the fda for pgn edodm1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the dm1 community said james mcarthur ph d president and ceo of pepgen patients with dm1 currently have no available treatment options that target the root cause of the disease which leads to progressive neuromuscular symptoms and reduction in life expectancy following robust preclinical data we are now evaluating pgn edodm1 in the ongoing freedom dm1 phase 1 trial and expect to report preliminary data later this year we believe that pgn edodm1 has the potential to be disease modifying and improve outcomes for patients living with dm1,pepgen receives u s fda fast track designation for pgn edodm1 for the treatment of myotonic dystrophy type 1,clinical_study,DOWN,-1.079917699762323,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,1,8,494,0.07045454545454546,1.4553932872573117,0.04170935545935545
media release,immutep announces first participant dosed in phase i study of imp761 a first in class agonist lag 3 antibody,clinical_study,UP,3.517584568207781,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,2,8,318,0.25,0.7476881311953882,0.1186765615337044
patient treated in trial achieved a remission after eight weeks of treatment demonstrating a significant reduction in proteinuria,eloxx pharmaceuticals intends to advance elx 02 into pivotal trial for the treatment of alport syndrome with nonsense mutations following achievement of remission in patient in phase 2 study,clinical_study,DOWN,-3.492435220091153,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,8,766,0.2916666666666667,2.2721670857062097,-0.03571428571428571
due to the increase in the price of electricity tallinna vesi has applied to the competition authority to revise the prices for water services the price change will take effect on 1 november and will amount to an average of one cent per cubic metre according to aleksandr timofejev chief executive officer of tallinna vesi the price of electricity has increased by approximately since the implementation of the current prices for water services the cost of electricity is undoubtedly one of the most significant and important factors affecting water treatment the production of clean drinking water and the treatment of wastewater are both activities that take place non stop around the clock this means that we do not have the possibility to opt for more favourable hours for our electricity consumption explained timofejev the company has previously stated that any further changes in production and operating costs could lead to price changes according to timofejev the ave,tallinna vesi the electricity price increase changes the price of water services by one cent,regulatory_filings,UP,0.4975143262281594,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,276,0.11818181818181818,0.8866002429130597,0.0
media release,le premier vêtement biorecyclé 100 fibre à fibre du monde dévoilé par carbios on patagonia puma pvh corp et salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
not for release publication or distribution into or in the united states canada australia japan south africa or any other state or jurisdiction in which such release publication or distribution would be unlawful not for distribution to any u s person please see the important notice at the end of this press release,qiagen n v launches non us offering of net share settled convertible bonds,shares_issue,DOWN,-2.2095785205917715,10135903232.0,214509546.0,1439980.0,0.673,1302400.0,0.02116333799663489,0.09346626282280733,1,2,298,0.06875,0.2568422597431085,0.0
planegg martinsried september 16 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will host an r d event on medigene s optimal 3s specific sensitive and safe tcrs for tcr guided precision immunotherapies on thursday october 10 2024 at 4 30 pm cet 10 30 am et a live q a session will follow the formal presentations and discussions,medigene to host virtual r d event on medigene s optimal 3s tcrs for tcr guided precision immunotherapies,conference_call_webinar,UP,1.7598301847663735,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,0,8,285,0.14727272727272728,1.3169799228985475,0.05486557302346776
dallas aug 19 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that dr jeffrey carter will present data from an ongoing prospective multicenter study analyzing the use of spectral ai s deepview system which utilizes non invasive multispectral imaging technology and proprietary ai to detect non healing areas of a wound following thermal burn injury,spectral ai announces podium presentation at bba isbi joint conference assessing burn wound severity using multispectral imaging and artificial intelligence,clinical_study,DOWN,-1.9354820846890508,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,0,8,313,-0.04285714285714284,0.9904696515070965,0.08747204184704187
moonlake immunotherapeutics reports second quarter 2024 financial results and announces a capital markets update for september 11,moonlake immunotherapeutics reports second quarter 2024 financial results and announces a capital markets update for september 11,financial_results,UP,1.4796301419609228,2935051776.0,28324751.0,691265.0,1.23,267600.0,0.009650511528148251,0.09346626282280733,2,8,325,0.0,0.5366763308656862,0.07083333333333333
needham mass june 18 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that paul peter tak md phd fmedsci candel s president and chief executive officer will participate in a fireside chat at the h c wainwright 2nd annual immune cell engager virtual conference on tuesday june 25 2024 at 3 00 p m et,candel therapeutics to participate in the h c wainwright 2nd annual immune cell engager virtual conference,conference_call_webinar,DOWN,-0.8310241623697936,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,1,8,375,0.0,1.2870358800144117,0.08716815514084421
palo alto calif aug 01 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today provided certain preliminary unaudited financial results for the month ended july 31 2024 scilex generates continuous sales growth in ztlido going into third quarter of 2024 with preliminary net sales for ztlido in the range of 4 0 million to 5 0 million,scilex holding company provides certain preliminary unaudited financial results for the month ended july 31 2024,financial_results,DOWN,-1.2578604092237398,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,331,0.19107142857142856,1.0327724261931344,0.26185360549943887
la jolla calif may 28 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova conducted two poster presentations at the 92nd european atherosclerosis society eas 2024 congress held online may 26 29 2024,medicinova announces two poster presentations at the 92nd eas congress 2024 the annual meeting of the european atherosclerosis society regarding the use of mn 001 tipelukast for cardiometabolic conditions,clinical_study,DOWN,-1.4925358528601556,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,396,0.0,0.8018560055721619,0.11601010101010101
yield10 bioscience achieves significant milestone enabling ramp up to commercial scale production of omega 3 fatty acids in camelina in the united states,usda aphis determines that yield10 bioscience s omega 3 camelina varieties may be planted and bred in the united states,regulatory_filings,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,464,0.05833333333333333,0.8866002429130597,0.05378968253968253
mainz deutschland 17 september 2024 globe newswire biontech se nasdaq bntx biontech veranstaltet zusammen mit ihrem tochterunternehmen für künstliche intelligenz artificial intelligence ai instadeep ltd instadeep am dienstag den 1 oktober 2024 um 15 00 uhr mesz 09 00 uhr edt den ai day eine ausgabe von biontechs innovation series in london vereinigtes königreich die veranstaltung gibt einen überblick über die strategie und die fähigkeiten von biontech und instadeep im bereich ai und informiert über die anwendung von ai in der pipeline und den internen prozessen von biontech,biontech veranstaltet am 1 oktober 2024 ai day als eine ausgabe der innovation series,conference_call_webinar,UP,3.18295963903887,24727029760.0,97284490.0,1237590.0,1.285,391100.0,0.003934337886282384,0.09346626282280733,1,6,284,-0.6,0.5503225880253886,0.14911662411662407
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions svensson sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name klas svenssonposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80007 4 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 744 unit price 41 9316 eur aggregated transactions 1 volume 744 volume weighted average price 41 9316 eur____________________________________________ transaction,sampo plc managers transactions svensson,regulatory_filings,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
media release,navamedic q3 2024 business remains strong in quarter impacted by cyclical nature of the business,earnings_releases_and_operating_results,DOWN,-2.272723613410148,381516480.0,12071448.0,11359.45,0.371,10764.0,0.0316406987189649,0.09346626282280733,3,7,240,0.43333333333333335,0.44210167862552907,0.0
as lhv group has decided the company s financial calendar for the 2025 financial year in 2025 lhv group plans to disclose information and organise the annual general meeting of shareholders according to the following schedule lhv group is the largest domestic financial group and capital provider in estonia the lhv group s key subsidiaries are lhv pank lhv varahaldus lhv kindlustus and lhv bank limited the group employs over 1 100 people as at the end of august lhv s banking services are used by 441 000 clients the pension funds managed by lhv have 118 000 active clients and lhv kindlustus protects a total of 168 000 clients lhv bank limited a subsidiary of the group holds a banking licence in the united kingdom and provides banking services to international financial technology companies as well as loans to small and medium sized enterprises priit rum communication manager phone 372 502 0786 email priit rum lhv ee,lhv group financial calendar for 2025,financial_calendar,UP,0.1430647955548679,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,254,-0.031746031746031744,0.8866002429130597,0.0838364315423139
transcode therapeutics completes initial dosing of first co hort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,transcode therapeutics completes initial dosing of first cohort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,clinical_study,DOWN,-0.7393730208448788,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,261,0.125,2.0874185587937095,-0.011931818181818184
tel aviv israel and miami jan 31 2024 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention carotid stent system eps for the prevention of stroke today announced that it has received ce mark recertification under the european union s new medical device regulation mdr regulatory framework mdr replaced the previous mdd framework which had governed the approval and marketing of medical devices in the eu until may of 2021,inspiremd receives ce mark recertification under eu s new medical device regulation mdr regulatory framework,regulatory_filings,DOWN,-0.3389827220887212,65865896.0,16849440.0,286250.0,0.613,4867100.0,0.2558143291636084,0.09346626282280733,2,7,514,0.01515151515151515,0.6085732039686736,0.10213636363636362
27 sep 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 26 sep 2024 estimated nav euro sharessterling sharesestimated nav 28 5200 25 6046estimated mtd return 0 70 0 48 estimated ytd return 3 53 4 21 estimated itd return 185 20 156 05 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 3 93 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 83 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,274,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
berwyn pa dec 11 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced its founder president and ceo was selected to participate in the 139th yale ceo summit in new york on december 11 12 2023,annovis bio to participate in the 139th yale ceo summit,press_releases,DOWN,-7.103823312288768,43843952.0,15624645.0,595065.0,1.618,805900.0,0.35636944862999576,0.09346626282280733,0,13,564,0.06818181818181818,1.368989555493872,0.0731060606060606
redwood city calif aug 27 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a late stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism hi today announced that management will participate in the following investor conferences,rezolute to participate in upcoming investor conferences,conference_call_webinar,UP,1.9148969412822696,376775840.0,77797779.0,825115.0,1.04,796000.0,0.20648292894788584,0.09346626282280733,1,8,305,0.09375,0.6820409900648857,-0.0010192258721670473
dallas sept 06 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that on september 3 2024 the compensation committee of taysha s board of directors granted one new employee an option to purchase 311 000 shares of the company s common stock in connection with their employment the stock option was granted under the taysha gene therapies inc 2023 inducement plan as an inducement material to the individual entering employment with taysha in accordance with nasdaq listing rule 5635 c 4,taysha gene therapies announces inducement grant under nasdaq listing rule 5635 c 4,corporate_action,UP,0.0,626364352.0,136885482.0,5054745.0,1.016,2606600.0,0.21853970706174544,0.09346626282280733,4,8,295,-0.04090909090909091,1.0149166236087122,0.01373000683527
durham n c july 16 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissues at commercial scale announced the addition of pharmaceutical industry veteran dr john p bamforth and distinguished health system and academic physician dr keith anthony tony jones to the company s board of directors,humacyte board of directors strengthened with addition of john p bamforth and keith anthony jones,management_changes,UP,5.238101833802261,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,347,0.0,1.1173068527438073,0.09810032139577594
nearing completion of enrollment the seismic extension phase 2b study in early cardiogenic shock patients is set to deliver new data nearing completion of enrollment the seismic extension phase 2b study in early cardiogenic shock patients is set to deliver new data,windtree therapeutics provides update on istaroxime clinical development and upcoming clinical trial data,clinical_study,DOWN,-0.8152165990639868,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,3,8,338,0.11818181818181818,2.339794177443606,0.017324033990700663
malvern pa june 20 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that the first patient has been dosed in its phase 3 limelight clinical trial for ocu400 a modifier gene therapy product candidate being developed for retinitis pigmentosa rp,ocugen inc announces first patient dosed in phase 3 limelight clinical trial for ocu400 first gene therapy in phase 3 with a broad retinitis pigmentosa indication,clinical_study,DOWN,-1.449273985189887,300791936.0,287364635.0,6243265.0,4.237,6951700.0,0.9553601696290156,0.09346626282280733,3,6,373,0.1825,0.7661975315521313,0.05111111111111111
media release,notification on the increase of share capital of as madara cosmetics,share_capital_increase,DOWN,-0.4201616694398021,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,9,240,0.0,0.8866002429130597,0.275
miami sept 04 2024 globe newswire fortress biotech inc nasdaq fbio fortress an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long term value for shareholders through product revenue equity holdings and dividend and royalty revenue today announced that lindsay a rosenwald m d chairman president and chief executive officer will present a corporate overview at the h c wainwright 26th annual global investment conference the presentation will be available for on demand viewing by conference attendees starting on september 9 2024 at 7 00 a m et the company will also attend one on one meetings during the conference,fortress biotech to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.5228411651818354,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,2,8,297,0.09444444444444446,0.6928276660424207,0.08099972943722943
media release,lhv group s unaudited financial results for q3 and nine months of 2024,financial_results,DOWN,-0.2861227694048171,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,8,249,0.0,0.8866002429130597,0.024418140320101107
copenhagen denmark october 9 2024 evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines has now evidence from three different clinical trials validating the vaccine target predictions of its ai platform,strong validation of evaxion s ai immunology platform in multiple clinical trials,clinical_study,UP,0.7042247017941755,15601928.0,155104950.0,157745.0,0.102,38700.0,9.94139634537475,0.09346626282280733,2,8,262,0.14444444444444446,1.4249795072460607,0.12794967216019845
new york sept 27 2024 globe newswire eyenovia inc nasdaq eyen eyenovia or the company an ophthalmic technology company with two fda approved products and a late stage asset in development for the treatment of pediatric progressive myopia today announced it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 8 695 653 shares of its common stock or common stock equivalents in lieu thereof and warrants to purchase up to an aggregate of 8 695 653 shares of common stock in a registered direct offering at a combined offering price of 0 46 per share and accompanying warrant the warrants have an exercise price of 0 50 per share will be exercisable commencing six months from the date of issuance and will expire five years from the initial exercise date the closing of the offering is expected to take place on or about september 30 2024 subject to the satisfaction of customary closing conditions,eyenovia inc announces pricing of 4 million registered direct offering,financing_agreements,DOWN,-4.967603008863069,27747046.0,2433609.0,8930490.0,1.002,41800300.0,0.08770695806681547,0.09346626282280733,4,8,274,-0.11303030303030304,2.4441832149286684,-0.00017015392015391485
venlo the netherlands oct 10 2024 globe newswire qiagen n v nyse qgen frankfurt stock exchange qia announced plans to release results for the third quarter 2024,qiagen n v to release results for q3 2024 and hold webcast,earnings_releases_and_operating_results,DOWN,-0.6074250914046934,10142400512.0,214509546.0,1439980.0,0.673,1302400.0,0.02114978064080615,0.09346626282280733,3,7,261,0.0,0.2568422597431085,0.11035353535353536
media release,heimar hf publication of q3 2024 results,financial_results,UP,0.0,62944354304.0,1625492261.0,3297090.9411764704,0.282,5897775.0,0.02582427413822407,0.1515999603296736,2,10,240,0.0,0.20649153033991688,0.0
fda grants pre bla meeting request and rolling bla submission after review of hope 2 and hope 2 ole 3 year results san diego june 11 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the successful completion of a type b meeting with the u s food and drug administration fda on next steps for the biologics license application bla submission with its lead asset cap 1002 for the treatment of duchenne muscular dystrophy dmd additionally deramiocel has been selected as the proposed international nonproprietary name inn for cap 1002 by the world health organization,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy with an aim to expedite bla pathway,clinical_study,DOWN,-0.554523730449676,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,382,0.2554545454545455,1.3427880947904531,0.09606060606060605
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
adelaide australia and cambridge mass oct 14 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that the company has been invited to present at the 2024 maxim healthcare virtual summit presented by maxim group llc starting tuesday october 15th 2024 at 9 00 a m e t,bionomics to participate in the 2024 maxim healthcare virtual summit presented by maxim group llc,conference_call_webinar,UP,3.214286892693865,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,257,0.000654761904761908,0.8866002429130597,0.05050668665629705
mainz biomed launches enhanced coloalert with cutting edge features to optimize screening efficiency and user convenience,mainz biomed launches enhanced coloalert with cutting edge features to optimize screening efficiency and user convenience,product_services_announcement,UP,1.9444441684970253,5512458.0,2706585.0,75055.0,0.305,78500.0,0.4909942170987969,0.09346626282280733,3,8,338,-0.6,34.079934680222834,0.03604465709728868
media release,eften real estate fund as unaudited results for 3rd quarter and nine months of 2024,financial_results,UP,0.2624732095101908,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,247,0.1,0.8866002429130597,0.10090089886964887
boston oct 16 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that on october 15 2024 elicio granted an aggregate of 5 900 inducement stock options to two new employees as an inducement material to each individual entering into employment with elicio in accordance with nasdaq listing rule 5635 c 4 the inducement stock options were approved by the compensation committee of elicio s board of directors and granted under the elicio therapeutics inc 2024 inducement incentive award plan,elicio therapeutics reports inducement grants,corporate_action,DOWN,-2.2271694817406407,128455904.0,10299137.0,63410.0,2.164,22500.0,0.08017643937953993,0.09346626282280733,2,8,255,0.06818181818181818,0.8558055682194762,0.040727605727605726
media release,immutep receives a 3 6 million r d tax incentive from french government,government_news,DOWN,-1.3100424405900453,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,1,8,277,0.0,0.7476881311953882,0.10528540507111936
media release,lhv group s unaudited financial results for q3 and nine months of 2024,clinical_study,DOWN,-0.2861227694048171,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,8,249,0.0,0.8866002429130597,0.024418140320101107
mainz deutschland 21 oktober 2024 globe newswire biontech se nasdaq bntx biontech oder das unternehmen wird am montag den 4 november 2024 die ergebnisse für das dritte quartal 2024 veröffentlichen darüber hinaus wird das unternehmen am selben tag um 14 00 uhr mez 8 00 uhr eastern time eine telefonkonferenz samt webcast für investoren finanzanalysten sowie die allgemeine öffentlichkeit durchführen um die finanzergebnisse sowie ein unternehmensupdate zu präsentieren,biontech veröffentlicht am 4 november 2024 ergebnisse für das dritte quartal 2024 und informiert über operativen fortschritt,clinical_study,DOWN,-0.1699873111909098,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,250,0.0,0.5503225880253886,0.004198532948532951
media release,danske bank a s revises 2024 net profit upwards now expects a net profit in the range of dkk 22 5 23 5 billion,earnings_releases_and_operating_results,DOWN,-0.994642651307372,212863959040.0,655783007.0,1036566.3333333334,0.707,1113237.0,0.003080761111263413,0.1515999603296736,3,7,240,0.0,0.2786156283369768,0.0
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
new york july 30 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions today announced that management will participate in two upcoming investor conferences in august,ovid therapeutics to present at upcoming august investor conferences,conference_call_webinar,DOWN,-0.9523800873701952,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,333,0.21266233766233766,0.7642184815786688,0.15311997526283241
immunocore announces transition of chief financial officer,immunocore announces transition of chief financial officer,management_changes,DOWN,-7.103823312288768,1603205376.0,37423034.0,614630.0,0.835,788600.0,0.023342632553647324,0.09346626282280733,3,7,303,0.0,0.44240182162750774,0.10378787878787878
completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the phase 1 2 3 ruby clinical trial of reni cel for severe sickle cell disease,editas medicine announces first quarter 2024 results and business updates,clinical_study,DOWN,-4.929572912559228,181573264.0,83382193.0,2526680.0,2.096,3015800.0,0.4592206537632104,0.09346626282280733,2,7,416,0.11666666666666665,1.3105556047468256,0.04286796536796537
phase 2 mira primary analysis trial results 12 week for moonlake s nanobody sonelokimab in hidradenitis suppurativa to be presented at a late breaking session at the european academy of dermatology and venereology congress,phase 2 mira primary analysis trial results 12 week for moonlake s nanobody sonelokimab in hidradenitis suppurativa to be presented at a late breaking session at the european academy of dermatology and venereology congress,clinical_study,UP,0.1382440513760035,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,2,7,633,0.03333333333333333,0.5366763308656862,-0.04791666666666666
multiple value creating catalysts across the annexon portfolio throughout 2024,annexon reports first quarter 2024 financial results and key anticipated milestones,clinical_study,UP,4.210522300318668,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,0,8,411,0.0625,0.7558344054121836,0.19477272727272726
media release,resolutions of the general extraordinary shareholders meeting of invl technology,clinical_study,UP,1.734102373353568,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19166666666666665,0.8866002429130597,0.1698705808080808
media release,inside information valmet confirms signing contracts for previously announced project with arauco,business_contracts,UP,0.3690043248877174,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,8,242,-0.16666666666666666,0.8866002429130597,0.04945114409400122
media release,bluenord announce third quarter 2024 results,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.1396780303030303
25 sep 2024 08 00 cest arctic bioscience as arctic bioscience presenterer i dag ny celleforskning på eadv kongressen i amsterdam celledataene viser effekter av fosfolipidestere fra silderogn i immunceller og hudceller som er forenlig med en anti psoriatisk virkning av medisinkandidaten hro350 disse dataene bidrar til å forklare hvorfor og hvordan hro350 kan virke mot psoriasis og er et supplement til det kliniske utviklingsprogrammet hvor den pågående fase 2b studien i mild til moderat psoriasis heropa har planlagt utlesning senere i september begynnelsen av oktober 2024 vi er veldig glade for å presentere ytterligere positive cellulære data om de anti psoriatiske egenskapene knyttet til vår medisinkandidat hro350 gjennom disse cellestudiene øker vi vår forståelse av hvordan hro350 virker sier ceo christer l valderhaug dataene fra cellestudiene viser at fosfolipidestere fra silderogn har immunmodulerende anti psoriatiske effekter som kan påvirke signalene,arctic bioscience ny celleforskning viser anti psoriatiske effekter,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,276,0.2803030303030303,0.8866002429130597,0.0
mainz biomed reports full year 2023 financial results,mainz biomed reports full year 2023 financial results,financial_results,UP,0.9259250061011975,5512458.0,2706585.0,75055.0,0.305,78500.0,0.4909942170987969,0.09346626282280733,1,8,445,0.175,34.079934680222834,0.03579545454545455
results in performance of the upper limb pul v2 0 continue to show slowing of disease progression in later stage dmd patients,capricor therapeutics announces long term benefit of deramiocel cap 1002 in both skeletal muscle and cardiac function in the hope 2 ole study in duchenne muscular dystrophy,clinical_study,UP,1.72413633637985,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,4,9,365,-0.025,1.3427880947904531,0.16053613053613053
media release,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,240,0.0,0.8866002429130597,0.1859980184621333
media release,bghl eur nav s,fund_data_announcement,UP,0.7246335247339231,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,-0.0035714285714285687
g1 therapeutics and pepper bio announce global excluding asia pac license agreement for lerociclib,g1 therapeutics and pepper bio announce global excluding asia pac license agreement for lerociclib,licensing_agreements,DOWN,-6.631299768297614,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,423,0.0,0.8866002429130597,0.03125
on the initiative and by decision of the board of ab amber grid legal entity code 303090867 registered office address laisvės av 10 lt 04215 vilnius lithuania the extraordinary general meeting of shareholders of ab amber grid is convened at the company s registered office address laisvės av 10 vilnius on 18 october 2024 at 10 00 am draft agenda of the meeting 1 approval of the conclusion of the humanitarian aid contract shareholder registration will commence at 9 15 a m 18 october 2024 shareholder registration will be closed at 9 45 a m 18 october 2024 record day of the general meeting of shareholders october 11 2024 attendance and voting at the general meeting of shareholders shall be open to those persons who will be shareholders of the company at the end of the record day of the general meeting of shareholders a person attending the general meeting of shareholders and entitled to vote must provide a proof of identity a person who is not a shareholder shall i,notice on convening an extraordinary general meeting of shareholders of ab amber grid,extraordinary_general_meeting,DOWN,-0.8771921569070334,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.09696969696969697,0.8866002429130597,0.0
irvine calif dec 18 2023 globe newswire biomerica inc nasdaq bmra the company a global provider of advanced medical diagnostic products today announced it has received u s food and drug administration fda 510 k clearance for its hp detect stool antigen elisa test k232892 a new product that is designed to detect the presence of the h pylori bacteria which infects approximately of the u s population h pylori infection is a disease which affects half the population of the world,biomerica received us fda 510 k clearance for their hp detect elisa test product designed to detect the presence of the h pylori bacteria that infects approximately of the u s population,product_services_announcement,UP,9.242146234319629,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,0,7,558,-0.06147186147186147,1.5245042583012947,0.07225579975579975
media release,steady growth for europris and öob integration proceeding according to plan,earnings_releases_and_operating_results,DOWN,-4.728297171868995,13779245056.0,131827655.0,273180.35,0.452,163716.0,0.009567117390266406,0.1515999603296736,3,7,240,0.16666666666666666,0.23704210464472134,0.0
invl asset management a part of invalda invl the leading asset management group in the baltics has launched the invl bsgf co invest fund ii as a new closed end fund for informed investors with the invl baltic sea growth fund now investing in its 10th portfolio company we believe that we can offer investors an attractive co investment opportunity says vytautas plunksnis a partner of the invl baltic sea growth fund he says priority to participate in co investment will be given to existing investors in the invl baltic sea growth fund the minimum investment in the invl bsgf co invest fund ii is eur 125 000 the invl baltic sea growth fund with a size of eur 165 million is a closed end private equity fund for professional investors to date the fund has invested in and developed industry leaders such as eco baltia inmedica eglės sanatorija and galinta as of the end of 2023 transactions completed by the invl baltic sea growth fund had a net internal rate of return of and,invl bsgf co invest fund ii established,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,283,0.09363636363636364,0.8866002429130597,0.0
media release,påminnelse om tegningsfrist for egenkapitalutvidelsen i morgen kl 08 00,shares_issue,DOWN,-7.103823312288768,31593468.0,146986679.0,21417158.75,0.312,14709376.0,4.652438883885745,0.1515999603296736,2,14,240,0.0,20.184452026301216,0.0
palo alto calif oct 08 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today provided certain preliminary unaudited financial results for the quarter ended september 30 2024,scilex holding company provides certain preliminary unaudited financial results for the quarter ended september 30 2024,earnings_releases_and_operating_results,DOWN,-5.730337063601907,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,13,262,0.25476190476190474,1.0327724261931344,0.24148572781385283
neffy offers adults and children 30 kg living with severe allergic reactions the first new delivery method for epinephrine in more than 35 years,ars pharmaceuticals receives fda approval of neffy epinephrine nasal spray the first and only needle free treatment for type i allergic reactions including anaphylaxis,product_services_announcement,UP,9.242146234319629,1691729280.0,51755600.0,1240295.0,0.872,1940800.0,0.030593311005410986,0.09346626282280733,4,12,322,0.23376623376623376,0.6899910717831225,0.2582912457912458
media release,guerbet nombre d actions et de droits de vote composant le capital de la société au 30 septembre 2024,voting_rights,DOWN,-1.6541330437911184,278437920.0,5878020.0,15366.363636363636,0.764,6888.0,0.02111070216298125,0.09346626282280733,2,15,240,0.0,0.41864543118833314,0.0
yavne israel nov 21 2023 globe newswire mediwound ltd nasdaq mdwd a fully integrated biopharmaceutical company focused on next generation enzymatic therapeutics for tissue repair today announced the appointment of shmulik hess ph d to the positions of chief operating officer and chief commercial officer effective as of december 1 2023 dr hess will lead and oversee all operational and commercial activities at mediwound,mediwound announces appointment of shmulik hess ph d as chief operating officer and chief commercial officer,management_changes,DOWN,-0.5841143491100693,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,7,585,0.12,0.6433034533898109,0.0
dallas aug 02 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that on august 1 2024 the compensation committee of taysha s board of directors granted two new employees in the aggregate options to purchase 356 000 shares of the company s common stock in connection with their employment the stock options were granted under the taysha gene therapies inc 2023 inducement plan as an inducement material to the individuals entering employment with taysha in accordance with nasdaq listing rule 5635 c 4,taysha gene therapies announces inducement grant under nasdaq listing rule 5635 c 4,corporate_action,DOWN,-3.240748559250933,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,4,8,330,-0.05454545454545454,1.0149166236087122,0.026702437912964238
media release,ramsay sante communiqué de mise à disposition du deu 2024,regulatory_filings,DOWN,-0.3773599300744398,1213981952.0,864097.0,637.0454545454545,0.184,1.0,0.0007117873528320791,0.09346626282280733,2,15,240,0.0,0.27493248995767877,0.0
all patients treated in the ruby trial are free of vaso occlusive events post renizgamglogene autogedtemcel reni cel infusion,editas medicine reports new safety and efficacy data from the ruby trial of reni cel in 18 patients with sickle cell disease presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1787878787878788,1.3105556047468256,0.06364859777903256
not for release publication or distribution in whole or in part directly or indirectly in or into the united states australia japan or hong kong or any other jurisdiction in which the distribution or release would be unlawful company announcement no 1137 completion of equity offering and directed issue of new shares raising gross proceeds of dkk 37 3 billion approx eur 5 billion today 4 october 2024 the offering the offering of 26 444 523 new shares the new shares in dsv a s dsv has been successfully completed through an accelerated bookbuilding process the new shares will be issued as a result of dsv s board of directors exercising the authorisation in article 4a1 of dsv s articles of association according to which the board of directors is authorised to make share capital increases up to nominally dkk 48 000 000 please refer to company announcement no 1136 of 3 october 2024 the offer price is dkk 1 410 50 per share raising gross proceeds to dsv of dkk 37,dsv 1137 dsv a s completes equity offering of 26 4 million new shares raising gross proceeds of dkk 37 3 billion approx eur 5 billion,shares_issue,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,1,267,0.13390151515151516,0.8866002429130597,0.0
dosing of all patients in the trial has been successfully completed final results are expected to be available in late q2 2024,biora therapeutics announces completion of multiple ascending dose mad cohorts for clinical trial of bt 600,clinical_study,UP,2.5682158414488137,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,1,8,424,0.017857142857142867,1.027516639474094,0.1477272727272727
data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate,intellia therapeutics to present the first ever clinical data from patients redosed with an investigational in vivo crispr gene editing therapy at the peripheral nerve society annual meeting 2024,clinical_study,DOWN,-0.5964199634410936,978341376.0,98412511.0,6353695.0,2.134,5288300.0,0.10059117749099472,0.09346626282280733,0,7,376,0.125,0.7800307612939593,-0.006857142857142862
investigational new drug ind application submitted to u s food and drug administration fda for elx 02 for the treatment of alport syndrome with nonsense mutations,eloxx pharmaceuticals provides program updates on elx 02 and zkn 013,clinical_study,UP,7.22432739674119,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,3,9,660,0.13636363636363635,2.2721670857062097,0.15778838808250575
irvine calif july 01 2024 globe newswire biomerica inc nasdaq bmra a global provider of advanced medical products is proud to announce a major enhancement to its infoods ibs system aimed at simplifying and transforming the patient experience,biomerica launches at home sample collection for infoods ibs significantly expanding access for millions of ibs sufferers,product_services_announcement,DOWN,-2.272725117600642,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,0,7,362,0.2729166666666667,1.5245042583012947,0.14687826062826068
news release regulated informationnovember 27 2023 1 00 am et 7 00 am cet,mdxhealth announces completion of mandatory ads exchange and commencement of transition period to single listing on nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,-0.07142857142857142,0.6181119561491973,0.0
as tallinna sadam signed an unsecured loan agreement with as swedbank in the amount of eur 10 million and a maturity of 4 years the interest rate of the loan is 6 month euribor plus interest margin the loan amount can be drawn until 31 december 2024 and the final maturity date is 13 september 2028 the funding will be used partially to refinance existing debt obligations and partially to finance the company s general business needs also as bridge financing for investments tallinna sadam is one of the largest cargo and passenger port complexes in the baltic sea region in addition to passenger and freight services tallinna sadam group also operates in shipping business via its subsidiaries oü ts laevad provides ferry services between the estonian mainland and the largest islands and oü ts shipping charters its multifunctional vessel botnica for icebreaking and offshore services in estonia and projects abroad tallinna sadam group is also a shareholder of an associate as green,changes in the debt obligations of as tallinna sadam,financing_agreements,UP,0.1890334886847508,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,287,-0.06999999999999999,0.8866002429130597,0.0
redwood city calif sept 10 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that health canada has cleared the company s clinical trial application cta for a phase 1b 2a asthma challenge study evaluating briquilimab in asthma,jasper therapeutics announces health canada clearance of clinical trial application for phase 1b 2a study of briquilimab in asthma,clinical_study,DOWN,-0.8290147862020221,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,7,291,0.3,0.9821837329226573,0.133255772005772
pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance,t2 biosystems inc and prxcision inc announce co marketing collaboration for rapid direct from blood diagnostics and ai powered decision support platform,partnerships,UP,1.8404890477013416,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,1,9,263,0.12424242424242422,1.9596557041969667,0.09956773995235534
kraig labs otcqb kblb achieved full capacity at its current production location and will open additional production facilities,kraig biocraft laboratories expands facilities to support spider silk production growth,capital_investment,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,8,362,0.11666666666666665,0.8071333009212691,0.1303503787878788
moonlake immunotherapeutics to host a capital markets day on monday september 11,moonlake immunotherapeutics to host a capital markets day on monday september 11,conference_call_webinar,UP,0.2178229907951732,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,2,7,661,0.0,0.5366763308656862,-0.06388888888888888
planegg martinsried october 24 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer today reported financial results and provided a business update for the third quarter ended september 30 2024 the quarterly statement q3 2024 can be found on the website https medigene com investors media reports presentations during the third quarter of 2024 our focus remained on executing our strategic plan and creating additional value for both patients and our shareholders beyond t cell receptor engineered t cell tcr t therapies by expanding our ability to apply our sensitive specific and potentially safer 3s tcrs into new modalities said selwyn ho ceo at medigene we are excited to have announced a three year strategic partnership with wuxi biologics to co research tcr guided t cell engagers tcr tces for solid tumors extending our pipeline our mdg3010 program will be a joint development with wuxi biologics aiming to create bispecific therapeutics that target cancer cells with precision while minimizing off target effects the target for this bispecific will be revealed later as for our lead program mdg1015 we received fda clearance for our investigational new drug application and are on track for the clinical trial application submission filing with the european medicines agency ema in q4 2024 in line with our guidance since 2023 and subject to additional financing we anticipate initiating and generating an early data read out for the epitome 1015 i trial by the end of 2025,medigene ag reports financial results and business update for q3 2024,clinical_study,DOWN,-3.751342462021844,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,1,247,0.04256628787878788,1.3169799228985475,0.061390128968253965
media release,financial results for q1 q3 2024,financial_results,DOWN,-0.3053388522781488,24061241344.0,114481009.0,12961.055555555555,0.103,2569.0,0.0047579011973356644,0.1515999603296736,3,8,240,0.0,0.4833531340410722,0.0
toronto jan 10 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to announce that it has completed the formulation development work of the company s next generation lyophilized formulation of bucillamine new bucillamine conducted at the university of waterloo the new bucillamine has the potential to unlock the therapeutic utility of bucillamine for treating public health medical emergencies including pandemic influenza emerging infectious diseases and medical countermeasure incidents and attacks,revive therapeutics successfully completes development of a novel lyophilized formulation of bucillamine,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,7,535,0.16570247933884297,1.8889707456546947,0.12690476190476188
media release,fiskars corporation s directed share issue without consideration based on the restricted share plan,shares_issue,DOWN,-2.9754206792492868,1157121792.0,36127016.0,13413.65,0.866,11916.0,0.03122144639377771,0.1515999603296736,1,9,242,0.0,0.21141844058764958,0.0
portland maine aug 29 2023 globe newswire immucell corporation nasdaq iccc immucell or the company a growing animal health company that develops manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle announced today that it recently submitted the chemistry manufacturing and controls cmc technical section for re tain to the fda,immucell announces submission of cmc technical section to the fda,regulatory_filings,UP,0.4415006622562565,57165168.0,6007971.0,25445.0,0.306,14200.0,0.10509845785811388,0.09346626282280733,1,8,669,0.0,0.6298264199719535,0.0
transcode therapeutics announces fda clearance to initiate phase 1 2 clinical trial with ttx mc138 in patients with advanced solid tumors,transcode therapeutics announces fda clearance to initiate phase 1 2 clinical trial with ttx mc138 in patients with advanced solid tumors,clinical_study,UP,0.1610285247101568,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,0,9,439,0.2,2.0874185587937095,0.0
mainz biomed to present results of colorectal cancer screening study eaarly detect at digestive disease week 2024 in washington d c,mainz biomed to present results of colorectal cancer screening study eaarly detect at digestive disease week 2024 in washington d c,clinical_study,UP,2.7027000903735274,5531532.0,2706585.0,75055.0,0.305,78500.0,0.4893011556292181,0.09346626282280733,1,8,417,0.0,34.079934680222834,0.06999999999999999
mainz germany october 21 2024 globe newswire biontech se nasdaq bntx biontech or the company will announce its financial results for the third quarter 2024 on monday november 4 2024 additionally the company will host a conference call and webcast that day at 8 00 a m et 2 00 p m cet for investors financial analysts and the general public to discuss its financial results and provide a corporate update,biontech to report third quarter 2024 financial results and corporate update on november 4 2024,clinical_study,DOWN,-0.1699873111909098,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,250,0.005000000000000002,0.5503225880253886,0.004198532948532951
27 sep 2024 08 00 cest artmarket com ex artprice com télécharger la pièce jointe cette publication dispose du service actusnews security master security master key yzlrz5lpypecng5syzdlm5jjaw1myjwwz2mwm5noaj7jngpkx2dibsjgznfonmho pour contrôler cette clé https www security master key com information réglementée rapports financiers et d audit semestriels examens réduits rapport financier semestriel euronext compartiments a b ccommuniqué intégral et original au format pdf https www actusnews com news 87932 artmarket com rapport financier 1s 2024 pdf information réglementée rapports financiers et d audit semestriels examens réduits rapport financier semestriel euronext compartiments a b c communiqué intégral et original au format pdf https www actusnews com news 87932 artmarket com rapport financier 1s 2024 pdf 87932_fr0000074783 pdf artmarket com actusnewswire artmarket com ex artprice com fr000007478,rapport financier semestriel au 30 juin 2024,financial_results,UP,1.1494296972653992,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,274,0.1875,0.8866002429130597,0.0
more than 100 patients enrolled in ongoing shield ii phase 3 trial of d plex100 for the prevention of abdominal colorectal surgical site infections,polypid provides corporate update and reports fourth quarter and full year 2023 financial results,clinical_study,UP,3.1383500085819445,37239588.0,4610773.0,1395250.0,1.25,337200.0,0.12381374895984348,0.09346626282280733,2,7,500,0.16999999999999998,0.7168605096826995,-0.09973544973544973
milestone achievement supports planned fda submission of deepview ai burn in 2025,spectral ai announces last patient out in u s burn pivotal study at burn centers,clinical_study,UP,2.7777750183035925,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,2,8,241,0.25,0.9904696515070965,0.09167601338055884
transcode therapeutics announces first patients treated in phase 1 clinical trial with first in class lead therapeutic candidate,transcode therapeutics announces first patients treated in phase 1 clinical trial with first in class lead therapeutic candidate,clinical_study,UP,5.384615031925167,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,1,7,284,0.25,2.0874185587937095,-0.029393939393939403
why emacc is the optimal tool for measuring cognitive change in early alzheimer s trials webinar to be held on november 7 2024 at 1 pm et,inmune bio inc to host webinar on cognitive testing using emacc and cdr sb,conference_call_webinar,UP,4.243542727600003,163658592.0,15213010.0,781395.0,1.567,974600.0,0.09295576733300993,0.09346626282280733,0,8,243,0.1,0.8435084668920305,0.12028060588245773
waltham mass july 02 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the issuance and sale of an aggregate of 5 853 659 shares of its common stock or common stock equivalents in lieu thereof at a purchase price of 2 05 per share of common stock or per common stock equivalent in lieu thereof in a registered direct offering priced at the market under nasdaq rules in addition in a concurrent private placement checkpoint will issue and sell unregistered warrants to purchase up to 5 853 659 shares of common stock the warrants will have an exercise price of 2 05 per share will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrant and will expire five years following the issuance date,checkpoint therapeutics announces 12 million registered direct offering priced at the market under nasdaq rules,financing_agreements,UP,0.9756088483765962,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,1,8,361,-0.07012987012987014,0.8866002429130597,0.08067708333333333
ad hoc announcement pursuant to art 53 lr,addex therapeutics reports 2024 half year and second quarter financial results and provides corporate update,financial_results,UP,9.242146234319629,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,0,1,271,-0.041666666666666664,0.972373032385036,-0.004985970819304151
oric 944 a potent and selective allosteric prc2 inhibitor demonstrates superior preclinical drug properties and longer clinical half life which supports a potential best in class profile versus competitor prc2 inhibitors,oric pharmaceuticals presents preclinical data on two programs at the 2024 american association for cancer research aacr annual meeting,clinical_study,UP,0.7292609093775566,917376128.0,46263412.0,2075030.0,1.48,1197300.0,0.05043014592156468,0.09346626282280733,0,8,446,0.33888888888888885,0.9062890169720547,0.0
rockville md july 19 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported today that its german subsidiary curetis gmbh has met all milestones under its extended and expanded research and development r d collaboration agreement with find following the delivery of a comprehensive milestone report at the end of the second quarter of 2023 find recently confirmed that all requirements have been met successfully,opgen s subsidiary curetis meets milestones of extended and expanded r d collaboration with find,press_releases,UP,0.1538496751051682,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,2,7,710,0.22999999999999998,1.807174583649316,0.15762987012987015
meaningful improvement in overall survival os and tolerability observed in patients receiving trilaciclib in combination with a trop2 adc,meaningful improvement in overall survival os and tolerability observed in patients receiving trilaciclib in combination with a trop2 antibody drug conjugate adc,clinical_study,DOWN,-0.733501434941693,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,396,0.25,0.8866002429130597,0.025
kraig labs otcqb kblb further boosts spider silk production with the introduction of new silk cocoon reeling protocols resulting in higher silk yields,kraig biocraft laboratories significantly increases spider silk reeling efficiency boosting per cocoon yield,press_releases,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,306,0.1903409090909091,0.8071333009212691,0.12168560606060605
based on a novel human cytomegalovirus vector platform vir 1388 was designed with the goal of creating a novel hiv vaccine,vir biotechnology announces first participant dosed in new phase 1 trial evaluating vir 1388 an investigational t cell vaccine for the prevention of hiv,clinical_study,DOWN,-0.3045754871435993,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,8,647,0.12878787878787878,0.8653389999075153,0.07692099567099565
the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases,neximmune announces research collaboration with national institute of neurological disorders and stroke ninds of the national institutes of health nih,partnerships,DOWN,-0.7692307692307693,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,996,0.0,2.2666992986423327,0.0
cambridge mass oct 24 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced positive phase 2 data from the ongoing phase 1 2 study of ntla 2002 in patients with hereditary angioedema hae with results continuing to indicate that ntla 2002 has the potential to eliminate hae attacks following a one time infusion ntla 2002 is an investigational in vivo crispr based gene editing therapy in development as a one time treatment for hae a rare genetic condition that leads to potentially life threatening swelling attacks results were published online today in the new england journal of medicine and will be presented on saturday october 26 at the 2024 american college of allergy asthma immunology acaai scientific meeting in boston massachusetts,intellia presents positive results from the phase 2 study of ntla 2002 an investigational in vivo crispr gene editing treatment for hereditary angioedema hae,clinical_study,DOWN,-7.103823312288768,974716032.0,98412511.0,6353695.0,2.134,5288300.0,0.10096531478821516,0.09346626282280733,3,8,247,0.11136363636363636,0.7800307612939593,0.05464752337034945
patient treated in trial achieved a remission after eight weeks of treatment demonstrating a significant reduction in proteinuria,eloxx pharmaceuticals intends to advance elx 02 into pivotal trial for the treatment of alport syndrome with nonsense mutations following achievement of remission in patient in phase 2 study,clinical_study,DOWN,-3.492435220091153,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,8,766,0.2916666666666667,2.2721670857062097,-0.03571428571428571
philogen new production facility in rosia has received the gmp certificate by competent authorities,philogen s p a announces receipt of the good manufacturing practice certificate for its new production facility in rosia siena italy by competent authorities,company_regulatory_filings,DOWN,-2.762430881006422,926076608.0,35018869.0,31367.18181818182,0.152,19588.0,0.25000035609542787,0.09346626282280733,1,2,571,0.39454545454545453,0.3376005673725286,0.22613636363636364
media release,immutep announces late breaking abstract in head neck cancer selected for oral presentation at esmo congress 2024,clinical_study,UP,4.3103511176128135,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,1,8,312,-0.3,0.7476881311953882,0.12640146967878058
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report first quarter 2024 financial results and provide a corporate update on thursday may 9,conference_call_webinar,DOWN,-0.4464302820210845,160853024.0,15213010.0,781395.0,1.567,974600.0,0.09457708423311954,0.09346626282280733,1,8,417,0.08333333333333333,0.8435084668920305,0.14913737717309147
santa ana calif oct 17 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today presented a poster with interim phase i trial data on the use of its investigational nk cell therapy snk01 to treat patients with alzheimer s disease ad at the xxvi world congress of neurology wcn annual meeting in montreal qc canada and online,nkgen biotech presents interim phase i trial data at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,DOWN,-1.9999980926513672,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,1,8,620,0.3,2.657355742098314,0.3
media release,polight asa continues to build positive momentum in several segments,business_contracts,DOWN,-7.103823312288768,725118720.0,112518348.0,613349.45,1.511,331673.0,0.15517231164573989,0.19535099655549074,3,7,240,0.11363636363636363,0.8385781649627817,0.0
vancouver british columbia oct 12 2023 globe newswire mydecine innovations group inc mydecine or the company neo myco aqse myig otc mycof fse 0nfa a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and ptsd announces that it has completed its admission to the access segment of the aqse growth market aqse and that trading commenced at 8 00 a m gmt on tuesday 10 october 2023 admission under the ticker myig,mydecine innovations group announces admission to trading on the aqse growth market in london uk,exchange_announcement,DOWN,-2.9411736347271384,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,3,2,625,0.1111111111111111,5.6468521991492,0.10396825396825397
baltic horizon fund the issuer applies for temporary waiver of debt service coverage ratio covenant in relation to baltic horizon fund eur 42 million 5 year floating rate bonds maturing in 2028 isin ee3300003235 the bonds the current outstanding nominal amount of the bonds is eur 22 000 000 as baltic horizon fund has mandatorily redeemed bonds in nominal amount of eur 20 000 000 as foreseen under the terms and conditions of the bonds terms and conditions in the light of the current situation of baltic economies the outlook for next year as well as the associated effects on the fund baltic horizon fund has decided to request the holders of the bonds the holders to amend and lower the debt service coverage ratio covenant in the terms and conditions for a period of 24 months starting from 30 september 2024 until 30 september 2026 baltic horizon fund confirms to all holders that its ability to fulfil the monetary obligations provided in the terms and conditions has not been,baltic horizon fund requests for partial early redemption and temporary waiver under the bond terms and conditions,financing_agreements,UP,1.0101081051682848,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.1125,0.8866002429130597,0.08882575757575759
new j code issued by the centers for medicare and medicaid services expected to standardize and streamline billing and reimbursement tampa fla oct 03 2024 globe newswire pacira biosciences inc nasdaq pcrx the industry leader in the delivery of innovative non opioid pain therapies today announced that the centers for medicare and medicaid services cms has established a permanent product specific healthcare common procedure coding system hcpcs j code for exparel bupivacaine liposome injectable suspension the new j code for exparel j0666 becomes effective january 1 2025 and will supersede the current c code c9290 which has been in place since 2019,pacira biosciences announces new product specific j code for exparel effective january 1 2025,product_services_announcement,DOWN,-1.0302630403297393,1110386688.0,45834212.0,557500.0,0.511,435200.0,0.04127770306986966,0.09346626282280733,3,8,268,0.15537190082644628,0.7130794063724827,0.12841738816738818
media release,immutep announces positive preliminary topline results from tacti 003 cohort b,clinical_study,UP,9.242146234319629,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,2,8,430,0.22727272727272727,0.7476881311953882,0.125
alvotech nasdaq alvo fundar með erlendum fjárfestum á heilbrigðisráðstefnu fjárfestingabankans jefferies í london dagana 19 20 nóvember n k stjórnendur alvotech munu einnig flytja kynningu á ráðstefnunni þriðjudaginn 19 nóvember n k kl 9 00 9 25 að íslenskum tíma,alvotech fundar með fjárfestum og heldur kynningu á heilbrigðisráðstefnu jefferies í london 19 20 nóvember 2024,clinical_study,UP,0.3831432184220352,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,4,8,246,0.0,0.44264539487962035,0.04412127224627225
media release,bluenord positive preliminary results on hemj well,product_services_announcement,UP,1.96078431372549,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.22727272727272727,0.8866002429130597,0.10416666666666667
alvotech nasdaq alvo and teva pharmaceuticals a u s affiliate of teva pharmaceutical industries ltd nyse and tase teva today announced that the u s food and drug administration fda has approved selarsdi ustekinumab aekn in a new presentation 130 mg 26 ml 5 mg ml solution in a single dose vial for intravenous infusion this approval paves the way for selarsdi to further align its label with the indications of the reference product stelara ustekinumab in the u s at launch which is expected in the first quarter of 2025,alvotech and teva announce u s fda approval of additional presentation of selarsdi ustekinumab aekn expanding its label to include further indications approved for reference product stelara ustekinumab,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.03582251082251082,0.44264539487962035,0.05175282234105764
cleared first four monotherapy doses and initial combination cohort with no dose limiting toxicities at any dose level,kineta provides update on its ongoing phase 1 2 vista 101 clinical trial of kva12123 in patients with advanced solid tumors,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,528,0.1625,0.8866002429130597,0.15144300144300146
redwood city calif feb 06 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on developing novel antibody therapies targeting c kit cd117 to address diseases such as chronic spontaneous urticaria csu and lower to intermediate risk myelodysplastic syndromes mds as well as novel stem cell transplant conditioning regimes announced today the pricing of its underwritten offering of 3 900 000 shares of its common stock each share of common stock will be sold at an offering price of 12 95 per share for gross proceeds of approximately 50 million before deducting underwriting discounts and commissions and offering expenses jasper intends to use the net proceeds from the offering for continued advancement of its preclinical and clinical development programs of briquilimab in mast cell driven diseases such as csu and chronic inducible urticaria cindu as well as general corporate purposes which may include capital expenditures working capital and general and administrative expenses all of the shares of common stock are being offered by jasper the offering is expected to close on or about february 8 2024 subject to the satisfaction of customary closing conditions,jasper therapeutics announces pricing of 50 million underwritten offering of common stock,shares_issue,UP,9.242146234319629,80969120.0,9908441.0,280900.0,2.725,505700.0,0.12237308494892868,0.09346626282280733,1,8,508,-0.07777777777777777,0.9821837329226573,0.0
novel il 12 immunotherapy administered with standard of care as first line treatment,imunon announces database lock for phase 2 ovation 2 study with imnn 001 in advanced ovarian cancer,clinical_study,UP,1.785712575121809,17822234.0,12808492.0,12655315.0,2.143,945100.0,0.7186804976300951,0.09346626282280733,0,8,369,0.21666666666666667,2.964855117372811,0.06267135642135642
data supports deramiocel s sustained efficacy and safety in treating dmd,capricor therapeutics announces positive long term data from hope 2 ole study in duchenne muscular dystrophy at 2024 world muscle society congress,clinical_study,UP,6.592771927388102,433538464.0,40176259.0,3124730.0,0.85,8768900.0,0.09267057559165039,0.09346626282280733,4,9,260,0.08863636363636362,1.3427880947904531,0.11811036501377412
oxurion receives transparency notification from atlas special opportunities llc,oxurion receives transparency notification from atlas special opportunities llc,major_shareholder_announcements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,4,13,385,0.35714285714285715,2.0692591020840054,0.1442640692640693
16 oct 2024 08 00 cest arctic bioscience as with reference to yesterday s stock exchange release regarding webcast to be hosted today at 12 00 cet to present the results from the heropa read out attached is the presentation material which will be presented at this webcast the webcast will be hosted by ceo christer l valderhaug and medical director runhild gammelsæter webcast details date wednesday 16 th of october 2024 time 12 00 cet format webcast language english the presentation can be accessed through the link below link https channel royalcast com landingpage hegnarmedia 20241016_1 this information is subject to the disclosure requirements pursuant to section 5 12 of the norwegian securities trading act for more information please contact christer l valderhaug ceo mobile 47 920 84 601 e mail christer arctic bioscience com about arctic bioscience arctic bioscience is a biotech company developing and commercializing pharmaceuti,arctic bioscience presentation for today s webcast,conference_call_webinar,UP,8.275862125664345,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,255,0.05555555555555556,0.8866002429130597,0.2348484848484848
south san francisco calif and san diego oct 23 2024 globe newswire oric pharmaceuticals inc nasdaq oric a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance today announced the company presented a poster highlighting certain best in class properties of oric 114 a brain penetrant orally bioavailable irreversible egfr her2 inhibitor to treat egfr exon 20 insertions and other atypical mutations at the eortc nci aacr symposium on molecular targets and cancer therapeutics,oric pharmaceuticals presents data further supporting potential best in class profile of oric 114 to treat egfr exon 20 insertions and other atypical mutations at the eortc nci aacr symposium on molecular targets and cancer therapeutics,clinical_study,UP,9.242146234319629,917376128.0,46263412.0,2075030.0,1.48,1197300.0,0.05043014592156468,0.09346626282280733,2,7,248,0.22142857142857145,0.9062890169720547,0.33888888888888885
media release,cenergy holdings reports on the progress of its share buyback program,changes_in_companys_own_shares,UP,2.441860800372244,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
cguard was the only investigational carotid stent approved by fda for inclusion in the trials,inspiremd congratulates crest 2 investigators on completion of trial enrollment,clinical_study,DOWN,-5.050508212877766,66380568.0,16849440.0,286250.0,0.613,4867100.0,0.25383091027482624,0.09346626282280733,0,7,327,0.0,0.6085732039686736,0.09527777777777775
positive phase 2b data announced for bnc210 on reduction of total symptom severity and multiple symptom clusters in post traumatic stress disorder ptsd with a discussion with the u s food drug administration fda anticipated in q2 24,bionomics provides a review of 2023 and of 2024 plans,clinical_study,DOWN,-4.761907645273734,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,523,0.07575757575757576,0.8866002429130597,0.03799212968368812
media release,international petroleum corporation to release third quarter 2024 financial and operational results on november 5 2024,earnings_releases_and_operating_results,DOWN,-0.4132231404958678,17525362688.0,64661008.0,268294.15789473685,1.53,842590.0,0.0036895674658005686,0.1515999603296736,3,9,240,0.0,0.413754093849161,0.0
conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time,mediwound to report second quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-2.8636885808582586,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,4,8,330,0.0,0.6433034533898109,0.14575491759702286
ex us partner neuraxpharm launches briumvi in germany the first european country ex us partner neuraxpharm launches briumvi in germany the first european country,tg therapeutics announces european launch of briumvi ublituximab xiiy,geographic_expansion,UP,1.351353673421812,5893779456.0,135060602.0,1756590.0,1.939,1677400.0,0.02291578824899959,0.09346626282280733,0,7,488,0.1,0.6256004090066075,0.0
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
in 2021 scandic hotels group ab publ scandic issued convertible bonds with a total nominal amount of 1 800 million sek the remaining convertible bonds with a total nominal amount of 19 million sek have as of today been converted into shares through the conversion the number of shares and votes increases by 438 168 to a total of 219 157 922 the share capital increases by 109 542 sek to a total of 54 789 480 50 sek through the conversion after the conversion there are no more outstanding convertible bonds for more information please contact rasmus blomqvist director investor relations scandic hotels group email rasmus blomqvist scandichotels com phone 46 702 335 367 about scandic hotels group scandic is the largest hotel company in the nordic countries with a network of about 280 hotels with 58 000 rooms in operation and under development in more than 130 destinations the company is the leader when it comes to integrating sustainability in all operations a,convertible bonds with a nominal amount of 19 million sek have been converted into shares and thereby all outstanding convertible bonds have been converted,share_capital_increase,UP,0.0,21688450.0,45859984.0,7124020.0,1.612,2186300.0,2.114488771673402,0.1515999603296736,4,7,274,0.19444444444444445,0.961003290910132,0.0
turku finland and boston march 14 2024 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company pursuing a clever approach to reprogramming myeloid cells to activate anti tumor immunity in hematological and solid tumor microenvironments today announces it will host a virtual bexmab update event on tuesday march 19 at 11 00 eet 9am gmt following the most recent data cut off and scheduled analysis,faron to host webcast to discuss latest data from phase 1 part of the bexmab study of bexmarilimab,clinical_study,DOWN,-0.4329012985813321,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,3,3,471,0.20238095238095236,0.7633342480324978,0.017102159992784992
lawrenceville n j oct 07 2024 globe newswire imunon inc nasdaq imnn the company a clinical stage company in late stage development with its dna mediated immunotherapy today announced that the compensation committee of the company s board of directors approved the grant of i inducement stock options to purchase a total of 60 000 shares of the company s common stock to one individual hired by imunon during the fourth quarter of 2024 and ii inducement stock options to purchase a total of 50 000 shares of common stock to susan eylward hired by imunon as general counsel and secretary effective october 7 2024 collectively the inducement option grants the inducement option grants were approved in accordance with nasdaq listing rule 5635 c 4 and were made on october 7 2024 as a material inducement to each employee s entry into employment with the company,imunon reports inducement grant under nasdaq listing rule 5635 c 4,management_changes,DOWN,-0.9259250061011975,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,264,-0.027777777777777766,2.964855117372811,0.05367330714552936
irvine calif jan 16 2024 globe newswire biomerica inc nasdaq bmra the company a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2024 ended november 30 2023,biomerica reports second quarter 2024 financial results,financial_results,UP,1.0638287753851583,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,1,8,529,0.05714285714285715,1.5245042583012947,0.053151848151848154
media release,delfingroup raises 4 9 million euros from citadele bank for business development,clinical_study,DOWN,-0.3745270276379158,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,249,0.0,0.8866002429130597,0.17936109212425003
transcode therapeutics awarded 2 million nih grant to support clinical evaluation of lead candidate,transcode therapeutics awarded 2 million nih grant to support clinical evaluation of lead candidate,clinical_study,UP,3.37552793021428,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,3,7,296,0.0,2.0874185587937095,0.029924242424242426
trial includes high risk aml patients that have relapsed post allo hsct and are refractory to salvage therapy,neximmune presents initial positive data from the nexi 001 phase 1 trial for relapsed refractory post allo hsct aml at the american society of clinical oncology 2023 annual meeting,clinical_study,UP,7.999997820172991,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,0,8,754,0.09681818181818182,2.2666992986423327,0.015151515151515152
media release,correction satisfied customers and high return on equity in the third quarter,financial_results,UP,1.1410738067002315,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,2,13,240,0.22,0.20896972559163385,0.03142857142857143
results presented at the department of defense s military health system research symposium mhsrs,humacyte presents positive long term results of atev in treatment of vascular trauma in military setting from ukraine humanitarian program,clinical_study,DOWN,-1.2765978745102613,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,305,-0.005681818181818191,1.1173068527438073,0.08202730429292929
celularity closed two financing transactions on january 16 2024 totaling 21 million in gross proceeds consisting of a 6 million private placement with its largest investor dragasac limited and a 15 million amended and restated senior secured loan agreement with an existing lender resorts world inc pte ltd celularity closed two financing transactions on january 16 2024 totaling 21 million in gross proceeds consisting of a 6 million private placement with its largest investor dragasac limited and a 15 million amended and restated senior secured loan agreement with an existing lender resorts world inc pte ltd,celularity and genting leaders comments on closing 21 million financing transactions,financing_agreements,DOWN,-5.000003178914389,45263988.0,11684589.0,65020.0,0.764,90700.0,0.2581431622860982,0.09346626282280733,3,9,520,-0.04285714285714286,1.6050367793919866,0.0916927303465765
yongin south korea and waltham mass july 15 2024 globe newswire gc cell krx 144510 ks and checkpoint therapeutics checkpoint nasdaq ckpt have announced a collaboration to explore the combined therapeutic potential of cosibelimab checkpoint s anti pd l1 antibody with dual mechanism of action with gc cell s immuncell lc an innovative autologous cytokine induced killer cik t cell therapy composed of cytotoxic t lymphocytes and natural killer t cells,gc cell and checkpoint therapeutics advance collaborative cancer research,clinical_study,UP,0.0,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,8,348,0.175,0.8866002429130597,0.07180608607079195
company continuing to prepare for advancement of clinical assets including elx 02 pivotal study in alport syndrome and zkn 013 phase 1 study company continuing to prepare for advancement of clinical assets including elx 02 pivotal study in alport syndrome and zkn 013 phase 1 study,eloxx pharmaceuticals granted extension by nasdaq to regain compliance with the market value of listed securities continued listing requirement,exchange_announcement,UP,2.388064609017005,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,753,0.5,2.2721670857062097,0.1981292517006803
media release,successful completion of secondary placement of existing shares in schibsted asa,prospectus_announcement,DOWN,-2.9585798816568047,74326786048.0,149678416.0,815521.947368421,0.905,160075.0,0.0020137883522010243,0.1515999603296736,1,8,242,0.225,0.31528577751184356,0.0
waltham mass march 18 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced the appointment of amit sharma m d facp fasn fnkf to its board as an independent non executive director effective immediately,checkpoint therapeutics announces appointment of accomplished life sciences executive amit sharma m d to board of directors,management_changes,UP,0.5208328482694815,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,8,467,0.26666666666666666,0.8866002429130597,0.056128787878787875
yield10 achieves a significant milestone in the development of camelina as a commercial crop for producing biofuels and omega 3 oils,usda aphis determines that yield10 bioscience s glufosinate tolerant camelina may be planted and bred in the united states,product_services_announcement,DOWN,-6.451613109971017,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,591,0.1875,0.8866002429130597,0.018571428571428572
fda grants pre bla meeting request and rolling bla submission after review of hope 2 and hope 2 ole 3 year results san diego june 11 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the successful completion of a type b meeting with the u s food and drug administration fda on next steps for the biologics license application bla submission with its lead asset cap 1002 for the treatment of duchenne muscular dystrophy dmd additionally deramiocel has been selected as the proposed international nonproprietary name inn for cap 1002 by the world health organization,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy with an aim to expedite bla pathway,clinical_study,DOWN,-0.554523730449676,434681184.0,40176259.0,3124730.0,0.85,8768900.0,0.09242695676470782,0.09346626282280733,1,9,382,0.2554545454545455,1.3427880947904531,0.09606060606060605
media release,improving macroeconomic environment and good customer activity drive progress supported by cost focus and strong credit quality net profit of dkk 17 6bn for q1 q3 of 2024 2024 net profit outlook revised upwards to dkk 22 5 23 5 billion,financial_results,DOWN,-0.994642651307372,212863959040.0,655783007.0,1036566.3333333334,0.707,1113237.0,0.003080761111263413,0.1515999603296736,3,7,240,0.2833333333333333,0.27861565888473866,0.0
presentation highlights positive 24 month results from hope 2 open label extension study of cap 1002 in duchenne muscular dystrophy presentation highlights positive 24 month results from hope 2 open label extension study of cap 1002 in duchenne muscular dystrophy,capricor therapeutics presents at 2024 muscular dystrophy association mda clinical scientific conference,clinical_study,UP,5.241930444456451,433264256.0,40176259.0,3124730.0,0.85,8768900.0,0.092729225740699,0.09346626282280733,2,8,479,0.11363636363636363,1.3427880947904531,0.0
dallas july 03 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has added two new u s clinical trial sites for its 2024 burn pivotal study the university of california san diego and the university of utah,spectral ai expands clinical trial sites for pivotal u s burn study,clinical_study,DOWN,-0.5524856784194297,55099652.0,17924135.0,466020.0,0.698,473400.0,0.3253039601774617,0.09346626282280733,2,8,360,0.2051948051948052,0.9904696515070965,0.13242424242424244
fireside chat scheduled for wednesday june 5 2024 at 1 30 pm et fireside chat scheduled for wednesday june 5 2024 at 1 30 pm et,tg therapeutics to participate in the jefferies global healthcare conference,conference_call_webinar,UP,1.349700803684202,5884635648.0,135060602.0,1756590.0,1.939,1677400.0,0.022951395817666774,0.09346626282280733,0,7,390,0.0,0.6256004090066075,0.05096049783549783
media release,two national airlines choose a seamless multi orbit ifc future with ses open orbits,product_services_announcement,DOWN,-4.347824604401455,33236662.0,5203991.0,38994.47368421053,-1.546,15503.0,0.15657381598669565,0.19535099655549074,2,8,241,0.03333333333333333,2.144966214298392,0.0888888888888889
malvern pa may 29 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that the company will present at the 2024 bio international convention taking place in san diego ca from june 3 6 2024,ocugen to present at bio international convention 2024,trade_show,DOWN,-3.5087754766280086,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,7,395,0.0,0.7661975315521313,0.10606060606060606
boca raton florida april 30 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease is pleased to share an update on two patients from the phase 1b trial completed in 2021 who have continued to receive xpro for treatment of alzheimer s disease ad for more than three years under the australian compassionate use program known as the special access scheme sas,inmune bio inc provides update on two patients from the phase 1b alzheimer s disease trial who continue to receive xpro under compassionate use for over three years,clinical_study,UP,5.352583995449589,162723408.0,15213010.0,781395.0,1.567,974600.0,0.09348999131089979,0.09346626282280733,1,8,424,0.3392857142857143,0.8435084668920305,0.117445987654321
longeveron to attend bio 2024 exploring potential partnership and strategic opportunities for its alzheimer s disease program,longeveron to attend bio international convention 2024,partnerships,UP,0.0,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,1,8,396,0.0,1.063123411629147,0.0
elx 02 treatment improved podocyte foot process effacement in all three patients by an average of based on a blinded kidney biopsy analysis by nipoka gmbh,eloxx pharmaceuticals reports additional confirmation that all nonsense mutation alport syndrome patients treated with elx 02 in phase 2 study had improvement in kidney morphology and clinical benefit of reduction or stabilization of proteinuria,clinical_study,DOWN,-0.4629625030505988,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,8,628,-0.15,2.2721670857062097,0.10655505364201018
rapt to host a conference call today at 8 30 am et,rapt therapeutics announces clinical hold on studies evaluating zelnecirnon,clinical_study,DOWN,-7.103823312288768,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,1,7,494,0.0,1.6028075568485736,0.11840367965367966
woburn mass march 26 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today reported that the plant biosafety office pbo of the canadian food inspection agency cfia recently reviewed information on the company s e3902 camelina sativa camelina and determined that e3902 is not a plant with novel trait pnt and is not subject to a pre market notification under part v of the seeds regulations yield10 s e3902 camelina combines genome edits in three proprietary genetic traits c3008a c3008b and c3009 that result in an increase in oil production by five percent and produce a lighter seed coat color as compared to the parental camelina line e3902 camelina remains subject to other applicable requirements of the seeds act and regulations in canada,yield10 bioscience announces that the plant biosafety office of the canadian food inspection agency has cleared genome edited e3902 camelina for planting in canada,regulatory_filings,DOWN,-2.7777860562003345,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,459,-0.05208333333333333,0.8866002429130597,0.05413919413919414
oslo 23 may 2024 pci biotech holding asa pci biotech or the company issue this notification on behalf of hans peter bøhn chair of the board of directors,disclosure of voting rights for chair of the board,annual_general_meeting,UP,0.0,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,3,3,401,0.0,0.8869841129646596,-0.01871693121693121
tkm auto oü subsidiary of tkm grupp as has resolved as the sole shareholder to prolong the authorities of all members of the supervisory board of kia auto aktsiaselts for another 3 year term until the 21st of september 2027 the members of the supervisory board of kia auto aktsiaselts are aarne õllek chairman of the supervisory board jüri käo enn kunila raul puusepp and kristo anton kia auto aktsiaselts is the importer and wholesaler of kia vehicles and spare parts in estonia latvia and lithuania raul puuseppchairman of the boardphone 372 731 5000,prolongation of authorities of members of the supervisory board of kia auto aktsiaselts,management_changes,UP,0.1059346326944422,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,281,0.0,0.8866002429130597,0.0
stada and alvotech launch uzpruvo the first approved ustekinumab biosimilar to stelara across europe,stada and alvotech launch uzpruvo the first approved ustekinumab biosimilar to stelara across europe,product_services_announcement,UP,0.8375241623460453,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,0,6,341,0.25,0.44264539487962035,0.04861111111111111
san diego may 01 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee anne c hansen who is joining oncternal as senior director clinical data management,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,DOWN,-2.406747928283236,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,423,0.13636363636363635,0.8866002429130597,-0.04194725028058362
media release,xplora technologies as announces strategic partnership with hmd global to expand into the youth phone market,partnerships,UP,0.0,1855892352.0,20356814.0,45065.4,0.201,14970.0,0.010968747178715675,0.1515999603296736,1,7,242,0.0,0.5164688145896636,0.0
lawrenceville n j may 06 2024 globe newswire imunon inc nasdaq imnn a clinical stage drug development company focused on developing dna mediated immunotherapy and next generation vaccines announces that the company will host a conference call at 11 00 a m et on monday may 13 2024 to discuss financial results for the first quarter ended march 31 2024 and provide an update on its clinical development programs with imnn 001 a dna based interleukin 12 il 12 immunotherapy in phase 2 clinical development for the treatment of first line locally advanced stage ovarian cancer and on its placcine modality a proprietary mono or multi cistronic dna plasmid and a synthetic dna delivery technology for the expression of pathogen antigens for the development of next generation vaccines,imunon to hold first quarter 2024 financial results and business update conference call on monday may 13 2024,conference_call_webinar,DOWN,-1.5037668789816911,17822234.0,12808492.0,12655315.0,2.143,945100.0,0.7186804976300951,0.09346626282280733,0,11,417,0.14375,2.964855117372811,0.01401515151515151
alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today its participation in the jefferies london healthcare conference november 19 20 2024 members of the management team will host one on one meetings on both days alvotech will be presenting at the conference on tuesday november 19 2024 at 9 00 9 25 am gmt,alvotech meeting investors and presenting at the jefferies 2024 london healthcare conference on november 19 20 2024,clinical_study,UP,0.3831432184220352,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,4,8,246,0.0,0.44264539487962035,0.04412127224627225
clinical trial demonstrates that nvns is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants clinical trial demonstrates that nvns is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants,non invasive vagus nerve stimulation nvns is effective at accelerating foreign language learning,clinical_study,DOWN,-1.037374046050865,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,3,8,331,0.41874999999999996,0.8324549917316175,0.08515085924176834
missing,valneva déclaration d actions et de droits de vote 31 juillet 2024,voting_rights,DOWN,-1.828822228271539,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,2,326,-0.2,0.6494694268312979,0.2126984126984127
warrington pa oct 23 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions and diseases today announced that the company has completed national phase filings of patent applications around the world including in the united states germany france italy japan and china,windtree announces istaroxime cardiogenic shock patent filings in countries around the world,clinical_study,UP,0.0,1352846.0,3660923.0,6680965.0,0.764,1224200.0,2.7060899762426764,0.09346626282280733,2,8,248,0.07500000000000001,2.339794177443606,0.05678504471118108
enea has signed a three year term based contract expansion valued at usd 2 7 million with an existing us customer operating in retail and logistics the customer has already deployed the ixengine and threat detection sdk to protect their internal networks the contract expansion adds the ixengine deep file inspection module and capacity upgrades together with the term based licences for td sdk and ixengine maintenance and support the value of the contract will be recognized over the three year period with some 300kusd during the fourth quarter 2024 the threat detection sdk product was launched a year ago and has already been deployed together with our market leading ixengine in several different customer environments from cybersecurity software to industrial network environments this product has opened up new doors for us says anders lidbeck president and ceo enea enea qosmos ixengine is the industry standard for embedded traffic intelligence based on deep packet inspection,enea signs contract for embedded threat detection worth usd 2 7 million with us customer,business_contracts,UP,0.1112330060331621,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,255,0.048484848484848485,0.8866002429130597,0.075
tampa fla feb 07 2024 globe newswire pacira biosciences inc nasdaq pcrx the industry leader in its commitment to non opioid pain management and regenerative health solutions has been awarded a national group purchasing agreement for brand pharmaceuticals with premier inc effective january 1 2024 the new agreement allows premier members at their discretion to take advantage of special pricing and terms pre negotiated by premier for exparel bupivacaine liposome injectable suspension,pacira biosciences awarded brand pharmaceuticals agreement with premier inc,business_contracts,DOWN,-2.0792764220916573,1112238976.0,45834212.0,557500.0,0.511,435200.0,0.041208960474336045,0.09346626282280733,2,8,507,0.3645021645021645,0.7130794063724827,0.0
marlborough mass may 06 2024 globe newswire akoya biosciences inc nasdaq akya the spatial biology company has opened its operations and manufacturing center of excellence in marlborough massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company s phenocycler fusion and the phenoimager ht platforms,akoya biosciences opens operations and manufacturing center of excellence in marlborough massachusetts,capital_investment,UP,0.9900980750178164,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,0,8,418,-0.1,0.8573192373918191,0.18323863636363635
michael j finney ph d to continue as chairman of the board of directors,vaxart inc appoints steven lo as president chief executive officer and director,management_changes,DOWN,-0.8264454667762735,120729968.0,226926647.0,9325470.0,1.148,2676900.0,1.8796215286000904,0.09346626282280733,2,8,479,0.0,1.025768835125998,-0.061111111111111116
10 oct 2024 08 27 cest ab science communique de presse ab science présente ses résultats financiers au premier semestre 2024 et les evenements clefs de la periode développement clinique plateforme masitinib réexamen du dossier en cours par l ema et santé canada concernant la demande d autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophiqueprécisions sur le développement du masitinib dans les formes progressives de la sclérose en plaques suite à la conférence 2024 de l ectrimsrésultats positifs de l étude de phase 2 du masitinib dans la covid 19renforcement de la propriété intellectuelle du masitinib dans la mastocytose plateforme microtubules précisions sur le programme microtubule ab8939 et en particulier sur la capacité d ab8939 à générer une réponse sur le réarrangement du gène mecom situation financière et corporate déficit opérationnel de 3 6 millions d euros au 30 juin 2024 en baisse de 59 par rapport au premier seme,ab science résultats financiers semestriels au 30 juin 2024 et point sur les activités d ab science,financial_results,UP,1.034125169013376,4469877760.0,90123946.0,193465.0,0.815,121600.0,0.02016250797874168,0.1515999603296736,3,8,261,0.0,0.28735916675162854,0.0
boston dec 04 2023 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that robert connelly chief executive officer will present at the upcoming h c wainwright 4th annual precision oncology virtual conference on december 6 2023 at 10 30 am et,elicio therapeutics to present at the h c wainwright 4th annual precision oncology virtual conference,conference_call_webinar,UP,3.735148930658242,128615880.0,10299137.0,63410.0,2.164,22500.0,0.0800767136997391,0.09346626282280733,0,8,572,0.0,0.8558055682194762,0.05333333333333334
cambridge mass march 04 2024 globe newswire immuneering corporation nasdaq imrx a clinical stage oncology company seeking to develop and commercialize universal ras raf medicines for broad populations of cancer patients today announced that management will participate in the cowen 44th annual health care conference which is taking place at the marriott copley place in boston from march 4 6 2024 to discuss the company s pipeline platform and business strategy participating will be ben zeskind chief executive officer brett hall chief scientific officer harold e b brakewood chief business officer and mallory morales chief accounting officer treasurer,immuneering to participate in the cowen 44th annual health care conference,conference_call_webinar,UP,9.242146234319629,114974312.0,27271404.0,2516685.0,0.002,1980700.0,0.23719562679357456,0.09346626282280733,0,8,481,0.03125,1.2966226301621697,0.09791666666666667
fréttatilkynning22 júlí 2024stada og alvotech hefja sölu á uzpruvo fyrstu líftæknilyfjahliðstæðunni við stelara í evrópu,stada og alvotech hefja sölu á uzpruvo fyrstu líftæknilyfjahliðstæðunni við stelara í evrópu,product_services_announcement,UP,0.8375241623460453,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,0,6,341,0.0,0.44264539487962035,0.11574074074074074
published data from two phase 3 clinical trials demonstrated rapid reversal of pharmacologically induced mydriasis with favorable safety profile published data from two phase 3 clinical trials demonstrated rapid reversal of pharmacologically induced mydriasis with favorable safety profile,ocuphire pharma announces publication of full phase 3 results of phentolamine ophthalmic solution 0 for pharmacologically induced mydriasis in ophthalmology,clinical_study,UP,2.3255884873024546,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,271,0.35,0.8866002429130597,-0.004584209441352297
notice to the shareholders of ab akola group the board of ab akola group has decided on 16 october 2024 to add item 9 to the agenda of the annual general meeting of shareholders to be held on 31 october 2024 the convening of which has been announced on 10 october 2024 and submitted a draft decision 9 determination of the remuneration of the members of the company s audit committee draft decision 9 1 grant an additional one off remuneration of eur 600 six hundred euros to each existing member of the audit committee for the increased workload of the audit committee in the financial year 2023 2024 9 2 set the annual remuneration to each member of the audit committee payable from 2025 onwards as follows eur 1 600 one thousand six hundred euros to the chairman of the audit committee and eur 1 200 one thousand two hundred euros to the audit committee member 9 3 determine that the annual remuneration to the members of the audit committee shall be paid within one month,supplement of the agenda of the annual general meeting of shareholders of ab akola group,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,254,0.03333333333333335,0.8866002429130597,0.13379574970484062
mainz biomed announces submission for fda breakthrough device designation for its next generation crc screening test,mainz biomed announces submission for fda breakthrough device designation for its next generation crc screening test,clinical_study,UP,9.242146234319629,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,1,3,354,0.0,34.079934680222834,0.038047138047138045
farmington hills mich feb 23 2024 globe newswire ocuphire pharma inc nasdaq ocup ocuphire a clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of retinal and refractive eye disorders today announced that george magrath m d m b a m s ceo of ocuphire will be presenting a company overview at the bio ceo investor conference being held february 26 27 2024 in new york city company management will also be participating in one on one meetings throughout the conference,ocuphire pharma to present in the bio ceo investor conference,conference_call_webinar,UP,0.7999992370605469,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,491,-0.03787878787878788,0.8866002429130597,-0.04886621315192744
rockaway n j july 31 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced that it will report financial results for the second quarter ended june 30 2024 after the close of the market on wednesday august 7 2024 management will host a conference call and webcast at 4 30 pm edt to discuss the financial results and answer questions,electrocore to announce second quarter june 30 2024 financial results on wednesday august 7 2024,earnings_releases_and_operating_results,DOWN,-0.3430797106445155,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,2,8,332,0.0,0.8324549917316175,0.10407327240660574
media release,lhv pank completed the acquisition of part of tbb pank s credit portfolio,mergers_acquisitions,DOWN,-0.142446610710075,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,250,0.0,0.8866002429130597,0.04395265257618199
šiaulių bankas ab plans an offering of fixed rate reset perpetual additional tier 1 temporary write down notes subject to market conditions this notice does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas on 14 october 2024 the management board of šiaulių bankas ab approved an offering of fixed rate reset perpetual additional tier 1 temporary write down which would follow subject to market conditions šiaulių bankas ab has mandated goldman sachs bank europe se as lead manager to arrange a series of virtual fixed income investor meetings commencing on 14 october relevant stabilisation regulations including fca icma will apply this communication is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful no action has been,šiaulių bankas ab plans a bond offering subject to market conditions,financing_agreements,DOWN,-0.6142500205394381,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,14,256,-0.01464646464646464,0.8866002429130597,0.10189814814814815
copenhagen denmark aug 14 2024 globe newswire evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines provides business update and announces second quarter 2024 financial results,evaxion announces business update and second quarter 2024 financial results,financial_results,UP,9.05730613263724,15601928.0,155104950.0,157745.0,0.102,38700.0,9.94139634537475,0.09346626282280733,2,7,318,0.0,1.4249795072460607,0.12818462401795735
seattle nov 28 2023 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it will host a virtual kol event to discuss new data from the vista 101 clinical trial of kva12123 in patients with advanced solid tumors details are as follows,kineta to host kol event to review new data from vista 101 clinical trial of kva12123 in patients with advanced solid tumors on december 5 2023,clinical_study,DOWN,-0.3225803474481751,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,578,0.1787878787878788,0.8866002429130597,0.18181818181818182
ad hoc announcement pursuant to art 53 lr,santhera closes financings and secures funds to reach break even expected in 2026,financing_agreements,UP,2.040819857186725,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,319,-0.1,0.5209522992128177,0.08896103896103896
series h warrants exercisable following release of positive outcomes results related to one year follow up from the company s c guardians pivotal trial,inspiremd announces full exercise of series h warrant tranche for gross proceeds of 17 9 million,warrants_and_certificates,DOWN,-1.1999988555908203,67091308.0,16849440.0,286250.0,0.613,4867100.0,0.25114192139464625,0.09346626282280733,0,7,362,0.17954545454545454,0.6085732039686736,0.0917893217893218
sydney australia june 05 2024 globe newswire immutep limited acn 009 237 889 asx imm nasdaq immp immutep or the company is pleased to announce the successful completion of its institutional placement placement and the institutional component institutional entitlement offer of its 1 for 16 pro rata accelerated non renounceable entitlement offer entitlement offer and together with the placement the offer of new fully paid ordinary shares in immutep new shares,immutep successfully completes institutional placement and institutional component of entitlement offer,shares_issue,DOWN,-7.103823312288768,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,2,6,388,0.2787569573283859,0.7476881311953882,0.09772727272727272
missing,valneva declaration of shares and voting rights august 31 2024,voting_rights,UP,0.4184063131376948,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,12,296,-0.2,0.6494694268312979,0.06282828282828283
toronto nov 21 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders provides an update on the development of a next generation lyophilized formulation of bucillamine,revive therapeutics provides update of novel bucillamine formulation development,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,585,0.09999999999999999,1.8889707456546947,0.0
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl gbp nav s,fund_data_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
redwood city calif march 15 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu announced additional positive phase 1b 2a data on briquilimab as a conditioning agent in the treatment of fanconi anemia fa,new positive data presented on briquilimab conditioning in patients with fanconi anemia,clinical_study,DOWN,-0.4106791782468576,81044232.0,9908441.0,280900.0,2.725,505700.0,0.12225966926307599,0.09346626282280733,4,8,470,0.2381818181818182,0.9821837329226573,0.09158730158730159
ad hoc announcement pursuant to art 53 lr,addex therapeutics reports full year 2023 financial results and provides corporate update,financial_results,UP,9.242146234319629,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,3,1,436,0.11666666666666665,0.972373032385036,-0.011666666666666662
imm 1 104 has been well tolerated demonstrating the potential for a differentiated safety profile,immuneering announces positive topline results from phase 1 portion of its phase 1 2a clinical trial of imm 1 104 in ras mutant solid tumors,clinical_study,DOWN,-7.103823312288768,112995104.0,27271404.0,2516685.0,0.002,1980700.0,0.2413503154968555,0.09346626282280733,3,7,471,0.07575757575757576,1.2966226301621697,0.08854166666666667
rockaway n j oct 23 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced that it will report financial results for the third quarter ended september 30 2024 after the close of the market on wednesday november 13 2024 management will host a conference call and webcast at 4 30 pm est to discuss the financial results and answer questions,electrocore to announce third quarter september 30 2024 financial results on wednesday november 13 2024,clinical_study,UP,0.0,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,2,8,248,0.0,0.8324549917316175,0.13377408539173244
lawrenceville n j may 15 2024 globe newswire imunon inc nasdaq imnn a clinical stage drug development company focused on developing non viral dna mediated immunotherapy and next generation vaccines announces that an abstract describing a phase 2 study with imnn 001 plus bevacizumab avastin and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the american society of clinical oncology asco annual meeting to be held in chicago from may 31st to june 4th,abstract on phase 2 study with imunon s imnn 001 plus bevacizumab accepted for presentation at the american society of clinical oncology annual meeting,clinical_study,DOWN,-1.4814800424667631,17677966.0,12808492.0,12655315.0,2.143,945100.0,0.7245455727203005,0.09346626282280733,2,8,409,0.1,2.964855117372811,0.04996843434343434
palo alto calif oct 08 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today provided certain preliminary unaudited financial results for the quarter ended september 30 2024,scilex holding company provides certain preliminary unaudited financial results for the quarter ended september 30 2024,earnings_releases_and_operating_results,DOWN,-5.730337063601907,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,13,262,0.25476190476190474,1.0327724261931344,0.24148572781385283
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
san diego oct 07 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that company leadership will present at the 19th annual peptide therapeutics symposium taking place virtually and in person in la jolla california october 22 23 2024 details of the presentation are as follows,biora therapeutics to present at the 19th annual peptide therapeutics symposium,conference_call_webinar,DOWN,-1.7421586867605077,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,264,0.0,1.027516639474094,0.08571815089672234
san diego march 06 2024 globe newswire ars pharmaceuticals inc nasdaq spry a biopharmaceutical company dedicated to empowering at risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis today announced its participation in the leerink partners global biopharma conference 2024 being held march 11 13 2024 in miami florida,ars pharmaceuticals to participate in the leerink partners global biopharma conference 2024,conference_call_webinar,UP,1.3513500451867635,1693202432.0,51755600.0,1240295.0,0.872,1940800.0,0.03056669363442067,0.09346626282280733,2,9,479,0.16666666666666666,0.6899910717831225,0.32736742424242427
geneva switzerland july 12 2024 addex therapeutics six adxn and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that mikhail kalinichev head of translational science will present at the thirteenth london international cough symposium taking place july 18 19 2024 at imperial college in london u k,addex to present at the thirteenth london international cough symposium 13th lics,clinical_study,DOWN,-1.0119052619891058,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,351,-0.041666666666666664,0.972373032385036,-0.00401960784313725
west lafayette ind sept 16 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services has amended certain terms of its credit agreement in addition inotiv has closed the sale of 22 6 million aggregate principal amount of senior secured second lien pik notes due february 2027 the second lien notes and warrants to purchase common shares to certain investors in a private offering,inotiv inc amends its credit agreement and secures additional liquidity,financing_agreements,DOWN,-1.923075159625829,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,0,8,285,-0.010714285714285716,1.3015467599292592,0.03879818594104308
los angeles feb 13 2024 globe newswire renovaro inc nasdaq renb announced today that it completed its acquisition of gedi cube intl ltd gedicube renovaro which means renew combines the power of the ai health tech platform of gedicube with the advanced cell and gene therapy biotech platform of renovaro biosciences to accelerate precision personalized medicine and a new era in healthcare innovation the two subsidiaries will be under the parent organization which was renamed renovaro inc,ai pioneer gedi cube and biotech innovator renovaro biosciences combine forces to accelerate personalized medicine,mergers_acquisitions,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,501,0.2681818181818182,1.5631250973582267,0.15822510822510824
pratteln switzerland july 31 2024 santhera pharmaceuticals six sann announces the board of directors has appointed dr oliver p kronenberg as chief legal officer and corporate secretary of santhera pharmaceuticals ag effective august 1 2024,santhera appoints dr oliver p kronenberg as chief legal officer and company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.25,0.5209522992128177,0.03714285714285715
i april 2023 bekräftade moody s atrium ljungbergs rating på baa2 men ändrade utsikterna från stabila till negativa moody s har nu återigen bekräftat en oförändrad rating dvs baa2 med negative outlook ratingen återspeglar den höga kvalitén i fastighets och projektportföljen en bred kundstruktur en stabil balansräkning och god finansiell position atrium ljungberg eftersträvar en väldiversifierad finansiering avseende såväl finansieringskällor som löptider varför ratingen har stor betydelse nacka 2024 09 25 atrium ljungberg ab publ denna information är sådan information som atrium ljungberg ab publ är skyldig att offentliggöra enligt eu s marknadsmissbruksförordning informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 25 september 2024 kl 08 00 cet för mer information kontakta annica ånäs vd atrium ljungberg 070 341 53 37 annica anas al se atrium ljungberg är ett av sveriges största börsnoterade fastighetsbolag vi äger utveckla,moody s bekräftar atrium ljungberg baa2 rating med negative outlook,regulatory_filings,DOWN,-1.4373716632443532,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,276,-0.3,0.8866002429130597,0.0
vir biotechnology awarded approximately 50 million in barda funding to support development of antibody platform technologies for covid 19,vir biotechnology awarded barda funding to support development of antibody platform technologies for global infectious disease threats,government_news,UP,0.0,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,1,7,634,-0.2,0.8653389999075153,0.08037878787878787
turku finland and boston oct 03 2023 globe newswire faron pharmaceuticals oy aim farn first north faron a clinical stage biopharmaceutical company pioneering macrophage re programming for effective cancer immunotherapies today announces it will host a virtual call for investors to provide an update on the most recent phase i ii bexmab data in acute myeloid leukemia aml and myelodysplastic syndrome mds on wednesday october 11 at 08 00 est 13 00 bst 15 00 eest,faron to host webcast to discuss new data from phase i ii bexmab study of bexmarilimab and provide update on the development outlook for next 6 9 months,clinical_study,UP,2.84494741530867,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,2,634,0.29805194805194807,0.7633342480324978,0.03636569779426923
single well tolerated infusion of anx005 significantly accelerated recovery of gbs patients vs placebo in pivotal phase 3 trial potential to be first targeted therapy for gbs topline real world evidence rwe comparability data now expected by year end 2024,annexon reports second quarter 2024 portfolio and financial results and key anticipated milestones,clinical_study,UP,1.2773753908346157,262216464.0,82380157.0,1425435.0,1.259,925100.0,0.31416851460555123,0.09346626282280733,0,8,320,0.11535714285714285,0.7558344054121836,0.1465465078076685
palo alto calif aug 30 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced oral poster presentations and symposia on ztlido lidocaine topical system at the 2024 annual painweek conference in las vegas nv on september 3 5 2024,scilex holding company to present oral poster presentations and symposia on ztlido lidocaine topical system at the 2024 annual painweek conference in las vegas nv on september 3 5 2024,conference_call_webinar,UP,0.9009000301245093,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,4,9,302,0.22000000000000003,1.0327724261931344,0.257409638972139
top line data from vega 3 phase 3 trial expected in first half of 2025,ocuphire pharma initiates vega 3 phase 3 trial evaluating phentolamine ophthalmic solution 0 for presbyopia,clinical_study,DOWN,-0.8264454667762735,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,296,0.12083333333333335,0.8866002429130597,-0.023879216022073164
pratteln switzerland june 10 2024 santhera pharmaceuticals six sann announces that its partner sperogenix therapeutics has launched a paid for early access program eap for agamree vamorolone in china for patients with duchenne muscular dystrophy dmd,santhera announces launch of early access program in china for agamree by its partner sperogenix,geographic_expansion,UP,1.458326917555852,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,0,1,383,0.1,0.5209522992128177,0.03333333333333335
norwood mass april 02 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio announced today the first patient in the u s has been dosed in the phase 1 clinical trial of crb 701 sys6002 a next generation antibody drug conjugate adc targeting nectin 4,corbus announces dosing of first patient in u s phase 1 clinical trial of its next generation nectin 4 targeting adc,clinical_study,DOWN,-2.053178624722872,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,1,8,452,0.125,0.9919200800994142,0.02865151515151515
marlborough mass dec 20 2023 globe newswire akoya biosciences inc nasdaq akya akoya the spatial biology company today announced that it will be participating in the 42nd annual j p morgan healthcare conference,akoya to participate at 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-0.426438820522461,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,2,8,556,0.0,0.8573192373918191,0.2761363636363636
partners able to claim up to tax relief partners able to claim up to tax relief,centogene receives french research tax credit accreditation,government_news,DOWN,-2.3999977111816406,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,521,0.3333333333333333,3.598197549072007,0.07559523809523809
g1 therapeutics provides first quarter 2024 financial results and operational highlights,g1 therapeutics provides first quarter 2024 financial results and operational highlights,earnings_releases_and_operating_results,DOWN,-6.631299768297614,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,423,0.125,0.8866002429130597,0.025
malvern pa may 31 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced a positive outcome of the data and safety monitoring board dsmb review for its phase 1 2 armada clinical trial for ocu410 aav5 hrora a modifier gene therapy candidate being developed for geographic atrophy ga an advanced stage of dry age related macular degeneration damd ga affects approximately 2 3 million people in the u s and europe combined,data and safety monitoring board approves simultaneous enrollment in cohort 3 and phase 2 initiation in ocu410 armada study for geographic atrophy,clinical_study,UP,0.6289302046118699,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,4,8,393,0.043434343434343436,0.7661975315521313,0.05303030303030303
conference call and webcast scheduled for wednesday may 29th at 8 30 am eastern time conference call and webcast scheduled for wednesday may 29th at 8 30 am eastern time,mediwound to report first quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-1.0477316762418971,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,8,402,0.125,0.6433034533898109,0.1367929292929293
27 sep 2024 08 00 cest claranova se regulatory news claranova euronext paris fr0013426004 cla is happy to announce that several members of its management team have recently reinforced their commitment to the company by increasing their stake in the company s capital through share acquisitions on the market this initiative illustrates their confidence in claranova s growth strategy and their commitment to ensuring its long term success eric gareau chief executive officer of claranova and avanquest acquired 50 000 shares on september 26 2024 bringing his total holding to 153 689 shares xavier rojo chief financial officer of claranova acquired 25 993 shares on september 20 2024 bringing his total holding to 50 000 shares mathieu laforge executive vice president operations of avanquest acquired 19 600 shares on august 2 2024 these acquisitions reflect the renewed confidence of claranova s management in the group s future its solidity and it,claranova group management capitalizes on future,major_shareholder_announcements,UP,0.4048611328405748,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,274,0.10500000000000001,0.8866002429130597,0.0
planegg martinsried may 21 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of differentiated t cell immunotherapies for solid tumors and biontech se nasdaq bntx biontech have announced that their collaboration to advance t cell receptor tcr immunotherapies against cancer will extend beyond the initial three year term outlined at the signing of the agreement in february 2022 this extension will enable ongoing and future work required to potentially generate novel tcrs directed against multiple newly nominated antigen targets that could further expand the biontech warehouse of tcr candidates,medigene s global research collaboration agreement with biontech to extend beyond initially announced term,partnerships,DOWN,-7.103823312288768,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,4,403,0.013636363636363636,1.3169799228985475,0.09999999999999999
needham mass june 18 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that paul peter tak md phd fmedsci candel s president and chief executive officer will participate in a fireside chat at the h c wainwright 2nd annual immune cell engager virtual conference on tuesday june 25 2024 at 3 00 p m et,candel therapeutics to participate in the h c wainwright 2nd annual immune cell engager virtual conference,conference_call_webinar,DOWN,-0.8310241623697936,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,1,8,375,0.0,1.2870358800144117,0.08716815514084421
planegg martinsried july 3 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors announces today that the company has been issued a patent by the chinese patent office protecting its t cell receptor tcr targeting ny eso 1 new york esophageal squamous cell carcinoma 1 and lage 1a l antigen family member 1a both being well recognized and validated cancer testis antigens expressed in multiple tumor types,medigene ag expands patent portfolio with the patent grant for its ny eso 1 lage 1a targeted t cell receptor in china,patents,UP,0.0,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,5,360,0.02727272727272727,1.3169799228985475,0.04176623376623377
rīga latvija 2024 09 20 15 26 cest joint stock company saf tehnika hereby informs that it has received notification of an acquisition of major sharing from its shareholder koka zirgs ltd and notification of a disposal of major sharing from its shareholder andrejs grišāns the copies of the notifications are attached about saf tehnika saf tehnika jsc is an iso certified wireless data transmission equipment manufacturer the company s products are produced in latvia europe and sold in over 130 countries worldwide saf tehnika has been listed on nasdaq riga since 2004 saf tehnika wholly owns subsidiaries saf north america llc which operates from denver co usa and serves the north american market and saf tehnika asia pte ltd in singapore additional information zane jozepa cfo member of the board zane jozepa saftehnika com www saftehnika com attachments lidzdalibas pazinojums_ag_1pielikums pdf li,information regarding acquisition and disposal of a major holding,major_shareholder_announcements,UP,0.732600028819828,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,280,0.046875,0.8866002429130597,0.0
pharmacosmos group and g1 therapeutics announce expiration of hart scott rodino waiting period,pharmacosmos group and g1 therapeutics announce expiration of hart scott rodino waiting period,mergers_acquisitions,DOWN,-0.1402556622906882,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,296,0.0,0.8866002429130597,0.043500000000000004
transcode therapeutics reports positive data from first in human clinical study using novel lead therapeutic candidate ttx mc138,transcode therapeutics reports positive data from first in human clinical study using novel lead therapeutic candidate ttx mc138,clinical_study,DOWN,-7.103823312288768,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,2,9,395,0.1590909090909091,2.0874185587937095,0.022222222222222223
palo alto calif june 14 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced the publication of results of the pivotal registration trial of sp 102 semdexa in pain the official journal of the international association for the study of pain which features original research on the nature mechanisms and treatment of pain,scilex holding company announces publication in pain journal regarding phase 3 results of the pivotal registration trial of sp 102 semdexa in lumbosacral radicular pain sciatica,clinical_study,UP,7.333334287007649,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,4,13,378,0.41250000000000003,1.0327724261931344,0.22000000000000003
media release,satu kuulusa on nimitetty ovaron talousjohtajaksi,management_changes,UP,2.150535566956493,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,15,242,0.0,0.8866002429130597,0.0
boston march 12 2024 globe newswire x4 pharmaceuticals inc nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that it will be reporting financial results for the fourth quarter and full year ended december 31 2023 and providing corporate updates on thursday march 21 2024,x4 pharmaceuticals to report fourth quarter and full year 2023 financial results and host a conference call and webcast on march 21 2024,earnings_releases_and_operating_results,DOWN,-0.3285828496086658,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,1,8,473,0.12499999999999999,1.4412990038402507,0.0
bla supported by results from phase 2 3 clinical trial and outcomes of real world use of the hav under a humanitarian aid program to treat wartime trauma injuries in ukraine,humacyte submits biologics license application bla to u s fda seeking approval of human acellular vessel hav for the treatment of vascular trauma,clinical_study,UP,0.3649631543230379,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,564,0.1,1.1173068527438073,0.0
san mateo calif and cambridge mass dec 04 2023 globe newswire kronos bio inc nasdaq kron a company dedicated to transforming the lives of those affected by cancer today announced that jorge dimartino m d ph d chief medical officer and executive vice president of clinical development and charles lin ph d senior vice president of trn mapping will participate in a fireside chat at the h c wainwright 4th annual precision oncology virtual conference on wednesday december 6 2023 at 11 00 a m et,kronos bio announces participation in h c wainwright 4th annual precision oncology virtual conference,conference_call_webinar,DOWN,-1.666674945089223,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,0,8,572,0.0,0.6178272804340184,0.0
new market research shows strong interest from ophthalmic surgeons following their review of clobetasol s prescribing information new market research shows strong interest from ophthalmic surgeons following their review of clobetasol s prescribing information,eyenovia announces launch and commercial availability of clobetasol propionate ophthalmic suspension 0 for post operative inflammation and pain following ocular surgery,product_services_announcement,UP,4.077258365355376,28093560.0,2433609.0,8930490.0,1.002,41800300.0,0.08662515537368706,0.09346626282280733,3,7,275,0.14242424242424243,2.4441832149286684,-0.010355467944753656
media release,euronext oslo børs bw energy limited mottatt søknad om notering av obligasjonslån,exchange_announcement,DOWN,-0.4347842672596807,8877470720.0,51507273.0,112603.25,1.177,77531.0,0.005802021163974056,0.1515999603296736,3,14,239,-0.07142857142857142,0.38625946949671847,0.0
i henhold til vedtægternes pkt 4 5 indkaldes hermed til ekstraordinær generalforsamling i orphazyme a s til afholdelse den 21 oktober 2024 kl 10 00 på selskabets adresse hos visionhouse lyskær 8a 2730 herlev med følgende dagsorden,indkaldelse til ekstraordinær generalforsamling,corporate_action,UP,0.3382187147688839,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,3,278,0.0,0.8866002429130597,0.0
zug switzerland may 30 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced the results from its 2024 annual general meeting held on may 29 2024 at ochsen zug kolinplatz 11 ch 6300 zug switzerland at 3 30 p m cest including election of new members to its board of directors as well as the recent appointment of two new members to its scientific advisory board sab and the establishment of a loan facility of up to chf 50 million,oculis publishes results of 2024 annual general meeting and announces appointments to its board of directors and scientific advisory board,annual_general_meeting,DOWN,-1.0058665757705016,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,4,394,0.062121212121212126,0.4640841922034435,0.0
vega 3 phase 3 study of phentolamine ophthalmic solution in presbyopia is recruiting patients with top line data expected in 2025,ocuphire pharma announces financial results for second quarter 2024 and provides corporate update,clinical_study,DOWN,-3.614454456987672,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,319,0.08,0.8866002429130597,-0.03253581735724593
se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del vcn 01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos,theriva biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024,clinical_study,DOWN,-4.761904761904762,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,6,416,0.0,1.5225134880447404,0.08038383838383838
san diego aug 28 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that the company s management will provide a corporate update at the h c wainwright 26th annual global investment conference to be held september 9 11 2024,bioatla to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.117317394007622,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,2,8,304,-0.022222222222222223,1.087702859114621,0.015315355940355942
10 oct 2024 08 00 cest abg sundal collier holding asa abg sundal collier abgsc will publish its q3 2024 figures on 17 october 2024 at 08 00 cest the report will be available on our corporate website www abgsc com webcast presentation ceo jonas ström will present the q3 results through a webcast at 09 00 cest followed by a q a session the webcast presentation can be accessed through a web link or call in details presented on our corporate website www abgsc com for further information geir b olsen cfo 47 22 01 60 35 for media contacts anna tropp head of communications 46 722 30 94 17 more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site 629317_abgsc_to_publish_q3_2024_interim_report_on_17_october pdf abg sundal collier holding asa oslo børs newspoint abg sundal collier holding no0003021909 abg oslo børs,abgsc to publish q3 2024 interim report on 17 october,earnings_releases_and_operating_results,UP,1.0574044240404876,4773450240.0,16022805.0,137990.0,0.964,150500.0,0.0033566506812481196,0.1515999603296736,3,8,261,0.19999999999999998,0.3870366636024926,0.0
durham n c aug 12 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale will release its financial results for the second quarter ended june 30 2024 on tuesday august 13 2024 management will host a webcast and conference call at 8 30 a m et to discuss recent corporate updates from its acellular tissue engineered vessel atev programs,humacyte to present second quarter financial results and provide corporate update on august 13 2024,financial_results,DOWN,-7.103823312288768,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,0,8,320,0.0,1.1173068527438073,0.09839257964257965
malvern pa sept 05 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that arun upadhyay phd ocugen s chief scientific officer head of research development will be among the featured speakers at the 5th annual gene therapy for ophthalmic disorders conference which is being held september 10 12 2024 in boston mass,ocugen cso to participate in 5th annual gene therapy for ophthalmic disorders summit,conference_call_webinar,DOWN,-0.862068168189925,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,3,7,296,0.0,0.7661975315521313,0.06330718954248366
eurobio scientific completes acquisition of endopredict genomic test from myriad genetics,eurobio scientific completes acquisition of endopredict genomic test from myriad genetics,mergers_acquisitions,DOWN,-0.2036628864129181,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,4,1,330,0.0,0.4336088389568585,0.007326007326007327
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
arcutis today announced new pooled subgroup analysis results from the phase 3 integument 1 and 2 trials,new data shows zoryve roflumilast cream 0 provided consistent improvement of atopic dermatitis in individuals with diverse skin types,clinical_study,UP,0.0,1718296832.0,85869346.0,2010100.0,1.778,2359700.0,0.04997352285172577,0.09346626282280733,2,1,276,0.17424242424242423,0.6903751128737089,0.05549300439651317
not for release publication or distribution directly or indirectly in or into the united states australia hong kong japan canada new zealand singapore south africa or in any other jurisdiction in which the release publication or distribution of this press release would be unlawful subject to legal restrictions or would require registration or other measures nanologica ab publ nanologica or the company publishes a prospectus in connection with the rights issue of units corresponding to approximately sek 99 4 million that was resolved by the board of directors on august 29 2024 and that was approved by the extraordinary general meeting on september 23 2024 the rights issue prospectusthe prospectus has been prepared in connection to the rights issue and has today on september 26 2024 been approved by the swedish financial supervisory authorithy the prospectus which contains complete terms and conditions for the rights issue is available on the company s,nanologica publishes prospectus in connection with rights issue,prospectus_announcement,DOWN,-3.3333399560713786,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,274,0.04191919191919192,0.8866002429130597,0.0
oslo norway 12 february 2024 pci biotech ose pcib invites to a webcast presentation of the company s second half 2023 interim report on wednesday 14 february 2024 08 30am 09 30am cet local time,pci biotech invitation to second half interim 2023 results presentation,interim_information,DOWN,-4.176905875277916,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,0,3,502,-0.06666666666666667,0.8869841129646596,0.009773662551440335
achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing editas medicine s proprietary targeted lnp as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia,editas medicine announces progress towards 2024 goals including achievement of in vivo preclinical proof of concept and strategic update,clinical_study,DOWN,-0.2659571938462896,182418768.0,83382193.0,2526680.0,2.096,3015800.0,0.45709218362882487,0.09346626282280733,1,7,249,0.0,1.3105556047468256,0.06897522018211671
company maintains strong cash position of 231 6 million company maintains strong cash position of 231 6 million,rapt therapeutics reports first quarter 2023 financial results,financial_results,DOWN,-0.8138344285550466,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,3,8,779,0.2791666666666667,1.6028075568485736,0.05625000000000001
toronto july 02 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the research study evaluating bucillamine as a potential treatment for nerve agent exposure in partnership with defence r d canada suffield research centre drdc an agency of the canadian department of national defence the drdc is investigating pharmacological compounds including bucillamine that can mitigate nerve agent induced brain injury control studies have been initiated and the drdc expects to evaluate the data this month treatment studies will follow after the conclusion of the control group evaluation the research study is expected to be completed in august 2024,revive therapeutics provides update on research study evaluating bucillamine for nerve agent exposure,clinical_study,UP,9.242146234319629,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,13,360,0.049999999999999996,1.8889707456546947,0.09080071483751137
consortium includes top universities hospitals and industry partners led by the francis crick institute and the royal marsden nhs foundation trust,akoya s leading spatial proteomics platforms selected for use by ground breaking uk based manifest consortium to revolutionize cancer immunotherapy,partnerships,UP,0.7194237817389376,61693436.0,12648900.0,228670.0,1.352,488000.0,0.20502829506853856,0.09346626282280733,0,8,264,0.5,0.8573192373918191,0.18259090909090908
carmel ind sept 30 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that both the rationale and design of the phase 2 avail trial of mbx 2109 the company s potential long acting parathyroid hormone pth peptide prodrug in adults with hypoparathyroidism hp were featured in a poster presentation at the american society for bone and mineral research asbmr 2024 annual meeting held in toronto on canada september 27 30 2024,mbx biosciences presents mbx 2109 phase 2 avail hypoparathyroidism trial rationale and design at the asbmr 2024 annual meeting,clinical_study,DOWN,-2.5052207196509784,382040896.0,13610404.0,237885.0,0.8755,391100.0,0.03562551586100353,0.09346626282280733,0,8,271,-0.0125,0.928688678995062,0.0
missing,immix biopharma announces dr raymond comenzo internationally recognized al amyloidosis expert director of the myeloma and amyloid program at tufts medical center joins scientific advisory board,advisory,DOWN,-3.2786918350693264,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,3,9,282,-0.07500000000000001,0.9253604538231538,0.01770793876262626
saint herblain france october 3 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company today announced that it will host an investor day at the lotte new york palace hotel in new york ny on thursday october 10 2024 at 10 00 am et 4 00 pm cet the meeting will be conducted in a hybrid way in person and webcast to register click here,valneva to host investor day in new york on thursday october 10 2024 at 10 00 am et,conference_call_webinar,DOWN,-1.1383547598285657,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,268,0.13636363636363635,0.6494694268312979,0.03253787878787878
media release,ab utenos trikotažas announces results for the third quarter of 2024,interim_information,UP,9.090907243657693,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,239,0.0,0.8866002429130597,0.06302083333333333
zug switzerland june 27 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care announces in collaboration with euretina the ramin tadayoni award,oculis and euretina announces the ramin tadayoni award,contests_awards,DOWN,-0.8438850485279373,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,3,6,366,0.0,0.4640841922034435,0.06683501683501684
media release,børsmeddelelse nr 20 2024 cfo fratræder 31 12 2024,management_changes,DOWN,-2.588238435633042,164269808.0,35018869.0,11918.0,0.146,3511.0,0.25000035609542787,0.19535099655549074,3,11,239,0.0,0.8276089578042077,0.0
planegg martinsried june 27 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today provides a detailed overview of its lead candidate mdg1015 a first in class 3rd generation t cell receptor engineered t cell tcr t therapy at the 7th cell and gene therapy in depth focus summit from june 27 28 2024 in beijing china mdg1015 advances towards the clinic and targets the cancer testisantigens cta ny eso 1 lage 1a new york esophageal squamous cell carcinoma 1 l antigen family member 1a and is armored and enhanced by the company s pd1 41bb costimulatory switch protein csp,medigene presents efficient 6 day tcr t therapy production process with high stemness,clinical_study,DOWN,-1.2820501064172196,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,6,366,0.1351948051948052,1.3169799228985475,0.01840909090909091
media release,nordic unmanned launches contemplated private placement,financing_agreements,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,241,0.0,0.8866002429130597,0.0
media release,avec sa technologie de biodétection innovante stmicroelectronics facilite la conception d une nouvelle génération de dispositifs portables pour les soins de santé et la forme physique,product_services_announcement,UP,2.001434533426933,26525786112.0,642508707.0,7578905.0,1.228,8781800.0,0.02422204206454547,0.19535099655549074,0,15,242,0.0,0.5353904487251331,-0.3
cambridge mass feb 14 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies will present its fourth quarter and full year 2023 financial results and operational highlights in a conference call on february 22 2024 at 8 a m et,intellia therapeutics to hold conference call to discuss fourth quarter and full year 2023 earnings and company updates,conference_call_webinar,UP,2.495273453212415,974716032.0,98412511.0,6353695.0,2.134,5288300.0,0.10096531478821516,0.09346626282280733,2,7,500,0.11666666666666665,0.7800307612939593,0.0
san diego may 01 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced the approval of an inducement award to one new employee anne c hansen who is joining oncternal as senior director clinical data management,oncternal therapeutics reports inducement award under nasdaq listing rule 5635 c 4,management_changes,DOWN,-2.406747928283236,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,423,0.13636363636363635,0.8866002429130597,-0.04194725028058362
media release,notification of major holdings,bond_fixing,DOWN,-0.6223677506822285,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,0,8,243,0.0625,0.4683640137646959,0.0
malvern pa april 29 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced the data from its phase ii iii alzheimer study of buntanetap in mild to moderate ad patients based on these data the company plans to conduct a pivotal phase iii trial in biomarker positive early ad patients,annovis bio announces statistically significant phase ii iii data in patients with early alzheimer s disease,clinical_study,DOWN,-7.103823312288768,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,0,10,424,0.2044507575757576,1.368989555493872,0.050015782828282826
tiziana life sciences announces platform presentation of new quantitative pet imaging data on foralumab at the american academy of neurology,tiziana life sciences announces platform presentation of new quantitative pet imaging data on foralumab at the annual meeting of the american academy of neurology,clinical_study,UP,0.0,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,3,7,443,0.06818181818181818,1.1109140250580023,0.062987012987013
rockville md aug 07 2023 globe newswire opgen inc nasdaq opgn opgen a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease and opgen subsidiary ares genetics which strives to become a leader in bacterial genomics and ai powered prediction of antimicrobial resistance amr announced today a major feature upgrade for the arescloud platform that has been implemented with our healthcare clients to enhance genomic surveillance,opgen s subsidiary ares genetics releases new features to its arescloud offering,product_services_announcement,UP,2.214652759376268,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,0,7,691,0.09943181818181818,1.807174583649316,0.15280663780663784
media release,diana shipping inc approval and publication of bond listing prospectus,prospectus_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,239,0.0,0.8866002429130597,0.1363985468722311
rockville md oct 12 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the company for cash the existing warrants wherein the investor agreed to exercise the existing warrants to purchase up to a maximum of 10 892 728 common shares at an exercise price of 0 7785 per share as part of the agreement the existing holder has agreed to pay an additional 0 25 consideration per share resulting in gross proceeds of up to approximately 11 2 million assuming full exercise of the existing warrants and before deducting offering fees and expenses,opgen enters into warrant inducement transaction for up to 11 2 million in gross proceeds,warrants_and_certificates,DOWN,-7.103823312288768,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,12,624,-0.10833333333333334,1.807174583649316,0.14746915584415585
se vedhæftede,ledende medarbejderes transaktioner,company_regulatory_filings,UP,0.5714285714285714,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,12,282,0.0,0.8866002429130597,0.0
tiziana life sciences to present at biotech showcase conference in san francisco january 8 10 2024,tiziana life sciences to present at biotech showcase conference in san francisco january 8 10 2024,clinical_study,UP,8.928573519295567,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,4,9,540,0.0,1.1109140250580023,0.0
media release,information regarding dividend from solstad maritime holding as,dividend_reports_and_estimates,DOWN,-4.296642448914433,4289897472.0,29760087.0,70112.7,2.413,93652.0,0.006937249012183385,0.1515999603296736,1,15,241,0.0,0.40970189616126773,0.0
tampa fla april 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its first quarter financial results after the close of the u s markets on tuesday may 7 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report first quarter 2024 financial results on tuesday may 7 2024,earnings_releases_and_operating_results,DOWN,-0.7293613522977731,1111081344.0,45834212.0,557500.0,0.511,435200.0,0.04125189595479339,0.09346626282280733,1,8,424,0.10606060606060606,0.7130794063724827,0.188501443001443
media release,equinor asa tilbakekjøp av egne aksjer,changes_in_companys_own_shares,UP,0.4419934464203499,686391361536.0,833726970.0,3882914.5,0.022,6264036.0,0.0012146524806697652,0.1515999603296736,1,8,242,0.0,0.2938846074394393,0.0
selskabsmeddelelse 29 2024,bestyrelsesmedlemmers direktørers eller nærtstående personers handel med orphazyme aktier _,corporate_action,UP,2.0080321285140563,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,14,263,0.0,0.8866002429130597,0.0
phase 2 open label connect1 edo51 study open in canada,pepgen reports second quarter 2023 financial results and recent corporate developments,clinical_study,DOWN,-0.2000045776367187,45482052.0,12870456.0,168500.0,1.294,155200.0,0.28297878908365875,0.09346626282280733,1,8,690,0.0,1.4553932872573117,0.0
dallas aug 19 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that dr jeffrey carter will present data from an ongoing prospective multicenter study analyzing the use of spectral ai s deepview system which utilizes non invasive multispectral imaging technology and proprietary ai to detect non healing areas of a wound following thermal burn injury,spectral ai announces podium presentation at bba isbi joint conference assessing burn wound severity using multispectral imaging and artificial intelligence,clinical_study,DOWN,-1.9354820846890508,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,0,8,313,-0.04285714285714284,0.9904696515070965,0.08747204184704187
alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide announced today that the european medicines agency ema has accepted a marketing authorization application for avt03 a proposed biosimilar candidate to prolia and xgeva denosumab,european medicines agency confirms acceptance of marketing application for avt03 a proposed biosimilar to prolia and xgeva,regulatory_filings,UP,0.0,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,5,261,0.0,0.44264539487962035,0.058653198653198645
waltham mass may 13 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a fireside chat at the h c wainwright 2nd annual bioconnect investor conference at nasdaq taking place on monday may 20 2024 at 12 30 p m et checkpoint will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the h c wainwright 2nd annual bioconnect investor conference,conference_call_webinar,UP,3.3333301544189453,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,8,411,0.0,0.8866002429130597,0.07522727272727271
palo alto calif aug 21 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that the u s patent and trademark office has allowed numerous claims from u s patent application no 17 562 229 and will issue a new patent containing those claims related to the treatment of acute pain the patent to scilex in late 2024 further strengthening the company s intellectual property position and coverage for its acute migraine treatment drug product elyxyb a liquid micro encapsulation formulation of celecoxib the patent titled methods of treating pain covers methods of treating acute pain,scilex holding company announces the u s patent and trademark office will be issuing new elyxyb patent related to the treatment of acute pain,patents,UP,0.0,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,9,311,0.2694805194805195,1.0327724261931344,0.2516139889151253
berwyn pa dec 17 2020 globe newswire annovis bio inc nyse american anvs a clinical stage drug platform company addressing alzheimer s disease ad parkinson s disease pd and other neurodegenerative diseases today announced an interview with its ceo maria maccecchini ph d will air on the redchip money report television program the redchip money report airs in 100 million homes on sundays at 6 p m local time in every country in europe on bloomberg international,annovis bio interview to air on bloomberg international on the redchip money report,clinical_study,UP,0.0,44036864.0,15624645.0,595065.0,1.618,805900.0,0.3548083033342247,0.09346626282280733,3,6,1654,-0.025,1.368989555493872,0.0
media release,euronext oslo børs b2 impact asa received application for listing of bonds,exchange_announcement,DOWN,-0.4115222299809098,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,9,241,0.0,0.2679946872688963,0.0
durham n c may 13 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale today announced that laura niklason m d ph d founder president and chief executive officer dale sander chief financial officer and b j scheessele chief commercial officer will represent humacyte at the following conferences in may,humacyte to participate at upcoming investor conferences in may,conference_call_webinar,UP,0.8510630526872615,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,0,8,411,0.0,1.1173068527438073,0.06590909090909092
media release,oslo børs status companies placed in recovery box and penalty bench,observation_status,DOWN,-0.862068168189925,31593468.0,146986679.0,21417158.75,0.312,14709376.0,4.652438883885745,0.1515999603296736,0,8,243,0.0,20.184452026301216,0.0
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
adagene s ceo dr peter luo participating in sitc webinar on september 22 focused on essential role of treg depletion for anti ctla 4 therapies,adagene to present at investor and scientific conferences in september,conference_call_webinar,DOWN,-4.059045460000049,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,6,660,0.0,0.845882180665701,0.24791666666666667
the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock,windtree announces publication of positive istaroxime phase 2b study trial design,clinical_study,DOWN,-7.103823312288768,1379940.0,3660923.0,6680965.0,0.764,1224200.0,2.65295809962752,0.09346626282280733,2,8,262,0.13168044077134985,2.339794177443606,0.04827501202501203
eight abstracts highlighting new data from vir s chronic hepatitis b and chronic hepatitis delta programs have been accepted for presentation at aasld,vir biotechnology announces multiple abstracts highlighting new chronic hepatitis b and hepatitis delta data accepted for presentation at aasld s the liver meeting 2023,clinical_study,DOWN,-0.9009000301245093,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,2,8,626,0.0909090909090909,0.8653389999075153,0.06285511363636363
27 sep 2024 08 20 cest clean seas seafood limited adelaide 27 september 2024 clean seas seafood limited asx css ose css has received notice of a share trade by director primary insider gary higgins the share trade is as follows opening balance of shares 0 shares acquired on market 80 000 closing balance of share 80 000 for further information please contact rob gratton ceo rob gratton cleanseas com au more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site 628665_240927 app 3y g higgins pdf clean seas seafood limited oslo børs newspoint clean seas seafood limited au000000css3 css euronext growth,notification of share trade by a primary insider,changes_in_companys_own_shares,UP,3.1250064028428435,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,274,0.22930402930402932,0.8866002429130597,0.0
new york und mainz deutschland 27 juni 2024 pfizer inc nyse pfe pfizer und biontech se nasdaq bntx biontech gaben heute bekannt dass der ausschuss für humanarzneimittel committee for medicinal products for human use chmp der europäischen arzneimittel agentur european medicines agency ema eine positive beurteilung für die marktzulassung marketing authorization des an omikron jn 1 angepassten monovalenten covid 19 impfstoffs comirnaty jn 1 der unternehmen für die aktive immunisierung zur vorbeugung von covid 19 verursacht durch sars cov 2 bei personen ab 6 monaten ausgesprochen hat die anpassung basiert auf der empfehlung der technischen beratungsgruppe für die zusammensetzung von covid 19 impfstoffen technical advisory group on covid 19 vaccine composition der weltgesundheitsorganisation world health organization who und der notfall taskforce emergency task force etf der ema die vorschlagen covid 19 impfstoffe zu aktualisieren um die sars cov 2 variante jn 1 für die impfkampagne 2024 2025 abzudecken die notfall taskforce erklärte es gibt hinweise darauf dass eine anpassung an jn 1 ausreichend ist um die wirksamkeit der impfstoffe gegen das sich fortlaufend weiterentwickelnde sars cov 2 aufrechtzuerhalten 1 2,pfizer und biontech erhalten positive chmp empfehlung für an omikron jn 1 angepassten covid 19 impfstoff in der europäischen union,regulatory_filings,DOWN,-2.6051151795463814,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,3,10,365,0.0984848484848485,0.5503225880253886,0.08888888888888889
boston oct 24 2024 globe newswire x4 pharmaceuticals inc nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that it will report financial results for the third quarter ended september 30 2024 and present results from its concluded phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on wednesday november 13 2024,x4 pharmaceuticals to report third quarter 2024 financial and phase 2 chronic neutropenia study results during conference call and webcast on november 13 2024,clinical_study,DOWN,-0.5952422485284217,12503571.0,4364496.0,363495.0,0.663,396700.0,0.34905996055046995,0.09346626282280733,3,8,247,0.049999999999999996,1.4412990038402507,0.1265977961432507
chief executive officer amro albanna to present at 9 00am eastern time on thursday october 12 2023 chief executive officer amro albanna to present at 9 00am eastern time on thursday october 12 2023,aditxt inc to present at 8th annual dawson james conference,conference_call_webinar,DOWN,-2.376912546027333,3413280.0,2120031.0,105450.0,1.329,58200.0,0.6211125369146393,0.09346626282280733,4,8,631,0.0,1.9040013355592613,0.0
arcutis today announced results from the integument ole long term open label study of once daily roflumilast cream 0,arcutis announces positive long term results of roflumilast cream 0 show durable and improved efficacy over time and favorable safety profile in treatment of children aged 2 to 5 with mild to moderate atopic dermatitis,clinical_study,UP,0.0,1721276800.0,85869346.0,2010100.0,1.778,2359700.0,0.049887005971381244,0.09346626282280733,2,8,304,0.04507575757575757,0.6903751128737089,0.0456595432785909
palo alto calif july 02 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that its chief executive officer and president jaisim shah and executive chairman henry ji ph d will ring the closing bell at the nasdaq marketsite in times square new york at 4 00 p m eastern time on friday july 5 2024 the ceremony will be held in celebration of scilex s launch of gloperba an innovative non opioid product and the first oral liquid medicine for the prophylactic treatment of painful gout flares,scilex holding company to ring nasdaq closing bell on friday july 5th at 4 00pm et at the nasdaq marketsite in times square new york,product_services_announcement,UP,4.255321442460307,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,9,361,0.20324675324675323,1.0327724261931344,0.29564333814333815
geneva switzerland april 11 2024 addex therapeutics six and nasdaq adxn a clinical stage pharmaceutical company pioneering allosteric modulation based drug development today announced that it will issue its full year 2023 financial results on april 18 2024 tim dyer ceo and mikhail kalinichev head of translational science will provide a business update and a review of the addex product pipeline during a teleconference and webcast for investors analysts and media at 16 00 cest 15 00 bst 10 00 edt 07 00 pdt the same day,addex therapeutics to release full year 2023 financial results and host conference call on april 18 2024,earnings_releases_and_operating_results,DOWN,-6.314241291507503,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,3,1,443,0.13999999999999999,0.972373032385036,-0.033333333333333326
san diego april 26 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced two poster presentations highlighting data on cd388 at the 34th european society of clinical microbiology and infectious diseases escmid conference being held april 27 30 2024 in barcelona spain,cidara therapeutics announces presentations highlighting phase 1 and phase 2a clinical data on cd388 at escmid 2024,clinical_study,DOWN,-2.6923106266902046,621253440.0,4118697.0,696580.0,0.795,3470400.0,0.0066296566502714255,0.09346626282280733,4,8,428,-0.1111111111111111,1.357695941787151,0.020093795093795094
mydecine is pleased to address its shareholders and provide a general update on the company s progress,mydecine provides q4 2023 business update,corporate_action,UP,0.0,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,3,2,611,0.275,5.6468521991492,0.10682539682539682
imm 1 104 has been well tolerated demonstrating the potential for a differentiated safety profile,immuneering announces positive topline results from phase 1 portion of its phase 1 2a clinical trial of imm 1 104 in ras mutant solid tumors,clinical_study,DOWN,-7.103823312288768,112995104.0,27271404.0,2516685.0,0.002,1980700.0,0.2413503154968555,0.09346626282280733,3,7,471,0.07575757575757576,1.2966226301621697,0.08854166666666667
west lafayette ind june 10 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today provided the following business updates,inotiv inc provides business updates,geographic_expansion,UP,0.0,62838508.0,31206932.0,922240.0,4.102,583600.0,0.4966211482933363,0.09346626282280733,0,7,383,0.0,1.3015467599292592,0.048497732426303855
kraig labs otcqb kblb entered the exponential specialized silkworm growth rearing phase for its third spider silk production cycle of the season,kraig biocraft laboratories enter rapid growth rearing phase for third spider silk production cycle,press_releases,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,334,0.0,0.8071333009212691,0.1213778409090909
new york aug 19 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the appointment of ivor elrifi as its chief executive officer ceo effective immediately,tiziana life sciences appoints new chief executive officer,management_changes,DOWN,-0.8264454667762735,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,0,7,313,0.21818181818181817,1.1109140250580023,0.037909696613400316
investor webcast to review the ntla 2002 phase 2 data is now planned for thursday october 24 at 8 30 a m et,intellia therapeutics announces new date for upcoming investor webcast,conference_call_webinar,DOWN,-1.303113581911116,970054784.0,98412511.0,6353695.0,2.134,5288300.0,0.10145046715217272,0.09346626282280733,3,7,261,0.13636363636363635,0.7800307612939593,0.05093315459792733
los angeles oct 16 2024 globe newswire renovaro inc nasdaq renb a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence today announced a strategic restructuring and leadership transition of senior management and the board of directors to realign resources focused on the company s ai platform renovarocube for multi cancer early detection and patient monitoring the board with the support of a supermajority of shareholders appointed david weinstein as director and new ceo and four new directors maurice van tilburg chairman douglas calder james a mcnulty cpa and mark a collins phd,renovaro announces strategic restructuring and leadership transition,management_changes,DOWN,-4.802256961851933,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,2,9,255,-0.05681818181818182,1.5631250973582267,0.06940345008526827
ash jayagopal ph d m b a appointed chief scientific and development officer,ocuphire pharma strengthens leadership team with key appointments,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,-0.07329931972789117
media release,nytt antal aktier och röster i itab shop concept ab publ,changes_in_share_capital_and_votes,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.012500000000000004
watertown mass april 08 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science presented a poster today at the american association for cancer research aacr annual meeting 2024 highlighting new preclinical data for cft1946 across multiple models of braf v600x mutant colorectal cancer crc and non small cell lung cancer nsclc additional braf inhibitor brafi resistant melanoma models and an intracranial model of braf v600e metastatic melanoma,c4 therapeutics presents new preclinical data for cft1946 highlighting superior activity as a single agent to clinically approved braf inhibitor standard of care combinations at the american association for cancer research annual meeting 2024,clinical_study,UP,0.5319143876925793,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,0,8,446,0.07236652236652236,0.8954742650579008,0.04375
media release,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,8,240,0.0,0.5536010581445269,0.0
12 13 overall response rate orr for relapsed refractory al amyloidosis patients enrolled in nexicart 1,immix biopharma announces positive nxc 201 relapsed refractory al amyloidosis clinical data in asgct 2024 late breaking oral presentation,clinical_study,UP,5.82524889858715,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,4,9,413,-0.024242424242424242,0.9253604538231538,0.03904380341880342
on september 19 2024 the register of enterprises registered the change of the legal address of ipas indexo and indexo bank as the new legal and actual address of the companies is roberta hirša iela 1 riga lv 1045 latvia please note that other company details remain unchanged about indexo indexo is a financial services group that includes pension management companies and indexo bank indexo an investment management company licensed by the bank of latvia offers modern 2nd and 3rd pillar pension plans in latvia and is one of the fastest growing pension managers in the baltics with over 137 thousand customers and more than 1 19 billion euros under management meanwhile indexo bank is a credit institution licensed by the european central bank which will provide a full range of convenient and advantageous banking services to latvian residents and within the next 6 9 months also to latvian companies indexo is founded and based in latvia and is list,notice of address change for ipas indexo and indexo bank,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,281,0.1040909090909091,0.8866002429130597,0.0
baltic horizon fund applied for bondholders approval for certain amendments to the terms and conditions the terms and conditions of the baltic horizon fund eur 42 million 5 year floating rate bonds maturing in 2028 isin ee3300003235 the bonds and temporary waiver of debt service coverage ratio covenant in relation to the bonds by way of written procedure on 26 september 2024 bondholders who were entered in the registry of bond holders maintained by nasdaq csd se on 25 september 2024 were entitled to vote in the written procedure the holders a notice by triniti collateral agent ix oü acting as the agent for holders was sent to the holders on 26 september 2024 altogether holders holding in aggregate bonds with the nominal value of eur 22 000 000 which constitutes of the aggregate nominal value of all bonds participated in the written procedure for amending the terms and conditions therefore the quorum for adopting the decision by way of written procedure was reached t,bondholders of baltic horizon fund approved the amendments to the bond terms and conditions,bond_fixing,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,271,0.10714285714285714,0.8866002429130597,0.09671717171717172
longeveron announces exercise of warrants for 4 4 million gross proceeds,longeveron announces exercise of warrants for 4 4 million gross proceeds,warrants_and_certificates,DOWN,-7.103823312288768,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,8,376,0.0,1.063123411629147,0.1125
arcutis today announced regulatory approval from health canada for zoryve roflumilast topical foam 0 for the treatment of seborrheic dermatitis,arcutis announces health canada approval of zoryve roflumilast foam 0 to treat seborrheic dermatitis in individuals 9 years of age and older,product_services_announcement,DOWN,-0.7376153478660306,1722468864.0,85869346.0,2010100.0,1.778,2359700.0,0.049852480816744676,0.09346626282280733,4,8,253,0.08333333333333333,0.6903751128737089,0.06143047538880873
immuneering granted orphan drug designation for imm 1 104 by fda in the treatment of pancreatic cancer,immuneering granted orphan drug designation for imm 1 104 by fda in the treatment of pancreatic cancer,clinical_study,UP,9.242146234319629,112275376.0,27271404.0,2516685.0,0.002,1980700.0,0.2428974631089189,0.09346626282280733,1,8,256,0.0,1.2966226301621697,0.08230519480519481
lexington mass may 15 2024 globe newswire t2 biosystems inc nasdaq ttoo a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2 025 317 shares of common stock or pre funded warrant in lieu thereof series a warrants to purchase up to 2 025 317 shares of common stock and short term series b warrants to purchase up to 2 025 317 shares of common stock at a purchase price of 3 95 per share of common stock or per pre funded warrant in lieu thereof and accompanying warrants in a private placement priced at the market under nasdaq rules the series a warrants and short term series b warrants will have an exercise price of 3 70 per share and will be exercisable immediately upon issuance the series a warrants will expire five and one half years from the date of issuance and the short term series b warrants will expire eighteen months from the date of issuance the private placement is expected to close on or about may 17 2024 subject to the satisfaction of customary closing conditions,t2 biosystems announces 8 million private placement priced at the market under nasdaq rules,shares_issue,UP,9.242146234319629,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,2,7,409,-0.12564102564102567,1.9596557041969667,0.1125
media release,klea holding annonce la mise à disposition de son rapport financier semestriel 2024,interim_information,UP,1.6574619748698909,54895992.0,186301764.0,303098.4090909091,-1.119,117419.0,3.393722514386843,0.09346626282280733,2,7,241,0.0,0.4428343691040069,0.0
qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024 qiastat dx respiratory panel mini erkennt die fünf relevantesten erreger von atemwegserkrankungen im ambulanten bereich und hilft ärzten dabei präzise behandlungsentscheidungen zu treffen mithilfe des neuen tests und des qiastat dx respiratory panel plus für 21 erreger können ärzte ihren diagnostischen ansatz individuell auf jeden patienten abstimmen und diese somit besser betreuen fda entscheidung ist für qiastat dx das dritte positive ergebnis bei us zulassungsbehörden im jahr 2024,qiagen erhält fda zulassung für qiastat dx mini panel für eine präzisere ambulante behandlung von atemwegserkrankungen,product_services_announcement,DOWN,-0.334926775607,10126157824.0,214509546.0,1439980.0,0.673,1302400.0,0.02118370557997734,0.09346626282280733,1,2,242,0.22727272727272727,0.2568422597431085,0.08276515151515151
media release,bekaert mise à jour relative au contrat de liquidité,clinical_study,UP,0.1158104066794088,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,246,0.0,0.8866002429130597,0.0
european orphan drug designation odd qualifies nxc 201 for,immix biopharma awarded european union orphan drug designation for nxc 201 in al amyloidosis,clinical_study,UP,9.242146234319629,61330060.0,18058632.0,290605.0,0.301,58200.0,0.2944499320561565,0.09346626282280733,2,9,506,-0.05555555555555555,0.9253604538231538,-0.07055555555555555
outcomes is the third study in the phase 3 synchrony clinical trial program,akero therapeutics announces first patient dosed in phase 3 synchrony outcomes study of efruxifermin in patients with compensated cirrhosis due to mash,clinical_study,UP,0.5300999260026725,4382076416.0,65983030.0,1904080.0,-0.16,4370200.0,0.015057480458140874,0.09346626282280733,0,7,292,0.041666666666666664,1.1395320392459187,-0.020229065547247363
upcoming pdufa goal date of january 3 2024,checkpoint therapeutics strengthens intellectual property protection for cosibelimab with new u s patent issuance,patents,DOWN,-0.3460204186943589,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,1,8,571,0.21818181818181817,0.8866002429130597,0.06860698824984539
poster presentation scheduled for june 1 2024 1 30 4 30 pm ct 2 30 5 30 pm et,bioxcel therapeutics announces late breaking abstract on preliminary findings from phase 2 investigator sponsored trial of bxcl701 and keytruda in metastatic pancreatic ductal adenocarcinoma pdac selected for presentation at 2024 asco annual meeting,clinical_study,DOWN,-7.103823312288768,12475463.0,5544250.0,450810.0,-0.13,78500.0,0.4444123636934357,0.09346626282280733,2,10,429,-0.3,1.4586588351104455,0.07094561688311687
all patients treated in the ruby trial are free of vaso occlusive events post renizgamglogene autogedtemcel reni cel infusion,editas medicine reports new safety and efficacy data from the ruby trial of reni cel in 18 patients with sickle cell disease presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1787878787878788,1.3105556047468256,0.06364859777903256
casgevy approved in the u s european union great britain the kingdom of saudi arabia and bahrain,crispr therapeutics provides business update and reports fourth quarter and full year 2023 financial results,product_services_announcement,UP,4.775808899422334,4073775360.0,85970729.0,2651100.0,1.742,2455300.0,0.02110345352965167,0.09346626282280733,2,7,493,0.22999999999999998,0.5620956775766307,-0.007691197691197696
west lafayette ind sept 16 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services has amended certain terms of its credit agreement in addition inotiv has closed the sale of 22 6 million aggregate principal amount of senior secured second lien pik notes due february 2027 the second lien notes and warrants to purchase common shares to certain investors in a private offering,inotiv inc amends its credit agreement and secures additional liquidity,financing_agreements,DOWN,-1.923075159625829,62865992.0,31206932.0,922240.0,4.102,583600.0,0.4964040335194265,0.09346626282280733,0,8,285,-0.010714285714285716,1.3015467599292592,0.03879818594104308
south san francisco calif may 08 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced that management will present at the bofa securities 2024 health care conference on tuesday may 14 2024 at 5 00 p m p t in las vegas nv,akero therapeutics to present at the bofa securities 2024 health care conference,conference_call_webinar,DOWN,-2.0436001525185925,4377293312.0,65983030.0,1904080.0,-0.16,4370200.0,0.015073933889491206,0.09346626282280733,2,7,416,-0.012222222222222218,1.1395320392459187,-0.06122592592592593
san carlos calif may 01 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer will report its first quarter 2024 financial results on thursday may 9 2024 management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4 30 p m et,iovance biotherapeutics to host first quarter 2024 financial results conference call and webcast on thursday may 9 2024,conference_call_webinar,DOWN,-0.2546666693652358,601114624.0,280347936.0,11775260.0,0.863,9708200.0,0.4663801624629914,0.09346626282280733,2,6,423,0.10606060606060606,0.901765204231867,0.004242424242424242
results presented at the department of defense s military health system research symposium mhsrs,humacyte presents positive long term results of atev in treatment of vascular trauma in military setting from ukraine humanitarian program,clinical_study,DOWN,-1.2765978745102613,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,305,-0.005681818181818191,1.1173068527438073,0.08202730429292929
turku finland and boston sept 06 2023 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company focused on tackling cancers via novel immunotherapies today announces that dr markku jalkanen phd ceo will present at the h c wainwright annual global investment conference in new york city on september 12 2023 in addition to the presentation company management will be available for one on one meetings with investors,faron pharmaceuticals ltd to present at the h c wainwright 25th annual global investment conference,conference_call_webinar,UP,0.0,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,2,2,661,0.11233766233766233,0.7633342480324978,-0.08333333333333333
27 september 2024 the annual general meeting of swedbank ab will be held in stockholm thursday 27 march 2025 the members of the nomination committee are lennart haglund appointed by sparbankernas ägareförening and chair of the nomination committee ylva wessén appointed by folksam anders oscarsson appointed by amf annette björkman appointed by the owner group sparbanksstiftelserna magnus tell appointed by alecta tjänstepension göran persson chair of the board of directors of swedbank ab publ the nomination committee is assigned to prepare and present proposals to the 2025 agm regarding the election of chair of the agm members and chair of the board of directors and external auditor the nomination committee will also make proposals regarding the number of board members remuneration to the board members as well as external auditor s fee furthermore proposals for principles on how the nomination committee for agm 2026 shall be appointed and instruction for the n,nomination committee for the agm 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.012500000000000004,0.8866002429130597,0.012500000000000004
watertown mass sept 19 2023 globe newswire eloxx pharmaceuticals inc nasdaq elox a leader in ribosomal rna targeted genetic therapies for rare diseases today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380 590 of its shares of common stock or common stock equivalents in lieu thereof at a purchase price of 5 255 per share or common stock equivalent in lieu thereof in a registered direct offering priced at the market under nasdaq rules in a concurrent private placement eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380 590 of its shares of common stock the warrants will have an exercise price 5 13 per share will become exercisable immediately upon issuance and have a term of five and one half years from the date of issuance the offering is expected to close on or about september 20 2023 subject to the satisfaction of customary closing conditions,eloxx pharmaceuticals announces 2 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-0.1831543738455693,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,648,-0.10303030303030303,2.2721670857062097,0.15067828662565508
media release,carl johan hugner new ceo of nyfosa,management_changes,DOWN,-0.0868042333074207,112574064.0,35018869.0,105765.0,0.8755,89500.0,0.25000035609542787,0.1515999603296736,0,7,243,0.13636363636363635,0.04641706443664286,0.0
needham mass oct 28 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced three presentations at the 16th annual international oncolytic virotherapy conference iovc taking place october 27 30 2024 in rotterdam the netherlands,candel therapeutics showcases innovative cancer therapy candidates at 16th annual international oncolytic virotherapy conference iovc,clinical_study,UP,4.285718786473254,244250656.0,41997569.0,917740.0,-0.866,856900.0,0.17194454945496646,0.09346626282280733,0,8,243,0.16666666666666666,1.2870358800144117,0.06779745399843438
new york and mainz germany august 16 2024 pfizer inc nyse pfe pfizer and biontech se nasdaq bntx biontech today announced top line results from their phase 3 clinical trial to evaluate the companies combined mrna vaccine candidate against influenza and covid 19 in healthy individuals 18 64 years of age the combination candidate consists of pfizer s mrna based influenza vaccine candidate with the companies licensed covid 19 vaccine the phase 3 trial measured two primary immunogenicity objectives immunogenicity against sars cov 2 as well as immunogenicity against influenza a and b of which one was met in a separate phase 2 trial pfizer evaluated trivalent tirv influenza mrna standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18 64 years of age the companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza b and will discuss next steps with health authorities,pfizer and biontech provide update on mrna based combination vaccine program against influenza and covid 19 in individuals 18 64 years of age,clinical_study,DOWN,-3.43839541547278,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,4,6,316,0.30727272727272725,0.5503225880253886,0.08867815055315056
16 oct 2024 07 00 cest nel asa october 16 2024 oslo norway nel asa nel ose nel reported revenues of nok 366 million in the third quarter of 2024 up from nok 303 million in the same quarter last year ebitda in the quarter was nok 90 million q3 2023 62 the alkaline segment contributed positively to group ebitda but this was more than offset by the negative contribution from the pem segment due to unusually low revenues in the quarter order intake was nok 161 million q3 2023 338 million at the end of the quarter the order backlog was nok 1 872 million down year over year the cash balance was nok 1 941 million at quarter end quarterly highlights revenue from continuing operations in the third quarter 2024 was nok 366 million up from the third quarter 2023 q3 2023 303 revenue was positively impacted by delivery of alkaline electrolyser equipment whereas revenue from sale of pem electrolyser equipment was low ebitda in th,nel asa third quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-0.4576654794112185,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,255,0.02493265993265993,0.8866002429130597,0.14211309523809523
04 oct 2024 07 00 cest alstom alstom note q2 and h1 2024 25 preview 4 october 2024 alstom presents below a preview to its q2 and h1 2024 25 results q2 2024 25 orders the table below summarizes the large orders more than 200m published and booked during the quarter orders value in million descriptionlink to press releaseproxima 850france 12 very high speed trains with 15y maintenancelink to the pr s bahn köln 3 600germany frame agreement of 90 trains and 34 years maintenance for 4bn o w 3 6bn to be booked in q2 and the rest at a later stage options link to the pr perth signalling 650western australia high capacity signalling project link to the pr total large orders 5 100 deals announced previously but to be booked at a later stage haifa nazareth systems contract for 700m expected booking in fy 2025 26 link to the press releasecp portugal for 700m awarded to alstom expecting end of competitors challenge expected booking in fy 2024 25,alstom sa alstom preview note q2 and h1 2024 25 preview,business_contracts,UP,0.4025806028880515,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,5,267,0.08453679653679652,0.8866002429130597,0.0
ad hoc mitteilung gemäss art 53 kr,santhera sichert sich bis zu chf 69 millionen durch royalty finanzierung und darlehen zur geschäftsfinanzierung bis zum cash flow break even,financing_agreements,UP,1.5544101361056366,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,375,0.0,0.5209522992128177,0.05000000000000001
commencing study startup activities in the u s participant enrollment anticipated in early 2025 commencing study startup activities in the u s participant enrollment anticipated in early 2025,fda lifts partial clinical holds on rz358 for the treatment of congenital hyperinsulinism and authorizes u s inclusion in ongoing phase 3 study,clinical_study,UP,9.242146234319629,376775840.0,77797779.0,825115.0,1.04,796000.0,0.20648292894788584,0.09346626282280733,0,7,292,0.03333333333333333,0.6820409900648857,0.00424573112073112
brisbane calif aug 29 2024 globe newswire annexon inc nasdaq annx a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body brain and eye today announced that douglas love esq president chief executive officer will participate in fireside chats during the following september investor conferences,annexon biosciences to participate in upcoming september investor conferences,conference_call_webinar,UP,0.1683459923964542,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,3,8,303,0.25,0.7558344054121836,0.14308102281316568
florham park n j jan 04 2024 globe newswire celularity inc nasdaq celu the company a biotechnology company developing allogeneic cell therapies and advanced biomaterial products today confirmed that it has entered into an exclusive u s strategic commercialization agreement with biocellgraft inc biocellgraft under which celularity will manufacture advanced biomaterial products for biocellgraft which biocellgraft will distribute in the united states for use in multiple dental oral healthcare applications a copy of biocellgraft s announcement of the agreement can be accessed here https www prweb com releases biocellgraft finalizes commercialization agreement with celularity for the manufacture and distribution of products for therapeutic use in oral healthcare 302025082 html,celularity confirms commercialization agreement with biocellgraft for the manufacture and distribution of advanced biomaterial products for use in oral healthcare,partnerships,DOWN,-7.103823312288768,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,13,540,0.32,1.6050367793919866,0.025778388278388274
palo alto calif july 17 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that that it has entered into a memorandum of understanding mou for collaboration agreement with acea a china based company focused on the development of innovative treatments for high unmet needs under the terms of the mou acea may receive exclusive rights to develop and commercialize of ztlido in mainland china taiwan hong kong macau including the current formulation and a right of first negotiation for a future next generation formulation of a 3x version of ztlido sp 103 the mou provides scilex with the opportunity to expand collaboration with acea across other products in scilex s non opioid pain management portfolio in the greater china region,scilex holding company announces collaboration to leverage acea therapeutics r d expertise and local market connections to support the expansion of ztlido program in ex us and potentially provide additional access to patients in certain key markets in far east region,partnerships,DOWN,-3.061227592911475,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,9,346,0.1865625,1.0327724261931344,0.27254419191919194
media release,bghl eur nav s,fund_data_announcement,UP,0.7246335247339231,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,-0.0035714285714285687
mainz biomed to present new pooled colorectal cancer screening data its largest study to date at asco 2024 annual meeting,mainz biomed to present new pooled colorectal cancer screening data its largest study to date at asco 2024 annual meeting,clinical_study,UP,8.04194791304558,5550607.0,2706585.0,75055.0,0.305,78500.0,0.4876196423202003,0.09346626282280733,1,8,396,0.06818181818181818,34.079934680222834,0.04666666666666666
10 000 subject phase 2b study would evaluate vaxart s next generation oral pill xbb covid 19 vaccine against an approved mrna vaccine comparator,vaxart receives 9 27 million barda project nextgen award to prepare for phase 2b clinical study evaluating its covid 19 oral pill vaccine candidate,clinical_study,UP,2.531643086491392,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,526,-0.08333333333333333,1.025768835125998,-0.1
jerusalem jan 30 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins announced that it will participate and be available for investor meetings at the oppenheimer 34th annual healthcare life sciences conference being held february 13 14 2024 in a virtual format,entera bio to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,DOWN,-0.7891802587540372,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,1,8,515,0.2,0.6915109749530333,0.050482503607503594
27 sep 2024 12 00 cest swedbank ab the annual general meeting of swedbank ab will be held in stockholm thursday 27 march 2025 the members of the nomination committee are lennart haglund appointed by sparbankernas ägareförening and chair of the nomination committee ylva wessén appointed by folksam anders oscarsson appointed by amf annette björkman appointed by the owner group sparbanksstiftelserna magnus tell appointed by alecta tjänstepension göran persson chair of the board of directors of swedbank ab publ the nomination committee is assigned to prepare and present proposals to the 2025 agm regarding the election of chair of the agm members and chair of the board of directors and external auditor the nomination committee will also make proposals regarding the number of board members remuneration to the board members as well as external auditor s fee furthermore proposals for principles on how the nomination committee for agm 2026 shall be appoin,nomination committee for the agm 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,10,273,0.012500000000000004,0.8866002429130597,0.0
petach tikva israel june 10 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will host a virtual key opinion leader kol event on monday june 17 2024 at 10 00 am et to discuss the significant unmet medical need in surgical site infections and provide an update on the company s ongoing d plex100 phase 3 trial to register click here,polypid to host virtual kol event on june 17 2024 and provide an update on the company s ongoing d plex₁₀₀ phase 3 trial,clinical_study,UP,2.9816429730008465,37196784.0,4610773.0,1395250.0,1.25,337200.0,0.123956226968439,0.09346626282280733,0,7,383,0.018750000000000003,0.7168605096826995,-0.04446278258778258
dallas june 27 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has surpassed of the enrollment target for pediatric patients at burn centers for its 2024 pivotal study designed to validate the ai driven algorithm used by its deepview system for its burn indication,spectral ai surpasses of pediatric enrollment target in burn centers for pivotal u s burn study,clinical_study,UP,1.7857197342682936,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,3,8,366,0.21666666666666667,0.9904696515070965,0.036363636363636376
burlington mass aug 12 2024 globe newswire scpharmaceuticals inc nasdaq scph the company a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies advance patient care and reduce healthcare costs today announced a proposed underwritten public offering of shares shares of its common stock or in lieu of shares pre funded warrants the pre funded warrants to purchase shares the offering scpharmaceuticals also expects to grant the underwriters a 30 day option to purchase up to an additional of shares offered in the offering all shares and pre funded warrants to be sold in the offering will be offered by scpharmaceuticals the offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering,scpharmaceuticals announces proposed underwritten public offering of common stock and pre funded warrants,shares_issue,DOWN,-4.157039988688057,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,6,320,-0.11145833333333333,0.7082528246818063,0.19772727272727272
company aligned with fda on demonstration of non clinical comparability allowing for immediate use of san diego manufacturing facility,capricor therapeutics announces positive type b meeting with fda for cap 1002 program for duchenne muscular dystrophy,regulatory_filings,UP,9.128631567429965,433538464.0,40176259.0,3124730.0,0.85,8768900.0,0.09267057559165039,0.09346626282280733,2,9,430,0.22727272727272727,1.3427880947904531,0.10681818181818181
vancouver british columbia sept 20 2023 globe newswire mydecine innovations group inc mydecine or the company neo myco otc mycof fse 0nfa a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and ptsd is pleased to announce that further to the company s news release dated september 15 2023 and september 19 2023 the company has closed its previously announced offering by way of prospectus supplement the offering pursuant to the offering the company issued 18 750 000 common shares of the company each a share at a price of 0 20 per share for aggregate gross proceeds of 3 750 000 a previous news release incorrectly stated that the company issued 18 7500 000 shares for aggregate gross proceeds of 3 7500 000,mydecine innovations announces amended press release relating to the closing of prospectus supplement financing,shares_issue,DOWN,-5.882356034843122,308777.0,60279444.0,98158.47619047618,2.331,40590.0,195.2199937171486,0.09346626282280733,2,12,646,0.030952380952380946,5.6468521991492,0.0
seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience seasoned executive brings more than 25 years of global financial and operational biopharmaceutical leadership experience,pacira biosciences appoints shawn cross as chief financial officer,clinical_study,DOWN,-1.0863381163181691,1110849792.0,45834212.0,557500.0,0.511,435200.0,0.04126049474022857,0.09346626282280733,0,8,250,0.15,0.7130794063724827,0.1382682491980013
san diego jan 31 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will present at guggenheim s 6th annual biotechnology conference,anaptys to present at guggenheim s 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.6268266469592575,687797504.0,17605381.0,784220.0,-0.266,445700.0,0.025596750348195505,0.09346626282280733,2,9,514,0.16666666666666666,0.871343469962729,0.23443865057501423
rockville md april 25 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that based on the strength of the science and its relevance virage the phase 2b randomized open label placebo controlled multicenter clinical trial of systemically administered vcn 01 in combination with standard of care soc chemotherapy gemcitabine nab paclitaxel as a first line therapy for patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma pdac has been accepted for presentation as a trial in progress poster at the 2024 american society of clinical oncology asco annual meeting being held in chicago il from may 31 june 4,theriva biologics to discuss the trial design for virage a phase 2b clinical study of systemically administered vcn 01 in combination with chemotherapy in pancreatic ductal adenocarcinoma at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-2.702702702702702,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,3,8,429,0.06070707070707071,1.5225134880447404,0.0
conference call and webcast scheduled for thursday march 21st at 8 30 am eastern time conference call and webcast scheduled for thursday march 21st at 8 30 am eastern time,mediwound to report fourth quarter and full year 2023 financial results,earnings_releases_and_operating_results,UP,0.6574647022940413,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,3,8,471,0.06999999999999999,0.6433034533898109,0.16345454545454546
guggenheim s inaugural healthcare innovation conference nov 11 13,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,3,240,0.0,0.5536010581445269,0.0
appointment brings more than 30 years of medical technology general management and commercial leadership experience to the inspiremd team,inspiremd announces appointment of medical technology executive pete ligotti as executive vice president and general manager of north america,management_changes,DOWN,-2.9520266634666377,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,2,7,542,0.10000000000000002,0.6085732039686736,0.10267045454545454
mainz biomed establishes strategic partnership with tomalab to expand availability of coloalert in italy,mainz biomed establishes strategic partnership with tomalab to expand availability of coloalert in italy,partnerships,UP,0.0,5607829.0,2706585.0,75055.0,0.305,78500.0,0.4826439964556694,0.09346626282280733,2,8,493,0.0,34.079934680222834,0.0
planegg martinsried august 8 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will report financial results and provide a corporate update for the six months ended june 30 2024 on wednesday august 14 2024,medigene ag to report half year 2024 financial results on august 14 2024,earnings_releases_and_operating_results,UP,1.8957441829536128,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,10,323,-0.03333333333333333,1.3169799228985475,0.04323376623376623
media release,immutep to participate in the 2024 maxim healthcare virtual summit,conference_call_webinar,UP,1.9999980926513672,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,3,8,261,0.0,0.7476881311953882,0.09155252614879945
oxurion receives transparency notification from atlas special opportunities llc,oxurion receives transparency notification from atlas special opportunities llc,major_shareholder_announcements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,0,13,410,0.35714285714285715,2.0692591020840054,0.1361904761904762
under 2021 emitterade scandic hotels group ab publ scandic konvertibler med ett nominellt belopp om totalt 1 800 miljoner sek de återstående konvertiblerna med ett nominellt belopp om totalt 19 miljoner sek har per idag konverterats till aktier genom konverteringen ökar antalet aktier och röster med 438 168 till totalt 219 157 922 genom konverteringen ökar aktiekapitalet med 109 542 sek till totalt 54 789 480 50 sek efter konverteringen finns inga ytterligare utestående konvertibler för ytterligare information vänligen kontakta rasmus blomqvist director investor relations scandic hotels group e post rasmus blomqvist scandichotels com telefon 46 702 335 367 om scandic hotels group scandic är det största hotellföretaget i norden med ett nätverk av omkring 280 hotell och 58 000 hotellrum i drift och under utveckling på över 130 destinationer scandic är ledande när det kommer till att integrera hållbarhet inom alla områden och dess prisbelönta koncept inom tillgän,konvertibler med ett nominellt belopp om 19 miljoner sek har konverterats till aktier och därmed har samtliga utestående konvertibler konverterats,share_capital_increase,UP,0.0,21688450.0,45859984.0,7124020.0,1.612,2186300.0,2.114488771673402,0.1515999603296736,4,7,274,0.0,0.961003290910132,0.0
waltham mass oct 02 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced the entry into a definitive agreement for the immediate exercise of certain outstanding i series a warrants to purchase up to an aggregate of 1 734 105 shares of common stock and series b series warrants to purchase up to an aggregate of 1 734 105 shares of common stock each having an exercise price of 4 075 per share issued by checkpoint on december 16 2022 and ii series a warrants to purchase up to an aggregate of 1 428 572 shares of common stock and series b series warrants to purchase up to an aggregate of 1 428 572 shares of common stock issued by checkpoint on february 22 2023 each having an exercise price of 5 00 per share at a reduced exercise price of 1 76 per share the shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on form s 3 file no 333 251005 and form s 3 file no 333 270474 respectively the gross proceeds to checkpoint from the exercise of the warrants are expected to be approximately 11 13 million prior to deducting placement agent fees and estimated offering expenses the closing of the offering is expected to occur on or about october 4 2023 subject to satisfaction of customary closing conditions,checkpoint therapeutics announces exercise of warrants for 11 13 million in gross proceeds,warrants_and_certificates,DOWN,-7.103823312288768,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,12,634,-0.059523809523809514,0.8866002429130597,0.04545454545454545
waltham mass jan 11 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a fireside chat at the b riley securities 4th annual oncology conference taking place on thursday january 18 2024 at 4 00 p m est,checkpoint therapeutics to participate in the b riley securities 4th annual oncology conference,conference_call_webinar,UP,1.5706853991273757,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,534,0.0,0.8866002429130597,0.08730384199134199
media release,supplement of the agenda of the annual general meeting of shareholders of ab akola group,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,254,0.05000000000000002,0.8866002429130597,0.13379574970484062
se venligst vedlagte,ledende medarbejderes transaktioner,company_regulatory_filings,UP,2.0454545454545454,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,12,276,0.0,0.8866002429130597,0.0
media release,euronext oslo børs diana shipping inc mottatt søknad om notering av obligasjonslån,initial_public_offerings,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,12,239,0.0,0.8866002429130597,0.1573829386987282
west lafayette ind nov 01 2023 globe newswire inotiv inc nasdaq notv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that robert leasure jr president and chief executive officer and beth taylor chief financial officer will participate in multiple upcoming investor conferences throughout november 2023,inotiv inc to participate in upcoming investor conferences,conference_call_webinar,UP,0.0,62350696.0,31206932.0,922240.0,4.102,583600.0,0.5005065540888268,0.09346626282280733,2,8,605,0.0,1.3015467599292592,0.0
kraig labs otcqb kblb achieved full capacity at its current production location and will open additional production facilities,kraig biocraft laboratories expands facilities to support spider silk production growth,capital_investment,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,8,362,0.11666666666666665,0.8071333009212691,0.1303503787878788
warrington pa april 17 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions today reported financial results for the fourth quarter and fiscal year ended december 31 2023 and provided key business updates,windtree therapeutics reports fourth quarter and year end 2023 financial results and provides key business updates,financial_results,UP,0.0,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,2,8,437,0.030000000000000006,2.339794177443606,-0.00035233285233285107
mainz germany july 22 2024 globe newswire biontech se nasdaq bntx biontech or the company will announce its financial results for the second quarter 2024 on monday august 5 2024 additionally the company will host a conference call and webcast that day at 8 00 a m edt 2 00 p m cest for investors financial analysts and the general public to discuss its financial results and provide a corporate update,biontech to report second quarter 2024 financial results and corporate update on august 5 2024,conference_call_webinar,UP,1.4743764916086926,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,341,0.005000000000000002,0.5503225880253886,0.0824915824915825
media release,coinshares appoints lisa avellini as group general counsel,management_changes,DOWN,-4.752851848902593,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,9,240,0.05000000000000002,0.8866002429130597,0.0
south san francisco calif may 29 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced that management will present at the jefferies global healthcare conference on wednesday june 5 2024 at 4 00 p m e t in new york ny,akero therapeutics to present at the jefferies global healthcare conference,conference_call_webinar,DOWN,-2.4102528889973955,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,2,7,395,0.007003367003367005,1.1395320392459187,-0.024357473544973543
transcode therapeutics and debiopharm announce collaboration to develop targeted nucleic acid therapeutics for cancer,transcode therapeutics and debiopharm announce collaboration to develop targeted nucleic acid therapeutics for cancer,partnerships,UP,9.242146234319629,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,0,8,516,0.0,2.0874185587937095,0.0
seismic extension study results are anticipated in mid 2024 and expected to provide dose optimization for phase 3,windtree therapeutics announces the start of patient dosing in phase 2 seismic extension study of istaroxime in early cardiogenic shock,clinical_study,UP,2.7397233430072485,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,0,8,558,0.0,2.339794177443606,-0.04711399711399711
san diego sept 09 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced a poster presentation at the upcoming 2024 european society for medical oncology esmo annual meeting to be held in barcelona spain from september 13 17 2024,bioatla announces upcoming poster presentation at the 2024 european society for medical oncology esmo annual meeting,clinical_study,UP,0.5747120924395414,23752800.0,45152550.0,596440.0,0.911,569400.0,1.9009358896635344,0.09346626282280733,0,8,292,-0.019047619047619046,1.087702859114621,0.0050778346232891675
media release,shell announces commencement of a share buyback programme,changes_in_companys_own_shares,UP,0.9792533652911048,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,3,8,240,0.0,0.21899594371062572,0.0
woburn mass may 15 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today announced that company has received a final delisting notice from nasdaq the delisting is a result of failure to regain compliance with the minimum stockholders equity requirement for continued listing on the nasdaq capital market set forth in nasdaq listing rule 5550 b 1 requiring companies listed on the nasdaq capital market to maintain stockholder s equity of at least 2 500 000 suspension of trading in the company s common stock on the nasdaq exchange will be effective at the open of trading on may 16 2024,yield10 bioscience announces delisting from nasdaq,delisting_notice,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,409,-0.05277777777777779,0.8866002429130597,0.041941964285714284
sunnyvale calif aug 30 2024 globe newswire biocardia inc nasdaq bcda a global leader in cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced the pricing of its upsized public offering with participation from management and directors institutional investors and certain existing investors of the company for the purchase and sale of 2 400 000 shares of common stock or pre funded warrants in lieu thereof and warrants to purchase up to 2 400 000 shares of common stock at a combined offering price of 3 00 per share and accompanying warrant priced at the market under nasdaq rules the company expects to receive aggregate gross proceeds of 7 2 million before deducting placement agent fees and other offering expenses the warrants will have an exercise price of 3 00 per share will be exercisable immediately and will expire five years from the issuance date,biocardia announces pricing of upsized 7 2 million public offering priced at the market under nasdaq rules,shares_issue,DOWN,-4.726369605023444,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,4,8,302,-0.06383928571428571,1.32107885633281,0.05875850340136054
moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,clinical_study,DOWN,-7.103823312288768,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,2,10,625,0.11363636363636363,0.5366763308656862,-0.03166666666666666
media release,arcadis reports transactions under its current share buyback program,changes_in_companys_own_shares,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,243,0.0,0.8866002429130597,-0.014285714285714287
g1 therapeutics and deimos biosciences announce global excluding asia pacific license agreement for lerociclib for radioprotective uses,g1 therapeutics and deimos biosciences announce global excluding asia pacific license agreement for lerociclib for radioprotective uses,licensing_agreements,UP,1.5452470547938502,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,402,0.0,0.8866002429130597,0.041666666666666664
copenhagen denmark october 28 2024 evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines will provide a business update and report its third quarter 2024 financial results on thursday october 31 2024 before opening of the nasdaq cm,evaxion to announce business update and third quarter 2024 financial results on october 31,conference_call_webinar,UP,1.4130447270664437,15601928.0,155104950.0,157745.0,0.102,38700.0,9.94139634537475,0.09346626282280733,0,8,243,0.0,1.4249795072460607,0.12877441077441076
rockville md may 16 2024 globe newswire opgen inc nasdaq opgn opgen or the company today announced that the company s board of directors has approved a 1 for 10 reverse stock split of its shares of common stock the reverse stock split the reverse stock split will become effective at 12 01 a m est on may 20 2024 and the company s common stock will open for trading on the nasdaq capital market on a post split basis under the company s existing trading symbol opgn the new cusip number for the company s common stock following the reverse stock split will be 68373l505,opgen announced 1 for 10 reverse stock split,corporate_action,DOWN,-4.328019658291313,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,408,-0.023376623376623377,1.807174583649316,0.0884378121878122
rockaway n j july 31 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced that it will report financial results for the second quarter ended june 30 2024 after the close of the market on wednesday august 7 2024 management will host a conference call and webcast at 4 30 pm edt to discuss the financial results and answer questions,electrocore to announce second quarter june 30 2024 financial results on wednesday august 7 2024,earnings_releases_and_operating_results,DOWN,-0.3430797106445155,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,2,8,332,0.0,0.8324549917316175,0.10407327240660574
los angeles ca jan 24 2024 globe newswire immix biopharma inc immix biopharma company we or us nasdaq immx a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced a statement on january 2024 fda labeling change notifications for approved car t products,immix biopharma statement on january 2024 fda labeling change notification for approved car t products,clinical_study,DOWN,-1.9148867958104072,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,2,8,521,0.0,0.9253604538231538,-0.15000000000000002
san mateo calif and cambridge mass dec 04 2023 globe newswire kronos bio inc nasdaq kron a company dedicated to transforming the lives of those affected by cancer today announced that jorge dimartino m d ph d chief medical officer and executive vice president of clinical development and charles lin ph d senior vice president of trn mapping will participate in a fireside chat at the h c wainwright 4th annual precision oncology virtual conference on wednesday december 6 2023 at 11 00 a m et,kronos bio announces participation in h c wainwright 4th annual precision oncology virtual conference,conference_call_webinar,DOWN,-1.666674945089223,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,0,8,572,0.0,0.6178272804340184,0.0
bnc210 demonstrated a statistically significant improvement in post traumatic stress disorder ptsd symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications,bionomics reports results of the full dataset analysis from attune phase 2b trial of bnc210 in patients with post traumatic stress disorder,clinical_study,UP,2.785787092210618,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,464,0.30625,0.8866002429130597,0.0468781169951911
se vedlagte,bestyrelsesmedlemmers direktørers eller nærtstående personers handel med orphazyme aktier,company_regulatory_filings,DOWN,-1.263155917889676,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,13,259,0.0,0.8866002429130597,0.0
25 sep 2024 08 00 cest riber 2024 first half earnings solid half year revenues growth gross margin up by and operating income at breakevennet profit of 0 2m despite the lower seasonal revenues strong increase in order book at june 30 2024 reaching 36 0m outlook confirmed revenues exceeding 40m with growth in earnings expected for the full year bezons september 25 2024 8 00am riber a global market leader for semiconductor industry equipment is releasing its earnings for the first half of 2024 m h1 2024h1 2023changerevenuessystems revenuesservices and accessories revenues13 79 44 312 28 53 6 13 10 19 gross margin of revenues4 834 8 3 932 3 21 2 5 ptsoperating income of revenues 0 0 0 2 1 1 9 3 97 9 1 ptsnet income of revenues0 21 2 1 2 10 2 113 11 4 pts key developments in the first half of 2024 despite an uncertain macroeconomic environment riber achieved solid business growth this performance reflects it,riber 2024 first half earnings,earnings_releases_and_operating_results,DOWN,-0.7782093947869452,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,6,276,0.06578947368421052,0.4818751066598002,0.0
media release,euronext oslo børs b2 impact asa mottatt søknad om notering av obligasjonslån,exchange_announcement,DOWN,-0.4115222299809098,5129965568.0,200341448.0,440241.3,0.79,356053.0,0.03905317596080988,0.1515999603296736,1,9,241,0.0,0.2679946872688963,0.0
reykjavik iceland oct 30 2024 globe newswire alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide will release financial results for first nine months of the year ended september 30 2024 after u s markets close on wednesday november 13 2024 and will conduct a conference call with analysts to present the financial results and recent business highlights on thursday november 14 2024 at 8 00 am et 13 00 gmt,alvotech to report financial results for the first nine months of 2024 on november 13 2024 and host conference call on november 14 2024 at 8 00 am et,financial_results,DOWN,-0.9259250401687472,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,2,8,241,0.0625,0.44264539487962035,0.03921890866335311
vilniaus baldai ab hereinafter the company has secured the financing of 30 million eur of which 24 million eur is a long term loan for a 5 year period and 6 million eur is a credit line for 2 year period from šiaulių bankas ab hereinafter the bank to refinance its existing long term financial liabilities together with the financing provided by the bank and the company s own funds it is planned to fully cover the existing liabilities to the european bank for reconstruction and development as citadele banka lithuanian branch kūb pagalbos verslui fondas and invalda privatus kapitalas ab the restructuring of funding sources opens a new business cycle having overcome the major challenges of the pandemic and post pandemic periods we are ready to maintain sustainable financial performance the financial ratios of recent periods already reflect the results of increased efficiency and the implemented changes in addition we are also striving for greater efficiency in managin,vilniaus baldai ab refinances long term financial liabilities,financing_agreements,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.0963474025974026,0.8866002429130597,0.0
media release,change in hkfoods plc s executive team,management_changes,UP,0.2409679392354332,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,239,0.0,0.8866002429130597,0.022679924242424244
oxurion announces extraordinary general shareholders meeting,oxurion announces extraordinary general shareholders meeting,corporate_action,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,1,13,388,0.19166666666666665,2.0692591020840054,0.13952380952380952
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
conference call begins today at 10 00 a m eastern time,imunon reports 2023 financial results and provides business update,financial_results,UP,8.571429057997108,17793786.0,12808492.0,12655315.0,2.143,945100.0,0.7198294955328787,0.09346626282280733,3,8,457,0.0,2.964855117372811,0.03535353535353535
cambridge mass and menlo park calif feb 15 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies and recode therapeutics a clinical stage genetic medicines company using tissue specific delivery to power the next wave of mrna and gene correction therapeutics today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis cf cf is a genetic disease caused by mutations in the cftr gene leading to the accumulation of thick mucus in the lungs digestive systems and other organs cf can result in life threatening infections respiratory failure and other serious complications,intellia therapeutics and recode therapeutics announce strategic collaboration to develop novel gene editing therapies for cystic fibrosis,partnerships,DOWN,-1.16690210641292,976673728.0,98412511.0,6353695.0,2.134,5288300.0,0.10076293462047543,0.09346626282280733,3,7,499,-0.17142857142857143,0.7800307612939593,0.11666666666666665
media release,archer limited notice of special general meeting,voting_rights,UP,3.0491852271965074,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,240,0.11190476190476191,0.8866002429130597,0.2261904761904762
irvine calif jan 23 2024 globe newswire biomerica inc nasdaq bmra a global biomedical company leading the way in innovative gastroenterology solutions today announced the appointment of jack kenny former ceo and board member of meridian bioscience inc to serve as the chairman of the board of directors of biomerica mr zack irani will continue to serve as ceo mr kenny joined the biomerica board of directors in august 2023 as an independent director,diagnostics industry leader jack kenny appointed as chairman of the board at biomerica,management_changes,UP,0.0,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,1,8,522,0.125,1.5245042583012947,0.05365072427572428
media release,gensight biologics annonce la publication de méta analyses démontrant une meilleure efficacité du traitement par lumevoq chez les patients nd4 nohl,clinical_study,UP,4.950490277705512,26181592.0,88078594.0,341553.13636363635,1.962,36807.0,3.364142027726962,0.09346626282280733,0,7,243,0.0,0.808158900198927,0.0
academic group to receive a total of 22 million for the trial academic group to receive a total of 22 million for the trial,medicinova to support nih funded expanded access clinical trial to evaluate mn166 ibudilast in amyotrophic lateral sclerosis als,clinical_study,UP,7.329842311072465,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,0,9,271,0.0,0.8018560055721619,0.05569097569097569
group to advise on the application of ovid s novel pipeline programs to broader disorders of the brain group to advise on the application of ovid s novel pipeline programs to broader disorders of the brain,ovid therapeutics expands scientific advisory board with appointments of leading neurologists neuroscientists and epileptologists,advisory,UP,0.9708728874782327,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,340,0.0,0.7642184815786688,0.16332797361368787
rokiskio suris ab in accordance with article 19 2 of the law on securities of the republic of lithuania provides information on the total number of voting rights and the size of the share capital the number of shares and their nominal value of all the issued shares of the company as of the date of 27 september 2024 ceo dalius trumpa tel 370 458 55200,information on the shares issued by rokiskio suris ab and the votes granted,voting_rights,UP,1.1976108173510196,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,273,0.0,0.8866002429130597,0.19166666666666665
as the financial results of as lhv group are ahead of the financial plan disclosed in february due to faster than forecast loan portfolio growth and higher interest levels the company will publish an updated financial plan for 2024 the updated financial plan builds on actual economic performance and takes into account the gradually falling interest rates and the slowly improving macroeconomic situation the quality of the credit portfolio remains at the projected level but the formation of provisions that continue to be forward looking has been taken into consideration primarily due to specific counterparties and changes in the model a success fee for lhv varahaldus has not been presumed in this year s plan compared to the financial plan released in february the new financial plan forecasts higher revenue higher expenses and higher net profit by the end of 2024 the higher growth in interest income is thanks to an larger loan portfolio and higher interest rate,lhv group updated its financial plan for the current year,financial_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,5,270,0.07145454545454545,0.8866002429130597,0.09002737458619813
new york und mainz deutschland 20 september 2024 pfizer inc nyse pfe pfizer und biontech se nasdaq bntx biontech gaben heute bekannt dass der ausschuss für humanarzneimittel committee for medicinal products for human use chmp der europäischen arzneimittel agentur european medicines agency ema eine positive beurteilung für die marktzulassung marketing authorization des an omikron kp 2 angepassten monovalenten covid 19 impfstoffs comirnaty kp 2 der unternehmen für die aktive immunisierung zur vorbeugung von covid 19 verursacht durch sars cov 2 bei personen ab 6 monaten ausgesprochen hat die europäische kommission ek wird die empfehlung des chmp prüfen eine endgültige entscheidung wird in kürze erwartet im anschluss an die entscheidung der ek werden pfizer und biontech den an omikron kp 2 angepassten covid 19 impfstoff den mitgliedstaaten der europäischen union eu ausliefern die genau diese formulierung bestellt haben,pfizer und biontech erhalten positive chmp empfehlung für an omikron kp 2 angepassten covid 19 impfstoff in der europäischen union,regulatory_filings,DOWN,-0.9599162834847244,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,4,8,281,0.1181818181818182,0.5503225880253886,0.06923440756774091
alvotech nasdaq alvo tilkynnti í dag að endurfjármögnun skulda félagsins væri nú lokið með því hefur félagið lækkað fjármagnskostnað og lengt lánstíma útistandandi skulda,alvotech lýkur við endurfjármögnun skulda með lægri fjármagnskostnaði og lengri lánstíma,financing_agreements,UP,0.0,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,4,352,0.0,0.44264539487962035,0.0
cambridge mass and rostock germany and berlin dec 13 2023 globe newswire centogene n v nasdaq cntg the essential life science partner for data driven answers in rare and neurodegenerative diseases today announced the company reached its initial recruitment and genetic testing milestone in the observational efront study being conducted to advance the genetic understanding of frontotemporal dementia ftd,centogene s frontotemporal dementia ftd genetic study efront reaches initial patient enrollment milestone,clinical_study,DOWN,-4.724405014224391,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,563,0.075,3.598197549072007,0.0
renovaro inc and amsterdam umc cancer center poised to advance cancer immunotherapy,renovaro inc and amsterdam umc cancer center poised to advance cancer immunotherapy,partnerships,UP,1.5151500099837776,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,4,9,400,-0.1,1.5631250973582267,0.09394164862914862
lexington mass june 25 2024 globe newswire t2 biosystems inc nasdaq ttoo a leader in the rapid detection of sepsis causing pathogens and antibiotic resistant genes today announced the execution of a territory exclusive distribution agreement in hong kong and macau under the terms of the agreement t2 biosystems will sell the t2dx instrument the t2bacteria panel the t2candida panel and the t2resistance panel through the newly appointed distributor,t2 biosystems announces commercial expansion through hong kong and macau distributor,geographic_expansion,DOWN,-0.9160369140381291,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,1,9,368,0.06818181818181818,1.9596557041969667,0.024839743589743585
oslo norway 12 february 2024 pci biotech ose pcib invites to a webcast presentation of the company s second half 2023 interim report on wednesday 14 february 2024 08 30am 09 30am cet local time,pci biotech invitation to second half interim 2023 results presentation,interim_information,DOWN,-4.176905875277916,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,0,3,502,-0.06666666666666667,0.8869841129646596,0.009773662551440335
fast track designation has the potential to accelerate lead asset imm 1 104 s path to u s fda submission for pancreatic ductal adenocarcinoma,immuneering receives fda fast track designation for imm 1 104 in pancreatic cancer,clinical_study,UP,6.969697648390823,111915520.0,27271404.0,2516685.0,0.002,1980700.0,0.24367848176910584,0.09346626282280733,1,8,494,0.13333333333333333,1.2966226301621697,0.115625
durocs årsredovisning och hållbarhetsrapport för 2023 2024 finns nu tillgängliga på svenska på www duroc se i pdf format samt esef format denna information är sådan som duroc är skyldigt att offentliggöra enligt eu s marknadsmissbruksförordning eu nr 596 2014 informationen lämnades genom angiven kontaktpersons försorg för offentliggörande den 27e september 2024 kl 08 00 duroc förvärvar utvecklar och förvaltar företag med tyngdpunkt på industri och handel med djup kunskap om teknik och marknad siktar koncernens företag på en ledande position i sina respektive branscher som ägare bidrar duroc aktivt till utvecklingen duroc är noterat på nasdaq stockholm kortnamn durc www duroc se bifogade filer 09253398 pdf 549300zy7ojroy97y052 2024 06 30 sv zip duroc hallbarhetsredovisning 2023 24 pdf,durocs årsredovsining och hållbarhetsrapport 2023 2024,annual_report,UP,1.5075434681407116,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.0,0.8866002429130597,0.0
redwood city calif march 15 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu announced additional positive phase 1b 2a data on briquilimab as a conditioning agent in the treatment of fanconi anemia fa,new positive data presented on briquilimab conditioning in patients with fanconi anemia,clinical_study,DOWN,-0.4106791782468576,81044232.0,9908441.0,280900.0,2.725,505700.0,0.12225966926307599,0.09346626282280733,4,8,470,0.2381818181818182,0.9821837329226573,0.09158730158730159
dallas july 24 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced a increase in its patent portfolio that strengthens and protects its proprietary ai driven deepview system wound assessment platform,spectral ai announces total u s and international patent portfolio now stands at 26 granted patents and 38 pending applications in support of its ai driven deepview system,patents,UP,0.5681812794001605,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,2,8,339,0.05000000000000002,0.9904696515070965,0.11089556277056278
cambridge mass feb 01 2024 globe newswire immuneering corporation nasdaq imrx a clinical stage oncology company seeking to develop universal ras raf medicines for broad populations of cancer patients today announced that management will participate in two february investor conferences to discuss the company s pipeline platform and business strategy participating will be ben zeskind ph d co founder and chief executive officer brett hall ph d chief scientific officer harold e b brakewood chief business officer and mallory morales cpa chief accounting officer treasurer,immuneering announces participation in february investor conferences,conference_call_webinar,UP,1.8739375751099767,114074672.0,27271404.0,2516685.0,0.002,1980700.0,0.23906624951768435,0.09346626282280733,3,8,513,0.03125,1.2966226301621697,0.2
media release,presentation of 3 rd quarter 2024 results,financial_results,UP,6.52037601435522,4289897472.0,29760087.0,70112.7,2.413,93652.0,0.006937249012183385,0.1515999603296736,1,7,242,0.0,0.40970189616126773,0.0
missing,valneva se declaration of shares and voting rights september 30 2024,voting_rights,UP,3.730018363735442,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,4,1,267,-0.2,0.6494694268312979,0.04756944444444444
malvern pa jan 30 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications this application follows the u s provisional application no 63 440 890 which was filed on january 24 2023,annovis bio announces the filing of new patent application for treatment of mental illnesses expanding the company s portfolio,patents,UP,5.448153596873155,44136244.0,15624645.0,595065.0,1.618,805900.0,0.35400939418406335,0.09346626282280733,1,8,515,0.018181818181818174,1.368989555493872,0.03574380165289256
ceo to participate in arvo sig panel on oral medications for retinal diseases,ocuphire pharma to highlight apx3330 for diabetic retinopathy at two scientific meetings in july,clinical_study,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,353,0.0,0.8866002429130597,-0.03070964749536178
irvine calif aug 03 2023 globe newswire biomerica inc nasdaq bmra the company today announced that cvs pharmacy has begun in store sales rollout of the company s ez detect colorectal disease screening test in over 7 000 stores nationwide throughout the cvs pharmacy retail system biomerica has shipped the ez detect product to cvs health distribution centers in the us and the product is projected to be on store shelves in september the company is also working with cvs health to introduce an additional biomerica product to be sold in cvs pharmacies,cvs health to begin nationwide in store sales of biomerica s ez detect colorectal disease screening test,product_services_announcement,UP,9.242146234319629,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,3,8,695,0.0,1.5245042583012947,0.0
san diego oct 04 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases announced today that the company will present the three year safety and efficacy results from its hope 2 open label extension ole study with lead asset deramiocel for treating duchenne muscular dystrophy dmd the data will highlight the long term multi modal benefits of deramiocel in a late breaking poster presentation at the 29th annual congress of the world muscle society wms 2024 taking place october 8 12 2024 in prague czechia,capricor therapeutics to present long term data from hope 2 open label extension study at 2024 world muscle society congress,clinical_study,UP,4.862331215844827,431504512.0,40176259.0,3124730.0,0.85,8768900.0,0.09310739026524942,0.09346626282280733,4,9,267,-0.012499999999999997,1.3427880947904531,0.12554640151515156
strive is the first phase 2 sub protocol trial initiated under vir s new prevail platform trial investigating the company s novel therapies in two chronic hepatitis b virus patient populations,vir biotechnology announces first patient dosed in new phase 2 chronic hepatitis b virus trial evaluating combinations of vir 2218 vir 3434 peg ifnα and an nrti,clinical_study,DOWN,-0.7364987775877799,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,3,8,779,0.19318181818181818,0.8653389999075153,0.13636363636363635
25 sep 2024 08 01 cest see attachment s voir document s joint s zie bijlage ver documento s em anexo 16165_1286169_communiqu_de_presse_cnp_assurances__participation_dans_cnp_unicredit_vita_25 09 24 pdf cnp assurances les echos,participation de cnp assurances dans cnp unicredit vita,capital_investment,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,276,0.0,0.8866002429130597,0.0
conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time conference call and webcast scheduled for wednesday august 14th at 8 30 am eastern time,mediwound to report second quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-2.8636885808582586,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,4,8,330,0.0,0.6433034533898109,0.14575491759702286
enefit green produced 141 gwh of electricity in september which is 48 more than in the same period last year during q3 as a whole enefit green s electricity production increased by 31 to 342 1 gwh mainly due to the addition of production from new wind and solar farms the result was about 109 gwh below what was previously planned mainly driven by the slower than expected production start at the sopi tootsi wind farm downregulation of production capacities and weak wind conditions wind energy enefit green s production volume in september was mostly driven by the y o y increase in the volume of wind energy production to 120 gwh an important contribution to the growth was made by new wind farms in lithuania and finland a tenth of the wind energy production in september was also provided by the sopi tootsi wind farm which is gradually being brought online delayed start of production of the sopi tootsi wind farm to the end of the quarter had a significant impact on the,enefit green production data september and q3 2024,earnings_releases_and_operating_results,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,9,260,0.047095959595959594,0.8866002429130597,-0.07277777777777779
geneva switzerland september 4 2024 addex therapeutics six nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that ceo tim dyer will be attending the h c wainwright 26th annual global investment conference taking place september 9 11 2024 at the lotte new york palace hotel,addex to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-7.103823312288768,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,297,-0.02840909090909091,0.972373032385036,-0.000335968379446638
jupiter fla and bunnik the netherlands feb 28 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health today announced its dutch subsidiary dyadic nederland bv has entered into a strategic partnership agreement and collaboration with rabian bv rabian a dutch innovative sme founded by experienced entrepreneurs and vaccine scientists the aim is to develop highly efficacious scalable and affordable rabies prophylactics and vaccines utilizing dyadic s c1 protein production platform this collaboration seeks to address the global burden of rabies a disease that annually claims tens of thousands of lives,dyadic announces strategic partnership agreement to develop affordable rabies prophylactics and vaccines using its proprietary c1 cell microbial protein production platform,partnerships,DOWN,-0.7042247017941755,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,486,0.26681818181818184,0.7846450948942033,0.07878787878787878
planegg martinsried october 16 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will present at the 16th annual protein antibody engineering summit pegs to be held from november 5 7 2024 in barcelona as well as at the cell 2024 conference by oxford global from november 6 8 2024 in london in addition two posters will be presented at the 39th society for immunotherapy of cancer sitc from november 6 10 2024 in houston tx usa,medigene to present at upcoming scientific conferences,conference_call_webinar,UP,4.285711385017371,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,5,255,0.0,1.3169799228985475,0.06307494588744589
the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases,neximmune announces research collaboration with national institute of neurological disorders and stroke ninds of the national institutes of health nih,partnerships,DOWN,-0.7692307692307693,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,996,0.0,2.2666992986423327,0.0
atev demonstrated superiority at six and 12 months co primary endpoints compared to autogenous fistula the current standard of care for hemodialysis,humacyte acellular tissue engineered vessel atev meets primary endpoints in v007 phase 3 clinical trial in arteriovenous access for hemodialysis,clinical_study,UP,0.0,336608256.0,121934248.0,3834265.0,2.0,1449900.0,0.3622437828738223,0.09346626282280733,2,7,332,0.2,1.1173068527438073,0.08992529461279462
02 oct 2024 08 58 cest aker horizons asa new ppa product gives businesses a better alternative for their electricity supply mainstream renewable power mainstream the pureplay global wind and solar company majority owned by aker horizons asa has reached financial close on its 50 mw ilikwa solar pv plant the power from the plant will supply multiple private commercial and industrial customers under flexible shorter term power purchase agreements ppas in a new to market product called renewable energy supply agreements resas this new product opens up the energy market in south africa by giving a wider range of businesses access to affordable reliable and renewable power through shorter term energy contracts of between five and 10 years commenting on the announcement mainstream s general manager for africa hein reyneke said we are excited to bring this new product to market offering customers the opportunity to secure flexible clean and lower cos,mainstream renewable power reaches financial close on 50 mw solar pv plant to provide new flexible ppas to private customers in south africa,product_services_announcement,DOWN,-0.6766964400073892,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.13961675579322638,0.8866002429130597,0.0
boston jan 16 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that robert connelly chief executive officer and christopher haqq m d ph d executive vice president head of research and development and chief medical officer will participate in a fireside chat at the b riley securities 4th annual oncology conference on january 18 2024 at 2 30 pm et,elicio therapeutics to present at the b riley securities 4th annual oncology conference,conference_call_webinar,UP,2.8625973648739893,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,1,8,529,0.0,0.8558055682194762,0.06854617604617605
planegg martinsried september 25 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer today announced the filing of a new patent application protecting mdg2021 a t cell receptor engineered t cell tcr t therapy targeting kirsten rat sarcoma viral oncogene homologue kras g12d with human leukocyte antigen hla a 11 for the tcr t therapy alone as well as in combination with the company s pd1 41bb costimulatory switch protein csp technology to the european patent office mdg2021 marks the second candidate within the kras library targeting kras g12d hla a 11 for which the company announced lead selection in june 2024 the addition of mdg2021 to company s kras targeting tcr library significantly impacts the addressable patient population with the combination of kras g12v and kras g12d mutations comprising of all kras mutations in all tumors pan cancer or even in pancreatic adenocarcinoma yang et al j clin med 2023,medigene ag expands protection of its kras library with filing of new patent application supporting mdg2021,patents,UP,1.851850012202395,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,3,276,0.11221590909090909,1.3169799228985475,0.059485930735930746
warrington pa may 07 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions and diseases today announced it has received a bid price compliance letter from the nasdaq stock market llc nasdaq informing windtree that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550 a 2 for continued listing on the nasdaq capital market,windtree therapeutics regains compliance with nasdaq,exchange_announcement,UP,1.4344199422675288,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,1,8,417,0.07500000000000001,2.339794177443606,0.010114538239538243
san diego oct 01 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced acceptance of an abstract for oral presentation at the upcoming society for melanoma research 21st international congress smr being held from october 10 13 2024 in new orleans la,bioatla announces upcoming oral presentation at the society for melanoma research 21st international congress,clinical_study,UP,9.242146234319629,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,1,8,270,0.00037878787878787776,1.087702859114621,0.00795963295963296
moonlake immunotherapeutics to host a capital markets updateon wednesday september 11,moonlake immunotherapeutics to host a capital markets update on wednesday september 11,conference_call_webinar,UP,0.7170752131136725,2929339136.0,28324751.0,691265.0,1.23,267600.0,0.009669331437901494,0.09346626282280733,0,7,292,0.0,0.5366763308656862,0.0677536231884058
oxurion receives transparency notifications from atlas special opportunities llc,oxurion receives transparency notifications from atlas special opportunities llc,major_shareholder_announcements,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,13,442,0.35714285714285715,2.0692591020840054,0.0
geneva switzerland september 4 2024 addex therapeutics six nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that ceo tim dyer will be attending the h c wainwright 26th annual global investment conference taking place september 9 11 2024 at the lotte new york palace hotel,addex to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-7.103823312288768,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,297,-0.02840909090909091,0.972373032385036,-0.000335968379446638
nufarm to pay up to usd 5 million in consideration for the license the parties will negotiate the sale of essentially all of yield10 s assets to nufarm,yield10 bioscience grants nufarm a commercial license to omega 3 assets for producing oil in camelina and yield10 and nufarm sign a memorandum of understanding for sale of assets,licensing_agreements,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,346,0.0,0.8866002429130597,0.028225623582766438
provides update on two late stage clinical programs for bxcl501 for potential treatment of agitation,bioxcel therapeutics reports financial results for the fourth quarter and full year 2023,clinical_study,UP,9.242146234319629,12595372.0,5544250.0,450810.0,-0.13,78500.0,0.4401815206410736,0.09346626282280733,1,7,473,0.009999999999999998,1.4586588351104455,-0.04424603174603175
media release,bghl eur nav s,clinical_study,UP,0.7246335247339231,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,246,0.0,0.8866002429130597,-0.005357142857142852
ozuriftamab vedotin the company s conditionally and reversibly active antibody drug conjugate directed against ror2 has shown promising clinical activity with a manageable safety profile in treatment refractory patients with squamous cell carcinoma of the head and neck scchn in its phase 2 clinical trial,bioatla granted fda fast track designation for ozuriftamab vedotin cab ror2 adc for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck,clinical_study,UP,3.448272554637248,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,1,8,340,0.0888888888888889,1.087702859114621,0.00878026294692961
biologics license application bla for hav accepted by fda,humacyte first quarter 2024 financial results and business update,regulatory_filings,DOWN,-0.4424774559935741,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,4,7,414,0.125,1.1173068527438073,0.03636363636363636
focused market access strategy generates estimated net revenue of approximately 1 1 million highest quarterly net revenue since commercial launch,bioxcel therapeutics announces preliminary estimated unaudited second quarter net revenues from sales of igalmi dexmedetomidine sublingual film,earnings_releases_and_operating_results,UP,0.8196713302251629,12081820.0,5544250.0,450810.0,-0.13,78500.0,0.45889195502002184,0.09346626282280733,1,7,347,-0.06666666666666667,1.4586588351104455,0.0403130797773655
boston feb 20 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the u s food and drug administration fda has granted fast track designation to pgn edodm1 an investigational candidate for the treatment of myotonic dystrophy type 1 dm1 receiving fast track designation from the fda for pgn edodm1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the dm1 community said james mcarthur ph d president and ceo of pepgen patients with dm1 currently have no available treatment options that target the root cause of the disease which leads to progressive neuromuscular symptoms and reduction in life expectancy following robust preclinical data we are now evaluating pgn edodm1 in the ongoing freedom dm1 phase 1 trial and expect to report preliminary data later this year we believe that pgn edodm1 has the potential to be disease modifying and improve outcomes for patients living with dm1,pepgen receives u s fda fast track designation for pgn edodm1 for the treatment of myotonic dystrophy type 1,clinical_study,DOWN,-1.079917699762323,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,1,8,494,0.07045454545454546,1.4553932872573117,0.04170935545935545
media release,vilniaus baldai ab interim condensed consolidated financial statement for the twelve months of fy2024 ended august 31 2024,financial_results,UP,2.312147650399959,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,242,0.0,0.8866002429130597,0.0963474025974026
i henhold til vedtægternes pkt 4 5 indkaldes hermed til ordinær generalforsamling i orphazyme a s til afholdelse den 18 april 2024 kl 15 00 på selskabets adresse hos visionhouse lyskær 8a 2730 herlev med følgende dagsorden,indkaldelse til ordinær generalforsamling den 18 april 2024 kl 15 00,annual_general_meeting,DOWN,-0.3361909426663528,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,458,0.0,0.8866002429130597,0.0
media release,sampo plc s share buybacks 25 october 2024,changes_in_companys_own_shares,UP,0.3200420274092861,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,243,0.0,0.8866002429130597,0.03409259259259259
malvern pa sept 09 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dr shankar musunuri chairman chief executive officer and co founder of ocugen will speak during the workshop titled u s india biotechnology cooperation realizing benefits reducing risks this two day event will take place from september 9 11 2024 in new delhi india,ocugen chairman ceo co founder dr shankar musunuri to speak during u s india initiative on critical and emerging technology workshop,conference_call_webinar,UP,0.8771921569070334,303712224.0,287364635.0,6243265.0,4.237,6951700.0,0.9461740828712907,0.09346626282280733,0,6,292,0.06818181818181818,0.7661975315521313,0.05664327485380117
oslo norway 14 february 2024 pci biotech ose pcib today announces its interim second half 2023 results please find enclosed the interim report and presentation,pci biotech second half 2023 interim results,earnings_releases_and_operating_results,UP,2.272731104063447,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,2,1,500,-0.08333333333333333,0.8869841129646596,-0.013746438746438742
dallas july 08 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has signed a memorandum of understanding mou with global medical device company and burn wound therapy leader polynovo limited polynovo under which the companies will collaborate to assist spectral ai in a potential limited deployment of its deepview system for burn indication in australia,spectral ai announces collaboration with global wound care company polynovo to introduce deepview system for burn indication to australian market,partnerships,UP,2.6041704501647103,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,0,8,355,0.014285714285714296,0.9904696515070965,0.14697835497835499
media release,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,240,0.0,0.8866002429130597,0.1859980184621333
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report first quarter 2024 financial results and provide a corporate update on thursday may 9,conference_call_webinar,DOWN,-0.4464302820210845,160853024.0,15213010.0,781395.0,1.567,974600.0,0.09457708423311954,0.09346626282280733,1,8,417,0.08333333333333333,0.8435084668920305,0.14913737717309147
châtillon france july 29 2024,dbv technologies to report second quarter 2024 financial results and business update on july 30 2024,conference_call_webinar,UP,0.7502646593083574,244630752.0,65520906.0,40445.0,0.319,55700.0,0.2678359342164799,0.09346626282280733,0,1,334,0.0,5.515503027122887,0.0
mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment,mediwound announces 25 million strategic private placement financing,financing_agreements,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,348,0.2,0.6433034533898109,0.13225718725718727
redwood city calif nov 17 2023 globe newswire rezolute inc nasdaq rzlt a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that the management team will participate in btig s 3rd annual ophthalmology day taking place virtually on november 27th,rezolute to participate in btig s 3rd annual ophthalmology day,conference_call_webinar,DOWN,-0.9888771398730164,376341760.0,77797779.0,825115.0,1.04,796000.0,0.20672109042589373,0.09346626282280733,4,8,589,-0.008333333333333331,0.6820409900648857,0.0
media release,glaston makes a change to the executive leadership team,management_changes,DOWN,-1.639344147877593,56298360.0,15339800.0,14584.2,0.607,41169.0,0.2724733011760911,0.1515999603296736,3,15,239,0.0,0.2342753450337208,0.0
rockaway n j sept 24 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company announced today that it has engaged fnk ir an institutionally focused investor relations consulting firm to develop and deploy an expanded outreach and communications program,electrocore engages fnk ir to execute expanded investor relations program,press_releases,UP,1.2598413371265045,38958256.0,5517155.0,83945.0,0.804,91500.0,0.14161709394794264,0.09346626282280733,1,8,277,-0.1,0.8324549917316175,0.1582772967772968
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
preliminary data from the 5 mg kg pgn edo51 dose level in the connect1 edo51 phase 2 trial are expected mid 2024 including initial safety exon 51 skipping and dystrophin protein production data,pepgen announces first patient dosed in connect1 edo51 phase 2 clinical trial of pgn edo51 for duchenne muscular dystrophy patients amenable to exon 51 skipping,clinical_study,DOWN,-1.6861233955604789,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,0,7,537,0.06999999999999999,1.4553932872573117,0.058884297520661155
alvotech nasdaq alvo tilkynnti í dag að matvæla og lyfjaeftirlit bandaríkjanna fda hefði veitt félaginu leyfi til sölu og markaðssetningar í bandaríkjunum á selarsdi ustekinumab aekn í áfylltu hettuglasi 130 mg 26 ml sem notað er til að hefja meðferð sjúklinga með crohns sjúkdóminn eða sáraristilbólgu selarsdi er líftæknilyfjahliðstæða alvotech við stelara ustekinumab og er áformað að hún komi á markað í bandaríkjunum í febrúar á næsta ári alvotech var fyrst til að markaðssetja hliðstæðu við stelara og er lyfið þegar komið á markað í kanada japan og evrópu,alvotech veitt aukið markaðsleyfi í bandaríkjunum fyrir selarsdi ustekinumab aekn líftæknilyfjahliðstæðu við stelara til meðferðar sjúkdóma í meltingarvegi,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.0,0.44264539487962035,0.05175282234105764
record revenues of 675 million in 2023,pacira biosciences reports fourth quarter and full year 2023 financial results,earnings_releases_and_operating_results,DOWN,-1.5379441217631988,1110386688.0,45834212.0,557500.0,0.511,435200.0,0.04127770306986966,0.09346626282280733,3,8,485,0.11666666666666665,0.7130794063724827,0.24973845598845595
in8bio announces upcoming presentation at 2024 european hematology association congress,in8bio announces upcoming presentation at 2024 european hematology association congress,clinical_study,UP,0.0,7446425.0,2577285.0,392516.85,0.183,187400.0,0.34611038182752124,0.09346626282280733,1,10,409,0.0,1.2777111391401192,0.10416666666666667
g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,g1 therapeutics to participate in td cowen s 5th annual oncology innovation summit,conference_call_webinar,DOWN,-6.304347127506984,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,10,401,0.0,0.8866002429130597,0.03571428571428571
information on the total number of voting rights denominator following conversion notice from atlas,information on the total number of voting rights denominator following conversion notice from atlas,voting_rights,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,1,13,409,0.0,2.0692591020840054,0.17301587301587304
évènement en présentiel et retransmis en direct à 10h00 et 16h00 cet,valneva organise une journée investisseurs à new york le 10 octobre 2024,conference_call_webinar,DOWN,-1.1383547598285657,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,268,0.11818181818181818,0.6494694268312979,0.03253787878787878
27 sep 2024 08 30 cest casino guichard perrachon le groupe casino vend pour plus de 200 m d immobilier commercial à tikehau capital paris le 27 septembre 2024 faisant suite à la signature en juin 2024 d un accord avec tikehau capital portant sur un portefeuille de 30 actifs immobiliers le groupe casino annonce avoir finalisé jeudi 26 septembre la cession de 26 d entre eux pour un prix net vendeur de plus de 200 millions d euros hors compléments de prix ultérieurs la cession des autres actifs prévue dans les accords sera finalisée dans les prochaines semaines une fois levées les conditions suspensives usuelles le portefeuille global est composé de murs d hypermarchés et de supermarchés loués aux enseignes casino intermarché carrefour et auchan ainsi que de lots annexes au sein de ces ensembles immobiliers certains présentant des potentiels de promotion immobilière la gestion immobilière de ces actifs est confiée par tikehau capital au groupe casino penda,groupe casino cessions immobilières,business_contracts,DOWN,-0.3016839287324527,112574064.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.1515999603296736,4,6,274,0.0,0.8866002429130597,0.0
study achieved its objective and demonstrated no evidence of tachyphylaxis tolerance or withdrawal with 180 mcg dose highest approved dose,bioxcel therapeutics announces positive topline results from post marketing requirement study evaluating prn treatment of igalmi dexmedetomidine sublingual film for agitation associated with bipolar disorders or schizophrenia,clinical_study,UP,5.882347048478309,11990979.0,5544250.0,450810.0,-0.13,78500.0,0.46236841879216034,0.09346626282280733,1,7,368,0.11363636363636363,1.4586588351104455,0.034672827172827186
kraig labs otcqb kblb launched its third and largest production cycle of the 2024 spider silk production season,kraig biocraft laboratories further expands spider silk production levels with launch of third production cycle,production_services_announcement,UP,8.333331781129008,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,341,0.0,0.8071333009212691,0.12946969696969698
alvotech nasdaq alvo tilkynnti í dag að hafin væri klínísk virknirannsókn á sjúklingum fyrir avt16 fyrirhugaða líftæknilyfjahliðstæðu við entyvio vedolizumab markmið rannsóknarinnar er að sýna fram á sambærilega klíníska virkni öryggi og ónæmingarverkun avt16 og samanburðarlyfsins í sjúklingum á aldrinum 18 80 ára sem haldnir eru miðlungs virkri eða mjög virkri sáraristilbólgu alvotech er eitt tveggja fyrirtækja sem vitað er að hafi byrjað alþjóðlega klíníska rannsókn á sjúklingum fyrir fyrirhugaða hliðstæðu við entyvio,alvotech hefur klíníska rannsókn á avt16 fyrirhugaðri líftæknilyfjahliðstæðu við entyvio,clinical_study,UP,0.2685741518915451,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,2,5,276,0.0,0.44264539487962035,0.07366372053872054
san diego jan 08 2024 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today announced that the fourth patient has now been enrolled into its phase 1 2 study of onct 534 its dual action androgen receptor inhibitor for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors arpi the last two patients were enrolled into the third dosing cohort to receive onct 534 at a dose of 160 mg taken orally each day the study utilizes an adaptive bayesian optimal interval boin design under which the first two dosing cohorts treated one patient each at 40 mg onct 534 per day and 80 mg onct 534 per day respectively the decision to proceed to dose level 3 was confirmed by the study s safety review committee src,oncternal therapeutics enrolls patients into the third dosing cohort of its phase 1 2 study of onct 534 for the treatment of r r metastatic castration resistant prostate cancer,clinical_study,UP,5.735291993329328,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,9,537,0.12777777777777777,0.8866002429130597,-0.17151515151515148
media release,be semiconductor industries n v announces q3 24 results,clinical_study,UP,0.9471554529783618,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,7,247,0.0,0.8866002429130597,0.0
media release,nanologica s rights issue registered conversion of btu to shares and warrants,shares_issue,DOWN,-3.404252210749046,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,10,240,0.0,0.8866002429130597,0.04191919191919192
stockholm sweden october 4 2024 egetis therapeutics ab publ egetis or the company nasdaq stockholm egtx today announced that peder walberg has decided to resign from the board of directors with immediate effect to focus on his role as a major shareholder of the company peder will continue to support the company in his current operational role as a consultant to the company mats blom chairman of the board of directors said i would like to thank peder for his invaluable contributions to the board of egetis and i m pleased that he will continue to support the company as a major shareholder and consultant for further information please contact mats blom chairman of the board of directors 46 761 45 70 90 about egetis therapeutics egetis therapeutics is an innovative and integrated pharmaceutical company focusing on projects in late stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug,change in the board of directors of egetis therapeutics,management_changes,DOWN,-0.6528777876166163,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,0.08666666666666667,0.8866002429130597,0.0
planning initiation of serenity at home pivotal phase 3 trial of bxcl501 for acute treatment of agitation associated with bipolar disorders or schizophrenia,bioxcel therapeutics reports second quarter 2024 financial results,clinical_study,UP,8.69565020211481,12051540.0,5544250.0,450810.0,-0.13,78500.0,0.4600449403146818,0.09346626282280733,1,7,326,0.275,1.4586588351104455,0.028234803391053394
missing,immix biopharma announces dr marko radic autoimmune car t pioneer and associate professor at the university of tennessee health science center joins scientific advisory board,advisory,DOWN,-7.103823312288768,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,0,9,557,-0.15000000000000002,0.9253604538231538,0.0
media release,shareholding disclosure nordnet ab publ,changes_in_share_capital_and_votes,UP,0.9063417451213552,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,7,242,0.0,0.8866002429130597,0.0
gaithersburg md oct 19 2023 globe newswire neximmune inc a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen specific t cells in oncology autoimmune and infectious diseases today announced that three abstracts have been accepted for poster presentation at the upcoming society for immunotherapy of cancer sitc 38th annual meeting in san diego ca being held november 1 5 2023,neximmune announces presentations at the society for immunotherapy of cancer s 38th annual meeting,conference_call_webinar,DOWN,-6.592180616329356,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,8,618,0.0,2.2666992986423327,0.017114448051948054
next confirms nexobrid s proven safety and efficacy in eschar removal significantly reducing surgical procedures for burn patients next confirms nexobrid s proven safety and efficacy in eschar removal significantly reducing surgical procedures for burn patients,mediwound announces positive results from the u s nexobrid expanded access protocol next,clinical_study,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,327,0.16287878787878787,0.6433034533898109,0.12587924701561065
santa ana calif oct 19 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today announced an upcoming poster presentation on a final report of a phase i dose escalation study of snk01 in subjects with alzheimer s disease at the 16th clinical trials on alzheimer s disease annual meeting to be held in boston ma usa from october 24 27 2023,nkgen biotech announces poster presentation at the 16th annual clinical trials on alzheimer s disease ctad conference,clinical_study,UP,1.0309268214748768,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,3,8,618,0.19999999999999998,2.657355742098314,0.3
watertown mass sept 19 2023 globe newswire eloxx pharmaceuticals inc nasdaq elox a leader in ribosomal rna targeted genetic therapies for rare diseases today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380 590 of its shares of common stock or common stock equivalents in lieu thereof at a purchase price of 5 255 per share or common stock equivalent in lieu thereof in a registered direct offering priced at the market under nasdaq rules in a concurrent private placement eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380 590 of its shares of common stock the warrants will have an exercise price 5 13 per share will become exercisable immediately upon issuance and have a term of five and one half years from the date of issuance the offering is expected to close on or about september 20 2023 subject to the satisfaction of customary closing conditions,eloxx pharmaceuticals announces 2 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-0.1831543738455693,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,648,-0.10303030303030303,2.2721670857062097,0.15067828662565508
company to host conference call may 13 2024 at 4 30 p m et company to host conference call may 13 2024 at 4 30 p m et,capricor therapeutics to present first quarter 2024 financial results and recent corporate update on may 13,earnings_releases_and_operating_results,UP,0.0,431938688.0,40176259.0,3124730.0,0.85,8768900.0,0.09301380060681205,0.09346626282280733,0,9,418,0.05,1.3427880947904531,0.14696969696969697
watertown mass sept 03 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced the continued evolution of its board of directors with the appointment of stephen steve fawell ph d as a director with this appointment malcolm salter has decided to retire from the board of directors after nearly a decade of service,c4 therapeutics appoints veteran biotechnology leader stephen fawell ph d to board of directors,management_changes,DOWN,-0.1582314653514814,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,1,7,298,0.05,0.8954742650579008,0.04428887085137085
waltham mass sept 21 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a panel presentation at the cantor global healthcare conference on thursday september 28 2023 at 10 20 a m et in new york city the company will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the cantor global healthcare conference,conference_call_webinar,DOWN,-1.1904750923180183,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,646,0.04545454545454545,0.8866002429130597,0.0
saint herblain france new york le 3 septembre 2024 valneva se nasdaq valn euronext paris vla et pfizer inc nyse pfe ont annoncé aujourd hui des données positives sur l immunogénicité et l innocuité de l étude de phase 2 vla15 221 suite à une deuxième vaccination de rappel avec son candidat vaccin contre la maladie de lyme vla15 administrée un an après la première dose de rappel la réponse immunitaire et le profil d innocuité de vla15 un mois après avoir reçu cette deuxième dose de rappel étaient similaires à ceux rapportés après avoir reçu la première dose de rappel démontrant ainsi le bénéfice potentiel que pourrait avoir une vaccination de rappel avant chaque saison de maladie de lyme il n existe actuellement aucun vaccin humain contre la maladie de lyme et vla15 est le candidat vaccin le plus avancé contre cette maladie avec deux essais de phase 3 en cours les centres américains de contrôle et de prévention des maladies cdc estiment qu environ 476 000 personnes sont diagnostiquées et traitées contre la maladie de lyme chaque année aux états unis et que 129 000 cas sont signalés chaque année en europe 1 2,valneva et pfizer annoncent de nouvelles données positives de phase 2 après une vaccination de rappel pour le candidat vaccin contre la maladie de lyme,clinical_study,UP,0.0,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,1,1,298,0.13636363636363635,0.6494694268312979,0.056410256410256404
27 sep 2024 08 15 cest bekaert s a mise à jour relative au contrat de liquidité période allant du 19 septembre 2024 au 25 septembre 2024 contrat de liquiditédans le cadre du contrat de liquidité reconduit avec kepler cheuvreux annoncé le 25 juin 2024 bekaert annonce aujourd hui que kepler cheuvreux a acheté 13 600 actions pour le compte de bekaert durant la période comprise entre le 19 septembre 2024 et le 25 septembre 2024 sur euronext bruxelles au cours de la même période kepler cheuvreux a vendu 6 100 actions pour le compte de bekaert sur euronext bruxelles les tableaux ci dessous donnent un aperçu des transactions effectuées dans le cadre du contrat de liquidité au cours de la période comprise entre le 19 septembre 2024 et le 25 septembre 2024 achat d actions datenombre d actionsprix moyen prix le plus élevé prix le plus bas montant total 19 septembre 202460036 7536 8036 7022 05020 septembre 20244 30036 2936 7035 96156 04723 septembre 20241 50035 7835,bekaert mise à jour relative au contrat de liquidité,changes_in_companys_own_shares,UP,0.4955955580622765,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.0,0.8866002429130597,0.0
media release,norden rapporterer resultat på usd 25 millioner i q3 2024 og fortsætter med at returnere overskud til aktionærerne,financial_results,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.37515160223877836,0.0
media release,invl baltic real estate interim unaudited information for 9 months of 2024,earnings_releases_and_operating_results,UP,0.8695644061371431,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,9,240,0.2,0.8866002429130597,0.19142101284958427
los angeles feb 13 2024 globe newswire renovaro inc nasdaq renb announced today that it completed its acquisition of gedi cube intl ltd gedicube renovaro which means renew combines the power of the ai health tech platform of gedicube with the advanced cell and gene therapy biotech platform of renovaro biosciences to accelerate precision personalized medicine and a new era in healthcare innovation the two subsidiaries will be under the parent organization which was renamed renovaro inc,ai pioneer gedi cube and biotech innovator renovaro biosciences combine forces to accelerate personalized medicine,mergers_acquisitions,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,501,0.2681818181818182,1.5631250973582267,0.15822510822510824
results demonstrate superiority of escharex a bromelain based gel vs santyl a collagenase ointment in wound debridement promotion of granulation tissue and time to wound closure in patients with chronic venous leg ulcers vlu results demonstrate superiority of escharex a bromelain based gel vs santyl a collagenase ointment in wound debridement promotion of granulation tissue and time to wound closure in patients with chronic venous leg ulcers vlu,mediwound announces positive results in head to head comparison of escharex vs santyl within the chronex phase ii randomized controlled study,clinical_study,UP,5.630252922450889,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,502,0.22727272727272727,0.6433034533898109,0.1475
adelaide australia and cambridge mass dec 06 2023 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced the presentation of data on the psychometric validity and reliability of suds as an outcome measure in assessing anxiety in sad clinical trials at the 2023 american college of neuropsychopharmacology annual meeting taking place december 3 6 in tampa florida,bionomics presents detailed data on the validity and reliability of the subjective units of distress scale at the 2023 american college of neuropsychopharmacology annual meeting,clinical_study,UP,3.3898375288438505,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,570,-0.009476190476190471,0.8866002429130597,0.04576126148764874
kineta has completed enrollment in the monotherapy cohorts of the phase 1 vista 101 clinical trial,kineta announces completion of enrollment in the monotherapy arm of the vista 101 phase 1 clinical study in advanced solid tumors,clinical_study,UP,3.9592722657265695,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,263,0.2,0.8866002429130597,0.09664855977355977
boca raton florida may 30 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company is set to join the broad market russell 3000 index at the conclusion of the 2024 russell us indexes annual reconstitution effective at the open of us equity markets on monday july 1st according to a preliminary list of additions posted friday may 24th,inmune bio inc to join russell 3000 index,corporate_action,UP,0.1036293189342012,163787184.0,15213010.0,781395.0,1.567,974600.0,0.09288278623802458,0.09346626282280733,3,8,394,0.22083333333333333,0.8435084668920305,0.129396164021164
not for release publication or distribution directly or indirectly in or into the united states hong kong canada japan or australia or any other jurisdiction in which the distribution or release would be unlawful the board of directors of naxs is pleased to announce its appointment of the board member nikolai jebsen as interim ceo effective october 7 the board thanks gösta lundgren for his committed service as interim ceo following the above appointment naxs management will consist of mr jebsen as ceo and mr lundgren in his longstanding position as cfo contact information gösta lundgren interim ceo phone 46 70 710 47 88 this press release and further information is available on the company s website www naxs se naxs ab publ corp reg no 556712 2972 alma nybrogatan 8 114 34 stockholm sweden e mail info naxs se naxs is listed on nasdaq stockholm naxs primarily invests in private equity funds with a nordic focus but may also make direct investments or co invest,appointment of nikolai jebsen as interim ceo of naxs ab publ,management_changes,DOWN,-0.675678244466031,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,268,0.18125,0.8866002429130597,0.0
not for release publication or distribution directly or indirectly in or into the united states hong kong canada japan or australia or any other jurisdiction in which the distribution or release would be unlawful the board of directors of naxs is pleased to announce its appointment of the board member nikolai jebsen as interim ceo effective october 7 the board thanks gösta lundgren for his committed service as interim ceo following the above appointment naxs management will consist of mr jebsen as ceo and mr lundgren in his longstanding position as cfo contact information gösta lundgren interim ceo phone 46 70 710 47 88 this press release and further information is available on the company s website www naxs se naxs ab publ corp reg no 556712 2972 alma nybrogatan 8 114 34 stockholm sweden e mail info naxs se naxs is listed on nasdaq stockholm naxs primarily invests in private equity funds with a nordic focus but may also make direct investments or co invest,appointment of nikolai jebsen as interim ceo of naxs ab publ,management_changes,DOWN,-0.675678244466031,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,268,0.18125,0.8866002429130597,0.0
new haven conn oct 29 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience today announced that vimal mehta ph d ceo and vincent j o neill m d executive vice president chief of product development and medical officer will present at the thinkequity conference in new york city the presentation is set for wednesday october 30 at 2 p m et,bioxcel therapeutics to present at thinkequity conference,conference_call_webinar,DOWN,-1.499248954662312,12057596.0,5544250.0,450810.0,-0.13,78500.0,0.4598138799807192,0.09346626282280733,1,7,242,-0.05454545454545454,1.4586588351104455,0.06835701737875652
media release,20241028 retirement announcement jean kreusch from shurgard,management_changes,UP,0.6451612903225806,3716609024.0,32358822.0,0.5454545454545454,0.732,0.0,0.008706544538594974,0.1515999603296736,1,9,242,0.0,0.2933285721665957,0.0
data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate data to offer insight into the safety and pharmacodynamics of redosing patients with a systemically delivered lnp based crispr gene editing candidate,intellia therapeutics to present the first ever clinical data from patients redosed with an investigational in vivo crispr gene editing therapy at the peripheral nerve society annual meeting 2024,clinical_study,DOWN,-0.5964199634410936,978341376.0,98412511.0,6353695.0,2.134,5288300.0,0.10059117749099472,0.09346626282280733,0,7,376,0.125,0.7800307612939593,-0.006857142857142862
vid årsstämman 2015 i investment ab öresund publ öresund eller bolaget antogs såväl principer för utseende av valberedning som instruktion för valberedningen som skall gälla till dess att bolagsstämman beslutar annorlunda enligt gällande principer för utseende av valberedning i bolaget skall valberedningen bestå av en representant för envar av de fyra största aktieägarna eller aktieägar grupperna i bolaget namnen på valberedningens ledamöter samt de ägare dessa företräder skall offentliggöras senast sex månader före årsstämman och baseras på det kända ägandet omedelbart före offentliggörandet valberedningens mandatperiod sträcker sig fram till dess att ny valberedning utsetts ordförande i valberedningen skall vara den ledamot som representerar den största aktieägaren om inte val beredningen enas om annat det åligger valberedningens ordförande att sammankalla valberedningen valberedningen har nu utsetts och utgörs av följande ledamöter mats qviberg har utsetts till ord,öresunds valberedning inför årsstämman 2025,annual_general_meeting,UP,0.1574779120017224,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
conference call and webcast to be held at 8 30 a m est,inspiremd to report fourth quarter and full year 2023 financial results and provide corporate business update on wednesday march 6th,conference_call_webinar,DOWN,-5.128208935020021,65865896.0,16849440.0,286250.0,0.613,4867100.0,0.2558143291636084,0.09346626282280733,2,7,486,0.0875,0.6085732039686736,0.08206293706293705
dallas oct 04 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that on october 1 2024 the compensation committee of taysha s board of directors granted one new employee an option to purchase 501 600 shares of the company s common stock in connection with their employment the stock option was granted under the taysha gene therapies inc 2023 inducement plan as an inducement material to the individual entering employment with taysha in accordance with nasdaq listing rule 5635 c 4,taysha gene therapies announces inducement grant under nasdaq listing rule 5635 c 4,corporate_action,UP,1.4851471125267248,626364352.0,136885482.0,5054745.0,1.016,2606600.0,0.21853970706174544,0.09346626282280733,4,8,267,-0.04090909090909091,1.0149166236087122,0.00340295182400446
investor webcast on monday march 4 at 8 00 a m et to present clinical data investor webcast on monday march 4 at 8 00 a m et to present clinical data,akero therapeutics to present topline week 96 results from phase 2b harmony study investigating efruxifermin in patients with pre cirrhotic mash,clinical_study,UP,2.93794035203086,4362944000.0,65983030.0,1904080.0,-0.16,4370200.0,0.015123510638688005,0.09346626282280733,3,8,485,0.0,1.1395320392459187,0.019851851851851857
la jolla calif may 28 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that medicinova conducted two poster presentations at the 92nd european atherosclerosis society eas 2024 congress held online may 26 29 2024,medicinova announces two poster presentations at the 92nd eas congress 2024 the annual meeting of the european atherosclerosis society regarding the use of mn 001 tipelukast for cardiometabolic conditions,clinical_study,DOWN,-1.4925358528601556,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,396,0.0,0.8018560055721619,0.11601010101010101
media release,archer limited disclosure of large shareholding,shares_issue,UP,3.0491852271965074,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,240,0.07142857142857142,0.8866002429130597,0.2261904761904762
mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment,mediwound announces 25 million strategic private placement financing,financing_agreements,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,348,0.2,0.6433034533898109,0.13225718725718727
norwood mass sept 05 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will present at the 2024 cantor global health conference to be held september 17 19 2024 in new york ny dr cohen will participate in a fireside chat with cantor analyst prakhar agrawal and participate in one on one investor meetings,corbus pharmaceuticals to present at the 2024 cantor global health conference,conference_call_webinar,DOWN,-0.7584001002925084,101687816.0,7524021.0,127840.0,3.117,146300.0,0.07399137178833697,0.09346626282280733,3,8,296,0.02727272727272727,0.9919200800994142,0.07029166666666667
moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,moonlake immunotherapeutics reports first quarter 2024 financial results and provides a business update,financial_results,DOWN,-1.5947867861013068,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,1,8,417,0.125,0.5366763308656862,0.04025252525252525
on 30 september 2024 the supervisory board of šiaulių bankas ab approved a new dividend policy for the bank dividend policy commits to a minimum payout of of the previous year s net earnings with the new dividend policy we reaffirm our commitment to increasing returns to shareholders while maintaining a solid foundation for the bank s sustainable growth we believe that reinvesting profits into our core business and technology expanding the loan portfolio and enhancing our product offerings will help us achieve the faster than market organic growth we are targeting additionally by optimizing our capital structure through the use of capital market instruments we are able to ensure higher returns for shareholders and enhance the bank s attractiveness to investors says vytautas sinius ceo of šiaulių bankas the dividend policy document of šiaulių bankas is attached šiaulių bankas invites shareholders investors analysts and all interested parties to a webinar presentat,šiaulių bankas ab approve new dividend policy,dividend_reports_and_estimates,UP,0.4178302232243772,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,13,270,0.13804713804713806,0.8866002429130597,-0.009999999999999998
new york aug 19 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the appointment of ivor elrifi as its chief executive officer ceo effective immediately,tiziana life sciences appoints new chief executive officer,management_changes,DOWN,-0.8264454667762735,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,0,7,313,0.21818181818181817,1.1109140250580023,0.037909696613400316
malvern pa april 29 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced the data from its phase ii iii alzheimer study of buntanetap in mild to moderate ad patients based on these data the company plans to conduct a pivotal phase iii trial in biomarker positive early ad patients,annovis bio announces statistically significant phase ii iii data in patients with early alzheimer s disease,clinical_study,DOWN,-7.103823312288768,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,0,10,424,0.2044507575757576,1.368989555493872,0.050015782828282826
media release,mandatory notification of trade protector forsikring asa,changes_in_companys_own_shares,UP,0.1724137931034483,35361251328.0,76386911.0,85178.45,0.504,161575.0,0.0021601868749343374,0.1515999603296736,1,13,241,0.0,0.2828170076921634,0.0
jerusalem dec 26 2023 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins announced that on december 22 2023 it closed a private placement with certain existing and new investors the company issued and sold 7 916 879 units at a price of 0 835 per unit each consisting of one ordinary share of entera or one pre funded warrant in lieu thereof and one five year warrant gross proceeds to entera before offering expenses were approximately 6 6 million extending the company s cash runway into 2025,entera bio announces closing of private placement extends cash runway into 2025,financing_agreements,UP,3.0769294253470134,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,1,8,550,-0.049918831168831175,0.6915109749530333,0.09862012987012986
carmel ind sept 30 2024 globe newswire mbx biosciences inc nasdaq mbx a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders today announced that both the rationale and design of the phase 2 avail trial of mbx 2109 the company s potential long acting parathyroid hormone pth peptide prodrug in adults with hypoparathyroidism hp were featured in a poster presentation at the american society for bone and mineral research asbmr 2024 annual meeting held in toronto on canada september 27 30 2024,mbx biosciences presents mbx 2109 phase 2 avail hypoparathyroidism trial rationale and design at the asbmr 2024 annual meeting,clinical_study,DOWN,-2.5052207196509784,382040896.0,13610404.0,237885.0,0.8755,391100.0,0.03562551586100353,0.09346626282280733,0,8,271,-0.0125,0.928688678995062,0.0
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
successfully delivered first development candidate to biogen 8 million payment earned,c4 therapeutics reports first quarter 2024 financial results and recent business highlights,financial_results,UP,0.5891010615280053,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,2,7,416,0.25,0.8954742650579008,0.05328884078884078
poster to be presented at acr convergence annual meeting tampa fla sept 26 2024 globe newswire pacira biosciences inc nasdaq pcrx the industry leader in the delivery of innovative non opioid pain therapies today announced the upcoming presentation of new data in support of its gene therapy candidate pcrx 201 enekinragene inzadenovec the data will be presented at the american college of rheumatology s annual acr convergence meeting being held in washington d c november 14 19,pacira announces the presentation of 104 week safety and efficacy data following local administration of pcrx 201 for moderate to severe osteoarthritis of the knee,clinical_study,UP,0.9345802722284278,1108997632.0,45834212.0,557500.0,0.511,435200.0,0.04132940475025288,0.09346626282280733,3,8,275,0.10606060606060606,0.7130794063724827,0.1295940609098504
zug switzerland and boston may 29 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today announced that members of its senior management team are scheduled to participate in the following investor conferences in june,crispr therapeutics to participate in upcoming investor conferences,conference_call_webinar,DOWN,-2.151714627812774,4069457152.0,85970729.0,2651100.0,1.742,2455300.0,0.021125846959157268,0.09346626282280733,2,8,395,-0.16666666666666666,0.5620956775766307,0.04026875901875901
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
publication titled a novel class of ribosome modulating agents exploits cancer ribosome heterogeneity to selectively target the cms2 subtype of colorectal cancer published in cancer research communications,eloxx pharmaceuticals announces publication demonstrating the power of its turbo zm platform to target the human ribosome for therapeutic benefit,research_analysis_and_reports,UP,1.1049779429876614,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,9,719,0.0,2.2721670857062097,0.20633866133866136
record fourth quarter 2023 cguard eps revenue of 1 76 million increased 71 over fourth quarter 2022,inspiremd reports fourth quarter and full year 2023 financial results and provides business update,earnings_releases_and_operating_results,DOWN,-2.6616033694073624,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,2,7,479,0.06999999999999999,0.6085732039686736,0.08245129870129868
patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract,biora therapeutics announces new patent covering its biojet liquid jet delivery technology,patents,DOWN,-1.5256606509349646,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,446,0.06818181818181818,1.027516639474094,0.22727272727272727
media release,oslo børs status companies placed in recovery box and penalty bench,exchange_announcement,DOWN,-0.1739108080223499,580726080.0,80428108.0,4091945.0,0.575,4211400.0,0.13849577411780783,0.09346626282280733,0,8,243,0.0,0.963882818724342,0.0
cambridge mass aug 01 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies will present its second quarter 2024 financial results and operational highlights in a conference call on august 8 2024 at 8 a m et,intellia therapeutics to hold conference call to discuss second quarter 2024 earnings and company updates,financial_results,UP,1.6024421631619286,976642688.0,98412511.0,6353695.0,2.134,5288300.0,0.10076613710335791,0.09346626282280733,3,7,331,0.0,0.7800307612939593,0.05165172934704184
palo alto calif sept 26 2024 globe newswire scilex holding company nasdaq sclx scilex an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that the u s bankruptcy court for the southern district of texas the court has extended the expiration of the restrictions on transfer of the shares of common stock of scilex that were previously distributed by sorrento therapeutics inc otc srneq sorrento scilex s former controlling stockholder to sorrento s stockholders as a dividend on january 19 2023 the dividend stock such lock up period was previously set to expire on the earlier of i september 30 2024 or ii the date on which sorrento and its official committee of unsecured creditors agreed in writing or on the record in sorrento s chapter 11 cases certain claims that may be asserted in potential litigation to avoid sorrento s distribution of dividend stock and to recover such dividend stock should not be pursued or on such date that the court deems just and proper on september 25 2024 the court approved a motion to extend the lock up period on the dividend stock to january 31 2025,scilex holding company announces that the u s bankruptcy court has extended the lockup period on shares of scilex dividend stock previously distributed by sorrento to its stockholders as a dividend to january 31 2025,bankruptcy,UP,0.0,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,275,0.03428571428571429,1.0327724261931344,0.25239099168375484
boca raton florida oct 11 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of alzheimer s disease ad today announced that management will participate in the upcoming maxim healthcare virtual summit to be held october 15 17 2024,inmune bio inc to participate in the maxim healthcare virtual summit,conference_call_webinar,DOWN,-0.1991982486588004,163892400.0,15213010.0,781395.0,1.567,974600.0,0.09282315714456559,0.09346626282280733,4,8,260,0.0,0.8435084668920305,0.13531568161776494
not for release publication or distribution directly or indirectly in or into the united states hong kong canada japan or australia or any other jurisdiction in which the distribution or release would be unlawful the board of directors of naxs is pleased to announce its appointment of the board member nikolai jebsen as interim ceo effective october 7 the board thanks gösta lundgren for his committed service as interim ceo following the above appointment naxs management will consist of mr jebsen as ceo and mr lundgren in his longstanding position as cfo contact information gösta lundgren interim ceo phone 46 70 710 47 88 this press release and further information is available on the company s website www naxs se naxs ab publ corp reg no 556712 2972 alma nybrogatan 8 114 34 stockholm sweden e mail info naxs se naxs is listed on nasdaq stockholm naxs primarily invests in private equity funds with a nordic focus but may also make direct investments or co invest,appointment of nikolai jebsen as interim ceo of naxs ab publ,management_changes,DOWN,-0.675678244466031,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,268,0.18125,0.8866002429130597,0.0
châtillon france may 31 2024,dbv technologies announces plan to implement ads ratio change,corporate_action,DOWN,-6.666669978035689,244630752.0,65520906.0,40445.0,0.319,55700.0,0.2678359342164799,0.09346626282280733,4,9,392,0.0,5.515503027122887,0.0
san diego feb 29 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will participate in a panel discussion at td cowen s 44th annual health care conference,anaptys to present at td cowen s 44th annual health care conference and 2024 aad annual meeting,conference_call_webinar,UP,1.6272765787855088,687209856.0,17605381.0,784220.0,-0.266,445700.0,0.02561863868262099,0.09346626282280733,3,9,485,0.25,0.871343469962729,0.20363320334394713
copenhagen denmark june 26 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines receives positive feedback on its recent patent application for a new type of personalized vaccine targets underscoring its novelty and inventiveness,evaxion receives positive feedback on patent application for ai based novel cancer vaccine target identification method,Patents,UP,6.7615680103010405,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,2,7,367,0.1477272727272727,1.4249795072460607,0.11428872053872054
geneva switzerland july 12 2024 addex therapeutics six adxn and nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that mikhail kalinichev head of translational science will present at the thirteenth london international cough symposium taking place july 18 19 2024 at imperial college in london u k,addex to present at the thirteenth london international cough symposium 13th lics,clinical_study,DOWN,-1.0119052619891058,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,4,1,351,-0.041666666666666664,0.972373032385036,-0.00401960784313725
media release,resolutions of the general extraordinary shareholders meeting of invl baltic farmland,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19166666666666665,0.8866002429130597,0.19437229437229436
the new coupon rate of delfingroup bonds with a variable rate with quarterly interest rate fixing from 25 september 2024 to 24 december 2024 is as follows bonds included in the nasdaq riga baltic first north market bonds subscribe to delfingroup news and updates here about delfingroup as delfingroup is a licenced fintech company established in 2009 and operates under the brand names banknote and vizia the company has been profitable every year since 2010 delfingroup continuously develops and offers consumer and pawn loans loans developed for senior citizens buy now pay later loans bnpl loans and the sale of pre owned goods online and at more than 90 branches across latvia and lithuania since 2014 delfingroup has been known on the nasdaq riga stock exchange as a bond issuer and since 2021 as a listed company on the baltic main list the company regularly pays dividends to its shareholders the sustainability of delfingroup is based on focused corporate gove,delfingroup announces fixing of coupon rate for the floating rate bonds effective from 25 september 2024,bond_fixing,UP,0.7843153296136918,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,13,280,0.18530303030303033,0.8866002429130597,0.20633040935672514
rockville md oct 12 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease announced today that it has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase common shares of the company for cash the existing warrants wherein the investor agreed to exercise the existing warrants to purchase up to a maximum of 10 892 728 common shares at an exercise price of 0 7785 per share as part of the agreement the existing holder has agreed to pay an additional 0 25 consideration per share resulting in gross proceeds of up to approximately 11 2 million assuming full exercise of the existing warrants and before deducting offering fees and expenses,opgen enters into warrant inducement transaction for up to 11 2 million in gross proceeds,warrants_and_certificates,DOWN,-7.103823312288768,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,12,624,-0.10833333333333334,1.807174583649316,0.14746915584415585
watertown mass sept 19 2023 globe newswire eloxx pharmaceuticals inc nasdaq elox a leader in ribosomal rna targeted genetic therapies for rare diseases today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380 590 of its shares of common stock or common stock equivalents in lieu thereof at a purchase price of 5 255 per share or common stock equivalent in lieu thereof in a registered direct offering priced at the market under nasdaq rules in a concurrent private placement eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380 590 of its shares of common stock the warrants will have an exercise price 5 13 per share will become exercisable immediately upon issuance and have a term of five and one half years from the date of issuance the offering is expected to close on or about september 20 2023 subject to the satisfaction of customary closing conditions,eloxx pharmaceuticals announces 2 million registered direct offering priced at the market under nasdaq rules,shares_issue,DOWN,-0.1831543738455693,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,648,-0.10303030303030303,2.2721670857062097,0.15067828662565508
media release,norden iværksætter aktietilbagekøb,changes_in_companys_own_shares,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.37515160223877836,0.0
media release,two national airlines choose a seamless multi orbit ifc future with ses open orbits,product_services_announcement,DOWN,-4.347824604401455,33236662.0,5203991.0,38994.47368421053,-1.546,15503.0,0.15657381598669565,0.19535099655549074,2,8,241,0.03333333333333333,2.144966214298392,0.0888888888888889
media release,new number of shares and votes in itab shop concept ab publ,shares_issue,DOWN,-3.345723536405933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.13636363636363635,0.8866002429130597,0.012500000000000004
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,-0.2
media release,program for acquisition of equity certificates for employees of sparebanken vest,corporate_action,UP,1.1410738067002315,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,2,14,240,0.0,0.20896972559163385,0.055
g1 therapeutics announces inducement grants under nasdaq listing rule 5635 c 4,g1 therapeutics announces inducement grants under nasdaq listing rule 5635 c 4,corporate_action,UP,0.626958638487933,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,7,388,0.0,0.8866002429130597,0.0625
eight abstracts highlighting new data from vir s chronic hepatitis b and chronic hepatitis delta programs have been accepted for presentation at aasld,vir biotechnology announces multiple abstracts highlighting new chronic hepatitis b and hepatitis delta data accepted for presentation at aasld s the liver meeting 2023,clinical_study,DOWN,-0.9009000301245093,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,2,8,626,0.0909090909090909,0.8653389999075153,0.06285511363636363
on 17 10 2024 eften härgmäe oü finalized the transaction by which the company acquired the properties located at härgmäe str 8 and piimamehe str 7 in tallinn from the conus assets oü previously 20 09 2024 the fund has notified the stock exchange of the conclusion of a contract of sale under the law of obligations all the agreed preconditions for the transfer of ownership and the conclusion of a real right contract have been met the properties will be used by the logistics company elp logistics oü under a long term lease 10 5 years viljar arakasmember of the management boardtel 655 9515email viljar arakas eften ee,subsidiary of eften real estate fund as acquired the elp logistics oü logistics center,mergers_acquisitions,UP,0.5235621961910748,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,253,0.062380952380952384,0.8866002429130597,0.11580437309603979
rockville md july 31 2024 globe newswire theriva biologics inc nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the u s food and drug administration fda granted rare pediatric drug designation rpdd for vcn 01 for the treatment of retinoblastoma vcn 01 theriva s lead product candidate is a systemic selective stroma degrading oncolytic adenovirus previously the fda granted orphan drug designation to vcn 01 for treatment of retinoblastoma,theriva biologics receives rare pediatric drug designation by the u s fda for vcn 01 for the treatment of retinoblastoma,product_services_announcement,DOWN,-7.103823312288768,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,8,332,0.0988888888888889,1.5225134880447404,0.049659320477502294
san diego dec 26 2023 globe newswire oncternal therapeutics inc nasdaq onct a clinical stage biopharmaceutical company focused on the development of novel oncology therapies today updated the status of its dose escalation dose expansion phase 1 2 study onct 808 101 evaluating the company s ror1 targeting autologous car t cell therapy onct 808 for the treatment of patients with relapsed or refractory aggressive b cell lymphoma including patients who have failed previous cd19 car t treatment,oncternal therapeutics updates the status of its phase 1 2 study of onct 808 a ror1 targeting autologous car t in patients with relapsed or refractory aggressive b cell lymphoma,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,9,550,-0.3333333333333333,0.8866002429130597,0.0
new haven conn march 01 2024 globe newswire bioxcel therapeutics inc nasdaq btai a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno oncology today announced that it will release its fourth quarter and full year 2023 financial results on tues march 12 2024 before the open of the u s financial markets bioxcel therapeutics management team will also host a conference call and webcast at 8 00 am et that day to discuss the company s financial results and provide a general business update,bioxcel therapeutics to report fourth quarter and full year 2023 financial results on march 12 2024,earnings_releases_and_operating_results,UP,2.201255716141545,12057596.0,5544250.0,450810.0,-0.13,78500.0,0.4598138799807192,0.09346626282280733,4,7,484,0.023863636363636365,1.4586588351104455,-0.0783008658008658
ad hoc announcement pursuant to art 53 lr,addex provisional 2024 half year and second quarter result increased from a net loss to a net profit,earnings_releases_and_operating_results,UP,1.8769583139913464,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,3,1,282,-0.041666666666666664,0.972373032385036,-0.003575174825174822
dr olivier litzka has resigned from the board effective june 13 2024 dr olivier litzka has resigned from the board effective june 13 2024,mineralys therapeutics appoints biopharmaceutical executive alexander m gold m d to its board of directors,management_changes,DOWN,-2.3640602598939204,916364736.0,43490817.0,793180.0,-0.18,767600.0,0.0474601600120937,0.09346626282280733,4,8,379,0.6,0.8131647725786432,0.016800144300144298
ad hoc announcement pursuant to art 53 lr,santhera announces half year 2024 financial results and provides corporate update,financial_results,DOWN,-2.766398067949684,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,3,1,289,-0.05555555555555555,0.5209522992128177,0.07142857142857142
media release,rentefastsettelse,bond_fixing,DOWN,-0.1940257513701026,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,0,13,242,0.0,0.20896972559163385,0.0
27 sep 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 26 sep 2024 estimated nav euro sharessterling sharesestimated nav 28 5200 25 6046estimated mtd return 0 70 0 48 estimated ytd return 3 53 4 21 estimated itd return 185 20 156 05 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 3 93 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 83 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,274,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
longeveron to attend cell gene meeting on the mesa to highlight its cellular therapy program in alzheimer s disease and cdmo facilities and services,longeveron to attend alliance for regenerative medicine s cell gene meeting on the mesa,partnerships,DOWN,-1.538466146946781,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,3,9,275,0.0,1.063123411629147,0.11790633608815426
media release,miscellaneous,management_changes,UP,1.3605442176870748,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,243,0.0,0.8866002429130597,0.0
mainz biomed reports mid year 2024 financial results and provides corporate update,mainz biomed reports mid year 2024 financial results and provides corporate update,clinical_study,DOWN,-2.9702981009232525,5588755.0,2706585.0,75055.0,0.305,78500.0,0.48429122407405584,0.09346626282280733,0,8,250,0.0,34.079934680222834,-0.013751646903820816
mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment mölnlycke health care a global leader in innovative wound care solutions leads the pipe with a 15 million investment,mediwound announces 25 million strategic private placement financing,financing_agreements,DOWN,-7.103823312288768,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,0,7,348,0.2,0.6433034533898109,0.13225718725718727
mainz biomed reports mid year 2024 financial results and provides corporate update,mainz biomed reports mid year 2024 financial results and provides corporate update,clinical_study,DOWN,-2.9702981009232525,5588755.0,2706585.0,75055.0,0.305,78500.0,0.48429122407405584,0.09346626282280733,0,8,250,0.0,34.079934680222834,-0.013751646903820816
media release,court approved ab utenos trikotazas submitted restructuring plan court decision came into force,restructuring,UP,1.626013453082938,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.12604166666666666
redwood city calif march 04 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 in mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced results for the fiscal quarter and year ended december 31 2023 and reported recent corporate developments,jasper therapeutics reports fiscal 2023 financial results and recent corporate developments,earnings_releases_and_operating_results,UP,6.7934782843433545,81265056.0,9908441.0,280900.0,2.725,505700.0,0.121927449357815,0.09346626282280733,0,7,481,0.08571428571428572,0.9821837329226573,0.09305555555555556
topline data from the phase 1 portion of phase 1 2a trial of imm 1 104 expected in march 2024,immuneering reports fourth quarter and full year 2023 financial results and provides business updates,clinical_study,DOWN,-1.9354820846890508,113175024.0,27271404.0,2516685.0,0.002,1980700.0,0.2409666288208607,0.09346626282280733,4,8,484,0.06249999999999999,1.2966226301621697,0.12152777777777779
berwyn pa dec 11 2023 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases such as alzheimer s ad and parkinson s disease pd today announced its founder president and ceo was selected to participate in the 139th yale ceo summit in new york on december 11 12 2023,annovis bio to participate in the 139th yale ceo summit,press_releases,DOWN,-7.103823312288768,43843952.0,15624645.0,595065.0,1.618,805900.0,0.35636944862999576,0.09346626282280733,0,13,564,0.06818181818181818,1.368989555493872,0.0731060606060606
media release,immutep receives a 3 6 million r d tax incentive from french government,government_news,DOWN,-1.3100424405900453,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,1,8,277,0.0,0.7476881311953882,0.10528540507111936
communiqué de presse information réglementée27 novembre 2023 1 00 edt 7 00 cet,mdxhealth annonce la réalisation de l échange obligatoire d ads et le début de la période de transition vers une cotation unique sur le nasdaq,exchange_announcement,DOWN,-7.103823312288768,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,0,1,579,0.375,0.6181119561491973,0.0
media release,lleida net records sales worth 4 38 million euros in the third quarter of 2024,earnings_releases_and_operating_results,UP,0.0,18273132.0,10263673.0,665.2727272727273,0.816,500.0,0.5616811064463388,0.1515999603296736,1,8,242,0.09999999999999999,0.3985556235691757,0.0
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
encouraging preclinical studies demonstrate potential to combine aav atp7a gene therapy with cutx 101 which could be the first fda approved treatment for menkes disease,fortress biotech and cyprium therapeutics announce 4 1 million grant from ninds to further development of aav atp7a gene therapy for menkes disease,clinical_study,UP,2.469133379885459,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,0,8,481,0.08333333333333333,0.6928276660424207,0.027489177489177483
media release,eften real estate fund as unaudited results for 3rd quarter and nine months of 2024,clinical_study,UP,0.2624732095101908,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,8,247,0.1,0.8866002429130597,0.10090089886964887
dallas june 24 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has provided support to nasdaq and the state securities authorities in florida louisiana and texas to bring to their attention potential market manipulation of the company s common stock primarily in the form of naked short selling,spectral ai supports naked short selling inquiry,law_legal_issues,UP,0.6289302046118699,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,0,8,369,0.036363636363636376,0.9904696515070965,0.0
cosibelimab is the first pd l1 blocking antibody to demonstrate a robust durable and clinically meaningful objective response and a manageable safety profile in patients with metastatic cutaneous squamous cell carcinoma,checkpoint therapeutics announces publication of cosibelimab pivotal trial results in the journal for immunotherapy of cancer,clinical_study,UP,4.123707285899507,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,2,8,619,0.3125,0.8866002429130597,0.027958152958152956
media release,building a combined commercial and residential project,business_contracts,UP,0.0,1404396416.0,38253134.0,8.090909090909092,0.581,0.0,0.027238131316905896,0.1515999603296736,0,9,243,0.0,0.5820288170314594,0.0
media release,as eesti gaas is establishing new subsidiary,capital_investment,UP,0.2509467820514514,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,243,0.13636363636363635,0.8866002429130597,0.046666666666666676
dallas aug 19 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that dr jeffrey carter will present data from an ongoing prospective multicenter study analyzing the use of spectral ai s deepview system which utilizes non invasive multispectral imaging technology and proprietary ai to detect non healing areas of a wound following thermal burn injury,spectral ai announces podium presentation at bba isbi joint conference assessing burn wound severity using multispectral imaging and artificial intelligence,clinical_study,DOWN,-1.9354820846890508,55120248.0,17924135.0,466020.0,0.698,473400.0,0.32518240846811863,0.09346626282280733,0,8,313,-0.04285714285714284,0.9904696515070965,0.08747204184704187
planegg martinsried october 29 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will attend bio europe from november 4 6 2024 in stockholm as well as at the investival showcase biotech heathcare medtech conference on november 18 2024 in london in addition the company will present at the deutsches eigenkapitalforum from november 25 27 2024 in frankfurt,medigene to present at upcoming investor conferences,trade_show,DOWN,-1.6930006855879798,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,6,242,0.0,1.3169799228985475,0.05994214119214119
ab kauno grūdai a subsidiary of ab akola group has increased its investment in the breadcrumb factory which it plans to build in kėdainiai the company which has one breadcrumb coatings factory in the kaunas region will build a second and more giant factory once built the production capacity will more than double to over 21 thousand tons per year the investment was planned as early as 2022 and has since grown 1 5 times the planned capacity of the factory has also increased the total investment will amount to eur 6 7 million we will use our own and borrowed funds seb bank has granted a eur 5 million loan to kauno grūdai most of which will be used to build and equip the new factory the planned payback period of the factory is 6 7 years and the ebitda earnings before interest taxes depreciation and amortization of the breadcrumb coatings business is expected to increase by eur 1 5 million to eur 3 3 million annually says mažvydas šileika cfo of ab akola group a plo,ab akola group subsidiary increases investment in breadcrumb factory and borrows eur 5 million,capital_investment,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,274,0.20330578512396694,0.8866002429130597,0.0
company maintains strong cash position of 231 6 million company maintains strong cash position of 231 6 million,rapt therapeutics reports first quarter 2023 financial results,financial_results,DOWN,-0.8138344285550466,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,3,8,779,0.2791666666666667,1.6028075568485736,0.05625000000000001
south san francisco calif nov 27 2023 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based biopharmaceutical company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced that results from its previously disclosed phase 1a 1b clinical trial of zelnecirnon formerly rpt193 were published in allergy the phase 1a portion of the trial was a standard single and multiple dose escalation study in 72 healthy volunteers the phase 1b portion of the trial was a randomized double blind placebo controlled study examining zelnecirnon as monotherapy in 31 patients with moderate to severe atopic dermatitis ad,rapt therapeutics announces publication of phase 1a 1b clinical trial of zelnecirnon rpt193 to treat atopic dermatitis in allergy,clinical_study,DOWN,-1.2247844012412883,142045104.0,6191111.0,99294.6,-0.137,87900.0,0.04358552900211189,0.09346626282280733,0,8,579,-0.01028138528138528,1.6028075568485736,0.17821969696969697
clinical trial demonstrates that nvns is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants clinical trial demonstrates that nvns is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants,non invasive vagus nerve stimulation nvns is effective at accelerating foreign language learning,clinical_study,DOWN,-1.037374046050865,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,3,8,331,0.41874999999999996,0.8324549917316175,0.08515085924176834
media release,immutep appoints leading research institute to conduct first in human phase i study of imp761,clinical_study,DOWN,-0.4424774559935741,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,3,8,436,0.125,0.7476881311953882,0.0
évènement en présentiel et retransmis en direct à 10h00 et 16h00 cet,valneva organise une journée investisseurs à new york le 10 octobre 2024,conference_call_webinar,DOWN,-1.1383547598285657,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,268,0.11818181818181818,0.6494694268312979,0.03253787878787878
best in class anti ctla 4 candidates designed for more than 30 fold increase in therapeutic index addressing patient populations where ctla 4 mediated treg depletion is essential for efficacy,adagene reports six month financial results for 2023 and provides corporate update,clinical_study,UP,0.8474669590729236,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,7,667,0.3,0.845882180665701,0.23055555555555554
media release,odfjell se presentasjon av resultater for tredje kvartal 2024,earnings_releases_and_operating_results,DOWN,-0.3021102076463132,8592970752.0,15844521.0,49070.1,0.011,52497.0,0.0018438932771081774,0.1515999603296736,1,13,241,0.0,0.4144217819042367,0.0
zug switzerland and boston march 13 2024 globe newswire crispr therapeutics nasdaq crsp a biopharmaceutical company focused on creating transformative gene based medicines for serious diseases today announced it proposes to elect christian rommel ph d to its board of directors at the company s annual general meeting to be held this year,crispr therapeutics proposes new appointment to the board of directors,management_changes,DOWN,-0.9163378664566236,4071184640.0,85970729.0,2651100.0,1.742,2455300.0,0.021116882824553002,0.09346626282280733,2,8,472,0.13060606060606061,0.5620956775766307,0.03192400192400192
selskabet annoncerede i selskabsmeddelelse 13 2024 at man havde indledt en proces med at gennemføre et identitetsskifte med nasdaq for fortsat at kunne bevare sin status som børsnoteret selskab,business update opdatering på identitetsændring,exchange_announcement,DOWN,-0.5681818181818182,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,9,283,0.0,0.8866002429130597,0.0
se vedhæftede,storaktionærmeddelelse,company_regulatory_filings,UP,0.5714285714285714,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,13,282,0.0,0.8866002429130597,0.0
boston may 13 2024 globe newswire x4 pharmaceuticals nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that management will be participating in the upcoming h c wainwright 2nd annual bioconnect investor conference taking place on may 20th 2024 at the nasdaq stock exchange in new york city,x4 pharmaceuticals to participate in the h c wainwright 2nd annual bioconnect investor conference,conference_call_webinar,UP,0.9523800873701952,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,0,8,411,0.08727272727272727,1.4412990038402507,0.09
27 sep 2024 08 30 cest casino guichard perrachon le groupe casino vend pour plus de 200 m d immobilier commercial à tikehau capital paris le 27 septembre 2024 faisant suite à la signature en juin 2024 d un accord avec tikehau capital portant sur un portefeuille de 30 actifs immobiliers le groupe casino annonce avoir finalisé jeudi 26 septembre la cession de 26 d entre eux pour un prix net vendeur de plus de 200 millions d euros hors compléments de prix ultérieurs la cession des autres actifs prévue dans les accords sera finalisée dans les prochaines semaines une fois levées les conditions suspensives usuelles le portefeuille global est composé de murs d hypermarchés et de supermarchés loués aux enseignes casino intermarché carrefour et auchan ainsi que de lots annexes au sein de ces ensembles immobiliers certains présentant des potentiels de promotion immobilière la gestion immobilière de ces actifs est confiée par tikehau capital au groupe casino penda,groupe casino cessions immobilières,business_contracts,DOWN,-0.3016839287324527,112574064.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.1515999603296736,4,6,274,0.0,0.8866002429130597,0.0
novaturas group the leader in the baltic tourism market announces that darius undzėnas will take up the position of the company s chief financial officer cfo from october 7 with many years of comprehensive experience in financial management mr undzėnas joins the group s top management team in lithuania latvia and estonia we are confident that darius s diverse experience in finance and his management skills gained in international companies will contribute to the goal of strengthening the position of novaturas in the tourism market at the same time we set a strategic goal for the new cfo to strengthen the company s financial position which is important both for ensuring the long term trust of our customers and partners and for creating long term value for the company s shareholders said kristijonas kaikaris chief executive officer of novaturas group the new cfo of the company has more than 15 years of experience in various financial management positions in the transpor,darius undzėnas becomes chief financial officer of novaturas group,management_changes,UP,0.9803912402207476,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,267,0.1513368983957219,0.8866002429130597,0.23737373737373735
jerusalem may 15 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and small therapeutic proteins today announced the appointment of rachel b wagman md face facp as key clinical advisor and member of its scientific advisory board dr wagman brings more than 20 years of metabolic bone disease and women s health research and drug development experience to entera she has successfully advanced the development of five molecules including the osteoporosis products teriparatide forteo denosumab prolia and romosozumab evenity through clinical development registration and lifecycle management,entera bio appoints dr rachel b wagman as key clinical advisor and scientific advisory board member,management_changes,DOWN,-1.593623984263234,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,2,8,409,0.13,0.6915109749530333,0.04140286796536797
south san francisco calif aug 08 2024 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today reported financial results for the second quarter and six months ended june 30 2024,rapt therapeutics reports second quarter 2024 financial results,financial_results,UP,1.659749395371494,145435008.0,6191111.0,99294.6,-0.137,87900.0,0.042569606074487926,0.09346626282280733,3,8,324,0.020833333333333332,1.6028075568485736,0.10170804685510566
new york april 04 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions today announced that management will participate in a virtual presentation at the 23rd annual needham virtual healthcare conference on thursday april 11 2024 at 9 30 a m et,ovid therapeutics to present at the 23rd annual needham virtual healthcare conference,conference_call_webinar,UP,1.3114741796192448,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,3,8,450,0.23409090909090907,0.7642184815786688,0.14862178637688842
draft decision proposed by the board of ab utenos trikotažas on the issues included in the agenda of the ordinary general meeting of shareholders draft decisiongrant thornton baltic uab to be the auditor of ab utenos trikotažas for the audit of the set of financial statements for the years 2024 2025 determine that the remuneration for the audit is as follows in the first year eur 32 900 plus vat in the second year eur 34 300 plus vat additional information is available from aurimas likus finance director tel no 370 618 07809 nomeda kaučikienė managing director of ab utenos trikotažas attachment attachments 1 voting ballot docx,draft decisions of the of shareholders meeting to be held on 03 october 2024,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,281,0.07500000000000001,0.8866002429130597,0.0
04 oct 2024 07 00 cest arcadis n v arcadis starts buyback program to repurchase up to 810 000 shares to cover employee incentive plan obligations amsterdam october 4 2024 arcadis euronext arcad the leading data driven global design consultancy organization for natural and built assets today announced the start of a share buyback program to repurchase up to 810 000 shares to cover existing and expected future obligations under arcadis employee incentive plans maturing in the next 3 4 years this is in line with arcadis commitment to avoid shareholder dilution from share based remunerations the repurchase of shares will commence on october 4 2024 and is expected to be completed no later than february 4 2025 the share buyback program will be executed within the parameters of the exemption for buyback programs provided by article 5 of regulation eu no 596 2014 and commission delegated regulation eu 2016 1052 the program will be executed by an intermed,arcadis starts buyback program to repurchase up to 810 000 shares to cover employee incentive plan obligations,changes_in_companys_own_shares,UP,0.7936507936507936,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,267,-0.014285714285714287,0.8866002429130597,0.0
26 sep 2024 15 02 cest brie picardie crcam rapport financier semestriel 2024 la caisse régionale de crédit agricole mutuel brie picardie compte au 30 juin 2024 206 agences de proximité 1 agence gestion de la relation à distance 2 agences crédit agricole en ligne 3 agences courtiers 1 agence habitat à distance 3 agences banque privée 5 centres d affaires entreprises 3 agences collectivités publiques 3 centres d affaires professionnels de l immobilier 2 pôles institutionnels et associations 3 équipes de conseillers mobiles assurances agriculteurs et professionnels 1 plateforme front office assurances agriculteurs et professionnels 1 plateforme allocation d actifs et gestion conseillée 1 banque d affaires 1 agence evènements de la vie 85 caisses locales 18 administrateurs de la caisse régionale 859 administrateurs de caisses locales plus de 433 000 sociétaires plus de 1 1 million de clients pièce jointe rapport financier semestriel 2024 rapport,crédit agricole brie picardie rapport financier semestriel 2024,financial_results,DOWN,-0.474321679287626,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
redwood city calif nov 17 2023 globe newswire rezolute inc nasdaq rzlt a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that the management team will participate in btig s 3rd annual ophthalmology day taking place virtually on november 27th,rezolute to participate in btig s 3rd annual ophthalmology day,conference_call_webinar,DOWN,-0.9888771398730164,376341760.0,77797779.0,825115.0,1.04,796000.0,0.20672109042589373,0.09346626282280733,4,8,589,-0.008333333333333331,0.6820409900648857,0.0
media release,announcement of net asset value of invl baltic real estate on 30 september 2024,fund_data_announcement,UP,0.8695644061371431,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,9,240,0.1,0.8866002429130597,0.1935657596371882
alvotech nasdaq alvo mun senda út tilkynningu með uppgjöri fyrir fyrstu níu mánuði ársins 2024 eftir lokun markaða í bandaríkjunum miðvikudaginn 13 nóvember nk þá mun alvotech halda kynningarfund um niðurstöðuna fyrir fjárfesta í beinu streymi fimmtudaginn 14 nóvember nk kl 13 00 að íslenskum tíma,alvotech mun birta uppgjör fyrstu níu mánaða ársins miðvikudaginn 13 nóvember nk og streyma uppgjörsfundi fimmtudaginn 14 nóvember nk kl 13 00 að íslenskum tíma,earnings_releases_and_operating_results,DOWN,-0.9259250401687472,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,2,8,241,0.0,0.44264539487962035,0.03921890866335311
immunocore reports first quarter financial results and provides a business update,immunocore reports first quarter financial results and provides a business update,financial_results,DOWN,-2.8178263350346566,1595419136.0,37423034.0,614630.0,0.835,788600.0,0.023456553300361067,0.09346626282280733,2,7,416,0.125,0.44240182162750774,0.1125
lexington mass june 25 2024 globe newswire t2 biosystems inc nasdaq ttoo a leader in the rapid detection of sepsis causing pathogens and antibiotic resistant genes today announced the execution of a territory exclusive distribution agreement in hong kong and macau under the terms of the agreement t2 biosystems will sell the t2dx instrument the t2bacteria panel the t2candida panel and the t2resistance panel through the newly appointed distributor,t2 biosystems announces commercial expansion through hong kong and macau distributor,geographic_expansion,DOWN,-0.9160369140381291,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,1,9,368,0.06818181818181818,1.9596557041969667,0.024839743589743585
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
cambridge mass april 29 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the acceptance of an oral presentation from the phase 1 portion of the ongoing ntla 2002 phase 1 2 study at the european academy of allergy and clinical immunology eaaci congress 2024 taking place may 31 june 3 in valencia spain ntla 2002 is an investigational in vivo crispr based gene editing therapy in development as a single dose treatment for hereditary angioedema hae a rare genetic condition that leads to potentially life threatening swelling attacks the presentation will include updated safety and efficacy results from the phase 1 study across all three dose cohorts 25 mg 50 mg and 75 mg,intellia therapeutics to present updated data from phase 1 2 study of ntla 2002 for the treatment of hereditary angioedema hae at the eaaci congress 2024,clinical_study,UP,1.4450830142245392,970293056.0,98412511.0,6353695.0,2.134,5288300.0,0.10142555426058826,0.09346626282280733,0,7,425,0.045714285714285714,0.7800307612939593,-0.06785714285714287
san diego april 22 2024 globe newswire cidara therapeutics inc nasdaq cdtx the company a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced that the company effected a reverse stock split of its issued and outstanding common stock at a ratio of 1 for 20 the effective time of the reverse stock split will be 5 p m et on april 23 2024 the company s common stock will begin trading on a split adjusted basis commencing upon market open on april 24 2024,cidara therapeutics announces reverse stock split,corporate_action,DOWN,-7.103823312288768,633963840.0,4118697.0,696580.0,0.795,3470400.0,0.006496738047393997,0.09346626282280733,0,8,432,0.02380952380952381,1.357695941787151,0.018855218855218858
west lafayette ind may 14 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that it will issue its financial results for the fiscal 2024 second quarter ended march 31 2024 on wednesday may 15 2024 after the close of the stock market the company will host a conference call that same day at 4 30 p m eastern time to discuss the results,inotiv inc to report fiscal 2024 second quarter financial results and host conference call on wednesday may 15 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,62350696.0,31206932.0,922240.0,4.102,583600.0,0.5005065540888268,0.09346626282280733,1,7,410,0.0,1.3015467599292592,0.03673469387755102
media release,aker horizons asa invitation to presentation of third quarter results 2024,clinical_study,DOWN,-3.2496329736071154,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,247,0.0,0.8866002429130597,0.13961675579322638
company to demonstrate mydcombi and avenova and share data for clobetasol propionate ophthalmic suspension 0 at the american society of cataract and refractive surgery ascrs annual meeting april 5 8 in boston,eyenovia to feature its suite of commercial products and the optejet dispenser at upcoming national eyecare meetings,trade_show,DOWN,-1.970953741106604,27891188.0,2433609.0,8930490.0,1.002,41800300.0,0.08725368743705,0.09346626282280733,2,7,451,0.0,2.4441832149286684,0.0
se vedhæftede,storaktionærmeddelelse,company_regulatory_filings,UP,0.5714285714285714,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,13,282,0.0,0.8866002429130597,0.0
data demonstrate lowest reported primary endpoint event rate of 1 through twelve months post procedure for any carotid stent or embolic protection device pivotal trial,inspiremd announces presentation of positive one year follow up results from the c guardians u s investigational device exemption ide clinical trial of cguard at linc 2024,clinical_study,UP,0.787400835704065,65865896.0,16849440.0,286250.0,0.613,4867100.0,0.2558143291636084,0.09346626282280733,1,8,396,0.3757575757575758,0.6085732039686736,0.07759090909090909
more than 200 patients enrolled in ongoing shield ii phase 3 trial of d plex100 for the prevention of abdominal colorectal surgical site infections,polypid provides corporate update and reports first quarter 2024 financial results,clinical_study,UP,0.781885368939005,37502512.0,4610773.0,1395250.0,1.25,337200.0,0.12294571094330961,0.09346626282280733,2,7,416,0.1875,0.7168605096826995,-0.065550308277581
current cfo john gandolfo to remain with the company through november as part of planned retirement transition current cfo john gandolfo to remain with the company through november as part of planned retirement transition,eyenovia announces appointment of experienced finance and accounting executive andrew jones as chief financial officer,management_changes,UP,1.8181800448205243,27751082.0,2433609.0,8930490.0,1.002,41800300.0,0.08769420233776831,0.09346626282280733,1,7,298,0.2,2.4441832149286684,-0.003748045935545933
ad hoc announcement pursuant to art 53 lr,santhera announces half year 2024 financial results and provides corporate update,financial_results,DOWN,-2.766398067949684,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,3,1,289,-0.05555555555555555,0.5209522992128177,0.07142857142857142
strategic partnership aims to further develop cube s award winning ai guided platform for software as a service saas for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring for improved health outcomes strategic partnership aims to further develop cube s award winning ai guided platform for software as a service saas for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring for improved health outcomes,personalaize and cube forge groundbreaking partnership to accelerate ai driven healthcare platform and point of care diagnostics,partnerships,UP,9.242146234319629,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,3,9,282,0.16285714285714287,1.5631250973582267,0.06648302218614718
communiqué du 22 octobre 2024,offre publique d achat visant les actions de la société eurobio scientific initiée par la société eb development communiqué de mise à disposition du public de la note en réponse de la société eurobio scientific sa,clinical_study,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,10,248,0.0,0.4336088389568585,-0.0031055900621118006
media release,cenergy holdings fait état de l avancement de son programme de rachat d actions propres,changes_in_companys_own_shares,UP,2.441860800372244,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
media release,chiffre d affaires de capgemini au 3ème trimestre 2024,earnings_releases_and_operating_results,DOWN,-1.7892695828851255,24334401536.0,169611141.0,417051.0,0.951,403238.0,0.006970014888144237,0.19535099655549074,2,7,241,0.0,0.29691516676147794,0.0
dallas sept 17 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today provided an outline of its regulatory pathway strategy to enter the u s market with its flagship deepview system for burn indication deepview ai burn,spectral ai outlines u s regulatory pathway for deepview system for burn indication,regulatory_filings,UP,0.8064508376086847,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,1,8,284,0.07500000000000002,0.9904696515070965,0.056749259512417424
elx 02 treatment improved podocyte foot process effacement in all three patients by an average of based on a blinded kidney biopsy analysis by nipoka gmbh,eloxx pharmaceuticals reports additional confirmation that all nonsense mutation alport syndrome patients treated with elx 02 in phase 2 study had improvement in kidney morphology and clinical benefit of reduction or stabilization of proteinuria,clinical_study,DOWN,-0.4629625030505988,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,0,8,628,-0.15,2.2721670857062097,0.10655505364201018
media release,delisting of kindred group plc,exchange_announcement,DOWN,-0.390625,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,14,242,0.0,0.8866002429130597,0.0
10 oct 2024 07 00 cest bw lpg limited singapore 10 october 2024 bw lpg limited bw lpg or the company ose ticker code bwlpg ol nyse ticker code bwlp today provides an update on its product services bw product services q3 2024 segment performance for the quarter ended 30 september 2024 bw product services reported an estimated gross profit of approximately usd 71 million this gross profit was mainly a result of usd 86 million of unrealised marked to market value of open cargo contracts and hedging transactions realised trading gains of usd 16 million offset by hedging loss of usd 31 million on the realised positions the open cargo value is reflected in the overall trading book value and will be gradually revalued and realised in the next 12 months as per standard methodology after general and administrative expenses and income taxes bw product services reported an estimated net profit of approximately usd 60 million for the quarter the a,bw lpg limited update on bw lpg s product services q3 2024 segment performance,earnings_releases_and_operating_results,UP,2.752293577981652,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,261,-0.04360119047619048,0.8866002429130597,0.0
globally renowned alport syndrome experts will provide key insights,eloxx pharmaceuticals to host investor and analyst call on alport syndrome,clinical_study,DOWN,-7.103823312288768,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,13,737,0.0,2.2721670857062097,0.2181746031746032
resultat du 1er semestre 2024,eurobio scientific resultat du 1er semestre 2024,financial_results,UP,0.2003977376017373,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,12,276,0.0,0.4336088389568585,0.005602240896358544
according to the previous agm resolution the chairman of the board has consulted with the company s four largest shareholders for a nomination committee the nomination committee will prepare proposals for the annual general meeting 2025 regarding chairman of the agm board of directors chairman of the board and auditors the nomination committee will also prepare proposals concerning fees to the board of directors and auditors and remuneration for committee work the nomination committee appointed for the 2025 annual general meeting in hms networks ab publ consists of the following members johan menckel investment ab latour chairmansophie larsén amf fonderanette dahlberg första ap fondenstaffan dahlström private shareholdingcharlotte brogren chairman of the board the four owner representatives in the nomination committee represent in total 52 percent of the votes of all shares in the company based on ownership as of august 31 2024 the nomination committee s proposals,nomination committee appointed in hms networks ab publ,annual_general_meeting,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,8,267,-0.011111111111111105,0.8866002429130597,0.0
new york july 30 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions today announced that management will participate in two upcoming investor conferences in august,ovid therapeutics to present at upcoming august investor conferences,conference_call_webinar,DOWN,-0.9523800873701952,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,1,8,333,0.21266233766233766,0.7642184815786688,0.15311997526283241
reveal adolescent and adult trial will proceed to high dose cohort following independent data monitoring committee approval of company s request to initiate dose escalation dosing of first patient in cohort two high dose n 3 expected in q2 2024,taysha gene therapies announces updates to tsha 102 clinical program in rett syndrome,clinical_study,UP,2.6515125174716108,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,3,8,485,0.08142857142857143,1.0149166236087122,0.0
guggenheim s inaugural healthcare innovation conference nov 11 13,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,3,240,0.0,0.5536010581445269,0.0
media release,nekkar asa subsidiary wins naval ship transfer system contract,business_contracts,UP,2.669406930098804,1031056768.0,50858000.0,57696.85,0.461,92406.0,0.04932609103439783,0.1515999603296736,2,8,241,0.3,0.35598282350474375,0.0
the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases,neximmune announces research collaboration with national institute of neurological disorders and stroke ninds of the national institutes of health nih,partnerships,DOWN,-0.7692307692307693,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,996,0.0,2.2666992986423327,0.0
dallas july 15 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today provided an update on its ongoing initiatives to expose what it believes is potential market manipulation of the company s common stock primarily in the form of naked short selling,spectral ai continues support of naked short selling inquiry,law_legal_issues,UP,0.5291000285156192,55225816.0,17924135.0,466020.0,0.698,473400.0,0.3245607996086468,0.09346626282280733,0,8,348,0.036363636363636376,0.9904696515070965,0.12486291486291488
palo alto calif oct 16 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that its board of directors has authorized management to explore ways to maximize the value of its wholly owned subsidiary scilex pharma including by way of conducting a spinoff or public listing of securities of scilex pharma in markets and on securities exchanges outside of the u s including hong kong and or a potential strategic transaction or dividend of scilex pharma common stock to scilex stockholders,scilex holding company announces that its board of directors has authorized management to explore ways to maximize the value of its wholly owned subsidiary scilex pharmaceuticals inc including by way of conducting a spinoff or public listing of securities of scilex pharmaceuticals inc scilex pharmaceuticals commercial products include three non opioid approved products and pipeline of phase 3 ready sp 103 with greater than a 1 0 billion revenue potential,corporate_action,UP,5.198019089862187,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,7,255,0.13636363636363635,1.0327724261931344,0.23560295632306505
planegg martinsried july 23 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today announced the presentation of two posters at the esmo congress 2024 being held on september 13 17 2024 in barcelona spain the posters will be showcasing recent advancements in the company s library of t cell receptors tcr targeting kirsten rat sarcoma viral oncogene homologue kras as well as its unitope tracr technology a universal tagging and tracking system for tcr t cells,medigene to present at esmo congress 2024,clinical_study,UP,0.8658000615553437,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,5,340,0.0,1.3169799228985475,0.04044864226682409
san diego july 31 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that gsk has received u s food and drug administration fda approval for jemperli dostarlimab gxly plus carboplatin and paclitaxel chemotherapy for the treatment of adult patients with mismatch repair deficient dmmr microsatellite instability high msi h primary advanced or recurrent endometrial cancer the supplemental biologics license application sbla supporting this new indication received priority review and was approved ahead of the sept 23 2023 prescription drug user fee act action date,anaptysbio and gsk partnered immuno oncology agent jemperli dostarlimab gxly plus chemotherapy approved in the u s for dmmr msi h primary advanced or recurrent endometrial cancer,clinical_study,UP,9.242146234319629,685153280.0,17605381.0,784220.0,-0.266,445700.0,0.02569553633312534,0.09346626282280733,0,13,697,0.22239669421487604,0.871343469962729,0.0
saint herblain france september 13 2024 valneva se nasdaq valn euronext paris vla valneva or the company a specialty vaccine company today announces the successful pricing of its private placement as defined below for a final amount of 61 180 000,valneva announces the success of its private placement raising approximately 60 million,shares_issue,DOWN,-7.103823312288768,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,4,2,288,0.10833333333333332,0.6494694268312979,0.031907308377896605
g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,conference_call_webinar,DOWN,-4.402516540601384,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,10,449,0.0,0.8866002429130597,0.0
baltic horizon fund the issuer applies for temporary waiver of debt service coverage ratio covenant in relation to baltic horizon fund eur 42 million 5 year floating rate bonds maturing in 2028 isin ee3300003235 the bonds the current outstanding nominal amount of the bonds is eur 22 000 000 as baltic horizon fund has mandatorily redeemed bonds in nominal amount of eur 20 000 000 as foreseen under the terms and conditions of the bonds terms and conditions in the light of the current situation of baltic economies the outlook for next year as well as the associated effects on the fund baltic horizon fund has decided to request the holders of the bonds the holders to amend and lower the debt service coverage ratio covenant in the terms and conditions for a period of 24 months starting from 30 september 2024 until 30 september 2026 baltic horizon fund confirms to all holders that its ability to fulfil the monetary obligations provided in the terms and conditions has not been,baltic horizon fund requests for partial early redemption and temporary waiver under the bond terms and conditions,financing_agreements,UP,1.0101081051682848,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.1125,0.8866002429130597,0.06515151515151515
media release,resolutions of the general extraordinary shareholders meeting of invl baltic real estate,corporate_action,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19444444444444442,0.8866002429130597,0.18537414965986393
25 sep 2024 08 01 cest see attachment s voir document s joint s zie bijlage ver documento s em anexo 16165_1286167_pressrelease_cnp_assurances__shareholding_in_cnp_unicredit_vita_25 09 24 pdf cnp assurances les echos,cnp assurances shareholding in cnp unicredit vita,press_releases,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,276,0.0,0.8866002429130597,0.0
kraig labs otcqb kblb expanded its production of spider silk with the creation of the next generation of bam 1 hybrid,kraig biocraft laboratories increases spider silk production with next generation of hybrid eggs completed,product_services_announcement,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,1,7,368,0.0,0.8071333009212691,0.14897186147186145
som annonceret i selskabsmeddelelse 14 2024 ønsker selskabet løbende at foretage kapitalrejsninger via rettede emissioner for at kunne understøtte selskabets fremtidige strategi og for at få en større kritisk masse til at dække selskabets faste omkostninger,kapitalforhøjelse ved rettet emission,shares_issue,UP,0.5714285714285714,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,12,282,0.0,0.8866002429130597,0.0
media release,scandic s interim report for the third quarter 2024 good quarter stable bookings and capital returns to shareholders,earnings_releases_and_operating_results,DOWN,-0.0684504444474616,21665896.0,45859984.0,7124020.0,1.612,2186300.0,2.1166899351866175,0.1515999603296736,2,7,241,0.35,0.961003290910132,0.16111111111111112
new york march 08 2024 globe newswire tg therapeutics inc nasdaq tgtx today announced the schedule of data presentations highlighting data from the ultimate i ii phase 3 trials evaluating briumvi ublituximab xiiy in patients with relapsing forms of multiple sclerosis rms at the upcoming american academy of neurology 2024 annual meeting being held april 13 18 2024 in dever colorado abstracts are now available online and can be accessed on the aan meeting website at https www aan com msa public events index 49 details of the upcoming presentations are outlined below,tg therapeutics announces schedule of data presentations for briumvi ublituximab in multiple sclerosis at the american academy of neurology 2024 annual meeting,clinical_study,UP,1.166661580403646,5889810432.0,135060602.0,1756590.0,1.939,1677400.0,0.022931230734728,0.09346626282280733,4,7,477,0.06704545454545455,0.6256004090066075,0.04199134199134199
santa ana calif oct 17 2023 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer cell therapeutics today presented a poster with interim phase i trial data on the use of its investigational nk cell therapy snk01 to treat patients with alzheimer s disease ad at the xxvi world congress of neurology wcn annual meeting in montreal qc canada and online,nkgen biotech presents interim phase i trial data at the xxvi world congress of neurology wcn annual meeting 2023,clinical_study,DOWN,-1.9999980926513672,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,1,8,620,0.3,2.657355742098314,0.3
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
san diego and suzhou china oct 09 2024 globe newswire adagene inc adagene nasdaq adag a company transforming the discovery and development of novel antibody based therapies today announced poster presentations at the upcoming sitc 39th annual meeting taking place in houston nov 6 10 2024,adagene announces upcoming poster presentations on masked anti ctla 4 safebody adg126 muzastotug at society for immunotherapy of cancer sitc 39th annual meeting,clinical_study,DOWN,-3.9946135377027217,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,2,6,262,0.0,0.845882180665701,0.12332057823129253
media release,missing,bond_fixing,DOWN,-0.8217465719567179,50104786944.0,180674806.0,194732.25,1.288,311574.0,0.0036059390134106865,0.1515999603296736,3,14,239,-0.2,0.42045203073713133,-0.2
media release,cantargia reports new results from clinical studies investigating nadunolimab in several forms of cancer supporting ongoing strategies,clinical_study,UP,5.191255184260595,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,14,242,0.12878787878787878,0.8866002429130597,0.24795454545454548
appointment brings more than 30 years of medical technology general management and commercial leadership experience to the inspiremd team,inspiremd announces appointment of medical technology executive pete ligotti as executive vice president and general manager of north america,management_changes,DOWN,-2.9520266634666377,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,2,7,542,0.10000000000000002,0.6085732039686736,0.10267045454545454
media release,xano delårsrapport 1 januari 30 september 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,3523049728.0,15958705.0,22093.78947368421,0.619,17473.0,0.004529798394035044,0.1515999603296736,3,14,239,0.0,0.4615949135995517,0.0
media release,akastor asa resultat for tredje kvartal 2024,financial_results,UP,1.6081820792888155,3347887616.0,49279280.0,50456.2,0.215,44471.0,0.014719514407977068,0.1515999603296736,2,7,241,0.0,0.29384574384909407,0.0
media release,påminnelse om tegningsfrist for egenkapitalutvidelsen i morgen kl 08 00,shares_issue,DOWN,-7.103823312288768,31593468.0,146986679.0,21417158.75,0.312,14709376.0,4.652438883885745,0.1515999603296736,2,14,240,0.0,20.184452026301216,0.0
palo alto calif june 13 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced it will be presenting a poster on elyxyb celecoxib oral solution at the 66th annual scientific meeting of the american headache society ahs to be held in san diego ca on june 13 16 2024,scilex holding company to present poster on elyxyb celecoxib oral solution at the 66th annual scientific meeting of the american headache society ahs to be held in san diego ca on june 13 16 2024,product_services_announcement,UP,2.083331263727694,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,380,0.22000000000000003,1.0327724261931344,0.0
alvotech nasdaq alvo tilkynnti í dag að matvæla og lyfjaeftirlit bandaríkjanna fda hefði veitt félaginu leyfi til sölu og markaðssetningar í bandaríkjunum á selarsdi ustekinumab aekn í áfylltu hettuglasi 130 mg 26 ml sem notað er til að hefja meðferð sjúklinga með crohns sjúkdóminn eða sáraristilbólgu selarsdi er líftæknilyfjahliðstæða alvotech við stelara ustekinumab og er áformað að hún komi á markað í bandaríkjunum í febrúar á næsta ári alvotech var fyrst til að markaðssetja hliðstæðu við stelara og er lyfið þegar komið á markað í kanada japan og evrópu,alvotech veitt aukið markaðsleyfi í bandaríkjunum fyrir selarsdi ustekinumab aekn líftæknilyfjahliðstæðu við stelara til meðferðar sjúkdóma í meltingarvegi,clinical_study,DOWN,-0.5714260801977041,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,1,7,249,0.0,0.44264539487962035,0.05175282234105764
proposed listing on nasdaq with radx ticker symbolform 20 f registration filed with securities and exchange commissiontrading expected to commence late march 2023,radiopharm theranostics initiates process for nasdaq listing,regulatory_filings,UP,3.8458964129017255,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,1,8,865,-0.2,0.9771277191333917,0.0
durham n c sept 03 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale today announced that laura niklason m d ph d founder president and chief executive officer and dale sander chief financial officer will represent humacyte at the following conferences in september,humacyte to participate at upcoming investor conferences in september,conference_call_webinar,DOWN,-0.8264494075791097,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,1,8,298,0.0,1.1173068527438073,0.0644854797979798
sydney australia sept 16 2024 globe newswire immutep limited asx imm nasdaq immp immutep or the company a clinical stage biotechnology company developing novel lag 3 immunotherapies for cancer and autoimmune disease today announces positive efficacy and safety results from the tacti 003 phase iib trial evaluating eftilagimod alpha efti in combination with msd s merck co inc rahway nj usa anti pd 1 therapy keytruda pembrolizumab as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients 1l hnscc,immutep s efti in combination with msd s keytruda leads to positive efficacy with favourable safety in first line head and neck cancer,clinical_study,DOWN,-7.103823312288768,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,0,8,285,0.17662337662337663,0.7476881311953882,0.10271249914107056
geneva switzerland march 14 2024 addex therapeutics six adxn a clinical stage pharmaceutical company pioneering allosteric modulation based drug discovery and development announced today that ceo tim dyer will present at the bio europe spring 2024 conference taking place march 18 20 2024 in barcelona spain dr robert lütjens head of discovery biology will also be attending this event,addex to present at the bio europe spring 2024 conference,conference_call_webinar,UP,2.9411746937130423,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,3,2,471,0.0,0.972373032385036,-0.046666666666666655
conference call begins today at 11 00 a m eastern time,imunon reports first quarter 2024 financial results and provides business update,conference_call_webinar,UP,2.898547970379774,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,411,0.125,2.964855117372811,0.04058948863636363
rockville md may 16 2024 globe newswire opgen inc nasdaq opgn opgen or the company today announced that the company s board of directors has approved a 1 for 10 reverse stock split of its shares of common stock the reverse stock split the reverse stock split will become effective at 12 01 a m est on may 20 2024 and the company s common stock will open for trading on the nasdaq capital market on a post split basis under the company s existing trading symbol opgn the new cusip number for the company s common stock following the reverse stock split will be 68373l505,opgen announced 1 for 10 reverse stock split,corporate_action,DOWN,-4.328019658291313,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,408,-0.023376623376623377,1.807174583649316,0.0884378121878122
50mg p 0 001 and 28mg p 0 07 efx groups demonstrated 1 stage improvement in fibrosis without worsening of mash approximately three and two fold the placebo rate,akero therapeutics reports statistically significant histological improvements at week 96 in phase 2b harmony study,clinical_study,UP,9.242146234319629,4365335552.0,65983030.0,1904080.0,-0.16,4370200.0,0.015115225213275884,0.09346626282280733,0,6,481,-0.012500000000000011,1.1395320392459187,0.01323456790123457
los angeles ca jan 24 2024 globe newswire immix biopharma inc immix biopharma company we or us nasdaq immx a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced a statement on january 2024 fda labeling change notifications for approved car t products,immix biopharma statement on january 2024 fda labeling change notification for approved car t products,clinical_study,DOWN,-1.9148867958104072,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,2,8,521,0.0,0.9253604538231538,-0.15000000000000002
new york aug 13 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions today reported business updates and financial results for the second quarter ended june 30 2024,ovid therapeutics reports business updates and second quarter 2024 financial results,financial_results,DOWN,-0.5917224457964548,21752398.0,50354780.0,1012130.0,0.065,720700.0,2.3149070736936683,0.09346626282280733,1,8,319,0.07272727272727272,0.7642184815786688,0.16675896722325292
santa ana calif march 04 2024 globe newswire nkgen biotech inc nasdaq nkgn nkgen or the company a clinical stage biotechnology company focused on the development and commercialization of innovative autologous allogeneic and car nk natural killer nk cell therapeutics today announced the acceptance of an abstract for presentation on the effect of snk01 nk cell therapy on csf proteins plasma proteins and cognitive function in patients with advanced alzheimer s disease the data will be presented at the tau2024 global conference held march 25 26 2024 virtually and at the westin washington dc downtown in washington d c,nkgen biotech announces upcoming presentation on snk01 in alzheimer s disease at the tau2024 global conference,clinical_study,UP,0.0,16445044.0,10616620.0,134195.0,1.199,86400.0,0.6455817327092588,0.09346626282280733,0,8,481,0.2,2.657355742098314,0.225
results presented at the department of defense s military health system research symposium mhsrs,humacyte presents positive long term results of atev in treatment of vascular trauma in military setting from ukraine humanitarian program,clinical_study,DOWN,-1.2765978745102613,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,305,-0.005681818181818191,1.1173068527438073,0.08202730429292929
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions alsaker sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name knut arne alsakerposition chief financial officerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80013 5 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 3 018 unit price 41 9316 eur aggregated transactions 1 volume 3 018 volume weighted average price 41 9316 eur____________________________________________ tra,sampo plc managers transactions alsaker,regulatory_filings,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.061111111111111116,0.8866002429130597,0.1625
malvern pa may 09 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today announced successful completion of data cleaning for its phase iii study of buntanetap in patients with early parkinson s disease pd topline efficacy data is expected in june,annovis announces unblinding of the buntanetap phase iii data in parkinson s disease,clinical_study,UP,5.80912288380023,44136244.0,15624645.0,595065.0,1.618,805900.0,0.35400939418406335,0.09346626282280733,3,7,415,0.25,1.368989555493872,0.07705026455026454
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
dallas sept 24 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it has achieved patient enrollment at emergency departments ed for its u s burn pivotal study and added two new ed clinical trial sites for this study medstar washington hospital center in washington dc led by principal investigator shawn tejiram md and the university of utah led by principal investigator giavonni lewis md facs the addition of these two clinical research sites expands participating eds to 11 facilities,spectral ai achieves patient enrollment at emergency departments for u s burn pivotal study and adds two new clinical trial sites,clinical_study,UP,2.9702942250534496,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,1,8,277,0.16363636363636364,0.9904696515070965,0.05766179653679655
media release,neste appoints a new leadership team and eeva sipilä as cfo,management_changes,DOWN,-1.0480036062946114,8842487808.0,419729896.0,3546183.5,1.115,2479992.0,0.04746739889426376,0.1515999603296736,0,8,243,0.13636363636363635,0.4498875103976574,0.0
turku finland and boston april 16 2024 globe newswire faron pharmaceuticals ltd faron or the company aim farn first north faron a clinical stage biopharmaceutical company pursuing a clever approach to reprogramming myeloid cells to activate anti tumor immunity in hematological and solid tumor microenvironments today announces ongoing plans and activities for the coming months following the recent announcement of the proposed appointment of dr juho jalkanen as chief executive officer effective 1 may 2024,faron confirms plans for the coming months under new leadership,clinical_study,UP,3.3149239497397813,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,2,438,0.16471861471861468,0.7633342480324978,0.03540603402445508
boston jan 17 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced a trial in progress poster presentation on the phase 1 2 amplify 7p study design at the asco gastrointestinal cancers asco gi symposium being held january 18 20 2024 in san francisco ca,elicio therapeutics to present eli 002 7p amplify 7p trial in progress poster on phase 1 2 study of lymph node targeted vaccine at asco gi symposium,clinical_study,UP,1.893937512479722,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,2,8,528,0.0,0.8558055682194762,0.05875386518243662
biovascular pancreas bvp product candidate is under development as a potential treatment for type 1 diabetes,humacyte presents positive preclinical data for its biovascular pancreas bvp program,clinical_study,UP,0.0,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,1,8,368,0.11363636363636363,1.1173068527438073,0.07764450056116723
ad hoc mitteilung gemäss art 53 kr,santhera veröffentlicht einladung zur ordentlichen generalversammlung,annual_general_meeting,DOWN,-0.6410199587943396,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,396,0.0,0.5209522992128177,0.0
tampa fla july 23 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its second quarter financial results after the close of the u s markets on tuesday july 30 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report second quarter 2024 financial results on tuesday july 30 2024,conference_call_webinar,DOWN,-0.3463616922080888,1112470400.0,45834212.0,557500.0,0.511,435200.0,0.041200387893466646,0.09346626282280733,1,8,340,0.022727272727272724,0.7130794063724827,0.1496315836940837
media release,fiskars oyj abp n suunnattu maksuton osakeanti ehdollisen osakepalkkiojärjestelmän perusteella,shares_issue,DOWN,-2.9754206792492868,1157121792.0,36127016.0,13413.65,0.866,11916.0,0.03122144639377771,0.1515999603296736,1,9,242,0.0,0.21141844058764958,0.0
san diego oct 17 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced the pricing of its underwritten offering of 4 412 000 shares of common stock at a public offering price of 17 00 per share capricor also granted the underwriters a 30 day option to purchase up to an additional 661 800 shares of its common stock at the public offering price less the underwriting discounts and commissions the offering is expected to close on october 18 2024 subject to the satisfaction of customary closing conditions,capricor therapeutics announces pricing of approximately 75 million public offering of common stock,shares_issue,DOWN,-5.850808140165851,433538464.0,40176259.0,3124730.0,0.85,8768900.0,0.09267057559165039,0.09346626282280733,3,6,254,-0.13030303030303034,1.3427880947904531,0.11682888669301712
certara today unveiled its next generation coauthor regulatory writing software coauthor is an advanced writing platform designed for medical writers,certara launches next generation coauthor generative ai regulatory writing software,product_services_announcement,UP,0.3357907045513833,1740770688.0,121837605.0,1806725.0,1.448,1507200.0,0.06999061153768692,0.09346626282280733,0,8,376,0.1,0.5462989777603723,0.04727272727272728
seattle feb 07 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will participate in a virtual h c wainwright home fireside chat series on february 13 2024 shawn iadonato ph d chief executive officer of kineta and thierry guillaudeux ph d chief scientific officer of kineta will present an overview of recent clinical results of kva12123 the company s vista blocking immunotherapy in development for patients with advanced solid tumors,kineta to participate in h c wainwright virtual home fireside chat series,clinical_study,DOWN,-1.372543061434859,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,507,0.1,0.8866002429130597,0.15302257266542982
moonlake immunotherapeutics announces positive regulatory feedback from both fda and ema on path for the phase 3 program for the nanobody sonelokimab in psoriatic arthritis,moonlake immunotherapeutics announces positive regulatory feedback from both fda and ema on path for the phase 3 program for the nanobody sonelokimab in psoriatic arthritis,clinical_study,DOWN,-0.7199406053349006,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,0,8,383,0.22727272727272727,0.5366763308656862,0.05518939393939394
this class of serca2a activators selectively activates serca2a and may lead to novel therapies for heart failure beyond the company s current lead program this class of serca2a activators selectively activates serca2a and may lead to novel therapies for heart failure beyond the company s current lead program,windtree therapeutics announces issuance of new pure serca2a activator patent,patents,UP,3.2608751989269087,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,3,8,590,-0.04711399711399711,2.339794177443606,0.0
preclinical data demonstrate that inhibiting the p300 kat domain reactivates p53 in hpv driven tumors resulting in anti tumor activity preclinical data demonstrate that inhibiting the p300 kat domain reactivates p53 in hpv driven tumors resulting in anti tumor activity,kronos bio data presentation at eortc nci aacr symposium highlights the importance of p300 kat inhibition in hpv driven tumors,clinical_study,UP,6.6666671081825655,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,2,8,248,0.0,0.6178272804340184,0.038616085093357816
new york march 05 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough neuro immunomodulation therapies today announced that dr howard weiner will present positive data of intranasal anti cd3 monoclonal antibody in models of alzheimer s and parkinson s disease at ad pd march 5 9 2024 ad pd is the annual international conference on alzheimer s and parkinson s diseases and related neurological disorders in lisbon portugal,tiziana life sciences announces podium presentation at ad pd of nasal anti cd3 in alzheimer s disease,clinical_study,DOWN,-2.127657550770317,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,7,480,0.07272727272727272,1.1109140250580023,0.05000000000000001
latvian financial technology or fintech company delfingroup announces that it has successfully raised 15 million euros at a fixed interest rate of in a public bond offering total demand for the bonds was significantly higher at 22 3 million euros from more than 2 700 retail and institutional investors exceeding the initial offering by 1 5 times didzis ādmīdiņš chairman of the management board of delfingroup says we have not only achieved but also significantly exceeded our target total demand for bonds was almost higher than the issue size the company now has 9 500 shareholders who have shown their confidence in delfingroup and more than 3 000 bondholders their high level of interest is a clear signal of confidence in our company its solid business model and strong corporate governance thanks to the bondholders for this confidence the majority of the 2 700 investors come from estonia but in terms of investment of all demand comes from latvian investo,delfingroup bond issue is 1 5 times oversubscribed demand reaches 22 3 million euros,financing_agreements,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,283,0.1904385964912281,0.8866002429130597,0.2222222222222222
company to rededicate efforts toward updating stakeholders oncorporate vision strategy and ongoing activities,medicinova chief business officer david h crean ph d assumes communications role overseeing investor engagement and public relations,press_releases,UP,3.053441435840466,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,3,6,373,0.0,0.8018560055721619,0.06033189033189033
amsterdam sept 13 2024 globe newswire nasdaq renb renovarocube cube the company a leading ai driven innovator using multi omics technology for cancer profiling is pleased to announce two scientific presentations at a leading cancer conference the european society for medical oncology esmo congress on september 15 2024,renovarocube to present cutting edge cancer diagnostics research at european society for medical oncology congress,conference_call_webinar,DOWN,-2.0933996157467987,60224444.0,90925076.0,7542515.0,0.529,816400.0,1.50977028530143,0.09346626282280733,4,9,288,-0.014285714285714282,1.5631250973582267,0.07979998396665063
resultat annuel 2023,eurobio scientific resultat annuel 2023,earnings_releases_and_operating_results,UP,0.4975119657066306,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,11,443,0.0,0.4336088389568585,0.0
herbicide technology critical to enabling large acreage adoption of camelina in north america herbicide technology critical to enabling large acreage adoption of camelina in north america,usda aphis determines that yield10 bioscience s stacked herbicide tolerant camelina may be planted and bred in the united states,regulatory_filings,DOWN,-6.451613109971017,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,591,0.10714285714285714,0.8866002429130597,0.10303571428571429
lexington mass june 25 2024 globe newswire t2 biosystems inc nasdaq ttoo a leader in the rapid detection of sepsis causing pathogens and antibiotic resistant genes today announced the execution of a territory exclusive distribution agreement in hong kong and macau under the terms of the agreement t2 biosystems will sell the t2dx instrument the t2bacteria panel the t2candida panel and the t2resistance panel through the newly appointed distributor,t2 biosystems announces commercial expansion through hong kong and macau distributor,geographic_expansion,DOWN,-0.9160369140381291,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,1,9,368,0.06818181818181818,1.9596557041969667,0.024839743589743585
on 27 09 2024 eften paemurru oü a subsidiary of the eften real estate fund as signed a contract under law of obligation with teearu arenduse oü a member of the restate group for the acquisition of a property located on paemurru tee 3 laabi village harju county harku municipality near tallinn in cooperation with eventus ehitus oü the fund will construct an iconfit production trade and warehouse building on the property eventus ehitus oü started construction in july 2024 and completion of the building is planned by the end of april 2025 the investment is financed from the fund s equity and from the loan agreement to be signed with as seb pank completion of the purchase transaction is planned by the end of this year at the latest total investment of the fund will be 5 9 million euros plus vat the tenant of the property is iconfit european foods oü the leading sports diet and healthy food manufacturer in the baltic states who will after the completion of the buil,establishment of a subsidiary and construction of the iconfit production and warehouse on the property purchased from the restate group,capital_investment,UP,0.271745355683728,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,5,271,0.21666666666666667,0.8866002429130597,0.10310470779220782
media release,recording of lhv group s 22 october investor webinar,clinical_study,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
arcutis today announced the commercial launch of zoryve roflumilast cream 0 for the treatment of mild to moderate atopic dermatitis,arcutis launches zoryve roflumilast cream 0 for the treatment of atopic dermatitis,product_services_announcement,DOWN,-0.09929767140568,1727832960.0,85869346.0,2010100.0,1.778,2359700.0,0.04969771267704026,0.09346626282280733,0,7,334,0.1111111111111111,0.6903751128737089,0.0764750681417348
media release,le premier vêtement biorecyclé 100 fibre à fibre du monde dévoilé par carbios on patagonia puma pvh corp et salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
bong ab publ bolaget meddelar idag att bolaget har initierat ett skriftligt förfarande det skriftliga förfarandet bland obligationsinnehavarna av sina utestående obligationer utgivna i oktober 2021 med isin se0016829642 obligationerna i enlighet med villkoren för obligationerna genom att instruera nordic trustee agency ab publ agenten i egenskap av agent under obligationerna att skicka ett meddelande om skriftligt förfarande inklusive röstningsinstruktioner till direktregistrerade ägare och registrerade förvaltare av obligationerna i bolagets skuldbok förd av euroclear sweden per den 24 september 2024 i det skriftliga förfarandet efterfrågas obligationsinnehavarnas godkännande att justera villkoren för obligationerna rörande en förlängning av obligationernas löptid samt vissa följdändringar av detta och att bolaget över tid har eller kommer att återköpa vissa obligationer över marknaden för mer information om det skriftliga förfarandet och en mer detaljerad be,bong ab publ initierar skriftligt förfarande i syfte att ändra villkoren för utestående obligationer med isin se0016829642,bond_fixing,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,276,-0.16666666666666666,0.8866002429130597,0.0
needham mass dec 12 2023 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the u s food and drug administration fda granted fast track designation for its lead investigational adenovirus asset can 2409 plus prodrug valacyclovir for the treatment of patients with pancreatic ductal adenocarcinoma pdac to improve overall survival,candel therapeutics receives fda fast track designation for can 2409 in pancreatic cancer,clinical_study,UP,9.242146234319629,243749632.0,41997569.0,917740.0,-0.866,856900.0,0.17229797910012845,0.09346626282280733,1,8,564,0.13333333333333333,1.2870358800144117,-0.012959001782531194
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
philogen new production facility in rosia has received the gmp certificate by competent authorities,philogen s p a announces receipt of the good manufacturing practice certificate for its new production facility in rosia siena italy by competent authorities,company_regulatory_filings,DOWN,-2.762430881006422,926076608.0,35018869.0,31367.18181818182,0.152,19588.0,0.25000035609542787,0.09346626282280733,1,2,571,0.39454545454545453,0.3376005673725286,0.22613636363636364
media release,circio holding asa registration of share capital increase following conversion of convertible bonds,share_capital_increase,DOWN,-7.103823312288768,112574064.0,35018869.0,1395416.9473684211,0.8755,515815.0,0.25000035609542787,0.1515999603296736,3,10,239,0.0,3.1777118544203193,0.0
media release,argan completed its bolbec logistics parc normandy,geographic_expansion,UP,0.2894422316255524,1612706688.0,12060258.0,31954.954545454544,0.782,14598.0,0.0074782712130725655,0.1515999603296736,1,7,242,0.0,0.2170511352010478,0.0
dear sirs transactions with shares in sydbank by managers and closely associated persons under article 19 of the market abuse regulation sydbank makes public transactions with shares in the bank conducted by managers and persons closely associated with them reference is made to the attached table showing detailed information about the transaction yours sincerely sydbank a s attachments attachments attachment jrn adam mller pdf attachment stig westergaard pdf,transactions with shares in sydbank by managers and closely associated persons,changes_in_companys_own_shares,UP,0.7430321660942337,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,268,0.3,0.8866002429130597,0.0
the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases the collaboration will explore ebv and htlv 1 antigen specific immune responses in immunological diseases,neximmune announces research collaboration with national institute of neurological disorders and stroke ninds of the national institutes of health nih,partnerships,DOWN,-0.7692307692307693,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,3,7,996,0.0,2.2666992986423327,0.0
mainz biomed partners with liquid biosciences to leverage the power of ai for the expansion and optimization of biomarker selection for pancalert,mainz biomed partners with liquid biosciences to leverage the power of artificial intelligence for the expansion and optimization of biomarker selection for pancalert,partnerships,UP,0.2544496459059496,5512458.0,2706585.0,75055.0,0.305,78500.0,0.4909942170987969,0.09346626282280733,2,4,297,-0.6,34.079934680222834,0.004242424242424239
media release,wästbygg gruppen ab publ publishes bond prospectus and applies for admission to trading of its bonds on nasdaq stockholm,prospectus_announcement,DOWN,-1.2195052453833148,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,10,239,0.0,0.8866002429130597,0.0
media release,totens sparebank siste handelsdag i dag,mergers_acquisitions,UP,0.5442480256261943,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,7,240,0.0,0.8866002429130597,0.0
miami nov 10 2023 globe newswire fortress biotech inc nasdaq fbio fortress or company an innovative biopharmaceutical company focused on efficiently acquiring developing and commercializing or monetizing promising therapeutic products and product candidates today announced the pricing of its public offering of an aggregate of 5 885 000 units at a public offering price of 1 70 per unit consisting of i one share of common stock or one pre funded warrant in lieu thereof and ii one warrant to purchase one share of common stock immediately exercisable at a price of 1 70 per share and expiring five years from the date of issuance,fortress biotech announces pricing of 10 0 million public offering,shares_issue,DOWN,-7.103823312288768,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,4,8,596,0.014285714285714282,0.6928276660424207,0.06818181818181818
toronto june 12 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the type c meeting written responses received by the company from the u s food drug administration fda for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the study,revive therapeutics provides update on fda type c meeting for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-6.666661699612825,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,9,381,0.04,1.8889707456546947,0.09926750064376327
10 minute at home psa test for early detection of prostate cancer,the saudi food and drug authority sfda approves biomerica s at home psa screening test to detect early signs of prostate cancer,product_services_announcement,UP,6.976744347227267,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,2,8,297,0.1,1.5245042583012947,0.16375260850260848
farmington hills mich june 06 2024 globe newswire ocuphire pharma inc nasdaq ocup ocuphire a clinical stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders today announced that clinical updates on the company s lead candidate apx3330 for diabetic retinopathy dr will be featured in upcoming presentations at the clinical trials at the summit meeting on june 8 in park city utah and the retinal imaging biomarkers endpoints summit meeting june 25 27 in boston,ocuphire pharma announces presentations on the development of apx3330 for diabetic retinopathy at retina meetings in june,clinical_study,UP,0.5714280264718192,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,7,387,-0.25,0.8866002429130597,-0.0063440527726242035
london united kingdom october 1 2024 globe newswire biontech se nasdaq bntx biontech or the company alongside its artificial intelligence ai subsidiary instadeep ltd instadeep today presents an overview of its ai approach during an edition of the company s innovation series ai day,biontech highlights ai capabilities and r d use cases at inaugural ai day,press_releases,UP,0.9598442799227952,24739051520.0,97284490.0,1237590.0,1.285,391100.0,0.003932426023744341,0.09346626282280733,1,6,270,-0.6,0.5503225880253886,0.07133170327614773
media release,immutep completes patient enrolment in randomised phase ii of aipac 003 trial in metastatic breast cancer,clinical_study,UP,0.9434066238083006,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,3,8,268,0.0,0.7476881311953882,0.09571400461010851
transcode therapeutics announces phase 1 clinical trial initiation,transcode therapeutics announces phase 1 clinical trial initiation,clinical_study,UP,1.3157921395198335,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,317,0.0,2.0874185587937095,0.03264462809917356
new grant from the bill melinda gates foundation supports the phase 1 development of vir 1388 an investigational hiv t cell vaccine based on a novel vector,vir biotechnology receives expanded support to develop its novel t cell vaccine platform with new 10 million grant for hiv prevention,clinical_study,DOWN,-0.596182907154119,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,1,9,788,0.13636363636363635,0.8653389999075153,0.0
moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,moonlake immunotherapeutics presents positive 12 week data from the phase 2 mira trial with nanobody sonelokimab for hidradenitis suppurativa at the european academy of dermatology and venereology congress,clinical_study,DOWN,-7.103823312288768,2921087232.0,28324751.0,691265.0,1.23,267600.0,0.00969664674498841,0.09346626282280733,2,10,625,0.11363636363636363,0.5366763308656862,-0.03166666666666666
se espera que la inscripción a virage el ensayo clínico de fase 2b de vcn 01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico pdac finalice en el tercer trimestre de 2024,theriva biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2024,clinical_study,UP,0.0,3603094.0,8173972.0,1624850.0,0.833,91200.0,2.268598043792363,0.09346626282280733,1,15,318,0.0,1.5225134880447404,0.058863005050505054
new york aug 19 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the appointment of ivor elrifi as its chief executive officer ceo effective immediately,tiziana life sciences appoints new chief executive officer,management_changes,DOWN,-0.8264454667762735,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,0,7,313,0.21818181818181817,1.1109140250580023,0.037909696613400316
completed construction of new nexobrid manufacturing facility,mediwound reports second quarter 2024 financial results and provides company update,financial_results,DOWN,-5.436572327795004,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,2,7,318,0.04545454545454545,0.6433034533898109,0.1289625420875421
plans to report topline data mid second quarter 2024 plans to report topline data mid second quarter 2024,rezolute completes enrollment of its phase 2 study in diabetic macular edema dme,clinical_study,UP,7.142857649699376,375907648.0,77797779.0,825115.0,1.04,796000.0,0.2069598195565311,0.09346626282280733,2,8,563,0.0,0.6820409900648857,-0.008333333333333331
san diego july 01 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced that the company is set to join the russell 2000 index and the broad market russell 3000 index effective at the open of u s equity markets today july 1 2024,capricor therapeutics set to join russell 2000 and russell 3000 indexes,corporate_action,UP,2.935007694872201,432240384.0,40176259.0,3124730.0,0.85,8768900.0,0.09294887864989496,0.09346626282280733,0,9,362,0.24062499999999998,1.3427880947904531,0.1472835497835498
redwood city calif may 14 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced results for the fiscal quarter ended march 31 2024 and reported recent corporate developments,jasper therapeutics reports first quarter 2024 financial results and recent corporate developments,clinical_study,DOWN,-0.7225415071122696,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,8,410,0.10625,0.9821837329226573,0.15356637806637807
missing,immix biopharma expands u s clinical sites for relapsed refractory al amyloidosis trial nexicart 2,clinical_study,DOWN,-3.478257624548573,61887608.0,18058632.0,290605.0,0.301,58200.0,0.2917972205356523,0.09346626282280733,2,9,303,-0.2,0.9253604538231538,0.03222180134680134
in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,in8bio doses first patient in phase 2 clinical trial of inb 400 in newly diagnosed glioblastoma,clinical_study,DOWN,-1.0101000370632516,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,1,6,424,0.19318181818181818,1.2777111391401192,0.022727272727272724
šiaulių bankas ab plans an offering of fixed rate reset perpetual additional tier 1 temporary write down notes subject to market conditions this notice does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas on 14 october 2024 the management board of šiaulių bankas ab approved an offering of fixed rate reset perpetual additional tier 1 temporary write down which would follow subject to market conditions šiaulių bankas ab has mandated goldman sachs bank europe se as lead manager to arrange a series of virtual fixed income investor meetings commencing on 14 october relevant stabilisation regulations including fca icma will apply this communication is not an offer of securities or investments for sale nor a solicitation of an offer to buy securities or investments in any jurisdiction where such offer or solicitation would be unlawful no action has been,šiaulių bankas ab plans a bond offering subject to market conditions,financing_agreements,DOWN,-0.6142500205394381,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,14,256,-0.01464646464646464,0.8866002429130597,0.10189814814814815
media release,international petroleum corporation to release third quarter 2024 financial and operational results on november 5 2024,earnings_releases_and_operating_results,DOWN,-0.4132231404958678,17525362688.0,64661008.0,268294.15789473685,1.53,842590.0,0.0036895674658005686,0.1515999603296736,3,9,240,0.0,0.413754093849161,0.0
mdxhealth announces resignation of board member,mdxhealth announces resignation of board member,management_changes,UP,0.0,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,4,8,498,0.0,0.6181119561491973,0.126984126984127
media release,vinci acquires fm conway limited in the united kingdom,mergers_acquisitions,DOWN,-0.5811123236039649,68908859392.0,414372263.0,1028346.7727272727,0.967,1204247.0,0.006013338004084083,0.1515999603296736,2,8,241,-0.07142857142857142,0.19953586312605776,0.0
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl gbp nav s,fund_data_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
media release,xplora technologies as announces strategic partnership with hmd global to expand into the youth phone market,partnerships,UP,0.0,1855892352.0,20356814.0,45065.4,0.201,14970.0,0.010968747178715675,0.1515999603296736,1,7,242,0.0,0.5164688145896636,0.0
company anticipates completing enrollment by the end of 2024 and reporting topline results in mid year 2025 company anticipates completing enrollment by the end of 2024 and reporting topline results in mid year 2025,rezolute initiates phase 3 clinical study for rz358 in congenital hyperinsulinism,clinical_study,UP,3.2967000577117043,378078048.0,77797779.0,825115.0,1.04,796000.0,0.205771743193088,0.09346626282280733,3,8,562,0.0,0.6820409900648857,-0.006249999999999999
26 sep 2024 15 02 cest brie picardie crcam rapport financier semestriel 2024 la caisse régionale de crédit agricole mutuel brie picardie compte au 30 juin 2024 206 agences de proximité 1 agence gestion de la relation à distance 2 agences crédit agricole en ligne 3 agences courtiers 1 agence habitat à distance 3 agences banque privée 5 centres d affaires entreprises 3 agences collectivités publiques 3 centres d affaires professionnels de l immobilier 2 pôles institutionnels et associations 3 équipes de conseillers mobiles assurances agriculteurs et professionnels 1 plateforme front office assurances agriculteurs et professionnels 1 plateforme allocation d actifs et gestion conseillée 1 banque d affaires 1 agence evènements de la vie 85 caisses locales 18 administrateurs de la caisse régionale 859 administrateurs de caisses locales plus de 433 000 sociétaires plus de 1 1 million de clients pièce jointe rapport financier semestriel 2024 rapport,crédit agricole brie picardie rapport financier semestriel 2024,financial_results,DOWN,-0.474321679287626,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,274,0.0,0.8866002429130597,0.0
media release,bygger kombinert nærings og boligprosjekt,business_contracts,UP,0.0,1404396416.0,38253134.0,8.090909090909092,0.581,0.0,0.027238131316905896,0.1515999603296736,0,9,243,0.0,0.5820288170314594,0.0
biocardia announced today that the fda has approved an important protocol amendment for the cardiamp heart failure ii trial its confirmatory phase 3 trial,fda approves cardiamp heart failure ii protocol amendment to use proprietary cell population analysis screening to define treatment,clinical_study,UP,0.0,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,2,7,311,-0.07777777777777777,1.32107885633281,0.07827380952380952
new york aug 21 2024 globe newswire eyenovia inc eyenovia or the company nasdaq eyen a commercial stage ophthalmic company announced today that it has agreed to sell 12 850 000 shares of common stock at a price per share of 0 40 the offering,eyenovia announces pricing of 5 14 million public offering,shares_issue,DOWN,-7.103823312288768,28395680.0,2433609.0,8930490.0,1.002,41800300.0,0.08570349433434946,0.09346626282280733,2,9,311,-0.04090909090909091,2.4441832149286684,0.002865981240981244
windtree to receive potential future milestones up to 138mm plus up to low double digit royalties and full coverage for all development manufacturing regulatory and commercialization costs for products in the licensed territory,windtree therapeutics announces license agreement with lee s pharmaceuticals to develop and commercialize istaroxime dual mechanism serca2a activators and rostafuroxin for greater china asia pacific region,licensing_agreements,UP,1.694918146096621,1384333.0,3660923.0,6680965.0,0.764,1224200.0,2.6445392835394372,0.09346626282280733,2,8,528,0.14166666666666666,2.339794177443606,-0.023556998556998554
25 sep 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 24 sep 2024 estimated nav euro sharessterling sharesestimated nav 28 5679 25 6374estimated mtd return 0 53 0 36 estimated ytd return 3 70 4 34 estimated itd return 185 68 156 37 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 4 09 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 95 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,276,-0.006122448979591831,0.8866002429130597,0.0
norwood mass feb 28 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today announced the appointment of dr dominic smethurst ma mrcp as the company s chief medical officer cmo in this role dr smethurst will lead the clinical development of the company s investigational oncology drugs crb 701 a next generation nectin 4 targeting antibody drug conjugate adc developed in partnership with cspc and crb 601 a tgfβ blocking monoclonal antibody targeting the integrin αvβ8 additionally dr smethurst will help guide strategic development of crb 913 the company s highly peripherally restricted cb1 inverse agonist for the treatment of obesity,corbus pharmaceuticals appoints dr dominic smethurst as chief medical officer,management_changes,DOWN,-1.764476754343736,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,8,486,0.052000000000000005,0.9919200800994142,-0.057575757575757586
16 oct 2024 08 00 cest beerenberg as not for release publication or distribution in whole or in part directly or indirectly into or within canada australia new zealand south africa hong kong japan or any other jurisdiction in which the release publication or distribution would be unlawful 16 october 2024 reference is made to the announcement made on 4 september 2024 by beerenberg as beerenberg or the company and altrad investment authority s a s altrad or the offeror regarding the issuance of an offer document the offer document and the start of the offer period for the board recommended unregulated voluntary cash offer to acquire all outstanding shares in the company the shares not already owned by the offeror the offer reference is also made to the announcement on 9 october 2024 where altrad announced the fulfilment of the condition related to regulatory approvals shareholders who want to accept the offer must complete and retur,reminder of last day of offer period for altrad s recommended cash offer to acquire all outstanding shares in beerenberg,mergers_acquisitions,DOWN,-1.474207070199145,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,255,0.15681818181818183,0.8866002429130597,0.16932659932659933
malvern pa aug 05 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that it has received notification from fda to begin its expanded access program eap for the treatment of adult patients aged 18 and older with retinitis pigmentosa rp with ocu400 a modifier gene therapy product candidate,ocugen inc announces fda approval of expanded access program for patients with retinitis pigmentosa,clinical_study,DOWN,-3.673475544336368,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,6,327,0.05555555555555555,0.7661975315521313,0.08801010101010101
media release,le premier vêtement biorecyclé 100 fibre à fibre du monde dévoilé par carbios on patagonia puma pvh corp et salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
malvern pa july 29 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that it will host a conference call and live webcast to discuss the company s second quarter 2024 financial results and provide a business update at 8 30 a m et on thursday august 8 2024,ocugen to host conference call on thursday august 8 at 8 30 a m et to discuss business updates and second quarter 2024 financial results,conference_call_webinar,DOWN,-1.219511042741837,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,7,334,0.02727272727272727,0.7661975315521313,0.10319444444444445
irvine calif nov 10 2023 globe newswire biomerica inc nasdaq bmra the company a global provider of advanced medical products today announced that it will participate in the 14th annual craig hallum alpha select conference on november 16 2023 at the sheraton new york times square hotel in new york city zackary irani chief executive officer of biomerica will be hosting meetings during the event which consists of one on one and small group meetings,biomerica to participate in 14th annual craig hallum alpha select conference on november 16,conference_call_webinar,UP,3.2967000577117043,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,4,8,596,0.07045454545454545,1.5245042583012947,0.07261605061605061
media release,stmicroelectronics reports 2024 third quarter financial results,financial_results,DOWN,-0.689650206789829,26516213760.0,642508707.0,7578905.0,1.228,8781800.0,0.024230786220664408,0.19535099655549074,3,7,240,0.0,0.5353904986560228,-0.15
south san francisco calif march 20 2024 globe newswire vaxart inc nasdaq vxrt the company or vaxart today announced that the compensation committee of the board of directors approved certain equity awards to the company s new president and chief executive officer steven lo effective march 18 2024 the awards were made pursuant to the company s previously disclosed offer letter with mr lo and as a material inducement to his joining the company as president and chief executive officer and a member of the board of directors,vaxart inc reports inducement grants under nasdaq listing rule 5635 c 4,management_changes,UP,2.5862147812329632,120729968.0,226926647.0,9325470.0,1.148,2676900.0,1.8796215286000904,0.09346626282280733,2,8,465,0.195995670995671,1.025768835125998,0.06458333333333333
led by new investor ecor1 capital and sr one with participation from existing and new investors,crispr therapeutics announces 280 million registered direct offering,financing_agreements,DOWN,-5.29827697855226,4064042496.0,85970729.0,2651100.0,1.742,2455300.0,0.02115399361217703,0.09346626282280733,1,8,501,0.12424242424242422,0.5620956775766307,-0.0171957671957672
tiziana life sciences to dose first patient with moderate alzheimer s disease with foralumab,tiziana life sciences to dose first patient with moderate alzheimer s disease with foralumab,clinical_study,DOWN,-4.123713430708066,199810080.0,63394363.0,242895.0,0.107,139700.0,0.31727309753341776,0.09346626282280733,2,7,367,0.125,1.1109140250580023,0.030540688267961
palo alto calif sept 05 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced the acceptance of a presentation at the 2024 american college of rheumatology convergence conference to be held at the walter e washington convention center in washington d c on november 14 19 2024,scilex holding company announces acceptance of presentation at the 2024 american college of rheumatology convergence conference to be held at the walter e washington convention center in washington d c on november 14 19 2024,conference_call_webinar,UP,0.917430289635912,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,296,0.15,1.0327724261931344,0.2440314754689755
tampa fla april 02 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will participate in an analyst led fireside chat at the 23rd annual needham virtual healthcare conference at 8 00 am et on monday april 8 2024 live audio of the virtual event can be accessed by visiting the events page of the company s website at investor pacira com a replay of the webcast will also be available for two weeks following the event,pacira biosciences to participate in fireside chat at the 23rd annual needham virtual healthcare conference,conference_call_webinar,DOWN,-1.2006874307032096,1111081344.0,45834212.0,557500.0,0.511,435200.0,0.04125189595479339,0.09346626282280733,1,8,452,0.1787878787878788,0.7130794063724827,0.18958072791406122
27 9 2024 08 30 02 eest consti oyj financial calendar consti plc stock exchange release 27 september 2024 at 8 30 a m consti plc s financial reporting and annual general meeting in 2025 consti plc s financial statements bulletin for 2024 will be published on 7 february 2025 the electronic version of the annual report which includes the full financial statements for 2024 will be published in week 11 2025 consti plc s annual general meeting for 2025 is scheduled to take place on thursday 3 april 2025 in helsinki consti shall publish three interim reports during 2025 consti observes a 30 day closed period preceding the publication of its financial statements bulletin and interim reports during this time the company s representatives do not comment on the company s financial position or future outlook and do not meet with representatives of the capital markets or financial media consti plc further information esa korkeela ceo consti plc tel 358 40 730 8568 anders,consti plc s financial reporting and annual general meeting in 2025,financial_calendar,UP,1.860463342001272,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,274,0.02666666666666667,0.8866002429130597,0.0
warrington pa feb 01 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing late stage interventions for critical cardiovascular disorders today announced that it has renewed its partnership with chang gung university in taiwan to further research on serca2a an important target for the company s cardiovascular portfolio windtree personnel from its offices in taipei taiwan will participate in the collaboration,windtree renews agreement with chang gung university for scientific collaboration to further serca2a research,partnerships,UP,4.761906564010437,1360169.0,3660923.0,6680965.0,0.764,1224200.0,2.6915206860323972,0.09346626282280733,3,8,513,0.020000000000000007,2.339794177443606,-0.004422799422799423
media release,sopra steria le chiffre d affaires du 3ème trimestre 2024 résiste à 1 356 9 m,earnings_releases_and_operating_results,UP,2.013030952124983,3920863744.0,13004248.0,30175.454545454544,1.178,35707.0,0.003316679397466968,0.19535099655549074,3,7,240,0.0,0.34381159326312405,0.0
boston jan 11 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that the first patient has been dosed at northwell health cancer institute and the feinstein institutes for medical research new york as part of the randomized phase 2 amplify 7p study of eli 002 7p as an adjuvant monotherapy in kras mutated pancreatic ductal adenocarcinoma pdac,elicio therapeutics announces first patient dosed in randomized phase 2 pancreatic cancer study,clinical_study,DOWN,-1.6245515019423795,127896016.0,10299137.0,63410.0,2.164,22500.0,0.08052742628042456,0.09346626282280733,3,8,534,0.1590909090909091,0.8558055682194762,0.02327380952380953
oxurion share consolidation,oxurion share consolidation,corporate_action,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,12,337,0.0,2.0692591020840054,0.15580357142857143
rockville md june 22 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported that its german subsidiary curetis gmbh has received the full set of ten unyvero a30 c series instruments which have been assembled by its development partner dmtpe in germany the instruments have successfully passed electrical and functional testing and will allow rapid sample to answer molecular testing with numerous chemistries and assay formats,opgen s subsidiary curetis receives batch of ten new c series unyvero a30 instruments,product_services_announcement,DOWN,-1.5873075943202797,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,737,0.17662337662337663,1.807174583649316,0.020454545454545454
media release,resolutions of the annual general meeting of shareholders of ab akola group,annual_general_meeting,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.05000000000000002,0.8866002429130597,0.07018496654860291
publication in the journal of ocular pharmacology and therapeutics highlights the ability of the optejet to achieve a therapeutic dose of medication with far less exposure to harmful preservatives,eyenovia announces publication of study demonstrating favorable impact on the ocular surface of medication delivered with the optejet,clinical_study,UP,1.2891398357941382,28093560.0,2433609.0,8930490.0,1.002,41800300.0,0.08662515537368706,0.09346626282280733,2,7,248,-0.033333333333333326,2.4441832149286684,0.014283530796688695
kraig labs otcqb kblb achieves major milestone completes new bam 1 1st gen parental strain rearing and cocoons at rates that exceeded expectations,kraig biocraft laboratories successfully completes recombinant cocoon production from spring trials,press_releases,UP,9.242146234319629,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,432,0.3162878787878788,0.8071333009212691,0.4431818181818182
interim analysis of the phase iii fibrosarc trial investigating l19tnf in patients with first line soft tissue sarcoma,philogen provides update on pre planned interim analysis of the phase iii fibrosarc trial investigating onfekafusp alfa l19tnf in patients with first line advanced or metastatic soft tissue sarcoma,clinical_study,UP,2.0895545162371736,926076608.0,35018869.0,31367.18181818182,0.152,19588.0,0.25000035609542787,0.09346626282280733,1,1,494,0.22000000000000003,0.3376005673725286,0.3103409090909091
new york sept 04 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions today announced that management will participate in two upcoming investor conferences in september,ovid therapeutics to present at upcoming september investor conferences,conference_call_webinar,UP,1.834860579271824,21659954.0,50354780.0,1012130.0,0.065,720700.0,2.324787024016764,0.09346626282280733,2,8,297,0.14545454545454545,0.7642184815786688,0.1622812674853491
tampa fla may 07 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will participate in an analyst led fireside chat at the 2024 rbc capital markets global healthcare conference at 10 30 am et on tuesday may 14 2024 in new york live audio of the event can be accessed by visiting the events page of the company s website at investor pacira com a replay of the webcast will also be available for two weeks following the event,pacira biosciences to participate in fireside chat at the 2024 rbc capital markets global healthcare conference,conference_call_webinar,UP,0.9433962264150944,1110849792.0,45834212.0,557500.0,0.511,435200.0,0.04126049474022857,0.09346626282280733,1,8,417,0.11212121212121212,0.7130794063724827,0.16947663447663447
international energy terminal operator ab kn energies kn or the company has established a german subsidiary kn energies deutschland gmbh within its corporate group the company will be responsible for the smooth execution of its commitments to the german state owned company deutsche energy terminal gmbh det by providing technical operation and maintenance services for the second floating lng import terminal at wilhelmshaven wilhelmshaven 2 all shares in the german subsidiary are held entirely by companies within the kn energies group kn energies deutschland gmbh is registered in wilhelmshaven lower saxony kn energies deutschland gmbh team will involve specialists in human resources health safety and environment hse as well as mechanical electrical and automation engineering operations and maintenance management active recruitment for team members is currently underway the german team will be supported by a skilled kn energies staff from lithuania who will provid,kn energies subsidiary starts operations in germany,geographic_expansion,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,6,283,0.06444444444444446,0.8866002429130597,0.0
redwood city calif sept 10 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that health canada has cleared the company s clinical trial application cta for a phase 1b 2a asthma challenge study evaluating briquilimab in asthma,jasper therapeutics announces health canada clearance of clinical trial application for phase 1b 2a study of briquilimab in asthma,clinical_study,DOWN,-0.8290147862020221,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,7,291,0.3,0.9821837329226573,0.133255772005772
san diego july 03 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced that the compensation committee of its board of directors granted corrina pavetto a new employee a non qualified stock option award and restricted stock units rsus for an aggregate of 10 275 shares of its common stock pursuant to the cidara therapeutics inc 2020 inducement incentive plan with a grant date of june 28 2024 the stock option has an exercise price of 11 94 per share which is equal to the closing price of cidara s common stock on the grant date the shares subject to the option will vest over four years with of the shares vesting on the one year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter all rsus vest in four equal annual installments with 1 4 vesting on each of the first second third and fourth anniversaries of the quarterly vesting date that occurs during the calendar quarter that includes the date of grant quarterly vesting date means march 10 june 10 september 10 or december 10 the awards are subject to the award holder s continuous service through each vesting date and to the terms and conditions of cidara s 2020 inducement incentive plan and its standard forms of grant agreements thereunder,cidara therapeutics reports inducement grant under nasdaq listing rule 5635 c 4,corporate_action,UP,3.313503606460677,633315328.0,4118697.0,696580.0,0.795,3470400.0,0.006503390677447807,0.09346626282280733,2,13,359,-0.058686868686868676,1.357695941787151,-0.03264481550195836
lawrenceville n j may 06 2024 globe newswire imunon inc nasdaq imnn a clinical stage drug development company focused on developing dna mediated immunotherapy and next generation vaccines announces that the company will host a conference call at 11 00 a m et on monday may 13 2024 to discuss financial results for the first quarter ended march 31 2024 and provide an update on its clinical development programs with imnn 001 a dna based interleukin 12 il 12 immunotherapy in phase 2 clinical development for the treatment of first line locally advanced stage ovarian cancer and on its placcine modality a proprietary mono or multi cistronic dna plasmid and a synthetic dna delivery technology for the expression of pathogen antigens for the development of next generation vaccines,imunon to hold first quarter 2024 financial results and business update conference call on monday may 13 2024,conference_call_webinar,DOWN,-1.5037668789816911,17822234.0,12808492.0,12655315.0,2.143,945100.0,0.7186804976300951,0.09346626282280733,0,11,417,0.14375,2.964855117372811,0.01401515151515151
snk01 a cryopreserved autologous enhanced natural killer cell therapy delivered in highest dose to date demonstrates preliminary clinical benefit without any drug related adverse events,nkgen biotech s snk01 nk cell therapy cleared to start phase 2 clinical trial in alzheimer s disease,clinical_study,UP,9.242146234319629,16295543.0,10616620.0,134195.0,1.199,86400.0,0.651504524887572,0.09346626282280733,0,8,404,0.05,2.657355742098314,0.19895104895104895
amsterdam sept 13 2024 globe newswire nasdaq renb renovarocube cube the company a leading ai driven innovator using multi omics technology for cancer profiling is pleased to announce two scientific presentations at a leading cancer conference the european society for medical oncology esmo congress on september 15 2024,renovarocube to present cutting edge cancer diagnostics research at european society for medical oncology congress,conference_call_webinar,DOWN,-2.0933996157467987,60224444.0,90925076.0,7542515.0,0.529,816400.0,1.50977028530143,0.09346626282280733,4,9,288,-0.014285714285714282,1.5631250973582267,0.07979998396665063
media release,delårsrapport 9 månader 1 januari 30 september 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,0.02500000000000001
jupiter fla march 01 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective affordable and accessible biopharmaceutical products for human and animal health and alternative proteins for food nutrition and wellness today announced that its management will be attending the following industry events during the month of march 2024,dyadic to attend industry events in march,trade_show,DOWN,-2.222220063700145,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,8,484,0.184375,0.7846450948942033,0.1916060606060606
enrollment in the two pivotal trials of lorundrostat for the treatment of uhtn or rhtn is on track with topline data expected for advance htn trial in q4 2024 and launch htn trial in 2h 2025,mineralys therapeutics reports fourth quarter and full year 2023 financial results and provides corporate update,clinical_study,DOWN,-0.2987301032667582,916690560.0,43490817.0,793180.0,-0.18,767600.0,0.04744329100541845,0.09346626282280733,3,7,464,0.125,0.8131647725786432,-0.0671590909090909
boston aug 28 2024 globe newswire x4 pharmaceuticals nasdaq xfor a company driven to improve the lives of people with rare diseases of the immune system today announced that management will be participating in three upcoming investor conferences in september 2024,x4 pharmaceuticals to participate in upcoming september investor conferences,conference_call_webinar,DOWN,-1.5714253965688671,12445684.0,4364496.0,363495.0,0.663,396700.0,0.35068349799014664,0.09346626282280733,2,8,304,0.3,1.4412990038402507,0.10925757575757575
media release,shell plc publishes third quarter 2024 press release,earnings_releases_and_operating_results,UP,0.9792533652911048,183067475968.0,5864055990.0,5107151.363636363,0.301,9263908.0,0.03203221085008585,0.1515999603296736,3,8,240,0.0,0.21899597021789582,0.0
boston feb 07 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced the pricing of an underwritten offering of 7 530 000 shares of its common stock at a price to the public of 10 635 per share the aggregate gross proceeds to pepgen from this offering are expected to be approximately 80 1 million before deducting underwriting discounts and commissions and offering expenses payable by pepgen the offering is expected to close on or about february 9 2024 subject to customary closing conditions,pepgen announces pricing of 80 1 million underwritten offering of common stock,shares_issue,UP,9.242146234319629,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,2,7,507,-0.15185185185185188,1.4553932872573117,0.0565986790986791
sampo plc stock exchange release 4 october 2024 at 8 30 am eest sampo plc s share buybacks 3 october 2024 on 3 october 2024 sampo plc business code 0142213 3 lei 743700uf3rl386wida22 has acquired its own a shares isin code fi4000552500 as follows rounded to two decimals on 17 june 2024 sampo announced a share buyback programme of up to a maximum of eur 400 million in compliance with the market abuse regulation eu 596 2014 mar and the commission delegated regulation eu 2016 1052 on 16 september 2024 the board of directors of sampo plc resolved to increase the share buyback programme to eur 475 million the programme which started on 18 june 2024 is based on the authorisation granted by sampo s annual general meeting on 25 april 2024 after the disclosed transactions the company owns in total 7 947 141 sampo a shares representing 1 44 per cent of the total number of shares in sampo plc taking the issuance of shares on 16 september 20,sampo plc s share buybacks 3 october 2024,changes_in_companys_own_shares,DOWN,-0.0241714257426052,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,267,0.1625,0.8866002429130597,0.001990740740740736
in8bio announces fda guidance for registrational trial of inb 100 as of aml patients remain in complete remission,in8bio solidifies position as a clinical leader of gamma delta t cell therapy in oncology with of treated aml patients in complete remission and receives fda guidance for registrational trial of inb 100,clinical_study,DOWN,-1.2875541238313355,7480178.0,2577285.0,392516.85,0.183,187400.0,0.34454861903018885,0.09346626282280733,0,8,320,0.1,1.2777111391401192,0.09814049586776857
waltham mass june 24 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced it has reached alignment with the food and drug administration fda on its biologics license application bla resubmission strategy for cosibelimab accordingly checkpoint plans to move forward with a mid year bla resubmission seeking the u s marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma cscc who are not candidates for curative surgery or curative radiation,checkpoint therapeutics announces alignment with fda enabling upcoming cosibelimab bla resubmission,regulatory_filings,UP,9.242146234319629,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,0,7,369,0.1340909090909091,0.8866002429130597,0.0698538961038961
boca raton florida april 23 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage immunology company focused on developing treatments that harness the patient s innate immune system to fight disease is delighted to announce the successful completion of the extended stability validation for xprotm continuous storage in solution at 2 8c the 24 and 30 month stability test samples passed all chemistry and potency assays allowing the company to make a conservative claim of 24 month stability the 24 month stability claim is consistent with other pegylated cytokines such as alpha interferon and allows the company to design a global supply chain using proven and established systems with this data the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid formulation drugs at 2 8c which is routine across the pharmaceutical industry the 24 month stability data confirms that xprotm can mirror these established supply chain strategies,inmune bio inc announces 24 month stability validation of xpro for phase iii readiness and commercial supply chain modeling development of novel immunogenicity assay,press_releases,DOWN,-2.4000010770909923,158748848.0,15213010.0,781395.0,1.567,974600.0,0.09583067966578251,0.09346626282280733,1,8,431,0.196875,0.8435084668920305,0.0645959595959596
palo alto calif oct 30 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced it had a successful end of phase ii meeting with the fda leading to an agreed path forward to nda upon completion of phase iii trials for blockbuster product candidate sp 103 lidocaine topical system 5 a next generation triple strength formulation of ztlido for the treatment of chronic neck pain associated with muscle spasms,scilex pharmaceuticals inc a wholly owned subsidiary of scilex holding company announces successful end of phase ii meeting with fda leading to an agreed path forward to nda upon completion of phase iii trials for blockbuster product candidate sp 103 lidocaine topical system 5 a next generation triple strength formulation of ztlido for the treatment of chronic neck pain associated with muscle spasms,clinical_study,UP,1.5075362435176205,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,2,6,241,0.325,1.0327724261931344,0.22299769096644095
toronto jan 10 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders is pleased to announce that it has completed the formulation development work of the company s next generation lyophilized formulation of bucillamine new bucillamine conducted at the university of waterloo the new bucillamine has the potential to unlock the therapeutic utility of bucillamine for treating public health medical emergencies including pandemic influenza emerging infectious diseases and medical countermeasure incidents and attacks,revive therapeutics successfully completes development of a novel lyophilized formulation of bucillamine,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,7,535,0.16570247933884297,1.8889707456546947,0.12690476190476188
durham n c sept 03 2024 globe newswire humacyte inc nasdaq huma a clinical stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale today announced that laura niklason m d ph d founder president and chief executive officer and dale sander chief financial officer will represent humacyte at the following conferences in september,humacyte to participate at upcoming investor conferences in september,conference_call_webinar,DOWN,-0.8264494075791097,337383840.0,121934248.0,3834265.0,2.0,1449900.0,0.3614110503929293,0.09346626282280733,1,8,298,0.0,1.1173068527438073,0.0644854797979798
évènement en présentiel et retransmis en direct à 16h00 cet,valneva organise une journée investisseurs aujourd hui à new york,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.11818181818181818,0.6494694268312979,0.028525641025641018
the combined companies aim to disrupt cancer diagnosis and treatment through early disease and recurrence detection prediction of response to treatment and personalized therapy,cutting edge ai company gedicube and cyclomics sign binding loi to join forces and position themselves at the forefront of the global liquid biopsy marketplace,mergers_acquisitions,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,9,500,-0.16666666666666666,1.5631250973582267,0.18178726035868895
arcutis today announced new patient reported outcome data demonstrating that zoryve cream 0 improved the impact of ad on patients and families,arcutis presents positive patient reported outcome data for zoryve roflumilast cream 0 in atopic dermatitis at american college of allergy asthma and immunology 2024 annual scientific meeting,clinical_study,DOWN,-0.1197632146703656,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,247,0.12121212121212122,0.6903751128737089,0.062473468624262264
new york april 25 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced for the first time quantitative data showing improvement in white matter z scores measured from pet images taken at 3 months in nasal foralumab treated patients with non active secondary progressive multiple sclerosis na spms white matter z scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain,tiziana life sciences reports positive 3 month neuroimaging scores in multiple sclerosis patients receiving intranasal foralumab,clinical_study,UP,9.242146234319629,199716608.0,63394363.0,242895.0,0.107,139700.0,0.3174215886943163,0.09346626282280733,3,10,428,0.02003367003367004,1.1109140250580023,0.0396043771043771
redwood city calif oct 23 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that it is commencing an open label extension study in chronic urticarias that will roll over patients from the beacon and spotlight studies upon completion of their initial follow up period additionally jasper also announced it has obtained regulatory clearance in the us and in the eu to further expand the beacon study in csu by adding a 360mg single dose cohort n 4 and that enrollment in this cohort has commenced jasper continues to plan to report initial data from all doses of the beacon study up through 240mg in csu during the week of january 6th 2025 data from the newly added 360mg single dose cohort is expected to be reported in the first half of 2025,jasper therapeutics announces further expansion of clinical program in chronic spontaneous urticaria,clinical_study,DOWN,-0.747010055279865,81119344.0,9908441.0,280900.0,2.725,505700.0,0.12214646361045524,0.09346626282280733,2,8,248,0.08405998763141619,0.9821837329226573,0.16296825396825396
toronto feb 01 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders announced today its initiative in bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the company aims to advance the clinical development of bucillamine by leveraging the published research and existing data from its previous phase 3 clinical trial the study and is preparing a clinical package that includes a proposed phase 2 3 clinical protocol for long covid to present to the fda and international health regulatory bodies,revive therapeutics explores the use of bucillamine for long covid,clinical_study,UP,4.545455315142628,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,3,7,513,-0.00185185185185185,1.8889707456546947,0.13253705890069525
boston march 04 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced that the uk medicines healthcare products regulatory agency mhra has authorized its clinical trial application cta to initiate the connect2 edo51 phase 2 clinical trial of pgn edo51 in patients with duchenne muscular dystrophy dmd amenable to an exon 51 skipping approach,pepgen announces clearance of cta by uk medicines healthcare products regulatory agency to begin connect2 edo51 a phase 2 clinical trial designed to support potential accelerated approval of pgn edo51 for the treatment of duchenne muscular dystrophy,clinical_study,UP,0.0601583696048976,45482052.0,12870456.0,168500.0,1.294,155200.0,0.28297878908365875,0.09346626282280733,0,7,481,0.06666666666666667,1.4553932872573117,0.0492738791423002
dallas july 01 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced its inclusion in the russell microcap index following the annual russell reconstitution which took effect after the market close on june 28 2024 the reconstituted russell microcap index will commence trading on july 1 2024,spectral ai joins russell microcap index,exchange_announcement,UP,2.272725117600642,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,0,8,362,0.06000000000000002,0.9904696515070965,0.12651515151515152
redwood city calif march 15 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu announced additional positive phase 1b 2a data on briquilimab as a conditioning agent in the treatment of fanconi anemia fa,new positive data presented on briquilimab conditioning in patients with fanconi anemia,clinical_study,DOWN,-0.4106791782468576,81044232.0,9908441.0,280900.0,2.725,505700.0,0.12225966926307599,0.09346626282280733,4,8,470,0.2381818181818182,0.9821837329226573,0.09158730158730159
media release,euronext oslo børs bw energy limited mottatt søknad om notering av obligasjonslån,exchange_announcement,DOWN,-0.4347842672596807,8877470720.0,51507273.0,112603.25,1.177,77531.0,0.005802021163974056,0.1515999603296736,3,14,239,-0.07142857142857142,0.38625946949671847,0.0
la jolla calif may 07 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that it has received an issue notification from the u s patent and trademark office for a new patent which covers extended release oral formulations of mn 166 ibudilast this new patent is expected to expire no earlier than september 2040 the allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of mn 166 ibudilast,medicinova receives issue notification for new patent covering extended release formulations of mn 166 ibudilast,patents,UP,1.5151500099837776,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,417,0.04415584415584416,0.8018560055721619,0.11305916305916307
redwood city calif feb 23 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 in mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu is presenting results from three preclinical studies evaluating briquilimab at the 2024 american academy of allergy asthma immunology aaaai annual meeting being held february 23 26 in washington d c one study will be featured in an oral presentation and two studies in poster presentations,jasper therapeutics presents data from preclinical briquilimab studies at the american academy of allergy asthma and immunology aaaai annual meeting,clinical_study,DOWN,-0.8247414977229304,81870440.0,9908441.0,280900.0,2.725,505700.0,0.12102586721165784,0.09346626282280733,4,8,491,0.15,0.9821837329226573,0.036111111111111115
an ongoing complete response cr with an overall response rate orr of achieved across two dosing regimens,bioatla presented phase 2 ozuriftamab vedotin clinical trial data demonstrating meaningful antitumor activity with manageable tolerability among heavily pretreated patients with squamous cell carcinoma of the head and neck scchn at the 2024 european society for medical oncology esmo annual meeting,clinical_study,UP,2.209949299826521,23495760.0,45152550.0,596440.0,0.911,569400.0,1.9217318358716637,0.09346626282280733,0,8,285,0.06666666666666667,1.087702859114621,0.003067380150713483
new york may 31 2024 globe newswire tg therapeutics inc nasdaq tgtx today announced presentations highlighting study designs for post marketing studies being undertaken for briumvi ublituximab xiiy in patients with relapsing forms of multiple sclerosis rms at the 2024 consortium of multiple sclerosis centers cmsc annual meeting presentations are now public and can be viewed using the below links,tg therapeutics announces presentations for briumvi ublituximab in multiple sclerosis at the 2024 consortium of multiple sclerosis centers annual meeting,clinical_study,UP,0.5920685913761188,5897748992.0,135060602.0,1756590.0,1.939,1677400.0,0.022900364559970746,0.09346626282280733,4,7,393,0.022727272727272724,0.6256004090066075,0.053527154663518296
25 sep 2024 08 00 cest riber 2024 first half earnings solid half year revenues growth gross margin up by and operating income at breakevennet profit of 0 2m despite the lower seasonal revenues strong increase in order book at june 30 2024 reaching 36 0m outlook confirmed revenues exceeding 40m with growth in earnings expected for the full year bezons september 25 2024 8 00am riber a global market leader for semiconductor industry equipment is releasing its earnings for the first half of 2024 m h1 2024h1 2023changerevenuessystems revenuesservices and accessories revenues13 79 44 312 28 53 6 13 10 19 gross margin of revenues4 834 8 3 932 3 21 2 5 ptsoperating income of revenues 0 0 0 2 1 1 9 3 97 9 1 ptsnet income of revenues0 21 2 1 2 10 2 113 11 4 pts key developments in the first half of 2024 despite an uncertain macroeconomic environment riber achieved solid business growth this performance reflects it,riber 2024 first half earnings,earnings_releases_and_operating_results,DOWN,-0.7782093947869452,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,6,276,0.06578947368421052,0.4818751066598002,0.0
special closed ended type private equity investment company invl technology legal entity code 300893533 the registered address gyneju str 14 vilnius lithuania hereinafter the company or invl technology informs that on the initiative and decision of the management company invl asset management uab hereinafter the management company the general extraordinary shareholders meeting hereinafter the meeting is to be held on 21 october 2024 the place of the meeting the office of company the address gyneju str 14 vilnius the meeting will start at 09 00 a m registration starts at 08 45 a m the meeting s accounting day 14 october 2024 the persons who are shareholders of the company at the end of accounting day of the meeting or authorized persons by them or the persons with whom shareholders concluded the agreements on the disposal of voting right shall have the right to attend and vote at the meeting the total number of shares of the company is 12 175 321 unit,convocation of the general extraordinary shareholders meeting of invl technology and draft resolutions on agenda issue,voting_rights,DOWN,-0.5813947847045612,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,0.16320346320346318,0.8866002429130597,0.1765376984126984
oslo norway 1 september 2023 pci biotech holding asa ose pcib reference is made to the resolution made by the annual general meeting 25 may 2023 in respect of a write down of share capital by reducing the par value of pci biotech holding asa s shares from nok 3 00 to nok 0 03,pci biotech write down of share capital registered,changes_in_share_capital_and_votes,UP,0.0,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,4,5,666,-0.08703703703703702,0.8869841129646596,0.025000000000000005
media release,recording of lhv group s 22 october investor webinar,clinical_study,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
zug switzerland aug 27 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis or the company a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced results for the quarter ended june 30 2024 and provided an overview of the company s progress,oculis reports q2 2024 financial results and provides recent company update,clinical_study,UP,1.1814294104779912,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,1,4,305,0.0,0.4640841922034435,0.0321010101010101
company plans to launch multiple direct from blood diagnostics over the next 15 months for antimicrobial resistance pediatric candida infections lyme disease and candida auris company plans to launch multiple direct from blood diagnostics over the next 15 months for antimicrobial resistance pediatric candida infections lyme disease and candida auris,t2 biosystems provides updates on its new product development pipeline progress,product_services_announcement,UP,1.6949136104436064,3909529.0,11899158.0,66195.0,0.448,154300.0,3.0436295523066845,0.09346626282280733,0,9,292,0.048051948051948054,1.9596557041969667,0.04341491841491841
san diego jan 31 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer will present at guggenheim s 6th annual biotechnology conference,anaptys to present at guggenheim s 6th annual biotechnology conference,conference_call_webinar,DOWN,-0.6268266469592575,687797504.0,17605381.0,784220.0,-0.266,445700.0,0.025596750348195505,0.09346626282280733,2,9,514,0.16666666666666666,0.871343469962729,0.23443865057501423
transcode therapeutics completes initial dosing of first co hort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,transcode therapeutics completes initial dosing of first cohort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,clinical_study,DOWN,-0.7393730208448788,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,261,0.125,2.0874185587937095,-0.011931818181818184
immunocore announces upcoming presentation and posters at asco 2024,immunocore announces upcoming presentation and posters at asco 2024,clinical_study,UP,2.13100649904476,1595419136.0,37423034.0,614630.0,0.835,788600.0,0.023456553300361067,0.09346626282280733,2,10,429,0.0,0.44240182162750774,0.135
media release,rockwool a s transactions in connection with share buy back programme,changes_in_companys_own_shares,UP,0.2677376171352075,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,240,0.0,0.8866002429130597,0.12222222222222223
malvern pa aug 28 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dosing is complete in the third cohort of its phase 1 2 gardian clinical trial for ocu410st aav hrora a modifier gene therapy candidate being developed for stargardt disease stargardt disease affects approximately 100 000 people in the united states u s and europe,ocugen announces completion of dosing in subjects with stargardt disease in high dose cohort of phase 1 2 gardian clinical trial of ocu410st a modifier gene therapy,clinical_study,DOWN,-0.7518789579387514,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,6,304,-0.008000000000000007,0.7661975315521313,0.07476911976911978
redwood city calif may 14 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced results for the fiscal quarter ended march 31 2024 and reported recent corporate developments,jasper therapeutics reports first quarter 2024 financial results and recent corporate developments,clinical_study,DOWN,-0.7225415071122696,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,8,410,0.10625,0.9821837329226573,0.15356637806637807
company to demonstrate mydcombi and avenova and share data for clobetasol propionate ophthalmic suspension 0 at the american society of cataract and refractive surgery ascrs annual meeting april 5 8 in boston,eyenovia to feature its suite of commercial products and the optejet dispenser at upcoming national eyecare meetings,trade_show,DOWN,-1.970953741106604,27891188.0,2433609.0,8930490.0,1.002,41800300.0,0.08725368743705,0.09346626282280733,2,7,451,0.0,2.4441832149286684,0.0
media release,invitation vallourec q3 2024 results release conference call on friday november 15 2024,conference_call_webinar,UP,1.1430547769766444,3525931264.0,162901440.0,740660.0,2.188,750859.0,0.04620096870952502,0.1515999603296736,2,11,240,0.0,0.31596392785341165,-0.6
los angeles and amsterdam april 24 2024 globe newswire renovaro inc nasdaq renb a trailblazer in ai driven early cancer diagnostics and therapeutics and cyclomics a leader in ultra sensitive 4th generation multi omics molecular biology proudly announce a significant milestone in their collaboration renovarocube has entered into an amendment to its binding letter of intent to acquire ownership of cyclomics further cementing their shared commitment to advancing state of the art technologies in cancer diagnostics and treatment their combined relationships with oxford nanopore and nvidia will further position renovarocube to be a leader in early cancer diagnostics and monitoring of treatment efficacy oxford nanopore is a leader in sequencing technologies and nvidia will provide vital super computing power and front edge software solutions such as parabricks bionemo monai and nemo,renovarocube to acquire ownership of cyclomics reinforcing cutting edge cancer diagnostics partnership,mergers_acquisitions,DOWN,-6.4356433890658415,60207228.0,90925076.0,7542515.0,0.529,816400.0,1.5102019976737677,0.09346626282280733,2,9,430,0.11893939393939394,1.5631250973582267,0.08446969696969697
in8bio to present at the h c wainwright 26th annual global investment conference,in8bio to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-0.9523800873701952,7508421.0,2577285.0,392516.85,0.183,187400.0,0.3432525959852278,0.09346626282280733,3,6,303,0.0,1.2777111391401192,0.09829545454545453
non dilutive funding strengthens balance sheet and extends current operating runway,imunon receives 1 3 million from sale of its new jersey net operating losses,financing_agreements,DOWN,-3.409087676400963,17714540.0,12808492.0,12655315.0,2.143,945100.0,0.7230496529969167,0.09346626282280733,0,8,460,0.04545454545454545,2.964855117372811,0.0
in accordance with the instruction to the nomination committee scandic s nomination committee is made up of scandic s three largest shareholders as per august 31 2024 and the chair of the board of directors the nomination committee is composed as follows shareholders wishing to submit nominations to the nomination committee may do so by email to nominationcommittee scandichotels com by december 31 2024 scandic s annual general meeting will be held on may 6 2025 at vasateatern grand central in stockholm for more information please contact rasmus blomqvist director investor relations scandic hotels group email rasmus blomqvist scandichotels com phone 46 702 335 367 camilla köhler general counsel scandic hotels group email camilla kohler scandichotels com phone 46 709 735 159 about scandic hotels group scandic is the largest hotel company in the nordic countries with a network of about 280 hotels with 58 000 rooms in operation and under development in more than 13,nomination committee for scandic s agm 2025 appointed,annual_general_meeting,UP,0.0,21658378.0,45859984.0,7124020.0,1.612,2186300.0,2.1174246751072494,0.1515999603296736,4,8,267,0.26666666666666666,0.961003290910132,0.09722222222222222
sunnyvale calif may 09 2024 globe newswire biocardia inc nasdaq bcda a developer of cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced it will report its financial results for the the three months ended march 31 2024 and provide a corporate update by conference call on tuesday may 14 2024 at 4 30 pm et following management s formal remarks there will be a question and answer session,biocardia to host q1 2024 financial results and corporate update conference call on may 14 2024,conference_call_webinar,DOWN,-2.5641042361154187,11236022.0,3886990.0,44615.0,0.838,135000.0,0.3459400488891887,0.09346626282280733,3,7,415,0.0,1.32107885633281,0.17876984126984127
châtillon france 29 juillet 07 30 cest 2024,dbv technologies présente ses résultats financiers du premier semestre 2024 et fait le point sur l évolution de ses activités,conference_call_webinar,UP,0.7502646593083574,244630752.0,65520906.0,40445.0,0.319,55700.0,0.2678359342164799,0.09346626282280733,0,1,334,0.0,5.515503027122887,0.0
media release,banco comercial português s a informs about bank millennium poland results in 9m 2024,financial_results,UP,0.0710947833929026,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,242,0.0,0.8866002429130597,0.0
media release,archer limited disclosure of large shareholding,major_shareholder_announcements,UP,3.0491852271965074,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,240,0.07142857142857142,0.8866002429130597,0.2261904761904762
cambridge mass june 26 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today announced the appointment of edward dulac as executive vice president chief financial officer cfo and treasurer effective july 22 2024 mr dulac will succeed glenn goddard who will step down from his role effective june 30 2024,intellia therapeutics announces cfo transition,management_changes,DOWN,-0.583330790201823,970572672.0,98412511.0,6353695.0,2.134,5288300.0,0.1013963341840311,0.09346626282280733,2,7,367,0.26111111111111107,0.7800307612939593,0.029633580705009273
arcutis today announced that management will participate in the morgan stanley 22nd annual global healthcare conference,arcutis to present at the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,DOWN,-0.2398136378626535,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,3,8,310,0.0,0.6903751128737089,0.0913190865571818
media release,transactions by persons discharging managerial responsibilities and persons closely associated with them,regulatory_filings,DOWN,-1.5075402250875831,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,240,0.0,0.8866002429130597,0.0
media release,the goldman sachs group inc disclosure in norwegian air shuttle asa,company_regulatory_filings,DOWN,-0.3354173423953867,14229910528.0,710032904.0,13180369.8,0.752,19866086.0,0.04989721492646619,0.1515999603296736,3,7,240,0.0,0.4683640137646959,0.03125
zug switzerland oct 21 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announces the acceleration of patient enrollment for both phase 3 diamond trials of ocs 01 eye drops in dme and expansion of the diamond program committees with globally renowned retina experts,oculis accelerates enrollment in both diamond phase 3 trials of ocs 01 in diabetic macular edema and expands its diamond program committees,clinical_study,UP,2.637205221676264,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,0,4,250,0.0,0.4640841922034435,0.037482386894151606
remedy entertainment plc inside information september 27 2024 at 9 00 a m eest inside information remedy enters into a eur 15 million convertible loan agreement with tencent remedy entertainment plc remedy or company has today signed a convertible loan agreement with an affiliate of tencent holdings limited tencent to issue a eur 15 million unsecured convertible loan loan the loan carries an annual non cash interest and has a fixed conversion rate of eur 27 2 per share corresponding to a 63 premium of the closing price for remedy s shares on nasdaq helsinki on 26 september 2024 the loan is subject to approval by remedy s extraordinary general meeting which is expected to be held by 24 october 2024 remedy will publish the invitation to call the extraordinary general meeting separately the loan will be paid to remedy according to the convertible loan agreement after the extraordinary general meeting s approval and fulfillment of certain customary,inside information remedy enters into a eur 15 million convertible loan agreement with tencent,financing_agreements,UP,0.2409578750574071,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,0.10238095238095238,0.8866002429130597,0.0
only program that has demonstrated significant vision protection in standard and low light conditions and significant preservation of photoreceptors in the fovea region critical for visual acuity,annexon to present phase 2 archer data on protection of vision and photoreceptors with anx007 in ga at the retina society 57th annual meeting and 24th euretina congress,clinical_study,UP,0.5217427792756454,263313616.0,82380157.0,1425435.0,1.259,925100.0,0.31285946488995847,0.09346626282280733,0,8,292,0.12777777777777777,0.7558344054121836,0.13524810957440825
malvern pa sept 24 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dr arun upadhyay chief scientific officer head of research development will participate in an in person fireside chat moderated by daniil gataulin phd senior biotech research analyst at chardan s 8th annual genetic medicines conference being held september 30 october 1 2024 in new york new york,ocugen to participate in a fireside chat at chardan s 8th annual genetic medicines conference,conference_call_webinar,DOWN,-0.9615375798129148,302719328.0,287364635.0,6243265.0,4.237,6951700.0,0.9492774607374921,0.09346626282280733,1,7,277,0.13636363636363635,0.7661975315521313,0.057220202020202025
stockholm tisdagen den 22 oktober 2024 offentliggör tele2 ab tele2 nasdaq stockholm tel2 a och tel2 b resultatet för det tredje kvartalet 2024 presentationen görs av kjell johnsen vd och charlotte hansson finanschef dessutom kommer hendrik de groot chief commercial officer att ge en uppdatering om den svenska konsumentverksamheten tele2 offentliggör resultatet för det tredje kvartalet 2024 tisdagen den 22 oktober 2024 klockan 07 00 cest 06 00 bst 01 00 edt webbsändning och telefonkonferens en webbsändning och telefonkonferens med presentation kommer att hållas tisdagen den 22 oktober 2024 klockan 10 00 cest 09 00 bst 04 00 edt presentationen kommer att hållas på engelska och som längst pågå i 1 timme och 20 minuter registrering för webbsändningen och en separat registrering till telefonkonferensen kommer att finnas tillgänglig på www tele2 com för telefonkonferensen observera att uppringningsnummer och unik pin kod eller en call me funktion kom,tele2 bjuder in till presentation av resultatet för tredje kvartalet 2024,earnings_releases_and_operating_results,UP,0.1755195989408967,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,267,0.0,0.8866002429130597,0.0
media release,bghl eur nav s,fund_data_announcement,DOWN,-0.7194203635955471,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,243,0.0,0.8866002429130597,-0.004761904761904758
missing,immix biopharma advances car t nxc 201 to expansion cohort dose level in u s al amyloidosis trial nexicart 2,clinical_study,DOWN,-2.666664123535156,61887608.0,18058632.0,290605.0,0.301,58200.0,0.2917972205356523,0.09346626282280733,2,9,268,-0.2,0.9253604538231538,0.007407056677890011
mainz biomed presents coloalert at udh congress 2024 leading the way in evidence based cancer screening innovations,mainz biomed presents coloalert at udh congress 2024 leading the way in evidence based cancer screening innovations,trade_show,UP,3.773592756753207,5512458.0,2706585.0,75055.0,0.305,78500.0,0.4909942170987969,0.09346626282280733,1,8,473,0.0,34.079934680222834,0.0125
san diego oct 07 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced that company leadership will present at the 19th annual peptide therapeutics symposium taking place virtually and in person in la jolla california october 22 23 2024 details of the presentation are as follows,biora therapeutics to present at the 19th annual peptide therapeutics symposium,conference_call_webinar,DOWN,-1.7421586867605077,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,264,0.0,1.027516639474094,0.08571815089672234
media release,the world s first fiber to fiber biorecycled clothing unveiled by multi brand consortium carbios on patagonia puma pvh corp and salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.25,0.8866002429130597,0.0
avec pour objectif l ajout des adolescents et de la persistance des anticorps jusqu à deux ans,valneva soumet des demandes d élargissement de l indication de son vaccin contre le chikungunya ixchiq à l ema et santé canada,regulatory_filings,UP,1.647444840272518,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,1,283,0.0,0.6494694268312979,0.036153198653198645
collaboration focused on two targeted protein degraders from c4t s internal discovery pipeline,c4 therapeutics announces strategic discovery research collaboration with merck kgaa darmstadt germany against critical oncogenic proteins,licensing_agreements,UP,7.825301440056926,106155624.0,49730521.0,1021690.0,2.946,941900.0,0.4684680766418932,0.09346626282280733,0,7,481,0.0,0.8954742650579008,0.0875
boca raton florida sept 13 2024 globe newswire inmune bio inc nasdaq inmb the company or inmune bio a clinical stage inflammation and immunology company focused on developing treatments that harness a patient s innate immune system to fight disease today announced it has entered into securities purchase agreements with new and existing institutional investors and certain directors and officers and employees of the company the directors and officers and employees herein referred to as the insiders for the purchase and sale of 2 341 260 shares of its common stock and warrants to purchase up to an aggregate of 2 341 260 shares of common stock at a combined purchase price per share and accompanying warrant of 5 50 for the institutional investors and 6 50 per share and accompanying warrant for the insiders pursuant to a registered direct offering the warrants will be exercisable commencing six months from the date of issuance at a price of 6 40 per share and will expire five years from the initial exercise date the warrant term may be subject to acceleration following the satisfaction of certain conditions in the case of insiders that participated in the offering if the warrant termination date is on a blackout date then the insiders will have an additional 60 days from the termination of the blackout date to exercise the warrant,inmune bio announces 13 0 million registered direct offering,shares_issue,DOWN,-7.103823312288768,160853024.0,15213010.0,781395.0,1.567,974600.0,0.09457708423311954,0.09346626282280733,4,8,288,-0.0001731601731601723,0.8435084668920305,0.11759580928330929
media release,valmet s interim review january 1 september 30 2024 record high third quarter margin but slower market activity than expected,earnings_releases_and_operating_results,DOWN,-0.0830583796804002,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,240,0.02,0.8866002429130597,-0.016941094619666055
summary highlights including post period events,faron reports half year financial results january 1 june 30 2023,financial_results,DOWN,-0.5347588469389063,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,1,0,669,-0.08333333333333333,0.7633342480324978,0.0
redwood city calif may 14 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu and chronic inducible urticaria cindu today announced results for the fiscal quarter ended march 31 2024 and reported recent corporate developments,jasper therapeutics reports first quarter 2024 financial results and recent corporate developments,clinical_study,DOWN,-0.7225415071122696,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,8,410,0.10625,0.9821837329226573,0.15356637806637807
call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial call scheduled for study clinical leadership to discuss results and details on pivotal randomized trial,biocardia completes enrollment of cardiamp cell therapy for the treatment of chronic myocardial ischemia trial open label roll in cohort,clinical_study,DOWN,-2.6315723429754274,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,3,9,429,0.3333333333333333,1.32107885633281,-0.09702380952380951
warrington pa april 18 2024 globe newswire windtree therapeutics inc nasdaq wint windtree or the company a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions today announced that the company s board of directors has approved a 1 for 18 reverse stock split of its issued and outstanding common stock par value of 0 001 per share the reverse stock split the reverse stock split will become effective at 11 59 p m eastern time on april 19 2024 and the company s common stock will open for trading on the nasdaq capital market on a split adjusted basis under the symbol wint on april 22 2024 at such time the company s common stock will also commence trading under a new cusip number 97382d 501,windtree therapeutics announces reverse stock split,changes_in_share_capital_and_votes,UP,0.0,1381404.0,3660923.0,6680965.0,0.764,1224200.0,2.6501465176009336,0.09346626282280733,3,8,436,0.05303030303030303,2.339794177443606,0.003983714698000413
adagene s ceo dr peter luo participating in sitc webinar on september 22 focused on essential role of treg depletion for anti ctla 4 therapies,adagene to present at investor and scientific conferences in september,conference_call_webinar,DOWN,-4.059045460000049,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,6,660,0.0,0.845882180665701,0.24791666666666667
media release,recording of lhv group s 22 october investor webinar,financial_results,DOWN,-1.5781873742957673,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,12,248,0.0,0.8866002429130597,0.019978478443719087
not for release publication or distribution into or in the united states canada australia japan south africa or any other state or jurisdiction in which such release publication or distribution would be unlawful not for distribution to any u s person please see the important notice at the end of this press release,qiagen n v announces successful placement of new net share settled convertible bonds,financing_agreements,DOWN,-0.939601737078268,10135903232.0,214509546.0,1439980.0,0.673,1302400.0,0.02116333799663489,0.09346626282280733,1,11,297,0.19356060606060607,0.2568422597431085,0.06875
media release,first patient in bioporto initiates patient enrollment for us study of pronephro aki ngal for adult use at massachusetts general hospital,clinical_study,UP,2.380961571691675,631973184.0,427650961.0,317575.1666666667,0.924,137009.0,0.6766916252573147,0.09346626282280733,1,8,242,0.13333333333333333,0.44416720361162,0.0
planegg martinsried june 21 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors will present virtually at the 7th cell and gene therapy in depth focus summit taking place from june 27 28 2024 in beijing china,medigene to present at the cell and gene therapy in depth focus summit 2024,conference_call_webinar,DOWN,-3.6290287692390817,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,4,4,372,0.0,1.3169799228985475,0.02454545454545454
02 oct 2024 11 47 cest borr drilling limited folketrygdfondet har i dag 2 oktober 2024 solgt 60 000 aksjer i borr drilling ltd etter salget har folketrygdfondet netto 13 190 440 aksjer tilsvarende 4 99 av aksjene i selskapet more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site borr drilling limited oslo børs newspoint borr drilling bmg1466r1732 borr oslo børs,flagging i borr drilling ltd,major_shareholder_announcements,UP,1.117794830826217,443918176.0,174743108.0,6645095.0,1.794,4344400.0,0.3936381014504799,0.1515999603296736,2,9,268,0.2142857142857143,0.6240735968346586,0.03392857142857143
media release,tme pharma reçoit une subvention fédérale allemande de 2 4 millions d euros pour soutenir l essai de phase 2 de nox a12 dans le cancer du cerveau,financing_agreements,UP,8.108104298461395,7567473.0,35018869.0,709344.8636363636,1.573,202300.0,0.25000035609542787,0.09346626282280733,3,8,240,0.0,0.8573564202514549,0.0
cambridge mass and menlo park calif feb 15 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies and recode therapeutics a clinical stage genetic medicines company using tissue specific delivery to power the next wave of mrna and gene correction therapeutics today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis cf cf is a genetic disease caused by mutations in the cftr gene leading to the accumulation of thick mucus in the lungs digestive systems and other organs cf can result in life threatening infections respiratory failure and other serious complications,intellia therapeutics and recode therapeutics announce strategic collaboration to develop novel gene editing therapies for cystic fibrosis,partnerships,DOWN,-1.16690210641292,976673728.0,98412511.0,6353695.0,2.134,5288300.0,0.10076293462047543,0.09346626282280733,3,7,499,-0.17142857142857143,0.7800307612939593,0.11666666666666665
rockaway n j aug 08 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company announced today that the company s ceo dan goldberger is scheduled to participate in the 9th annual needham virtual medtech diagnostics 1x1 conference august 12 13 2024 please contact needham to schedule a 1x1 meeting,electrocore to participate in upcoming investor conferences,conference_call_webinar,UP,3.7704921749066864,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,3,8,324,0.0,0.8324549917316175,0.13647380397380396
media release,odfjell se presentation of third quarter 2024 results,earnings_releases_and_operating_results,DOWN,-0.3021102076463132,8592970752.0,15844521.0,49070.1,0.011,52497.0,0.0018438932771081774,0.1515999603296736,1,13,241,0.0,0.4144217492691169,0.0
brisbane calif sept 03 2024 globe newswire annexon inc nasdaq annx a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body brain and eye today announced the strengthening of its senior leadership team with the appointment of shikhar agarwal m b a as senior vice president head of commercial sunil b mehta pharm d as senior vice president of medical affairs and myoung kim phd m a m b a as vice president of health economics and outcomes research,annexon expands senior leadership in commercial medical affairs and health economics to advance global late stage neuroinflammatory targeted portfolio,management_changes,DOWN,-1.5789417326723645,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,1,8,298,-0.049999999999999996,0.7558344054121836,0.15377292053184907
waltham mass july 02 2024 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced it has completed the resubmission of its biologics license application bla to the u s food and drug administration fda for cosibelimab its anti programmed death ligand 1 pd l1 antibody as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma cscc who are not candidates for curative surgery or curative radiation,checkpoint therapeutics announces biologics license application resubmission for cosibelimab,regulatory_filings,UP,0.9756088483765962,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,1,7,361,0.1787878787878788,0.8866002429130597,0.07413636363636363
interim results in mss crc suggest that safebody precision masking technology enables a new standard for anti ctla 4 therapy at higher more frequent and repeat doses by overcoming longtime safety limited efficacy challenges with this proven immunotherapy target,adagene to present interim results of masked anti ctla 4 safebody adg126 muzastotug in combination with pembrolizumab in mss crc at asco gi symposium,clinical_study,UP,2.588238435633042,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,3,5,541,0.13070500927643786,0.845882180665701,0.16944444444444443
patient treated in trial achieved a remission after eight weeks of treatment demonstrating a significant reduction in proteinuria,eloxx pharmaceuticals intends to advance elx 02 into pivotal trial for the treatment of alport syndrome with nonsense mutations following achievement of remission in patient in phase 2 study,clinical_study,DOWN,-3.492435220091153,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,8,766,0.2916666666666667,2.2721670857062097,-0.03571428571428571
25 sep 2024 08 00 cest arctic bioscience as arctic bioscience are today presenting new research on cells at the eadv congress in amsterdam these cellular data show anti psoriatic effects from phospholipid esters from herring roe oil in immune cells and skin cells these data contribute to the understanding of how the investigational medicinal product hro350 could impact psoriasis and are supportive data to the ongoing clinical development program where the ongoing phase 2b heropa clinical trial in mild to moderate psoriasis has a planned read out later in september early october 2024 we are very pleased to present additional positive cellular data on the anti psoriatic properties related to our investigational medicine hro350 through these cellular studies we are increasing our understanding of how hro350 works says ceo christer l valderhaug the data from the cellular studies show that phospholipid esters from herring roe can have immunomodulatory anti ps,arctic bioscience new cellular research showing anti psoriatic effects,clinical_study,UP,9.242146234319629,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,276,0.18939393939393936,0.8866002429130597,0.0
mdxhealth reports q1 2024 results and announces growth capital from orbimed,mdxhealth reports q1 2024 results and announces growth capital from orbimed,earnings_releases_and_operating_results,UP,0.7999992370605469,110378976.0,35018869.0,71620.0,-490677.56,106500.0,0.31726031776196223,0.09346626282280733,2,7,423,0.0,0.6181119561491973,0.1142857142857143
media release,dividend payment procedure for shareholders of ab akola group,dividend_reports_and_estimates,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.03757706939525122
oxurion receives transparency notification from atlas special opportunities llc,oxurion receives transparency notification from atlas special opportunities llc,major_shareholder_announcements,UP,9.242146234319629,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,13,407,0.35714285714285715,2.0692591020840054,0.14829931972789118
petach tikva israel oct 30 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the u s financial markets on wednesday november 13 2024 the company will host a conference call and webcast at 8 30 am eastern time to discuss the results and provide an update on business operations,polypid to report third quarter 2024 financial results and operational highlights on november 13 2024,conference_call_webinar,UP,4.87106234468208,37239588.0,4610773.0,1395250.0,1.25,337200.0,0.12381374895984348,0.09346626282280733,2,8,241,-0.04285714285714286,0.7168605096826995,-0.028897807439474107
new york aug 19 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate intranasal foralumab a fully human anti cd3 monoclonal antibody today announced the appointment of ivor elrifi as its chief executive officer ceo effective immediately,tiziana life sciences appoints new chief executive officer,management_changes,DOWN,-0.8264454667762735,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,0,7,313,0.21818181818181817,1.1109140250580023,0.037909696613400316
27 sep 2024 12 00 cest swedbank ab the annual general meeting of swedbank ab will be held in stockholm thursday 27 march 2025 the members of the nomination committee are lennart haglund appointed by sparbankernas ägareförening and chair of the nomination committee ylva wessén appointed by folksam anders oscarsson appointed by amf annette björkman appointed by the owner group sparbanksstiftelserna magnus tell appointed by alecta tjänstepension göran persson chair of the board of directors of swedbank ab publ the nomination committee is assigned to prepare and present proposals to the 2025 agm regarding the election of chair of the agm members and chair of the board of directors and external auditor the nomination committee will also make proposals regarding the number of board members remuneration to the board members as well as external auditor s fee furthermore proposals for principles on how the nomination committee for agm 2026 shall be appoin,nomination committee for the agm 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,10,273,0.012500000000000004,0.8866002429130597,0.0
media release,two national airlines choose a seamless multi orbit ifc future with ses open orbits,product_services_announcement,DOWN,-4.347824604401455,33236662.0,5203991.0,38994.47368421053,-1.546,15503.0,0.15657381598669565,0.19535099655549074,2,8,241,0.03333333333333333,2.144966214298392,0.0888888888888889
yavne israel nov 21 2023 globe newswire mediwound ltd nasdaq mdwd a fully integrated biopharmaceutical company focused on next generation enzymatic therapeutics for tissue repair today announced the appointment of shmulik hess ph d to the positions of chief operating officer and chief commercial officer effective as of december 1 2023 dr hess will lead and oversee all operational and commercial activities at mediwound,mediwound announces appointment of shmulik hess ph d as chief operating officer and chief commercial officer,management_changes,DOWN,-0.5841143491100693,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,7,585,0.12,0.6433034533898109,0.0
oxurion announces results on the extraordinary general meeting egm of 24 july 2024,oxurion announces results on the extraordinary general meeting egm of 24 july 2024,extraordinary_general_meeting,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,2,12,338,0.19166666666666665,2.0692591020840054,0.15341269841269842
tel aviv israel and miami fla nov 02 2023 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for treatment of carotid artery disease and prevention of stroke today announced that the marvin slosman chief executive officer will participate in three upcoming investor conferences in november,inspiremd to participate in upcoming november investor conferences,conference_call_webinar,DOWN,-7.103823312288768,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,3,8,604,0.0,0.6085732039686736,0.07045454545454546
new york july 01 2024 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions and graviton bioscience corporation a privately held clinical stage biotechnology company focused on developing rho associated coiled coil containing protein kinase 2 rock2 inhibitors and other innovative therapeutic compounds today announced the results from their phase 1 healthy volunteer study evaluating the safety tolerability and pharmacokinetic pk profile of multiple ascending doses of ov888 gv101 capsule ovid and graviton plan to progress to a phase 2 clinical study in cerebral cavernous malformations ccm later this year,ovid therapeutics and graviton bioscience announce topline data from a phase 1 clinical trial studying ov888 gv101 capsule a potential first in class therapy for cerebral cavernous malformations,clinical_study,DOWN,-5.07151821092433,21844840.0,50354780.0,1012130.0,0.065,720700.0,2.305110955264493,0.09346626282280733,0,8,362,0.15613636363636363,0.7642184815786688,0.1723471964543393
single infusion of anx005 demonstrated significant improvements across multiple functional and prognostic measures that expedited recovery in gbs patients,annexon to present pivotal phase 3 data on early and durable benefits with first in class c1q blocking antibody anx005 in guillain barré syndrome at 2024 pns annual meeting,clinical_study,DOWN,-0.7462679264300778,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,1,8,375,0.16479591836734692,0.7558344054121836,0.1861627435064935
transcode therapeutics completes initial dosing of first co hort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,transcode therapeutics completes initial dosing of first cohort in phase 1 clinical trial with ttx mc138 a microrna targeted technology,clinical_study,DOWN,-0.7393730208448788,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,3,7,261,0.125,2.0874185587937095,-0.011931818181818184
expands available market to include over 200 children s hospitals in the united states expands available market to include over 200 children s hospitals in the united states,t2 biosystems receives fda clearance to market the t2candida panel for pediatric patients,product_services_announcement,UP,3.952574868853288,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,0,9,285,0.4,1.9596557041969667,0.04399454711954712
data show that p300 kat inhibitor kb 9558 was highly selective against human papillomavirus hpv oncoproteins e6 and e7 and therefore drove anti tumor effects,kronos bio to present data at the eortc nci aacr symposium that supports p300 kat inhibition in hpv driven tumors,clinical_study,UP,4.255321442460307,53652896.0,58898699.0,1370680.7894736843,1.643,0.0,1.0977729701673513,0.09346626282280733,2,8,262,0.05333333333333334,0.6178272804340184,0.037144360269360265
media release,indexo invites to a webinar on 9m 2024 financial results,conference_call_webinar,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,242,0.0,0.8866002429130597,0.15892676767676767
norwood mass feb 06 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will provide a corporate update and participate in one on one investor meetings at the oppenheimer 34th annual healthcare life sciences conference to be held virtually february 13 14 2024,corbus pharmaceuticals to present at the oppenheimer 34th annual healthcare life sciences conference,conference_call_webinar,UP,3.833862018261186,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,1,9,507,0.0,0.9919200800994142,-0.11515151515151517
sunnyvale calif july 17 2024 globe newswire biocardia inc nasdaq bcda a company focused on cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the unites states patent office has granted patent no 12 036 371 titled method of accessing the left atrium with a multi directional steerable catheter with a patent term that will expire in 2035,biocardia announces united states patent issuance on morph dna multi directional steerable catheter transseptal application,patents,UP,1.9047600305720729,11236022.0,3886990.0,44615.0,0.838,135000.0,0.3459400488891887,0.09346626282280733,2,7,346,0.0,1.32107885633281,0.12157738095238095
this announcement does not constitute or form part of any offer invitation to sell or issue or any solicitation of an offer to purchase or subscribe for any securities of akcinė bendrovė šiaulių bankas šiaulių bankas has successfully placed eur 50 million issue of fixed rate reset perpetual additional tier 1 temporary write down notes the annual fixed rate coupon on the notes up to the reset date will be 8 75 the nearest reset date is set after 5 years settlement will take place on 17 october 2024 it is intended to list the notes on the global exchange market multilateral trading facility operated by euronext dublin the notes have been allocated to almost 20 institutional and professional investors mostly from uk we have made another significant step for both the bank and the lithuanian capital market being the first issuer in the country to issue at1 notes we are grateful to our international investors who consistently show confidence in the bank s prospects this is,šiaulių bankas has successfully placed eur 50 million note issue on the international market,financing_agreements,DOWN,-0.3694533820828873,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,256,0.22281746031746036,0.8866002429130597,0.043625841750841755
terveystalo oyj pörssitiedote 27 9 2024 klo 12 45 terveystalo oyj n osakkeenomistajien nimitystoimikunta koostuu yhtiön neljän suurimman osakkeenomistajan edustajista 2 9 2024 omistustilanteen mukaan sekä yhtiön hallituksen puheenjohtajasta osakkeenomistajan jättäessä käyttämättä oikeuttaan edustajan nimeämiseen siirtyy nimitysoikeus osakasluettelon mukaan seuraavaksi suurimmalle osakkeenomistajalle nimitystoimikunnan tehtäviin kuuluvat muun muassa hallituksen jäsenehdokkaiden etsintä jäsenten ehdollepanon valmistelu ja esittely sekä hallituksen palkitsemisasiat nimitystoimikunta valitsee keskuudestaan puheenjohtajan edellä esitetyn mukaisesti terveystalon nimitystoimikunnan jäsenet ovat nimitystoimikunta valitsi järjestäytymiskokouksessaan 27 9 2024 puheenjohtajakseen risto murron osakkeenomistajien nimitystoimikunta toimittaa yhtiökokousta koskevat ehdotuksensa terveystalon hallitukselle viimeistään 1 helmikuuta 2025 lisätietoja nimitystoimikunnan tehtävistä ja kokoonpanost,terveystalo oyj n osakkeenomistajien nimitystoimikunnan kokoonpano,nomination_committee,DOWN,-0.4081628681073311,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,273,0.0,0.8866002429130597,0.0
mainz biomed publishes ceo statement ceo guido baechler eyes major growth and u s fda trials in 2025,mainz biomed publishes ceo statement ceo guido baechler eyes major growth and u s fda trials in 2025,clinical_study,UP,2.4096374726984093,5531532.0,2706585.0,75055.0,0.305,78500.0,0.4893011556292181,0.09346626282280733,1,8,270,0.0625,34.079934680222834,-0.024531024531024532
media release,bw energy limited prospectus approved for listing of bonds,prospectus_announcement,DOWN,-0.4347842672596807,8877470720.0,51507273.0,112603.25,1.177,77531.0,0.005802021163974056,0.1515999603296736,3,15,239,-0.07142857142857142,0.38625946949671847,-0.07142857142857142
communiqué du 23 octobre 2024,communiqué relatif à la mise à disposition des informations relatives aux caractéristiques notamment juridiques financières et comptables d eb development dans le cadre de l offre publique d achat visant les actions d eurobio scientific,clinical_study,UP,0.3875983892514247,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,2,248,0.0,0.4336088389568585,-0.0029761904761904756
redwood city calif sept 10 2024 globe newswire jasper therapeutics inc nasdaq jspr jasper a clinical stage biotechnology company focused on development of briquilimab a novel antibody therapy targeting c kit cd117 to address mast cell driven diseases such as chronic spontaneous urticaria csu chronic inducible urticaria cindu and asthma today announced that health canada has cleared the company s clinical trial application cta for a phase 1b 2a asthma challenge study evaluating briquilimab in asthma,jasper therapeutics announces health canada clearance of clinical trial application for phase 1b 2a study of briquilimab in asthma,clinical_study,DOWN,-0.8290147862020221,81488888.0,9908441.0,280900.0,2.725,505700.0,0.12159254154995955,0.09346626282280733,1,7,291,0.3,0.9821837329226573,0.133255772005772
media release,us district court for the southern district of new york orders a new trial on compensatory damages in atos litigation with trizetto,clinical_study,UP,1.983011155862438,24380684288.0,158122098.0,963560.0,0.703,746300.0,0.006485547990866957,0.1515999603296736,4,8,246,0.0909090909090909,0.17227975015947428,0.011363636363636362
media release,nanobiotix to participate in multiple investor conferences in november,conference_call_webinar,DOWN,-0.7575750277974386,186547712.0,20590720.0,130022.13636363637,1.564,72175.0,0.11037776759223936,0.09346626282280733,3,8,240,0.0,0.5536010581445269,0.0
transcode therapeutics announces pricing of 7 25 million public offering,transcode therapeutics announces pricing of 7 25 million public offering,shares_issue,DOWN,-7.103823312288768,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,3,13,526,0.0,2.0874185587937095,0.0
25 sep 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 24 sep 2024 estimated nav euro sharessterling sharesestimated nav 28 5679 25 6374estimated mtd return 0 53 0 36 estimated ytd return 3 70 4 34 estimated itd return 185 68 156 37 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 4 09 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 95 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,276,-0.006122448979591831,0.8866002429130597,0.0
adelaide australia and cambridge mass sept 14 2023 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced an update on the company s α7 nicotinic acetylcholine receptor nachr positive allosteric modulator pam collaboration with msd known as merck co inc rahway nj usa in the us and canada data for mk 4334 a novel clinical candidate developed by msd and derived from bionomics original α7 nachr pam candidate bnc375 was recently presented at the society for chemical industry sci and royal society of chemistry rsc 22nd medicinal chemistry symposium held in cambridge uk september 10 13 2023,bionomics announces update on the α7 nicotinic acetylcholine receptor nachr positive allosteric modulator pam collaboration with msd,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,6,653,0.08498032270759544,0.8866002429130597,-0.007776266061980347
missing,immix biopharma advances car t nxc 201 to expansion cohort dose level in u s al amyloidosis trial nexicart 2,clinical_study,DOWN,-2.666664123535156,61887608.0,18058632.0,290605.0,0.301,58200.0,0.2917972205356523,0.09346626282280733,2,9,268,-0.2,0.9253604538231538,0.007407056677890011
g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,conference_call_webinar,DOWN,-4.402516540601384,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,10,449,0.0,0.8866002429130597,0.0
gene therapy pioneer dr roger hajjar elected to longeveron board of directors as company advances it novel cellular therapy across multiple indications,gene therapy pioneer roger hajjar md elected to longeveron board of directors,management_changes,UP,0.0,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,9,355,0.0,1.063123411629147,0.09
malvern pa oct 02 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that dr shankar musunuri chairman chief executive officer and co founder of ocugen will present at the 2024 cell gene meeting on the mesa being held october 7 9 2024 at the arizona biltmore in phoenix az,ocugen to present at the 2024 cell gene meeting on the mesa,conference_call_webinar,DOWN,-1.05263058828844,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,2,6,269,0.0,0.7661975315521313,0.06098893698893699
immunocore to report fourth quarter and full year 2023 financial results and host call on february 28 2024,immunocore to report fourth quarter and full year 2023 financial results and host call on february 28 2024,earnings_releases_and_operating_results,DOWN,-0.3618468855857992,1604963584.0,37423034.0,614630.0,0.835,788600.0,0.023317061130279204,0.09346626282280733,2,7,493,0.11666666666666665,0.44240182162750774,0.0
planegg martinsried october 29 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will attend bio europe from november 4 6 2024 in stockholm as well as at the investival showcase biotech heathcare medtech conference on november 18 2024 in london in addition the company will present at the deutsches eigenkapitalforum from november 25 27 2024 in frankfurt,medigene to present at upcoming investor conferences,trade_show,DOWN,-1.6930006855879798,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,6,242,0.0,1.3169799228985475,0.05994214119214119
moonlake immunotherapeutics reports third quarter 2023 financial results and provides a business update,moonlake immunotherapeutics reports third quarter 2023 financial results and provides a business update,financial_results,UP,0.899923227523245,2929339136.0,28324751.0,691265.0,1.23,267600.0,0.009669331437901494,0.09346626282280733,1,8,592,0.0,0.5366763308656862,0.040984848484848485
immunocore to report fourth quarter and full year 2023 financial results and host call on february 28 2024,immunocore to report fourth quarter and full year 2023 financial results and host call on february 28 2024,earnings_releases_and_operating_results,DOWN,-0.3618468855857992,1604963584.0,37423034.0,614630.0,0.835,788600.0,0.023317061130279204,0.09346626282280733,2,7,493,0.11666666666666665,0.44240182162750774,0.0
media release,eviden manages coordination of cyderco project for the european cybersecurity competence center eccc,press_releases,DOWN,-0.4285659181827463,24371947520.0,158122098.0,963560.0,0.703,746300.0,0.006487872906760633,0.1515999603296736,0,10,242,-0.05,0.17227975015947428,0.04545454545454545
san diego may 08 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced that the company s management will participate in a fireside chat and one on one investor meetings at the citizens jmp life sciences conference to be held in new york ny may 13 14 2024,bioatla to participate in the citizens jmp life sciences conference,conference_call_webinar,DOWN,-1.9417457749564653,23425658.0,45152550.0,596440.0,0.911,569400.0,1.9274826773275697,0.09346626282280733,2,8,416,0.0007575757575757555,1.087702859114621,0.02409211159211159
los angeles oct 10 2023 globe newswire renovaro biosciences inc nasdaq renb renovaro an advanced pre clinical biotechnology firm in cell gene and immunotherapy focused on solid tumors with short life expectancy is pleased to announce the appointment of leni boeren and ruud hendriks as independent directors,renovaro biosciences appoints two finance industry experts to board of directors,management_changes,DOWN,-7.103823312288768,59949052.0,90925076.0,7542515.0,0.529,816400.0,1.516705818800938,0.09346626282280733,1,8,627,0.11666666666666665,1.5631250973582267,0.15
norwood mass march 12 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today provided a corporate update and reported financial results for the fourth quarter of 2023 and year ended 2023,corbus pharmaceuticals reports fourth quarter and year end 2023 financial results and provides corporate update,financial_results,UP,4.806688117197709,101687816.0,7524021.0,127840.0,3.117,146300.0,0.07399137178833697,0.09346626282280733,1,8,473,0.0,0.9919200800994142,0.032744588744588736
fda requires additional time to complete its review of atev acellular tissue engineered vessel bla for the treatment of vascular trauma,humacyte second quarter 2024 financial results and business update,clinical_study,DOWN,-0.0755803140854025,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,7,319,0.03333333333333333,1.1173068527438073,0.08527356902356903
redwood city calif nov 17 2023 globe newswire rezolute inc nasdaq rzlt a clinical stage biopharmaceutical company committed to developing novel transformative therapies for serious metabolic and rare diseases today announced that the management team will participate in btig s 3rd annual ophthalmology day taking place virtually on november 27th,rezolute to participate in btig s 3rd annual ophthalmology day,conference_call_webinar,DOWN,-0.9888771398730164,376341760.0,77797779.0,825115.0,1.04,796000.0,0.20672109042589373,0.09346626282280733,4,8,589,-0.008333333333333331,0.6820409900648857,0.0
during the investor conference webinar vytautas sinius ceo and tomas varenbergas head of investment management division introduced šiaulių bankas new dividend policy and answered to questions of participants the recording of it can be found on šiaulių bankas youtube channel here please find enclosed the information delivered during the presentation šiaulių bankas thanks all participants if you would like to receive šiaulių bankas news for investors directly to your inbox subscribe to our newsletter additional information tomas varenbergas head of investment management division tomas varenbergas sb lt attachment attachments dividend policy webinar 2024 pdf,the recording of šiaulių bankas investor conference webinar on new dividend policy,conference_call_webinar,UP,6.027392987619871,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,11,269,0.1431818181818182,0.8866002429130597,0.08813692480359148
kraig labs otcqb kblb is now in production with its bam 1 spider silk hybrids following the resounding successes of its spring production trials,kraig biocraft laboratories announces bam 1 spider silk hybrids are in production,product_services_announcement,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,390,0.0,0.8071333009212691,0.17736742424242424
žemaitijos pienas ab hereinafter the company provide i st half year of 2024 information i a set of consolidated financial statements for the first half of the financial year ii a consolidated half year report and iii approval of the responsible persons the person authorized to provide additional information arnas matuzashead of legale mail a matuzas zpienas lt attachments attachments approval of the responsible persons pdf a set of consolidated financial statements for the first half of the financial year pdf consolidated semi annual report pdf,žemaitijos pienas ab group half year information for the i st half of 2024,interim_information,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,13,270,-0.007142857142857136,0.8866002429130597,0.0
jupiter fla oct 09 2024 globe newswire dyadic international inc dyadic or the company nasdaq dyai a biotechnology company focused on the large scale efficient manufacturing of proteins for human and animal vaccines therapeutics and non pharmaceutical applications including food nutrition and wellness today announced its participation in several prominent industry events worldwide,dyadic expands global presence with participation in key industry events,trade_show,UP,0.8474669590729236,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,2,8,262,0.10204081632653061,0.7846450948942033,0.11020648211437685
g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negativ,g1 therapeutics provides update on phase 3 preserve 2 trial in patients receiving trilaciclib prior to first line chemotherapy in metastatic triple negative breast cancer mtnbc,clinical_study,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,369,0.04,0.8866002429130597,0.057692307692307696
dallas aug 05 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that it will report its financial results for the second quarter ended june 30 2024 and host a corporate update conference call and webcast on monday august 12 2024 at 8 30 am eastern time,taysha gene therapies to release second quarter 2024 financial results and host conference call and webcast on august 12,financial_results,DOWN,-5.714280524221172,626364352.0,136885482.0,5054745.0,1.016,2606600.0,0.21853970706174544,0.09346626282280733,0,8,327,0.0,1.0149166236087122,0.013161122503227776
san carlos calif feb 22 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer will report its fourth quarter and full year 2023 financial results on wednesday february 28 2024 management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4 30 p m et,iovance biotherapeutics to host fourth quarter and full year 2023 financial results conference call and webcast on wednesday february 28 2024,earnings_releases_and_operating_results,UP,3.804694762544173,591063232.0,280347936.0,11775260.0,0.863,9708200.0,0.47431124255754753,0.09346626282280733,3,8,492,0.10454545454545454,0.901765204231867,0.0
conference call to be held tuesday august 6 2024 at 8 30 am et conference call to be held tuesday august 6 2024 at 8 30 am et,tg therapeutics to host conference call on second quarter 2024 financial results and business update,conference_call_webinar,DOWN,-6.70270146550359,5894573568.0,135060602.0,1756590.0,1.939,1677400.0,0.022912701053254544,0.09346626282280733,0,7,327,0.0,0.6256004090066075,0.04368042671614099
norwood mass april 02 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio announced today the first patient in the u s has been dosed in the phase 1 clinical trial of crb 701 sys6002 a next generation antibody drug conjugate adc targeting nectin 4,corbus announces dosing of first patient in u s phase 1 clinical trial of its next generation nectin 4 targeting adc,clinical_study,DOWN,-2.053178624722872,102972672.0,7524021.0,127840.0,3.117,146300.0,0.0730681340385146,0.09346626282280733,1,8,452,0.125,0.9919200800994142,0.02865151515151515
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
san diego sept 06 2024 globe newswire capricor therapeutics nasdaq capr a biotechnology company developing transformative cell and exosome based therapeutics for the treatment of rare diseases today announced that the company is scheduled to present at various upcoming investor and scientific conferences,capricor therapeutics to present at upcoming investor and scientific conferences,press_releases,UP,0.4717089349841497,436052416.0,40176259.0,3124730.0,0.85,8768900.0,0.09213630638386372,0.09346626282280733,4,8,295,0.075,1.3427880947904531,0.14391216856060607
norwood mass sept 26 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that the company will participate in bmo capital markets oncology summit to be held october 8 2024 in new york ny dr dominic smethurst ma mrcp chief medical officer of corbus will participate in a panel titled capitalizing on validated mechanism in oncology dr smethurst will also be joined by yuval cohen ph d chief executive officer of corbus to participate in one on one investor meetings,corbus pharmaceuticals to participate in the bmo capital markets oncology summit,conference_call_webinar,UP,2.20140189675321,102544384.0,7524021.0,127840.0,3.117,146300.0,0.07337331120931986,0.09346626282280733,3,8,275,0.06818181818181818,0.9919200800994142,0.06776114081996434
partners able to claim up to tax relief partners able to claim up to tax relief,centogene receives french research tax credit accreditation,government_news,DOWN,-2.3999977111816406,9425032.0,11780726.0,14516.947368421053,-0.672,10007.0,1.2499401593543662,0.09346626282280733,2,6,521,0.3333333333333333,3.598197549072007,0.07559523809523809
elx 02 granted orphan drug designation odd from u s food and drug administration fda for treatment of alport syndrome,eloxx pharmaceuticals provides elx 02 and zkn 013 program updates,licensing_agreements,UP,2.040704123597667,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,7,438,-0.16666666666666666,2.2721670857062097,0.07910245310245312
provides clinicians with superior wound size measurement information that improves patient treatment decisions provides clinicians with superior wound size measurement information that improves patient treatment decisions,spectral ai completes proof of concept for wound measurement technology,product_services_announcement,UP,1.9801961500356329,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,3,8,268,0.7,0.9904696515070965,0.06270820449391878
media release,ab akola group s notification about the annual information for the financial year 2023 2024,financial_results,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.06441783324900209
kraig labs otcqb kblb completed the first phase of construction for its production facility expansion to support the company s third production wave,kraig biocraft laboratories completes phase one of its spider silk production facility expansion,capital_investment,UP,0.0,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,348,0.125,0.8071333009212691,0.12978896103896104
san diego oct 04 2024 globe newswire bioatla inc nasdaq bcab a global clinical stage biotechnology company focused on the development of conditionally active biologic cab antibody therapeutics for the treatment of solid tumors today announced a poster presentation at the upcoming 39th society for immunotherapy of cancer sitc annual meeting being held from november 8 10 2024 at the george r brown convention center in houston tx,bioatla announces upcoming poster presentation at the 39th society for immunotherapy of cancer annual meeting,clinical_study,DOWN,-0.8510630526872615,23390608.0,45152550.0,596440.0,0.911,569400.0,1.930370942046483,0.09346626282280733,4,9,267,-0.058333333333333334,1.087702859114621,0.007418144025286881
parsippany n j oct 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its third quarter financial results after the close of the u s markets on wednesday november 6 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report third quarter 2024 financial results on wednesday november 6 2024,conference_call_webinar,DOWN,-1.1641487740788885,1112970496.0,45834212.0,557500.0,0.511,435200.0,0.04118187513930288,0.09346626282280733,2,8,241,0.022727272727272724,0.7130794063724827,0.1400731339367703
seattle feb 29 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that it has completed a review of its business including the status of its programs resources and capabilities following this review kineta is implementing a significant corporate restructuring to substantially reduce expenses and preserve cash the restructuring includes a significant workforce reduction and the termination of enrollment of new patients in its ongoing vista 101 phase 1 2 clinical trial evaluating kva12123 in patients with advanced solid tumors patients currently enrolled in the trial will be permitted to continue to participate the company has made this decision in part because certain investors have indicated they will not fulfill their funding obligations pursuant the previously disclosed second tranche of the company s contemplated private placement later this year,kineta announces restructuring and exploration of strategic alternatives,corporate_action,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,485,0.1026140526140526,0.8866002429130597,0.09210317460317462
copenhagen denmark june 17 2024 globe newswire evaxion biotech a s nasdaq evax evaxion or the company a clinical stage techbio company specializing in developing ai immunology powered vaccines announces publication of data from its phase 1 dose escalation study of its lead personalized cancer vaccine candidate evx 01 for metastatic melanoma the study results published in the journal for immunotherapy of cancer demonstrated that eight out of 12 patients experienced objective clinical responses orr with six partial and two complete responses further evx 01 immunization did not induce vaccine related serious adverse events in patients co administered with anti pd1 therapy,evaxion publishes data showing objective response rate in metastatic melanoma for the ai designed personalized cancer vaccine evx 01 in leading medical journal,clinical_study,DOWN,-5.806446254067152,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,0,8,376,0.05185185185185186,1.4249795072460607,0.13510101010101008
south san francisco calif oct 21 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today announced an upcoming oral presentation and two late breaking poster presentations at the 75th annual american association for the study of liver diseases aasld the liver meeting 2024 taking place from november 15 19 2024 in san diego the presentations will highlight findings from the 96 week phase 2b harmony study evaluating the efficacy and safety of lead product candidate efruxifermin efx in patients with pre cirrhotic metabolic dysfunction associated steatohepatitis mash fibrosis stage 2 or 3 f2 f3 along with insights from an analysis using ai and digital based pathology,akero therapeutics to present data reinforcing the efficacy of efruxifermin at the 75th annual aasld the liver meeting 2024,clinical_study,DOWN,-0.8965699116267896,4378887680.0,65983030.0,1904080.0,-0.16,4370200.0,0.015068445418540627,0.09346626282280733,0,7,250,-0.04666666666666666,1.1395320392459187,-0.015071087862754526
needham mass april 09 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced the presentation of a poster during the american association for cancer research aacr annual meeting taking place april 5 through 10 in san diego which focused on a first in class multimodal immunotherapy candidate for induction of tertiary lymphoid structures tls being developed as a novel therapeutic strategy for solid tumors from candel s enlighten discovery platform,candel therapeutics presents preclinical data at aacr on immunotherapy candidate for induction of tertiary lymphoid structures in solid tumors,clinical_study,DOWN,-2.79937532105862,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,1,8,445,0.06999999999999999,1.2870358800144117,0.09025985962566843
conference call to begin at 4 30 p m et,vaxart to host second quarter 2024 business update and financial results conference call on august 8,conference_call_webinar,DOWN,-1.515159040990203,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,4,8,330,0.0,1.025768835125998,0.08874458874458874
la jolla calif may 14 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that it has received a notice of allowance from the u s patent and trademark office for a pending patent application which covers mn 166 ibudilast for the treatment of chlorine induced acute respiratory distress syndrome ards,medicinova receives notice of allowance for new patent covering mn 166 ibudilast for the treatment of chlorine induced acute respiratory distress syndrome,patents,UP,0.657894117680275,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,1,6,410,0.2672727272727273,0.8018560055721619,0.09583333333333334
second rare disease program with rz358 in phase 3 development,rezolute announces fda clearance of ind application for phase 3 registrational study of rz358 for treatment of hypoglycemia due to tumor hyperinsulinism,clinical_study,DOWN,-7.103823312288768,377643968.0,77797779.0,825115.0,1.04,796000.0,0.20600826596547148,0.09346626282280733,0,7,327,0.05833333333333333,0.6820409900648857,-0.008932900432900431
anx007 demonstrated significant vision protection in standard and low light conditions and significant photoreceptor preservation in the fovea region critical for visual acuity,annexon to present new phase 2 archer data for anx007 in dry amd patients with less advanced ga at the american academy of ophthalmology 2024 meeting,clinical_study,UP,0.4065004404605497,261119328.0,82380157.0,1425435.0,1.259,925100.0,0.3154885455281196,0.09346626282280733,1,8,256,0.11177156177156178,0.7558344054121836,0.1347592784199927
berwyn pa feb 16 2021 globe newswire annovis bio inc nyse american anvs a clinical stage drug platform company addressing alzheimer s disease ad parkinson s disease pd and other neurodegenerative diseases today announced that maria maccecchini ph d founder and chief executive officer will present at the bio ceo digital conference available online february 16 18 2021 annovis bio s presentation will be accessible on demand during the virtual event for all registered attendees,annovis bio to present at the bio ceo investor digital conference,conference_call_webinar,UP,9.242146234319629,44036864.0,15624645.0,595065.0,1.618,805900.0,0.3548083033342247,0.09346626282280733,1,6,1593,0.08125,1.368989555493872,-0.025
arcutis today announced the fda has accepted its snda for zoryve roflumilast foam 0 for scalp and body psoriasis,fda accepts arcutis supplemental new drug application for zoryve roflumilast foam for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over,regulatory_filings,DOWN,-0.2076890708825607,1724852992.0,85869346.0,2010100.0,1.778,2359700.0,0.049783573671651205,0.09346626282280733,1,8,277,0.13636363636363635,0.6903751128737089,0.04597881240038103
eurobio scientific levée de la dernière condition suspensive règlementaire au projet d opa initié par eb development,eurobio scientific levée de la dernière condition suspensive règlementaire au projet d opa initié par eb development,mergers_acquisitions,UP,0.194936238412485,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,10,254,0.0,0.4336088389568585,-0.003401360544217686
02 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 01 oct 2024 estimated nav euro shares sterling shares estimated nav 28 3502 25 4874 estimated mtd return 0 03 0 02 estimated ytd return 2 91 3 73 estimated itd return 183 50 154 87 nav and returns are calculated net of management and performance fees market information euro shares amsterdam aex london lse market close 27 20 n a premium discount to estimated nav 4 06 n a sterling shares amsterdam aex london lse market close n a gbx 2 360 00 premium discount to estimated nav n a 7 41 transactions in own securities purchased into treasury ordinary shares euro shares sterling s,bghl gbp nav s,fund_data_announcement,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,5,269,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
redwood city calif april 24 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced the first presentation of clinical data for chs 114 a highly selective cytolytic anti ccr8 antibody at the upcoming asco annual meeting which will be held from may 31 to june 4 2024 at mccormick place in chicago,coherus announces presentation at the 2024 american society of clinical oncology asco annual meeting,clinical_study,DOWN,-7.103823312288768,84909328.0,110892497.0,1236840.0,0.883,1425300.0,1.306010771867138,0.09346626282280733,2,10,429,0.1366666666666667,1.0144535837204522,0.23249999999999998
media release,carbios und das textilkonsortium der markenhersteller on patagonia puma pvh corp und salomon stellen das weltweit erste zu 100 biologisch von faser zu faser recycelte kleidungsstück vor,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.0,0.8866002429130597,0.0
zkn 013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa rdeb and jeb and familial adenomatous polyposis fap,eloxx pharmaceuticals announces fda clearance to begin single ascending dose study of zkn 013,clinical_study,DOWN,-1.2931056335432467,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,1,8,788,-0.03571428571428571,2.2721670857062097,0.0
16 oct 2024 08 00 cest arctic bioscience as med henvisning til gårsdagens børsmelding vedrørende webcast som vil bli holdt i dag klokken 12 00 for å presentere resultatene fra heropa utlesningen vedlagt er presentasjonsmaterialet som vil bli presentert i denne webcasten webcasten vil bli ledet av ceo christer l valderhaug og medisinsk direktør runhild gammelsæter webcast detaljer dato onsdag 16 oktober 2024 tidspunkt 12 00 format webcast språk engelsk presentasjonen kan nås via ved å følge linken under link https channel royalcast com landingpage hegnarmedia 20241016_1 denne opplysningen er informasjonspliktig etter verdipapirhandelloven 5 12 for mer informasjon vennligst kontakt christer l valderhaug ceo mobil 47 920 84 601 e post christer arctic bioscience com om arctic bioscience arctic bioscience er et bioteknologiselskap som utvikler og kommersialiserer farmasøytiske produkter og kosttilskudd basert på unike bioaktive marine,arctic bioscience presentasjon til dagens webcast,conference_call_webinar,UP,8.275862125664345,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,255,0.0,0.8866002429130597,0.2348484848484848
company announcement no 42 2024 27 september 2024 transactions in connection with share buyback programmeon 14 august 2024 netcompany group a s netcompany announced that a share buyback programme of up to dkk 150m and a maximum of 1 000 000 shares had been initiated with the purpose of adjusting netcompany s capital structure and meeting its obligations relating to share based incentive programmes the share buyback programme is executed in accordance with eu market abuse regulation eu regulation no 596 2014 of 16 april 2014 and the provisions of commission delegated regulation eu 2016 1052 of 8 march 2016 the safe harbour regulation the share buyback programme will end no later than 29 october 2024 transactions made under the share buyback programme will be announced through nasdaq copenhagen on a weekly basis the following transactions have been executed in the period 20 september 2024 to 26 september 2024 detailed,netcompany transactions in connection with share buyback programme,changes_in_companys_own_shares,DOWN,-1.0335956537291917,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,11,273,0.225,0.8866002429130597,0.0
arcutis today announced the submission of an snda in scalp and body psoriasis,arcutis submits supplemental new drug application for zoryve roflumilast foam to the fda for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over,regulatory_filings,DOWN,-0.5076161299336185,1726044928.0,85869346.0,2010100.0,1.778,2359700.0,0.049749195172745814,0.09346626282280733,1,8,340,0.13636363636363635,0.6903751128737089,0.056512212067767624
media release,fiskars corporation s directed share issue without consideration based on the restricted share plan,shares_issue,DOWN,-2.9754206792492868,1157121792.0,36127016.0,13413.65,0.866,11916.0,0.03122144639377771,0.1515999603296736,1,9,242,0.0,0.21141844058764958,0.0
in preclinical studies chs 1000 shows a high affinity for human ilt4 reverses ilt4 mediated immunosuppressive functions leading to activation of immune cells and increased cytokine secretion mechanism may enhance antitumor responses with immunotherapy first novel immuno oncology product candidate discovered and developed by coherus the chs 1000 ind submission is planned for q2 2024,coherus presents preclinical data for chs 1000 a novel anti ilt4 antibody at the 2024 aacr annual meeting,clinical_study,UP,0.8230444599618197,85523776.0,110892497.0,1236840.0,0.883,1425300.0,1.2966277003484972,0.09346626282280733,0,8,446,0.1275,1.0144535837204522,0.25
generated first quarter 2024 cguard eps revenue of 1 51 million an increase of 22 over the first quarter of 2023,inspiremd reports first quarter 2024 financial results and provides business update,earnings_releases_and_operating_results,UP,1.2499987582366163,67397664.0,16849440.0,286250.0,0.613,4867100.0,0.25000035609542787,0.09346626282280733,1,7,410,0.1875,0.6085732039686736,0.07180622009569378
sampo plc managers transactions 2 october 2024 at 3 00 pm eest sampo plc managers transactions thorsrud sampo plc business code 0142213 3 has received the following notification under article 19 of the market abuse regulation shares have been acquired in accordance with terms and conditions of the long term incentive scheme 2020 1 ____________________________________________ person subject to the notification requirement name morten thorsrudposition other senior managerissuer sampo plclei 743700uf3rl386wida22notification type initial notificationreference number 80020 5 6____________________________________________ transaction date 2024 09 30venue nasdaq helsinki ltd xhel instrument type shareisin fi4000552500nature of transaction receipt of a share based incentive transaction details 1 volume 3 578 unit price 41 9316 eur aggregated transactions 1 volume 3 578 volume weighted average price 41 9316 eur____________________________________________ transa,sampo plc managers transactions thorsrud,company_regulatory_filings,UP,0.2147974923874487,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,14,268,-0.08194444444444444,0.8866002429130597,0.1625
company announcement inside information,inside information faron announces positive bexmab study update in relapsed refractory aml and hma refractory mds patients,clinical_study,UP,6.151829822057976,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,2,7,626,0.22727272727272727,0.7633342480324978,0.06907647907647908
newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501 newly granted patent aligns with company s focus on expanding geographic coverage and strengthening intellectual property protection for bxcl501,bioxcel therapeutics announces european patent office s grant of patent for method of treating agitation in dementia using sublingual dexmedetomidine,patents,DOWN,-1.7421586867605077,12766154.0,5544250.0,450810.0,-0.13,78500.0,0.4342928966703676,0.09346626282280733,4,7,470,0.17454545454545456,1.4586588351104455,-0.030684523809523807
new york june 11 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced it has received acceptance of its submission for intranasal foralumab to receive fast track designation approval for the treatment of non active secondary progressive multiple sclerosis na spms to the u s food and drug administration fda,fda accepts tiziana life sciences fast track designation submission for treatment of multiple sclerosis,clinical_study,DOWN,-6.000000238418579,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,8,382,0.014718614718614726,1.1109140250580023,0.03405670461226017
event to highlight results from the clinical trial of bt 600 an orally administered drug device combination in development for ulcerative colitis,biora therapeutics to host virtual kol event on navicap targeted oral delivery platform and results from phase 1 clinical trial of bt 600 on july 17 2024,clinical_study,DOWN,-0.887580141792744,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,355,0.0,1.027516639474094,0.11515924551638838
cambridge mass feb 21 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that it will host a conference call and webcast on wednesday february 28 2024 at 8 00 a m et to discuss results for the fourth quarter and full year 2023 and to provide a corporate update,editas medicine announces fourth quarter and full year 2023 results conference call and upcoming investor events,conference_call_webinar,UP,0.0,181656992.0,83382193.0,2526680.0,2.096,3015800.0,0.45900899316883986,0.09346626282280733,2,7,493,0.13999999999999999,1.3105556047468256,0.023863636363636365
sunnyvale calif aug 29 2024 globe newswire biocardia inc nasdaq bcda a global leader in cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases announced today that the food and drug administration fda has cleared biocardia to market the morph dna steerable introducer product family subject to the general controls provisions of the federal food drug and cosmetic act,biocardia announces fda market clearance of morph dna steerable introducer product family,product_services_announcement,UP,9.242146234319629,11236022.0,3886990.0,44615.0,0.838,135000.0,0.3459400488891887,0.09346626282280733,3,8,303,-0.03888888888888888,1.32107885633281,0.06626984126984127
se venligst vedhæftede,ledende medarbejderes transaktioner,press_releases,DOWN,-0.8807045636509208,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,14,268,0.0,0.8866002429130597,0.0
media release,neste nimittää uuden johtoryhmän ja eeva sipilän talous ja rahoitusjohtajaksi,management_changes,DOWN,-1.0480036062946114,8842487808.0,419729896.0,3546183.5,1.115,2479992.0,0.04746739889426376,0.1515999603296736,0,8,243,0.0,0.4498875103976574,0.0
please be informed that on 17 september 2024 invl technology has transferred part of its shares 206 units to the employees of invl technology s subsidiaries who acquired the right to pre empt realization of the option right under the basis and terms of signed option agreements considering this invl technology hereby announces the data on its issued shares as of 17 september 2024 the person authorized to provide additional information invl technology managing partner kazimieras tonkūnas e mail k tonkunas invltechnology lt,information about shares issued by invl technology and votes granted,changes_in_companys_own_shares,DOWN,-2.424240147334014,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,13,282,0.2857142857142857,0.8866002429130597,0.0
san francisco july 20 2023 globe newswire vir biotechnology inc nasdaq vir today announced that the phase 2 peninsula prevention of illness due to influenza a trial evaluating vir 2482 for the prevention of symptomatic influenza a illness did not meet primary or secondary efficacy endpoints in participants who received the highest dose of vir 2482 1 200 mg a non statistically significant reduction of approximately in influenza a protocol defined illness was observed participants who received the highest dose showed an approximately reduction in symptomatic influenza a illness when defined according to cdc influenza like illness criteria which was one of two secondary endpoints vir 2482 was generally well tolerated and no safety signals were identified,vir biotechnology announces topline data from phase 2 peninsula trial evaluating vir 2482 for the prevention of seasonal influenza a illness,clinical_study,DOWN,-7.103823312288768,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,3,8,709,-0.0875,0.8653389999075153,0.08956876456876456
seattle oct 04 2024 globe newswire kineta inc otc pink kant a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that its abstract on the kva12123 clinical program has been accepted for poster presentation at the society for immunotherapy of cancer sitc 40th annual meeting to be held november 6 10 2024 in houston texas and virtually,kineta announces kva12123 abstract accepted for poster presentation at society for immunotherapy of cancer sitc 2024,clinical_study,DOWN,-2.833336479133905,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,9,267,-0.1,0.8866002429130597,0.10699848397216818
july september 2024 january september 2024 significant events during the quarter shareholders financial analysts and media are kindly invited to a webcast in english including presentation of the quarterly results and a q a today on the 16th of october 2024 at 11 00 cet if you wish to participate via webcast please register via the link below please note that it can take a few minutes to receive the confirmation e mail with the teams link following registration https events teams microsoft com event ef8fe4b3 cc62 47ab addd f56de753bdff 8a6f565d 42e1 4b27 93d3 51ae5cf1e4a2 the presentation will be available after the webcast at www flerie com for more information ted fjällman ceoemail ir flerie com flerie in briefflerie is an active long term life science investor with a broad and diversified portfolio of innovative companies based on pioneering science we invest in product development and commercial growth opportunities globally alongside other leading investors focus,interim report january september 2024,conference_call_webinar,UP,0.070469296480926,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,255,0.1286111111111111,0.8866002429130597,-0.003921568627450981
ad hoc announcement pursuant to art 53 lr,addex enters into at the market ads offering agreement with h c wainwright co llc,financing_agreements,DOWN,-1.563938160843887,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,514,0.0,0.972373032385036,-0.23333333333333328
boston jan 17 2024 globe newswire pepgen inc nasdaq pepg a clinical stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases today announced the expansion of its executive team with the appointment of mary beth delena as general counsel and secretary ms delena joins pepgen with over 20 years of experience advising global life science companies in a broad range of strategic transactional and corporate matters with extensive experience in business development finance securities corporate governance employment and commercial law,mary beth delena joins pepgen as general counsel and secretary,management_changes,UP,1.357461149279659,45645656.0,12870456.0,168500.0,1.294,155200.0,0.28196453130173,0.09346626282280733,2,7,528,0.01805555555555556,1.4553932872573117,0.05981060606060606
san carlos calif april 30 2024 globe newswire iovance biotherapeutics inc nasdaq iova a biotechnology company focused on innovating developing and delivering novel polyclonal tumor infiltrating lymphocyte til therapies for patients with cancer today announced that senior leadership plans to present at the following conferences,iovance biotherapeutics to present at upcoming conferences,press_releases,DOWN,-1.080632729231244,599411520.0,280347936.0,11775260.0,0.863,9708200.0,0.46770528534386524,0.09346626282280733,1,6,424,0.0,0.901765204231867,0.010606060606060605
furoscix is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure regardless of new york heart association nyha functional class,scpharmaceuticals announces fda approval of supplemental new drug application expanding the furoscix indication in heart failure,product_services_announcement,DOWN,-4.157039988688057,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,6,320,-0.055086580086580086,0.7082528246818063,0.012215909090909093
media release,quadient obtient un prêt schuldschein de 25 millions d euros auprès de la berd pour financer des programmes de r d en république tchèque,financing_agreements,DOWN,-1.960782480441495,528319008.0,22771639.0,0.0,1.149,0.0,0.04310206268406682,0.19535099655549074,2,7,241,0.0,0.39343620296100096,0.0
company expects to announce topline safety tolerability and immunogenicity data from primary immunization series by the end of the first quarter of 2025 followed by topline data from booster dose by the end of 2025 vax 24 a 24 valent pneumococcal conjugate vaccine pcv is designed to cover more serotypes than any infant pneumococcal vaccine on market or in u s clinics today,vaxcyte completes enrollment of phase 2 study evaluating vax 24 for the prevention of invasive pneumococcal disease ipd in infants,clinical_study,UP,0.1952299420385176,4309378560.0,115925698.0,1672660.0,1.204,957300.0,0.026900792396386732,0.09346626282280733,0,8,481,0.3833333333333333,0.8014129308283596,-0.05555555555555556
malvern pa may 13 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases provided updates from across the organization and announced first quarter financial results,annovis bio provides corporate updates and announces first quarter 2024 financial results,clinical_study,UP,9.242146234319629,44218088.0,15624645.0,595065.0,1.618,805900.0,0.35335415226456646,0.09346626282280733,0,7,411,0.1,1.368989555493872,0.08491161616161615
media release,ab akola group s notification about the annual information for the financial year 2023 2024,financial_results,DOWN,-0.796811992131617,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.0,0.8866002429130597,0.06441783324900209
planegg martinsried august 28 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will be presenting at the the annual german fall conference to be held in frankfurt from september 2 3 2024 as well as at the h c wainwright 26th annual global investment conference from september 9 11 2024 in new york and at the baader investment conference from september 23 26 2024 in munich,medigene to present at upcoming investor conferences,conference_call_webinar,DOWN,-3.1818150784359176,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,5,304,0.02727272727272727,1.3169799228985475,0.0563985088985089
new york nov 03 2023 globe newswire ovid therapeutics inc nasdaq ovid a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure related disorders today reported business updates and financial results for the third quarter ended september 30 2023,ovid therapeutics reports third quarter 2023 financial results and corporate updates,financial_results,UP,1.6997151066808331,21731064.0,50354780.0,1012130.0,0.065,720700.0,2.317179683424613,0.09346626282280733,4,8,603,0.05454545454545454,0.7642184815786688,0.06866110080395794
tampa fla april 30 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced that it will report its first quarter financial results after the close of the u s markets on tuesday may 7 2024 following the release the company will host a live conference call and webcast at 4 30 p m et,pacira to report first quarter 2024 financial results on tuesday may 7 2024,earnings_releases_and_operating_results,DOWN,-0.7293613522977731,1111081344.0,45834212.0,557500.0,0.511,435200.0,0.04125189595479339,0.09346626282280733,1,8,424,0.10606060606060606,0.7130794063724827,0.188501443001443
new york and mainz germany august 16 2024 pfizer inc nyse pfe pfizer and biontech se nasdaq bntx biontech today announced top line results from their phase 3 clinical trial to evaluate the companies combined mrna vaccine candidate against influenza and covid 19 in healthy individuals 18 64 years of age the combination candidate consists of pfizer s mrna based influenza vaccine candidate with the companies licensed covid 19 vaccine the phase 3 trial measured two primary immunogenicity objectives immunogenicity against sars cov 2 as well as immunogenicity against influenza a and b of which one was met in a separate phase 2 trial pfizer evaluated trivalent tirv influenza mrna standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18 64 years of age the companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza b and will discuss next steps with health authorities,pfizer and biontech provide update on mrna based combination vaccine program against influenza and covid 19 in individuals 18 64 years of age,clinical_study,DOWN,-3.43839541547278,24731838464.0,97284490.0,1237590.0,1.285,391100.0,0.00393357291822881,0.09346626282280733,4,6,316,0.30727272727272725,0.5503225880253886,0.08867815055315056
media release,first phosphate dépose le rapport technique ni 43 101 pour l estimation initiale des ressources minérales du site de bégin lamarche saguenay lac saint jean québec,regulatory_filings,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,14,239,0.25,0.8866002429130597,0.12787363769271665
media release,norden iværksætter aktietilbagekøb,changes_in_companys_own_shares,DOWN,-0.2601934465024619,5957698048.0,19692529.0,75994.27777777778,0.303,53141.0,0.0033053922574358707,0.1515999603296736,3,8,240,0.0,0.37515160223877836,0.0
rapt to host a conference call today at 8 30 am et,rapt therapeutics announces clinical hold on studies evaluating zelnecirnon,clinical_study,DOWN,-7.103823312288768,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,1,7,494,0.0,1.6028075568485736,0.11840367965367966
se han presentado datos de primera línea del ensayo de fase 1 patrocinado por investigadores del vcn 01 por vía intravítrea en pacientes pediátricos con retinoblastoma refractario el comité de vigilancia del estudio dictaminó que los resultados del ensayo son positivos,theriva biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024,clinical_study,DOWN,-4.761904761904762,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,6,416,0.0,1.5225134880447404,0.08038383838383838
media release,immutep quarterly activities report q3 fy24,clinical_study,UP,4.905655522412875,228090976.0,1232826146.0,113325.0,1.522,138900.0,5.404975539233959,0.09346626282280733,0,8,425,0.0,0.7476881311953882,0.1590909090909091
zug sviss june 10 2024 globe newswire oculis holding ag nasdaq ocs xice ocs oculis eða félagið alþjóðlegt líftæknifyrirtæki sem hefur það að markmiði að þróa augnlyf sem bæta sjón í alvarlegum augnsjúkdómum tilkynnti í dag um jákvæðar niðurstöður úr fasa 2b relief rannsókninni með licaminlimab nýjum tnfα hamlara líftækniaugndropum með staðfesta tvíþætta virkni sem dregur úr bólgu og hamlar frumudauða hjá sjúklingum með augnþurrk ded,oculis kynnir jákvæðar niðurstöður úr fasa 2b relief rannsókn með licaminlimab hannað til að umbylta meðferð augnþurrks með nákvæmnislyfjameðferð,clinical_study,UP,1.2658195249076385,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,0,5,383,0.0,0.4640841922034435,0.08686868686868687
bong ab publ the company announces today that it has initiated a written procedure the written procedure among the noteholders of its outstanding notes issued in october 2021 with isin se0016829642 the notes in accordance with the terms and conditions of the notes by instructing nordic trustee agency ab publ the agent as agent under the notes to send a notice of written procedure including voting instructions to directly registered owners and registered nominees of the notes in the company s debt register maintained by euroclear sweden as of 24 september 2024 the written procedure seeks the noteholders approval to amend the notes terms and conditions with respect to extending the tenor of the notes and certain consequential changes relating thereto and to the fact that the company over time has or will repurchase certain notes over the market for more information on the written procedure and a more detailed description of the proposed amendments please r,bong ab publ initiates a written procedure in order to amend the terms and conditions of the outstanding notes with isin se0016829642,bond_fixing,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,276,0.36607142857142855,0.8866002429130597,0.0
redwood city calif july 31 2024 globe newswire rezolute inc nasdaq rzlt rezolute or the company a late stage biopharmaceutical company committed to developing novel transformative therapies for serious rare diseases today announced that nevan charles elam chief executive officer and founder of rezolute will participate in a fireside chat during the btig virtual biotechnology conference on monday august 5 2024 at 12 00 p m et,rezolute to participate in the btig virtual biotechnology conference,conference_call_webinar,DOWN,-0.222227308485243,379380256.0,77797779.0,825115.0,1.04,796000.0,0.20506543967327598,0.09346626282280733,2,8,332,-0.1111111111111111,0.6820409900648857,0.016611652236652237
palo alto calif sept 12 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that it has received the drug distributor accreditation from the national association of boards of pharmacy nabp scilex has satisfied all the drug distributor criteria set in place by the nabp,scilex holding company announces it has received the drug distributor accreditation from the national association of boards of pharmacy nabp,press_releases,UP,0.0,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,289,0.5333333333333333,1.0327724261931344,0.23453502992105935
eurneffy positioned to be the first and only needle free adrenaline option authorized for emergency treatment of allergic reactions anaphylaxis in europe,ars pharmaceuticals announces eurneffy adrenaline nasal spray recommended for approval by chmp for emergency treatment of allergic reactions anaphylaxis,regulatory_filings,UP,3.4782574700241216,1698113280.0,51755600.0,1240295.0,0.872,1940800.0,0.03047829647737046,0.09346626282280733,4,6,365,0.21666666666666667,0.6899910717831225,0.2556818181818182
san diego feb 12 2024 globe newswire cidara therapeutics inc nasdaq cdtx a biotechnology company using its proprietary cloudbreak platform to develop drug fc conjugate dfc immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases today announced receipt of an 11 14 million milestone payment from mundipharma following the european approval of rezzayo rezafungin acetate a novel once weekly echinocandin antifungal approved for the treatment of invasive candidiasis in adults,cidara therapeutics receives 11 14 million milestone payment following european approval of rezzayo,regulatory_filings,UP,0.2747250048093086,636817152.0,4118697.0,696580.0,0.795,3470400.0,0.006467628874418257,0.09346626282280733,0,8,502,-0.05555555555555555,1.357695941787151,0.0
la jolla calif june 05 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced that it has received a notice of allowance from the u s patent and trademark office for a pending patent application which covers mn 166 ibudilast for the prevention of metastasis in various cancers including pancreatic cancer lung cancer breast cancer colorectal cancer melanoma and ovarian cancer,medicinova receives notice of allowance for new patent covering mn 166 ibudilast for the prevention of metastasis of various solid cancer,patents,UP,0.0,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,2,6,388,0.022727272727272724,0.8018560055721619,0.06375049193231011
oral presentations include additional comparative data between escharex and santyl and new analyses show strong correlation between wound bed preparation and wound healing,mediwound to present new data from escharex phase ii studies at three leading wound care conferences,clinical_study,UP,2.2171653568238296,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,3,8,429,0.1765151515151515,0.6433034533898109,0.1311183261183261
media release,sopra steria group revenue for q3 2024 resilient at 1 356 9 million,earnings_releases_and_operating_results,UP,2.013030952124983,3920863744.0,13004248.0,30175.454545454544,1.178,35707.0,0.003316679397466968,0.19535099655549074,3,7,240,0.0,0.34381159326312405,0.0
the company will provide an update on its leading asset bnc210 and their partnership strategy the company will provide an update on its leading asset bnc210 and their partnership strategy,bionomics to present at biotech showcase 2024,press_releases,UP,8.461539872299337,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,6,540,0.0,0.8866002429130597,0.04115814049066213
record revenues of 675 million in 2023,pacira biosciences reports fourth quarter and full year 2023 financial results,earnings_releases_and_operating_results,DOWN,-1.5379441217631988,1110386688.0,45834212.0,557500.0,0.511,435200.0,0.04127770306986966,0.09346626282280733,3,8,485,0.11666666666666665,0.7130794063724827,0.24973845598845595
media release,muutos glastonin johtoryhmään,management_changes,DOWN,-1.639344147877593,56298360.0,15339800.0,14584.2,0.607,41169.0,0.2724733011760911,0.1515999603296736,3,15,239,0.0,0.2342753450337208,0.0
planegg martinsried october 2 2024 medigene ag medigene or the company fse mdg1 prime standard an oncology platform company focused on the research and development of t cell receptor tcr guided therapies for the treatment of cancer will present a poster at the american society of gene cell therapy asgct to be held october 16 17 2024 in philadelphia pa in the us in addition the company will host an r d event on medigene s optimal 3s specific sensitive and safe tcrs for tcr guided precision immunotherapies on thursday october 10 2024 at 4 30 pm cest 10 30 am et,medigene will present at asgct 2024 and host r d event,conference_call_webinar,UP,0.0,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,9,269,0.08571428571428572,1.3169799228985475,0.061996882086167805
media release,aurskog sparebank utstedelse og nedkvittering av obligasjonslån,financing_agreements,DOWN,-0.4077240121211105,1093013760.0,3215204.0,1019.2,0.073,3536.0,0.002941595172598742,0.1515999603296736,1,9,242,0.0,0.17286104219100148,0.0
chmp opinion on neffy marketing authorization application anticipated in the second quarter of 2024,ars pharmaceuticals submits response for neffy epinephrine nasal spray marketing authorization application to ema s chmp and enters license agreement with csl seqirus for commercialization of neffy in australia and new zealand,licensing_agreements,DOWN,-0.2325634520524733,1693202432.0,51755600.0,1240295.0,0.872,1940800.0,0.03056669363442067,0.09346626282280733,1,9,424,0.06818181818181818,0.6899910717831225,0.2869318181818182
planegg martinsried may 28 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today announced the submission of three patents to the european patent office this underscores medigene s commitment to advancing t cell based immunotherapies for the treatment of solid tumors,medigene ag expands its end to end platform by submitting three development optimization technology patents to the european patent office,patents,DOWN,-3.278695092153664,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,3,396,0.0,1.3169799228985475,0.04242424242424242
norwood mass oct 29 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in a fireside chat and one on one investor meetings at the guggenheim securities healthcare innovation conference to be held november 11 13 2024 in boston ma,corbus pharmaceuticals to present at the guggenheim securities healthcare innovation conference,conference_call_webinar,DOWN,-0.9791912234882628,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,1,8,242,0.0,0.9919200800994142,0.0701116427432217
enefit green has reached a settlement with ge vernova concerning the incident during construction of the akmene wind farm resulting in the collapse of a wind turbine as a part of the negotiated outcome enefit green and ge vernova have agreed to a settlement associated with the above incident resulting in contractual adjustment to the akmene wind farm turbine supply agreement tsa between the parties including material compensation totaling about 8 million with approximately one half in cash and the remainder in non cash elements andres maasing interim chairman of the management board of enefit green comments the months following the incident have been fast paced and focused on resolving key steps with ge vernova our external technical advisors at dnv legal advisors at sorainen insurance advisors at marsh and other parties our initial priority was to identify the root cause and to ensure the safety of the remaining turbines and the safety of the community that lived and o,enefit green and ge vernova reach settlement regarding akmene wind farm incident,business_contracts,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,6,274,-0.07277777777777779,0.8866002429130597,0.0
new grant from the bill melinda gates foundation supports the phase 1 development of vir 1388 an investigational hiv t cell vaccine based on a novel vector,vir biotechnology receives expanded support to develop its novel t cell vaccine platform with new 10 million grant for hiv prevention,clinical_study,DOWN,-0.596182907154119,707087360.0,93935488.0,1328370.0,1.229,971400.0,0.13284848989522313,0.09346626282280733,1,9,788,0.13636363636363635,0.8653389999075153,0.0
first patient dosed with imm 1 104 in combination with modified gemcitabine plus nab paclitaxel for first line treatment of pancreatic ductal adenocarcinoma pdac,immuneering doses first patient in phase 2a clinical trial of imm 1 104 in ras mutant solid tumors,clinical_study,UP,0.6097555213709185,112275376.0,27271404.0,2516685.0,0.002,1980700.0,0.2428974631089189,0.09346626282280733,0,8,474,0.1875,1.2966226301621697,0.08680555555555554
jerusalem nov 29 2023 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins reported today interim data from an ongoing phase 1 study designed to assess and compare the pharmacokinetic pk and early pharmacodynamic pd profile of current and several next generation compositions of its oral peptide platform nct05965167,interim results from ongoing clinical study confirm eb613 optimized profile for osteoporosis treatment and potential for entera s next generation oral peptide platform,clinical_study,UP,2.564103434942551,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,2,8,577,0.016666666666666666,0.6915109749530333,0.12593795093795093
advancing tranquility and serenity program plans for two pivotal phase 3 trials to expand bxcl501 market potential in acute treatment of agitation,bioxcel therapeutics reports first quarter 2024 financial results,financial_results,UP,7.547174267346414,11997035.0,5544250.0,450810.0,-0.13,78500.0,0.4621350191943259,0.09346626282280733,3,7,415,0.27,1.4586588351104455,0.027620129870129878
south san francisco calif feb 13 2024 globe newswire rapt therapeutics inc nasdaq rapt a clinical stage immunology based therapeutics company focused on discovering developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology today announced the appointment of nipun davar ph d as senior vice president of technical operations,rapt therapeutics bolsters leadership team with the appointment of nipun davar ph d as senior vice president of technical operations,management_changes,DOWN,-5.179587144485008,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,1,8,501,0.03125,1.6028075568485736,0.12808742183742183
petach tikva israel sept 03 2024 globe newswire polypid ltd nasdaq pypd polypid or the company a late stage biopharma company aiming to improve surgical outcomes today announced that the company s management will participate in the following three investor conferences,polypid to participate in three upcoming fall investor conferences,conference_call_webinar,UP,0.0,37333344.0,4610773.0,1395250.0,1.25,337200.0,0.12350281292776774,0.09346626282280733,1,7,298,-0.15,0.7168605096826995,-0.024677368927368923
yield10 bioscience and biomar group have signed an loi to form a long term partnership to commercialize a camelina crop containing enriched levels of epa and dha equal to fish oil after a decade of research this omega 3 camelina technology is now advancing toward market availability and has the potential to become another important high quality supplement to the scarce supply of marine long chain fatty acids,yield10 bioscience and biomar aim to grow fish oil on land,partnerships,UP,6.451613109971017,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,8,606,0.037142857142857144,0.8866002429130597,0.0
arcutis today announced the commercial launch of zoryve roflumilast cream 0 for the treatment of mild to moderate atopic dermatitis,arcutis launches zoryve roflumilast cream 0 for the treatment of atopic dermatitis,product_services_announcement,DOWN,-0.09929767140568,1727832960.0,85869346.0,2010100.0,1.778,2359700.0,0.04969771267704026,0.09346626282280733,0,7,334,0.1111111111111111,0.6903751128737089,0.0764750681417348
saint herblain france and schlieren zurich august 1 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company and limmatech biologics ag a clinical stage biotech company developing vaccines for the prevention of life threatening diseases today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development manufacturing and commercialization of shigella4v s4v a tetravalent bioconjugate vaccine candidate against shigellosis,valneva and limmatech enter into a strategic partnership to accelerate the development of the world s most clinically advanced tetravalent shigella vaccine candidate,licensing_agreements,DOWN,-1.4966004753969215,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,331,0.45,0.6494694268312979,0.06944444444444443
new york april 08 2024 globe newswire eyenovia inc nasdaq eyen a commercial stage ophthalmic company today announced its plans for accelerating development of its potential multi billion dollar product for pediatric progressive myopia micropine and initiated a process to explore strategic alternatives to maximize shareholder value as part of this process the company plans to consider a wide range of options including potential sale of assets of the company a sale of the company a merger or other strategic action in conjunction with the strategic process and focus on its late stage micropine asset eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company s two fda approved products,eyenovia announces updated strategy and corporate priorities to focus on shareholder value generation and immediate commercial opportunities,mergers_acquisitions,UP,2.2471956014182424,27559664.0,2433609.0,8930490.0,1.002,41800300.0,0.0883032899094851,0.09346626282280733,0,7,446,0.017613636363636363,2.4441832149286684,0.0
new york june 24 2024 globe newswire in8bio inc nasdaq inab a leading clinical stage biopharmaceutical company focused on innovative gamma delta t cell therapies today announced that william ho ceo and co founder will participate in a fireside chat during the h c wainwright 2nd annual immune cell engager virtual conference on tuesday june 25 2024 at 2 30 p m et,in8bio to present at the h c wainwright 2nd annual immune cell engager virtual conference,conference_call_webinar,DOWN,-2.587176821637626,7446425.0,2577285.0,392516.85,0.183,187400.0,0.34611038182752124,0.09346626282280733,0,8,369,0.12727272727272726,1.2777111391401192,0.09166666666666666
watertown mass oct 09 2024 globe newswire c4 therapeutics inc c4t nasdaq cccc a clinical stage biopharmaceutical company dedicated to advancing targeted protein degradation science today announced its participation in the 7th annual targeted protein degradation induced proximity summit to be held october 28 31 2024 in boston ma four members of the company s leadership team will deliver oral presentations or participate on panels to demonstrate the company s expertise in designing and developing highly catalytic orally bioavailable degraders that have the potential to transform patients lives,c4 therapeutics announces presentations and participation in 7th annual targeted protein degradation induced proximity summit,trade_show,UP,0.0,106865688.0,49730521.0,1021690.0,2.946,941900.0,0.46535536270538025,0.09346626282280733,2,7,262,0.08,0.8954742650579008,0.039942580567580564
presented positive 30 day follow up results from the c guardians u s investigational device exemption ide clinical trial demonstrating an overall major adverse events rate dsmi of 0 from procedure through 30 days at the vascular interventional advances annual meeting viva23,inspiremd reports third quarter 2023 financial results and provides business update,clinical_study,DOWN,-6.37681233534865,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,0,7,600,0.05795454545454546,0.6085732039686736,0.017613636363636366
collaboration to focus on the development of a formulation of senju s sjp 0035 for use with eyenovia s optejet dispensing technology following consultation with fda,eyenovia and senju pharmaceutical co ltd sign collaboration agreement for potential new treatment for chronic dry eye disease,partnerships,UP,1.6666650109821552,28308330.0,2433609.0,8930490.0,1.002,41800300.0,0.08596794653729133,0.09346626282280733,1,7,340,0.017424242424242425,2.4441832149286684,-0.024570964749536177
geneva switzerland september 4 2024 addex therapeutics six nasdaq adxn a clinical stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders announced today that ceo tim dyer will be attending the h c wainwright 26th annual global investment conference taking place september 9 11 2024 at the lotte new york palace hotel,addex to participate in the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-7.103823312288768,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,297,-0.02840909090909091,0.972373032385036,-0.000335968379446638
eurobio scientific signe un accord pour l acquisition du test d expression génique pour le cancer du sein endopredict,eurobio scientific signe un accord pour l acquisition du test d expression génique pour le cancer du sein endopredict,mergers_acquisitions,UP,0.6954063073684339,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,1,12,416,0.0,0.4336088389568585,0.0
florham park n j jan 04 2024 globe newswire celularity inc nasdaq celu the company a biotechnology company developing allogeneic cell therapies and advanced biomaterial products today confirmed that it has entered into an exclusive u s strategic commercialization agreement with biocellgraft inc biocellgraft under which celularity will manufacture advanced biomaterial products for biocellgraft which biocellgraft will distribute in the united states for use in multiple dental oral healthcare applications a copy of biocellgraft s announcement of the agreement can be accessed here https www prweb com releases biocellgraft finalizes commercialization agreement with celularity for the manufacture and distribution of products for therapeutic use in oral healthcare 302025082 html,celularity confirms commercialization agreement with biocellgraft for the manufacture and distribution of advanced biomaterial products for use in oral healthcare,partnerships,DOWN,-7.103823312288768,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,13,540,0.32,1.6050367793919866,0.025778388278388274
data from radar natural history study indicates that alport syndrome patients with autosomal recessive col4a4 mutations have severest disease with a more rapid progression to kidney failure,eloxx pharmaceuticals highlights recent alport syndrome natural history data presented at 60th era congress,clinical_study,UP,1.4112937726413528,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,9,738,0.07666666666666666,2.2721670857062097,0.23586309523809526
palo alto calif oct 29 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today provides information to its stockholders regarding ways to demand the delivery of dividend shares that were distributed by sorrento in 2023 from brokerage firms to record holders,scilex holding company following its prior announcement of the record date for a dividend of preferred stock reiterates information previously provided to scilex stockholders regarding manipulative and naked short selling of scilex common stock,corporate_action,UP,3.869652531625363,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,1,6,242,0.07916666666666666,1.0327724261931344,0.2287509319384319
media release,oslo børs status companies placed in recovery box and penalty bench,observation_status,DOWN,-0.862068168189925,31593468.0,146986679.0,21417158.75,0.312,14709376.0,4.652438883885745,0.1515999603296736,0,8,243,0.0,20.184452026301216,0.0
kraig labs otcqb kblb successfully completed cocoon production for the first commercial production run of its bam 1 hybrids,kraig biocraft laboratories successfully completes cocooning in first commercial production run of bam 1 spider silk hybrids,product_services_announcement,UP,7.142860944173759,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,7,376,0.3333333333333333,0.8071333009212691,0.1182449494949495
sydney australia may 09 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of a world class platform of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce that the us food and drug administration fda has granted orphan drug designation to ga68 trivehexin rad 301 radiopharmaceutical technology for imaging of patients with pancreatic ductal adenocarcinoma pdac,radiopharm theranostics receives fda orphan drug designation for trivehexin rad 301 in pancreatic cancer,product_services_announcement,UP,5.882607345892501,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,1,7,781,0.5,0.9771277191333917,0.1896103896103896
waltham mass sept 21 2023 globe newswire checkpoint therapeutics inc checkpoint nasdaq ckpt a clinical stage immunotherapy and targeted oncology company today announced that james oliviero president and chief executive officer will participate in a panel presentation at the cantor global healthcare conference on thursday september 28 2023 at 10 20 a m et in new york city the company will also attend in person one on one meetings during the conference,checkpoint therapeutics to participate in the cantor global healthcare conference,conference_call_webinar,DOWN,-1.1904750923180183,370705216.0,66454795.0,6519704.25,1.137,0.0,0.17926587523386778,0.09346626282280733,3,8,646,0.04545454545454545,0.8866002429130597,0.0
san diego sept 30 2024 globe newswire biora therapeutics inc nasdaq bior the biotech company reimagining therapeutic delivery today announced an upcoming poster presentation at the american college of gastroenterology acg annual scientific meeting which will be held in philadelphia october 25 30 2024,biora therapeutics announces award winning abstract to be presented at american college of gastroenterology annual scientific meeting 2024,contests_awards,UP,1.1673140921804177,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,271,0.16666666666666666,1.027516639474094,0.07949134199134202
in8bio announces oral presentation at the upcoming american society of gene cell therapy asgct 2024 annual meeting,in8bio announces oral presentation at the upcoming american society of gene cell therapy asgct 2024 annual meeting,clinical_study,UP,2.884624201870852,7439537.0,2577285.0,392516.85,0.183,187400.0,0.3464308329940425,0.09346626282280733,2,8,430,0.0,1.2777111391401192,0.04545454545454545
media release,rentefastsettelse,bond_fixing,DOWN,-0.1940257513701026,15326919680.0,213368008.0,155147.57894736843,0.8755,165890.0,0.01392112782312173,0.1515999603296736,0,13,242,0.0,0.20896972559163385,0.0
furoscix is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure regardless of new york heart association nyha functional class,scpharmaceuticals announces fda approval of supplemental new drug application expanding the furoscix indication in heart failure,product_services_announcement,DOWN,-4.157039988688057,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,6,320,-0.055086580086580086,0.7082528246818063,0.012215909090909093
los angeles june 17 2024 globe newswire immix biopharma inc immixbio company we or us or immx a clinical stage biopharmaceutical company trailblazing cell therapies in autoimmune disease today announced that it will present and host institutional investor meetings at the stifel 2024 cell therapy forum,immix biopharma to present at the stifel 2024 cell therapy forum,clinical_study,UP,0.0,61608836.0,18058632.0,290605.0,0.301,58200.0,0.2931175651492588,0.09346626282280733,0,9,375,0.0,0.9253604538231538,0.03452335858585858
10 oct 2024 08 27 cest ab science press release ab science presents its financial results for the first half of 2024 and the key events of the period clinical development masitinib platform ongoing re examination by ema and health canada of the marketing authorisation application for masitinib in amyotrophic lateral sclerosis als update on the development of masitinib in progressive forms of multiple sclerosis following the ectrims 2024 conferencepositive results from the phase 2 study of masitinib in covid 19strengthening the intellectual property of masitinib in mastocytosis microtubule platform update on the ab8939 microtubule program and in in particular on the ability of ab8939 to generate a response on mecom rearrangement financial and corporate situation operating deficit of 3 6 million euros as of june 30 2024 down 59 compared to the first half of 2023cash position of 9 1 million euros as of june 30 2023 to which is added 5 million euros from,ab science revenues for the first half of 2024 and update on ab science s activities,financial_results,UP,1.034125169013376,4469877760.0,90123946.0,193465.0,0.815,121600.0,0.02016250797874168,0.1515999603296736,3,8,261,0.03740740740740741,0.28735916320410826,0.0
ai company gedicube and renovaro biosciences sign definitive agreement to combine ai company gedicube and renovaro biosciences sign definitive agreement to combine,message from renovaro biosciences ceo the hon mark dybul md,mergers_acquisitions,UP,3.524225743535128,60190016.0,90925076.0,7542515.0,0.529,816400.0,1.5106338566183468,0.09346626282280733,0,12,634,0.0,1.5631250973582267,0.19999999999999998
planegg martinsried may 21 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of differentiated t cell immunotherapies for solid tumors and biontech se nasdaq bntx biontech have announced that their collaboration to advance t cell receptor tcr immunotherapies against cancer will extend beyond the initial three year term outlined at the signing of the agreement in february 2022 this extension will enable ongoing and future work required to potentially generate novel tcrs directed against multiple newly nominated antigen targets that could further expand the biontech warehouse of tcr candidates,medigene s global research collaboration agreement with biontech to extend beyond initially announced term,partnerships,DOWN,-7.103823312288768,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,1,4,403,0.013636363636363636,1.3169799228985475,0.09999999999999999
redwood city calif aug 01 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced that its second quarter 2024 financial results will be released after market close on thursday august 8 2024 starting at 5 00 p m edt on august 8 2024 coherus management team will host a conference call and webcast to discuss financial results and provide a general business update,coherus to report second quarter 2024 financial results on august 8 2024,earnings_releases_and_operating_results,UP,0.0,85338280.0,110892497.0,1236840.0,0.883,1425300.0,1.2994461219513682,0.09346626282280733,3,9,331,0.007142857142857145,1.0144535837204522,0.15639141414141414
presented positive 30 day follow up results from the c guardians u s investigational device exemption ide clinical trial demonstrating an overall major adverse events rate dsmi of 0 from procedure through 30 days at the vascular interventional advances annual meeting viva23,inspiremd reports third quarter 2023 financial results and provides business update,clinical_study,DOWN,-6.37681233534865,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,0,7,600,0.05795454545454546,0.6085732039686736,0.017613636363636366
as amber latvijas balzams announces that andrejs visnausks was appointed as the chairman of management board andrejs visnausks has held ceo and chairman positions at prominent companies including ventamonjaks as and vk tranzīts sia where he successfully performed general management strategic development financial control and operational efficiency his expertise includes leading corporate structures optimizing operational processes and driving significant growth in revenue and efficiency andrejs visnausks holds a master s degree in management from the university of latvia and a bachelor s degree in business management and marketing from the riga international school of economics and business administration guntars betlers the former chairman of the board will continue his involvement in the company as a board member meanwhile the former board member valizhan abidov has decided to leave his office we are confident that with andrejs visnausks expertise and g,notification of changes to the management board of as amber latvijas balzams,management_changes,DOWN,-1.648357867215424,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,11,287,0.21749999999999997,0.8866002429130597,0.0
moonlake immunotherapeutics inks three year technology partnership with komodo health to advance research on inflammatory skin and joint conditions,moonlake immunotherapeutics inks three year technology partnership with komodo health to advance research on inflammatory skin and joint conditions,partnerships,DOWN,-1.6898415305397727,2935368960.0,28324751.0,691265.0,1.23,267600.0,0.009649468733225277,0.09346626282280733,2,7,444,0.0,0.5366763308656862,0.043127705627705626
communiqué du 23 octobre 2024offre publique d achat visant les actions de la sociétéinitiée par la société eb developmentagissant de concert avec ik x luxco 3 s a r l eurobionext fpci pepites et territoires nextstage evergreen monsieur denis fortier madame cathie marsais monsieur olivier bosc monsieur jean michel carle grandmougin monsieur herve duchesne de lamotte madame catherine courboillet et monsieur jerome de castriescommuniqué de mise à disposition du public des informations relatives aux caractéristiques notamment juridiques financières et comptables de la société eurobio scientific sale présent communiqué a été établi et est diffusé en application des dispositions de l article 231 28 i du règlement général de l autorité des marchés financiers l amf en application des articles l 621 8 du code monétaire et financier et 231 23 de son règlement général l amf a en application de sa décision de conformité de l offre publique d achat l offre en date du 22 octobre 2024 apposé le visa n 24 444 sur la note en réponse établie par la société eurobio scientific sa la note en réponse les informations relatives aux caractéristiques notamment juridiques financières et comptables d eurobio scientific sa ont été déposées auprès de l amf le 22 octobre 2024 et complètent la note en réponse établie par eurobio scientific sa les informations relatives aux caractéristiques notamment juridiques financières et comptables d eurobio scientific sa ainsi que la note en réponse visée sont disponibles sur les sites internet de l amf www amf france org et d eurobio scientific sa www eurobio scientific com et peuvent être obtenues sans frais sur simple demande auprès d eurobio scientific sa 7 avenue de scandinavie za de courtaboeuf 91953 les ulis préalablement à l ouverture de l offre l amf et euronext publieront respectivement un avis d ouverture et de calendrier et un avis annonçant les modalités et le calendrier de l offre avertissement ce communiqué a été préparé à des fins d informations uniquement il ne constitue ni une offre d achat ou d échange ni une sollicitation d une offre pour la vente ou l échange de titres eurobio scientific sa ni une offre d achat ou d échange ni une sollicitation d une offre pour la vente ou l échange de titres eurobio scientific sa la diffusion de ce communiqué l offre et son acceptation peuvent faire l objet d une règlementation spécifique ou de restrictions dans certains pays l offre ne s adresse pas aux personnes soumises à de telles restrictions ni directement ni indirectement et n est pas susceptible de faire l objet d une quelconque acceptation depuis un pays où l offre ferait l objet de telles restrictions le présent communiqué n est pas destiné à être diffusé dans ces pays en conséquence les personnes en possession du présent communiqué sont tenues de se renseigner sur les restrictions locales éventuellement applicables et de s y conformer ni eurobio scientific sa ni ses actionnaires et conseils ou représentants respectifs n accepte une quelconque responsabilité quant à une éventuelle violation par toute personne de ces restrictions,eurobio scientific communiqué de mise à disposition du public des informations relatives aux caractéristiques notamment juridiques financières et comptables de la société eurobio scientific sa,clinical_study,UP,0.3875983892514247,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,2,248,0.0,0.4336088389568585,-0.0029761904761904756
copenhagen denmark october 3 2024 evaxion biotech a s nasdaq evax evaxion a clinical stage techbio company specializing in developing ai immunology powered vaccines continues to gather clinical evidence for the steady improvement of its ai immunology platform,recent clinical data confirms significantly improved predictive power of evaxion s ai immunology platform,clinical_study,UP,0.0,15310102.0,155104950.0,157745.0,0.102,38700.0,10.130889395772805,0.09346626282280733,3,8,268,0.18055555555555555,1.4249795072460607,0.1250271230826786
amsterdam sept 13 2024 globe newswire nasdaq renb renovarocube cube the company a leading ai driven innovator using multi omics technology for cancer profiling is pleased to announce two scientific presentations at a leading cancer conference the european society for medical oncology esmo congress on september 15 2024,renovarocube to present cutting edge cancer diagnostics research at european society for medical oncology congress,conference_call_webinar,DOWN,-2.0933996157467987,60224444.0,90925076.0,7542515.0,0.529,816400.0,1.50977028530143,0.09346626282280733,4,9,288,-0.014285714285714282,1.5631250973582267,0.07979998396665063
planegg martinsried may 15 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors today presents the company s proprietary t cell receptor tcr discovery process to obtain optimal affinity 3s sensitive specific and safe tcrs at the 21th association for cancer immunotherapy cimt annual meeting in mainz from may 15 17 2024 data presented also shows the clear benefit of adding the pd1 41bb costimulatory switch protein csp to further armor and enhance these 3s tcr t cells which enables them to overcome the immunosuppressive tumor microenvironment,medigene presents preclinical data on optimal affinity tcrs targeting the neoantigen mutant kras,conference_call_webinar,UP,2.684561181007224,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,2,9,409,0.09999999999999999,1.3169799228985475,0.0
media release,pareto bank asa vurderer utstedelse av senior preferred obligasjonslån,financing_agreements,DOWN,-0.9077132949647496,6372872704.0,46145176.0,38558.55,0.663,36744.0,0.007240875213314162,0.1515999603296736,0,11,242,0.0,0.2272865108365386,0.0
sunnyvale calif may 01 2024 globe newswire biocardia inc nasdaq bcda a developer of cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced the primary endpoint results of the open label roll in cohort of the cardiamp cell therapy in chronic myocardial ischemia trial,biocardia s cardiamp cell therapy chronic myocardial ischemia trial results show patient benefits in important outcomes,clinical_study,UP,0.0,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,2,7,423,0.26666666666666666,1.32107885633281,0.1611904761904762
turku finland and boston march 14 2024 globe newswire faron pharmaceuticals ltd aim farn first north faron a clinical stage biopharmaceutical company pursuing a clever approach to reprogramming myeloid cells to activate anti tumor immunity in hematological and solid tumor microenvironments today announces it will host a virtual bexmab update event on tuesday march 19 at 11 00 eet 9am gmt following the most recent data cut off and scheduled analysis,faron to host webcast to discuss latest data from phase 1 part of the bexmab study of bexmarilimab,clinical_study,DOWN,-0.4329012985813321,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,3,3,471,0.20238095238095236,0.7633342480324978,0.017102159992784992
media release,bghl gbp nav s,fund_data_announcement,UP,0.8333333333333334,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,243,0.0,0.8866002429130597,-0.005180533751962319
pharmacosmos group and g1 therapeutics announce successful closing of tender offer,pharmacosmos group and g1 therapeutics announce successful closing of tender offer,mergers_acquisitions,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,283,0.75,0.8866002429130597,0.03954545454545455
enrollment in the two pivotal trials of lorundrostat for the treatment of uhtn or rhtn is on track with topline data expected for advance htn trial in q4 2024 and launch htn trial in 2h 2025,mineralys therapeutics reports fourth quarter and full year 2023 financial results and provides corporate update,clinical_study,DOWN,-0.2987301032667582,916690560.0,43490817.0,793180.0,-0.18,767600.0,0.04744329100541845,0.09346626282280733,3,7,464,0.125,0.8131647725786432,-0.0671590909090909
burlington mass aug 12 2024 globe newswire scpharmaceuticals inc nasdaq scph the company a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies advance patient care and reduce healthcare costs today announced a proposed underwritten public offering of shares shares of its common stock or in lieu of shares pre funded warrants the pre funded warrants to purchase shares the offering scpharmaceuticals also expects to grant the underwriters a 30 day option to purchase up to an additional of shares offered in the offering all shares and pre funded warrants to be sold in the offering will be offered by scpharmaceuticals the offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering,scpharmaceuticals announces proposed underwritten public offering of common stock and pre funded warrants,shares_issue,DOWN,-4.157039988688057,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,6,320,-0.11145833333333333,0.7082528246818063,0.19772727272727272
media release,lleida net records sales worth 4 38 million euros in the third quarter of 2024,financial_results,UP,0.0,18273132.0,10263673.0,665.2727272727273,0.816,500.0,0.5616811064463388,0.1515999603296736,1,8,242,0.09999999999999999,0.3985556235691757,0.0
alvotech nasdaq alvo a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide today announced the closing of its previously announced senior secured first lien term loan facility the facility the closing has allowed alvotech to refinance outstanding debt obligations reduce the cost of capital and improve its overall debt maturity profile,alvotech announces closing of private debt financing,financing_agreements,UP,0.0,2847161600.0,100126591.0,236865.0,0.191,235600.0,0.03516716121768431,0.09346626282280733,3,4,352,0.09722222222222222,0.44264539487962035,0.0
addex receives chf5m and share of neurosterix,addex and perceptive launch neurosterix with 63 million to accelerate development of allosteric modulator therapeutics for neurological disorders,financing_agreements,UP,9.242146234319629,9793322.0,36066686.0,7035.0,1.989,11000.0,3.6827836356243573,0.09346626282280733,2,1,451,0.0,0.972373032385036,-0.03888888888888888
results of human device function studies for the navicap targeted oral delivery platform in healthy volunteers and patients with uc,biora therapeutics to present clinical data on device function of the navicap oral delivery platform at digestive disease week 2024,clinical_study,UP,2.4623779719234884,994994.0,35018869.0,0.0,0.8755,0.0,0.25000035609542787,0.09346626282280733,0,8,418,0.16666666666666666,1.027516639474094,0.10443722943722944
kraig labs otcqb kblb achieved full capacity at its current production location and will open additional production facilities,kraig biocraft laboratories expands facilities to support spider silk production growth,capital_investment,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,8,362,0.11666666666666665,0.8071333009212691,0.1303503787878788
media release,oslo børs status companies placed in recovery box and penalty bench,exchange_announcement,DOWN,-0.1739108080223499,580726080.0,80428108.0,4091945.0,0.575,4211400.0,0.13849577411780783,0.09346626282280733,0,8,243,0.0,0.963882818724342,0.0
sisäpiiritieto valmet toimittaa sellutehtaan sekä kattavat automaatio ja virtauksensäätöratkaisut araucolle brasiliaan valmet oyj n pörssitiedote sisäpiiritieto 25 syyskuuta 2024 klo 01 45 araucon hallitus on tänään hyväksynyt kokonaisen sellutehtaan investoinnin ja valinnut valmetin projektin toimittajaksi valmet toimittaa araucolle kokonaisen sellutehtaan joka sisältää myös tehtaan kattavat automaatio ja virtauksensäätöratkaisut uusi sellutehdas tulee olemaan maailman suurin yhdessä vaiheessa toteutettu sellutehdasprojekti 3 5 miljoonan tonnin vuotuisella tuotantokapasiteetillaan uuden tehtaan arvioidaan käynnistyvän vuoden 2027 jälkimmäisellä puoliskolla sellutehdas rakennetaan inocênciaan mato grosso do sulin osavaltioon brasiliaan sopimus on tarkoitus viimeistellä vuoden 2024 loppuun mennessä tilauksen arvo valmetille on yli miljardi euroa ja sen odotetaan sisältyvän valmetin vuoden 2024 neljännen neljänneksen saatuihin tilauksiin odotetulla toimituksella o,sisäpiiritieto valmet toimittaa sellutehtaan sekä kattavat automaatio ja virtauksensäätöratkaisut araucolle brasiliaan,business_contracts,UP,8.428963680972963,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,0,276,0.0,0.8866002429130597,0.0
malvern pa may 28 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced its expected upcoming inclusion in the russell 3000 index according to preliminary russell reconstruction information posted on the ftse russell website the newly reconstructed index will take effect after the market closes on june 28 2024,ocugen set to join russell 3000 index effective june 28 2024,exchange_announcement,UP,0.0,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,1,7,396,0.21212121212121213,0.7661975315521313,0.0
transcode therapeutics reports 2023 results provides business update,transcode therapeutics reports 2023 results provides business update,financial_results,DOWN,-1.026388515146004,6527236.0,780142.0,37160.0,1.332,50100.0,0.11952103463089124,0.09346626282280733,2,9,451,0.0,2.0874185587937095,0.0
dr olivier litzka has resigned from the board effective june 13 2024 dr olivier litzka has resigned from the board effective june 13 2024,mineralys therapeutics appoints biopharmaceutical executive alexander m gold m d to its board of directors,management_changes,DOWN,-2.3640602598939204,916364736.0,43490817.0,793180.0,-0.18,767600.0,0.0474601600120937,0.09346626282280733,4,8,379,0.6,0.8131647725786432,0.016800144300144298
xolremdi targets cxcr4 pathway dysfunction the underlying cause of whim syndrome,x4 pharmaceuticals announces fda approval of xolremdi mavorixafor capsules first drug indicated in patients with whim syndrome,clinical_study,UP,2.1459310030935064,12561458.0,4364496.0,363495.0,0.663,396700.0,0.34745138661451563,0.09346626282280733,0,6,425,0.25,1.4412990038402507,0.09999999999999999
yavne israel sept 03 2024 globe newswire mediwound ltd nasdaq mdwd the global leader in next generation enzymatic therapeutics for tissue repair today announced that ofer gonen chief executive officer will participate in a fireside chat hosted by swayampakula ramakanth managing director senior equity research on tuesday september 10 2024 at 3 30 p m et at the h c wainwright 26th annual global investment conference,mediwound to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-1.6313172757874788,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,8,298,0.0,0.6433034533898109,0.12562222222222222
tampa fla may 10 2024 globe newswire pacira biosciences inc nasdaq pcrx today announced the pricing of 250 0 million aggregate principal amount of convertible senior notes due 2029 the notes in a private placement to qualified institutional buyers pursuant to rule 144a under the securities act of 1933 as amended the securities act pacira also granted the initial purchasers of the notes an option to purchase for settlement within a period of 13 days from and including the date the notes are first issued up to an additional 37 5 million aggregate principal amount of notes the sale of the notes to the initial purchasers is expected to settle on may 14 2024 subject to customary closing conditions,pacira biosciences inc announces pricing of 250 0 million aggregate principal amount of 2 convertible senior notes due 2029,financing_agreements,UP,0.0,1112007296.0,45834212.0,557500.0,0.511,435200.0,0.04121754611221544,0.09346626282280733,4,7,414,-0.03333333333333333,0.7130794063724827,0.16537981859410428
transaction aligns with coherus strategic focus on oncology transaction aligns with coherus strategic focus on oncology,coherus biosciences announces divestiture of yusimry adalimumab aqvh in a 40 million upfront all cash transaction,business_contracts,UP,2.409643485941096,84758616.0,110892497.0,1236840.0,0.883,1425300.0,1.3083330312991426,0.09346626282280733,3,8,366,0.0,1.0144535837204522,0.16756222943722943
boston oct 11 2023 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that it will present updated preliminary data from the ongoing phase 1 amplify 201 study of its lead asset eli 002 targeting mutated kras in patients with high relapse risk pancreatic and colorectal cancers and preclinical data on eli 007 and eli 008 eli 007 a mutant braf peptide vaccine and eli 008 a p53 hotspot mutation peptide vaccine are being evaluated in studies funded by a grant from the gastro intestinal gi research foundation with the aim of developing multivalent cancer vaccines targeting several mutations,elicio therapeutics announces upcoming presentations at the society for immunotherapy of cancer s sitc 2023 annual meeting,clinical_study,UP,0.0,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,2,8,626,0.05333333333333334,0.8558055682194762,0.0
visit neffy com to get neffy now and access the comprehensive patient assistance programs available through neffyconnect visit neffy com to get neffy now and access the comprehensive patient assistance programs available through neffyconnect,ars pharmaceuticals announces u s availability of neffy epinephrine nasal spray the first and only needle free treatment for type i allergic reactions including anaphylaxis,product_services_announcement,UP,0.0676998977495869,1695657728.0,51755600.0,1240295.0,0.872,1940800.0,0.030522433357494185,0.09346626282280733,0,8,278,0.29000000000000004,0.6899910717831225,0.23684613997113999
יופיטר פלורידה ונס ציונה ישראל feb 23 2024 globe newswire dyadic international inc דיאדיק או החברה נאסד ק dyai חברת ביוטכנולוגיה גלובלית המתמחה בפלטפורמות מיקרוביאליות מתקדמות לפיתוח חלבונים וייצור ביולוגי ומתן מענה לצרכים קליניים והמכון למחקר ביולוגי iibr הודיעו כי קידמו את שיתוף הפעולה עם המכון למחקר ביולוגי iibr והזרוע המסחרית שלו life science research israel lsri כדי להתמקד בפתרונות מתפתחים למחלות שותפות זו נועדה למנף את המומחיות של dyadic בפלטפורמות מיקרוביאליות לייצור ביולוגי של חלבונים בקנה מידה גמיש ואת יכולות גילוי הנוגדנים והאנטיגנים של המכון כדי לפתח ולייצר פתרונות חדשניים לטיפול במחלות מתפתחות ובאיומים ביולוגיים פוטנציאליים באמצעות שיתוף פעולה זה שני הצדדים פועלים לפיתוח טיפולים וחיסונים יעילים למאבק באתגרי הבריאות העולמיים מתוך כוונה למסחור עתידי נכון להיום המסגרת אינה מחייבת וכפופה לביצוע הסכם מחייב שיידון על ידי הצדדים באמצעות יוזמות שיתוף פעולה של רישוי חוץ,dyadic מקדמת שיתוף פעולה עם המכון הביולוגי הישראלי iibr להתמקדות באיומים ביולוגיים ופתרונות למחלות מתפתחות,partnerships,UP,0.0,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,4,2,491,0.0,0.7846450948942033,0.0
company to host webcast on tuesday june 18 2024 at 8 00 am eastern time,taysha gene therapies to present clinical data from both reveal phase 1 2 trials during company hosted webcast and at 2024 irsf rett syndrome scientific meeting,clinical_study,UP,1.0666656494140625,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,2,7,381,0.0,1.0149166236087122,0.15571428571428575
to potentially include adolescents and antibody persistence up to two years,valneva submits label extension applications for its chikungunya vaccine ixchiq to ema and health canada,regulatory_filings,UP,1.647444840272518,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,1,283,0.0,0.6494694268312979,0.036153198653198645
warrington pa oct 21 2024 globe newswire windtree therapeutics inc windtree or the company nasdaqcm wint a biotechnology company focused on advancing early and late stage innovative therapies for critical conditions and diseases today announced that craig fraser chairman and chief executive officer will be presenting a corporate update at the thinkequity conference on oct 30th at 12 30pm et windtree management will also be participating in 1x1 meetings with investors at the event,windtree to present at the thinkequity conference on october 30th,clinical_study,UP,9.242146234319629,1360169.0,3660923.0,6680965.0,0.764,1224200.0,2.6915206860323972,0.09346626282280733,0,8,250,0.05000000000000001,2.339794177443606,0.05714215232755902
gaithersburg md oct 18 2023 globe newswire neximmune inc nasdaq nexi the company a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen specific t cells in oncology autoimmune and infectious diseases today announced that the board of directors and stockholders of the company approved a 1 for 25 reverse stock split of the company s common stock at a special meeting of the company held on october 17 2023 the reverse stock split will take effect after the close of trading on the nasdaq capital market at 5 00 p m eastern time on wednesday october 18 2023 the company s common stock will open for trading under a new cusip number 65344d 208 on the nasdaq capital market on october 19 2023 on a split adjusted basis under the current ticker symbol nexi the reverse stock split is intended to increase the per share trading price of the company s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on the nasdaq capital market,neximmune announces 1 for 25 reverse stock split,corporate_action,DOWN,-7.103823312288768,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,2,11,618,-0.05081168831168831,2.2666992986423327,0.02681818181818182
rockville md july 31 2024 globe newswire theriva biologics inc nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the u s food and drug administration fda granted rare pediatric drug designation rpdd for vcn 01 for the treatment of retinoblastoma vcn 01 theriva s lead product candidate is a systemic selective stroma degrading oncolytic adenovirus previously the fda granted orphan drug designation to vcn 01 for treatment of retinoblastoma,theriva biologics receives rare pediatric drug designation by the u s fda for vcn 01 for the treatment of retinoblastoma,product_services_announcement,DOWN,-7.103823312288768,3602275.0,8173972.0,1624850.0,0.833,91200.0,2.2691138239029502,0.09346626282280733,2,8,332,0.0988888888888889,1.5225134880447404,0.049659320477502294
new york june 24 2024 globe newswire in8bio inc nasdaq inab a leading clinical stage biopharmaceutical company focused on innovative gamma delta t cell therapies today announced that william ho ceo and co founder will participate in a fireside chat during the h c wainwright 2nd annual immune cell engager virtual conference on tuesday june 25 2024 at 2 30 p m et,in8bio to present at the h c wainwright 2nd annual immune cell engager virtual conference,conference_call_webinar,DOWN,-2.587176821637626,7446425.0,2577285.0,392516.85,0.183,187400.0,0.34611038182752124,0.09346626282280733,0,8,369,0.12727272727272726,1.2777111391401192,0.09166666666666666
ad hoc mitteilung gemäss art 53 kr,santhera schliesst finanzierungen ab und sichert sich mittel bis erreichen des für 2026 erwarteten break even,financing_agreements,UP,2.040819857186725,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,1,319,0.0,0.5209522992128177,0.08896103896103896
biocardia inc today reported it has submitted a 510 k for approval of its patented morph dna steerable introducer sheath with the fda,biocardia submits for fda approval of morph dna steerable introducer product family,regulatory_filings,UP,2.208199733693222,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,1,7,333,0.0,1.32107885633281,0.09392857142857143
norwood mass july 30 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company today announced that yuval cohen ph d chief executive officer of corbus will participate in two investor conferences during the month of august dr cohen will provide a corporate update and participate in one on one investor meetings at the following events,corbus pharmaceuticals to participate in upcoming investor conferences in august,conference_call_webinar,UP,4.240784781572429,102544384.0,7524021.0,127840.0,3.117,146300.0,0.07337331120931986,0.09346626282280733,1,8,333,0.0,0.9919200800994142,0.040358974358974356
the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock the company recently announced the positive topline results from the phase 2b study with istaroxime in acute heart failure patients with early cardiogenic shock,windtree announces publication of positive istaroxime phase 2b study trial design,clinical_study,DOWN,-7.103823312288768,1379940.0,3660923.0,6680965.0,0.764,1224200.0,2.65295809962752,0.09346626282280733,2,8,262,0.13168044077134985,2.339794177443606,0.04827501202501203
sydney australia march 28 2023 globe newswire radiopharm theranostics asx rad radiopharm or the company a developer of radiopharmaceutical products for both diagnostic and therapeutic uses is pleased to announce that the company will participate in jefferies inaugural radiopharma innovation summit being held in new york city on april 3rd 2023 riccardo canevari chief executive officer and managing director of radiopharm theranostics and vittorio puppo chief operating officer will be available for 1x1 meetings,radiopharm theranostics invited to participate in jefferies radiopharma innovation summit,trade_show,DOWN,-2.85755628922936,53681536.0,1484820415.0,2976041.238095238,0.844,828490.0,27.65979749536228,0.09346626282280733,1,7,823,0.2590909090909091,0.9771277191333917,0.14166666666666666
not for distribution publication or release in whole or in part directly or indirectly in the united states or to any us person or to any other jurisdiction in which the distribution publication or release would be unlawful,eurobio scientific first half 2024 a solid start to the financial year in an uncertain environment proposed tender offer,earnings_releases_and_operating_results,UP,0.0,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,2,15,331,0.0369047619047619,0.4336088389568585,0.0
media release,aker horizons asa invitation to presentation of third quarter results 2024,clinical_study,DOWN,-3.2496329736071154,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,247,0.0,0.8866002429130597,0.13961675579322638
media release,loomis interim report january september 2024,earnings_releases_and_operating_results,UP,0.7495296080540479,26788276224.0,68321667.0,152052.05263157896,0.624,194074.0,0.00255043163019163,0.1515999603296736,1,7,242,0.0,0.29653145860700736,0.0
funds to be used for clinical development of escharex to treat diabetic foot ulcers dfus,mediwound announces 16 25 million funding from the european innovation council accelerator program,financing_agreements,UP,2.96423099833114,213174320.0,7695421.0,59885.0,0.8755,55000.0,0.03609919337376097,0.09346626282280733,1,7,347,0.0,0.6433034533898109,0.1481966726084373
xbrane biopharma ab publ xbrane or the company has received scientific advice from the us food and drug administration fda on the development of its opdivo biosimilar candidate xdivane fda concurs with emas previous feedback finding xbranes proposed streamlined clinical development plan adequate to support a future biologics license application bla xbranes development plan includes a single clinical trial and reduces the clinical development budget with at least from approx 120m to 50m or lower vs a traditional approach with separate phase 1 and phase 3 trials xdivane is one out of few opdivo biosimilar candidates available for out licensing on path to enable a launch upon loss of exclusivity in us in december 2028 opdivo is a so called immune oncology drug pd1 inhibitor used in treatment of different cancers with sales of approx 8 billion usd globally in 2023 and expected to grow to 14 billion usd by 2028 as communicated on the 12th of august the,xbrane provides update from scientific advice with us fda on xdivane opdivo biosimilar candidate,clinical_study,UP,0.1111047091310007,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,9,274,-0.009523809523809523,0.8866002429130597,0.0
kr ht5 is based on akoya s phenoimager ht platform kr ht5 is based on akoya s phenoimager ht platform,akoya biosciences and shanghai kr pharmtech announce chinese regulatory agency premarket approval for kr ht5 in china to support next generation pathology clinical workflows,regulatory_filings,UP,1.5151500555948771,60944124.0,12648900.0,228670.0,1.352,488000.0,0.207549131397803,0.09346626282280733,3,8,422,0.0,0.8573192373918191,0.20941558441558442
norwood mass jan 31 2024 globe newswire corbus pharmaceuticals holdings inc nasdaq crbp corbus or the company a precision oncology company with a diversified portfolio today announced the pricing of an underwritten public offering of 4 325 000 shares of its common stock at a public offering price of 19 00 per share for a total public offering size of approximately 82 2 million before deducting underwriting discounts and estimated offering expenses in addition corbus has granted the underwriters a 30 day option to purchase up to an additional 648 750 shares of its common stock on the same terms and conditions all of the securities in the offering are being sold by corbus the offering is expected to close on or about february 2 2024 subject to customary closing conditions,corbus pharmaceuticals announces pricing of public offering,shares_issue,UP,9.242146234319629,102242136.0,7524021.0,127840.0,3.117,146300.0,0.07359021724663499,0.09346626282280733,2,9,514,-0.11515151515151517,0.9919200800994142,0.0
rockaway n j may 01 2024 globe newswire electrocore inc nasdaq ecor a commercial stage bioelectronic medicine and wellness company today announced that it will report financial results for the first quarter ended march 31 2024 after the close of the market on wednesday may 8 2024 management will host a conference call and webcast at 4 30 pm edt to discuss the financial results and answer questions,electrocore to announce first quarter march 31 2024 financial results on wednesday may 8 2024,earnings_releases_and_operating_results,UP,1.618854167693674,39440596.0,5517155.0,83945.0,0.804,91500.0,0.13988518327664218,0.09346626282280733,2,8,423,0.08333333333333333,0.8324549917316175,0.15854545454545454
sunnyvale calif aug 30 2024 globe newswire biocardia inc nasdaq bcda a global leader in cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced the pricing of its upsized public offering with participation from management and directors institutional investors and certain existing investors of the company for the purchase and sale of 2 400 000 shares of common stock or pre funded warrants in lieu thereof and warrants to purchase up to 2 400 000 shares of common stock at a combined offering price of 3 00 per share and accompanying warrant priced at the market under nasdaq rules the company expects to receive aggregate gross proceeds of 7 2 million before deducting placement agent fees and other offering expenses the warrants will have an exercise price of 3 00 per share will be exercisable immediately and will expire five years from the issuance date,biocardia announces pricing of upsized 7 2 million public offering priced at the market under nasdaq rules,shares_issue,DOWN,-4.726369605023444,11132464.0,3886990.0,44615.0,0.838,135000.0,0.34915810192604263,0.09346626282280733,4,8,302,-0.06383928571428571,1.32107885633281,0.05875850340136054
los angeles feb 14 2024 globe newswire the following is a statement by renovaro nasdaq renb in response to hindenburg s recent opinion piece,statement of renovaro inc,management_statements,UP,9.242146234319629,60224444.0,90925076.0,7542515.0,0.529,816400.0,1.50977028530143,0.09346626282280733,2,10,499,0.0,1.5631250973582267,0.13823051948051945
results presented at the department of defense s military health system research symposium mhsrs,humacyte presents positive long term results of atev in treatment of vascular trauma in military setting from ukraine humanitarian program,clinical_study,DOWN,-1.2765978745102613,335832640.0,121934248.0,3834265.0,2.0,1449900.0,0.36308039623545824,0.09346626282280733,1,8,305,-0.005681818181818191,1.1173068527438073,0.08202730429292929
the board of directors of senzime ab publ senzime or the company has today resolved on a directed share issue of a maximum of 13 873 000 shares at the subscription price of sek 6 20 per share hereinafter the share issue the subscription price corresponds to the volume weighted average price vwap of the share during the latest 5 trading days the persons entitled to subscribe for the share issue include a few existing shareholders with a long term engagement for the company such as the crafoord family segulah medical acceleration fjärde ap fonden carnegie fonder swedbank robur fonder fredrik rapp and professor sorin j brull as well as a number of new swedish and international institutional investors for example ab strati binding subscription forms or subscription undertakings have been entered into for the entire share issue through the share issue senzime will raise a total of approximately 86 msek before transaction costs about the share issuethe share i,senzime carries out a directed share issue of 86 million sek,shares_issue,DOWN,-0.143681448664164,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,8,274,-0.014876033057851245,0.8866002429130597,0.0
toronto aug 28 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the research study evaluating bucillamine as a potential treatment for nerve agent exposure in partnership with defence r d canada suffield research centre drdc an agency of the canadian department of national defence the drdc is investigating pharmacological compounds including bucillamine that can mitigate nerve agent induced brain injury the research study is progressing and is expected to be now completed in october 2024,revive therapeutics provides update on research study evaluating bucillamine for nerve agent exposure and expansion into viral infections,clinical_study,UP,9.242146234319629,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,7,304,0.049999999999999996,1.8889707456546947,0.08894613689035179
oslo norway and saint herblain france july 22 2024 the coalition for epidemic preparedness innovations cepi and valneva se nasdaq valn euronext paris vla a specialty vaccine company have expanded their partnership to support broader access to the world s first chikungunya vaccine ixchiq in low and middle income countries lmics as well as post marketing trials and potential label extensions in children adolescents and pregnant women,cepi expands partnership with valneva with a 41 3 million grant to support broader access to the world s first chikungunya vaccine,partnerships,UP,3.2033218696848333,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,0,1,341,0.13888888888888887,0.6494694268312979,0.0
san diego nov 01 2023 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer of anaptys and or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in november,anaptys announces participation in november investor conferences,conference_call_webinar,DOWN,-1.0423058360543165,687503680.0,17605381.0,784220.0,-0.266,445700.0,0.02560768983811112,0.09346626282280733,2,9,605,0.125,0.871343469962729,0.3438773011500284
media release,navamedic q3 2024 business remains strong in quarter impacted by cyclical nature of the business,earnings_releases_and_operating_results,DOWN,-2.272723613410148,381516480.0,12071448.0,11359.45,0.371,10764.0,0.0316406987189649,0.09346626282280733,3,7,240,0.43333333333333335,0.44210167862552907,0.0
radnor pa aug 28 2024 globe newswire mineralys therapeutics inc nasdaq mlys a clinical stage biopharmaceutical company focused on developing medicines to target hypertension chronic kidney disease ckd and other diseases driven by dysregulated aldosterone today announced that management will be participating in a fireside chat at the wells fargo healthcare conference being held in boston ma on september 4 6 2024,mineralys therapeutics to participate in the wells fargo healthcare conference,conference_call_webinar,UP,0.9836056347144336,919949376.0,43490817.0,793180.0,-0.18,767600.0,0.04727522854474984,0.09346626282280733,2,8,304,-0.125,0.8131647725786432,0.1001144094001237
burlington mass aug 12 2024 globe newswire scpharmaceuticals inc nasdaq scph the company a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies advance patient care and reduce healthcare costs today announced a proposed underwritten public offering of shares shares of its common stock or in lieu of shares pre funded warrants the pre funded warrants to purchase shares the offering scpharmaceuticals also expects to grant the underwriters a 30 day option to purchase up to an additional of shares offered in the offering all shares and pre funded warrants to be sold in the offering will be offered by scpharmaceuticals the offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering,scpharmaceuticals announces proposed underwritten public offering of common stock and pre funded warrants,shares_issue,DOWN,-4.157039988688057,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,0,6,320,-0.11145833333333333,0.7082528246818063,0.19772727272727272
message from renovaro biosciences ceo the hon mark dybul md,ai company gedicube and renovaro biosciences sign definitive agreement to combine,mergers_acquisitions,UP,1.5659994395296315,60190016.0,90925076.0,7542515.0,0.529,816400.0,1.5106338566183468,0.09346626282280733,0,9,635,0.0,1.5631250973582267,0.3
cambridge mass may 09 2024 globe newswire intellia therapeutics inc nasdaq ntla a leading clinical stage gene editing company focused on revolutionizing medicine with crispr based therapies today reported operational highlights and financial results for the first quarter ended march 31 2024,intellia therapeutics announces first quarter 2024 financial results and highlights recent company progress,financial_results,UP,5.608699632727582,973680192.0,98412511.0,6353695.0,2.134,5288300.0,0.10107272573539218,0.09346626282280733,3,7,415,0.1,0.7800307612939593,-0.02408163265306123
single infusion of anx005 demonstrated significant improvements across multiple functional and prognostic measures that expedited recovery in gbs patients,annexon to present pivotal phase 3 data on early and durable benefits with first in class c1q blocking antibody anx005 in guillain barré syndrome at 2024 pns annual meeting,clinical_study,DOWN,-0.7462679264300778,262765024.0,82380157.0,1425435.0,1.259,925100.0,0.3135126423827244,0.09346626282280733,1,8,375,0.16479591836734692,0.7558344054121836,0.1861627435064935
in8bio presents progression free survival update from phase 1 study of inb 200 at 2024 american society of clinical oncology annual meeting,in8bio presents progression free survival update from phase 1 study of inb 200 at 2024 american society of clinical oncology annual meeting,clinical_study,UP,3.361341170559033,7539764.0,2577285.0,392516.85,0.183,187400.0,0.34182568579069583,0.09346626282280733,0,6,390,0.2,1.2777111391401192,0.078125
missing,immix biopharma advances car t nxc 201 to expansion cohort dose level in u s al amyloidosis trial nexicart 2,clinical_study,DOWN,-2.666664123535156,61887608.0,18058632.0,290605.0,0.301,58200.0,0.2917972205356523,0.09346626282280733,2,9,268,-0.2,0.9253604538231538,0.007407056677890011
saint herblain france and schlieren zurich october 16 2024 valneva se nasdaq valn euronext paris vla a specialty vaccine company and limmatech biologics ag a clinical stage biotech company developing vaccines for the prevention of life threatening diseases announced today that the u s food and drug administration fda has granted fast track designation to shigella4v s4v the world s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate for which valneva obtained an exclusive worldwide license from limmatech,valneva and limmatech awarded fda fast track designation for tetravalent shigella vaccine candidate s4v,product_services_announcement,UP,2.003645502739252,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,2,11,254,0.325,0.6494694268312979,0.04760890151515151
longeveron announces u s fda grants lomecel b tm regenerative medicine advanced therapy rmat designation for the treatment of mild alzheimer s disease,longeveron announces u s fda grants lomecel b regenerative medicine advanced therapy rmat designation for the treatment of mild alzheimer s disease,clinical_study,UP,9.242146234319629,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,7,353,0.36666666666666664,1.063123411629147,0.0642857142857143
media release,resolutions of the general extraordinary shareholders meeting of invl technology,annual_general_meeting,UP,1.734102373353568,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,9,250,0.19166666666666665,0.8866002429130597,0.1698705808080808
cambridge mass jan 03 2024 globe newswire editas medicine inc nasdaq edit a clinical stage genome editing company today announced that the company s president and ceo gilmore o neill m b m m sc will present at the 42nd annual j p morgan healthcare conference on tuesday january 9 2024 4 30 p m pt 7 30 p m et in san francisco ca,editas medicine to present at the 42nd annual j p morgan healthcare conference,conference_call_webinar,DOWN,-2.0040061967810527,181238416.0,83382193.0,2526680.0,2.096,3015800.0,0.46006908932596274,0.09346626282280733,2,7,542,0.0,1.3105556047468256,0.057272727272727274
g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,g1 therapeutics to participate in the 23rd annual needham virtual healthcare conference,conference_call_webinar,DOWN,-4.402516540601384,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,10,449,0.0,0.8866002429130597,0.0
toronto june 12 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases medical countermeasures and rare disorders announced today an update on the type c meeting written responses received by the company from the u s food drug administration fda for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long covid the study,revive therapeutics provides update on fda type c meeting for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-6.666661699612825,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,9,381,0.04,1.8889707456546947,0.09926750064376327
longeveron to present at the emerging growth virtual conference,longeveron to present at the emerging growth virtual conference on june 12 2024,conference_call_webinar,UP,2.884624201870852,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,0,9,383,0.0,1.063123411629147,0.125
media release,lhv pank updated equity research on eften real estate fund as,research_analysis_and_reports,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,8,241,0.2,0.8866002429130597,0.10072071909571911
adelaide australia and cambridge mass may 20 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that spyridon spyros papapetropoulos m d phd president and chief executive officer of bionomics will be giving an oral presentation and presenting two posters about bnc210 as a potential treatment for social anxiety disorder and post traumatic stress disorder ptsd at the 2024 american society of clinical psychopharmacology ascp annual meeting taking place may 28 31 in miami beach florida details of the presentations are as follows,bionomics to present at the 2024 american society of clinical psychopharmacology annual meeting,clinical_study,UP,3.104212508662332,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,6,404,0.003506493506493509,0.8866002429130597,0.06128766605101383
media release,equinor asa share buy back,changes_in_companys_own_shares,UP,0.4419934464203499,686391361536.0,833726970.0,3882914.5,0.022,6264036.0,0.0012146524806697652,0.1515999603296736,1,8,242,0.0,0.2938846268878241,0.0
west lafayette ind may 14 2024 globe newswire inotiv inc nasdaq notv the company or inotiv a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services today announced that it will issue its financial results for the fiscal 2024 second quarter ended march 31 2024 on wednesday may 15 2024 after the close of the stock market the company will host a conference call that same day at 4 30 p m eastern time to discuss the results,inotiv inc to report fiscal 2024 second quarter financial results and host conference call on wednesday may 15 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,62350696.0,31206932.0,922240.0,4.102,583600.0,0.5005065540888268,0.09346626282280733,1,7,410,0.0,1.3015467599292592,0.03673469387755102
adelaide australia and cambridge mass aug 23 2023 globe newswire bionomics limited nasdaq bnox asx bno bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that the last patient last visit has been completed in its phase 2 attune study in ptsd and disclosed timing of the end of phase 2 eoph2 meeting to review advancing bnc210 into phase 3 program in patients with sad,bionomics completes last patient last visit in the phase 2b attune study for post traumatic stress disorder ptsd and confirms expected 2023 milestones with its lead asset bnc210,clinical_study,UP,5.833327538437544,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,675,-0.04956349206349206,0.8866002429130597,-0.0008117283950617272
la jolla calif jan 17 2024 globe newswire medicinova inc a biopharmaceutical company traded on the nasdaq global market nasdaq mnov and the standard market of the tokyo stock exchange code number 4875 today announced it has received a notice of grant from the chinese patent office for a new patent which covers mn 166 ibudilast for the treatment of macular injury associated with progressive multiple sclerosis,medicinova receives a notice of grant for a new patent covering mn 166 ibudilast for the treatment of macular injury in china,patents,UP,0.0,64740988.0,42081189.0,10605.0,0.415,5200.0,0.6499929997979024,0.09346626282280733,2,6,528,0.04545454545454545,0.8018560055721619,0.08333333333333333
zug switzerland june 04 2024 globe newswire the attached notifications relate to the annual equity incentive awards granted to directors of the company as well as the one time equity incentive awards issued to new directors upon their election to the board of directors of the company,oculis publishes notifications of transactions by persons discharging managerial responsibilities,corporate_action,UP,1.0660980463382403,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,1,13,388,0.13636363636363635,0.4640841922034435,0.062121212121212126
needham mass march 28 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today reported financial results for the fourth quarter and year ended december 31 2023 and provided a corporate update,candel therapeutics reports fourth quarter and full year 2023 financial results and recent corporate highlights,financial_results,DOWN,-0.6493500461665078,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,457,0.04375,1.2870358800144117,0.11384358288770052
the combined companies aim to disrupt cancer diagnosis and treatment through early disease and recurrence detection prediction of response to treatment and personalized therapy,cutting edge ai company gedicube and cyclomics sign binding loi to join forces and position themselves at the forefront of the global liquid biopsy marketplace,mergers_acquisitions,DOWN,-2.7397233430072485,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,3,9,499,-0.16666666666666666,1.5631250973582267,0.13009931245225362
key highlights,inside information additional positive data from the phase 1 part of the bexmab study in both higher risk hma failed mds and r r aml,clinical_study,UP,9.242146234319629,257301008.0,73287625.0,486977.75,1.176,255774.0,0.2848322498604436,0.09346626282280733,0,9,467,-0.005681818181818177,0.7633342480324978,0.037688692480359144
oslo norvège et saint herblain france le 22 juillet 2024 la coalition pour les innovations en préparation aux epidémies cepi et valneva se nasdaq valn euronext paris vla société spécialisée dans les vaccins ont élargi leur partenariat afin d accroître l accessibilité du premier vaccin au monde contre le chikungunya ixchiq dans les pays à revenus faibles et intermédiaires lmic de mener les études requises après l introduction commerciale du vaccin et de permettre l élargissement potentiel de son indication aux enfants adolescents et femmes enceintes,cepi renforce son partenariat avec valneva en lui octroyant un nouveau financement de 41 3 millions visant à accroître l accessibilité du premier vaccin au monde contre le chikungunya,partnerships,UP,3.2033218696848333,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,0,1,341,0.0,0.6494694268312979,0.0
the webinar will be hosted by vytautas sinius ceo and tomas varenbergas head of investment management division who will introduce the bank s new dividend policy and will answer to questions of participants please find enclosed the information to be delivered during the presentation additional information tomas varenbergas head of investment management division tomas varenbergas sb lt attachment attachments dividend policy webinar 2024 pdf,information to be delivered by šiaulių bankas at the investor conference webinar on new dividend policy,conference_call_webinar,UP,1.248266732515606,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,270,0.13636363636363635,0.8866002429130597,0.06402356902356902
oxurion announces results on the annual shareholders meeting of 16 may 2024,oxurion announces results on the annual shareholders meeting of 16 may 2024,annual_general_meeting,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,13,400,0.0,2.0692591020840054,0.155026455026455
media release,le tribunal américain du district sud de new york ordonne la tenue d un nouveau procès sur les dommages compensatoires dans le cadre du litige entre atos et trizetto,clinical_study,UP,1.983011155862438,24380684288.0,158122098.0,963560.0,0.703,746300.0,0.006485547990866957,0.1515999603296736,4,8,246,0.13636363636363635,0.1722797808926716,0.011363636363636362
media release,antin infrastructure partners flagship fund v commitments nearing 10bn target,financial_results,UP,2.7290421708080856,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.0,0.8866002429130597,0.0
media release,neste appoints a new leadership team and eeva sipilä as cfo,management_changes,DOWN,-1.0480036062946114,8842487808.0,419729896.0,3546183.5,1.115,2479992.0,0.04746739889426376,0.1515999603296736,0,8,243,0.13636363636363635,0.4498875103976574,0.0
évènement en présentiel et retransmis en direct à 16h00 cet,valneva organise une journée investisseurs aujourd hui à new york,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.11818181818181818,0.6494694268312979,0.028525641025641018
longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society mtg,longeveron lomecel b 5 year long term transplant free survival data in hlhs selected for oral presentation at the congenital heart surgeons society chss 51st annual meeting,clinical_study,DOWN,-0.5434777327093245,19211904.0,12130821.0,143460.0,0.206,412100.0,0.6314221120405349,0.09346626282280733,2,9,262,0.17500000000000002,1.063123411629147,0.09264069264069263
tampa fla feb 07 2024 globe newswire pacira biosciences inc nasdaq pcrx the industry leader in its commitment to non opioid pain management and regenerative health solutions has been awarded a national group purchasing agreement for brand pharmaceuticals with premier inc effective january 1 2024 the new agreement allows premier members at their discretion to take advantage of special pricing and terms pre negotiated by premier for exparel bupivacaine liposome injectable suspension,pacira biosciences awarded brand pharmaceuticals agreement with premier inc,business_contracts,DOWN,-2.0792764220916573,1112238976.0,45834212.0,557500.0,0.511,435200.0,0.041208960474336045,0.09346626282280733,2,8,507,0.3645021645021645,0.7130794063724827,0.0
rockville md may 23 2024 globe newswire theriva biologics nyse american tovx a diversified clinical stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need today announced that the u s food and drug administration fda has granted fast track designation ftd to lead clinical candidate vcn 01 in combination with gemcitabine and nab paclitaxel to improve progression free survival and overall survival in patients with metastatic pancreatic adenocarcinoma in virage the ongoing multinational phase 2b clinical study intravenous vcn 01 is being evaluated in combination with standard of care soc chemotherapy gemcitabine nab paclitaxel as a first line therapy for patients with pancreatic ductal adenocarcinoma pdac previously the fda granted orphan drug designation to vcn 01 for treatment of pdac,theriva biologics announces fast track designation granted by the u s fda for vcn 01 for the treatment of metastatic pancreatic cancer,clinical_study,UP,9.242146234319629,3592451.0,8173972.0,1624850.0,0.833,91200.0,2.2753189953043202,0.09346626282280733,3,8,401,0.10433333333333332,1.5225134880447404,0.04419191919191919
los angeles jan 25 2024 globe newswire renovaro biosciences inc nasdaq renb the company a biotechnology corporation focusing on cell gene and immunotherapy announced today the results of the company s special meeting of shareholders held at 12 00 pm et on january 25 2024,renovaro biosciences announces results of special meeting of shareholders,voting_rights,UP,4.838707527269189,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,3,12,519,0.35714285714285715,1.5631250973582267,0.13833333333333334
san diego and suzhou china oct 09 2024 globe newswire adagene inc adagene nasdaq adag a company transforming the discovery and development of novel antibody based therapies today announced poster presentations at the upcoming sitc 39th annual meeting taking place in houston nov 6 10 2024,adagene announces upcoming poster presentations on masked anti ctla 4 safebody adg126 muzastotug at society for immunotherapy of cancer sitc 39th annual meeting,clinical_study,DOWN,-3.9946135377027217,89508240.0,12798488.0,70910.0,0.739,3200.0,0.14298670155954357,0.09346626282280733,2,6,262,0.0,0.845882180665701,0.12332057823129253
an open letter to shareholders regarding a reverse stock split,transcode therapeutics open letter to shareholders,corporate_action,DOWN,-7.103823312288768,6585590.0,780142.0,37160.0,1.332,50100.0,0.11846197531276621,0.09346626282280733,0,8,411,0.0,2.0874185587937095,0.025
new york aug 13 2024 globe newswire eyenovia inc nasdaq eyen an ophthalmic technology company commercializing mydcombi tropicamide and phenylephrine hydrochloride ophthalmic spray 2 for mydriasis clobetasol propionate ophthalmic suspension 0 for postsurgical inflammation and pain and developing the optejet device for use both in connection with its own drug device therapeutic product for pediatric progressive myopia and dry eye as well as out licensing for additional indications today announced that the company will participate in the h c wainwright 4th annual ophthalmology virtual conference which is being held on thursday august 15th,eyenovia to participate in the h c wainwright 4th annual ophthalmology virtual conference,conference_call_webinar,UP,1.366738545250243,27530836.0,2433609.0,8930490.0,1.002,41800300.0,0.0883957537649783,0.09346626282280733,1,7,319,0.22323232323232323,2.4441832149286684,-0.021619167869167864
planegg martinsried june 20 2024 medigene ag medigene the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors announces today that it has selected its lead candidate for mdg2021 a t cell receptor engineered t cell tcr t therapy targeting kirsten rat sarcoma viral oncogene homologue kras g12d with human leukocyte antigen hla a 11 being developed in combination with the company s pd1 41bb costimulatory switch protein csp technology,medigene ag announces lead selection for mdg2021 expanding tcr t kras library targeting solid tumors,clinical_study,UP,1.6666650109821552,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,8,373,0.02,1.3169799228985475,0.025454545454545452
seattle jan 04 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that management will participate in the 13th annual lifesci partners corporate access event taking place january 8 10 2024 at the beacon grand hotel in san francisco california during j p morgan week,kineta to participate in the 13th annual lifesci partners corporate access event,press_releases,UP,2.461536114032452,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,3,8,541,0.1,0.8866002429130597,0.16173160173160175
16 oct 2024 07 00 cest nel asa october 16 2024 oslo norway nel asa nel ose nel reported revenues of nok 366 million in the third quarter of 2024 up from nok 303 million in the same quarter last year ebitda in the quarter was nok 90 million q3 2023 62 the alkaline segment contributed positively to group ebitda but this was more than offset by the negative contribution from the pem segment due to unusually low revenues in the quarter order intake was nok 161 million q3 2023 338 million at the end of the quarter the order backlog was nok 1 872 million down year over year the cash balance was nok 1 941 million at quarter end quarterly highlights revenue from continuing operations in the third quarter 2024 was nok 366 million up from the third quarter 2023 q3 2023 303 revenue was positively impacted by delivery of alkaline electrolyser equipment whereas revenue from sale of pem electrolyser equipment was low ebitda in th,nel asa third quarter 2024 financial results,earnings_releases_and_operating_results,DOWN,-0.4576654794112185,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,255,0.02493265993265993,0.8866002429130597,0.14211309523809523
27 september 2024 swedbanks årsstämma kommer att hållas i stockholm torsdagen den 27 mars 2025 valberedningen består av följande ledamöter lennart haglund utsedd sparbankernas ägareförening tillika valberedningens ordförande ylva wessén utsedd av folksam anders oscarsson utsedd av amf annette björkman utsedd av ägargruppen sparbanksstiftelserna magnus tell utsedd av alecta tjänstepension göran persson styrelseordförande swedbank ab publ valberedningens uppdrag är att bereda och lämna förslag till årsstämman 2025 om val av ordförande vid årsstämman ledamöter och ordförande i styrelsen samt revisor valberedningen kommer även att lämna förslag till antalet styrelseledamöter arvode till styrelse och revisor principer för hur valberedning inför årsstämman 2026 ska utses samt instruktion för valberedningen avseende arbete inför årsstämman 2026 aktieägare som vill lämna förslag till valberedningen ska göra detta senast den 8 januari 2025 antingen via e post ti,valberedningen inför årsstämman 2025,annual_general_meeting,DOWN,-0.0459798177083333,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,12,273,0.0,0.8866002429130597,0.012500000000000004
intranasal foralumab attenuated microglial activation in patients with non active secondary progressive multiple sclerosis and progression independent of relapse pira data presented in a platform session at the annual meeting of the american academy of neurology in denver colorado,tiziana life sciences announces study results from intranasal anti cd3 foralumab in multiple sclerosis patients with pira highlighted in neurology today,clinical_study,UP,1.5624985448084443,200791600.0,63394363.0,242895.0,0.107,139700.0,0.3157221865854946,0.09346626282280733,4,7,435,-0.07222222222222223,1.1109140250580023,0.060353535353535354
needham mass april 11 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the u s food and drug administration fda has granted orphan drug designation to can 2409 candel s most advanced multimodal biological immunotherapy candidate for the treatment of pancreatic cancer,candel therapeutics receives fda orphan drug designation for can 2409 for the treatment of pancreatic cancer,clinical_study,UP,9.242146234319629,244501184.0,41997569.0,917740.0,-0.866,856900.0,0.17176836656954594,0.09346626282280733,3,9,443,0.45,1.2870358800144117,0.08620788770053475
company to host conference call august 7 2024 at 4 30 p m et,capricor therapeutics to present second quarter 2024 financial results and recent corporate update on august 7,financial_results,UP,1.4705868603311214,431710144.0,40176259.0,3124730.0,0.85,8768900.0,0.09306304139103111,0.09346626282280733,2,9,332,0.0,1.3427880947904531,0.15350631313131313
analysis further supports obesity associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment resistant hypertension,mineralys therapeutics presents new post hoc analysis from target htn phase 2 trial of lorundrostat in late breaking poster session at asn kidney week 2023 meeting,clinical_study,DOWN,-0.1280377992053975,916364736.0,43490817.0,793180.0,-0.18,767600.0,0.0474601600120937,0.09346626282280733,3,10,603,-0.05454545454545454,0.8131647725786432,0.0
information on the total number of voting rights denominator following conversion notice from atlas,information on the total number of voting rights denominator following conversion notice from atlas,voting_rights,UP,0.0,297370.0,2615197.0,215098.0909090909,0.57,596546.0,8.794421091569426,0.09346626282280733,3,2,401,0.0,2.0692591020840054,0.1744047619047619
planegg martinsried june 21 2024 medigene ag medigene or the company fse mdg1 prime standard an immuno oncology platform company focusing on the discovery and development of t cell immunotherapies for solid tumors will present virtually at the 7th cell and gene therapy in depth focus summit taking place from june 27 28 2024 in beijing china,medigene to present at the cell and gene therapy in depth focus summit 2024,conference_call_webinar,DOWN,-3.6290287692390817,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,4,4,372,0.0,1.3169799228985475,0.02454545454545454
media release,the world s first fiber to fiber biorecycled clothing unveiled by multi brand consortium carbios on patagonia puma pvh corp and salomon,environmental_social_governance,UP,2.431284791848484,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,6,242,0.25,0.8866002429130597,0.0
topline safety tolerability and immunogenicity data from vax 31 phase 1 2 study n 1 015 expected in third quarter of 2024 vax 31 is designed to provide coverage for approximately of ipd circulating in the u s adult population,vaxcyte completes enrollment of phase 1 2 study evaluating vax 31 for the prevention of invasive pneumococcal disease ipd in adults aged 50 and older,clinical_study,UP,0.2643536072053945,4299703808.0,115925698.0,1672660.0,1.204,957300.0,0.02696132179716878,0.09346626282280733,0,8,516,-0.05555555555555556,0.8014129308283596,0.0
first quarter 2024 briumvi u s net revenue of 50 5 million representing quarter over quarter growth,tg therapeutics provides business update and reports first quarter 2024 financial results,financial_results,UP,9.242146234319629,5889810432.0,135060602.0,1756590.0,1.939,1677400.0,0.022931230734728,0.09346626282280733,2,7,423,0.125,0.6256004090066075,0.04301948051948051
malvern pa feb 27 2024 globe newswire annovis bio inc nyse anvs a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the international conference on alzheimer s and parkinson s diseases ad pd 2024 taking place in lisbon portugal march 5 9 2024,annovis bio announces participation in forum discussion at ad pd 2024,conference_call_webinar,DOWN,-0.6764314173224029,43851744.0,15624645.0,595065.0,1.618,805900.0,0.35630612547587615,0.09346626282280733,1,8,487,0.0,1.368989555493872,0.03591686091686091
immunocore announces randomization of first patient in the global registrational phase 3 clinical trial testing brenetafusp for the treatment of first line advanced or metastatic cutaneous melanoma,immunocore announces randomization of first patient in the global registrational phase 3 clinical trial testing brenetafusp for the treatment of first line advanced or metastatic cutaneous melanoma,clinical_study,DOWN,-0.40551911076616,1601447168.0,37423034.0,614630.0,0.835,788600.0,0.02336826012608116,0.09346626282280733,1,7,375,0.22499999999999998,0.44240182162750774,0.11458333333333333
media release,egetis therapeutics publishes prospectus for admission to trading of shares on nasdaq stockholm,shares_issue,DOWN,-0.1097615322102727,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,8,243,0.0,0.8866002429130597,0.08666666666666667
data from an analysis of five nhp studies showed lumbar it administration led to widespread and consistent biodistribution of aav9 gene therapy vectors across brain and spinal cord regions,taysha gene therapies to present biodistribution data from an analysis evaluating aav9 gene therapy delivery at the upcoming 31st annual esgct congress,clinical_study,DOWN,-0.4950490375089082,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,1,8,249,0.125,1.0149166236087122,-5.66684777210658e-06
alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in col4a and patients have significant unmet medical needs with no disease modifying treatments currently available,eloxx pharmaceuticals key opinion leader event highlights significant unmet need in treatment of alport syndrome patients with nonsense mutations and additional positive results from phase 2 clinical study evaluating elx 02,clinical_study,DOWN,-0.9852207491816546,314.0,2907070.0,613.2105263157895,-153600.22,0.0,9258.184713375796,0.09346626282280733,2,9,731,0.2396103896103896,2.2721670857062097,0.19635714285714287
reykjavik iceland oct 30 2024 globe newswire alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide will release financial results for first nine months of the year ended september 30 2024 after u s markets close on wednesday november 13 2024 and will conduct a conference call with analysts to present the financial results and recent business highlights on thursday november 14 2024 at 8 00 am et 13 00 gmt,alvotech to report financial results for the first nine months of 2024 on november 13 2024 and host conference call on november 14 2024 at 8 00 am et,financial_results,DOWN,-0.9259250401687472,2845615104.0,100126591.0,236865.0,0.191,235600.0,0.035186273385762856,0.09346626282280733,2,8,241,0.0625,0.44264539487962035,0.03921890866335311
media release,klea holding releases its h1 2023 financial report,financial_results,UP,1.6574619748698909,54895992.0,186301764.0,303098.4090909091,-1.119,117419.0,3.393722514386843,0.09346626282280733,2,7,241,0.0,0.4428343691040069,0.0
oslo norway 31 august 2023 pci biotech ose pcib today announces its interim first half 2023 results please find enclosed the report and presentation highlights review,pci biotech first half 2023 interim results,earnings_releases_and_operating_results,DOWN,-7.103823312288768,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,3,1,667,0.04166666666666668,0.8869841129646596,0.022222222222222227
immuneering announces fda clearance of ind application for phase 1 2a trial of imm 6 415 to treat advanced solid tumors with raf or ras mutations,immuneering announces fda clearance of ind application for phase 1 2a trial of imm 6 415 to treat advanced solid tumors with raf or ras mutations,clinical_study,UP,5.68989483061734,111555664.0,27271404.0,2516685.0,0.002,1980700.0,0.2444645392456272,0.09346626282280733,1,8,564,0.2,1.2966226301621697,0.0
san diego aug 29 2024 globe newswire anaptysbio inc nasdaq anab a clinical stage biotechnology company focused on delivering innovative immunology therapeutics today announced that daniel faga president and chief executive officer of anaptys and or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences,anaptys announces participation in september investor conferences,conference_call_webinar,UP,0.244765165807573,687209856.0,17605381.0,784220.0,-0.266,445700.0,0.02561863868262099,0.09346626282280733,3,9,303,0.125,0.871343469962729,0.19573159164068255
10 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 09 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 3795 25 5158estimated mtd return 0 07 0 09 estimated ytd return 3 02 3 85 estimated itd return 183 79 155 16 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 20n apremium discount to estimated nav 4 16 n a sterling sharesamsterdam aex london lse market closen agbx 2 380 00premium discount to estimated navn a 6 72 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl eur nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,261,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk the phase 2b trial will enroll 5 000 subjects across clinical sites in the us and uk,cidara therapeutics announces first subjects dosed in phase 2b navigate trial evaluating cd388 for the prevention of seasonal influenza,clinical_study,DOWN,-0.7985816231790068,629035328.0,4118697.0,696580.0,0.795,3470400.0,0.006547640198675773,0.09346626282280733,0,8,278,0.25,1.357695941787151,-0.02205339105339105
media release,tonner drones signe son premier contrat pour son activité de conseil,advisory,UP,2.272723424286861,10594011.0,70055589.0,12466009.545454545,1.018,14797393.0,6.612754036219143,0.1515999603296736,0,8,243,0.0,1.793725488267577,0.0
media release,kesko interim report 1 1 30 9 2024 a turn for the better in building and technical trade,earnings_releases_and_operating_results,UP,4.41912221461097,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,7,241,0.25,0.8866002429130597,0.05625
northern horizon capital as the management company of baltic horizon fund raised eur 6 29 million in private placement the private placement mainly targeting institutional investors in select european countries took place under the resolution taken by the general meeting of investors announced on 6 august 2024 and was closed on 12 september 2024 the transaction received strong interest from investors with total orders exceeding the maximum supply permitted in accordance with the resolution adopted during the general meeting of baltic horizon fund s investors held on 6 august 2024 the new units to be issued represent less than of the number of baltic horizon fund units already admitted to trading over a period of 12 months therefore northern horizon capital as intends to issue 23 927 085 new units corresponding to a gross value of eur 6 29 million the proceeds will be used for investments into existing real estate properties and or to deleverage baltic horizon fund s port,baltic horizon fund closes private placement of new units,shares_issue,UP,0.3201275095770819,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,0,7,285,0.06515151515151515,0.8866002429130597,0.0
malvern pa aug 05 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that it has received notification from fda to begin its expanded access program eap for the treatment of adult patients aged 18 and older with retinitis pigmentosa rp with ocu400 a modifier gene therapy product candidate,ocugen inc announces fda approval of expanded access program for patients with retinitis pigmentosa,clinical_study,DOWN,-3.673475544336368,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,6,327,0.05555555555555555,0.7661975315521313,0.08801010101010101
media release,šiaulių bankas results for 9m 2024,financial_results,UP,0.7370985601597579,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,7,240,0.0,0.8866002429130597,0.07224015042196862
needham mass may 22 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that paul peter tak md phd fmedsci candel s president and chief executive officer will present a company overview at the jefferies global healthcare conference on wednesday june 5 2024 at 5 30 p m et,candel therapeutics to present at the jefferies global healthcare conference,conference_call_webinar,UP,0.325998046949688,242747568.0,41997569.0,917740.0,-0.866,856900.0,0.17300922660531043,0.09346626282280733,2,8,402,0.0,1.2870358800144117,0.08313136618283677
south san francisco calif feb 29 2024 globe newswire akero therapeutics inc nasdaq akro a clinical stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need today reported fourth quarter and full year financial results for the period ending december 31 2023,akero therapeutics reports fourth quarter and full year 2023 financial results and provides business update,clinical_study,UP,2.93794035203086,4362944000.0,65983030.0,1904080.0,-0.16,4370200.0,0.015123510638688005,0.09346626282280733,3,7,485,0.06266666666666668,1.1395320392459187,-0.022962962962962966
conference call to begin at 4 30 p m et conference call to begin at 4 30 p m et,vaxart to host full year 2023 business update and financial results conference call on march 14,conference_call_webinar,DOWN,-5.000004967053534,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,3,8,478,0.175,1.025768835125998,-0.04583333333333334
media release,nanologica s rights issue registered conversion of btu to shares and warrants,shares_issue,DOWN,-3.404252210749046,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,10,240,0.0,0.8866002429130597,0.04191919191919192
miami sept 26 2024 globe newswire fortress biotech inc nasdaq fbio fortress an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long term value for shareholders through product revenue equity holdings and dividend and royalty revenue today announced that lindsay a rosenwald m d chairman president and chief executive officer will participate in the following upcoming october 2024 investor conferences,fortress biotech to participate in october 2024 investor conferences,press_releases,UP,8.510638837525091,53808348.0,21991150.0,243185.0,1.772,331000.0,0.4086940190024046,0.09346626282280733,3,8,275,0.15,0.6928276660424207,0.07327200577200578
media release,xano delårsrapport 1 januari 30 september 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,3523049728.0,15958705.0,22093.78947368421,0.619,17473.0,0.004529798394035044,0.1515999603296736,3,14,239,0.0,0.4615949135995517,0.0
data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv data support the potential impact of vir 2218 and vir 3434 in addressing both hbv and hdv and underscore the company s confidence in its approach to a functional cure for hbv,vir biotechnology announces multiple abstracts highlighting new hepatitis b and d data accepted for presentation at easl congress 2023,clinical_study,DOWN,-0.3840260290086915,705705024.0,93935488.0,1328370.0,1.229,971400.0,0.13310871370528884,0.09346626282280733,2,2,752,0.03409090909090909,0.8653389999075153,0.14863636363636362
the planned interim analysis confirms the accuracy of the sample size calculations and statistical power for emacc the primary endpoint,inmune bio inc completes blinded interim analysis of phase ii alzheimer s disease trial,clinical_study,UP,3.9780516237384576,160151632.0,15213010.0,781395.0,1.567,974600.0,0.09499128925517288,0.09346626282280733,3,8,366,0.4,0.8435084668920305,0.13770863395863395
boston sept 17 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that on september 16 2024 elicio granted an aggregate of 4 800 inducement stock options to a new employee as an inducement material to the individual entering into employment with elicio in accordance with nasdaq listing rule 5635 c 4 the inducement stock options were approved by the compensation committee of elicio s board of directors and granted under the elicio therapeutics inc 2024 inducement incentive award plan,elicio therapeutics reports inducement grants,corporate_action,UP,0.2421247401353017,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,1,8,284,0.06818181818181818,0.8558055682194762,0.03843975468975469
jerusalem nov 09 2023 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins reports today that the american society for bone and mineral research asbmr has announced that the sabre strategy to advance bmd as a regulatory endpoint project team has submitted to the u s food and drug administration fda its full qualification plan to use the treatment related change in bone mineral density bmd as a surrogate endpoint for fractures in future trials of new anti osteoporosis drugs,entera bio reports key milestone relating to oral pth 1 34 peptide eb613 phase 3 program asbmr sabre has submitted to fda the full qualification plan to approve bmd as a surrogate endpoint for osteoporosis,clinical_study,UP,9.242146234319629,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,3,14,596,0.11948051948051948,0.6915109749530333,0.3
25 sep 2024 08 00 cest riber résultats du premier semestre 2024 croissance solide du chiffre d affaires semestriel 13 progression de la marge brute 21 et résultat opérationnel à l équilibrerésultat net positif de 0 2 m malgré la saisonnalité traditionnelle des ventesforte augmentation du carnet de commandes au 30 juin 2024 18 à 36 0 m perspectives confirmées chiffre d affaires supérieur à 40 m et croissance de la rentabilité attendus sur l ensemble de l exercice bezons le 25 septembre 2024 8h00 riber un leader mondial d équipement pour l industrie des semiconducteurs annonce ses résultats du premier semestre 2024 en m s1 2024s1 2023variationchiffre d affaires ca systèmesca services et accessoires13 79 44 312 28 53 6 13 10 19 marge bruteen ca4 834 8 3 932 3 21 2 5 ptsrésultat opérationnelen ca 0 0 0 2 1 1 9 3 97 9 1 ptsrésultat neten ca0 21 2 1 2 10 2 113 11 4 pts faits marquants du semestre au premier semestre,riber résultats du premier semestre 2024,financial_results,DOWN,-0.7782093947869452,71241952.0,35018869.0,45757.36363636364,0.907,16940.0,0.25000035609542787,0.19535099655549074,2,6,276,0.0,0.4818751066598002,0.0
biocardia stemcardia biotechnology company partnership targets heart failure the leading cause of death and a condition with limited treatment options,biocardia and stemcardia announce biotherapeutic delivery partnership,partnerships,UP,2.6315807085398863,11158353.0,3886990.0,44615.0,0.838,135000.0,0.34834800440530966,0.09346626282280733,2,7,472,-0.19404761904761902,1.32107885633281,0.0
the combined companies aim to disrupt cancer diagnosis and treatment through early disease and recurrence detection prediction of response to treatment and personalized therapy,cutting edge ai company gedicube and cyclomics sign binding loi to join forces and position themselves at the forefront of the global liquid biopsy marketplace,mergers_acquisitions,DOWN,-2.7397233430072485,60155592.0,90925076.0,7542515.0,0.529,816400.0,1.51149831590054,0.09346626282280733,3,9,499,-0.16666666666666666,1.5631250973582267,0.13009931245225362
jupiter fla sept 23 2024 globe newswire dyadic international inc dyadic we us our or the company nasdaq dyai a biotechnology company focused on the efficient large scale manufacture of proteins for use in non pharmaceutical applications including food nutrition and wellness as well as animal and human health therapeutics and vaccines today provided an update on business progress and announced its attendance at the bioprocess international conference in boston september 23 26 2024,dyadic provides alternative proteins business update and announces attendance at bioprocess international conference,press_releases,DOWN,-2.439022026387315,28610238.0,19290822.0,39215.0,0.9,51800.0,0.6742628984771116,0.09346626282280733,0,9,277,0.04285714285714286,0.7846450948942033,0.11812993379169849
adelaide australia and cambridge mass sept 03 2024 globe newswire bionomics limited nasdaq bnox bionomics or company a clinical stage biotechnology company developing novel first in class allosteric ion channel modulators to treat patients suffering from serious central nervous system cns disorders with high unmet medical need today announced that it will be participating and presenting at the h c wainwright 26th annual global investment conference being held september 9 11 2024 virtually and in person at the lotte new york palace hotel in new york ny,bionomics to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,DOWN,-3.8880304048573615,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,1,6,298,0.025269578905942544,0.8866002429130597,0.056342997922100645
west lafayette ind oct 16 2023 globe newswire inotiv inc nasdaq notv a leading contract research organization today announced the appointment of terry coelho to its board of directors ms coelho is replacing richard a johnson phd who is leaving the board as part of the board s succession planning ms coelho was also appointed to serve as a member of the compensation committee and the audit committee and as a member and the chair of the nominating corporate governance committee of the board,inotiv inc announces changes to its board composition,management_changes,UP,3.4146309693180865,62522460.0,31206932.0,922240.0,4.102,583600.0,0.49913154408831645,0.09346626282280733,0,8,621,0.0,1.3015467599292592,0.0
woburn mass may 15 2024 globe newswire yield10 bioscience inc nasdaq yten yield10 or the company an agricultural bioscience company today announced that company has received a final delisting notice from nasdaq the delisting is a result of failure to regain compliance with the minimum stockholders equity requirement for continued listing on the nasdaq capital market set forth in nasdaq listing rule 5550 b 1 requiring companies listed on the nasdaq capital market to maintain stockholder s equity of at least 2 500 000 suspension of trading in the company s common stock on the nasdaq exchange will be effective at the open of trading on may 16 2024,yield10 bioscience announces delisting from nasdaq,delisting_notice,DOWN,-7.103823312288768,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,409,-0.05277777777777779,0.8866002429130597,0.041941964285714284
se venligst vedlagte,ledende medarbejderes transaktioner,company_regulatory_filings,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,4,5,274,0.0,0.8866002429130597,0.0
palo alto calif june 20 2024 globe newswire scilex holding company nasdaq sclx scilex or the company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that in anticipation of selling our commercially available products to new and current special customers scilex has entered into a non exclusive distribution agreement with a well known and highly respected distributor with over 10 years of sales excellence endeavor distribution llc endeavor endeavor has logistics expertise to sell and distribute our currently marketed non opioid products nationally,scilex holding company partners with new national distributor endeavor distribution llc,business_contracts,UP,3.8251328743840936,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,3,9,373,0.25443001443001445,1.0327724261931344,0.31625000000000003
moonlake immunotherapeutics announces positive feedback from both fda and ema on regulatory path for the phase 3 program of the nanobody sonelokimab slk in hidradenitis suppurativa hs,moonlake immunotherapeutics announces positive feedback from both fda and ema on regulatory path for the phase 3 program of the nanobody sonelokimab slk in hidradenitis suppurativa hs,clinical_study,UP,0.0,2929339136.0,28324751.0,691265.0,1.23,267600.0,0.009669331437901494,0.09346626282280733,0,8,488,0.22727272727272727,0.5366763308656862,0.037258953168044076
02 oct 2024 09 23 cest borr drilling limited please see attachment on www newsweb no more information access the news on oslo bors newsweb site more information access the news on oslo bors newsweb site 628880_borr drilling cob 30 sept 2024 form pdf borr drilling limited oslo børs newspoint borr drilling bmg1466r1732 borr oslo børs,notification of major holdings,regulatory_filings,UP,0.4317789178092859,443918176.0,174743108.0,6645095.0,1.794,4344400.0,0.3936381014504799,0.1515999603296736,2,7,269,0.03392857142857143,0.6240735940428164,0.0
boston aug 28 2024 globe newswire elicio therapeutics inc nasdaq eltx elicio therapeutics or elicio a clinical stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer today announced that robert connelly chief executive officer will present at the upcoming h c wainwright 26th annual global investment conference on september 11 2024 at 2 30 p m et,elicio therapeutics to present at the h c wainwright 26th annual global investment conference,conference_call_webinar,UP,2.611940785365037,127656064.0,10299137.0,63410.0,2.164,22500.0,0.08067879172586741,0.09346626282280733,2,8,304,0.0,0.8558055682194762,0.04612770562770563
oslo norway 25 august 2023 pci biotech ose pcib invites to a webcast presentation of the company s first half 2023 interim report on thursday 31 august 2023 08 30am 09 30am cest local time,pci biotech invitation to first half interim 2023 results presentation,interim_information,UP,1.1976108173510196,62708352.0,30573300.0,50456.55,1.795,36908.0,0.48754749606559583,0.09346626282280733,4,8,673,0.03333333333333334,0.8869841129646596,0.020000000000000007
dallas july 29 2024 globe newswire spectral ai inc nasdaq mdai spectral ai or the company an artificial intelligence ai company focused on medical diagnostics for faster and more accurate treatment decisions in wound care today announced that it will report financial results for the second quarter ended june 30 2024 on monday august 12 2024 after the close of the stock market the company will host a corresponding conference call at 5 00 pm eastern time that day to discuss the results,spectral ai schedules 2024 second quarter financial results and conference call,conference_call_webinar,DOWN,-0.558658697003811,55328804.0,17924135.0,466020.0,0.698,473400.0,0.3239566682120944,0.09346626282280733,0,9,334,0.03750000000000001,0.9904696515070965,0.10412938912938914
alvotech nasdaq alvo a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide announces its participation in the morgan stanley 22nd annual global healthcare conference in new york members of the management team will hold an in person fireside chat on september 5 2024 starting at 5 35 pm edt 21 35 gmt,alvotech to participate in the morgan stanley 22nd annual global healthcare conference,conference_call_webinar,UP,0.5046212296880009,2848708096.0,100126591.0,236865.0,0.191,235600.0,0.035148069800690455,0.09346626282280733,0,9,306,0.02727272727272727,0.44264539487962035,0.08049943883277216
tel aviv israel and miami fla nov 02 2023 globe newswire inspiremd inc nasdaq nspr developer of the cguard embolic prevention stent system eps for treatment of carotid artery disease and prevention of stroke today announced that the marvin slosman chief executive officer will participate in three upcoming investor conferences in november,inspiremd to participate in upcoming november investor conferences,conference_call_webinar,DOWN,-7.103823312288768,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,3,8,604,0.0,0.6085732039686736,0.07045454545454546
needham mass june 11 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that the company is set to join the broad market russell 3000 index at the conclusion of the 2024 russell us indexes annual reconstitution effective at the open of us equity markets on monday july 1 2024 according to a preliminary list of additions posted friday may 24 2024,candel therapeutics to join russell 3000 index,exchange_announcement,DOWN,-1.1379857490131404,243499136.0,41997569.0,917740.0,-0.866,856900.0,0.1724752280024517,0.09346626282280733,1,8,382,0.22083333333333333,1.2870358800144117,0.08048489623121977
02 oct 2024 08 58 cest aker horizons asa new ppa product gives businesses a better alternative for their electricity supply mainstream renewable power mainstream the pureplay global wind and solar company majority owned by aker horizons asa has reached financial close on its 50 mw ilikwa solar pv plant the power from the plant will supply multiple private commercial and industrial customers under flexible shorter term power purchase agreements ppas in a new to market product called renewable energy supply agreements resas this new product opens up the energy market in south africa by giving a wider range of businesses access to affordable reliable and renewable power through shorter term energy contracts of between five and 10 years commenting on the announcement mainstream s general manager for africa hein reyneke said we are excited to bring this new product to market offering customers the opportunity to secure flexible clean and lower cos,mainstream renewable power reaches financial close on 50 mw solar pv plant to provide new flexible ppas to private customers in south africa,product_services_announcement,DOWN,-0.6766964400073892,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,6,269,0.13961675579322638,0.8866002429130597,0.0
pratteln switzerland july 31 2024 santhera pharmaceuticals six sann announces the board of directors has appointed dr oliver p kronenberg as chief legal officer and corporate secretary of santhera pharmaceuticals ag effective august 1 2024,santhera appoints dr oliver p kronenberg as chief legal officer and company secretary,management_changes,DOWN,-0.3246724427955373,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,2,1,332,0.25,0.5209522992128177,0.03714285714285715
jerusalem jan 03 2024 globe newswire entera bio ltd nasdaq entx entera or the company a leader in the development of orally delivered peptides and therapeutic proteins announced that on december 27 2023 it received an extension of 180 calendar days from the nasdaq stock market llc nasdaq to regain compliance with the nasdaq s minimum 1 00 bid price requirement set forth in nasdaq listing rule 5550 a 2 for continued listing on the nasdaq capital market the bid price requirement the nasdaq determination is based on the company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the nasdaq capital market with the exception of the bid price requirement,entera bio receives extension from nasdaq to regain compliance with minimum bid price rule,exchange_announcement,UP,0.7633671839197399,89727184.0,28901215.0,43070.0,1.482,13900.0,0.3221009922700795,0.09346626282280733,2,8,542,-0.041666666666666664,0.6915109749530333,0.06891233766233765
seattle feb 14 2024 globe newswire kineta inc nasdaq ka a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today that the company will be attending and presenting at the following upcoming investors conferences,kineta to present at upcoming investor conferences,press_releases,DOWN,-6.870222755762177,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,2,8,500,0.0,0.8866002429130597,0.14639475108225108
gaithersburg md oct 24 2023 globe newswire neximmune inc nasdaq nexi announces the extension of the research partnership between neximmune yale and jdrf to explore the use of neximmune s aim nanoparticles in combination with an anti cd3 mab to tolerize deplete or modulate diabetes antigen specific t cells the extension includes an additional 300 000 grant funded by jdrf to yale as a part of its cures research portfolio which includes therapies for the prevention of type 1 diabetes t1d,neximmune yale and jdrf extend research partnership for type 1 diabetes,partnerships,UP,5.8968000244628,139.0,1178371.0,90.94736842105263,1.981,0.0,8477.489208633093,0.09346626282280733,1,8,613,0.0,2.2666992986423327,0.013691558441558444
media release,eviden coordonne le projet cyderco pour le centre européen de compétences en cybersécurité eccc,press_releases,DOWN,-0.4285659181827463,24371947520.0,158122098.0,963560.0,0.703,746300.0,0.006487872906760633,0.1515999603296736,0,10,242,0.0,0.1722797808926716,0.04545454545454545
new york march 01 2024 globe newswire tg therapeutics inc nasdaq tgtx today announced the presentation of data from the ultimate i ii phase 3 trials and the enhance phase 3b trial evaluating briumvi ublituximab xiiy in patients with relapsing forms of multiple sclerosis rms at the americas committee for treatment and research in multiple sclerosis actrims annual forum being held in west palm beach florida links to each presentation are included below,tg therapeutics announces presentation of data for briumvi in multiple sclerosis at the americas committee for treatment and research in multiple sclerosis annual forum,clinical_study,UP,1.8583136755684029,5883460608.0,135060602.0,1756590.0,1.939,1677400.0,0.022955979651899456,0.09346626282280733,4,7,484,0.022727272727272724,0.6256004090066075,0.04584415584415584
mainz germany and shanghai china june 24 2024 biontech se nasdaq bntx biontech and duality biologics suzhou co ltd dualitybio today announced that the u s food and drug administration fda granted fast track designation for bnt324 db 1311 for the treatment of patients with advanced unresectable or metastatic castration resistant prostate cancer crpc who have progressed on or after standard systemic regimens bnt324 db 1311 is a next generation antibody drug conjugate adc candidate targeting the transmembrane glycoprotein b7 h3 an immune checkpoint protein which is overexpressed in a range of tumor types and has been associated with disease progression and poor prognosis for patients the candidate is currently being evaluated in an ongoing phase 1 2 study nct05914116 in patients with advanced solid tumors,biontech and dualitybio receive fda fast track designation for antibody drug conjugate candidate bnt324 db 1311 in prostate cancer,clinical_study,UP,2.76465499073638,24764291072.0,97284490.0,1237590.0,1.285,391100.0,0.003928418129037246,0.09346626282280733,0,6,369,0.08888888888888889,0.5503225880253886,0.0
all patients treated in the edithal trial maintained hemoglobin levels above the transfusion threshold and are transfusion free post renizgamglogene autogedtemcel reni cel infusion,editas medicine announces new safety and efficacy data from the edithal trial of reni cel in 7 patients with transfusion dependent beta thalassemia presented at the european hematology association eha annual congress,clinical_study,DOWN,-0.54644324630056,179564160.0,83382193.0,2526680.0,2.096,3015800.0,0.46435877293107936,0.09346626282280733,4,3,379,0.1340909090909091,1.3105556047468256,0.048818637502848025
cambridge mass may 02 2024 globe newswire editas medicine inc nasdaq edit a clinical stage gene editing company today announced that it will host a conference call and webcast on wednesday may 8 2024 at 8 00 a m et to discuss results for the first quarter 2024 and to provide a corporate update,editas medicine announces first quarter 2024 results conference call and upcoming investor events,conference_call_webinar,UP,1.2797106827480222,181573264.0,83382193.0,2526680.0,2.096,3015800.0,0.4592206537632104,0.09346626282280733,3,7,422,0.16666666666666666,1.3105556047468256,0.03461471861471862
record fourth quarter 2023 cguard eps revenue of 1 76 million increased 71 over fourth quarter 2022,inspiremd reports fourth quarter and full year 2023 financial results and provides business update,earnings_releases_and_operating_results,DOWN,-2.6616033694073624,66172252.0,16849440.0,286250.0,0.613,4867100.0,0.25462999203956366,0.09346626282280733,2,7,479,0.06999999999999999,0.6085732039686736,0.08245129870129868
rapt to host a conference call today at 8 30 am et,rapt therapeutics announces clinical hold on studies evaluating zelnecirnon,clinical_study,DOWN,-7.103823312288768,145352320.0,6191111.0,99294.6,-0.137,87900.0,0.042593823063849276,0.09346626282280733,1,7,494,0.0,1.6028075568485736,0.11840367965367966
irvine calif aug 29 2024 globe newswire biomerica inc nasdaq bmra today reported its financial results for the fiscal year ended may 31 2024 the company achieved a modest increase in net sales to 5 4 million compared to 5 3 million in the prior year this growth was primarily driven by strong demand for ez detect colorectal screening tests and aware breast self exam products in the middle east including the united arab emirates,biomerica reports fiscal 2024 year end results,financial_results,UP,4.347821861674596,7950917.0,2384045.0,25145.0,0.333,12400.0,0.29984528828561535,0.09346626282280733,3,9,303,0.14791666666666667,1.5245042583012947,0.16488374720517576
valberedningen inför scandics årsstämma 2025 utgörs enligt valberedningens instruktion av scandics tre största aktieägare per den 31 augusti 2024 samt styrelsens ordförande och har följande sammansättning aktieägare som vill lägga fram förslag till valberedningen kan göra detta via e post till nominationcommittee scandichotels com senast den 31 december 2024 årsstämman kommer att äga rum den 6 maj 2025 på vasateatern scandic grand central i stockholm för mer information vänligen kontakta rasmus blomqvist director investor relations scandic hotels group email rasmus blomqvist scandichotels com telefon 46 702 335 367 camilla köhler general counsel scandic hotels group email camilla kohler scandichotels com telefon 46 709 735 159 om scandic hotels group scandic är det största hotellföretaget i norden med ett nätverk av omkring 280 hotell och 58 000 hotellrum i drift och under utveckling på över 130 destinationer scandic är ledande när det kommer till att integrera hållb,valberedning inför scandics årsstämma 2025 utsedd,annual_general_meeting,UP,0.0,21658378.0,45859984.0,7124020.0,1.612,2186300.0,2.1174246751072494,0.1515999603296736,4,8,267,0.18333333333333335,0.961003290910132,0.09722222222222222
dallas july 05 2024 globe newswire taysha gene therapies inc nasdaq tsha a clinical stage biotechnology company focused on advancing adeno associated virus aav based gene therapies for severe monogenic diseases of the central nervous system cns today announced that on july 3 2024 the compensation committee of taysha s board of directors granted four new employees in the aggregate options to purchase 484 000 shares of the company s common stock in connection with their employment the stock options were granted under the taysha gene therapies inc 2023 inducement plan as an inducement material to the individuals entering employment with taysha in accordance with nasdaq listing rule 5635 c 4,taysha gene therapies announces inducement grant under nasdaq listing rule 5635 c 4,corporate_action,UP,0.9302316297384028,623749056.0,136885482.0,5054745.0,1.016,2606600.0,0.2194560146957561,0.09346626282280733,4,8,358,-0.05454545454545454,1.0149166236087122,0.04701441102756893
needham mass april 25 2024 globe newswire candel therapeutics inc candel or the company nasdaq cadl a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer today announced that two abstracts were accepted for presentation at the 2024 american society of clinical oncology asco annual meeting taking place may 31 to june 4 2024 in chicago il the first presentation will feature data from the ongoing phase 1 clinical trial of can 3110 in patients with recurrent high grade glioma the presentation will focus on patients recruited in cohort c treated with multiple injections of can 3110 up to six demonstrating that this approach is both feasible and well tolerated the second presentation will show topline overall survival data from the phase 2 clinical trial of can 2409 plus valacyclovir in combination with continued immune checkpoint inhibitor ici treatment in patients with non resectable stage iii iv non small cell lung cancer nsclc who have an inadequate response to front line anti pd l 1 therapy,candel therapeutics announces upcoming presentations at the 2024 asco annual meeting,clinical_study,DOWN,-2.479340341131657,240993984.0,41997569.0,917740.0,-0.866,856900.0,0.1742681219793437,0.09346626282280733,3,8,429,0.02285714285714286,1.2870358800144117,0.11927989790957705
rīga latvija 2024 09 19 15 07 cest jsc saf tehnika informs about the purchase and sale of its shares by koka zirgs ltd and andrejs grišāns information in files attached about saf tehnika saf tehnika jsc is an iso certified wireless data transmission equipment manufacturer the company s products are produced in latvia europe and sold in over 130 countries worldwide saf tehnika has been listed on nasdaq riga since 2004 saf tehnika wholly owns subsidiaries saf north america llc which operates from denver co usa and serves the north american market and saf tehnika asia pte ltd in singapore additional information zane jozepa cfo member of the board zane jozepa saftehnika com www saftehnika com attachments ag_safakcijas_160924 pdf kokazirgs_safakcijas_160924 pdf,on transactions under regulation no 596 2014,changes_in_companys_own_shares,UP,1.509432468434731,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,13,281,0.0,0.8866002429130597,0.0
webinar to focus on a nephrologist s perspective on the use of furoscix for fluid overload in heart failure and potential use in chronic kidney disease webinar to focus on a nephrologist s perspective on the use of furoscix for fluid overload in heart failure and potential use in chronic kidney disease,scpharmaceuticals to host key opinion leader kol webinar on october 22 2024,conference_call_webinar,DOWN,-0.4728127857288839,207187472.0,31628202.0,294455.0,0.361,185600.0,0.152654992575999,0.09346626282280733,1,8,256,-0.09047619047619047,0.7082528246818063,-0.02412281295093794
antibody rise observed in lactating mothers and in their breast milk,vaxart announces positive results for its bivalent norovirus vaccine candidate in lactating mothers,clinical_study,UP,5.633806009374048,120958184.0,226926647.0,9325470.0,1.148,2676900.0,1.8760751814858596,0.09346626282280733,1,8,424,0.22727272727272727,1.025768835125998,0.07126623376623376
malvern pa april 02 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases today provided a summary of corporate updates and reported fourth quarter and full year 2023 financial results,annovis bio provides corporate updates and reports fourth quarter and full year 2023 financial results,clinical_study,UP,2.3411348835963155,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,452,0.0875,1.368989555493872,0.047516835016835006
04 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 03 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 3746 25 5064estimated mtd return 0 05 0 05 estimated ytd return 3 00 3 81 estimated itd return 183 75 155 06 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 40n apremium discount to estimated nav 3 43 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 47 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.8474527642290024,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,5,267,-0.006122448979591831,0.8866002429130597,-0.006122448979591831
media release,apranga group interim information for 9 months of 2024,financial_results,UP,0.1757425649229707,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,9,242,0.0,0.8866002429130597,-0.08787878787878789
management to host conference call and webcast at 4 30 pm et on that day,inmune bio inc to report second quarter 2024 financial results and provide a corporate update on thursday august 1 2024,conference_call_webinar,DOWN,-0.2421362858288849,162489600.0,15213010.0,781395.0,1.567,974600.0,0.09362451504588601,0.09346626282280733,3,8,338,0.0,0.8435084668920305,0.17036884411884412
announced positive outcomes from the c guardians ide clinical trial of the cguard prime carotid stent system demonstrating a one year primary endpoint event rate of 1 the lowest for any carotid stent or embolic protection device pivotal trial,inspiremd reports second quarter 2024 financial results and provides business update,clinical_study,DOWN,-2.7027000903735274,67091308.0,16849440.0,286250.0,0.613,4867100.0,0.25114192139464625,0.09346626282280733,1,8,326,0.2254545454545455,0.6085732039686736,0.08794871794871795
palo alto calif sept 09 2024 globe newswire scilex holding company nasdaq sclx scilex or company an innovative revenue generating company focused on acquiring developing and commercializing non opioid pain management products for the treatment of acute and chronic pain today announced that jaisim shah chief executive officer and president of scilex will present at the 26th annual h c wainwright global investment conference taking place september 9 11 2024 in new york city,scilex holding company to present at the 26th annual h c wainwright global investment conference,conference_call_webinar,UP,2.884624201870852,29279608.0,4990167.0,137255.0,1.143,131300.0,0.17043148255263527,0.09346626282280733,0,9,292,0.17662337662337663,1.0327724261931344,0.23815450825216453
florham park n j and tampa fla july 27 2023 globe newswire celularity inc nasdaq celu celularity a biotechnology company developing placental derived allogeneic cell therapies and biomaterial products and verséa ophthalmics llc verséa ophthalmics a tampa fl based company that focuses on providing complete ocular point of care diagnostic and therapeutic interventions today announced that the companies have entered into an exclusive u s commercialization agreement in which verséa ophthalmics will distribute celularity s biovance and biovance 3l ocular products to support the treatment of ocular surface disease and ocular surgical applications,celularity and verséa ophthalmics announce exclusive u s commercialization agreement to distribute biovance and biovance 3l ocular for ophthalmic applications,partnerships,DOWN,-1.428570066179548,45503480.0,11684589.0,65020.0,0.764,90700.0,0.25678451406353975,0.09346626282280733,3,9,702,0.1,1.6050367793919866,0.09409722222222222
planegg martinsried august 8 2024 medigene ag medigene fse mdg1 prime standard and wuxi biologics stock code 2269 hk enter into a three year multi target strategic partnership to design and co research t cell receptor tcr guided t cell engagers tcr tces for the treatment of difficult to treat tumors the collaboration combines the respective expertise of each company with medigene s 3s sensitive specific and safe tcr generation and characterization capabilities and wuxi biologics unique anti cd3 mab its industry leading tce platform and proprietary bispecific antibody platform wuxibody,medigene and wuxi biologics enter into a research collaboration for off the shelf tcr guided t cell engagers,partnerships,DOWN,-2.7649852114563966,1967469.0,14242559.0,363495.0,1.174,331336.5,7.239025875375927,0.09346626282280733,3,4,324,0.06785714285714285,1.3169799228985475,0.03707792207792208
lexington mass april 24 2024 globe newswire t2 biosystems inc nasdaq ttoo a leader in the rapid detection of sepsis causing pathogens and antibiotic resistance genes announced today that it will report financial results for the first quarter 2024 and business updates after market close on monday may 6 2024 company management will host a corresponding conference call beginning at 4 30 p m eastern time,t2 biosystems to report first quarter 2024 financial results and business updates on may 6 2024,earnings_releases_and_operating_results,UP,0.7352934086817846,3910931.0,11899158.0,66195.0,0.448,154300.0,3.0425384646264533,0.09346626282280733,2,9,430,0.125,1.9596557041969667,0.0
toronto march 27 2024 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders announced today that it has submitted a type c meeting request package to the u s food drug administration fda for the evaluation of a proposed clinical study of bucillamine an oral thiol based drug with anti inflammatory and antiviral properties as a potential treatment for long term covid following the submission of the type c meeting request package the company expects to hear from the fda on a firm date for the meeting,revive therapeutics submits type c meeting request package to fda for clinical study of bucillamine to treat long covid,clinical_study,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,2,9,458,0.0,1.8889707456546947,0.11281651620494597
rockville md june 22 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported that its german subsidiary curetis gmbh has received the full set of ten unyvero a30 c series instruments which have been assembled by its development partner dmtpe in germany the instruments have successfully passed electrical and functional testing and will allow rapid sample to answer molecular testing with numerous chemistries and assay formats,opgen s subsidiary curetis receives batch of ten new c series unyvero a30 instruments,product_services_announcement,DOWN,-1.5873075943202797,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,737,0.17662337662337663,1.807174583649316,0.020454545454545454
not for release publication or distribution directly or indirectly in or into the united states hong kong canada japan or australia or any other jurisdiction in which the distribution or release would be unlawful the board of directors of naxs is pleased to announce its appointment of the board member nikolai jebsen as interim ceo effective october 7 the board thanks gösta lundgren for his committed service as interim ceo following the above appointment naxs management will consist of mr jebsen as ceo and mr lundgren in his longstanding position as cfo contact information gösta lundgren interim ceo phone 46 70 710 47 88 this press release and further information is available on the company s website www naxs se naxs ab publ corp reg no 556712 2972 alma nybrogatan 8 114 34 stockholm sweden e mail info naxs se naxs is listed on nasdaq stockholm naxs primarily invests in private equity funds with a nordic focus but may also make direct investments or co invest,appointment of nikolai jebsen as interim ceo of naxs ab publ,management_changes,DOWN,-0.675678244466031,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,2,11,268,0.18125,0.8866002429130597,0.0
pratteln schweiz 18 juni 2024 santhera pharmaceuticals six sann gibt bekannt dass die aktionäre an der heutigen generalversammlung gv in pratteln schweiz allen anträgen des verwaltungsrats mit grosser mehrheit zugestimmt haben die teilnehmenden aktionäre vertraten 4 535 785 aktien oder 35 des aktienkapitals des unternehmens,santhera s aktionäre stimmen an heutiger generalversammlung allen anträgen des verwaltungsrats zu,annual_general_meeting,DOWN,-0.3061197182379018,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,9,375,0.0,0.5209522992128177,0.04000000000000001
results in performance of the upper limb pul 2 0 continue to show benefits in skeletal muscle function after 3 years of cap 1002 treatment p 0 001 stabilization in left ventricular ejection fraction lvef suggests preservation of cardiac function,capricor therapeutics announces positive 3 year efficacy results from hope 2 open label extension study of cap 1002 in duchenne muscular dystrophy,clinical_study,UP,1.5957474240858738,432793472.0,40176259.0,3124730.0,0.85,8768900.0,0.09283009472009782,0.09346626282280733,1,9,389,0.03545454545454545,1.3427880947904531,0.10818181818181818
media release,pareto bank asa vurderer utstedelse av senior preferred obligasjonslån,financing_agreements,DOWN,-0.9077132949647496,6372872704.0,46145176.0,38558.55,0.663,36744.0,0.007240875213314162,0.1515999603296736,0,11,242,0.0,0.2272865108365386,0.0
eurobio scientific suspension du contrat de liquidité,eurobio scientific suspension du contrat de liquidité,corporate_action,UP,0.204078518614477,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,3,11,330,0.0,0.4336088389568585,0.007936507936507938
boca raton florida sept 03 2024 globe newswire inmune bio inc nasdaq inmb the company a clinical stage inflammation and immunology company focused on developing treatments that harness a patient s innate immune system to fight disease today announced that management will participate in the following investor conferences in september and october 2024,inmune bio inc to present at the baird 2024 global healthcare conference,conference_call_webinar,DOWN,-0.3021145207289472,160967584.0,15213010.0,781395.0,1.567,974600.0,0.09450977409215511,0.09346626282280733,1,9,298,0.0,0.8435084668920305,0.13834801092154034
zug switzerland june 10 2024 globe newswire oculis holding ag nasdaq ocs oculis a global biopharmaceutical company purposefully driven to save sight and improve eye care today announced positive topline results from its phase 2b relief trial with licaminlimab a novel anti tnfα biologic eye drop with an established dual anti inflammatory and anti apoptotic mechanism of action in patients with dry eye disease ded,oculis announces positive topline results of phase 2b relief trial with licaminlimab designed to transform the treatment paradigm of dry eye disease with a precision medicine strategy,clinical_study,UP,1.2658195249076385,990053760.0,41222545.0,32175.0,0.144,32100.0,0.041636673345899926,0.09346626282280733,0,5,383,0.07020202020202021,0.4640841922034435,0.08686868686868687
malvern pa aug 05 2024 globe newswire ocugen inc ocugen or the company nasdaq ocgn a biotechnology company focused on discovering developing and commercializing novel gene and cell therapies and vaccines today announced that it has received notification from fda to begin its expanded access program eap for the treatment of adult patients aged 18 and older with retinitis pigmentosa rp with ocu400 a modifier gene therapy product candidate,ocugen inc announces fda approval of expanded access program for patients with retinitis pigmentosa,clinical_study,DOWN,-3.673475544336368,302252096.0,287364635.0,6243265.0,4.237,6951700.0,0.9507448874730053,0.09346626282280733,0,6,327,0.05555555555555555,0.7661975315521313,0.08801010101010101
farmington hills mich feb 05 2024 globe newswire ocuphire pharma inc nasdaq ocup a clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of retinal and refractive eye disorders today announced that clinical data from its zeta 1 trial on a person level scale evaluating apx3330 in diabetic retinopathy dr were presented at the 21st annual angiogenesis exudation and degeneration 2024 conference which took place virtually on saturday february 3 2024 the presentation titled apx3330 oral treatment to slow the progression of diabetic retinopathy using a binocular drss severity scale as a registrational endpoint was delivered by veeral sheth m d m b a a practicing retina specialist at university retina and clinical assistant professor at the university of illinois,ocuphire pharma announces presentation on apx3330 at the annual angiogenesis exudation and degeneration 2024 conference,clinical_study,UP,0.7547162342173653,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.1515999603296736,0,8,509,-0.18333333333333335,0.8866002429130597,0.03673469387755103
renovaro announces 10m in equity committed,renovaro inc announces 10 million in equity committed,financing_agreements,UP,0.6896544920278584,60190016.0,90925076.0,7542515.0,0.529,816400.0,1.5106338566183468,0.09346626282280733,4,9,379,0.0,1.5631250973582267,0.08618398268398268
redwood city calif may 08 2024 globe newswire coherus biosciences inc coherus nasdaq chrs today announced that the cancer research institute cri and its immunotherapy platform study in platinum resistant high grade serous ovarian cancer iproc drug selection committee dsc have selected loqtorzi toripalimab tpzi anti pd 1 antibody to explore in combination with enb 003 a first in class small molecule inhibitor of endothelin b receptor etbr for the treatment of drug resistant cancers in the iproc platform study endothelin b receptor is implicated in tumorigenesis and tumor immune suppression for several solid tumors including melanoma ovarian and pancreatic cancers,coherus announces clinical collaboration with the cancer research institute for a novel combination evaluating loqtorzi toripalimab tpzi with enb therapeutics enb 003 for the treatment of ovarian cancer,clinical_study,UP,0.0,84886144.0,110892497.0,1236840.0,0.883,1425300.0,1.3063674679344606,0.09346626282280733,2,9,416,-0.04,1.0144535837204522,0.2112037037037037
pratteln schweiz 18 juni 2024 santhera pharmaceuticals six sann gibt bekannt dass die aktionäre an der heutigen generalversammlung gv in pratteln schweiz allen anträgen des verwaltungsrats mit grosser mehrheit zugestimmt haben die teilnehmenden aktionäre vertraten 4 535 785 aktien oder 35 des aktienkapitals des unternehmens,santhera s aktionäre stimmen an heutiger generalversammlung allen anträgen des verwaltungsrats zu,annual_general_meeting,DOWN,-0.3061197182379018,153885728.0,9852656.0,27757.2,-0.406,39125.0,0.06402579451682484,0.09346626282280733,1,9,375,0.0,0.5209522992128177,0.04000000000000001
puuilo plc stock exchange release 4 october 2024 at 8 45 am puuilo oyj managers transactions ____________________________________________ person subject to the notification requirementname lasse ahoposition member of the board deputy memberissuer puuilo oyjlei 743700ujut6fwhbxpr69notification type initial notificationreference number 80314 7 6 ____________________________________________ transaction date 2024 10 03venue nasdaq helsinki ltd xhel instrument type shareisin fi4000507124nature of transaction acquisitiontransaction details 1 volume 1113 unit price 9 43 euraggregated transactions 1 volume 1113 volume weighted average price 9 43 eurfor further information please contact ville ranta cfo mobile phone 358 40 555 4995,puuilo plc managers transactions aho,management_changes,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,4,7,267,-0.07916666666666666,0.8866002429130597,0.0
media release,immutep presents data from safety lead in phase of aipac 003 at esmo breast 2024,clinical_study,UP,5.119448925981286,227072048.0,1232826146.0,113325.0,1.522,138900.0,5.429228990791504,0.09346626282280733,2,8,409,0.0,0.7476881311953882,0.11727272727272726
media release,new number of shares and votes in senzime ab publ,shares_issue,UP,0.3184710232218929,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,15,239,0.13636363636363635,0.8866002429130597,-0.014876033057851245
media release,wärtsilän tammi syyskuun osavuosikatsaus 2024,earnings_releases_and_operating_results,DOWN,-7.103823312288768,11530422272.0,388303386.0,1013444.6,1.147,878088.0,0.033676423711119396,0.1515999603296736,1,7,242,0.0,0.32861945847596113,0.0
launch preparations underway in anticipation of possible u s approval of mavorixafor for whim syndrome u s pdufa target action date set for april 30 2024,x4 pharmaceuticals reports fourth quarter and full year 2023 financial results and provides corporate update,clinical_study,UP,0.9803912402207476,12156248.0,4364496.0,363495.0,0.663,396700.0,0.35903314904401423,0.09346626282280733,3,6,464,0.075,1.4412990038402507,0.12499999999999999
new york april 18 2024 globe newswire tg therapeutics inc nasdaq tgtx today announced two additional data presentations from the ultimate i ii phase 3 trials evaluating briumvi ublituximab xiiy in patients with relapsing forms of multiple sclerosis rms at the 2024 american academy of neurology aan annual meeting being held in denver colorado links to the data presented yesterday are included below,tg therapeutics announces additional data presentations for briumvi ublituximab xiiy in multiple sclerosis at the american academy of neurology 2024 annual meeting,clinical_study,UP,1.2301018816781355,5891398656.0,135060602.0,1756590.0,1.939,1677400.0,0.022925048852779586,0.09346626282280733,3,7,436,0.022727272727272724,0.6256004090066075,0.04555600649350649
philochem philogen and blue earth diagnostic bracco announce the three first patients in the phase i trial have been imaged with 68ga oncofap,philochem and blue earth diagnostics announce first three patients imaged in phase 1 clinical trial of 68ga oncofap 68ga oncofap dotaga for diagnostic imaging in solid tumors,licensing_agreements,UP,0.0,926076608.0,35018869.0,31367.18181818182,0.152,19588.0,0.25000035609542787,0.09346626282280733,0,3,572,0.1,0.3376005673725286,0.35227272727272724
rockville md june 22 2023 globe newswire opgen inc nasdaq opgn opgen or the company a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease reported that its german subsidiary curetis gmbh has received the full set of ten unyvero a30 c series instruments which have been assembled by its development partner dmtpe in germany the instruments have successfully passed electrical and functional testing and will allow rapid sample to answer molecular testing with numerous chemistries and assay formats,opgen s subsidiary curetis receives batch of ten new c series unyvero a30 instruments,product_services_announcement,DOWN,-1.5873075943202797,49132328.0,2828132.0,5594.736842105263,-1.682,5300.0,0.057561530567002646,0.09346626282280733,3,7,737,0.17662337662337663,1.807174583649316,0.020454545454545454
malvern pa may 21 2024 globe newswire annovis bio inc nyse anvs annovis or the company a clinical stage drug platform company developing novel therapies for neurodegenerative diseases announced the publication of a new article focused on the comparison of pharmacokinetic profiles of posiphen or buntanetap across different species in a peer reviewed journal biomolecules as part of the special issue role of amyloid protein in neurological diseases,annovis announces new publication in a peer reviewed journal,clinical_study,DOWN,-0.5714307512555803,43941384.0,15624645.0,595065.0,1.618,805900.0,0.35557926441279136,0.09346626282280733,1,7,403,0.15746753246753248,1.368989555493872,0.08556763285024153
live event and webcast today at 10 am et,valneva hosts investor day in new york city,conference_call_webinar,DOWN,-1.7241444513996895,468942464.0,116850962.0,9015.0,1.093,7400.0,0.24917974158979128,0.09346626282280733,3,1,261,0.13636363636363635,0.6494694268312979,0.028525641025641018
media release,fly play hf manager s transactions,company_regulatory_filings,UP,9.242146234319629,1730814080.0,11842744.0,1296563.9411764706,0.45,1037764.0,0.006842297007429013,0.1515999603296736,2,10,240,0.8,0.7000376628051228,0.8
kraig labs otcqb kblb achieved full capacity at its current production location and will open additional production facilities,kraig biocraft laboratories expands facilities to support spider silk production growth,capital_investment,DOWN,-7.103823312288768,83802400.0,786095486.0,777347.3684210526,1.048,627100.0,9.38034574188806,0.1515999603296736,0,8,362,0.11666666666666665,0.8071333009212691,0.1303503787878788
media release,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,1,7,242,0.0,0.8866002429130597,-0.004810495626822154
03 oct 2024 07 30 cest boussard gavaudan holding ltd boussard gavaudan holding limited ordinary shares the directors of boussard gavaudan holding limited would like to announce the following information for the company close of business 02 oct 2024 estimated nav euro sharessterling sharesestimated nav 28 3626 25 4973estimated mtd return 0 01 0 02 estimated ytd return 2 96 3 77 estimated itd return 183 63 154 97 nav and returns are calculated net of management and performance fees market information euro sharesamsterdam aex london lse market close 27 20n apremium discount to estimated nav 4 10 n a sterling sharesamsterdam aex london lse market closen agbx 2 360 00premium discount to estimated navn a 7 44 transactions in own securities purchased into treasury ordinary shares euro sharessterling sharesnumber of sharesn an aaverage pricen an arange of pricen an a,bghl gbp nav s,fund_data_announcement,UP,0.0,112574064.0,35018869.0,363495.0,0.8755,331336.5,0.25000035609542787,0.09346626282280733,3,5,268,-0.006122448979591831,0.8866002429130597,-0.006122448979591832
communiqué du 30 septembre 2024 relatif au dépôt du projet de note d information,eurobio scientific communiqué du 30 septembre 2024 en réponse au projet d offre publique d achat visant les actions de eurobio scientific s a initiée par la société eb development,mergers_acquisitions,UP,1.6032048348648946,254875328.0,35018869.0,592.0,0.426,421.0,0.25000035609542787,0.09346626282280733,0,11,270,0.0,0.4336088389568585,-0.0037593984962406004
new york june 11 2024 globe newswire tiziana life sciences ltd nasdaq tlsa tiziana or the company a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery today announced it has received acceptance of its submission for intranasal foralumab to receive fast track designation approval for the treatment of non active secondary progressive multiple sclerosis na spms to the u s food and drug administration fda,fda accepts tiziana life sciences fast track designation submission for treatment of multiple sclerosis,clinical_study,DOWN,-6.000000238418579,198641600.0,63394363.0,242895.0,0.107,139700.0,0.3191394098718496,0.09346626282280733,1,8,382,0.014718614718614726,1.1109140250580023,0.03405670461226017
immunocore announces transition of chief financial officer,immunocore announces transition of chief financial officer,management_changes,DOWN,-7.103823312288768,1603205376.0,37423034.0,614630.0,0.835,788600.0,0.023342632553647324,0.09346626282280733,3,7,303,0.0,0.44240182162750774,0.10378787878787878
toronto nov 21 2023 globe newswire revive therapeutics ltd revive or the company otcqb rvvtf cse rvv frankfurt 31r a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders provides an update on the development of a next generation lyophilized formulation of bucillamine,revive therapeutics provides update of novel bucillamine formulation development,product_services_announcement,DOWN,-7.103823312288768,7115588.0,412235577.0,277578.94736842107,1.403,392500.0,57.934154844265855,0.09346626282280733,1,7,585,0.09999999999999999,1.8889707456546947,0.0
